<SEC-DOCUMENT>0001513162-22-000114.txt : 20220829
<SEC-HEADER>0001513162-22-000114.hdr.sgml : 20220829
<ACCEPTANCE-DATETIME>20220829165447
ACCESSION NUMBER:		0001513162-22-000114
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		70
CONFORMED PERIOD OF REPORT:	20220531
FILED AS OF DATE:		20220829
DATE AS OF CHANGE:		20220829

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOMERICA INC
		CENTRAL INDEX KEY:			0000073290
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				952645573
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0531

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37863
		FILM NUMBER:		221211813

	BUSINESS ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614
		BUSINESS PHONE:		9496452111

	MAIL ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NMS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19871130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR MEDICAL SYSTEMS INC
		DATE OF NAME CHANGE:	19830216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR INSTRUMENTS INC
		DATE OF NAME CHANGE:	19720508
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>bmra-20220531.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Aug 29 19:33:50 UTC 2022 -->
<html xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:bmra="http://www.biomerica.com/20220531" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:pf0="http://fasb.org/srt/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml"><head><title>Form 10-K</title>
<meta content="text/html" http-equiv="Content-Type" />
</head> <body><div style="WORD-WRAP:break-word; "><div> </div><div style="page:WordSection1"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><b><span style="COLOR:black">SECURITIES AND EXCHANGE COMMISSION</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><b><span style="COLOR:black">WASHINGTON, D.C. 20549</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><b><span style="FONT-SIZE:10pt; COLOR:black">FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><b><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport">[X]</ix:nonNumeric> Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><b><span style="FONT-SIZE:10pt; COLOR:black">For The Fiscal Year Ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate">May 31</ix:nonNumeric>, 2022</ix:nonNumeric> </span></b><span style="FONT-SIZE:10pt; COLOR:black">or</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport">[ ]</ix:nonNumeric> Transition Report Under Section 13 or 15(d) of The Securities Exchange Act Of 1934</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">For The Transition Period From ______ To ______</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><b><span style="FONT-SIZE:10pt; COLOR:black">Commission File Number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber">001-37863</ix:nonNumeric></span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName"><b><span style="text-decoration:underline"><span style="FONT-SIZE:14pt; COLOR:black">BIOMERICA, INC.</span></span></b></ix:nonNumeric></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">(Exact Name of registrant as specified in its charter)</span>&#160;&#160; </p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p> <div style="text-align: left;"> <div style="page: WordSection1;">
<div style="text-align: center;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; width: 6.25in; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="600">
<tr>
<td style="padding: 0in; width: 40%;" valign="bottom">
<p style="margin: 0in; text-align: center; font-family: 'Times New Roman',serif; font-size: 12pt; text-align: center;"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><strong><span style="color: black; font-size: 10pt;">Delaware</span></strong></ix:nonNumeric></p>
<p style="margin: 0in; text-align: center; font-family: 'Times New Roman',serif; font-size: 12pt; text-align: center;"><span style="color: black; font-size: 10pt;">(State or other jurisdiction of</span></p>
<p style="margin: 0in; text-align: center; font-family: 'Times New Roman',serif; font-size: 12pt; text-align: center;"><span style="color: black; font-size: 10pt;">Incorporation of organization)</span></p>
</td>
<td style="padding: 0in; width: 20%;" valign="top">
<p style="margin: 0in; font-family: 'Times New Roman',serif; font-size: 12pt;">&#160;</p>
</td>
<td style="padding: 0in; width: 40%;" valign="bottom">
<p style="margin: 0in 0in 0in 1.5pt; text-align: center; text-indent: -1.5pt; font-family: 'Times New Roman',serif; font-size: 12pt; text-align: center;"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber"><strong><span style="color: black; font-size: 10pt;">95-2645573</span></strong></ix:nonNumeric></p>
<p style="margin: 0in; text-align: center; font-family: 'Times New Roman',serif; font-size: 12pt; text-align: center;"><span style="color: black; font-size: 10pt;">(I.R.S. Employer <br/>Identification No.)</span></p>
</td>
</tr>
<tr style="height: 1.9pt;">
<td colspan="3" style="padding: 0in; width: 40%; height: 1.9pt; width: 40%;" valign="top">
<p style="margin: 0in; font-family: 'Times New Roman',serif; font-size: 12pt;"><br/><br/></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 40%;" valign="bottom">
<p style="margin: 0in; text-align: center; font-family: 'Times New Roman',serif; font-size: 12pt; text-align: center;"><strong><span style="color: black; font-size: 10pt;"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1">17571 Von Karman Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">Irvine</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span></strong></p>
<p style="margin: 0in; text-align: center; font-family: 'Times New Roman',serif; font-size: 12pt; text-align: center;"><span style="color: black; font-size: 10pt;">(Address of principal executive offices)</span></p>
</td>
<td style="padding: 0in; width: 20%;" valign="top">
<p style="margin: 0in; font-family: 'Times New Roman',serif; font-size: 12pt;">&#160;</p>
</td>
<td style="padding: 0in; width: 40%;" valign="bottom">
<p style="margin: 0in; text-align: center; font-family: 'Times New Roman',serif; font-size: 12pt; text-align: center;"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode"><strong><span style="color: black; font-size: 10pt;">92614</span></strong></ix:nonNumeric></p>
<p style="margin: 0in; text-align: center; font-family: 'Times New Roman',serif; font-size: 12pt; text-align: center;"><span style="color: black; font-size: 10pt;">(Zip Code)</span></p>
</td>
</tr>
</table>
</div>
</div></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> </p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">REGISTRANT'S TELEPHONE NUMBER:</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">(<b><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode">949</ix:nonNumeric>) <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber">645-2111</ix:nonNumeric></b></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Securities registered under Section 12(b) of the Exchange Act:</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><b><span style="FONT-SIZE:10pt; COLOR:black">None</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Securities registered under Section 12(g) of the Exchange Act:</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="text-decoration:underline"><span style="FONT-SIZE:10pt; COLOR:black">(Title of each class)</span></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle"><b><span style="FONT-SIZE:10pt; COLOR:black">COMMON STOCK, PAR VALUE $0.08</span></b></ix:nonNumeric></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="text-decoration:underline"><span style="FONT-SIZE:10pt; COLOR:black">(Name of each exchange on which registered)</span></span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif"><ix:nonNumeric contextRef="c0" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric> Capital Market</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">(Trading symbol)</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">BMRA</span></ix:nonNumeric></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act &#160;&#160;</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Yes [ &#160;&#160;]&#160; <ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric> [X]</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Securities Act. &#160;</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Yes [&#160; ] &#160;<ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric> [X]</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Indicate by check whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric> [X]&#160; No [ &#160;]</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation (paragraph 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric> [X]&#160; No [ &#160;]</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Indicate by check mark whether the registrant is a large accelerated, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. &#160;See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <table cellpadding="0" cellspacing="0" style="WIDTH:6.25in; BORDER-COLLAPSE:collapse" width="600"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt">Large Accelerated Filer [ &#160;]</span></p></td> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"></td> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt">Accelerated Filer&#160;&#160;&#160;[ &#160;]</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-Accelerated Filer</ix:nonNumeric> &#160;&#160;[X]</span></p></td> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"></td> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt">Smaller Reporting Company <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness">[X]</ix:nonNumeric></span></p></td></tr> <tr style="HEIGHT:15pt"> <td colspan="2" style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt">Emerging Growth Company <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany">[&#160; ]</ix:nonNumeric></span>&#160;</p></td> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr></table> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:#333333">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided </span><span style="FONT-SIZE:10pt">pursuant to </span><span style="FONT-SIZE:10pt; TEXT-DECORATION:none; COLOR:windowtext">Section 13(a) of the Exchange Act</span><span style="FONT-SIZE:10pt">. [&#160; <span style="COLOR:#333333">]</span></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:#333333">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under </span><span style="FONT-SIZE:10pt; TEXT-DECORATION:none; COLOR:windowtext">Section 404(b) of the Sarbanes-Oxley Act</span><span style="FONT-SIZE:10pt"> (</span><span style="FONT-SIZE:10pt; TEXT-DECORATION:none; COLOR:windowtext">15 U.S.C. 7262(b)</span><span style="FONT-SIZE:10pt">) <span style="COLOR:#333333">by the registered public accounting firm that prepared or issued its audit report.&#160; [ ]</span></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Act).</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Yes [ &#160;]&#160; No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany">[X]</ix:nonNumeric></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was sold, or the average bid and asked price of such common equity, as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter (based upon 11,486,578 shares held by non-affiliates and the closing price of $4.85 per share for Common Stock as of November 30, 2021): $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="dei:EntityPublicFloat" scale="0" unitRef="usd">55,709,903</ix:nonFraction>. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The outstanding number of shares of common stock, par value $0.08, as of August 29, 2022 was <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares">13,391,901</ix:nonFraction>. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-AUTOSPACE:"><span style="FONT-SIZE:10pt; COLOR:black">DOCUMENTS INCORPORATED BY REFERENCE: Portions of the registrant&#8217;s definitive Proxy Statement for the 2022 annual meeting of stockholders, to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form 10-K, are incorporated by reference in Part III, Items 10-14 of this Form 10-K. Except for the portions of the Proxy Statement specifically incorporated by reference in this Form 10-K, the Proxy Statement shall not be deemed to be filed as part hereof.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">2</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><i><span style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black">Except for historical financial information contained herein, the matters discussed in this Form 10-K may be considered forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, and subject to the safe harbor created by the Securities Litigation Reform Act of 1995. Such statements include declarations regarding our intent, belief, or current expectations, and those of our management. </span><span style="FONT-SIZE:10pt; COLOR:black">In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other comparable terminology.&#160; <span style="BACKGROUND:white">Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks, uncertainties and other factors, some of which are beyond our control. Actual results could differ materially from those indicated by such forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, but are not limited to, those risks and uncertainties identified under &#8220;Risk Factors,&#8221; in this Form 10-K and the other risks detailed from time-to-time in our reports and registration statements filed with the Securities and Exchange Commission, or SEC. Except as required by law, we undertake no obligation to revise or update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.</span></span></i></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">3</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">PART I</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ITEM 1. &#160;&#160;&#160;&#160; BUSINESS</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">BUSINESS OVERVIEW</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">THE COMPANY</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Biomerica, Inc. ("Biomerica," the "Company," "we," &#8220;us,&#8221; or "our") was incorporated in Delaware in September 1971 as Nuclear Medical Systems, Inc., and later changed its name to Biomerica, Inc. The Company has two wholly owned subsidiaries, Biomerica de Mexico, which is used for assembly/manufacturing, and BioEurope GmbH, which acts as a distributor of Biomerica products in certain markets. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <a id="_Hlk79659987"></a><a id="_Hlk48290852"></a><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">We are a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. Our products are designed to enhance the health and well-being of people, while reducing total healthcare costs. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <a id="_Hlk79659731"></a><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our primary focus is the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided therapy (&#8220;DGT&#8221;) products to treat gastrointestinal diseases, such as irritable bowel syndrome, and other inflammatory diseases. These products are directed at chronic inflammatory illnesses that are widespread and common, and as such address very large markets. Our InFoods&#174; IBS product uses a simple blood sample and is designed to identify patient-specific foods that, when removed from the diet, may alleviate </span><span style="FONT-SIZE:10pt">Irritable Bowel Syndrome (&#8220;IBS&#8221;)<span style="COLOR:black"> symptoms such as pain, bloating, diarrhea and constipation. Instead of broad and difficult to manage dietary restrictions, the InFoods&#174; IBS product works by identifying a patient&#8217;s above normal immunoreactivity to specific foods.&#160; A food identified as positive, and causing an abnormal immune response in the patient is simply removed from the diet to help alleviate IBS symptoms.</span></span></p><div style="FONT-SIZE:10pt"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">During fiscal 2022, we completed an endpoint determination clinical trial on our InFoods&#174; IBS product. This trial was conducted at Mayo Clinics in Florida and Arizona, Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, University of Texas Health Science Center at Houston, Houston Methodist, the University of Michigan and other institutions. This trial monitored IBS patients over an 8-week period to determine the efficacy of our InFoods&#174; IBS product to improve the patients&#8217; IBS symptoms or endpoints. The top-line trial results were reported in February 2022. Multiple endpoints demonstrated statistically significant improvements, indicating that the elimination of specific foods may meaningfully reduce the symptoms of IBS in all patient subtypes (including patients with IBS-Constipation, IBS-Diarrhea &amp; IBS-Mixed). The greatest clinical improvements, including but not limited to abdominal pain and bloating, were seen in patients diagnosed with IBS-Mixed and IBS-Constipation, in the top line data. The purpose of the endpoint study was to determine the primary symptom endpoint, or endpoints to be used in a final pivotal trial that will be conducted to attain the validation data needed to apply for U.S. Food and Drug Administration (&#8220;FDA&#8221;) clearance for the product. We are now in the process of reviewing the complete dataset and selecting the target endpoint(s) to be used in the pivotal trial. We are also writing the protocols for this trial and expect to present these protocols to the FDA during fiscal 2023, with the intention of beginning the trial by the end of fiscal 2023, or May 31, 2023. The trial is expected to include the large medical institution participants that conducted the endpoint trial, in addition to other new institutions and a Clinical Research Organization. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <a id="_Hlk111638255"></a><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Following the successful completion and positive results from the Company&#8217;s InFoods<sup>&#174;</sup> IBS clinical trial we&#8217;ve seen significant interest from Gastroenterology (&#8220;GI&#8221;) physicians who would like to provide the InFoods<sup>&#174;</sup> IBS Product to for their patients immediately.&#160; Therefore, while we are proceeding with the work needed to seek FDA clearance for this product, we also are currently preparing to launch the InFoods<sup>&#174;</sup> IBS product through a CLIA-certified, high-complexity laboratory facility and offering the product as a laboratory developed test (&#8220;LDT&#8221;). Our expectation is that we will begin to generate revenues from this product by the end of December 31, 2022. In preparation for the launch of this LDT, we are in negotiations with large physician groups that would like to offer the LDT to their IBS patients.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">We are also beginning the work of selecting and validating at least one new disease (such as ulcerative colitis or migraines), where there is evidence that certain foods can trigger or contribute to the symptoms found in these indications. We expect any new disease we target will follow a similar development pathway as InFoods IBS in simultaneously seeking FDA clearance of the product while also launching the product as an LDT.</span> </p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">We will also continue to evaluate partnership/licensing opportunities, as they arise, with </span><span style="FONT-SIZE:10pt">U.S. and multinational companies that could help us commercialize, or accelerate revenue growth of, the InFoods products in the United States and overseas.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">4</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">Our existing medical diagnostic products are sold worldwide primarily in two markets: 1) clinical laboratories and 2) point-of-care (physicians' offices and over-the-counter drugstores like Walmart and Walgreens). The diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens, or other substances, which may exist in a patient&#8217;s body, stools, or blood, often in extremely small concentrations.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <a id="_Hlk79657334"></a><a id="_Hlk48293512"></a><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">During fiscal 2022, we finalized development of our H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. H. Pylori infection is extremely common, and if left untreated, can lead to ulcers and possibly stomach cancers. During our fourth quarter of fiscal 2022, we applied for FDA clearance of this product though a 510(k) premarket submission. We have been in communications with the FDA answering certain follow-up questions and providing additional data as requested. We are currently awaiting FDA clearance of the product. Once cleared, we will begin marketing the product in the U.S. market.&#160; </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <a id="_Hlk111640981"></a><a id="_Hlk111643953"></a><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Following fiscal year-end, we announced that Walmart has begun selling our Aware<sup>&#174;</sup> Breast Self Exam product through their on-line retailing platform, Walmart.com. We are also in final discussions with Walmart to offer this product in their U.S. based retail stores. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">We have added new employees in our sales and marketing department in order to increase sales of existing products <span style="COLOR:black">during fiscal 2022. Through</span> these efforts, our EZ Detect colon disease home screening test and our <span style="COLOR:black">Aware<sup>&#174;</sup> Breast Self Exam product </span>are seeing an increased interest from retailers such as Walmart, distributors, and screening programs in other countries. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Due to the global 2019 SARS-CoV-2 novel coronavirus pandemic<span style="COLOR:black">, in March 2020 we</span> began developing COVID-19 products to indicate if a person has been infected by COVID-19, or is currently infected. While we offer a COVID-19 antibody diagnostic test to determine if a person has previously been infected by the COVID-19 virus, all of our COVID-19 revenues <span style="COLOR:black">in fiscal 2022</span> have come from international sales of our COVID-19 antigen tests that use a patient&#8217;s nasal fluid sample to detect if the patient is currently infected with the virus.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">While sales continue to occur in our COVID-19 products, </span><span style="FONT-SIZE:10pt">the majority of our research and development efforts are focused on development and commercialization of non-COVID related products such as our H. Pylori product, and our InFoods&#174; IBS product. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The other existing products that contributed to our 2022 revenues are primarily focused on gastrointestinal diseases, food intolerances, and certain esoteric tests. These diagnostic test products utilize immunoassay technology. Most of our products are CE marked and/or sold for diagnostic use where they are registered by each country&#8217;s regulatory agency. In addition, some products are cleared for sale in the United States by the FDA.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Technological advances in medical diagnostics have made it possible to perform diagnostic tests within the home and the physician's office (the point-of-care), rather than in the clinical laboratory. One of our objectives also has been to develop and market rapid diagnostic tests that are accurate, employ easily obtained specimens, and are simple to perform without instrumentation. &#160;Our over-the-counter (home use) and professional use (doctor&#8217;s office, clinics, etc.) rapid diagnostic products help to manage existing medical conditions and may save lives through early detection and prompt diagnosis. Typically, tests of this kind require the services of medical technologists and sophisticated instrumentation. &#160;Further, results are often not available until at least the following day. We believe that rapid point-of-care tests can be as accurate as laboratory tests when used properly, require limited to no instrumentation, give reliable results in minutes and can be performed with confidence in the home or the physician's office.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">We expend considerable funds in research and development of certain new products that diagnose and, in certain cases, are designed to be used as a therapy for several major medical diseases. These products are both internally developed and licensed from others. &#160;We employ experienced and highly trained technical personnel (including Ph.D.&#8217;s and scientists) to develop new products and evaluate and implement technology technical transfer activities. Our technical staff, many of whom have been previously employed at large diagnostic manufacturing companies, has extensive industry experience. We also rely on our Scientific Advisory Board of leading medical doctors and clinicians to assist in guiding our clinical studies and product development.</span></p>
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">&#160;</span></p>
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">Biomerica maintains its headquarters in Irvine, California, where it houses administration, finance, regulatory compliance, product development, sales and marketing, customer services and its primary manufacturing operations. Biomerica maintains manufacturing and assembly operations in Mexicali, Mexico, in order to reduce the cost of manufacturing and compete more effectively worldwide. Biomerica also has a legal entity in Europe, BioEurope GmbH, for the purpose of selling certain products internationally. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Additional information about Biomerica is available on our website at www.biomerica.com. The content on any website referred to in this Form 10-K is not a part of or incorporated by reference in this Form 10-K unless expressly noted. Our Annual Report on Form 10-K, Quarterly Reports on Forms 10-Q, Current Reports on Forms 8-K, Proxy Statements and all other filings we make with the Securities and Exchange Commission (&#8220;SEC&#8221;) are available on our website, free of charge, as soon as reasonably practical after we file them with or furnish them to the SEC and are also available online at the SEC&#8217;s website at </span><span style="text-decoration:underline"><span style="FONT-SIZE:10pt; COLOR:#6600cc">www.sec.gov</span></span><span style="FONT-SIZE:10pt; COLOR:black">.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">5</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">PRODUCTION</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Most of our diagnostic test kits are manufactured and/or assembled at our facilities in Irvine, California and in Mexicali, Mexico. We established our manufacturing facility in Mexicali, Mexico in fiscal 2003 and moved a significant portion of our diagnostic packaging and assembly to that facility. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Production of diagnostic tests can involve formulating component antibodies and antigens in specified concentrations, attaching a tracer to the antigen, filling components into vials, packaging and labeling. We continually engage in quality control procedures to assure the consistency and quality of our products and to comply with applicable FDA and international regulations. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our manufacturing operations and facilities are regulated by the FDA Good Manufacturing Practices for medical devices. We have an internal quality department that monitors and evaluates product quality and output. We also have an internal Quality Systems department whose goal is to ensure that our operating procedures are in compliance with current FDA, CE Mark and </span><span style="FONT-SIZE:10pt">International Organization for Standardization</span><span style="FONT-SIZE:8pt; COLOR:black">&#160;</span><span style="FONT-SIZE:10pt; COLOR:black">(&#8220;ISO&#8221;) regulations. We either produce our own antibodies and antigens or purchase these materials from qualified vendors. We have alternate, approved sources for most critical raw materials and are working to procure alternate sources for the few that we do not have. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">RESEARCH AND DEVELOPMENT</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">During most of the fiscal year, in addition to our focus on development our InFoods<sup>&#174;</sup> IBS product, we also focused a portion of our Research and Development (&#8220;R&amp;D&#8221;) resources on developing a </span><span style="FONT-SIZE:10pt">H. Pylori diagnostic test.<span style="COLOR:black">&#160; Our research and development spending are due to our focus on these tests and outside clinical studies intended to demonstrate the feasibility of FDA clearance for such tests. We also utilize technical personnel, with Ph.D. and other degrees and extensive experience in development and production of health diagnostic tests, to conduct other development activities and improve existing products, as well as explore potential new technologies that we may wish to develop and commercialize. Research and development expenses include the costs of materials, supplies, personnel, consultants, facilities, outside clinical trial sites and equipment as well as outside contract services. Consolidated research and development expenses incurred by Biomerica for the years ended May 31, 2022 and 2021, aggregated to approximately $1,812,000, and $2,194,000, respectively. As Biomerica moves forward with development, validation and commercialization of additional key products that address diseases with large market opportunities, research and development expenses are expected to increase during upcoming quarters. </span></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">We&#8217;ve developed a unique diagnostic-guided therapy that is designed to allow physicians to identify patient-specific foods (e.g. pork, milk, onions, sugar, chickpeas, etc.), that when removed from the patient&#8217;s diet, may alleviate or improve their symptoms of IBS. The United States Patent and Trademark Office (&#8220;USPTO&#8221;) has issued the Company two patents with broad claims that protect this InFoods&#174; IBS product. Patents have also been issued in the countries of Australia, Japan, Korea, Mexico, and Singapore. Additional patent application pertaining to the InFoods<sup><span style="COLOR:black">&#174;</span></sup><span style="COLOR:black"> IBS product</span> have been filed in the United States and in other countries. We are also developing and have filed patents for products that target other diseases utilizing the InFoods<sup><span style="COLOR:black">&#174;</span></sup> technology platform which include:&#160; Functional Dyspepsia, Crohn&#8217;s disease, Ulcerative Colitis, Gastroesophageal Reflux disease (&#8220;GERD&#8221;), Migraine Headaches, Depression and Osteoarthritis. Our first patent to be allowed for a disease/illness other than IBS was allowed in Japan in August 2021. This patent covers the use of our InFoods&#174; technology to diagnose and treat persons suffering from depression. We are planning to pursue FDA Clearance through a De Novo submission with the FDA rather than a Premarket Approval Application (&#8220;PMA&#8221;) or 510(k) for the InFoods&#174; IBS product.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">During the fourth quarter of fiscal 2022, we also submitted our proprietary H. Pylori test to the FDA for clearance through a 510(k) submission. The clinical studies for our H. Pylori were conducted at the University of Southern California (&#8220;USC&#8221;), a European University and several other U.S. locations. Biomerica&#8217;s test is designed to provide highly accurate sensitivity and specificity for H. pylori testing and for monitoring of treatment.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">6</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">MARKETS AND METHODS OF DISTRIBUTION</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <a id="_Hlk80101849"></a><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">Biomerica has approximately 250 current customers for its diagnostic business, of which approximately 80 are foreign distributors, 10 are domestic distributors and the balance are primarily domestic hospital and clinical laboratories, medical research institutions, medical schools, pharmaceutical companies, chain drugstores, wholesalers, physicians' offices, and e-commerce customers.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">We employ a director of sales and marketing for Europe and South America who is headquartered in Germany.&#160; She has over 20 years of experience selling and marketing diagnostic and life science products across multiple diagnostics technologies and disciplines. She possesses broad international business experience, with communication skills in German, English, Spanish, French and Portuguese, and scientific and technical understanding of gastrointestinal diagnostic products. She also has strong relationships with key strategic entities in Europe, Eastern Europe, Latin America, Canada and the United States and we expect that she will continue to help Biomerica add new distributors for existing products and add new product-lines for future distribution by us. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">We rely on affiliated and unaffiliated distributors, advertising in medical and trade journals, exhibitions at trade shows, direct mailings and an internal sales staff to market our diagnostic products. We target two main markets: (a) clinical laboratories and (b) point-of-care testing (physicians' offices and over-the-counter drug stores).&#160;</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Due to</span><span style="FONT-SIZE:10pt"> the Coronavirus global pandemic, our operations have been negatively impacted.<span style="COLOR:black"> We have faced disruptions in certain of the following areas, and may face further challenges from supply chain disruptions, loss of contracts and/or customers, closure of our manufacturing or distribution facilities or of the facilities of our suppliers, partners and customers, travel, shipping and logistical disruptions, government responses of all types, international business risks in countries where we make and/or sell our products, loss of human capital or personnel at the Company, its partners and its customers, interruptions of production, customer credit risk, and general economic calamities. These ongoing pandemic related disruptions can materially negatively impact our operations and financial performance and may continue to have significant material negative impacts on us.&#160;&#160; </span></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 11.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our net sales were approximately $18,871,000 for fiscal 2022 compared to $7,199,000 for fiscal 2021. For the fiscal years ended May 31, 2022 and 2021, the Company had two distributors, which accounted for a total of 65% and 60% of our net sales, respectively. Of this, for the fiscal years ended May 31, 2022 and 2021, the largest of the distributors mentioned above accounted for 55% and 33%, respectively, of net sales. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 11.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total gross receivables at May 31, 2022 and 2021 were approximately $927,000 and $2,292,000, respectively. As of May 31, 2022 and 2021, the Company had one distributor and two distributors, respectively, which accounted for a total of 50% and 73%, respectively, of gross accounts receivable. Of the 50% as of May 31, 2022, 50% was owed by a distributor in Asia. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">BACKLOG</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">On May 31, 2022 and 2021, Biomerica had a backlog of unshipped orders of approximately $754,000 and $85,000, respectively. On May 31, 2022, this consisted primarily of orders to a distributor in Asia.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">RAW MATERIALS</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The principal raw materials utilized by Biomerica consist of various chemicals, serums, reagents and packaging supplies. Almost all of our raw materials are available from several sources, and we are not dependent upon any single source of supply or a few suppliers. &#160;&#160;However, due to the limited number of suppliers of some materials, especially those such as antibodies, there is always the possibility that we may encounter difficulty in the future obtaining key raw materials for its manufacturing processes or that such materials may be exceedingly costly. For the fiscal years ended May 31, 2022 and 2021, the Company had one vendor, which accounted for 84% and 58%, respectively of our purchases of raw materials.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our inventory consists of various types of materials including antibodies, antigens, bottles, boxes, various chemicals and reagents utilized in the manufacture of our test kits as well as products in various stages of completion.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our sourcing and receiving of raw materials have been negatively impacted due to the global COVID-19 pandemic. Many of our suppliers have been impacted by plant shut-downs, state or national mandated or recommended shut-downs, restrictions and constraints on distribution channels including ship freight, air freight and trucking, among other things. These suppliers are also experiencing their own disruptions in sourcing raw materials.&#160; It is unclear to what extent raw material availability will be impacted in the foreseeable future, and how that will impact our production and sales. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">7</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">INFLATION</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Due to the global and domestic supply chain disruptions, and overall inflationary pressures in the economy, we have experienced material increases in the cost of our raw materials and in our operating and labor costs. While we have attempted to respond by increasing the selling price of our own products, the gross margins on our products sold have been negatively impacted. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">COMPETITION</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Immunodiagnostic products, including COVID-19 products, are currently produced globally by hundreds of companies. Biomerica is not a significant player in the overall market for most of the product categories in which we compete. However, we do have certain proprietary products, such as our EZ Detect colon disease home test, the Aware Breast Self Exam product and our InFoods<sup>&#174;</sup> IBS that do not have significant competition from tests offered by competitors, and that do not have the features and benefits of our tests.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our competitors vary greatly in size. Many are divisions or subsidiaries of well-established medical and pharmaceutical companies which are much larger than Biomerica and expend substantially greater amounts than we do for research and development, manufacturing, advertising, and marketing.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The primary competitive factors affecting the sale of diagnostic products are uniqueness, technology, quality of product, performance, price, service, and marketing. We believe we compete primarily on the basis of the uniqueness of our products, the quality of our products, the speed of our test results, our patent position, our pricing and our prompt shipment of orders. We offer a broad range of products but have had limited marketing capability. However, during the past 18 months, we have expanded our sales and marketing capability, through marketing and strategic cooperation with larger companies and distributors and by hiring new employees with marketing and sales expertise. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <a id="_Hlk79487021"></a><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">GOVERNMENT REGULATION OF OUR DIAGNOSTIC BUSINESS </span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our primary business consists of selling products that are generally legally defined to be in vitro diagnostic medical devices and medical devices. As a result, we are considered to be an in vitro diagnostic medical devices and medical device manufacturer, and as such are subject to the regulations of numerous governmental entities. These agencies include the FDA, Environmental Protection Agency, Federal Trade Commission, Occupational Safety and Health Administration, U.S. Department of Agriculture ("USDA"), and Consumer Product Safety Commission, as well as European Government agencies. These activities are also regulated by various agencies of the states and localities in which our products are sold. These regulations govern the introduction of new in vitro diagnostic medical devices and medical devices, the observance of certain standards with respect to the manufacture and labeling of medical devices, the maintenance of certain records, the reporting of potential product problems, and other matters.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Food, Drug &amp; Cosmetic Act of 1938 (the "FDCA") regulates medical devices in the United States by classifying them into one of three classes based on the extent of regulation believed necessary to ensure safety and effectiveness. Class I devices are those devices for which safety and effectiveness can reasonably be assured through general controls, such as device listing, adequate labeling, and adherence to the Quality System Regulation ("QSR") as well as Medical Device Reporting (&#8220;MDR&#8221;), labeling and other regulatory requirements. Some Class I medical devices are exempt from the requirement of Pre-Market Notification or clearance. Class II devices are those devices for which safety and effectiveness can reasonably be ensured through the use of special controls, such as performance standards, post-market surveillance and patient registries, as well as adherence to the general controls&#8217; provisions applicable to Class I devices. Class III devices are devices that generally must receive clearance prior to marketing by the FDA pursuant to a pre-market approval to ensure their safety and effectiveness. Generally, Class III devices are limited to life-sustaining, life-supporting or implantable devices. However, this classification can also apply to novel technology or new intended uses or applications for existing devices. Our products are primarily either Class I or Class II medical devices. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">Pursuant to FDA requirements, we have registered our manufacturing facility with the FDA as a medical device manufacturer and listed the medical devices we manufacture. We are also subject to inspection on a routine basis for compliance with FDA regulations. This includes the QSR, which requires that we manufacture our products and maintain our documents in a prescribed manner with respect to issues such as design controls, manufacturing, testing and validation activities. Further, we are required to comply with other FDA requirements with respect to labeling and MDR regulation which requires that we provide information to the FDA on deaths or serious injuries alleged to have been associated with the use of our products, as well as product malfunctions that are likely to cause or contribute to death or serious injury if the malfunction were to recur. We believe that we are currently in material compliance with all relevant QSR and MDR requirements.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">8</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">In addition, our facility is required to have a California Medical Device Manufacturing License. The license is not transferable and must be renewed biannually. Our current license is valid until November 19, 2022. Through compliance with FDA and California regulations, we can market some of our medical devices throughout the United States. International sales of medical devices are also subject to the regulatory requirements of each country. In Europe, the directives of the European Union (&#8220;EU&#8217;) require that a device have a CE Mark in order to be sold in EU countries. We comply with In Vitro Diagnostic Medical Devices Directive (&#8220;IVDD&#8221;) 98/79/EC and Medical Devices Regulation 2017/745 (&#8220;MDR&#8221;). We also comply with ISO 13485:2016 Medical Devices Quality Management Systems - Requirements for Regulatory Purposes.&#160; </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">At present, outside the EU the regulatory international review process varies from country to country. We work with our distributors and sales representatives in the foreign countries in which we market our products to ensure that we comply with the regulatory laws of those countries. We believe that our international sales to date have been in compliance with the laws of all foreign countries in which we have made sales. Exports of most medical devices are also subject to certain FDA regulatory controls.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">The designing, development, manufacturing, marketing, post-market surveillance, distribution, advertising and labeling of Biomerica&#8217;s immunoassay in vitro diagnostic (&#8220;IVD&#8221;) medical device products are subject to regulation in the United States by the Center for Devices and Radiological Health of the FDA and state agencies.&#160; FDA regulations require that some new products have pre-marketing clearance or approval by the FDA and require these products to be manufactured in accordance with the FDA&#8217;s current Good Manufacturing Practice (cGMP) regulations, to be extensively tested and to be properly labeled to disclose test results and performance claims and limitations.&#160; After a product that is subject to FDA regulation is placed on the market, numerous regulatory requirements apply, including, for example, the requirement that we comply with recordkeeping and reporting requirements, such as the FDA&#8217;s medical device reporting regulations and reporting of corrections and removals.&#160; The FDA enforces these requirements by inspection and post -market surveillance. The last FDA announced inspection was in November 2019 and no observations were noted. We believe that all Biomerica products sold in the United States comply with the FDA and state regulations.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">We are an FDA regulated and ISO 13485:2016 certified In Vitro Diagnostic Medical Devices company. Our goal is to provide high quality medical diagnostic products that generally meet or exceed customer requirements and comply with all applicable regulatory requirements: FDA 21 CFR Part 820 Quality Management System, ISO 13485:2016, Medical Devices Quality Management Systems - Requirements for Regulatory Purposes, In Vitro Diagnostic Medical Devices Directive&#160; 98/79/EC &amp; and Medical Device Regulation 2017/745, Guidelines related to Medical Devices Directive/Regulation and Guidance on CE Marking, etc.&#160; Biomerica involves its employees in a continuous improvement process to increase productivity, improve quality and maintain the suitability, adequacy, and effectiveness of our quality management system. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">The new EU In Vitro Diagnostic Medical Device Regulation (&#8220;IVDR&#8221;) 2017/746 was effective on May 26, 2022. Manufacturers need to update their technical documentation and processes to meet the new, more stringent regulatory requirements of the European Union. Notified Bodies can begin certifying devices to the new IVDR requirements once they have been designated under IVDR by their Competent Authority. Since August 19, 2021, our Notified Body is officially designated under the IVDR and listed in the European Commission NANDO database. We are working closely with our Notified Body to update our technical documentation to comply with these new and more stringent IVDR requirements.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Per IVDR 2017/746 Amendment 2021/0323 (COD), devices with a CE certificate that was issued in accordance with IVDD may be placed on the market or put into service until May 26, 2025. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">Exceptional Renewal of CE Certificate for IVDD Quality System was granted to Biomerica. Biomerica received an extended CE Certificate on May 24, 2022, which remains effective until May 26, 2025. Biomerica has until May 26, 2025, to update the technical documentation and processes to meet the new, more stringent regulatory requirements of IVDR 2017/746.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify;MARGIN:0in"><span style="FONT-SIZE:10pt">Per IVDR 2017/746 Amendment 2021/0323 (COD), devices without a CE certificate that was issued in accordance with IVDD, for which a declaration of conformity was drawn up prior to May 26, 2022, per IVDD and for which the conformity assessment procedure pursuant to IVDR requires the involvement of a Notified Body, may be placed on the market or put into service until the following dates. Biomerica also has until the following dates to update the technical documentation and processes to meet the new, more stringent regulatory requirements of IVDR 2017/746:</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">9</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in 0in 0in 0.5in; TEXT-INDENT:-0.25in"><span style="FONT-SIZE:10pt">(1)<span style="FONT:7pt &#34;Times New Roman&#34;">&#160;&#160;&#160; </span>May 26, 2025, for class D devices;</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in 0in 0in 0.5in; TEXT-INDENT:-0.25in"><span style="FONT-SIZE:10pt">(2)<span style="FONT:7pt &#34;Times New Roman&#34;">&#160;&#160;&#160; </span>May 26, 2026, for class C devices;</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in 0in 0in 0.5in; TEXT-INDENT:-0.25in"><span style="FONT-SIZE:10pt">(3)<span style="FONT:7pt &#34;Times New Roman&#34;">&#160;&#160;&#160; </span>May 26, 2027, for class B devices; and</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in 0in 0in 0.5in; TEXT-INDENT:-0.25in"><span style="FONT-SIZE:10pt">(4)<span style="FONT:7pt &#34;Times New Roman&#34;">&#160;&#160;&#160; </span>May 26, 2027, for class A devices placed on the market in sterile condition.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in 0in 0in 0.5in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">SEASONALITY OF BUSINESS</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our businesses have not been subject to significant seasonal fluctuations.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">INTERNATIONAL BUSINESS</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The following table sets forth the dollar volume of revenue attributable to sales to domestic customers and foreign customers during our last two fiscal years:</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <div style="text-align: left;"> <table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:61.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td colspan="7" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:38.34%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">For the year ended May 31,</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:61.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td colspan="3" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:18.32%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2022</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td colspan="3" style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:18.36%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2021</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:61.66%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Asia</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.66%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.66%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">13,375,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:5%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">71%</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.66%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,908,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:5%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">26%</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:61.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Europe</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">4,339,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">23%</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">4,301,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">60%</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:61.66%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">North America</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.66%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:11.66%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">997,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:5%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">5%</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.66%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:11.68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">548,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:5%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">8%</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:61.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">South America</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">90,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1%</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">250,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">3%</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:61.66%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Middle East</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.66%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.66%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">70,000</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:5%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">0%</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.66%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.68%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.68%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">192,000</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:5%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">3%</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:61.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Total</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.66%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.66%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">18,871,000</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:5%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">&#160;100%</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:1.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.68%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.68%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">7,199,000</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:5%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">&#160;100%</span></b></p></td></tr></table></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">We recognize that our foreign sales could be subject to some special or unusual risks, which are not present in the ordinary course of business in the United States. Changes in economic factors, government regulations, terrorism, tariffs, embargos, trade wars, import/export restrictions, disruptions in shipping and distribution channels and drop in demand for our products due to regional or national shut-downs from the COVID-19 pandemic, and other disease outbreaks that cause patients&#8217; fear or refusal to visit hospitals and healthcare providers due to the pandemic where our products are sold and used, the erosion of economic conditions in those countries, and many other factors all could impact sales within certain foreign countries. In addition, these factors could also impact our ability to collect foreign accounts receivable. Foreign countries have licensing requirements applicable to the sale of diagnostic products, which vary substantially from domestic requirements; depending upon the product and the foreign country, these may be more or less restrictive than requirements within the United States and may change without notice. Foreign sales of our diagnostic products are made primarily through a network of approximately 80 independent distributors in approximately 30 countries.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The COVID-19 related factors mentioned above and in &#8220;Risk Factors&#8221; negatively impacted domestic and international sales of our non-COVID-19 products during fiscal 2022 and may continue to negatively impact our sales into the foreseeable future. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">INTELLECTUAL PROPERTY</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">We regard the protection of our methodologies, designs, product formulations, manufacturing processes, diagnostic procedures, copyrights, service marks, trademarks, and trade secrets as important to our future success. We rely on a combination of copyright, trademark, patent, service mark and trade secret laws and contractual restrictions to establish and protect our proprietary rights in products and services. We have entered into confidentiality and invention assignment agreements with our employees and contractors, and nondisclosure agreements with most of our fulfillment partners and strategic partners to limit access to and disclosure of proprietary information. We cannot be certain that these contractual arrangements or the other steps taken by us to protect our intellectual property will prevent misappropriation of our technology. We have licensed in the past, and expect that we may license in the future, certain of our proprietary rights, such as trademarks, patents, trade secrets, or copyrighted material, to third parties. While we attempt to ensure that the quality of our product brands is maintained by such licensees, we cannot be certain that such licensees will not take actions that might hurt the value of our proprietary rights or reputation.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">10</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;<i><span style="FONT-SIZE:10pt; COLOR:black">LICENSE OF THIRD-PARTY INTELLECTUAL PROPERTY</span></i></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">On occasion, we in-licensed both exclusive and non-exclusive rights to intellectual property and patents owned by third parties. These license agreements typically require royalties and other payments. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">We have a royalty agreement in which we obtained rights to manufacture and market an ACTH test (used to detect chronic metabolic conditions). Royalty expense of approximately $19,000 and $11,000, respectively, is included in cost of sales for this agreement for the fiscal years ended May 31, 2022 and 2021. Sales of products manufactured under this agreement are not material to total sales for the fiscal years ended May 31, 2022 and 2021, respectively. We may license other products or technology in the future as it deems necessary or opportunistic for conducting business.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">In May 2020, we signed an exclusive license agreement with The Regents of the University of California, to license patents pertaining to a CRISPR-based technology that we may use to produce a more accurate rapid test for the COVID-19 virus, that could be used to test individuals to determine if they are currently infected with the COVID-19 virus. This agreement requires the payment of certain milestone payments and a royalty on all sales that utilize the licensed technology. Collaboration efforts on a CRISPR product that may be commercialized using this technology continues, however, there are no imminent plans to launch a product from this collaboration. &#160;&#160;&#160;</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Some of the products that we manufacture, sell or use may be covered by claims in issued patents held by other persons or entities, and as such, upon notice from such persons or entity we may be required to pay a license fee or may be required to cease all manufacture, sale or use of such products, which could negatively impact us. While we have not been notified of any such claims by third parties, we cannot guarantee that such claims will not be made in the future. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><i><span style="FONT-SIZE:10pt; COLOR:black">BRANDS AND TRADEMARKS</span></i></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">We occasionally register our tradenames with the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;). Of note, we registered the tradename &#8220;InFoods&#8221; on December 24, 2016. Our unregistered tradenames are "EZ Detect," "EZ-H.P.," and "EZ-PSA". A trademark for "Aware" was issued and assigned in 2001, renewed in 2011 and 2021. On January 11, 2020, the USPTO renewed our &#8220;FORTEL&#8221; trademark for another ten years. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The laws of some foreign countries do not protect our proprietary rights to the same extent as do the laws of the United States. Effective copyright, trademark and trade secret protection may not be available in such jurisdictions. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><i><span style="FONT-SIZE:10pt; COLOR:black">PATENTS AND INFOODS TECHNOLOGY</span></i></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <a id="_Hlk49356926"></a><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">We have filed over 100 international and Patent Corporation Treaty patents and have over 10 provisional and non-provisional patents currently filed with the USPTO. Some of these patent applications pertain to COVID-19 and other products, however, the majority of our patents that are pending, allowed or issued pertain to the InFoods&#174; technology platform.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">Our most important family of patent applications pertains to our</span><span style="font-size: 10pt;"> InFoods<sup>&#174;</sup> technology platform, which is a new method of diagnosing and treating symptoms of many different inflammatory diseases. Our first planned product launch using this technology is the InFoods<sup>&#174;</sup> IBS product which is designed to diagnose and treat IBS. Using a patient blood sample, a physician or lab can run our test to identify specific foods (e.g., pork, milk, shrimp, broccoli, eggs) that, if eliminated from an IBS patient&#8217;s diet, can alleviate or reduce the individual's IBS symptoms, including, but not limited to, constipation, diarrhea, bloating, cramping, severe pain and indigestion. <span style="color: black;">We have filed many patent applications with the USPTO and with other such similar agencies in other countries outside of the United States pertaining to this </span>InFoods<sup>&#174;</sup> <span style="color: black;">technology. These patent applications include claims that address the diagnosis and treatment of several disease states including IBS, functional dyspepsia, Crohn&#8217;s disease, ulcerative colitis, gastroesophageal reflux disease, osteoarthritis, psoriasis, migraine headaches and depression. These applications include the use of this technology in both humans and animals.&#160; The first InFoods</span><sup>&#174; </sup><span style="color: black;">patents filed by us pertained to IBS. Several of the patents pertaining to the</span> InFoods<sup>&#174;</sup> IBS<span style="color: black;"> technology have been issued and many more are in active review and prosecution.&#160; </span></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <a id="_Hlk79479372"></a><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">In August 2018, we received our first patent from the Korean Intellectual Property Office, covering our InFoods&#174; IBS product. Since then we have been granted an additional 11 patents; 3 in Japan, 2 in the United States, 2 in Korea, 1 in Singapore, 1 in Mexico, 1 in Canada, and 1 in Australia. Additionally, we have filed for over 100 international and USPTO patents.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">11</span></p> <div style="TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p>  <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">We believe the claims in these issued InFoods&#174; IBS patents and claims in our pending patents that protect the use of the </span><span style="FONT-SIZE:10pt">InFoods&#174; <span style="COLOR:black">technology to diagnose and treat various diseases, provide us with broad protections from other companies making or selling competing products in this highly disruptive new field of medicine.&#160; </span></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <a id="_Hlk48224651"></a><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">In addition to the use of our own patents, we have acquired from third parties the rights to manufacture and sell certain products that are protected by patents or intellectual property owned by these third parties. In some cases, royalties are paid on the sales of these products. We anticipate that we will license or purchase the rights to other products or technologies in the future.&#160;</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">We recently completed an endpoint determination clinical trial on our InFoods&#174; IBS product. Our business model for this product includes the possible out-licensing of this product and the related patents to a large international life sciences or technology company that would commercialize the product or assist us with the commercialization.&#160; </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">EMPLOYEES</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">As of May 31, 2022 and 2021, we employed a total of 64 and 67 employees, respectively, in the United States, Mexico, and Germany, of which 64 and 67 were full-time employees, respectively. Various employees listed in the production department also perform research and development duties as a routine function of their job. We occasionally employs temporary employees when needed.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">12</span></p> <div style="TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The following is a breakdown of employees by departments:</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <div style="text-align: left;"> <a id="new_id"></a><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td colspan="3" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:26%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 26%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">May 31,</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2022</span></p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2.16%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.84%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2021</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Administrative</span></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">8</span></p></td> <td style="HEIGHT:15pt; WIDTH:2.16%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.84%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">10</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Research &amp; Development</span></p></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">8</span></p></td> <td style="HEIGHT:15pt; WIDTH:2.16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:11.84%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">8</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Sales &#160;&amp; Marketing</span></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">6</span></p></td> <td style="HEIGHT:15pt; WIDTH:2.16%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.84%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">5</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Production &amp; Operations</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">42</span></p></td> <td style="HEIGHT:15pt; WIDTH:2.16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.84%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">44</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Total</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">64</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2.16%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.84%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">67</span></b></p></td></tr></table></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">We also engage the services of many outside Ph.D.&#8217;s, M.D.&#8217;s and other types of industry expert consultants and organizations as well as medical institutions for technical support, regulatory advisors, marketing and public relations advisors, financial advisors, contract product development and manufacturing organization, and other advisors on a regular basis. We try to protect the Company with the use of confidentiality, intellectual property ownership and indemnifications agreements. However, we cannot guarantee that the use of such experts will fully protect the Company from third-party claims or from theft of our intellectual property.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ITEM 1A.&#160;&#160;&#160;RISK FACTORS</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in; LINE-HEIGHT:120%">&#160;</p> <a id="s9B1D8344AA2ED028FBF5BF856A071139"></a><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">The risks described below are not the only ones we face. Additional risks and uncertainties we are not presently aware of or that we currently believe are immaterial may also impair our business operations. Our business could be harmed by any of these risks and uncertainties. The trading price of our common stock could decline due to any of these risks, and you may lose all or part of your investment. In assessing these risks, you should also refer to the other information contained or incorporated by reference into this annual report on Form&#160;10-K, including our consolidated financial statements and related notes.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in; LINE-HEIGHT:120%"><b><span style="FONT-SIZE:10pt; LINE-HEIGHT:120%">RISKS RELATED TO OUR BUSINESS</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in; LINE-HEIGHT:120%">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Our business could be adversely affected by the effects of widespread public health epidemics<i>.</i></span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:#222222">We are susceptible to ongoing outbreaks of illness or other health issue, such as the recent COVID-19 Coronavirus outbreak. The outbreak of the COVID-19 virus caused various governments, including the United States, to implement quarantines, various restrictions on travel and shelter in place orders and other restrictions. Governments have also implemented work restrictions that prohibit many employees from going to work, and for businesses that are allowed to remain open, many employees are electing to remain at home to avoid spread of the disease. As a result of this COVID-19 outbreak and potential future pandemic outbreaks, the Company faces significant risks including, but not limited to: a) supply chain disruptions making it difficult for the Company to contract and receive materials needed for production of its products, and needed to ship finished products to our end customers, b) loss of contracts and customers from the financial strains or other disruptions they are experiencing as a result of the pandemic, c) financial risks pertaining to receivables due from customers that may fall into insolvency or otherwise be unable to pay their bills, d) government responses including orders that make it difficult to remain open for business, restrict imports of raw materials or exports of finished goods, refusal to allow the Company&#8217;s product to be licensed for sale in their countries, and other seen and unforeseen actions taken by government agencies, e) absenteeism or loss of employees at the Company, or at our partner&#8217;s companies, due to health reasons or government restrictions, that are needed to develop, validate, manufacture and perform other necessary functions for our operations, f) equipment failures, loss of utilities and other disruptions that could impact our operations or render them inoperable, g) litigation or government actions against the Company pertaining to existing products and new products sold by the Company that are directed at limiting or treating the spread of the pandemic outbreak, h) a local or global recession or depression that could harm the international banking system, limit demand for all products including those made by the Company,&#160; i) a drop in demand for our products, that are all medical related, due to patients&#8217; reluctance or refusal to visit hospitals, labs, and doctors&#8217; offices where our products are used due to their fear of contracting a disease, and many other seen and unforeseen events and circumstances, all of which could negatively impact the Company. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in; LINE-HEIGHT:120%">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">We have a history of operating losses.</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black">We have historically incurred net losses. There can be no assurance that we will generate net profits in future periods.&#160;Further, there can be no assurance that we will be cash flow positive in future periods.&#160;In the event that we fail to achieve profitability in future periods, the value of our common stock may decline.&#160;In addition, if we are unable to achieve or maintain positive cash flows, we would be required to seek additional funding, which may not be available on favorable terms, if at all.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in; LINE-HEIGHT:120%">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">13</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:120%; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in; LINE-HEIGHT:120%">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">Our operating results may fluctuate adversely as a result of many factors that are outside our control, which may negatively impact our stock price. </span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Our operating results are dependent upon many factors that are substantially outside of our control that could materially and adversely affect our business, results of operations and financial condition.&#160; Factors that are beyond our control and that could affect our operating results in the future include:</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0in 0.25in; TEXT-INDENT:-0.25in"><span style="FONT-SIZE:10pt">&#8226;<span style="FONT:7pt &#34;Times New Roman&#34;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>regulatory clearance;</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0in 0.25in; TEXT-INDENT:-0.25in"><span style="FONT-SIZE:10pt">&#8226;<span style="FONT:7pt &#34;Times New Roman&#34;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>changes in the level of competition, such as would occur if one of our competitors introduced a new, better performing or lower priced product to compete with one or more of our products;</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0in 0.25in; TEXT-INDENT:-0.25in"><span style="FONT-SIZE:10pt">&#8226;<span style="FONT:7pt &#34;Times New Roman&#34;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>changes in the reimbursement systems or reimbursement amounts that end-users may rely upon in choosing to use our products;</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in 0in 0in 0.25in; text-indent: -0.25in;"><span style="font-size: 10pt;">&#8226;<span style="font: 7pt 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>changes in economic conditions in our domestic and international markets, such as economic downturns, decreased healthcare spending, reduced consumer demand, inflation and currency fluctuations; changes in government laws and regulations affecting our business; reluctance for consumers to visit healthcare providers;</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0in 0.25in; TEXT-INDENT:-0.25in"><span style="FONT-SIZE:10pt">&#8226;<span style="FONT:7pt &#34;Times New Roman&#34;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>lower than anticipated market penetration of our new or more recently introduced products;</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0in 0.25in; TEXT-INDENT:-0.25in"><span style="FONT-SIZE:10pt">&#8226;<span style="FONT:7pt &#34;Times New Roman&#34;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>significant quantities of our product or that of our competitors in our distributors&#8217; inventories or distribution channels;</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0in 0.25in; TEXT-INDENT:-0.25in"><span style="FONT-SIZE:10pt">&#8226;<span style="FONT:7pt &#34;Times New Roman&#34;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>changes in distributor buying patterns;</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0in 0.25in; TEXT-INDENT:-0.25in"><span style="FONT-SIZE:10pt">&#8226;<span style="FONT:7pt &#34;Times New Roman&#34;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>government mandated shelter-in-place or other lock-down orders;</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0in 0.25in; TEXT-INDENT:-0.25in"><span style="FONT-SIZE:10pt">&#8226;<span style="FONT:7pt &#34;Times New Roman&#34;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>continued spread of the COVID-19 virus or mutations of the virus; and</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0in 0.25in; TEXT-INDENT:-0.25in"><span style="FONT-SIZE:10pt">&#8226;<span style="FONT:7pt &#34;Times New Roman&#34;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>changes in the healthcare market including consolidation in our customer base.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">Fluctuations in our operating results, for any reason, could cause operating losses as a result of significant fixed expenses. </span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">We base the scope of our operations and related expenses on our estimates of future revenues. A significant portion of our operating expenses are fixed, and we may not be able to rapidly adjust our expenses if our revenues fall short of our expectations. Our revenue estimates for future periods are based, among other factors, on estimated end-user demand for our products. If end-user consumption is less than estimated, revenues from our distribution partners and other distribution channels would be expected to fall short of expectations, and because such a significant portion of our costs are fixed, could result in operating losses.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">To remain competitive, we must continue to develop, obtain and protect our proprietary technology rights; otherwise, we may lose market share or need to reduce prices as a result of competitors selling technologically superior products that compete with our products, or selling products at lower prices.</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Our ability to compete successfully in the diagnostic market depends on continued development and introduction of new products, technology and the improvement of existing technology. If we cannot continue to improve upon or develop, obtain and protect our technology, our operating results could be adversely affected.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Our competitive position is heavily dependent on obtaining and protecting our own proprietary technology or obtaining licenses from others. Our ability to obtain patents and licenses, and their benefits, is uncertain.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">The Company is required to obtain government or regulatory certification in many countries and the European community to sell its products in those countries or regions.&#160; There is no assurance that the Company will be able to retain its certification in the future. This includes the possibility and risk that the Company&#8217;s products do not meet the new EU IVDR testing and documentation requirements in the future as described in the above &#8220;Research and Development&#8221; section of this document. </span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">Significant government regulation exists in countries in which we conduct business. </span><span style="font-size: 10pt;">A large part of the Company&#8217;s sales is to distributors in Europe, China, and other countries, which require us to maintain certain certifications to sell our products.&#160; <span style="color: black;">Failure to comply with current governmental regulations and quality assurance guidelines could cause the loss of these certifications, which could materially adversely affect the results of the Company.&#160; Loss of certifications could lead to temporary manufacturing shutdowns, product recalls, product shortages or delays in product manufacturing and a decline in sales.</span></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">The Company maintains a manufacturing plant in Mexico which presents risks to the Company including risks associated with doing business outside the United States.</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">The Company has a significant investment in its manufacturing facility in Mexico through its subsidiary, Biomerica de Mexico. In addition, the Company warehouses a significant amount of its inventory at the Mexico facility. </span><span style="FONT-SIZE:10pt; COLOR:black">There are a number of risks associated with doing business in Mexico, including, exposure to local economic and political conditions, social unrest, including risks of terrorism or other hostilities, export and import restrictions, the potential for shortages of trained labor, and the possible effects of currency exchange rate fluctuations.<b><i> </i></b></span><span style="FONT-SIZE:10pt">These risks could lead to additional costs that we cannot foresee at this time and may materially adversely impact our business, results of operations and financial condition.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">14</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><strong><span style="font-size: 10pt;">We use hazardous materials in our research and production that may result in unexpected and substantial claims against us relating to handling, storage, or disposal. </span></strong></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">We use hazardous materials in our research and production. The risk of accidental contamination or injury from these materials cannot be completely eliminated. In the event of such an accident, the Company could be held liable for any harm or damages that result and any such liability could exceed the resources of the Company.&#160; The Company may incur substantial costs to comply with environmental regulations.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">If any governmental authorities were to impose new environmental regulations requiring compliance in addition to that required by existing regulations or alter their interpretation of the requirements of such existing regulations, such environmental and safety regulations could impair our research, development, or production efforts by imposing additional, and possibly substantial, costs, restrictions, or compliance procedures on our business. In addition, because of the nature of the penalties provided for in some of these environmental and safety regulations, we could be required to pay sizable fines, penalties, or damages in the event of noncompliance with regulations and environmental laws. Any environmental or safety violation or remediation requirement could also partially or completely shut down our research and manufacturing facilities and operations, which would have a material adverse effect on our business. The risk of accidental contamination or injury from these hazardous materials cannot be completely eliminated and exposure of individuals to these materials could result in substantial fines, penalties or damages that may not be covered by insurance.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">To remain competitive, we must expend considerable resources to research new technologies and products and develop new markets, and there is no assurance our efforts to develop new technologies, products or markets will be successful or such technologies, products or markets will be commercially viable.</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">We devote a significant amount of financial and other resources to researching and developing new technologies, new products, and new markets. The development, manufacture and sale of diagnostic products require a significant investment of resources. The development of new products and markets also requires a substantial investment of resources, such as new employees, offices and manufacturing facilities, consultants, and clinical trials. No assurances can be given that our efforts to develop new technologies or products will be successful, that such technologies and products will be commercially viable, or our expansion into new markets will be profitable.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">There is also no guarantee that our new products, including our InFoods&#174; IBS products, will get approval and be well accepted into the marketplace.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Our operations will be adversely affected if our operating results do not correspondingly increase with our increased expenditures or if our technology, product, and market development efforts are unsuccessful or delayed. Furthermore, our failure to successfully introduce new technologies or products and develop new markets could have a material adverse effect on our business and prospects.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">We rely on a limited number of key distributors that account for a substantial majority of our total revenue. The loss of any key distributor or an unsuccessful effort by us to directly distribute our products could lead to reduced sales.</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">Our net sales were approximately $18,871,000 for fiscal 2022 compared to $7,199,000 for fiscal 2021. For the fiscal years ended May 31, 2022 and 2021, the Company had two distributors, which accounted for a total of 65% and 60% of our net sales, respectively. Of this, for the fiscal years ended May 31, 2022 and 2021, the largest of the distributors mentioned above accounted for 55% and 33%, respectively, of net sales. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total gross receivables on May 31, 2022 and 2021 were approximately $927,000 and $2,292,000, respectively. As of May 31, 2022 and 2021, the Company had one distributor and two distributors, respectively, which accounted for a total of 50% and 73%, respectively, of gross accounts receivable. Of the 50% as of May 31, 2022, 50% was owed by a distributor in Asia. Adverse changes in our relationships with these distributors and other partners, or adverse developments in their financial condition, performance or purchasing patterns, could adversely affect our business and consolidated financial statements.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">15</span></p> <div style="TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">We extend credit to customers outside the United States which can be difficult to collect.</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">We extend credit to many of our customers including those outside of the United States. It is often difficult to obtain adequate credit information on these customers. Further, our ability to collect receivables from these customers through the court systems in those countries can be more difficult than here in the United States.&#160; Our inability to collect on receivables from customers, in particular those outside of the United States could negatively impact the Company. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">If we are not able to manage our growth strategy our operating results may be adversely affected.</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Our business strategy contemplates further growth, which would likely result in expanding into larger facilities, expanding the scope of operating and financial systems and the geographical area of our operations, including further expansion outside the United States, as new products and technologies are developed and commercialized or new geographical markets are entered. Because we have a small executive staff, acquisitions and other future growth may divert management&#8217;s attention from core aspects of our business and place a strain on existing management and our operational, financial and management information systems. Furthermore, we may expand into markets in which we have less experience or incur higher costs. Any and all of these potential growth and expansion strategies and events could impose material risks and cause the Company to incur adverse operating and financial results.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">Intellectual property risks and third-party claims of infringement, misappropriation of proprietary rights or other claims against us could adversely affect our ability to market our products, require us to redesign our products or attempt to seek licenses from third parties, result in significant costs, and materially adversely affect our operating results. </span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Companies in or related to our industry often aggressively protect and pursue their intellectual property rights. There are often intellectual property risks associated with developing and producing new products and entering new markets, and we may not be able to obtain, at reasonable cost or upon commercially reasonable terms, if at all, licenses to intellectual property of others that is alleged to be part of such new or existing products. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">We have hired and will continue to hire individuals or contractors who have experience in medical diagnostics and these individuals or contractors may have confidential trade secret or proprietary information of third parties. We cannot assure that these individuals or contractors will not use this third-party information in connection with performing services for us or otherwise reveal this third-party information to us. Thus, we could be sued for misappropriation of proprietary information and trade secrets. Such claims are expensive to defend and could divert our attention and result in substantial damage awards and injunctions that could have a material adverse effect on our business, financial condition, or results of operations. In addition, to the extent that individuals or contractors apply technical or scientific information independently developed by them to our projects, disputes may arise as to the proprietary rights to such data and may result in litigation.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">The defense and prosecution of patent and trade secret claims are both costly and time consuming. We or our customers may be sued by other parties that claim that our products have infringed their patents or misappropriated their proprietary rights or that may seek to invalidate one or more of our patents. An adverse determination in any of these types of disputes could prevent us from manufacturing or selling some of our products, limit or restrict the type of work that employees involved with such products may perform for us, increase our costs and expose us to significant liability. In addition, the defense of such claims could result in significant costs and divert the attention of our management and other key employees.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">In addition to the foregoing, we may also be required to indemnify some customers, distributors, and strategic partners under our agreements with such parties if a third party alleges or if a court finds that our products or activities have infringed upon, misappropriated or misused another person&#8217;s proprietary rights. Further, our products may contain technology provided to us by other parties such as contractors, suppliers, or customers. We may have little or no ability to determine in advance whether such technology infringes the intellectual property rights of a third party. Our contractors, suppliers and licensors may not be required or financially able to indemnify us in the event that a claim of infringement is asserted against us, or they may be required to indemnify us only up to a maximum amount, above which we would be responsible for any further costs or damages.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Some of the products that we manufacture, sell or use may be covered by claims in issued patents held by other persons or entities, and as such, upon notice from such persons or entity, we may be required to pay a license fee or may be required to cease all manufacture, sale or use of such products, which could negatively impact our financial results or operations. We cannot guarantee that such claims will not be made in the future. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">16</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">We need to continue to raise additional funds to finance our future capital or operating needs, which could have adverse consequences on our operations and the interests of our stockholders.</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">As a company focused on research and development of new products that do not yet generate revenues, we need to continue to raise funds through public or private debt or sale of equity to achieve our business strategy. When we raise funds or acquire other technologies or businesses through issuance of equity, this dilutes the interests of our stockholders. Moreover, the availability of additional capital, whether debt or equity from private capital sources (including banks) or the public capital markets, fluctuates as our financial condition and industry or market conditions in general change. There may be times when the private capital markets and the public debt or equity markets lack sufficient liquidity or when our securities cannot be sold at attractive prices, in which case we would not be able to access capital from these sources on favorable terms, if at all. We can give no assurance as to the terms or availability of additional capital.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Our inability to raise additional funds to finance our future capital or operating needs could force us to delay, reduce or eliminate our development programs or commercialization efforts.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Costs related to development projects and approvals are hard to estimate due to factors that are unknown to us at this time. These future costs could be much higher than anticipated and current operations are unlikely be able to cover these costs.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of studies and trials may not be predictive of future trial results.</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Clinical trials are expensive, time consuming and difficult to design and implement. Regulatory agencies may analyze or interpret the results differently than we do. Even if the results of our clinical trials are favorable, the clinical trials for a number of our product candidates may take a significant amount of time to complete. Regulatory authorities, including state and local authorities, may suspend, delay or terminate our clinical trials at any time, require us to conduct additional clinical trials, require a particular clinical trial to continue for a longer duration than originally planned, or require a change to our development plans such that we conduct clinical trials for a product candidate in a different order.&#160; </span><span style="FONT-SIZE:10pt">There is no assurance that the results of the clinical trials will be positive.&#160; A negative clinical trial could affect our ability to obtain regulatory clearances and/or potential licensing partners.&#160; There is also no assurance that our clinical trials will not be delayed or will be completed. &#160;<span style="COLOR:black">Any of the foregoing could have a material adverse effect on our business, results of operations and financial condition.</span></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">Our results of operations and financial conditions may be adversely affected by the financial soundness of our customers, distributors and suppliers.</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">If our customers&#8217; or suppliers&#8217; operating and financial performance deteriorates, or if they are unable to make scheduled payments or obtain credit, our customers may not be able to pay, or may delay payment of, accounts receivable owed to us, and our suppliers may restrict credit or impose different payment terms or reduce or terminate production of products they supply to us, or may cease all operations. Any inability of customers to pay us for our products and services, or any demands by suppliers for different payment terms, or inability for such suppliers to continue operations may adversely affect our operating results and financial condition. Additionally, both state and federal government sponsored and private payers, as a result of budget deficits or reductions, may seek to reduce their healthcare expenditures by cutting or eliminating reimbursements for, or cutting purchase of our products. Any reduction in payments by such government sponsored or private payers may adversely affect our earnings and cash flow. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">We may not achieve market acceptance of our new products among healthcare providers and physicians, and this would have a negative effect on future sales.</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">We believe our ability to introduce new products that gain acceptance among consumers, healthcare providers and physicians is an important part of our ability to grow our revenue in future periods. However, any new products we introduce may not gain market acceptance to the extent we anticipate or project. </span><span style="FONT-SIZE:10pt">The acceptance in the medical community for any of our new products is unpredictable at this time. In addition, the Company will need to spend considerable funds in order to introduce new products into the marketplace. Sales, if any, of these products in the future are uncertain.<span style="COLOR:black">&#160; In addition, </span></span><span style="FONT-SIZE:10pt; COLOR:black">our competitors may offer different products and product formats at suggested prices that are lower than our products or whose products are more accurate than our products. We can provide no assurances that consumers and the medical community will purchase our products or that they will not prefer to purchase a competitive product.&#160; </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">17</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">The industry and market segments in which we operate are highly competitive, and intense competition with other providers of diagnostic products may reduce our sales and margins.</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Our diagnostic tests compete with similar products made by our competitors. There are a large number of multinational and regional competitors making investments in competing technologies and products. We also face competition from our distributors as some have created, and others may decide to create their own products to compete with ours. A number of our competitors have a potential competitive advantage because they have substantially greater financial, technical, research and other resources, larger, more established marketing, sales, distribution and service organizations; more established relationships with healthcare professionals; and </span><span style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black">greater experience in conducting research and development, manufacturing, clinical trials, and obtaining regulatory approval for products</span><span style="FONT-SIZE:10pt">. Moreover, some competitors offer broader product lines and have greater name recognition than we have. If our competitors&#8217; products are more effective than ours or take market share from our products through more effective marketing or competitive pricing, our operating results could be materially and adversely affected.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">In addition, there has been a trend toward industry consolidation in our markets over the last few years. We may not be able to compete successfully in an increasingly consolidated industry. We expect this trend toward industry consolidation may continue as companies attempt to strengthen or hold their market positions in an evolving industry and as companies are acquired or are unable to continue operations.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">Our business and products are highly regulated by various governmental agencies. Our results of operations would be negatively affected by failures or delays in the receipt of regulatory approvals or clearances, the loss of previously received approvals or other changes to the existing laws and regulations that adversely impact our ability to manufacture and market our products.</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">The testing, manufacture and sale of our products are subject to regulation by numerous governmental authorities in the United States, principally the FDA and corresponding state and foreign regulatory agencies. Our future performance depends on, among other matters, if, when and at what cost we will receive regulatory approval for new products, and if we can continue to comply with the many regulatory requirements that enable us to manufacture and sell medical related products and tests. Regulatory review can be a lengthy, expensive and uncertain process, making the timing and costs of clearances and approvals difficult to predict. Meeting all regulatory requirements, laws and mandates, and maintaining compliance with such in order to manufacture and sell medical products can be difficult and expensive. Our results of operations would be negatively affected by failures or delays in the receipt of regulatory approvals or clearances, the loss of previously received approvals or clearances, the placement of limits on the marketing and use of our products, and restrictions on our ability to manufacture our products. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">Changes in government policy could adversely affect our business and potential profitability.</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Changes in government policy could have a significant impact on our business by increasing the cost of doing business, affecting our ability to sell our products and negatively impacting our profitability. Such changes could include tariffs, embargos, trade wars or modifications to existing legislation, such as U.S. tax policy, or entirely new legislation, such as the Affordable Healthcare Act in the United States. We cannot predict the many ways that healthcare reform in the United States and internationally, and changing trade legislation and policies could adversely affect our business. It is unclear whether and to what extent, if at all, other anticipated developments, including changes due to new presidential administration priorities, or changes resulting from healthcare reform, such as a change in the number of people with health insurance, may impact us. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">We are subject to numerous government regulations in addition to FDA regulation, and compliance with laws, including changed or new laws, could increase our costs and adversely affect our operations.&#160; There is also the risk that our facilities could fail to get the proper licensing at our next inspection or renewal.</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">In addition to FDA and other regulations referred to above, numerous laws relating to such matters as safe working conditions, manufacturing practices, data privacy, environmental protection, fire hazard control and disposal of hazardous or potentially hazardous substances impact our business operations. If these laws or their interpretation change or new laws regulating any of our businesses are adopted, the costs of compliance with these laws could substantially increase our overall costs. Failure to comply with any laws, including laws regulating the manufacture and marketing of our products, could result in substantial costs and loss of sales or customers. Because of the number and extent of the laws and regulations affecting our industry, and the number of governmental agencies whose actions could affect our operations, it is impossible to reliably predict the full nature and impact of future legislation or regulatory developments relating to our industry and our products. To the extent the costs and procedures associated with meeting new or changing requirements are substantial, our business, results of operations and financial condition could be adversely affected.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">18</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">Our total revenue could be affected by third-party reimbursement policies and potential cost constraints.</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">The end-users of our products are primarily physicians, labs, and other healthcare providers. In the United States, healthcare providers such as hospitals and physicians who purchase diagnostic products generally rely on third-party payers, principally private health insurance plans, federal Medicare, and state Medicaid, to reimburse all or part of the cost of the procedure. Use of our products would be adversely impacted if physicians and other healthcare providers do not receive adequate reimbursement for the cost of our products by their patients&#8217; third-party payers both in the United States and in foreign markets. Our total revenue could also be adversely affected by changes or trends in reimbursement policies of governmental or private healthcare payers. We believe that the overall escalating cost of medical products and services has led to, and will continue to lead to, increased pressures on the healthcare industry, both foreign and domestic, to reduce the cost of products and services. Given the efforts to control and reduce healthcare costs in recent years, currently available levels of reimbursement may not continue to be available in the future for our existing products or products under development. Third-party reimbursement and coverage may not be available or adequate in either the United States or foreign markets, current reimbursement amounts may be decreased in the future and future legislation, regulation or reimbursement policies of third-party payers may reduce the demand for our products or adversely impact our ability to sell our products on a profitable basis.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">Unexpected increases in, or inability to meet, demand for our products could require us to spend considerable resources to meet the demand or harm our reputation and customer relationships if we are unable to meet demand.</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Our inability to meet customer demand for our products, whether as a result of manufacturing problems or supply shortfalls, could harm our customer relationships and impair our reputation within the industry. In addition, our product manufacturing of certain product lines is concentrated in our two manufacturing sites. Weather, natural disasters (including pandemics), fires, terrorism, political change, governmental restrictions or stay-at-home orders in response to natural disasters (including pandemics), failure to follow specific internal protocols and procedures, equipment malfunction, environmental factors or damage to one or more of our facilities could adversely affect our ability to manufacture our products. This, in turn, could have a material adverse effect on our business.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">If we experience unexpected increases in the demand for our products, we may be required to expend additional capital resources or engage third-party manufacturers to meet these demands. These capital resources could involve the cost of new machinery or even the cost of new manufacturing facilities. In addition, engaging third-party manufacturers would increase manufacturing costs and reduce margins. This would increase our capital costs or third-party expenses, which could adversely affect our earnings and cash resources. If we are unable to develop or obtain necessary manufacturing capabilities in a timely manner or to engage third-party manufacturers to meet demand, our total revenue could be adversely affected. Failure to cost-effectively increase production volumes, if required, or lower than anticipated yields or production problems, including those encountered as a result of changes that we may make in our manufacturing processes to meet increased demand or changes in applicable laws and regulations, could result in shipment delays as well as increased manufacturing costs, which could also have a material adverse effect on our business, operating results and financial condition.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Unexpected increases in demand for our products could also require us to obtain additional raw materials in order to manufacture products to meet the demand. Some raw materials require significant ordering lead time and we may not be able to timely access sufficient raw materials in the event of an unexpected increase in demand, particularly those obtained from a sole supplier or a limited group of suppliers.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-INDENT:24pt">&#160;</p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><strong><span style="font-size: 10pt;">If one or more of our products is claimed to be defective or does not meet the performance criteria we claim in our marketing materials we could be subject to product recalls, claims of liability and harm to patients or users of our products, or harm to our reputation that could adversely affect our business.</span></strong></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">A claim of a defect in the design or manufacture of our products could have a material adverse effect on our reputation in the industry and subject us to claims of liability for injuries and otherwise. Further, a claim that one of our products is defective or does not actually meet the performance criteria we claim in our marketing materials, could require a product recall or otherwise have a substantial impact on our revenues and financial performance. Any substantial underinsured loss resulting from such a claim or defect would have a material adverse effect on our operating results and financial conditions and the damage to our reputation or product lines in the industry could have a material adverse effect on our business.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">19</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">We are exposed to business risks which, if not covered by insurance, could have an adverse effect on our results of operations. We face potential product liability exposure, and, if claims brought against us are successful, we could incur substantial liabilities.</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">We face a number of business risks, including exposure to product liability claims, employment law claims, claims that the Company or its officers, directors or employees have engaged in illegal or wrongful acts, claims of violation of environmental laws and many other possible claims. Although we maintain insurance for a number of these risks, we may face claims for types of damages, or for amounts of damages, that are not covered by our insurance. For example, although we currently carry product liability insurance for liability losses, there is a risk that product liability or other claims may exceed the amount of our insurance coverage or may be excluded from coverage under the terms of our policy. Also, our existing insurance may not be renewed at the same cost and level of coverage as currently in effect or may not be renewed at all. Further, we do not currently have insurance against many environmental risks we confront in our business. If we are held liable for a claim against which we are not insured or for damages exceeding the limits of our insurance coverage, whether arising out of product liability matters, cybersecurity matters, or from some other matter, that claim could have a material adverse effect on our results of operations.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">We may rely on third parties to conduct or be part of our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to seek or obtain regulatory approval for or commercialize our product candidates.</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">We rely on third-party contract research organizations (&#8220;CROs&#8221;), universities or/clinical sites (&#8220;Vendors&#8221;), to coordinate, monitor and conduct of our clinical trials and to manage, analyze and interpret data for our clinical programs. We, our Vendors, and our clinical sites are required to comply with current Good Clinical Practices (&#8220;GCPs&#8221;), regulations and guidelines issued by the FDA and by similar governmental authorities in other countries where we are conducting clinical trials. We have an ongoing obligation to monitor the activities conducted by our Vendors and at our clinical sites to confirm compliance with these requirements. In the future, if we, our Vendors or our clinical sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before approving our marketing applications. If our Vendors do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenue could be delayed.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">Failures in our information technology and storage systems could significantly disrupt our business or force us to expend excessive costs.</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">We utilize complex information technology systems&#160;to support our business and store information. We cannot be sure that our systems will meet our future business needs or that necessary upgrades will operate as designed, which could result in excessive costs or disruptions in portions of our business. In particular, any disruptions, delays or deficiencies caused by our enterprise resource planning system could adversely affect our ability to process orders, ship products, provide services and customer support, send invoices and track payments, fulfill contractual obligations or otherwise operate our business. In addition, despite the implementation of security measures, information technology systems are vulnerable to damage from a variety of sources, including computer viruses, unauthorized access, telecommunications or network failures, malicious human acts, terrorism, and natural disasters. Moreover, despite network security and back-up measures, some of our servers are potentially vulnerable to physical or electronic break-ins, computer viruses and similar disruptive problems. Cyber security is a great and growing risk to operating companies. Cyber-attacks may result in loss of vital Company documentation and data, or confidential third-party documents held by the Company, that are necessary for the Company to operate. Despite the precautionary measures we have taken to prevent unanticipated problems that could affect our systems, sustained or repeated system failures that interrupt our ability to generate and maintain data, could result in a material disruption in our operations and material adverse financial costs to the Company. Furthermore, to the extent that any disruption or security breach resulted in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could face a variety of negative consequences, including regulatory actions or litigation, fines or penalties, adverse publicity, increased cybersecurity protection costs, and lost revenue.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">There is a risk that our measures to protect our systems from cyber-attack are not sufficient to avoid attacks by new sources and methods.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">Our business could be negatively affected by the loss of or the inability to hire key personnel.</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Our future success depends in part on our ability to retain our key technical, sales, marketing and executive personnel and our ability to identify and hire additional qualified personnel. Competition for these personnel is intense, both in the industry in which we operate and where our operations are located. Further, we expect to grow our operations, and our needs for additional management and other key personnel are expected to increase. If we are not able to retain existing key personnel, or timely identify and hire replacement or additional qualified personnel to meet expected growth, our business could be adversely impacted. In addition, the loss of any of our key personnel, particularly key research and development personnel, could harm our business and prospects and could impede the achievement of our research and development, operation or strategic objectives.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">20</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">The Company&#8217;s lease obligations and growth expectations could create financial and operating risks.</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Given the recent growth in the Company&#8217;s operations, it is uncertain the current leased facilities will be able to accommodate the Company&#8217;s operations in the future. As such, the Company may need to move to new facilities that would require the Company to seek to sublease its current facilities for the remainder of the lease(s) at a potential discount to the existing monthly lease obligation cost. Alternatively, the Company could be required to move a portion of its operations to a new facility which could be disruptive both short term and long term to the Company&#8217;s operations and create additional fixed costs. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><strong><span style="font-size: 10pt;">We face risks relating to our international sales, including inherent economic, political, and regulatory risks, which could impact our financial performance, cause interruptions in our current business operations and impede our growth strategy. </span></strong></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Our products are primarily sold internationally, with the majority of our international sales to our distributors in Asia, Europe and South America. We currently sell and market our products through distributor organizations and sales agents which creates foreign risks include, among others:</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-INDENT:24pt">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0in 0.25in; TEXT-INDENT:-0.25in"><span style="FONT-SIZE:10pt">&#8226;<span style="FONT:7pt &#34;Times New Roman&#34;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>compliance with multiple different registration requirements and new and changing registration requirements, our inability to benefit from registration for our products inasmuch as registrations may be controlled by a distributor, and the difficulty in transitioning our product registrations;</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0in 0.25in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0in 0.25in; TEXT-INDENT:-0.25in"><span style="FONT-SIZE:10pt">&#8226;<span style="FONT:7pt &#34;Times New Roman&#34;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>compliance with complex foreign and U.S. laws and regulations that apply to our international operations, including U.S. laws such as import/export limitations, the Foreign Corrupt Practices Act, and local laws;</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0in 0.25in; TEXT-INDENT:-0.25in"><span style="FONT-SIZE:10pt">&#8226;<span style="FONT:7pt &#34;Times New Roman&#34;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>tariffs or other barriers as we continue to expand into new countries and geographic regions, especially related to China as tariffs are changing constantly;</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-INDENT:0in"><span style="FONT-SIZE:10pt">&#8226;<span style="FONT:7pt &#34;Times New Roman&#34;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>exposure to currency exchange fluctuations against the U.S. dollar;</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-INDENT:0in"><span style="FONT-SIZE:10pt">&#8226;<span style="FONT:7pt &#34;Times New Roman&#34;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>longer payment cycles, generally lower average selling prices and greater difficulty in accounts receivable collection;</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-INDENT:0in"><span style="FONT-SIZE:10pt">&#8226;<span style="FONT:7pt &#34;Times New Roman&#34;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>lack of ability to enforce receivables collections contracts in foreign legal courts;</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-INDENT:0in"><span style="FONT-SIZE:10pt">&#8226;<span style="FONT:7pt &#34;Times New Roman&#34;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>reduced, or lack of, protection for, and enforcement of, intellectual property rights;</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0in 0.25in; TEXT-INDENT:-0.25in"><span style="FONT-SIZE:10pt">&#8226;<span style="FONT:7pt &#34;Times New Roman&#34;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>political and economic instability in some of the regions where we currently sell our products or that we may expand into in the future;</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-INDENT:0in"><span style="FONT-SIZE:10pt">&#8226;<span style="FONT:7pt &#34;Times New Roman&#34;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>complex and potentially adverse tax consequences; and</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-INDENT:0in"><span style="FONT-SIZE:10pt">&#8226;<span style="FONT:7pt &#34;Times New Roman&#34;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>diversion to the United States of our products sold into international markets at lower prices.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Currently, most of our international sales are negotiated for and paid in U.S. dollars. Nonetheless, these sales are subject to currency risks, since changes in the values of foreign currencies relative to the value of the U.S. dollar can render our products comparatively more expensive. These exchange rate fluctuations could negatively impact international sales of our products, as could changes in the general economic conditions in those markets. In order to maintain a competitive price for our products internationally, we may have to continue to provide discounts or otherwise effectively reduce our prices, resulting in a lower margin on products sold internationally. Continued change in the values of the Euro, the Mexican peso and other foreign currencies could have a negative impact on our business, financial condition and results of operations.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">In addition, we have certain supply agreements with foreign vendors whereby we share the foreign currency exchange fluctuation risk. We may, in the future, enter into similar arrangements.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">Sales of our common stock in the public market could lower the market price for our common stock and adversely impact the trading price of our securities.</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Future sales by the Company of a substantial number of shares of our common stock in the public market, or the perception that such sales may occur, could adversely affect the then prevailing market price of our common stock and could make it more difficult for us to raise funds in the future through a public offering of our securities.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">On July 21, 2020, we filed with the SEC a &#8220;shelf&#8221; registration statement on Form S-3. The registration statement registers common shares that may be issued by the Company in a maximum aggregate amount of up to $90,000,000.&#160; Shares of our common stock may be sold from time to time under this registration statement for up to three years from the filing date. On January 22, 2021, we filed a prospectus supplement for the sale of up to $15,000,000 of shares of our common stock in an at-the-market offering under the shelf registration statement, of which approximately $9,600,000, remains available for sale under the prospectus supplement.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">21</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">The issuance of additional shares of our common stock, or issuances of additional securities, could dilute the ownership interest of our common stockholders and could depress the market price of shares of our common stock and impair our ability to raise capital through the sale of additional equity securities. We cannot predict the size of future issuances or the effect, if any, that they may have on the market price for our common stock.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">We also have a number of stockholders who own large blocks of our common stock. If one or more of these stockholders were to sell large portions of their holdings in a relatively short time, for liquidity or other reasons, the prevailing market price of shares of our common stock could be negatively affected.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">The price of our stock may fluctuate unpredictably in response to factors unrelated to our operating performance.</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in; LINE-HEIGHT:120%">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">The stock market periodically experiences significant price and volume fluctuations that are unrelated to the operating performance of particular companies. These broad market fluctuations may cause the market price of our common stock to drop. In particular, the market price of our common stock has been very volatile and unpredictable and may vary substantially in the future in response to:</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <table cellpadding="0" cellspacing="0" style="WIDTH:750pt; BORDER-COLLAPSE:collapse" width="1000"> <tr style="HEIGHT:14.5pt"> <td style="HEIGHT:14.5pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#8226;</span></p></td> <td style="HEIGHT:14.5pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">announcements by us or our competitors concerning technological innovations;</span></p></td></tr> <tr style="HEIGHT:9.9pt"> <td style="HEIGHT:9.9pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:9.9pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:14.5pt"> <td style="HEIGHT:14.5pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#8226;</span></p></td> <td style="HEIGHT:14.5pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">introductions of new products;</span></p></td></tr> <tr style="HEIGHT:12.6pt"> <td style="HEIGHT:12.6pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:12.6pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:14.5pt"> <td style="HEIGHT:14.5pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#8226;</span></p></td> <td style="HEIGHT:14.5pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">FDA, SEC, Financial Industry Regulation Authority and foreign regulatory actions against the Company;</span></p></td></tr> <tr style="HEIGHT:10.35pt"> <td style="HEIGHT:10.35pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:10.35pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:14.5pt"> <td style="HEIGHT:14.5pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#8226;</span></p></td> <td style="HEIGHT:14.5pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">developments or disputes relating to patents or proprietary rights;</span></p></td></tr> <tr style="HEIGHT:9.9pt"> <td style="HEIGHT:9.9pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:9.9pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:14.5pt"> <td style="HEIGHT:14.5pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#8226;</span></p></td> <td style="HEIGHT:14.5pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">failure to meet the expectations of stock market analysts and investors;</span></p></td></tr> <tr style="HEIGHT:12.6pt"> <td style="HEIGHT:12.6pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:12.6pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:14.5pt"> <td style="HEIGHT:14.5pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#8226;</span></p></td> <td style="HEIGHT:14.5pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">the Company reporting material weakness in our internal control;</span></p></td></tr> <tr style="HEIGHT:12.6pt"> <td style="HEIGHT:12.6pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:12.6pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:14.5pt"> <td style="HEIGHT:14.5pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#8226;</span></p></td> <td style="HEIGHT:14.5pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">changes in stock market analyst recommendations regarding our common stock;</span></p></td></tr> <tr style="HEIGHT:12.6pt"> <td style="HEIGHT:12.6pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:12.6pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:14.5pt"> <td style="HEIGHT:14.5pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#8226;</span></p></td> <td style="HEIGHT:14.5pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">changes in healthcare policy in the United States or other countries; </span></p></td></tr> <tr style="HEIGHT:12.6pt"> <td style="HEIGHT:12.6pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:12.6pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:14.5pt"> <td style="HEIGHT:14.5pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#8226;</span></p></td> <td style="HEIGHT:14.5pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">lawsuits or liability claims from shareholders or other parties;</span></p></td></tr> <tr style="HEIGHT:12.6pt"> <td style="HEIGHT:12.6pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:12.6pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:24.3pt"> <td style="HEIGHT:24.3pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="top"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#8226;</span></p></td> <td style="HEIGHT:24.3pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">legal disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our product candidates, and the results of any proceedings or lawsuits, including patent or shareholder litigation;</span></p></td></tr> <tr style="HEIGHT:11.7pt"> <td style="HEIGHT:11.7pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:11.7pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:14.5pt"> <td style="HEIGHT:14.5pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#8226;</span></p></td> <td style="HEIGHT:14.5pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">sales of our common stock or other securities by us or our stockholders in the future;</span></p></td></tr> <tr style="HEIGHT:12.15pt"> <td style="HEIGHT:12.15pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:12.15pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:14.5pt"> <td style="HEIGHT:14.5pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#8226;</span></p></td> <td style="HEIGHT:14.5pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">trading volume of our common stock;</span></p></td></tr> <tr style="HEIGHT:12.6pt"> <td style="HEIGHT:12.6pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:12.6pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:14.5pt"> <td style="HEIGHT:14.5pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#8226;</span></p></td> <td style="HEIGHT:14.5pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">actual or anticipated variations in quarterly operating results;</span></p></td></tr> <tr style="HEIGHT:12.6pt"> <td style="HEIGHT:12.6pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:12.6pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:14.5pt"> <td style="HEIGHT:14.5pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#8226;</span></p></td> <td style="HEIGHT:14.5pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></p></td></tr> <tr style="HEIGHT:12.6pt"> <td style="HEIGHT:12.6pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:12.6pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:14.5pt"> <td style="HEIGHT:14.5pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#8226;</span></p></td> <td style="HEIGHT:14.5pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">effects of natural or man-made catastrophic events, including widespread public health epidemics like the pandemic related to COVID-19; and</span></p></td></tr> <tr style="HEIGHT:12.6pt"> <td style="HEIGHT:12.6pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:12.6pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:14.5pt"> <td style="HEIGHT:14.5pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#8226;</span></p></td> <td style="HEIGHT:14.5pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">general stock market conditions and other factors unrelated to our operating performance.</span></p></td></tr> <tr style="HEIGHT:12.15pt"> <td style="HEIGHT:12.15pt; WIDTH:5%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 5%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:12.15pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:14.5pt"> <td colspan="2" style="HEIGHT:14.5pt; WIDTH:100%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 100%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Trading of our common stock is not significant, therefore sales of a larger volume of the stock could adversely affect the stock price.</span></p></td></tr></table> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">As of August 26, 2016, our Company's stock has been traded on the Nasdaq Capital Market. Trading of our stock is limited and liquidation of the Company&#8217;s stock may be difficult as there is a limited market for our stock.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in; LINE-HEIGHT:120%"><b><span style="FONT-SIZE:10pt; LINE-HEIGHT:120%">Our ability to use our net operating loss carry forwards in the future may be subject to limitation.</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in; LINE-HEIGHT:120%">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Although we have Federal income tax net operating loss carryforwards of approximately $17,116,000 and California state income tax net operating loss carryforwards of approximately $10,805,000, use of these loss carryforwards will depend on future income in relationship to expirations dates of these carryforwards.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">22</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">We face risks related to our intellectual property including our patents (IP).</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">We rely on IP for the current products we sell and for the new products in research, development and in clinical trials. While the Company tries to protect its IP with confidentiality agreements and internal policies, we still face risks that our IP will be stolen or otherwise misappropriated, by parties inside or outside of the United States.&#160; Further, we have filed over 100 patents around the world on much of the research and development done by the Company, and the proposed products to come from this research. The vast majority of these filed patents are still under review and have not yet been allowed or issued. We may not be able to attain patent claims that adequately protect the company from competitors developing similar products or copying our products.&#160; Finally, there is a great number of issued patents owned by others that pertain to the product categories in which we operate. While we do not know of any patents with claims that we are violating by manufacturing or selling our current products, there is a risk that certain third-party patents will emerge that prohibit us from selling our products or that require us to pay royalty payments. Such third-party claims could have a material negative impact on the Company. Any of these IP related risks could cause material damage to future revenues and to the long-term enterprise values of the Company.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in; LINE-HEIGHT:120%">&#160;</p></div></div><div style="FONT-SIZE:10pt"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ITEM 1B.&#160; UNRESOLVED STAFF COMMENTS</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">None.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ITEM 2.&#160; &#160;PROPERTIES</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <a id="_Hlk79495059"></a><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in 0in 0pt 0in;"><span style="font-size: 10pt;">The Company leases its facilities. On May 31, 2022, the Company had approximately 22,000 square feet of floor space at its corporate headquarters at 17571 Von Karman Avenue in Irvine, California, 92614 which it has been leasing since 2009. The lease for its headquarters expired on August 31, 2016. &#160;The Company had an option to extend the term of its lease for two additional sixty-month periods. On November 30, 2015, the Company exercised its option to extend its lease for an additional sixty-month period and entered into the First Amendment to Lease wherein it extended its lease until August 31, 2021. On April 9, 2021, the Company exercised its second option to extend its lease for an additional five years. &#160;When the Company extended its lease in April 2021, it was also granted an additional five- year lease extension option. The current rent is approximately $25,000 per month and will increase on September 1, 2022, to $26,000 per month.&#160; The security deposit is approximately $22,000.<span style="color: black;">&#160;</span> </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0in"><span style="FONT-SIZE:10pt">In November 2016, the Company&#8217;s Mexican subsidiary, Biomerica de Mexico, entered into a 10-year lease for approximately 8,100 square feet of manufacturing space located in Mexicali, Mexico. The Company has one 10-year option to renew at the end of the initial lease period. The current rent is approximately $3,400 per month. &#160;Biomerica de Mexico also leases a smaller unit on a month-to-month basis for use in one manufacturing process. In addition, the Company leases a small office in Lindau, Germany on a month-to-month basis, as headquarters for BioEurope GmbH, its Germany subsidiary.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ITEM 3.&#160;&#160;&#160;&#160;&#160; LEGAL PROCEEDINGS </span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <a id="_Hlk48056653"></a><a id="_Hlk48148933"></a><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company is, from time to time, involved in legal proceedings, claims and litigation arising in the ordinary course of business. While the amounts claimed may be substantial, the ultimate liability cannot be estimated because of considerable uncertainties that exist. Therefore, it is possible the outcome of such legal proceedings, claims and litigation could have a material negative effect on quarterly or annual operating results or cash flows when resolved in a future period. However, based on facts currently available, management believes such matters will not have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">There were no legal proceedings pending as of May 31, 2022.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ITEM 4.&#160; &#160;&#160;&#160; MINE SAFETY DISCLOSURES</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Not applicable.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">23</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">PART II</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ITEM 5.&#160;&#160;&#160;&#160;&#160; MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">On August 26, 2016, the Company&#8217;s common stock became listed and began trading on the Nasdaq Capital Market stock exchange where it trades under the symbol BMRA. &#160;Previous to that date, the Company&#8217;s stock traded on the OTC Bulletin Board.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <a id="_aciFooter11"></a><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">As of August 29, 2022, the number of holders of record of Biomerica's common stock was approximately 800, excluding stock held in street name. The number of record holders does not bear any relationship to the number of beneficial owners of the common stock as most of the Company&#8217;s common stock is held in street name at securities brokerage firms. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company has not paid any cash dividends on its common stock in the past and does not plan to pay any cash dividends on its common stock in the foreseeable future. The Company's Board of Directors (&#8220;Board&#8221;) intends, for the foreseeable future, to retain any earnings to finance the continued operation and expansion of the Company's business.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">We did not sell any unregistered equity securities during the year ended May 31, 2022.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">We did not purchase any of our shares of common stock or other securities during our fiscal year ended May 31, 2022. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">The table below provides information relating to our equity compensation plans as of May 31, 2022:&#160; </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;<span style="FONT-SIZE:10pt">&#160;</span></p> <div style="text-align: left;"> <table cellpadding="0" cellspacing="0" style="WIDTH:600pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="800"> <tr style="HEIGHT:14.85pt"> <td colspan="6" style="HEIGHT:14.85pt; WIDTH:79.84%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td rowspan="4" style="BORDER-TOP:0px; HEIGHT:14.85pt; BORDER-RIGHT:0px; WIDTH:20.16%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Securities Remaining</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Available for Future Issuance</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Under Compensation Plans</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">(Excluding those Reflected in</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Second Column)</span></p></td></tr> <tr style="HEIGHT:15pt"> <td rowspan="3" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:25.28%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Securities Plan</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Category</span></p></td> <td style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td rowspan="3" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:22.36%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Number of Securities to be</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">&#160;Issued Upon Exercise of </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">&#160;Outstanding Options</span></p></td> <td style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td rowspan="3" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:22.36%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Compensation Plans</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Weighted-Average <br/>Exercise Price of <br/>Outstanding Options</span></p></td> <td style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td rowspan="3" style="HEIGHT:15pt; WIDTH:25.28%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Equity compensation </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160; Plans approved by <br/>&#160; Securities holders </span></p></td> <td style="HEIGHT:15pt; WIDTH:3.28%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:22.36%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:3.28%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:22.36%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:3.28%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:20.16%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:3.28%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15.75pt; WIDTH:22.36%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2,321,616</span></p></td> <td style="HEIGHT:15.75pt; WIDTH:3.28%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="HEIGHT:15.75pt; WIDTH:22.36%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$3.72</span></p></td> <td style="HEIGHT:15.75pt; WIDTH:3.28%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="HEIGHT:15.75pt; WIDTH:20.16%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">102,801</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:3.28%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:22.36%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:3.28%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:22.36%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:3.28%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:20.16%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"></td></tr></table></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ITEM 6.&#160;&#160;&#160;&#160; &#160;RESERVED</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Not required.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ITEM 7.&#160; &#160;&#160;&#160; MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><i><span style="FONT-SIZE:10pt; COLOR:black">You should read the following discussion and analysis in conjunction with our consolidated financial statements and the accompanying notes thereto included in Part II, Item 8 of this Report. This discussion and analysis contains forward-looking statements that are based on our management&#8217;s current beliefs and assumptions, which statements are subject to substantial risks and uncertainties. Our actual results may differ materially from those expressed or implied by these forward-looking statements as a result of many factors, including those discussed in &#8220;Risk Factors&#8221; included in Part I, Item 1A of this Report.&#160;</span></i></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">OVERVIEW</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">Biomerica, Inc. and its subsidiaries (which includes wholly-owned subsidiaries, Biomerica de Mexico and BioEurope GmbH), is</span><span style="font-size: 10pt;"> a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care </span><span style="font-size: 10pt; color: black;">(physicians' offices and over-the-counter through drugstores and online)</span><span style="font-size: 10pt;"> and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases</span><span style="font-size: 10pt; color: black;">. Our diagnostic test kits are used to analyze blood, urine, nasal or fecal material from patients in the diagnosis of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens, or other substances, which may exist in the human body in extremely small concentrations. The</span><span style="font-size: 10pt;"> Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">24</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our primary focus is the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided therapy (&#8220;DGT&#8221;) products to treat gastrointestinal diseases, such as irritable bowel syndrome, and other inflammatory diseases. These products are directed at chronic inflammatory illnesses that are widespread and common, and as such address very large markets. Our InFoods&#174; IBS product uses a simple blood sample and is designed to identify patient-specific foods that, when removed from the diet, may alleviate </span><span style="FONT-SIZE:10pt">Irritable Bowel Syndrome (&#8220;IBS&#8221;)<span style="COLOR:black"> symptoms such as pain, bloating, diarrhea and constipation. Instead of broad and difficult to manage dietary restrictions, the InFoods&#174; IBS product works by identifying a patient&#8217;s above normal immunoreactivity to specific foods.&#160; A food identified as positive, and causing an abnormal immune response in the patient is simply removed from the diet to help alleviate IBS symptoms. </span></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">During fiscal 2022, we completed an endpoint determination clinical trial on our InFoods&#174; IBS product. This trial was conducted at Mayo Clinics in Florida and Arizona, Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, University of Texas Health Science Center at Houston, Houston Methodist, the University of Michigan, and other institutions. This trial monitored IBS patients over an 8-week period to determine the efficacy of our InFoods&#174; IBS product to improve the patients&#8217; IBS symptoms or endpoints. The top-line trial results were reported in February 2022. Multiple endpoints demonstrated statistically significant improvements, indicating that the elimination of specific foods may meaningfully reduce the symptoms of IBS in all patient subtypes (including patients with IBS-Constipation, IBS-Diarrhea &amp; IBS-Mixed). The greatest clinical improvements, including but not limited to abdominal pain and bloating, were seen in patients diagnosed with IBS-Mixed and IBS-Constipation, in the top line data. The purpose of the endpoint study was to determine the primary symptom endpoint, or endpoints to be used in a final pivotal trial that will be conducted to attain the validation data needed to apply for U.S. Food and Drug Administration (&#8220;FDA&#8221;) clearance for the product. We are now in the process of reviewing the complete dataset and selecting the target endpoint(s) to be used in the pivotal trial. We are also writing the protocols for this trial and expect to present these protocols to the FDA during fiscal 2023, with the intention of beginning the trial by the end of fiscal 2023, or May 31, 2023. The trial is expected to include the large medical institution participants that conducted the endpoint trial, in addition to other new institutions and a Clinical Research Organization. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Following the successful completion and positive results from the Company&#8217;s InFoods<sup>&#174;</sup> IBS clinical trial we&#8217;ve seen significant interest from Gastroenterology (GI) physicians who would like to provide the InFoods<sup>&#174;</sup> IBS Product to for their patients immediately.&#160; Therefore, while we are proceeding with the work needed to seek FDA clearance for this product, we also are currently preparing to launch the InFoods<sup>&#174;</sup> IBS product through a CLIA-certified, high-complexity laboratory facility and offering the product as a laboratory developed test (LDT). Our expectation is that we will begin to generate revenues from this product by the end of December 31, 2022. In preparation for the launch of this LDT, we are in negotiations with large physician groups that would like to offer the LDT to their IBS patients.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">We are also beginning the work of selecting and validating at least one new disease (such as ulcerative colitis or migraines), where there is evidence that certain foods can trigger or contribute to the symptoms found in these indications. We expect any new disease we target will follow a similar development pathway as InFoods IBS in simultaneously seeking FDA clearance of the product while also launching the product as an LDT.</span> </p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">We will also continue to evaluate partnership/licensing opportunities, as they arise, with </span><span style="FONT-SIZE:10pt">U.S and multinational companies that could help us commercialize, or accelerate revenue growth of, the InFoods products in the United States and overseas.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">Our existing medical diagnostic products are sold worldwide primarily in two markets: 1) clinical laboratories and 2) point-of-care (physicians' offices and over-the-counter drugstores like Walmart and Walgreens). The diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens, or other substances, which may exist in a patient&#8217;s body, stools, or blood, often in extremely small concentrations.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">During fiscal 2022, we finalized development of our H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. H. Pylori infection is extremely common, and if left untreated, can lead to ulcers and possibly stomach cancers. During our fourth quarter of fiscal 2022, we applied for FDA clearance of this product though a 510(k) premarket submission. We have been in communications with the FDA answering certain follow-up questions and providing additional data as requested. We are currently awaiting FDA clearance of the product. Once cleared, we will begin marketing the product in the U.S. market.&#160; </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Following fiscal year-end, we announced that Walmart has begun selling our Aware<sup>&#174;</sup> Breast Self Exam product through their on-line retailing platform, Walmart.com. We are also in final discussions with Walmart to offer this product in their U.S. based retail stores. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">25</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">We have added new employees in our sales and marketing department in order to increase sales of existing products <span style="COLOR:black">during fiscal 2022. Through</span> these efforts, our EZ Detect colon disease home screening test and our <span style="COLOR:black">Aware<sup>&#174;</sup> Breast Self Exam product </span>are seeing an increased interest from retailers such as Walmart, distributors, and screening programs in other countries</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Due to the global 2019 SARS-CoV-2 novel coronavirus pandemic<span style="COLOR:black">, in March 2020 we</span> began developing COVID-19 products to indicate if a person has been infected by COVID-19 or is currently infected. While we offer a COVID-19 antibody diagnostic test to determine if a person has previously been infected by the COVID-19 virus, all our COVID-19 revenues <span style="COLOR:black">in fiscal 2022</span> have come from international sales of our COVID-19 antigen tests that use a patient&#8217;s nasal fluid sample to detect if the patient is currently infected with the virus.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">While sales continue to occur in our COVID-19 products, </span><span style="FONT-SIZE:10pt">the majority of our research and development efforts are focused on development and commercialization of non-COVID related products such as our H. Pylori product, and our InFoods&#174; IBS product. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The other existing products that contributed to our fiscal 2022 revenues are primarily focused on gastrointestinal diseases, food intolerances, and certain esoteric tests. These diagnostic test products utilize immunoassay technology. Most of our products are CE marked and/or sold for diagnostic use where they are registered by each country&#8217;s regulatory agency. In addition, some products are cleared for sale in the United States by the FDA.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">RESULTS OF OPERATIONS</span></b></p><br/> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><i><span style="FONT-SIZE:10pt; COLOR:black">Net Sales and Cost of Sales</span></i></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black">The following is a breakdown of revenues according to markets to which the products are sold:</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <div style="text-align: left;"> <table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:46%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 46%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td colspan="5" rowspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:26%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 26%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Twelve Months Ended</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">May 31,</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:46%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 46%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:26%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 26%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Increase (Decrease)</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:46%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 46%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2022</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2021</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td colspan="2" style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">%</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:46%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 46%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Physician's office</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">14,259,000 </span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$ </span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">2,801,000 </span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$ </span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">11,458,000 </span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;&#160;</span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">409%</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:46%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 46%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Clinical lab</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">3,064,000 </span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">3,077,000 </span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(13,000)</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">0%</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:46%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 46%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Over-the-counter</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,089,000 </span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">766,000 </span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">323,000 </span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">42%</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:46%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 46%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Contract manufacturing</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">459,000 </span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">555,000 </span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(96,000)</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-17%</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:46%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 46%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">18,871,000 </span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$ </span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">7,199,000 </span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$ </span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">11,672,000 </span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;&#160;</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">162%</span></b></p></td></tr></table></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <a id="_Hlk49411916"></a><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our net sales were approximately $18,871,000 for fiscal 2022 compared to $7,199,000 for fiscal 2021, an increase of $11,672,000, or 162%.&#160;This increase in annual sales is primarily attributable to sales of COVID-19 tests. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our cost of sales were approximately $15,894,000 for fiscal 2022 compared to $6,833,000 for fiscal 2021, an increase of $9,061,000, or 133%. This increase was driven by the cost of additional COVID-19 sales. The percentage of cost of sales in fiscal 2022 was 84%, versus 95% in fiscal 2021. In fiscal 2021, we recorded a non-recurring inventory allowance, this increased our cost of sales to 95%.&#160; We don&#8217;t expect to record a significant inventory allowance in future years. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in"><i><span style="FONT-SIZE:10pt; COLOR:black">Operating Expenses</span></i></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The following is a summary of operating expenses:</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <div style="text-align: left;"> <table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:33.58%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td colspan="9" rowspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:47.08%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Twelve Months Ended</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">May 31, </span></p></td> <td style="HEIGHT:15pt; WIDTH:0.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.38%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:7.96%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:8.16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:33.58%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:0.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">&#160; </td> <td style="HEIGHT:15pt; WIDTH:1.38%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:7.96%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:8.16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:33.58%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td colspan="4" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:23.2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2022 </span></p></td> <td style="HEIGHT:15pt; WIDTH:0.66%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><b><span style="FONT-SIZE:10pt; COLOR:black">&#160; </span></b></p></td> <td colspan="4" style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:23.2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2021</span></p></td> <td style="HEIGHT:15pt; WIDTH:0.66%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td colspan="4" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:18.68%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Increase (Decrease)</span></p></td></tr> <tr style="HEIGHT:26.25pt"> <td style="HEIGHT:26.25pt; WIDTH:33.58%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:26.25pt; BORDER-RIGHT:0px; WIDTH:13.88%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Operating Expense&#160; </span></p></td> <td style="HEIGHT:26.25pt; WIDTH:0.66%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:26.25pt; BORDER-RIGHT:0px; WIDTH:8.66%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">As a % of Total Revenues</span></p></td> <td style="HEIGHT:26.25pt; WIDTH:0.66%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:26.25pt; BORDER-RIGHT:0px; WIDTH:13.88%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Operating Expense&#160; </span></p></td> <td style="HEIGHT:26.25pt; WIDTH:0.66%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:26.25pt; BORDER-RIGHT:0px; WIDTH:8.66%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">As a % of Total Revenues</span></p></td> <td style="HEIGHT:26.25pt; WIDTH:0.66%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:26.25pt; BORDER-RIGHT:0px; WIDTH:9.34%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:26.25pt; WIDTH:1.2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:26.25pt; BORDER-RIGHT:0px; WIDTH:8.16%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">%</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:33.58%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Selling, General and Administrative Expenses&#160; </span></p></td> <td style="HEIGHT:15pt; WIDTH:2.32%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.56%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">5,699,000 </span></p></td> <td style="HEIGHT:15pt; WIDTH:0.66%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:8.66%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">30%</span></p></td> <td style="HEIGHT:15pt; WIDTH:0.66%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2.32%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160; $ </span></p></td> <td style="HEIGHT:15pt; WIDTH:11.56%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">5,672,000 </span></p></td> <td style="HEIGHT:15pt; WIDTH:0.66%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:8.66%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">79%</span></p></td> <td style="HEIGHT:15pt; WIDTH:0.66%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.38%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="HEIGHT:15pt; WIDTH:7.96%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">27,000 </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:8.16%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">0%</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:33.58%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Research and Development</span></p></td> <td style="HEIGHT:15pt; WIDTH:2.32%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.56%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,812,000 </span></p></td> <td style="HEIGHT:15pt; WIDTH:0.66%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:8.66%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">10%</span></p></td> <td style="HEIGHT:15pt; WIDTH:0.66%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2.32%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160; $ </span></p></td> <td style="HEIGHT:15pt; WIDTH:11.56%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">2,194,000 </span></p></td> <td style="HEIGHT:15pt; WIDTH:0.66%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:8.66%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">30%</span></p></td> <td style="HEIGHT:15pt; WIDTH:0.66%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.38%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="HEIGHT:15pt; WIDTH:7.96%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(382,000)</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:8.16%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-17%</span></p></td></tr></table></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">26</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><i><span style="FONT-SIZE:10pt; COLOR:black">Selling, General and Administrative Expenses</span></i></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our selling, general and administrative expenses were approximately $5,699,000 for fiscal 2022 compared to $5,672,000 for fiscal 2021, an increase of $27,000, or 0%.&#160;The increase was due to an approximate increase of $400,000 in wages, $300,000 in consulting fees, and $200,000 in amortization. Which was primarily offset by a decrease of $800,000 in bad debt expense related to a specific customer charge in the fiscal 2021. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><i><span style="FONT-SIZE:10pt; COLOR:black">Research and Development</span></i></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our research and development expenses were approximately $1,812,000 for fiscal 2022 compared to $2,194,000 for fiscal 2021, a decrease of $382,000, or 17%, primarily as a result of decreases in costs related to the research, development and validation of COVID-19, IBS and H. Pylori. See &#8220;Research and Development&#8221; for a more extensive description of the research being conducted. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><i><span style="FONT-SIZE:10pt; COLOR:black">Interest and Dividend Income</span></i></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <a id="_Hlk100307789"></a><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">Interest expense decreased in fiscal 2022 to $0, as compared to $367 in fiscal 2021. Interest and dividend income for those same years decreased to approximately $27,000 from $67,000, respectively. The $40,000 decrease was due to lower dividend payment from our investment.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">LIQUIDITY AND CAPITAL RESOURCES</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black">The following are the principal sources of liquidity:</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <div style="page:WordSection1"> <div style="text-align: center;">  <table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733">

<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.14%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td colspan="5" style="border-top: 0px; height: 15pt; border-right: 0px; width: 29.86%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">May 31,</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.14%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 14.04%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">2022</span></p>
</td>
<td style="border-top: windowtext 1pt solid; height: 15pt; border-right: 0px; width: 1.8%; background: white; border-bottom: 0px; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td colspan="2" style="border-top: windowtext 1pt solid; height: 15pt; border-right: 0px; width: 14.02%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">2021</span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 70.14%; background: #b4c6e7; text-align: left; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Cash and cash equivalents</span></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12.04%; background: #b4c6e7; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">5,917,000 </span></p>
</td>
<td style="height: 15.75pt; width: 1.8%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$ </span></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12.02%; background: #b4c6e7; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">4,199,000 </span></p>
</td>
</tr>
<tr style="height: 16.5pt;">
<td style="height: 16.5pt; width: 70.14%; background: white; text-align: left; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Working capital including cash and cash equivalents</span></p>
</td>
<td style="border-top: 0px; height: 16.5pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 16.5pt; border-right: 0px; width: 12.04%; background: white; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">7,416,000 </span></p>
</td>
<td style="height: 16.5pt; width: 1.8%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 16.5pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$ </span></p>
</td>
<td style="border-top: 0px; height: 16.5pt; border-right: 0px; width: 12.02%; background: white; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">7,931,000 </span></p>
</td>
</tr>

</table></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">As of May 31, 2022 and 2021, the Company had cash and cash equivalents of approximately $5,917,000 and $4,199,000, respectively. &#160;As of May 31, 2022 and 2021, the Company had working capital of approximately $7,416,000 and $7,931,000, respectively. We believe that the aggregate of our existing cash and cash equivalents is sufficient to meet our operating cash requirements and strategic objectives for growth for at least the next year. To satisfy our capital requirements, including ongoing future operations, we may seek to raise additional financing through debt and equity financings.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><i><span style="FONT-SIZE:10pt; COLOR:black">Operating Activities</span></i></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <a id="_Hlk100847884"></a><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">During fiscal 2022, cash used in operating activities were approximately $486,000, as compared to $5,252,000 for fiscal 2021. The primary factors that contributed to this was a loss of approximately $4,531,000, a decrease in inventory reserves of $772,000, and a decrease in the allowance on accounts receivable of $684,000. These were partially offset by a decrease in accounts receivable of $1,365,000, a decrease in inventories of $1,562,000, an increase in accounts payable and accrued expenses of $389,000, and non-cash expenses of approximately $1,855,000.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">During fiscal 2021, the Company had a net loss of approximately $7,446,000, an increase in accounts receivable of $456,000, an increase in inventories of $1,906,000, and an increase in prepaid expenses of $1,139,000. These were offset by an increase in accrued compensation of approximately $110,000, a non-cash stock option expense of $1,355,000 and depreciation and amortization of $138,000.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><i><span style="FONT-SIZE:10pt; COLOR:black">Investing Activities</span></i></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">During fiscal 2022, cash used in investing activities were approximately $170,000, as compared to $296,000 for fiscal 2021. During fiscal 2022, the Company purchased approximately $57,000 of property and equipment and had $113,000 in expenditures related to patents. During fiscal 2021, the Company purchased approximately $136,000 of property and equipment and $160,000 in expenditures related to patents. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">27</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><i><span style="FONT-SIZE:10pt; COLOR:black">Financing Activities</span></i></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <a id="_Hlk79675490"></a><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Cash provided by financing activities for fiscal 2022 were approximately $2,395,000 as compared to $1,114,000 for fiscal 2021.&#160; In fiscal 2022 and 2021, the Company had proceeds from the exercise of stock options of approximately $77,000 and $102,000, respectively. During fiscal 2022 and 2021, the Company received approximately $2,317,000 and $1,011,000, respectively, in net proceeds from the sale of common stock. The common stock sold and issued in fiscal 2021 and 2022 was issued under the S-3 &#8220;shelf&#8221; Registration Statement base prospectus filed with the SEC on July 21, 2020 (the &#8220;2020 Shelf Registration Statement&#8221;) and declared effective by the SEC on September 30, 2020, and under the prospectus supplement filed with the SEC on January 22, 2021 (&#8220;2021 Prospectus Supplement&#8221;) (See Shareholders&#8217; Equity and Subsequent Events in the notes to the consolidated financial statements for further details about SEC registrations).</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">The 2020 Shelf Registration Statement registers common shares that may be issued by the Company in a maximum aggregate amount of up to $90,000,000.&#160; On January 22, 2021, we filed the 2021 Prospectus Supplement for the sale of up to $15,000,000 of shares of our common stock in an at-the-market offering under the 2020 Shelf Registration Statement, of which $9,609,945 remains available for sale under the 2021 Prospectus Supplement. </span><span style="font-size: 10pt;">As of August 29, 2022, the date on which this Annual Report on Form 10-K for the fiscal year ended May 31, 2022, is filed with the SEC, our 2020 Registration Statement remains subject to the offering limits set forth in General Instruction I.B.6 of Form S-3 because our public float is less than $75 million.&#160; For so long as the Company's public float is less than $75 million, the aggregate market value of securities sold by the Company under the 2020 Shelf Registration Statement pursuant to Instruction I.B.6 to Form S-3 during any 12 consecutive months may not exceed one-third of the Company&#8217;s public float.&#160; We have sold $3,374,328 of our common stock pursuant to General Instruction I.B.6 of Form S-3 in the 12 calendar months preceding the date of filing this Annual Report on Form 10-K. For purposes of this limitation, the aggregate market value of our outstanding common stock held by non-affiliates, or public float, was $39,995,179, based on 12,193,652 shares of our outstanding common stock held by non-affiliates and a price of $3.28 per share, which was the price at which our common stock was last sold on The Nasdaq Capital Market on August 22, 2022 (a date within 60 days of the date hereof), calculated in accordance with General Instruction I.B.6 of Form S-3. After giving effect to the $13,331,726 offering limit imposed by General Instruction I.B.6 of Form S-3, and after deducting the shares we sold within the preceding 12 months, as of the date of filing this Annual Report, we may offer and sell from time to time up &#160;to $9,609,945 under the 2021 Prospectus Supplement. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">The Company intends to use the net proceeds from these offerings for general corporate purposes, including, without limitation, sales and marketing activities, clinical studies, and product development, making acquisitions of assets, businesses, companies or securities, capital expenditures, and for working capital needs.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">SUBSEQUENT EVENTS</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Subsequent to May 31, 2022, the Company sold 523,977 shares of its common stock under its S-3 &#8220;shelf&#8221; Registration statement.&#160; The average sale price was $3.46 per share. Net proceeds to the Company were approximately $1,765,000.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">On July 14, 2022, the Company announced they had entered into a General Merchandise Supplier Agreement with Walmart, for the Company&#8217;s Aware<sup>&#174;</sup> Breast Self Exam product to be sold in Walmart&#8217;s retail system.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">OFF BALANCE SHEET ITEMS </span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">There were no off-balance sheet arrangements as of May 31, 2022.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">CRITICAL ACCOUNTING POLICIES</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make a number of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Such estimates and assumptions affect the reported amounts of revenues and expenses during the reporting period. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements. On an ongoing basis, we evaluate estimates and assumptions based upon historical experience and various other factors and circumstances. We believe our estimates and assumptions are reasonable under the current conditions; however, actual results may differ from these estimates under different future conditions.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">28</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">We believe that the estimates and assumptions that are most important to the portrayal of our financial condition and results of operations, in that they require subjective or complex judgments, form the basis for the accounting policies deemed to be most critical to us. These relate to revenue recognition, bad debts, inventory overhead application, inventory reserve, lease liabilities and right-of-use assets. We believe estimates and assumptions related to these critical accounting policies are appropriate under the circumstances; however, should future events or occurrences result in unanticipated consequences, there could be a material impact on our future financial conditions or results of operations. We suggest that our significant accounting policies be read in conjunction with this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. Please refer to Note 2 for information on Significant Accounting Policies.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">REVENUE RECOGNITION</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">The Company has various contracts with customers.&#160; All the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred, and at which point title passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company regularly evaluates the status of these contracts and does not believe that any discounts will be given through the end of the contract periods. </span><span style="font-size: 10pt;">Services for some contract work are invoiced and recognized for work that has been performed as the project progresses. <span style="color: black;">The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools, and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors.&#160; Physicians&#8217; office products are sold to physicians and distributors, all of whom are categorized below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international manufacturers. </span></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">SHARE-BASED COMPENSATION</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company follows the guidance of ASC 718, Share-based Compensation (&#8220;ASC 718&#8221;), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes options-pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the foreseeable future. Expected volatilities are based on weighted averages of the historical volatility of the Company&#8217;s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the &#8220;simplified method&#8221; which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited exercise activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. The grant date fair value of the award is recognized under the straight-line attribution method.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">RECENT ACCOUNTING PRONOUNCEMENTS</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">See Note 2 to our consolidated&#160;financial statements for a listing of adopted and soon to be adopted accounting pronouncements.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">RECLASSIFICATIONS</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Certain comparative figures in the 2021 Statement of Operations have been reclassified to conform to the current year&#8217;s presentation. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ITEM 7A.&#160;&#160; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Not required.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ITEM 8.&#160;&#160;&#160;&#160;&#160; FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Exhibit 99.3, "Biomerica, Inc. and Subsidiaries Consolidated Financial Statements" is incorporated herein by this reference.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ITEM 9.&#160;&#160;&#160;&#160;&#160; CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">For year ended May 31,2022 the Company changed its auditor to Haskell &amp; White LLP. The Company&#8217;s previous auditor was PKF San Diego, LLP (&#8220;PKF&#8221;), there were no disagreements between the Company and PKF.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">29</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ITEM 9A.&#160;&#160; CONTROLS AND PROCEDURES</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Attached as exhibits to this Form 10-K are certifications of our Chief Executive Officer (&#8220;CEO&#8221;) and Chief Financial Officer (&#8220;CFO&#8221;) that are required in accordance with Rule 13a-14 of the Exchange Act. This &#8220;Disclosure Controls and Procedures&#8221; section includes information concerning the controls and controls evaluation referred to in the certifications.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">EVALUATION OF DISCLOSURE CONTROLS</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">Our management evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act as of the end of the period covered by this report. &#160;Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. The disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives and the CEO and CFO have concluded that our disclosure controls and procedures are effective at the &#8220;reasonable assurance&#8221; level. Based on that evaluation the CEO and CFO concluded that information required to be disclosed in the reports that we file and submit under the Exchange Act is (1) recorded, processed, summarized, and reported within the time periods specified in the Commission&#8217;s rules and forms; and (2) accumulated and communicated to the Company&#8217;s management, including its CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Company management, including the CEO and CFO concluded that, as of May 31, 2022, the Company's internal control over financial reporting was effective. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">There have been no changes in our internal control over financial reporting identified in connection with the evaluation that occurred during the quarter ended May 31, 2022, that have materially affected, or that are reasonably likely to affect, our internal control over financial reporting.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">MANAGEMENT'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Company management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934. The Company's internal control over financial reporting is designed to provide reasonable assurance to the Company's management and Board of Directors regarding the reliability of financial reporting and the preparation and fair presentation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">A Company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the consolidated financial statements.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">The effectiveness of any system of internal control over financial reporting is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures. Because of these inherent limitations, internal control over financial reporting cannot provide absolute assurance regarding the reliability of financial reporting and may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Company management, with the participation of the CEO and the CFO, evaluated the effectiveness of the Company's disclosure controls and procedures as defined in Rules 13(a)-15(e) and 15(d)-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of the end of the period covered by this report. In making this assessment, Management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) in Internal Control - Integrated Framework (2013). Based on this assessment, management, with the participation of the CEO and CFO, believes that, as of May 31, 2022, the Company's internal control over financial reporting was effective based on those criteria.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">30</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Company management will continue to monitor and evaluate the effectiveness of its disclosure controls and procedures and its internal controls over financial reporting on an ongoing basis and are committed to taking further action and implementing improvements, as necessary and as funds allow.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Note: This 10-K does not include an attestation report of the Company's independent registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by the Company's independent registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit the Company to provide only management's report in this 10-K.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ITEM 9B.&#160;&#160; OTHER INFORMATION.</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">None.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">PART III</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ITEM 10.&#160;&#160;&#160; DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</span></b><span style="FONT-SIZE:10pt; COLOR:black">.&#160;</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">This information is incorporated by reference to the Company's proxy statement for its 2022 Annual Meeting of Stockholders, which will be filed not later than 120 days after the end of the Company's fiscal year ended May 31, 2022.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ITEM 11.&#160;&#160; &#160;EXECUTIVE COMPENSATION</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">This information is incorporated by reference to the Company's proxy statement for its 2022 Annual Meeting of Stockholders, which will be filed not later than 120 days after the end of the Company's fiscal year ended May 31, 2022.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ITEM 12.&#160;&#160;&#160; SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">This information is incorporated by reference to the Company's proxy statement for its 2022 Annual Meeting of Stockholders, which will be filed not later than 120 days after the end of the Company's fiscal year ended May 31, 2022.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ITEM 13.&#160;&#160; CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Other information regarding related transactions is incorporated by reference to the Company's proxy statement for its 2022 Annual Meeting of Stockholders, which will be filed not later than 120 days after the end of the Company's fiscal year ended May 31, 2022.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ITEM 14.&#160;&#160; PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Please refer to the Company&#8217;s proxy statement for its 2022 Annual Meeting of Stockholders, which will be filed not later than 120 days after the end of the Company&#8217;s fiscal year ended May 31, 2022.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">PART IV</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse;" width="733">

<tr style="height: 14.5pt;">
<td colspan="3" style="height: 14.5pt; width: 100%; padding: 0in; white-space: nowrap; width: 100%;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-family: times new roman, times, serif;"><strong><span style="font-size: 10pt; color: black;">ITEM 15. EXHIBITS LIST AND FINANCIAL SCHEDULES</span></strong></span></p>
</td>
</tr>
<tr style="height: 14.5pt;">
<td style="height: 14.5pt; width: 8.36%; padding: 0in 5.4pt 0in 5.4pt; white-space: nowrap;" valign="bottom">&#160;</td>
<td style="height: 14.5pt; width: 3.9%; padding: 0in 5.4pt 0in 5.4pt; white-space: nowrap;" valign="bottom">&#160;</td>
<td style="height: 14.5pt; width: 87.72%; padding: 0in 5.4pt 0in 5.4pt; white-space: nowrap;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 14.5pt;">
<td colspan="3" style="height: 14.5pt; width: 100%; padding: 0in 5.4pt 0in 5.4pt; white-space: nowrap; width: 100%;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: times new roman, times, serif; color: black;">The following documents are filed as part of this Annual Report on Form&#160;10-K: </span></p>
</td>
</tr>
<tr style="height: 14.5pt;">
<td style="height: 14.5pt; width: 8.36%; padding: 0in 2.9pt 0in 2.9pt; white-space: nowrap;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal; text-align: right;"><span style="font-size: 10pt; font-family: times new roman, times, serif; color: black;">1.</span></p>
</td>
<td colspan="2" style="height: 14.5pt; width: 91.64%; padding: 0in; white-space: nowrap;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-family: times new roman, times, serif;"><em><span style="font-size: 10pt; color: black;">Consolidated Financial Statements</span></em></span></p>
</td>
</tr>
<tr style="height: 14.5pt;">
<td style="height: 14.5pt; width: 8.36%; padding: 0in 5.4pt 0in 5.4pt; white-space: nowrap;" valign="bottom">&#160;</td>
<td style="height: 14.5pt; width: 3.9%; padding: 0in 5.4pt 0in 5.4pt; white-space: nowrap;" valign="bottom">&#160;</td>
<td style="height: 14.5pt; width: 87.72%; padding: 0in 5.4pt 0in 5.4pt; white-space: nowrap;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: times new roman, times, serif; color: black;">Reference is made to the Index to the consolidated financial statements as set forth on page&#160;FS-1 of this Annual </span></p>
</td>
</tr>
<tr style="height: 14.5pt;">
<td style="height: 14.5pt; width: 8.36%; padding: 0in 5.4pt 0in 5.4pt; white-space: nowrap;" valign="bottom">&#160;</td>
<td style="height: 14.5pt; width: 3.9%; padding: 0in 5.4pt 0in 5.4pt; white-space: nowrap;" valign="bottom">&#160;</td>
<td style="height: 14.5pt; width: 87.72%; padding: 0in 5.4pt 0in 5.4pt; white-space: nowrap;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: times new roman, times, serif; color: black;">Report on Form 10-K. </span></p>
</td>
</tr>
<tr style="height: 9pt;">
<td style="height: 9pt; width: 8.36%; padding: 0in 5.4pt 0in 5.4pt; white-space: nowrap;" valign="bottom">&#160;</td>
<td style="height: 9pt; width: 3.9%; padding: 0in 5.4pt 0in 5.4pt; white-space: nowrap;" valign="bottom">&#160;</td>
<td style="height: 9pt; width: 87.72%; padding: 0in 5.4pt 0in 5.4pt; white-space: nowrap;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 14.5pt;">
<td style="height: 14.5pt; width: 8.36%; padding: 0in 2.9pt 0in 2.9pt; white-space: nowrap;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal; text-align: right;"><span style="font-size: 10pt; font-family: times new roman, times, serif; color: black;">2.</span></p>
</td>
<td colspan="2" style="height: 14.5pt; width: 91.64%; padding: 0in; white-space: nowrap;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-family: times new roman, times, serif;"><em><span style="font-size: 10pt; color: black;">Consolidated Financial Statement Schedules</span></em></span></p>
</td>
</tr>
<tr style="height: 14.5pt;">
<td style="height: 14.5pt; width: 8.36%; padding: 0in 5.4pt 0in 5.4pt; white-space: nowrap;" valign="bottom">&#160;</td>
<td style="height: 14.5pt; width: 3.9%; padding: 0in 5.4pt 0in 5.4pt; white-space: nowrap;" valign="bottom">&#160;</td>
<td style="height: 14.5pt; width: 87.72%; padding: 0in 5.4pt 0in 5.4pt; white-space: nowrap;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: times new roman, times, serif; color: black;">All schedules have been omitted as the pertinent information is either not required, not applicable, or otherwise</span></p>
</td>
</tr>
<tr style="height: 14.5pt;">
<td style="height: 14.5pt; width: 8.36%; padding: 0in 5.4pt 0in 5.4pt; white-space: nowrap;" valign="bottom">&#160;</td>
<td style="height: 14.5pt; width: 3.9%; padding: 0in 5.4pt 0in 5.4pt; white-space: nowrap;" valign="bottom">&#160;</td>
<td style="height: 14.5pt; width: 87.72%; padding: 0in 5.4pt 0in 5.4pt; white-space: nowrap;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: times new roman, times, serif; color: black;">included in the financial statements and notes thereto. </span></p>
</td>
</tr>
<tr style="height: 14.5pt;">
<td style="height: 14.5pt; width: 8.36%; padding: 0in 2.9pt 0in 2.9pt; white-space: nowrap;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal; text-align: right;"><span style="font-size: 10pt; font-family: times new roman, times, serif; color: black;">3.</span></p>
</td>
<td colspan="2" style="height: 14.5pt; width: 91.64%; padding: 0in; white-space: nowrap;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-family: times new roman, times, serif;"><em><span style="font-size: 10pt; color: black;">Exhibits</span></em></span></p>
</td>
</tr>
<tr style="height: 14.5pt;">
<td style="height: 14.5pt; width: 8.36%; padding: 0in 5.4pt 0in 5.4pt; white-space: nowrap;" valign="bottom">&#160;</td>
<td style="height: 14.5pt; width: 3.9%; padding: 0in 5.4pt 0in 5.4pt; white-space: nowrap;" valign="bottom">&#160;</td>
<td style="height: 14.5pt; width: 87.72%; padding: 0in 5.4pt 0in 5.4pt; white-space: nowrap;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: times new roman, times, serif; color: black;">See below.</span></p>
</td>
</tr>

</table>
<p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">31</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p>
<table cellpadding="0" cellspacing="0" style="width: 7.5in; height: 535px;" width="720">

<tr style="height: 20px;">
<td colspan="3" style="width: 716.2px; padding: 0in; height: 20px;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td colspan="2" style="height: 15px; width: 73.6333px; padding: 0in;">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Exhibit No.</span></p>
</td>
<td style="height: 15px; width: 640.667px; padding: 0in;">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Description</span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td colspan="2" style="height: 15px; width: 73.6333px; padding: 0in;">&#160;</td>
<td style="height: 15px; width: 640.667px; padding: 0in;">&#160;</td>
</tr>
<tr style="height: 0.35in;">
<td colspan="2" style="height: 0px; width: 73.6333px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">3.1</span></p>
</td>
<td style="height: 0px; width: 640.667px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in; text-align: justify;"><span style="font-size: 10pt; color: black;">First Amended and Restated Certificate of Incorporation of Registrant filed with the Secretary of State of Delaware on August 1, 2000 (incorporated by reference to Exhibit 3.8 filed with the Registrant's Annual Report on Form 10-KSB for the fiscal year ended May 31, 2000).</span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td colspan="2" style="height: 15px; width: 73.6333px; padding: 0in;" valign="top">&#160;</td>
<td style="height: 15px; width: 640.667px; padding: 0in;" valign="top">&#160;</td>
</tr>
<tr style="height: 15pt;">
<td colspan="2" style="height: 15px; width: 73.6333px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in; text-align: justify;"><span style="font-size: 10pt; color: black;">3.2</span></p>
</td>
<td style="height: 15px; width: 640.667px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in; text-align: justify;"><span style="font-size: 10pt; color: black;">Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 filed with Amendment No. 1 to Registration Statement on Form S-1, Commission File No. 2-83308).</span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td colspan="2" style="height: 15px; width: 73.6333px; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in; text-align: justify;">&#160;</p>
</td>
<td style="height: 15px; width: 640.667px; padding: 0in;" valign="top">&#160;</td>
</tr>
<tr style="height: 25.5pt;">
<td colspan="2" style="height: 25px; width: 73.6333px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in; text-align: justify;"><span style="font-size: 10pt; color: black;">4.1</span></p>
</td>
<td style="height: 25px; width: 640.667px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in; text-align: justify;"><span style="font-size: 10pt; color: black;">Specimen Stock Certificate of Common Stock of Registrant (incorporated by reference to Exhibit 4.1 filed with Registrant's Registration Statement on Form SB-2, Commission No. 333-87231 filed on September 16, 1999).</span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td colspan="2" style="height: 15px; width: 73.6333px; padding: 0in;" valign="top">&#160;</td>
<td style="height: 15px; width: 640.667px; padding: 0in;" valign="top">&#160;</td>
</tr>
<tr style="height: 25.5pt;">
<td colspan="2" style="height: 25px; width: 73.6333px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in; text-align: justify;"><span style="font-size: 10pt; color: black;"><a href="http://www.sec.gov/Archives/edgar/data/73290/000101968709003694/lease1.htm">10.1</a></span></p>
</td>
<td style="height: 25px; width: 640.667px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in; text-align: justify;"><span style="font-size: 10pt; color: black;"><a href="http://www.sec.gov/Archives/edgar/data/73290/000101968709003694/lease1.htm">Standard Industrial/Commercial Single-Tenant Lease, dated June 18, 2009, by and between Registrant and CNH, LLC for 17571 Von Karman Avenue, Irvine, CA 92614 (incorporated by reference to Exhibit 10.1 of the Company's August 31, 2009 Form 10Q filed October 15, 2009).</a></span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td colspan="2" style="height: 15px; width: 73.6333px; padding: 0in;" valign="top">&#160;</td>
<td style="height: 15px; width: 640.667px; padding: 0in;" valign="top">&#160;</td>
</tr>
<tr style="height: 25.5pt;">
<td colspan="2" style="height: 25px; width: 73.6333px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in; text-align: justify;"><span style="font-size: 10pt; color: black;"><a href="http://www.sec.gov/Archives/edgar/data/73290/000151316215000284/forms8.htm">10.2</a></span></p>
</td>
<td style="height: 25px; width: 640.667px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in; text-align: justify;"><span style="font-size: 10pt; color: black;"><a href="http://www.sec.gov/Archives/edgar/data/73290/000151316215000284/forms8.htm">2014 Stock Incentive Plan of Registrant (incorporated by reference to Exhibit 10.1 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 22, 2015).</a></span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td colspan="2" style="height: 15px; width: 73.6333px; padding: 0in;" valign="top">&#160;</td>
<td style="height: 15px; width: 640.667px; padding: 0in;" valign="top">&#160;</td>
</tr>
<tr style="height: 25.5pt;">
<td colspan="2" style="height: 25px; width: 73.6333px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in; text-align: justify;"><span style="font-size: 10pt; color: black;"><a href="http://www.sec.gov/Archives/edgar/data/73290/000151316218000116/forms8.htm">10.3</a></span></p>
</td>
<td style="height: 25px; width: 640.667px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in; text-align: justify;"><span style="font-size: 10pt; color: black;"><a href="http://www.sec.gov/Archives/edgar/data/73290/000151316218000116/forms8.htm">2017 Stock Incentive Plan of Registrant (incorporated by reference to Exhibit 10.1 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 10, 2018).</a></span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td colspan="2" style="height: 15px; width: 73.6333px; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in; text-align: justify;">&#160;</p>
</td>
<td style="height: 15px; width: 640.667px; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in; text-align: justify;">&#160;</p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td colspan="2" style="height: 15px; width: 73.6333px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in; text-align: justify;"><span style="font-size: 10pt; color: black;"><a href="http://www.sec.gov/Archives/edgar/data/73290/000151316221000072/forms8.htm">10.4</a></span></p>
</td>
<td style="height: 15px; width: 640.667px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in; text-align: justify;"><span style="font-size: 10pt; color: black;"><a href="http://www.sec.gov/Archives/edgar/data/73290/000151316221000072/forms8.htm">2020 Stock Incentive Plan of Registrant (incorporated by reference to Exhibit 10.1 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 21, 2021).</a></span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td colspan="2" style="height: 15px; width: 73.6333px; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15px; width: 640.667px; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15px; width: 35.8667px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">10.5</span></p>
</td>
<td style="height: 15px; width: 35.8667px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15px; width: 640.667px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Form of Executive Stock Option Agreement (attached herein)</span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15px; width: 35.8667px; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15px; width: 35.8667px; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15px; width: 640.667px; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td colspan="2" style="height: 15px; width: 73.6333px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">21.1</span></p>
</td>
<td style="height: 15px; width: 640.667px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Listing of Subsidiaries (attached herein).</span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td colspan="2" style="height: 15px; width: 73.6333px; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15px; width: 640.667px; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td colspan="2" style="height: 15px; width: 73.6333px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;"><a href="exhibit23_1.htm">23.1</a></span></p>
</td>
<td style="height: 15px; width: 640.667px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;"><a href="exhibit23_1.htm">Consent of Independent Registered Public Accounting Firm (Haskell &amp; White LLP).</a></span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td colspan="2" style="height: 15px; width: 73.6333px; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15px; width: 640.667px; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td colspan="2" style="height: 15px; width: 73.6333px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;"><a href="exhibit23_2.htm">23.2</a></span></p>
</td>
<td style="height: 15px; width: 640.667px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;"><a href="exhibit23_2.htm">Consent of Independent Registered Public Accounting Firm (PKF San Diego, LLP).</a></span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td colspan="2" style="height: 15px; width: 73.6333px; padding: 0in;" valign="top">&#160;</td>
<td style="height: 15px; width: 640.667px; padding: 0in;" valign="top">&#160;</td>
</tr>
<tr style="height: 15pt;">
<td colspan="2" style="height: 15px; width: 73.6333px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;"><a href="exhibit31_1.htm">31.1</a></span></p>
</td>
<td style="height: 15px; width: 640.667px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in; text-align: justify;"><span style="font-size: 10pt; color: black;"><a href="exhibit31_1.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Exchange Act, adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended.</a></span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td colspan="2" style="height: 10px; width: 73.6333px; padding: 0in;" valign="top">&#160;</td>
<td style="height: 10px; width: 640.667px; padding: 0in;" valign="top">&#160;</td>
</tr>
<tr style="height: 15pt;">
<td colspan="2" style="height: 15px; width: 73.6333px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in; text-align: justify;"><span style="font-size: 10pt; color: black;"><a href="exhibit31_2.htm">31.2</a></span></p>
</td>
<td style="height: 15px; width: 640.667px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in; text-align: justify;"><span style="font-size: 10pt; color: black;"><a href="exhibit31_2.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Exchange Act, adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended.</a></span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td colspan="2" style="height: 15px; width: 73.6333px; padding: 0in;" valign="top">&#160;</td>
<td style="height: 15px; width: 640.667px; padding: 0in;" valign="top">&#160;</td>
</tr>
<tr style="height: 15pt;">
<td colspan="2" style="height: 15px; width: 73.6333px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in; text-align: justify;"><span style="font-size: 10pt; color: black;"><a href="exhibit32_1.htm">32.1</a></span></p>
</td>
<td style="height: 15px; width: 640.667px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in; text-align: justify;"><span style="font-size: 10pt; color: black;"><a href="exhibit32_1.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended.</a></span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td colspan="2" style="height: 15px; width: 73.6333px; padding: 0in;" valign="top">&#160;</td>
<td style="height: 15px; width: 640.667px; padding: 0in;" valign="top">&#160;</td>
</tr>
<tr style="height: 15pt;">
<td colspan="2" style="height: 15px; width: 73.6333px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in; text-align: justify;"><span style="font-size: 10pt; color: black;"><a href="exhibit32_2.htm">32.2</a></span></p>
</td>
<td style="height: 15px; width: 640.667px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in; text-align: justify;"><span style="font-size: 10pt; color: black;"><a href="exhibit32_2.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended.</a></span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td colspan="2" style="height: 15px; width: 73.6333px; padding: 0in;" valign="top">&#160;</td>
<td style="height: 15px; width: 640.667px; padding: 0in;" valign="top">&#160;</td>
</tr>
<tr style="height: 15pt;">
<td colspan="2" style="height: 15px; width: 73.6333px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">99.3</span></p>
</td>
<td style="height: 15px; width: 640.667px; background: #b8cce4 none repeat scroll 0% 0%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Registrant and Subsidiaries Consolidated Financial Statements.</span></p>
</td>
</tr>

</table> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">32</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <table cellpadding="0" cellspacing="0" style="WIDTH:7.5in; BORDER-COLLAPSE:collapse" width="720"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">101.INS</span></p></td> <td style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">XBRL Instance Document.</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"></td> <td style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">101.SCH</span></p></td> <td style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">XBRL Taxonomy Extension Schema Document.</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"></td> <td style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">101.CAL</span></p></td> <td style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">XBRL Taxonomy Extension Calculation Linkbase Document.</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"></td> <td style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">101.DEF</span></p></td> <td style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">XBRL Taxonomy Extension Definition Linkbase Document.</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"></td> <td style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">101.LAB</span></p></td> <td style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">XBRL Taxonomy Extension Label Linkbase Document.</span></p></td></tr><tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"></td> <td style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">101.PRE</span></p></td> <td style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">XBRL Taxonomy Extension Presentation Linkbase Document.</span></p></td></tr><tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"></td> <td style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">104</span></p></td> <td style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Cover Page Interactive Data File. </span></p></td></tr> </table> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="font-size: 12pt; text-align: justify; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">The certifications attached as Exhibits 32.1 and 32.2 accompany this Annual Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended, and shall not be deemed &#8220;filed&#8221; by the registrant for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any of the registrant&#8217;s filings under the Securities Act or the Exchange Act, irrespective of any general incorporation language contained in any such filing.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">33</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="text-align: center; margin: 0in;"><span style="font-family: times new roman, times, serif;"><strong><span style="font-size: 10pt; color: black;">SIGNATURES</span></strong></span></p> <p style="MARGIN:0in">&#160;</p> <p style="margin: 0in;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;">In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p> <p style="MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"> </p><div style="text-align: right;"><table cellpadding="0" cellspacing="0" style="height: 152px; width: 800px; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="800">

<tr style="height: 13pt;">
<td style="height: 13px; width: 294.05px; white-space: nowrap; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 13px; width: 329.25px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in; text-align: left;"><span style="font-family: times new roman, times, serif;"><strong><span style="font-size: 10pt; color: black;">BIOMERICA, INC.</span></strong></span></p>
</td>
</tr>
<tr style="height: 13pt;">
<td style="height: 13px; width: 294.05px; white-space: nowrap; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 13px; width: 329.25px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in; text-align: left;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;">Registrant</span></p>
</td>
</tr>
<tr style="height: 13pt;">
<td style="height: 13px; width: 294.05px; white-space: nowrap; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 13px; width: 329.25px; border: 0px none; padding: 0in 5.4pt; text-align: left;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 13pt;">
<td style="height: 13px; width: 294.05px; white-space: nowrap; border: 0px none; padding: 0in 5.4pt 0in 150px;" valign="bottom">&#160;</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 13px; width: 329.25px; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in; text-align: left;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;">By <em>/s/ Zackary S. Irani</em></span></p>
</td>
</tr>
<tr style="height: 13pt;">
<td style="height: 13px; width: 294.05px; white-space: nowrap; border: 0px none; padding: 0in 5.4pt 0in 65px;" valign="bottom">&#160;</td>
<td style="height: 13px; width: 329.25px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in; text-align: left;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;">Zackary S. Irani,</span></p>
</td>
</tr>
<tr style="height: 13pt;">
<td style="height: 13px; width: 294.05px; white-space: nowrap; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 13px; width: 329.25px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in; text-align: left;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;">Chief Executive Officer</span></p>
</td>
</tr>
<tr style="height: 13pt;">
<td style="height: 13px; width: 294.05px; white-space: nowrap; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 13px; width: 329.25px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 13pt;">
<td style="height: 13px; width: 294.05px; white-space: nowrap; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 13px; width: 329.25px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in; text-align: left;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;">Dated: August 29, 2022</span></p>
</td>
</tr>

</table></div><p></p> <p style="MARGIN:0in">&#160;&#160;</p> <p style="MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:</span></p> <p style="MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Signature and Capacity</span></p> <p style="MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"> </p><table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; height: 324px;" width="733">

<tr style="height: 14.35pt;">
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 14px; width: 343.9px; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;"><em>/s/ Zackary S. Irani &#160;</em>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>
</td>
<td style="height: 14px; width: 119.533px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 14px; width: 224.8px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="text-align: right; margin: 0in; tab-stops: 67.1pt;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;">Date: August 29, 2022</span></p>
</td>
</tr>
<tr style="height: 15.1pt;">
<td style="height: 15px; width: 343.9px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;">Zackary S. Irani</span></p>
</td>
<td style="height: 15px; width: 119.533px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 15px; width: 224.8px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 15.1pt;">
<td style="height: 15px; width: 343.9px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;">Director, Chief Executive Officer</span></p>
</td>
<td style="height: 15px; width: 119.533px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 15px; width: 224.8px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 15.1pt;">
<td style="height: 15px; width: 343.9px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 15px; width: 119.533px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 15px; width: 224.8px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 14.35pt;">
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 14px; width: 343.9px; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;"><em>/s/ Steve Sloan</em> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>
</td>
<td style="height: 14px; width: 119.533px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 14px; width: 224.8px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="text-align: right; margin: 0in; tab-stops: 67.1pt;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;">Date: August 29, 2022</span></p>
</td>
</tr>
<tr style="height: 15.1pt;">
<td style="height: 15px; width: 343.9px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;">Steve Sloan</span></p>
</td>
<td style="height: 15px; width: 119.533px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 15px; width: 224.8px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 15.1pt;">
<td style="height: 15px; width: 343.9px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;">Chief Financial Officer</span></p>
</td>
<td style="height: 15px; width: 119.533px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 15px; width: 224.8px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 15.1pt;">
<td style="height: 15px; width: 343.9px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 15px; width: 119.533px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 15px; width: 224.8px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 14.35pt;">
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 14px; width: 343.9px; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;"><em>/s/ Allen Barbieri</em> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>
</td>
<td style="height: 14px; width: 119.533px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 14px; width: 224.8px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="text-align: right; margin: 0in; tab-stops: 67.1pt;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;">Date: August 29, 2022</span></p>
</td>
</tr>
<tr style="height: 15.1pt;">
<td style="height: 15px; width: 343.9px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;">Allen Barbieri</span></p>
</td>
<td style="height: 15px; width: 119.533px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 15px; width: 224.8px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 15.1pt;">
<td style="height: 15px; width: 343.9px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;">Director, Vice-Chairman</span></p>
</td>
<td style="height: 15px; width: 119.533px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 15px; width: 224.8px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 15.1pt;">
<td style="height: 15px; width: 343.9px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 15px; width: 119.533px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 15px; width: 224.8px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 14.35pt;">
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 14px; width: 343.9px; white-space: nowrap; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;"><em>/s/ Jane Emerson, M.D., Ph.D.</em> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>
</td>
<td style="height: 14px; width: 119.533px; white-space: nowrap; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 14px; width: 224.8px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="text-align: right; margin: 0in; tab-stops: 67.1pt;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;">Date: August 29, 2022</span></p>
</td>
</tr>
<tr style="height: 15.1pt;">
<td style="height: 15px; width: 343.9px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;">Jane Emerson, M.D., Ph.D.</span></p>
</td>
<td style="height: 15px; width: 119.533px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 15px; width: 224.8px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 15.1pt;">
<td style="height: 15px; width: 343.9px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;">Director</span></p>
</td>
<td style="height: 15px; width: 119.533px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 15px; width: 224.8px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 14.35pt;">
<td style="height: 14px; width: 343.9px; white-space: nowrap; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in;"><span style="font-size: 8pt; color: black; font-family: times new roman, times, serif;">&#160;</span></p>
</td>
<td style="height: 14px; width: 119.533px; white-space: nowrap; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in;">&#160;</p>
</td>
<td style="height: 14px; width: 224.8px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="text-align: right; margin: 0in; tab-stops: 67.1pt;">&#160;</p>
</td>
</tr>
<tr style="height: 14.35pt;">
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 14px; width: 343.9px; white-space: nowrap; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;"><em>/s/ Mark Sirgo,&#160; Pharm.D.&#160;&#160;&#160;</em>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>
</td>
<td style="height: 14px; width: 119.533px; white-space: nowrap; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 14px; width: 224.8px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="text-align: right; margin: 0in; tab-stops: 67.1pt;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;">Date: August 29, 2022</span></p>
</td>
</tr>
<tr style="height: 15.1pt;">
<td style="height: 15px; width: 343.9px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;">Mark Sirgo, Pharm.D.</span></p>
</td>
<td style="height: 15px; width: 119.533px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 15px; width: 224.8px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 15.1pt;">
<td style="height: 15px; width: 343.9px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in;"><span style="font-size: 10pt; font-family: times new roman, times, serif;">&#160;</span></p>
</td>
<td style="height: 15px; width: 119.533px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 15px; width: 224.8px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 15.1pt;">
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 343.9px; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;"><em>/s/ Catherine Coste, CPA &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</em>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>
</td>
<td style="height: 15px; width: 119.533px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in;">&#160;</p>
</td>
<td style="height: 15px; width: 224.8px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in; tab-stops: 67.1pt; text-align: right;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;Date: August 29, 2022</span></p>
</td>
</tr>
<tr style="height: 15.1pt;">
<td style="height: 15px; width: 343.9px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;">Catherine Coste, CPA </span></p>
</td>
<td style="height: 15px; width: 119.533px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in;">&#160;</p>
</td>
<td style="height: 15px; width: 224.8px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;">&#160;</span></p>
</td>
</tr>
<tr style="height: 15.1pt;">
<td style="height: 15px; width: 343.9px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;">Director</span></p>
</td>
<td style="height: 15px; width: 119.533px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in;">&#160;</p>
</td>
<td style="height: 15px; width: 224.8px; border: 0px none; padding: 0in 5.4pt;" valign="bottom">
<p style="margin: 0in;"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;">&#160;</span></p>
</td>
</tr>

</table><p></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">34</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div></div><span style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif"><span style="PAGE-BREAK-BEFORE:none; clear: both;"><br/></span></span> <div style="page:WordSection2"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><b><span style="FONT-SIZE:10pt; COLOR:black">BIOMERICA, INC. &#160;AND SUBSIDIARIES</span></b></p> <a id="TOC"></a><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><b><span style="FONT-SIZE:10pt; COLOR:black">TABLE OF CONTENTS</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <div style="text-align: left;"> <table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#Report">Reports of Independent Registered Public Accounting Firm</a></span></p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">&#160;FS-2 &#8211; FS-3</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"></td> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"></td> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">CONSOLIDATED FINANCIAL STATEMENTS</span></b></p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"></td> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"></td> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#BS">Consolidated Balance Sheets as of May 31, 2022 and 2021</a></span></p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">FS-4</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"></td> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"></td> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#IS">Consolidated Statements of Operations and Comprehensive Loss for the Years Ended May 31, 2022 and 2021</a></span></p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">FS-5</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"></td> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"></td> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#SHEQ">Consolidated Statements of Shareholders' Equity for the Years Ended May 31, 2022 and 2021</a>&#160;</span></p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">FS-6</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p></td> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"></td> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#CFS">Consolidated Statements of Cash Flows for the Years Ended May 31, 2022 and 2021</a></span></p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">FS-7</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"></td> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"></td> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#Notes">Notes to Consolidated Financial Statements</a></span></p></td> <td style="HEIGHT:15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">FS-8 &#8211; FS-21</span></p></td></tr></table></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><a href="#TOC"><span style="font-size: 13px; color: #0066cc;">Table of Contents</span></a></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p><a id="Report"></a><p style="font-size: 10pt; font-family: 'Arial',sans-serif; text-align: center; margin: 0in;"><strong><span style="font-family: 'Times New Roman',serif;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></strong></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">To the Shareholders and Board of Directors</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Arial&#34;,sans-serif; TEXT-ALIGN:left; MARGIN:0in; text-align: left;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">Biomerica, Inc.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in"><b><i><span style="FONT-SIZE:10pt; COLOR:black">Opinion on the Consolidated Financial Statements</span></i></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">We have audited the accompanying consolidated balance sheet of <b><i>Biomerica, Inc. </i></b>(the &#8220;Company&#8221;) as of May 31, 2022, the related consolidated statements of operations and comprehensive loss, shareholders&#8217; equity, and cash flows for the year then ended, and the related notes (collectively, the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of May 31, 2022, and the consolidated results of its operations and its cash flows for the year then ended, in conformity with U.S. generally accepted accounting principles.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in"><b><i><span style="FONT-SIZE:10pt; COLOR:black">Basis for Opinion</span></i></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audit.&#160; We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in"><b><i><span style="FONT-SIZE:10pt; COLOR:black">Critical Audit Matter</span></i></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The critical audit matter communicated below is a matter arising from the current-period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which they relate.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in"><b><i><span style="text-decoration:underline"><span style="FONT-SIZE:10pt; COLOR:black">Evaluation of Inventory Reserves</span></span></i></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in"><i><span style="FONT-SIZE:10pt; COLOR:black">Critical Audit Matter Description</span></i></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">As of May 31, 2022, the Company recorded reserves for slow-moving and obsolete inventories of approximately $846,000. As described in Note 2 to the consolidated financial statements, management periodically reviews inventories for excess quantities and obsolescence by evaluating quantities on hand and the physical condition and technical functionality of inventories, as these characteristics may be impacted by anticipated customer demand for current products and new product introductions.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Auditing the Company&#8217;s estimates for slow-moving and obsolete inventories was challenging due to the inherently judgmental nature of forecasting future sales and usage of a significant number of diverse inventory components.&#160; </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in"><i><span style="FONT-SIZE:10pt; COLOR:black">How the Critical Audit Matter Was Addressed in the Audit</span></i></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;"><span style="font-family: times new roman, times, serif;"><span style="font-size: 10pt;">To test the valuation and accuracy of the Company&#8217;s inventory reserve estimates, our audit</span> procedures included</span>:</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p>
<table cellpadding="0" cellspacing="0" style="width: 900px; border-collapse: collapse; height: 104px;">

<tr style="height: 14.5pt;">
<td style="height: 14px; width: 21.2833px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><span style="font-size: 10pt;">&#9679;<span style="font: 7pt 'Times New Roman';">&#160;</span></span></span></p>
</td>
<td style="height: 14px; width: 1556.87px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: times new roman, times, serif; color: black;"><span style="color: black;">Obtaining an understanding of the Company&#8217;s inventory reserve estimation processes and key internal controls and assessing their appropriateness; </span></span></p>
</td>
</tr>
<tr style="height: 12.15pt;">
<td style="height: 12px; width: 21.2833px; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 12px; width: 1556.87px; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 14.5pt;">
<td style="height: 14px; width: 21.2833px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><span style="font-size: 10pt;">&#9679;<span style="font: 7pt 'Times New Roman';">&#160;</span></span></span></p>
</td>
<td style="height: 14px; width: 1556.87px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: times new roman, times, serif; color: black;"><span style="color: black;">Observing and testing the Company&#8217;s year-end physical inventory counts; </span></span></p>
</td>
</tr>
<tr style="height: 12.6pt;">
<td style="height: 12px; width: 21.2833px; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 12px; width: 1556.87px; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 14.5pt;">
<td style="height: 14px; width: 21.2833px; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><span style="font-size: 10pt;">&#9679;<span style="font: 7pt 'Times New Roman';">&#160;</span></span></span></p>
</td>
<td style="HEIGHT:24.3pt; WIDTH:95%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 95%;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Testing the accuracy of key data inputs that are the primary drivers for determining the quantitative inventory reserves; these inputs included inventory quantities on hand, historical and expected sales and usage of inventory components, and estimated inventory reserve percentages; and </span></p>
</td>
</tr>
<tr style="height: 12.6pt;">
<td style="height: 12px; width: 21.2833px; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 12px; width: 1556.87px; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 14.5pt;">
<td style="height: 14px; width: 21.2833px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><span style="font-size: 10pt;">&#9679;<span style="font: 7pt 'Times New Roman';">&#160;</span></span></span></p>
</td>
<td style="height: 14px; width: 1556.87px; white-space: nowrap; padding: 0in;" valign="bottom"><span style="font-size: 10pt; color: black; font-family: times new roman, times, serif;">Inquiring of any qualitative adjustments to inventory reserves deemed necessary by management and assessing their appropriateness.</span></td>
</tr>
<tr style="height: 12.6pt;">
<td style="height: 12px; width: 21.2833px; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 12px; width: 1556.87px; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
</tr>

</table>    <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0in 0.5in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in 0in 6pt 3.5in"><i><span style="FONT-SIZE:10pt">/s/ Haskell &amp; White LLP</span></i></p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 0in 0in 3.5in;"><span style="font-size: 10pt;"><ix:nonNumeric contextRef="c0" name="dei:AuditorName">HASKELL &amp; WHITE LLP</ix:nonNumeric> <span style="font-family: 'Times New Roman',serif;">(<ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId">200</ix:nonNumeric>)</span><br/></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">We have served as the Company&#8217;s auditor since 2022.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation"><span style="FONT-SIZE:10pt; COLOR:black">Irvine, California</span></ix:nonNumeric></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">August 29, 2022</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Arial&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:6pt 0in; text-align: center;">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">FS-2</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><a href="#TOC"><span style="font-size: 13px; color: #0066cc;">Table of Contents</span></a></p> <p>&#160;</p>
<p style="font-size: 10pt; font-family: 'Arial',sans-serif; text-align: center; margin: 6pt 0in;"><strong><span style="font-family: 'Times New Roman',serif; background: white; color: black;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></strong></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Arial&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:6pt 0in; text-align: center;">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Arial&#34;,sans-serif; TEXT-ALIGN:left; MARGIN:0in; text-align: left;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; COLOR:black">Board of Directors and Shareholders<br/>Biomerica, Inc. and Subsidiaries</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Arial&#34;,sans-serif; TEXT-ALIGN:left; MARGIN:0in; text-align: left;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; COLOR:black">Irvine, California</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Arial&#34;,sans-serif; TEXT-ALIGN:left; MARGIN:0in; text-align: left;">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Arial&#34;,sans-serif; TEXT-ALIGN:justify; MARGIN:6pt 0in"><span style="text-decoration:underline"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; COLOR:black">Opinion on the Consolidated Financial Statements</span></span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Arial&#34;,sans-serif; TEXT-ALIGN:justify; MARGIN:6pt 0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; COLOR:black">We have audited the accompanying consolidated balance sheet of Biomerica, Inc. (a Delaware Corporation) and Subsidiaries (the &#8220;Company&#8221;) as of May 31, 2021, the related consolidated statements of operations and comprehensive loss, shareholders&#8217; equity, and cash flows for the year ended May 31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;).&#160; In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of May 31, 2021, and the results of its operations and its cash flows for the year ended May 31, 2021, in conformity with accounting principles generally accepted in the United States of America.</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Arial&#34;,sans-serif; TEXT-ALIGN:justify; MARGIN:6pt 0in"><span style="text-decoration:underline"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; COLOR:black">Basis for Opinion</span></span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Arial&#34;,sans-serif; TEXT-ALIGN:justify; MARGIN:6pt 0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; COLOR:black">These consolidated financial statements are the responsibility of the Company&#8217;s management.&#160; Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audit.&#160; We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p> <p style="font-size: 10pt; font-family: 'Arial',sans-serif; text-align: justify; margin: 6pt 0in;"><span style="font-family: 'Times New Roman',serif; background: white; color: black;">We conducted our audit in accordance with the standards of the PCAOB.&#160; Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.&#160; The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.&#160; As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.&#160; Accordingly, we express no such opinion.</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Arial&#34;,sans-serif; TEXT-ALIGN:justify; MARGIN:6pt 0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; COLOR:black">Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks.&#160; Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.&#160; Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.&#160; We believe that our audit provides a reasonable basis for our opinion.</span></p> <a id="_Hlk80257226"></a><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Arial&#34;,sans-serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="text-decoration:underline"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; COLOR:black">Critical Audit Matters</span></span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Arial&#34;,sans-serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="font-size: 10pt; font-family: 'Arial',sans-serif; text-align: justify; margin: 0in;"><span style="font-family: 'Times New Roman',serif; background: white; color: black;">The critical audit matters communicated below are matters arising from the May 31, 2021 audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments.&#160; The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Arial&#34;,sans-serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <a id="_Hlk67406666"></a><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Arial&#34;,sans-serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; COLOR:black">Evaluation of Inventory and Accounts Receivable Allowances</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">The Company recorded allowances for inventory and accounts receivable of approximately $1,600,000 and $840,000, respectively, as of May 31, 2021, primarily related to COVID-19 inventory items that have been slow moving and accounts receivable from foreign customers where collectability is questionable.&#160; As described in Note 2, these allowances are adjusted based on management&#8217;s ongoing evaluations and assessments based on current conditions.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Auditing the Company&#8217;s estimates for inventory and accounts receivable allowances was challenging due to the assumptions made by management based on anticipated future results of customers and marketplace developments.&#160; </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">We obtained an understanding and evaluated the assumptions, criteria and process used by management to determine the allowances for inventory items and accounts receivable. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">To test the valuation and accuracy of allowances for inventory and accounts receivable, our <span style="font-size: 10px;">audit</span> procedures included, among others, observation and testing of the cost and the valuation allowance for inventory items on hand, examining recent sales of items, testing of aging of accounts receivable balances, confirmation, and testing of subsequent cash receipts on accounts receivable, and discussions with management.</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Arial&#34;,sans-serif; TEXT-ALIGN:justify; MARGIN:0in 0in 6pt">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Arial&#34;,sans-serif; TEXT-ALIGN:justify; MARGIN:0in 0in 6pt">&#160;</p> <p style="font-size: 10pt; font-family: 'Arial',sans-serif; text-align: justify; margin: 0in;"><span style="font-family: 'Times New Roman',serif;">/s/PKF San Diego, LLP<br/></span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Arial&#34;,sans-serif; TEXT-ALIGN:justify; MARGIN:0in 0in 6pt"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">(formerly PKF, LLP)</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Arial&#34;,sans-serif; TEXT-ALIGN:justify; MARGIN:0in 0in 6pt">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Arial&#34;,sans-serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">We served as the Company&#8217;s auditor from 2004 to 2021.</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Arial&#34;,sans-serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Arial&#34;,sans-serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">San Diego, California</span></p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt;">August 27, 2021, except for the effect of the restatement disclosed in Note 11 of the May 31, 2021 consolidated financial statements, as to which the date is October 14, 2021</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">FS-3</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#TOC">Table of Contents</a></span></p> <div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><b><span style="FONT-SIZE:10pt; COLOR:black">BIOMERICA, INC. AND SUBSIDIARIES</span></b></p></div> <a id="BS"></a><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><b><span style="FONT-SIZE:10pt; COLOR:black">CONSOLIDATED BALANCE SHEETS </span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="width: 750pt; border-collapse: collapse; margin-left: auto; margin-right: auto; height: 771px;" width="1000">

<tr style="height: 15pt;">
<td style="height: 15px; width: 698.417px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td colspan="5" style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 298.733px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">May 31,</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 698.417px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td colspan="2" style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 139.85px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">2022</span></p>
</td>
<td style="border-color: windowtext currentcolor currentcolor; border-style: solid none none; border-width: 1pt 0px 0px; height: 15px; width: 19.9667px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td colspan="2" style="border-color: windowtext currentcolor; border-style: solid none; border-width: 1pt 0px; height: 15px; width: 138.917px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">2021</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 698.417px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Assets</span></strong></p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.95px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 698.417px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.95px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 698.417px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Current Assets:</span></strong></p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.95px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 685.083px; background: white none repeat scroll 0% 0%; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Cash and cash equivalents</span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="height: 15px; width: 115.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">5,916,983</ix:nonFraction> </span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$&#160;</span></p>
</td>
<td style="height: 15px; width: 115.083px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160; <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">4,199,311</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 26.25pt;">
<td style="height: 26px; width: 685.083px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Accounts receivable, less allowance for doubtful accounts <br/>&#160;&#160;&#160; of $<ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" unitRef="usd">153,231</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" unitRef="usd">837,415</ix:nonFraction> as of May 31, 2022 and 2021, respectively</span></p>
</td>
<td style="height: 26px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 26px; width: 115.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">773,818</ix:nonFraction> </span></p>
</td>
<td style="height: 26px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 26px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 26px; width: 115.083px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">1,455,051</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 685.083px; background: white none repeat scroll 0% 0%; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Inventories, net</span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 115.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">2,416,447</ix:nonFraction> </span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 115.083px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">3,206,255</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 685.083px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Prepaid expenses and other</span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 19.9667px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 115.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd">320,283</ix:nonFraction> </span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 19.9667px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 115.083px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd">370,290</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 698.417px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Total current assets</span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 115.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">9,427,531</ix:nonFraction> </span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 115.083px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">9,230,907</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 698.417px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 115.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 115.083px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
</tr>
<tr style="height: 26.25pt;">
<td style="height: 26px; width: 685.083px; background: white none repeat scroll 0% 0%; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Property and equipment, net of accumulated depreciation and amortization <br/>&#160;&#160;&#160; of $<ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">1,305,360</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">1,972,357</ix:nonFraction> as of May 31, 2022 and&#160; 2021, respectively</span></p>
</td>
<td style="height: 26px; width: 19.0167px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 26px; width: 115.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">214,487</ix:nonFraction> </span></p>
</td>
<td style="height: 26px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 26px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 26px; width: 115.083px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">310,520</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 685.083px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 115.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 115.083px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
</tr>
<tr style="height: 26.25pt;">
<td style="height: 26px; width: 685.083px; background: white none repeat scroll 0% 0%; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Right of use assets, net of accumulated amortization <br/>&#160;&#160;&#160; of $<ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="bmra:OperatingLeaseRightOfUseAssetAccumulatedAmortization" scale="0" unitRef="usd">724,802</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="bmra:OperatingLeaseRightOfUseAssetAccumulatedAmortization" scale="0" unitRef="usd">469,077</ix:nonFraction> as of May 31, 2022 and 2021, respectively</span></p>
</td>
<td style="height: 26px; width: 19.0167px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 26px; width: 115.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd">1,301,834</ix:nonFraction> </span></p>
</td>
<td style="height: 26px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 26px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 26px; width: 115.083px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd">1,553,081</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 685.083px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 115.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 115.083px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 685.083px; background: white none repeat scroll 0% 0%; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Investments</span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 115.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:Investments" scale="0" unitRef="usd">165,324</ix:nonFraction> </span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 115.083px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:Investments" scale="0" unitRef="usd">165,324</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 685.083px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 115.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 115.083px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
</tr>
<tr style="height: 26.25pt;">
<td style="height: 26px; width: 685.083px; background: white none repeat scroll 0% 0%; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Intangible assets, net of accumulated amortization <br/>&#160;&#160;&#160; of $<ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd">18,994</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd">126,769</ix:nonFraction> as of May 31, 2022 and 2021, respectively</span></p>
</td>
<td style="height: 26px; width: 19.0167px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 26px; width: 115.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd">169,516</ix:nonFraction> </span></p>
</td>
<td style="height: 26px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 26px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 26px; width: 115.083px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd">294,830</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 685.083px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 115.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 115.083px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 685.083px; background: white none repeat scroll 0% 0%; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Other assets</span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 19.9667px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 115.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd">95,588</ix:nonFraction> </span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 19.9667px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 115.083px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd">264,151</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15px; width: 698.417px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Total Assets</span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15px; width: 19.9667px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15px; width: 115.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">11,374,280</ix:nonFraction> </span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15px; width: 19.9667px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$&#160;</span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15px; width: 115.083px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160; <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">11,818,813</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15px; width: 698.417px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.95px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 698.417px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Liabilities and Shareholders' Equity</span></strong></p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.95px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 698.417px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.95px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 698.417px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Current Liabilities:</span></strong></p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.95px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 685.083px; background: white none repeat scroll 0% 0%; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Accounts payable and accrued expenses</span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="height: 15px; width: 115.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd">972,372</ix:nonFraction> </span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$&#160;</span></p>
</td>
<td style="height: 15px; width: 115.083px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd">583,380</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 685.083px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Accrued compensation</span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 115.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" unitRef="usd">646,944</ix:nonFraction> </span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 115.083px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" unitRef="usd">388,896</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 685.083px; background: white none repeat scroll 0% 0%; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Advance from customers</span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 115.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="0" unitRef="usd">50,670</ix:nonFraction> </span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 115.083px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="-sec-ix-hidden: hidden-fact-0; font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">-&#160; </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 685.083px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Lease liability, current portion</span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 19.9667px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 115.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd">341,296</ix:nonFraction> </span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 19.9667px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 115.083px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd">327,944</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 698.417px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Total current liabilities</span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 115.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">2,011,282</ix:nonFraction> </span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 115.083px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">1,300,220</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 685.083px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Lease liability, net of current portion</span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 19.9667px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 115.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd">1,038,284</ix:nonFraction> </span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 19.9667px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 115.083px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd">1,291,570</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 698.417px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Total Liabilities</span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 19.9667px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 115.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">3,049,566</ix:nonFraction> </span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 19.9667px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 115.083px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">2,591,790</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 698.417px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.95px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 685.083px; background: white none repeat scroll 0% 0%; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Commitments and contingencies (Notes 6 and 9)</span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.933px; background: text-align: right; white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-1">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</div></td>
<td style="height: 15px; width: 19.0167px; background: text-align: right; white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; text-align: right; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.95px; text-align: right; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-2">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</div></td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 698.417px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.95px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 698.417px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Shareholders' Equity:</span></strong></p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.95px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 698.417px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.95px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
</tr>
<tr style="height: 26.25pt;">
<td style="height: 26px; width: 685.083px; background: white none repeat scroll 0% 0%; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Preferred stock, Series A 5% convertible, $<ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.08</ix:nonFraction></ix:nonFraction> par value, <br/><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">571,429</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c5" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding as of May 31, 2022 and&#160; 2021</span></p>
</td>
<td style="height: 26px; width: 19.0167px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 26px; width: 115.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="-sec-ix-hidden: hidden-fact-3; font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">-&#160;&#160; </span></p>
</td>
<td style="height: 26px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 26px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 26px; width: 115.083px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="-sec-ix-hidden: hidden-fact-4; font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;-&#160;&#160; </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 685.083px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Preferred stock, undesignated, <ix:nonFraction contextRef="c3" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockNoParValue" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockNoParValue" scale="0" unitRef="usdPershares">no</ix:nonFraction></ix:nonFraction> par value, <br/><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="bmra:PreferredStockUndesignatedShares" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="bmra:PreferredStockUndesignatedShares" scale="0" unitRef="shares">4,428,571</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c3" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding as of May 31, 2022 and 2021</span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 115.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="-sec-ix-hidden: hidden-fact-5; font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">-&#160;&#160; </span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 115.083px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="-sec-ix-hidden: hidden-fact-6; font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">-&#160;&#160; </span></p>
</td>
</tr>
<tr style="height: 26.25pt;">
<td style="height: 26px; width: 685.083px; background: white none repeat scroll 0% 0%; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Common stock, $<ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.08</ix:nonFraction></ix:nonFraction> par value, <br/><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">25,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">12,867,924</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">12,307,157</ix:nonFraction></ix:nonFraction> issued and outstanding at <br/>May 31, 2022 and 2021,&#160; respectively</span></p>
</td>
<td style="height: 26px; width: 19.0167px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 26px; width: 115.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">1,029,432</ix:nonFraction> </span></p>
</td>
<td style="height: 26px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 26px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 26px; width: 115.083px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">984,571</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 685.083px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Additional paid-in-capital</span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 115.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">42,446,597</ix:nonFraction> </span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 115.083px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">38,836,743</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 685.083px; background: white none repeat scroll 0% 0%; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Accumulated other comprehensive loss</span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (<ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" sign="-" unitRef="usd">73,936</ix:nonFraction>)</span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.95px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" sign="-" unitRef="usd">47,956</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 685.083px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Accumulated deficit</span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 19.9667px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 118.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (<ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">35,077,379</ix:nonFraction>)</span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 19.9667px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 118.95px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">30,546,335</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 698.417px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Total Shareholders' Equity</span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 19.9667px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 115.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">8,324,714</ix:nonFraction> </span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 19.9667px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 115.083px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">9,227,023</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15px; width: 698.417px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Total Liabilities and Shareholders' Equity</span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15px; width: 19.9667px; background: #b4c6e7 none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15px; width: 115.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">11,374,280</ix:nonFraction> </span></p>
</td>
<td style="height: 15px; width: 19.0167px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15px; width: 19.9667px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$&#160;</span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15px; width: 115.083px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160; <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">11,818,813</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15px; width: 698.417px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.933px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 19.0167px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15px; width: 118.95px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td colspan="6" style="height: 15px; width: 998.1px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri', sans-serif; margin: 0in; line-height: normal; text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">See accompanying notes to consolidated financial statements</span></p>
</td>
</tr>

</table></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">FS-4</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:7pt; COLOR:black">.</span><b><span style="FONT-SIZE:10pt; COLOR:black">BIOMERICA, INC. AND SUBSIDIARIES</span></b></p></div> <a id="IS"></a><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><b><span style="FONT-SIZE:10pt; COLOR:black">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <div style="text-align: left;"> <table cellpadding="0" cellspacing="0" style="width: 750pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="1000">

<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td colspan="5" rowspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 30%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">For the year ended May 31,</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 14%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2022</span></p>
</td>
<td style="height: 15pt; width: 2%; background: white; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;">&#160;</p>
</td>
<td colspan="2" style="border-top: windowtext 1pt solid; height: 15pt; border-right: 0px; width: 14%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2021</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Net sales </span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="height: 15pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">18,871,409</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="height: 15pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">7,199,027</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Cost of sales </span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">15,893,991</ix:nonFraction>)</span></p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">6,832,742</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; background: #b4c6e7; white-space: nowrap; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Gross profit&#160; </span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd">2,977,418</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd">366,285</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Operating expenses: </span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; background: white; white-space: nowrap; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Selling, general and administrative </span></p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">5,698,958</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">5,671,517</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; background: #b4c6e7; white-space: nowrap; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Research and development </span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">1,812,424</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">2,194,461</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; background: white; white-space: nowrap; padding: 0in 0in 0in 20pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Total operating expense </span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">7,511,382</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">7,865,978</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Loss from operations </span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">4,533,964</ix:nonFraction>)</span></p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">7,499,693</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Other income: </span></p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; background: #b4c6e7; white-space: nowrap; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Dividend and interest income </span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="0" unitRef="usd">26,639</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="0" unitRef="usd">66,863</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; background: white; white-space: nowrap; padding: 0in 0in 0in 10pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Interest expense </span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="-sec-ix-hidden: hidden-fact-7; font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">-</span></p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd">367</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; background: #b4c6e7; white-space: nowrap; padding: 0in 0in 0in 20pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Total other income </span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" unitRef="usd">26,639</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" unitRef="usd">66,496</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Loss before income taxes </span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd">4,507,325</ix:nonFraction>)</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd">7,433,197</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Provision for income taxes </span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd">23,719</ix:nonFraction>)</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd">13,057</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 70%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Net loss </span></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">4,531,044</ix:nonFraction>)</span></p>
</td>
<td style="height: 15.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">7,446,254</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 70%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 70%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Basic net loss per common share </span></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.36</ix:nonFraction>)</span></p>
</td>
<td style="height: 15.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.62</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 70%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 70%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Diluted net loss per common share </span></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares">0.36</ix:nonFraction>)</span></p>
</td>
<td style="height: 15.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares">0.62</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 70%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Weighted average number of common and <br/>common equivalent shares: </span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 70%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Basic </span></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">12,673,245</ix:nonFraction> </span></p>
</td>
<td style="height: 15.75pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">11,928,941</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 70%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 70%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Diluted </span></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">12,673,245</ix:nonFraction> </span></p>
</td>
<td style="height: 15.75pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">11,928,941</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 70%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Net loss </span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">4,531,044</ix:nonFraction>)</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">7,446,254</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Other comprehensive loss, net of tax: </span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Foreign currency translation </span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="0" sign="-" unitRef="usd">25,980</ix:nonFraction>)</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="0" sign="-" unitRef="usd">8,115</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 70%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Comprehensive loss </span></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd">4,557,024</ix:nonFraction>)</span></p>
</td>
<td style="height: 15.75pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd">7,454,369</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 70%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15.75pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15.75pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15.75pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15.75pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15.75pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 15pt;">
<td colspan="6" style="height: 15pt; width: 100%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">See accompanying notes to consolidated financial statements&#160;</span></p>
</td>
</tr>

</table></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">FS-5</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><b><span style="FONT-SIZE:10pt; COLOR:black">BIOMERICA, INC. AND SUBSIDIARIES</span></b></p> <a id="SHEQ"></a><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><b><span style="FONT-SIZE:10pt; COLOR:black">CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><b><span style="FONT-SIZE:10pt; COLOR:black">FOR THE YEARS ENDED MAY 31, 2022 AND 2021</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <div style="text-align: left;"> <table cellpadding="0" cellspacing="0" style="WIDTH:800pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="1067"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:31.24%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:6.26%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.26%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.26%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:6.26%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.98%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td colspan="4" rowspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14.28%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Series A 5% Convertible</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Preferred Stock</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td colspan="2" rowspan="3" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:7.56%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Additional</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Paid-in Capital</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td colspan="2" rowspan="3" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:9.84%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Accumulated Other</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Comprehensive</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Loss</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.26%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:6.46%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.06%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.26%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:6.26%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:31.24%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td colspan="4" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15.02%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Common Stock</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.98%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td colspan="2" rowspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:7.72%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Accumulated</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Deficit</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.06%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:31.24%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.26%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Shares</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.26%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td colspan="2" style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:7.52%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Amount</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.98%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:5.54%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Shares</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.38%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td colspan="2" style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:7.36%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Amount </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.06%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:7.52%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Total</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:31.24%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Balances, May 31, 2020, restated</span></p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">11,740,089</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$ </span></p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">939,205</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.98%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:5.54%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">321,429</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.38%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.38%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$ </span></p></td> <td style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 6%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">25,714</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$ </span></p></td> <td style="HEIGHT:15pt; WIDTH:6.28%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">36,388,056</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2.18%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$ </span></p></td> <td style="HEIGHT:15pt; WIDTH:7.66%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">39,841</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$ </span></p></td> <td style="HEIGHT:15pt; WIDTH:6.46%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c12" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">23,100,081</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.06%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$ </span></p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c13" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">14,213,053</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:31.24%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Exercise of stock options</span></p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">86,750</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd">6,940</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.98%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:5.54%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.38%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.38%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 6%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.28%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c15" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd">95,315</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2.18%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:7.66%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.46%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.06%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd">102,255</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:31.24%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Net proceeds from ATM</span></p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">158,889</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">12,712</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.98%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:5.54%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.38%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.38%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 6%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.28%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c15" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">998,763</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2.18%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:7.66%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.46%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.06%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">1,011,475</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:31.24%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Foreign currency translation</span></p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.98%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:5.54%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.38%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.38%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 6%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.28%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2.18%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:7.66%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c16" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="0" sign="-" unitRef="usd">8,115</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.46%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.06%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="0" sign="-" unitRef="usd">8,115</ix:nonFraction>)</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:31.24%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Conversion of preferred to common stock</span></p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares">321,429</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="0" unitRef="usd">25,714</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.98%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:5.54%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c17" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" sign="-" unitRef="shares">321,429</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.38%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.38%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 6%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c17" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="0" sign="-" unitRef="usd">25,714</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.28%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2.18%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:7.66%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.46%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.06%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">- </span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:31.24%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Compensation expense in connection with options granted</span></p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.98%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:5.54%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.38%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.38%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 6%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.28%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c15" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd">1,354,609</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2.18%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:7.66%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.46%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.06%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd">1,354,609</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:31.24%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Net loss</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.26%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.26%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.26%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.26%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.98%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:5.54%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.38%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.38%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 6%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.26%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.28%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2.18%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:7.66%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.26%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.46%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c18" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">7,446,254</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.06%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.26%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.26%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">7,446,254</ix:nonFraction>)</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:31.24%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Balances, May 31, 2021, restated</span></p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c19" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">12,307,157</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c19" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">984,571</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.98%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:5.54%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-8; FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.38%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.38%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 6%; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-9; FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.28%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c21" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">38,836,743</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2.18%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:7.66%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c22" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">47,956</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.46%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c23" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">30,546,335</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.06%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">9,227,023</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:31.24%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Exercise of stock options</span></p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c24" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">39,500</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c24" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd">3,160</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.98%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:5.54%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.38%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.38%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 6%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.28%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c25" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd">74,200</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2.18%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:7.66%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.46%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.06%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd">77,360</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:31.24%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Net proceeds from ATM</span></p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c24" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">521,267</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c24" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">41,701</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.98%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:5.54%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.38%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.38%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 6%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.28%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c25" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">2,275,459</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2.18%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:7.66%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.46%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.06%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">2,317,160</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:31.24%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Foreign currency translation</span></p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.98%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:5.54%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.38%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.38%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 6%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.28%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2.18%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:7.66%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c26" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="0" sign="-" unitRef="usd">25,980</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.46%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.06%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="0" sign="-" unitRef="usd">25,980</ix:nonFraction>)</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:31.24%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Compensation expense in connection with options granted</span></p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.98%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:5.54%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.38%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.38%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 6%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.28%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c25" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd">1,260,195</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2.18%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:7.66%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.46%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.06%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:6.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd">1,260,195</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:31.24%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Net loss</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.26%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.26%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.26%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.26%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.98%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:5.54%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.38%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.38%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 6%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.26%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.28%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2.18%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:7.66%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.26%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.26%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.46%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c27" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">4,531,044</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.06%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.26%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.26%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">4,531,044</ix:nonFraction>)</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:31.24%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Balances, May 31, 2022</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6.26%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c28" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">12,867,924</ix:nonFraction> </span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.26%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.26%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$ </span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6.26%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c28" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">1,029,432</ix:nonFraction> </span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:1.98%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">&#160;&#160; </span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:5.54%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-10; FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">-</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.38%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.38%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$ </span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 6%; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-11; FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">-</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.26%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$ </span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6.28%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c30" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">42,446,597</ix:nonFraction> </span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2.18%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$ </span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:7.66%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c31" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">73,936</ix:nonFraction>)</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:1.26%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.26%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$ </span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6.46%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c32" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">35,077,379</ix:nonFraction>)</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:1.06%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.26%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$ </span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6.26%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">8,324,714</ix:nonFraction> </span></b></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:31.24%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:6.26%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:1.26%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:1.26%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:6.26%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:1.98%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:5.54%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:1.38%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:1.38%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:6%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 6%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:1.26%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:1.26%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:6.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:1.26%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:2.18%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:7.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:1.26%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:1.26%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:6.46%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:1.06%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:1.26%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:6.26%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td colspan="22" style="HEIGHT:15pt; WIDTH:100%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 100%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">See accompanying notes to consolidated financial statements.&#160;</span></p></td></tr></table></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">FS-6</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></div> <div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><b><span style="FONT-SIZE:10pt; COLOR:black">BIOMERICA, INC. AND SUBSIDIARIES</span></b></p></div> <a id="CFS"></a><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><b><span style="FONT-SIZE:10pt; COLOR:black">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <div style="text-align: left;"> <table cellpadding="0" cellspacing="0" style="width: 750pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="1000">

<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td colspan="5" rowspan="2" style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 306.217px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">Year ended May 31,</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td colspan="2" style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 142.467px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2022</span></p>
</td>
<td style="height: 15pt; width: 19.3833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;">&#160;</p>
</td>
<td colspan="2" style="border-color: windowtext currentcolor; border-style: solid none; border-width: 1pt 0px; height: 15pt; width: 142.467px; background: white none repeat scroll 0% 0%; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2021</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Cash flows from operating activities: </span></strong></p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.3833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Net loss </span></p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="height: 15pt; width: 121.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">4,531,044</ix:nonFraction>)</span></p>
</td>
<td style="height: 15pt; width: 19.3833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="height: 15pt; width: 121.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">7,446,254</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Adjustments to reconcile net loss to net cash used in operating activities: </span></strong></p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.3833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Depreciation and amortization </span></p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 118.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd">339,096</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 19.3833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 118.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd">138,267</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Loss on disposal of property and equipment&#160; </span></p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="0" sign="-" unitRef="usd">52,587</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 19.3833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="-sec-ix-hidden: hidden-fact-12; font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">-</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Provision for allowance on accounts receivable </span></p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" sign="-" unitRef="usd">684,184</ix:nonFraction>)</span></p>
</td>
<td style="height: 15pt; width: 19.3833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 118.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" unitRef="usd">766,434</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Inventory reserve </span></p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:InventoryLIFOReservePeriodCharge" scale="0" sign="-" unitRef="usd">771,736</ix:nonFraction>)</span></p>
</td>
<td style="height: 15pt; width: 19.3833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:InventoryLIFOReservePeriodCharge" scale="0" unitRef="usd">1,550,594</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Stock option expense </span></p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 118.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockOptionPlanExpense" scale="0" unitRef="usd">1,260,195</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 19.3833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 118.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockOptionPlanExpense" scale="0" unitRef="usd">1,354,609</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Amortization of right-of-use asset </span></p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" unitRef="usd">255,725</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 19.3833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" unitRef="usd">237,588</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Changes in assets and liabilities: </span></strong></p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.3833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Accounts receivable </span></p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" sign="-" unitRef="usd">1,365,417</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 19.3833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd">455,614</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Inventories </span></p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 118.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" sign="-" unitRef="usd">1,561,544</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 19.3833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" unitRef="usd">1,906,013</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Prepaid expenses and other </span></p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" sign="-" unitRef="usd">50,007</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 19.3833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" sign="-" unitRef="usd">1,138,793</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Reduction in lease liability </span></p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="bmra:IncreaseDecreaseInLeaseLiability" scale="0" sign="-" unitRef="usd">244,412</ix:nonFraction>)</span></p>
</td>
<td style="height: 15pt; width: 19.3833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="bmra:IncreaseDecreaseInLeaseLiability" scale="0" sign="-" unitRef="usd">241,132</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Other assets </span></p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" sign="-" unitRef="usd">168,563</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 19.3833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" unitRef="usd">95,958</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Accounts payable and accrued expenses </span></p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 118.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd">388,992</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 19.3833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" sign="-" unitRef="usd">403,331</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Accrued compensation </span></p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="0" unitRef="usd">258,048</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 19.3833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="0" unitRef="usd">110,269</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Advance from customers </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 20.5333px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 118.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" unitRef="usd">50,670</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 19.3833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 20.5333px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 118.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="-sec-ix-hidden: hidden-fact-13; font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">-</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Net cash used in operating activities </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 20.5333px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 121.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">480,532</ix:nonFraction>)</span></p>
</td>
<td style="height: 15pt; width: 19.3833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 20.5333px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 121.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">5,251,748</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.3833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Cash flows from investing activities: </span></strong></p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.3833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Expenditure related to intangibles </span></p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" unitRef="usd">113,436</ix:nonFraction>)</span></p>
</td>
<td style="height: 15pt; width: 19.3833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" unitRef="usd">159,727</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Purchases of property and equipment </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 20.5333px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 121.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd">56,900</ix:nonFraction>)</span></p>
</td>
<td style="height: 15pt; width: 19.3833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 20.5333px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 121.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd">135,856</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Net cash used in investing activities </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 20.5333px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 121.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">170,336</ix:nonFraction>)</span></p>
</td>
<td style="height: 15pt; width: 19.3833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 20.5333px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 121.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">295,583</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.3833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Cash flows from financing activities: </span></strong></p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.3833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Gross proceeds from sale of common stock </span></p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">2,401,734</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 19.3833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">1,177,394</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Costs from sale of common stock </span></p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" unitRef="usd">84,574</ix:nonFraction>)</span></p>
</td>
<td style="height: 15pt; width: 19.3833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" unitRef="usd">165,919</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Proceeds from exercise of stock options </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 20.5333px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" unitRef="usd">77,360</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 19.3833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 20.5333px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" unitRef="usd">102,255</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Net cash provided by financing activities </span></p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 118.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">2,394,520</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 19.3833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 118.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">1,113,730</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.3833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Effect of exchange rate changes in cash </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 20.5333px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 121.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" sign="-" unitRef="usd">25,980</ix:nonFraction>)</span></p>
</td>
<td style="height: 15pt; width: 19.3833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 20.5333px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 121.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" sign="-" unitRef="usd">8,115</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Net increase (decrease) in cash and cash equivalents </span></p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd">1,717,672</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 19.3833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd">4,441,716</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.3833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Cash and cash equivalents at beginning of year </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 20.5333px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">4,199,311</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 19.3833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 20.5333px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c13" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">8,641,027</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 118.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.3833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 118.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 690.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Cash and cash equivalents at end of year </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15.75pt; width: 20.5333px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15.75pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">5,916,983</ix:nonFraction> </span></p>
</td>
<td style="height: 15.75pt; width: 19.3833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15.75pt; width: 20.5333px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15.75pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">4,199,311</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 690.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 121.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 19.3833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 121.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Supplemental Disclosure of Cash Flow Information: </span></p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.3833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Cash paid during the year for: </span></strong></p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.3833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 121.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 690.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Income taxes </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15.75pt; width: 20.5333px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15.75pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaid" scale="0" unitRef="usd">23,719</ix:nonFraction> </span></p>
</td>
<td style="height: 15.75pt; width: 19.3833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15.75pt; width: 20.5333px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15.75pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaid" scale="0" unitRef="usd">27,171</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 690.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 118.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 19.3833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 19.5833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15.75pt; width: 118.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 690.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Non-cash investing and financing activities: </span></strong></p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.3833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 19.5833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 690.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Increase in right-of-use asset due to lease extension or establishment </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15.75pt; width: 20.5333px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15.75pt; width: 118.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="bmra:IncreaseInRightOfUseAsset" scale="0" unitRef="usd">4,478</ix:nonFraction> </span></p>
</td>
<td style="height: 15.75pt; width: 19.3833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15.75pt; width: 20.5333px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15.75pt; width: 118.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="bmra:IncreaseInRightOfUseAsset" scale="0" unitRef="usd">79,159</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 16.5pt;">
<td style="height: 16.5pt; width: 690.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Increase in lease liability due to lease extension or establishment </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 16.5pt; width: 20.5333px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 16.5pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="bmra:IncreaseInLeaseLiability" scale="0" unitRef="usd">4,478</ix:nonFraction> </span></p>
</td>
<td style="height: 16.5pt; width: 19.3833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 16.5pt; width: 20.5333px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 16.5pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="bmra:IncreaseInLeaseLiability" scale="0" unitRef="usd">79,159</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 16.5pt;">
<td style="height: 16.5pt; width: 690.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Write off of fixed assets, cost </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 16.5pt; width: 20.5333px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 16.5pt; width: 118.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="bmra:WriteOffOfFixedAssetsCost" scale="0" unitRef="usd">819,931</ix:nonFraction> </span></p>
</td>
<td style="height: 16.5pt; width: 19.3833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 16.5pt; width: 20.5333px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 16.5pt; width: 118.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="-sec-ix-hidden: hidden-fact-14; font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">-</span></p>
</td>
</tr>
<tr style="height: 16.5pt;">
<td style="height: 16.5pt; width: 690.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Write off of fixed assets, accumulated depreciation </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 16.5pt; width: 20.5333px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 16.5pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="bmra:WriteOffOfFixedAssetsAccumulatedDepreciation" scale="0" unitRef="usd">767,344</ix:nonFraction> </span></p>
</td>
<td style="height: 16.5pt; width: 19.3833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 16.5pt; width: 20.5333px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 16.5pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="-sec-ix-hidden: hidden-fact-15; font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">-</span></p>
</td>
</tr>
<tr style="height: 16.5pt;">
<td style="height: 16.5pt; width: 690.933px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Write off of intangible assets, cost </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 16.5pt; width: 20.5333px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 16.5pt; width: 118.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="bmra:WriteOffOfIntangibleAssetsCost" scale="0" unitRef="usd">246,756</ix:nonFraction> </span></p>
</td>
<td style="height: 16.5pt; width: 19.3833px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 16.5pt; width: 20.5333px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 16.5pt; width: 118.067px; background: white none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="-sec-ix-hidden: hidden-fact-16; font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">-</span></p>
</td>
</tr>
<tr style="height: 16.5pt;">
<td style="height: 16.5pt; width: 690.933px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Write off of intangible assets, accumulated amortization </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 16.5pt; width: 20.5333px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 16.5pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="bmra:WriteOffOfIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd">37,221</ix:nonFraction> </span></p>
</td>
<td style="height: 16.5pt; width: 19.3833px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 16.5pt; width: 20.5333px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 16.5pt; width: 118.067px; background: #b4c6e7 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="-sec-ix-hidden: hidden-fact-17; font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">-</span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 690.933px; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15.75pt; width: 19.5833px; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15.75pt; width: 121.933px; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15.75pt; width: 19.3833px; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15.75pt; width: 19.5833px; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15.75pt; width: 121.933px; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 15pt;">
<td colspan="6" style="height: 15pt; width: 998.1px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 11pt; font-family: 'Times New Roman',sans-serif; color: black;">See accompanying notes to consolidated financial statements</span></p>
</td>
</tr>

</table></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">FS-7</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <a id="_aciHeader26"></a><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><b><span style="FONT-SIZE:10pt; COLOR:black">BIOMERICA, INC. AND SUBSIDIARIES</span></b></p> <a id="Notes"></a><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><b><span style="FONT-SIZE:10pt; COLOR:black">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><b><span style="FONT-SIZE:10pt; COLOR:black">YEARS ENDED MAY 31, 2022 AND 2021</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">NOTE 1: &#160;&#160;&#160;ORGANIZATION </span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric>  <ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1"><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">Biomerica, Inc. and its subsidiaries (which includes wholly-owned subsidiaries, Biomerica de Mexico and BioEurope GmbH) is</span><span style="font-size: 10pt;"> a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care </span><span style="font-size: 10pt; color: black;">(physicians' offices and over-the-counter through drugstores and online) </span><span style="font-size: 10pt;">and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases</span><span style="font-size: 10pt; color: black;">. Our diagnostic test kits are used to analyze blood, urine, nasal or fecal material from patients in the diagnosis of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which may exist in the human body in extremely small concentrations. The</span><span style="font-size: 10pt;"> Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our primary focus is the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided therapy (&#8220;DGT&#8221;) products to treat gastrointestinal diseases, such as irritable bowel syndrome, and other inflammatory diseases. These products are directed at chronic inflammatory illnesses that are widespread and common, and as such address very large markets. Our InFoods&#174; IBS product uses a simple blood sample and is designed to identify patient-specific foods that, when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea and constipation. Instead of broad and difficult to manage dietary restrictions, the InFoods&#174; IBS product works by identifying a patient&#8217;s above normal immunoreactivity to specific foods.&#160; A food identified as positive and causing an abnormal immune response in the patient is simply removed from the diet to help alleviate IBS symptoms. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_4" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our existing medical diagnostic products are sold worldwide primarily in two markets: 1) clinical laboratories and 2) point-of-care (physicians' offices and over-the-counter drugstores like Walmart and Walgreens). The diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens, or other substances, which may exist in a patient&#8217;s body, stools, or blood, often in extremely small concentrations.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <a id="_Hlk111716322"></a><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_5" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_4"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Due to the global 2019 SARS-CoV-2 novel coronavirus pandemic<span style="COLOR:black">, in March 2020 we</span> began developing COVID-19 products to indicate if a person has been infected by COVID-19 or is currently infected. While we offer a COVID-19 antibody diagnostic test to determine if a person has previously been infected by the COVID-19 virus, all of our COVID-19 revenues <span style="COLOR:black">in fiscal 2022</span> have come from international sales of our COVID-19 antigen tests that use a patient&#8217;s nasal fluid sample to detect if the patient is currently infected with the virus.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <a id="_Hlk111716362"></a><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_5"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The other existing products that contributed to our 2022 revenues are primarily focused on gastrointestinal diseases, food intolerances, and certain esoteric tests. These diagnostic test products utilize immunoassay technology. Most of our products are CE marked and/or sold for diagnostic use where they are registered by each country&#8217;s regulatory agency. In addition, some products are cleared for sale in the United States by the FDA.</span></p></ix:continuation> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">NOTE 2: &#160;&#160;&#160;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_ConsolidationPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">PRINCIPLES OF CONSOLIDATION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation id="_ConsolidationPolicyTextBlock-c0_cont_1"><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">The consolidated financial statements for the years ended May 31, 2022 and 2021, include the accounts of Biomerica, Inc. ("Biomerica") as well as its wholly-owned German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ACCOUNTING ESTIMATES</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:continuation continuedAt="_UseOfEstimates-c0_cont_2" id="_UseOfEstimates-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates, which are calculated based on historical data; inventory obsolescence, which is based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, the likelihood of lease extensions to occur, asset valuation, among other things; and other items that may be necessary to estimate using current, historical and judgment based information. Actual results could materially differ from those estimates. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">FS-8</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:continuation id="_UseOfEstimates-c0_cont_2"><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">Due to the Coronavirus global pandemic, the Company&#8217;s operations have been negatively impacted. <span style="color: black;">The Company has faced disruptions in the following areas, (and may face further challenges): supply chain disruptions, loss of contracts and/or customers, closure of the Company&#8217;s manufacturing or distribution facilities or of the facilities of the Company&#8217;s suppliers, partners and customers, travel, shipping and logistical disruptions, government responses of all types, international business risks in countries where the Company makes and/or sells its products, loss of human capital or personnel at the Company, its partners and its customers, interruptions of production, customer credit risk, and general economic calamities. These ongoing pandemic related disruptions can materially negatively impact the Company&#8217;s operations and financial performance and may continue to have significant material negative impacts on the Company.&#160;&#160; </span></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" continuedAt="_LiquidityPolicyTextBlock-c0_cont_1" escape="true" name="bmra:LiquidityPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">LIQUIDITY</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_8" id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:continuation continuedAt="_LiquidityPolicyTextBlock-c0_cont_2" id="_LiquidityPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company has incurred net losses and negative cash flows from operations and has an accumulated deficit of approximately $<ix:nonFraction contextRef="c32" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" unitRef="usd">35.3</ix:nonFraction> million as of May 31, 2022.&#160; Management expects to continue to incur significant costs as it advances its trials and development activities. As of May 31, 2022, the Company had cash and cash equivalents of approximately $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">5,917,000</ix:nonFraction> and working capital of approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="bmra:WorkingCapital" scale="0" unitRef="usd">7,416,000</ix:nonFraction>.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_9" id="_SignificantAccountingPoliciesTextBlock-c0_cont_8"><ix:continuation continuedAt="_LiquidityPolicyTextBlock-c0_cont_3" id="_LiquidityPolicyTextBlock-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">On January 22, 2021, the Company filed a Prospectus Supplement for purposes of raising up to $<ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="bmra:ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" scale="0" unitRef="usd">15,000,000</ix:nonFraction> to the base prospectus filed with the SEC on July 21, 2020, and was declared effective by the SEC on September 30, 2020, and an ATM &#8220;at the market offering&#8221; Agreement. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_10" id="_SignificantAccountingPoliciesTextBlock-c0_cont_9"><ix:continuation continuedAt="_LiquidityPolicyTextBlock-c0_cont_4" id="_LiquidityPolicyTextBlock-c0_cont_3"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">The Company intends to use the net proceeds from such offering for general corporate purposes, including, without limitation, sales and marketing activities, clinical studies, and product development, making acquisitions of assets, businesses, companies or securities, capital expenditures, and for working capital needs.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_11" id="_SignificantAccountingPoliciesTextBlock-c0_cont_10"><ix:continuation continuedAt="_LiquidityPolicyTextBlock-c0_cont_5" id="_LiquidityPolicyTextBlock-c0_cont_4"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Under an ATM Agreement, sales of the Placement Shares are deemed to be &#8220;at the market offering&#8221; as defined in Rule 415 promulgated under the Securities Act.&#160; The agent acts as sales agent under the ATM and uses commercially reasonable efforts to sell on the Company&#8217;s behalf all the Placement Shares requested to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the agent and the Company. The Company has no obligation to sell any of the Placement Shares under the ATM Agreement, and may at any time suspend offers under, or terminate the ATM Agreement.&#160; </span></p></ix:continuation></ix:continuation> <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_12" id="_SignificantAccountingPoliciesTextBlock-c0_cont_11"><ix:continuation continuedAt="_LiquidityPolicyTextBlock-c0_cont_6" id="_LiquidityPolicyTextBlock-c0_cont_5"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"><span style="FONT-SIZE:10pt">During the year ended May 31, 2022, the Company sold <ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">521,267</ix:nonFraction> shares of its common stock at prices ranging from $<ix:nonFraction contextRef="c35" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares">4.02</ix:nonFraction> to $<ix:nonFraction contextRef="c36" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares">5.63</ix:nonFraction> under its Form S-3 Registration Statement (</span><span style="FONT-SIZE:10pt; COLOR:black">File No. 333-239980) </span><span style="FONT-SIZE:10pt">and ATM Agreement which resulted in gross proceeds of approximately $<ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">2,402,000</ix:nonFraction> and net proceeds to the Company of $<ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" unitRef="usd">2,317,000</ix:nonFraction> after deducting commissions for each sale and legal, accounting, and other fees related to the filing of the Form S-3.</span></p></ix:continuation></ix:continuation> <a id="_Hlk80862558"></a><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_13" id="_SignificantAccountingPoliciesTextBlock-c0_cont_12"><ix:continuation id="_LiquidityPolicyTextBlock-c0_cont_6"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"><span style="FONT-SIZE:10pt">As a result of cash and cash equivalents on hand on May 31, 2022, and the ability to raise additional funds through the ATM noted above, management believes the Company has sufficient funds to operate through at least August 2023.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_14" id="_SignificantAccountingPoliciesTextBlock-c0_cont_13"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">FAIR VALUE OF FINANCIAL INSTRUMENTS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_15" id="_SignificantAccountingPoliciesTextBlock-c0_cont_14"><ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company has financial instruments whereby the fair market value of the financial instruments could be different than that recorded on a historical basis. The Company's financial instruments consist of its cash and cash equivalents, accounts receivable,&#160;and accounts payable. The carrying amounts of the Company's financial instruments approximate their fair values. The Company also maintains an investment in privately held company (see below). </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_16" id="_SignificantAccountingPoliciesTextBlock-c0_cont_15"><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">CONCENTRATION OF CREDIT RISK</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_17" id="_SignificantAccountingPoliciesTextBlock-c0_cont_16"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_2" id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies.&#160; As of May 31, 2022, the Company had approximately $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashUninsuredAmount" scale="0" unitRef="usd">5,702,000</ix:nonFraction> of uninsured cash. The Company does not believe it is exposed to any significant credit risks.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_18" id="_SignificantAccountingPoliciesTextBlock-c0_cont_17"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_3" id="_ConcentrationRiskCreditRisk-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company provides credit in the normal course of business to customers throughout the United States and in foreign markets.&#160; The Company performs ongoing credit evaluations of its customers and requires accelerated prepayment in some circumstances. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"></p></ix:continuation></ix:continuation>  <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_19" id="_SignificantAccountingPoliciesTextBlock-c0_cont_18"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_4" id="_ConcentrationRiskCreditRisk-c0_cont_3"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our net sales were approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">18,871,000</ix:nonFraction> for fiscal 2022 compared to $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">7,199,000</ix:nonFraction> for fiscal 2021. For the fiscal years ended May 31, 2022 and 2021, the Company had two distributors, which accounted for a total of <ix:nonFraction contextRef="c37" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">65</ix:nonFraction>% and <ix:nonFraction contextRef="c38" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">60</ix:nonFraction>% of our net sales, respectively. Of this, for the fiscal years ended May 31, 2022 and 2021, the largest of the distributors mentioned above accounted for <ix:nonFraction contextRef="c39" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">55</ix:nonFraction>% and <ix:nonFraction contextRef="c40" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">33</ix:nonFraction>%, respectively, of net sales.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"></p></ix:continuation></ix:continuation>  <br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">FS-9</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#TOC">Table of Contents</a></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><a id="_Hlk48558057"></a><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_20" id="_SignificantAccountingPoliciesTextBlock-c0_cont_19"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_5" id="_ConcentrationRiskCreditRisk-c0_cont_4"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total gross receivables on May 31, 2022 and 2021 were approximately $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesGrossCurrent" scale="0" unitRef="usd">927,000</ix:nonFraction> and $<ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesGrossCurrent" scale="0" unitRef="usd">2,292,000</ix:nonFraction>, respectively. On May 31, 2022 and 2021, the Company had one distributor and two distributors, respectively, which accounted for a total of <ix:nonFraction contextRef="c42" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">50</ix:nonFraction>% and <ix:nonFraction contextRef="c43" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">73</ix:nonFraction>%, respectively, of gross accounts receivable. Of the 50% as of May 31, 2022, <ix:nonFraction contextRef="c44" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">50</ix:nonFraction>% was owed by a distributor in Asia.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_21" id="_SignificantAccountingPoliciesTextBlock-c0_cont_20"><ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_5"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">For the fiscal years ended May 31, 2022 and 2021, the Company had one vendor, which accounted for <ix:nonFraction contextRef="c45" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">84</ix:nonFraction>% and <ix:nonFraction contextRef="c46" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">58</ix:nonFraction>%, respectively, of our purchases of raw materials.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_22" id="_SignificantAccountingPoliciesTextBlock-c0_cont_21"><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskGeographicPolicyPolicyTextBlock-c0_cont_1" escape="true" name="bmra:ConcentrationRiskGeographicPolicyPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">GEOGRAPHIC CONCENTRATION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_23" id="_SignificantAccountingPoliciesTextBlock-c0_cont_22"><ix:continuation id="_ConcentrationRiskGeographicPolicyPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">As of May 31, 2022 and 2021, a</span><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">pproximately $<ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="0" unitRef="usd">621,000</ix:nonFraction> <span style="COLOR:black">and $<ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="0" unitRef="usd">803,000</ix:nonFraction>, respectively</span> of Biomerica&#8217;s gross inventory was located in Mexicali, Mexico, respectively. <span style="COLOR:black">As of May 31, 2022 and 2021,</span> approximately $<ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">17,000</ix:nonFraction> <span style="COLOR:black">and $<ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">25,000</ix:nonFraction>, respectively</span> of Biomerica&#8217;s property and equipment, net of accumulated depreciation and amortization, was located in Mexicali, Mexico, respectively.</span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_24" id="_SignificantAccountingPoliciesTextBlock-c0_cont_23"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">CASH AND</span></b><span style="FONT-SIZE:10pt"><b><span style="COLOR:black"> CASH EQUIVALENTS</span></b></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_25" id="_SignificantAccountingPoliciesTextBlock-c0_cont_24"><ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_26" id="_SignificantAccountingPoliciesTextBlock-c0_cont_25"><ix:nonNumeric contextRef="c0" continuedAt="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1" escape="true" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ACCOUNTS RECEIVABLE</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_27" id="_SignificantAccountingPoliciesTextBlock-c0_cont_26"><ix:continuation continuedAt="_TradeAndOtherAccountsReceivablePolicy-c0_cont_2" id="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company extends unsecured credit to its customers on a regular basis. &#160;International accounts are usually required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. &#160;&#160;Initial credit levels for individual distributors are approved by designated officers and managers of the Company. All increases in credit limits are also approved by designated upper-level management. &#160;Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. &#160;Balances over <ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="us-gaap:ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable">ninety days</ix:nonNumeric> old are usually reserved for unless collection is reasonably assured. &#160; </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_28" id="_SignificantAccountingPoliciesTextBlock-c0_cont_27"><ix:continuation continuedAt="_TradeAndOtherAccountsReceivablePolicy-c0_cont_3" id="_TradeAndOtherAccountsReceivablePolicy-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables. &#160; Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_29" id="_SignificantAccountingPoliciesTextBlock-c0_cont_28"><ix:continuation id="_TradeAndOtherAccountsReceivablePolicy-c0_cont_3"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">As of May 31, 2022 and 2021, the Company has established a reserve of approximately $<ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" unitRef="usd">153,000</ix:nonFraction> and $<ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" unitRef="usd">837,000</ix:nonFraction>, respectively, for doubtful accounts. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_30" id="_SignificantAccountingPoliciesTextBlock-c0_cont_29"><ix:nonNumeric contextRef="c0" continuedAt="_PrepaidsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="bmra:PrepaidsPolicyPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">PREPAIDS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_31" id="_SignificantAccountingPoliciesTextBlock-c0_cont_30"><ix:continuation continuedAt="_PrepaidsPolicyPolicyTextBlock-c0_cont_2" id="_PrepaidsPolicyPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">The Company occasionally prepays for items such as inventory, insurance, and other items.&#160; These items are reported as prepaids, until either the inventory is physically received or the insurance and other items are utilized.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_32" id="_SignificantAccountingPoliciesTextBlock-c0_cont_31"><ix:continuation id="_PrepaidsPolicyPolicyTextBlock-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">As of May 31, 2022 and 2021, the prepaids were approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidSupplies" scale="0" unitRef="usd">320,000</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidSupplies" scale="0" unitRef="usd">370,000</ix:nonFraction>, respectively, composed of prepayments to insurance and various other suppliers. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_33" id="_SignificantAccountingPoliciesTextBlock-c0_cont_32"><ix:nonNumeric contextRef="c0" continuedAt="_InventoryPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">INVENTORIES, NET</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_34" id="_SignificantAccountingPoliciesTextBlock-c0_cont_33"><ix:continuation continuedAt="_InventoryPolicyTextBlock-c0_cont_2" id="_InventoryPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black">The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_35" id="_SignificantAccountingPoliciesTextBlock-c0_cont_34"><ix:continuation continuedAt="_InventoryPolicyTextBlock-c0_cont_3" id="_InventoryPolicyTextBlock-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The following is a summary of approximate net inventories:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation> <div style="text-align: left;"> <p>&#160;</p>
<ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_36" id="_SignificantAccountingPoliciesTextBlock-c0_cont_35"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><ix:continuation continuedAt="_InventoryPolicyTextBlock-c0_cont_4" id="_InventoryPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733">

<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td colspan="5" style="border-top: 0px; height: 15pt; border-right: 0px; width: 29.82%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">May 31,</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">2022</span></p>
</td>
<td style="height: 15pt; width: 1.78%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">2021</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Raw materials</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 12.04%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" unitRef="usd">1,717,000</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 1.78%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;$ </span></p>
</td>
<td style="height: 15pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" unitRef="usd">1,812,000</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Work in progress</span></p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 12.04%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="0" unitRef="usd">763,000</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 1.78%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="0" unitRef="usd">1,687,000</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Finished products</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.04%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" unitRef="usd">782,000</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 1.78%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" unitRef="usd">1,324,000</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Total gross inventory</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.04%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="0" unitRef="usd">3,262,000</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 1.78%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;$ </span></strong></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="0" unitRef="usd">4,823,000</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Inventory reserve</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.04%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" unitRef="usd">846,000</ix:nonFraction>)</span></p>
</td>
<td style="height: 15pt; width: 1.78%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" unitRef="usd">1,617,000</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 70.18%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Net inventory </span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12.04%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">2,416,000</ix:nonFraction> </span></strong></p>
</td>
<td style="height: 15.75pt; width: 1.78%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">3,206,000</ix:nonFraction> </span></strong></p>
</td>
</tr>

</table></ix:continuation></ix:nonNumeric></ix:continuation></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">FS-10</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_37" id="_SignificantAccountingPoliciesTextBlock-c0_cont_36"><ix:continuation id="_InventoryPolicyTextBlock-c0_cont_4"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically reserve for obsolete inventory. As of May 31, 2022 and 2021, inventory reserves were approximately $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" unitRef="usd">846,000</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" unitRef="usd">1,617,000</ix:nonFraction>, respectively. During the fiscal 2022 the Company disposed of COVID-19 antibody inventory that wasn&#8217;t sellable, this has been partially reserved for in fiscal 2021. The reduction in our inventory reserve relates to the COVID-19 antibody disposal. The Company continues to sell COVID-19 antigen tests. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_38" id="_SignificantAccountingPoliciesTextBlock-c0_cont_37"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">PROPERTY AND EQUIPMENT, NET</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_39" id="_SignificantAccountingPoliciesTextBlock-c0_cont_38"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_40" id="_SignificantAccountingPoliciesTextBlock-c0_cont_39"><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from <ix:nonNumeric contextRef="c51" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric> to <ix:nonNumeric contextRef="c52" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric> years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment amounted to approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd">100,000</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd">105,000</ix:nonFraction> for the years ended May 31, 2022 and 2021, respectively. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_41" id="_SignificantAccountingPoliciesTextBlock-c0_cont_40"><ix:nonNumeric contextRef="c0" continuedAt="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">INTANGIBLE ASSETS, NET</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_42" id="_SignificantAccountingPoliciesTextBlock-c0_cont_41"><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_2" id="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (&#8220;ASC&#8221;), ASC 350 Intangibles &#8211; Goodwill and Other (&#8220;ASC 350&#8221;). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_43" id="_SignificantAccountingPoliciesTextBlock-c0_cont_42"><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_3" id="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Intangible assets are being amortized using the straight-line method over the useful life, not to exceed <ix:nonNumeric contextRef="c53" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">18</ix:nonNumeric> years for marketing and distribution rights, <ix:nonNumeric contextRef="c54" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">10</ix:nonNumeric> years for purchased technology use rights, and <ix:nonNumeric contextRef="c55" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">20</ix:nonNumeric> years for patents. Amortization amounted to approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd">239,000</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd">34,000</ix:nonFraction> for the years ended May 31, 2022 and 2021, respectively.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_44" id="_SignificantAccountingPoliciesTextBlock-c0_cont_43"><ix:continuation id="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_3"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset's balance over its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine whether there was any impairment. As of May 31, 2022 and 2021, an impairment adjustment was made of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetImpairmentCharges" scale="0" unitRef="usd">210,000</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetImpairmentCharges" scale="0" unitRef="usd">0</ix:nonFraction>, respectively.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_45" id="_SignificantAccountingPoliciesTextBlock-c0_cont_44"><ix:nonNumeric contextRef="c0" continuedAt="_InvestmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InvestmentPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">INVESTMENTS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_46" id="_SignificantAccountingPoliciesTextBlock-c0_cont_45"><ix:continuation continuedAt="_InvestmentPolicyTextBlock-c0_cont_2" id="_InvestmentPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">From time-to-time, the Company makes investments in privately held companies. Investments represent the Company&#8217;s investment in a Polish distributor, which is primarily engaged in distributing medical products and devices. The Company owns approximately <ix:nonFraction contextRef="c56" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">6</ix:nonFraction>% of the investee and, accordingly, applies the cost method holdings to account for the investment. The Company invested approximately $<ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Investments" scale="0" unitRef="usd">165,000</ix:nonFraction> into the Polish distributor.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation> <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_47" id="_SignificantAccountingPoliciesTextBlock-c0_cont_46"><ix:continuation continuedAt="_InvestmentPolicyTextBlock-c0_cont_3" id="_InvestmentPolicyTextBlock-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Equity holdings in nonmarketable unconsolidated entities in which the Company is not able to exercise significant influence ("Cost Method Holdings") are accounted for at the Company's initial cost, minus any impairment (if any), plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar holding or security of the same issuer. Dividends received are recorded as other income.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation> <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_48" id="_SignificantAccountingPoliciesTextBlock-c0_cont_47"><ix:continuation id="_InvestmentPolicyTextBlock-c0_cont_3"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company assesses its equity holdings for impairment whenever events or changes in circumstances indicate that the carrying value of an equity holding may not be recoverable. Management reviewed the underlying net assets of the Company's equity method holding as of May 31, 2022 and determined that the Company's proportionate economic interest in the entity indicates that the equity holding was not impaired. There were no observable price changes in orderly transactions for identical or a similar holding or security of the Company&#8217;s Cost Method Holding during the year ended May 31, 2022.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_49" id="_SignificantAccountingPoliciesTextBlock-c0_cont_48"><ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">SHARE-BASED COMPENSATION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <a id="_Hlk17621381"></a><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_50" id="_SignificantAccountingPoliciesTextBlock-c0_cont_49"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company follows the guidance of ASC 718, Share-based Compensation (&#8220;ASC 718&#8221;), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes options-pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the foreseeable future. Expected volatilities are based on weighted averages of the historical volatility of the Company&#8217;s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the &#8220;simplified method&#8221; which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited exercise activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. The grant date fair value of the award is recognized under the straight-line attribution method.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation> <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_51" id="_SignificantAccountingPoliciesTextBlock-c0_cont_50"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company expensed approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">1,260,000</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">1,355,000</ix:nonFraction> of stock-based compensation during the years ended May 31, 2022 and 2021, respectively.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">FS-11</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_52" id="_SignificantAccountingPoliciesTextBlock-c0_cont_51"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_4" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">In applying the Black-Scholes options-pricing model, assumptions used were as follows: &#160;</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <div style="text-align: left;"> <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_53" id="_SignificantAccountingPoliciesTextBlock-c0_cont_52"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_4"><table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733">

<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td colspan="4" style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">For the year ended May 31,</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2022</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2021</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Dividend yield</span></p>
</td>
<td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction>%</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction>%</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Expected volatility</span></p>
</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c51" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">102.54</ix:nonFraction> - <ix:nonFraction contextRef="c52" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">105.48</ix:nonFraction>% </span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">&#160;<ix:nonFraction contextRef="c58" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">71.19</ix:nonFraction> - <ix:nonFraction contextRef="c59" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">107.53</ix:nonFraction>% </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Risk free interest rate</span></p>
</td>
<td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">&#160;<ix:nonFraction contextRef="c51" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.97</ix:nonFraction>-<ix:nonFraction contextRef="c52" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">2.75</ix:nonFraction>% </span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">&#160;<ix:nonFraction contextRef="c58" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.34</ix:nonFraction>-<ix:nonFraction contextRef="c59" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">1.18</ix:nonFraction>% </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Expected term</span></p>
</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">&#160;<ix:nonNumeric contextRef="c51" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.50</ix:nonNumeric>-<ix:nonNumeric contextRef="c52" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.25</ix:nonNumeric> Years </span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">&#160;<ix:nonNumeric contextRef="c58" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.50</ix:nonNumeric>-<ix:nonNumeric contextRef="c59" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.25</ix:nonNumeric> Years </span></p>
</td>
</tr>

</table></ix:continuation></ix:nonNumeric></ix:continuation></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_54" id="_SignificantAccountingPoliciesTextBlock-c0_cont_53"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">REVENUE RECOGNITION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <a id="_Hlk49511094"></a><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_55" id="_SignificantAccountingPoliciesTextBlock-c0_cont_54"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company has various contracts with customers.&#160; All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred, and at which point title passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company regularly evaluates the status of these contracts and does not believe that any additional discounts will be given through the end of the contract periods. </span><span style="FONT-SIZE:10pt">Services for contract work are invoiced and recognized for work that has been performed as the project progresses. <span style="COLOR:black">The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools, and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors. &#160;Physicians&#8217; office products are sold to physicians and distributors, all of whom are categorized below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international manufacturers. </span></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_56" id="_SignificantAccountingPoliciesTextBlock-c0_cont_55"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_3" id="_RevenueRecognitionPolicyTextBlock-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Disaggregation of revenue:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_57" id="_SignificantAccountingPoliciesTextBlock-c0_cont_56"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_4" id="_RevenueRecognitionPolicyTextBlock-c0_cont_3"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The following is an approximate breakdown of revenues according to primary markets to which the products are sold:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <div style="text-align: left;"> <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_58" id="_SignificantAccountingPoliciesTextBlock-c0_cont_57"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_5" id="_RevenueRecognitionPolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733">

<tr style="height: 15pt;">
<td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="5" style="border-top: 0px; height: 15pt; border-right: 0px; width: 165pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">For the year ended May 31,</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 77pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2022</span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 77pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2021</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 374pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Physician's office</span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c60" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd">14,259,000</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c61" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd">2,801,000</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Clinical lab</span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c62" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd">3,064,000</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c63" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd">3,077,000</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 374pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Over-the-counter</span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c64" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd">1,089,000</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c65" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd">766,000</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Contract manufacturing</span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c66" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd">459,000</ix:nonFraction> </span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c67" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd">555,000</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 374pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Total</span></strong></p>
</td>
<td style="height: 15.75pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 66pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd">18,871,000</ix:nonFraction> </span></strong></p>
</td>
<td style="height: 15.75pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 66pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd">7,199,000</ix:nonFraction> </span></strong></p>
</td>
</tr>

</table></ix:continuation></ix:nonNumeric></ix:continuation></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_59" id="_SignificantAccountingPoliciesTextBlock-c0_cont_58"><ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_5"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">See Note 8 for additional information regarding geographic revenue concentrations.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_60" id="_SignificantAccountingPoliciesTextBlock-c0_cont_59"><ix:nonNumeric contextRef="c0" continuedAt="_CostOfSalesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CostOfSalesPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">SHIPPING AND HANDLING FEES </span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_61" id="_SignificantAccountingPoliciesTextBlock-c0_cont_60"><ix:continuation id="_CostOfSalesPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company includes shipping and handling fees billed to customers in net sales. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_62" id="_SignificantAccountingPoliciesTextBlock-c0_cont_61"><ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">RESEARCH AND DEVELOPMENT</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_63" id="_SignificantAccountingPoliciesTextBlock-c0_cont_62"><ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Research and development costs are expensed as incurred. The Company expensed approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">1,812,000</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">2,194,000</ix:nonFraction> of research and development costs during the years ended May 31, 2022 and 2021, respectively.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_64" id="_SignificantAccountingPoliciesTextBlock-c0_cont_63"><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">INCOME TAXES</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_65" id="_SignificantAccountingPoliciesTextBlock-c0_cont_64"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company accounts for income taxes in accordance with ASC 740, Income Taxes (&#8220;ASC 740&#8221;). Deferred tax assets and liabilities arise from temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements that will result in taxable or deductible amounts in future years and the benefits of net operating loss and tax credit carryforwards. These temporary differences and the benefits of net operating loss and tax credit carryforwards are measured using enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets to the extent that management considers it is more likely than not that a deferred tax asset will not be realized. In determining the valuation allowance, the Company considers factors such as the reversal of deferred income tax assets, projected taxable income, and the character of income tax assets and tax planning strategies. A change to these factors could impact the estimated valuation allowance and income tax expense. On May 31, 2022 and 2021, in accordance with ASC 740, the Company has a valuation allowance for substantially all of its net deferred tax assets.&#160;&#160; During the fiscal year ended May 31, 2022, <span style="BACKGROUND:none">this valuation allowance was increased to $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd">6,967,000</ix:nonFraction>, which fully covers the net tax asset of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd">6,967,000</ix:nonFraction></span></span><span style="FONT-SIZE:9pt; BACKGROUND:none; COLOR:black">.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">FS-12</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_66" id="_SignificantAccountingPoliciesTextBlock-c0_cont_65"><ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company accounts for its uncertain tax provisions by using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, based solely on the technical merits, that the position will be sustained in an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the appropriate amount of the benefit to recognize. The amount of benefit to recognize is measured as the maximum amount which is more likely than not to be realized. The tax position is derecognized when it is no longer more likely than not capable of being sustained. On subsequent recognition and measurement, the maximum amount which is more likely than not to be recognized at each reporting date will represent the Company&#8217;s best estimate, given the information available at the reporting date, although the outcome of the tax position is not absolute or final. The Company elected to follow an accounting policy to classify accrued interest related to liabilities for income taxes within the &#8220;Interest expense&#8221; line and penalties related to liabilities for income taxes within the &#8220;Other expense&#8221; line of the consolidated statements of operations and comprehensive loss. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_67" id="_SignificantAccountingPoliciesTextBlock-c0_cont_66"><ix:nonNumeric contextRef="c0" continuedAt="_AdvertisingCostsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:AdvertisingCostsPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ADVERTISING COSTS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_68" id="_SignificantAccountingPoliciesTextBlock-c0_cont_67"><ix:continuation id="_AdvertisingCostsPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company reports the cost of all advertising as expense in the period in which those costs are incurred. Advertising costs were approximately <span style="BACKGROUND:white">$<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdvertisingExpense" scale="0" unitRef="usd">76,000</ix:nonFraction></span> and $<span style="BACKGROUND:white"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdvertisingExpense" scale="0" unitRef="usd">10,000</ix:nonFraction></span> for the years ended May 31, 2022 and 2021, respectively. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_69" id="_SignificantAccountingPoliciesTextBlock-c0_cont_68"><ix:nonNumeric contextRef="c0" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">FOREIGN CURRENCY TRANSLATION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_70" id="_SignificantAccountingPoliciesTextBlock-c0_cont_69"><ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the year, and revenues and costs are translated using average exchange rates for the year. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no foreign currency transactions that are included in the consolidated statements of operations for the years ended May 31, 2022 and 2021.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_71" id="_SignificantAccountingPoliciesTextBlock-c0_cont_70"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">RIGHT-OF-USE ASSETS AND LEASE LIABILITY</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_72" id="_SignificantAccountingPoliciesTextBlock-c0_cont_71"><ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued an accounting standard update which requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset.&#160; Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.&#160; Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term.&#160; Leases are classified as financing or operating which will drive the expense recognition pattern.&#160; The Company has elected to exclude short-term leases.&#160; The Company adopted this guidance as of June 1, 2019, the required effective date, &#160;which resulted in a right-of-use asset being recorded of approximately $<ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd">1,943,000</ix:nonFraction> and a lease liability being recorded of approximately $<ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd">1,981,000</ix:nonFraction>. On April 9, 2021, the Company exercised its second option to extend its lease for an additional five years.&#160; As part of that lease extension agreement, the Company was granted an additional right to extend its lease for five years, up through August 2031. However, given the recent growth in the Company&#8217;s operations, and the expectation that operations will continue to grow in the near future, the Company believes that it will be necessary to relocate into larger facilities by the end of the current lease term. Therefore, the Company has elected to not include the additional five-year extension option, from August 2026 to August 2031, into its right-of-use asset or its lease liability accounts. For additional information, see Note 9-Commitments and Contingencies. The Company leases office space and copy machines, all of which are operating leases.&#160; Most leases include the option to renew and the exercise of the renewal options is at the Company&#8217;s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.&#160; The leases do not include the options to purchase the leased property.&#160; The depreciable life of assets and leasehold improvements are limited by the expected lease term.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_73" id="_SignificantAccountingPoliciesTextBlock-c0_cont_72"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">NET LOSS PER SHARE </span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_74" id="_SignificantAccountingPoliciesTextBlock-c0_cont_73"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amounts of anti-dilutive stock options not included in the loss per share calculation for the years ended May 31, 2022 and 2021 were <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">2,321,616</ix:nonFraction> and <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">2,081,366</ix:nonFraction>, respectively. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">&#160;FS-13</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_75" id="_SignificantAccountingPoliciesTextBlock-c0_cont_74"><ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">SEGMENT REPORTING</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_76" id="_SignificantAccountingPoliciesTextBlock-c0_cont_75"><ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">ASC 280, Segment Reporting (&#8220;ASC 280&#8221;), establishes standards for reporting, by public business enterprises, information about operating segments, products and services, geographic areas, and major customers. The Company&#8217;s operations are analyzed by management and its chief operating decision maker as being part of a single industry segment: the design, development, marketing, and sales of diagnostic kits.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_77" id="_SignificantAccountingPoliciesTextBlock-c0_cont_76"><ix:nonNumeric contextRef="c0" continuedAt="_ComprehensiveIncomePolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">REPORTING COMPREHENSIVE LOSS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_78" id="_SignificantAccountingPoliciesTextBlock-c0_cont_77"><ix:continuation id="_ComprehensiveIncomePolicyPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Comprehensive loss represents net loss and any revenues, expenses, gains and losses that, under GAAP, are excluded from net loss and recognized directly as a component of shareholders&#8217; equity. Items of other comprehensive loss consist solely of foreign currency translation adjustments for the years ended May 31, 2022 and 2021. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_79" id="_SignificantAccountingPoliciesTextBlock-c0_cont_78"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">RECENT ACCOUNTING PRONOUNCEMENTS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_80" id="_SignificantAccountingPoliciesTextBlock-c0_cont_79"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">Recent ASU's issued by the FASB and guidance issued by the SEC did not, or are not believed by management to, have a material effect on the Company&#8217;s present or future consolidated financial statements. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_81" id="_SignificantAccountingPoliciesTextBlock-c0_cont_80"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in 0.1in 0in 0in;"><span style="font-size: 10pt; color: black;">In June 2016, the FASB issued ASU 2016-13, "Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments." This ASU will require the measurement of all expected credit losses for financial assets, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The guidance was initially effective for the Company for annual reporting periods beginning after December 15, 2019, and interim periods within those fiscal years. In November 2019, the FASB issued ASU 201&#183;9- 10, "Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates," which, among other things, defers the effective date of ASU 2016-13 for public filers that are considered smaller reporting companies as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including interim periods within those years. Early adoption is permitted. The Company is currently reviewing the requirements of this ASU to determine its impact on the Company&#8217;s consolidated results of operations and financial position. </span></p><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in 0.1in 0in 0in;">&#160;</p></ix:continuation></ix:continuation>

<ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_82" id="_SignificantAccountingPoliciesTextBlock-c0_cont_81"><ix:nonNumeric contextRef="c0" continuedAt="_PriorPeriodReclassificationAdjustmentDescription-c0_cont_1" escape="true" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p style="margin: 0in; text-align: justify;"><span style="font-family: times new roman, times, serif; font-size: 10pt;"><strong><span style="color: black;">RECLASSIFICATIONS</span></strong></span></p><p style="margin: 0in; text-align: justify;"><span style="font-family: times new roman, times, serif; font-size: 10pt;"><strong><span style="color: black;">&#160;</span></strong></span></p></ix:nonNumeric></ix:continuation>

<ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_82"><ix:continuation id="_PriorPeriodReclassificationAdjustmentDescription-c0_cont_1"><p style="margin: 0in; text-align: justify;"><span style="font-size: 10.0pt; color: black;"><span style="font-family: times new roman, times, serif;">Certain comparative figures in the 2021 Statement of Operations have been reclassified to conform to the current year&#8217;s presentation.</span> </span></p></ix:continuation></ix:continuation>
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in 0.1in 0in 0in;">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">NOTE 3: &#160;&#160;&#160;PROPERTY AND EQUIPMENT, NET</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></ix:nonNumeric>  <ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The following is an approximate breakdown of property and equipment, net of accumulated depreciation:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></ix:continuation>  <div style="text-align: left;"> <ix:continuation id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:165pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">May 31,</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:77pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2022</span></p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:77pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2021</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Equipment</span></p></td> <td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:66pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="bmra:Equipment" scale="0" unitRef="usd">1,292,000</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:66pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c4" decimals="-4" format="ixt:num-dot-decimal" name="bmra:Equipment" scale="0" unitRef="usd">1,850,000</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Furniture, fixtures and leasehold improvements</span></p></td> <td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:66pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="bmra:FurnitureFixturesAndLeaseholdImprovements" scale="0" unitRef="usd">227,000</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:66pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="bmra:FurnitureFixturesAndLeaseholdImprovements" scale="0" unitRef="usd">433,000</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Less accumulated depreciation</span></p></td> <td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">1,305,000</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">1,972,000</ix:nonFraction>)</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:374pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Net property and equipment</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">214,000</ix:nonFraction></span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">311,000</ix:nonFraction></span></b></p></td></tr></table></ix:nonNumeric></ix:continuation></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <ix:nonNumeric contextRef="c0" continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">NOTE 4: &#160;&#160;&#160;INTANGIBLE ASSETS, NET</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></ix:nonNumeric>  <ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_2" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The following is an approximate breakdown of intangible assets, net of accumulated amortization:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></ix:continuation>  <div style="text-align: left;"> <ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_3" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:26%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 26%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black"> May 31,</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2022</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2021</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Licenses</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-18; FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-&#160;&#160; </span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedLicenseAgreementsGross" scale="0" unitRef="usd">182,000</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Patents</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedPatentsGross" scale="0" unitRef="usd">189,000</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c4" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedPatentsGross" scale="0" unitRef="usd">240,000</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Less accumulated amortization-licenses</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-19; FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="bmra:FiniteLivedLicenseAccumulatedAmortization" scale="0" unitRef="usd">107,000</ix:nonFraction>)</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Less accumulated amortization-patents</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="bmra:FiniteLivedPatentsAccumulatedAmortization" scale="0" unitRef="usd">19,000</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c4" decimals="-4" format="ixt:num-dot-decimal" name="bmra:FiniteLivedPatentsAccumulatedAmortization" scale="0" unitRef="usd">20,000</ix:nonFraction>)</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Intangible asssets, net</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd">170,000</ix:nonFraction></span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd">295,000</ix:nonFraction></span></b></p></td></tr></table></ix:nonNumeric></ix:continuation></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_4" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_3"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Expected amortization of intangible assets for the years ending May 31:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></ix:continuation>  <div style="text-align: left;"> <ix:continuation id="_IntangibleAssetsDisclosureTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">2023</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="0" unitRef="usd">13,000</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">2024</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="0" unitRef="usd">13,000</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">2025</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="0" unitRef="usd">13,000</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">2026</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="0" unitRef="usd">13,000</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">2027</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="0" unitRef="usd">13,000</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Thereafter</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="0" unitRef="usd">105,000</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Total</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd">170,000</ix:nonFraction></span></b></p></td></tr></table></ix:nonNumeric></ix:continuation></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">FS-14</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <ix:nonNumeric contextRef="c0" continuedAt="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">NOTE 5:&#160;&#160;&#160; ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></ix:nonNumeric>  <ix:continuation continuedAt="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_2" id="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The following is an approximate breakdown of accounts payable and accrued expenses balances:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></ix:continuation>  <div style="text-align: left;"> <ix:continuation continuedAt="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_3" id="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="WIDTH:555.6pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="741"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:169pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">May 31,</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:78.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2022</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:78.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2021</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Accounts payable</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd">736,000</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd">431,000</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Accrued expenses</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd">236,000</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd">152,000</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Total</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd">972,000</ix:nonFraction></span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd">583,000</ix:nonFraction></span></b></p></td></tr></table></ix:nonNumeric></ix:continuation></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <ix:continuation id="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_3"><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">As of May 31, 2022 and 2021 the Company had two vendors and one vendor, respectively, which accounted for <ix:nonFraction contextRef="c68" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">69</ix:nonFraction>% and <ix:nonFraction contextRef="c69" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">17</ix:nonFraction>%, respectively, of accounts payable.</span></p></ix:continuation> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">NOTE 6: &#160;&#160;&#160;SHAREHOLDERS' EQUITY</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></ix:nonNumeric>  <ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">STOCK OPTION AND RESTRICTED STOCK PLANS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">In December 2014, the Company adopted a stock option and restricted stock plan (the "2014 Plan") which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of <ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" unitRef="shares">850,000</ix:nonFraction> shares of the Company's unissued common stock may be granted to affiliates, employees, or consultants of the Company. This plan was approved by shareholders in December 2014. &#160;The 2014 Plan expires in December 2024. Options granted under the 2014 Plan will be granted at prices not less than <ix:nonFraction contextRef="c71" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" unitRef="pure">80</ix:nonFraction>% of the then fair market value of the common stock and will expire not more than <ix:nonNumeric contextRef="c71" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">10</ix:nonNumeric> years after the date of grant.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">In December 2017, the Company adopted a stock option and restricted stock plan (the &#8220;2017 Plan&#8221;) which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of <ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" unitRef="shares">900,000</ix:nonFraction> shares of the Company&#8217;s unissued common stock may be granted to affiliates, employees, or consultants of the Company.&#160; This plan was approved by shareholders in December 2017.&#160; The 2017 Plan expires in December 2027.&#160; Options granted under the 2017 Plan will be granted at prices not less than <ix:nonFraction contextRef="c73" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" unitRef="pure">80</ix:nonFraction>% of the then fair market value of the common stock and will expire not more than <ix:nonNumeric contextRef="c73" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">10</ix:nonNumeric> years after the date of grant.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">In February 2020, the Board approved the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;) and on December 11, 2020, the shareholders of the Company approved The Plan. The 2020 Plan authorizes the issuance of an aggregate number of common stock options and/or restricted common shares to be issued in an amount not to exceed <ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" unitRef="shares">900,000</ix:nonFraction>. &#160;The 2020 Plan authorizes the issuance of common stock options and restricted common shares to employees, directors, and consultants of the Company. During fiscal 2020, certain common stock options were granted under this plan. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Stock option expense during fiscal 2022 was approximately $<ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">1,260,000</ix:nonFraction>. This included, by department, $<ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">954,000</ix:nonFraction> for administrative, $<ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">159,000</ix:nonFraction> for production, $<ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">80,000</ix:nonFraction> for research and development and $<ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">67,000</ix:nonFraction> for sales and marketing.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Stock option expense during fiscal 2021 was approximately $<ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">1,355,000</ix:nonFraction>. This included, by department, $<ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">957,000</ix:nonFraction> for administrative, $<ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">205,000</ix:nonFraction> for production, $<ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">125,000</ix:nonFraction> for research and development and $<ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">68,000</ix:nonFraction> for sales and marketing</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Activity as to aggregate stock options outstanding is as follows: </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </p></ix:continuation>  <div style="text-align: left;"> <ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="width: 550.7pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="734">

<tr style="height: 15pt;">
<td style="height: 15pt; width: 300.25pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 67.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">NUMBER OF <br/>STOCK OPTIONS</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.6pt; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66.05pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">EXCERCISE <br/>PRICE RANGE <br/>PER SHARE</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.6pt; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 79.4pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">WEIGHTED <br/>AVERAGE <br/>EXERCISE PRICE</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 300.25pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Options outstanding at May 31, 2020</span></strong></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c106" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">1,789,251</ix:nonFraction></span></strong></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 66.05pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$0.82-$8.18</span></strong></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$</span></strong></p>
</td>
<td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c106" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">2.75</ix:nonFraction></span></strong></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 300.25pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Options granted</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 67.2pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c107" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">430,616</ix:nonFraction></span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 66.05pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">$5.14-$8.70</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12.2pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 67.2pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c107" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">6.73</ix:nonFraction></span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 300.25pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Options excercised</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c108" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">86,750</ix:nonFraction>)</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 66.05pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">$0.82-$3.62</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c108" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">1.20</ix:nonFraction></span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 300.25pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Options canceled or expired</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 67.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c109" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" unitRef="shares">51,751</ix:nonFraction>)</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66.05pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">$2.35-$8.18</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 67.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c109" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">4.77</ix:nonFraction></span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 300.25pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Options outstanding at May 31, 2021</span></strong></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-bottom: windowtext 1pt solid; height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c110" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">2,081,366</ix:nonFraction></span></strong></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-bottom: windowtext 1pt solid; height: 15pt; width: 66.05pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$0.82-$8.70</span></strong></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$</span></strong></p>
</td>
<td style="border-bottom: windowtext 1pt solid; height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c110" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">3.59</ix:nonFraction></span></strong></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 300.25pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Options granted</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 67.2pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c111" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">344,000</ix:nonFraction></span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 66.05pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">$4.25-$4.46</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12.2pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 67.2pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c111" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">4.43</ix:nonFraction></span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 300.25pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Options excercised</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c112" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">39,500</ix:nonFraction>)</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 66.05pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">$1.20-$3.62</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c112" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">1.99</ix:nonFraction></span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 300.25pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Options canceled or expired</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 67.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c113" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" unitRef="shares">64,250</ix:nonFraction>)</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66.05pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">$1.61-$8.18</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 67.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c113" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">4.41</ix:nonFraction></span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 300.25pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Options outstanding at May 31, 2022</span></strong></p>
</td>
<td style="height: 15.75pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 67.2pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c114" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">2,321,616</ix:nonFraction></span></strong></p>
</td>
<td style="height: 15.75pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 66.05pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$0.82-$8.70</span></strong></p>
</td>
<td style="height: 15.75pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12.2pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 67.2pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c114" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">3.72</ix:nonFraction></span></strong></p>
</td>
</tr>

</table></ix:nonNumeric></ix:continuation></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">FS-15</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The weighted average fair value of options granted during 2022 and 2021 were $<ix:nonFraction contextRef="c75" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">4.43</ix:nonFraction> and $<ix:nonFraction contextRef="c80" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">6.73</ix:nonFraction>, respectively. The aggregate intrinsic value of options exercised during 2022 and 2021 was approximately $<ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" unitRef="usd">90,000</ix:nonFraction> and $<ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" unitRef="usd">501,000</ix:nonFraction>, respectively. The aggregate intrinsic value of options outstanding on May 31, 2022 and 2021 was approximately $<ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" unitRef="usd">1,838,000</ix:nonFraction> and $<ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" unitRef="usd">2,132,000</ix:nonFraction>, respectively. The aggregate intrinsic value of options vested and exercisable on May 31, 2022 and 2021 was approximately $<ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" unitRef="usd">1,731,000</ix:nonFraction> and $<ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" unitRef="usd">1,872,000</ix:nonFraction>, respectively.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt">The number of non-vested stock options included in the table above is as follows:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;&#160; </p></ix:continuation>  <div style="text-align: left;"> <ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:54.75pt"> <td style="HEIGHT:54.75pt; WIDTH:2.4in; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:54.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:54.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Number of<br/>&#160;shares</span></p></td> <td style="HEIGHT:54.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:54.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Stock options<br/>weighted<br/>average grant<br/>date fair value</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:2.4in; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Non-vested shares at May 31, 2021</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares">793,241</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">5.54</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:2.4in; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Granted</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">344,000</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">4.43</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:2.4in; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Vested&#160;</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares">347,279</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">5.40</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:2.4in; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Forfeited</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" scale="0" unitRef="shares">43,500</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">5.22</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:2.4in; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Non-vested shares at May 31, 2022</span></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares">746,462</ix:nonFraction></span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">5.11</ix:nonFraction></span></b></p></td></tr></table></ix:nonNumeric></ix:continuation></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <div> <ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">On May 31, 2022, total compensation cost related to non-vested stock option awards not yet recognized totaled approximately $<ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" unitRef="usd">1,982,000</ix:nonFraction>. The weighted-average period over which this amount is expected to be recognized is <ix:nonNumeric contextRef="c75" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">2.32</ix:nonNumeric> years. The weighted average remaining contractual term of options that were exercisable on May 31, 2022, was <ix:nonNumeric contextRef="c75" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">5.47</ix:nonNumeric> years.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></ix:continuation> </div> <ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The following summarizes information about all the Company's stock options outstanding on May 31, 2022. These options are comprised of those granted under the 2014, 2017 and 2020 plans.</span> </p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></ix:continuation>  <div style="text-align: left;"> <ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"><table cellpadding="0" cellspacing="0" style="WIDTH:550.1pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">RANGE OF<br/>EXERCISE PRICES</span></p></td> <td style="HEIGHT:15pt; WIDTH:1%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">NUMBER<br/>OUTSTANDING<br/>MAY 31, 2022</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">WEIGHTED<br/>AVERAGE<br/>REMAINING<br/>CONTRACTUAL<br/>LIFE IN YEARS</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">WEIGHTED<br/>&#160;AVERAGE<br/>EXERCISE PRICE</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">NUMBER<br/>EXCERCISABLE<br/>AT MAY 31, 2022</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">WEIGHTED<br/>AVERAGE<br/>EXERCISE PRICE</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$<ix:nonFraction contextRef="c115" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" unitRef="usdPershares">0.82</ix:nonFraction>-$<ix:nonFraction contextRef="c115" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" unitRef="usdPershares">1.52</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:1%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c116" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">456,000</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><ix:nonNumeric contextRef="c115" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"><span style="FONT-SIZE:10pt; COLOR:black">3.33</span></ix:nonNumeric></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$<ix:nonFraction contextRef="c116" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">1.04</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c116" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">456,000</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$<ix:nonFraction contextRef="c116" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares">1.04</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$<ix:nonFraction contextRef="c117" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" unitRef="usdPershares">2.25</ix:nonFraction>-$<ix:nonFraction contextRef="c117" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" unitRef="usdPershares">4.25</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c118" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">1,015,750</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><ix:nonNumeric contextRef="c117" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"><span style="FONT-SIZE:10pt; COLOR:black">6.14</span></ix:nonNumeric></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$<ix:nonFraction contextRef="c118" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">2.90</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c118" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">852,500</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$<ix:nonFraction contextRef="c118" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares">2.88</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$<ix:nonFraction contextRef="c119" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" unitRef="usdPershares">4.34</ix:nonFraction>-$<ix:nonFraction contextRef="c119" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" unitRef="usdPershares">8.70</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:1%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c120" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">849,866</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><ix:nonNumeric contextRef="c119" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"><span style="FONT-SIZE:10pt; COLOR:black">8.75</span></ix:nonNumeric></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$<ix:nonFraction contextRef="c120" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">6.13</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c120" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">266,654</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$<ix:nonFraction contextRef="c120" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares">7.06</ix:nonFraction></span></p></td></tr></table></ix:nonNumeric></ix:continuation></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <a id="_Hlk17185589"></a><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">COMMON STOCK ACTIVITY</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <a id="_Hlk47966232"></a><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_17" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">On January 22, 2021, the Company filed a Prospectus Supplement, for purposes of raising up to $<ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" unitRef="usd">15,000,000</ix:nonFraction> to the base prospectus filed with the SEC on July 21, 2020, and declared effective by the SEC on September 30, and an ATM Agreement. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_18" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_17"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black">On May 21, 2021, in conjunction with the Company&#8217;s 2020 Stock Incentive Plan, that was approved by shareholders at the Company&#8217;s annual meeting in December 2020, the Company filed an S-8 Registration Statement to register up to <ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" unitRef="shares">900,000</ix:nonFraction> shares of the Company&#8217;s common stock that could be issued under this Plan.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation> <ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_19" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_18"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Under ATM Agreements, sales of the Placement Shares are deemed to be &#8220;at the market offering&#8221; as defined in Rule 415 promulgated under the Securities Act.&#160; The agent acts as sales agent under the ATM and uses commercially reasonable efforts to sell on the Company&#8217;s behalf all of the Placement Shares requested to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the agent and the Company. The Company has no obligation to sell any of the Placement Shares under the ATM Agreement, and may at any time suspend offers under, or terminate the ATM Agreement.&#160; </span></p></ix:continuation> <a id="_Hlk49188299"></a><a id="_Aci_Pg1"></a><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_20" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_19"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"><span style="FONT-SIZE:10pt">During the year ended May 31, 2022, the Company sold <ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares">521,267</ix:nonFraction> shares of its common stock at prices ranging from $<ix:nonFraction contextRef="c90" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">4.02</ix:nonFraction> to $<ix:nonFraction contextRef="c91" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">5.63</ix:nonFraction> under its Form S-3 Registration Statement </span><span style="FONT-SIZE:10pt">(</span><span style="FONT-SIZE:10pt; COLOR:black">File No. 333-239980) </span><span style="FONT-SIZE:10pt">and ATM Agreement which resulted in gross proceeds of approximately $<ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" unitRef="usd">2,402,000</ix:nonFraction> and net proceeds to the Company of $<ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">2,317,000</ix:nonFraction> after deducting commissions for each sale and legal, accounting, and other fees related to the filing of the Form S-3.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"></p></ix:continuation> <ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_21" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_20"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"><span style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black">During the year ended May 31, 2021, the Company sold <ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares">158,889</ix:nonFraction> shares of its common stock at prices ranging from $<ix:nonFraction contextRef="c93" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">7.06</ix:nonFraction> to $<ix:nonFraction contextRef="c94" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">7.79</ix:nonFraction> under its Form S-3 Registration Statement&#160;(File No. 333-239980)&#160;and ATM Agreement which resulted in gross proceeds of approximately $<ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" unitRef="usd">1,177,000</ix:nonFraction> and net proceeds to the Company of $<ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">1,011,000</ix:nonFraction> after deducting commissions for each sale and legal, accounting, and other fees related to the filing of the Form S-3.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>
<ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_22" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_21"><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">During the year ended May 31, 2022, options to purchase <ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">39,500</ix:nonFraction> shares of common stock were exercised at prices ranging from $<ix:nonFraction contextRef="c96" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">1.20</ix:nonFraction> to $<ix:nonFraction contextRef="c97" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">3.62</ix:nonFraction>.&#160; Total net proceeds to the Company were approximately $<ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" unitRef="usd">77,000</ix:nonFraction>.</span></p><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">&#160;</span></p></ix:continuation>

<ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_23" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_22"><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">During the year ended May 31, 2021, <ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares">321,429</ix:nonFraction> shares of common stock were converted from Preferred Stock as described below in &#8220;Preferred Stock Activity&#8221;.</span></p><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">&#160;</span></p></ix:continuation>

<ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_24" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_23"><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><strong><span style="font-size: 10pt;">PREFERRED STOCK ACTIVITY</span></strong></p><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">&#160;</span></p></ix:continuation>

<ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_25" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_24"><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">On February 24, 2020, the Company entered into and closed on a Stock Purchase Agreement (the &#8220;Stock Purchase Agreement&#8221;) with Palm Global Small Cap Master Fund LP (&#8220;Palm&#8221;) pursuant to which the Company agreed to sell and issue to Palm, and Palm agreed to purchase from the Company, <ix:nonFraction contextRef="c99" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares">571,429</ix:nonFraction> shares of the Company&#8217;s Series A 5% Convertible Preferred Stock, $<ix:nonFraction contextRef="c99" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.08</ix:nonFraction> par value per share for a purchase price of approximately $<ix:nonFraction contextRef="c100" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" unitRef="usd">2</ix:nonFraction> million, or $<ix:nonFraction contextRef="c99" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">3.50</ix:nonFraction> per Series A Convertible Preferred Stock. Under the terms of the Stock Purchase Agreement, each share of issued Convertible Preferred Stock can be converted at any time by Palm into one share of the Company&#8217;s common stock, subject to certain adjustments.</span></p><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">&#160;</span></p></ix:continuation>

<ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_26" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_25"><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">The Series A 5% Convertible Preferred Stock accrued annual preferred dividends at a rate of $<ix:nonFraction contextRef="c101" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DividendsPayableAmountPerShare" scale="0" unitRef="usdPershares">0.175</ix:nonFraction> per Series A 5% Convertible Preferred Share. However, accruing dividends were payable only when, as, and if declared by the Board and the Company had no obligation to pay such accruing dividends.</span></p><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">&#160;</span></p></ix:continuation>

<ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_26"><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">On March 24, 2020, Palm converted <ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares">250,000</ix:nonFraction> shares of Convertible Preferred Stock into <ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" unitRef="shares">250,000</ix:nonFraction> shares of unregistered common stock. On July 21, 2020, the Company filed with the SEC a registration statement on Form S-3, that among other things, registered <ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" unitRef="shares">571,429</ix:nonFraction> common shares issued, or to be issued, to Palm upon conversion of the Convertible Preferred Stock into common shares. On September 30, 2020, the Company received a Notice of Effectiveness from the Securities and Exchange Commission for registration of these shares. On January 21, 2021, Palm Converted their remaining <ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" unitRef="shares">321,429</ix:nonFraction> Convertible Preferred Shares into registered common shares. On May 30, 2021, the Company had no shares of Preferred Stock outstanding. Under the terms of the Preferred Stock Purchase Agreement, none of the cumulative Dividends were paid to Palm during the period they owned the Preferred Stock. Once converted to common shares, Palm lost all rights to receive any past cumulative dividends.</span></p></ix:continuation> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">FS-16</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; BACKGROUND:none; COLOR:black">NOTE 7: &#160;&#160;&#160;INCOME TAXES</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></ix:nonNumeric>  <ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_2" id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Provision for income taxes for the years ended May 31 consists of the following:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></ix:continuation>  <div style="text-align: left;"> <ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_3" id="_IncomeTaxDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:169pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;For the year ended May 31,</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:78.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">2022</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:78.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">2021</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Current:</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">U.S. Federal</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-20; FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;-</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-21; FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;-</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Foreign Taxes Subsidiaries</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">23,000</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">12,000</ix:nonFraction>)</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">State and local</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">1,000</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">1,000</ix:nonFraction>)</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Total current</span></b></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">24,000</ix:nonFraction>)</span></b></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">13,000</ix:nonFraction>)</span></b></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Deferred:</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">U.S. Federal&#160;</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-22; FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;-</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-23; FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;-</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">State and local</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-24; FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;-</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-25; FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;-</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Total deferred</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-26; FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;-</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-27; FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;-</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Income tax expense</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif">&#160;<span style="COLOR:black">$</span></span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd">24,000</ix:nonFraction>)</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd">13,000</ix:nonFraction>)</span></b></p></td></tr></table></ix:nonNumeric></ix:continuation></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_4" id="_IncomeTaxDisclosureTextBlock-c0_cont_3"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Provision for income taxes differs from the amounts computed by applying the U.S. Federal income tax rate applicable for each year (<span style="BACKGROUND:none"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure">21</ix:nonFraction></ix:nonFraction>%</span> for 2022 and 2021) to pretax income as a result of the following:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></ix:continuation>  <div style="text-align: left;"> <ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_5" id="_IncomeTaxDisclosureTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733">

<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td colspan="5" style="border-top: 0px; height: 15pt; border-right: 0px; width: 30%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">For the year ended May 31,</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 14%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">2022</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 14%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">2021</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Computed "expected" tax benefit</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" unitRef="usd">947,000</ix:nonFraction></span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" unitRef="usd">1,561,000</ix:nonFraction></span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Increase (reduction) in income taxes resulting from:</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Change in valuation allowance</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" sign="-" unitRef="usd">1,022,000</ix:nonFraction>)</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" sign="-" unitRef="usd">2,292,000</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">State income taxes, net of federal benefit</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif;"><ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="0" unitRef="usd">300,000</ix:nonFraction></span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="top">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="0" unitRef="usd">217,000</ix:nonFraction></span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Research and development tax credits</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c0" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="0" unitRef="usd">50,000</ix:nonFraction></span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="top">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="0" unitRef="usd">456,000</ix:nonFraction></span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Permanent tax differences and other</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="0" sign="-" unitRef="usd">217,000</ix:nonFraction>)</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="0" sign="-" unitRef="usd">88,000</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Stock based compensation&#160;benefit</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; text-align: right; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in; text-align: right;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="0" unitRef="usd">11,000</ix:nonFraction></span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; text-align: right; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="top">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="0" unitRef="usd">145,000</ix:nonFraction></span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Foreign taxes of subsidiaries</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="0" sign="-" unitRef="usd">113,000</ix:nonFraction>)</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="0" sign="-" unitRef="usd">12,000</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Income tax expense</span></strong></p>
</td>
<td style="height: 15.75pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">24,000</ix:nonFraction>)</span></p>
</td>
<td style="height: 15.75pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">13,000</ix:nonFraction>)</span></p>
</td>
</tr>

</table></ix:nonNumeric></ix:continuation></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_6" id="_IncomeTaxDisclosureTextBlock-c0_cont_5"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The tax effect of significant temporary differences&#160;is presented below:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></ix:continuation>  <div style="text-align: left;"> <ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_7" id="_IncomeTaxDisclosureTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="WIDTH:550.1pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:30%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 30%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">May 31,</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">2022</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">2021</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Deferred tax assets:</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Accounts receivable, principally due to allowance for doubtful accounts</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="0" unitRef="usd">43,000</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif"><ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="0" unitRef="usd">200,000</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Inventory valuation&#160;&#160;&#160;</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInventory" scale="0" unitRef="usd">237,000</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInventory" scale="0" unitRef="usd">387,000</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Compensated absences</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif"><ix:nonFraction contextRef="c3" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" scale="0" unitRef="usd">120,000</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" scale="0" unitRef="usd">85,000</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Net operating loss carryforwards&#160;&#160;&#160;</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd">4,349,000</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd">3,194,000</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Tax credit carryforwards</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="0" unitRef="usd">1,096,000</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="0" unitRef="usd">1,055,000</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Deferred rent expense/Capitalized leases</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c3" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" scale="0" unitRef="usd">20,000</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" scale="0" unitRef="usd">15,000</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Stock Options</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="bmra:DefferedTaxAssetsStockOptions" scale="0" unitRef="usd">1,035,000</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="bmra:DefferedTaxAssetsStockOptions" scale="0" unitRef="usd">613,000</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Losses of foreign subsidiaries &amp; Other, net</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="bmra:DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" scale="0" unitRef="usd">41,000</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c4" decimals="-4" format="ixt:num-dot-decimal" name="bmra:DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" scale="0" unitRef="usd">370,000</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Accumulated depreciation and amortization</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="bmra:DeferredTaxAssetsAccumulatedDepreciationAndAmortization" scale="0" unitRef="usd">26,000</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="bmra:DeferredTaxAssetsAccumulatedDepreciationAndAmortization" scale="0" sign="-" unitRef="usd">15,000</ix:nonFraction>)</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Total deferred tax assets&#160;&#160;&#160;</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd">6,967,000</ix:nonFraction></span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd">5,904,000</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Less valuation allowance</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd">6,967,000</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd">5,904,000</ix:nonFraction>)</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Net deferred tax asset</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-28; FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;-</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-29; FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;-</span></b></p></td></tr></table></ix:nonNumeric></ix:continuation></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_8" id="_IncomeTaxDisclosureTextBlock-c0_cont_7"><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">The Company has provided a valuation allowance of approximately <span style="background: none;">$<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd">6,967,000</ix:nonFraction></span> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd">5,904,000</ix:nonFraction> as of May 31, 2022 and 2021, respectively. The net change in the valuation allowance for the years ended May 31, 2022 and 2021, was an increase of <span style="background: none;">$<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" unitRef="usd">1,063,000</ix:nonFraction></span> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" unitRef="usd">2,292,000</ix:nonFraction>, respectively.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_9" id="_IncomeTaxDisclosureTextBlock-c0_cont_8"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">On May 31, 2022, the Company has Federal income tax net operating loss carryforwards of approximately <span style="BACKGROUND:none">$<ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd">17,116,000</ix:nonFraction></span>. &#160;On May 31, 2022, the Company has California state income tax net operating loss carryforwards of approximately <span style="BACKGROUND:none">$<ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd">10,805,000</ix:nonFraction></span>. For tax reporting purposes, operating loss carryforwards are available to offset future taxable income; such carryforwards expire in varying amounts beginning in <span style="BACKGROUND:none">2023 and 2037</span> for federal and state purposes, respectively.&#160; Federal net operating losses beginning in <span style="BACKGROUND:none">2018</span> have no expiration date. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">FS-17</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_10" id="_IncomeTaxDisclosureTextBlock-c0_cont_9"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">On May 31, 2022, the Company has Federal research and development tax credit carryforward of approximately <span style="BACKGROUND:none">$<ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="0" unitRef="usd">784,000</ix:nonFraction></span>. &#160;The Federal credits begin to expire in <span style="BACKGROUND:none">2027</span>. &#160;The Company also had similar credit carryforwards for state purposes <span style="BACKGROUND:none">of $<ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="0" unitRef="usd">395,000</ix:nonFraction></span> on May 31, 2022, which don&#8217;t expire.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_11" id="_IncomeTaxDisclosureTextBlock-c0_cont_10"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Pursuant to Internal Revenue Code (&#8220;IRC&#8221;) Sections 382 and 383, annual use of the Company's net operating loss ("NOL") and credit carryforwards may be limited by statute because of a cumulative change in ownership of more than 50%. Pursuant to Sections 382 and 383 of the IRC, the annual use of the Company's NOLs and credit carryforwards would be limited if there is a cumulative change of ownership (as that term is defined in Section 382(g) of the IRC of greater than 50% in a three-year period. Management has not performed an analysis to determine if the Company has had a cumulative change in ownership of greater than 50%.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_11"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">For the year ended May 31, 2022, the Company did an analysis of its <span style="BACKGROUND:none">ASC 740 position and has not identified any uncertain tax positions as defined under ASC 740</span>. Should such position be identified in the future, and should the Company owe interest and penalties as a result of this, these would be recognized as interest expense and other expense, respectively, in the consolidated financial statements. The Company is no longer subject to any significant U.S. federal tax examinations by tax authorities for years before fiscal <span style="BACKGROUND:none">2018</span>.</span></p></ix:continuation> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <ix:nonNumeric contextRef="c0" continuedAt="_GeographicInformationDisclosureTextBlock-c0_cont_1" escape="true" name="bmra:GeographicInformationDisclosureTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">NOTE 8: &#160;&#160;&#160;GEOGRAPHIC INFORMATION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></ix:nonNumeric>  <ix:continuation continuedAt="_GeographicInformationDisclosureTextBlock-c0_cont_2" id="_GeographicInformationDisclosureTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company operates as <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" unitRef="pure">one</ix:nonFraction> segment. Geographic information regarding net sales is approximately as follows: </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></ix:continuation>  <div style="text-align: left;"> <ix:continuation id="_GeographicInformationDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock"><table cellpadding="0" cellspacing="0" style="width: 557.3pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="743">

<tr style="height: 15pt;">
<td style="height: 15pt; width: 286.9pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="7" style="border-top: 0px; height: 15pt; border-right: 0px; width: 258.6pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">For the year ended May 31,</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 286.9pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="3" style="border-top: 0px; height: 15pt; border-right: 0px; width: 123.4pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2022</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="3" style="border-top: 0px; height: 15pt; border-right: 0px; width: 123.4pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2021</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 286.9pt; background: #b8cce4; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Asia</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c125" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">13,375,000</ix:nonFraction></span></p>
</td>
<td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c126" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">71</ix:nonFraction>%</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c127" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">1,908,000</ix:nonFraction></span></p>
</td>
<td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c128" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">26</ix:nonFraction>%</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 286.9pt; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Europe</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c129" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">4,339,000</ix:nonFraction></span></p>
</td>
<td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c130" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">23</ix:nonFraction>%</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c131" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">4,301,000</ix:nonFraction></span></p>
</td>
<td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c132" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">60</ix:nonFraction>%</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 286.9pt; background: #b8cce4; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">North America</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c133" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">997,000</ix:nonFraction></span></p>
</td>
<td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c134" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">5</ix:nonFraction>%</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c135" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">548,000</ix:nonFraction></span></p>
</td>
<td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c136" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">8</ix:nonFraction>%</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 286.9pt; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">South America</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c137" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">90,000</ix:nonFraction></span></p>
</td>
<td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c138" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">1</ix:nonFraction>%</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c139" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">250,000</ix:nonFraction></span></p>
</td>
<td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c140" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">3</ix:nonFraction>%</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 286.9pt; background: #b8cce4; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Middle East</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 55.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c141" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">70,000</ix:nonFraction></span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 55.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c142" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">0</ix:nonFraction>%</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 55.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c143" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">192,000</ix:nonFraction></span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 55.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c144" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">3</ix:nonFraction>%</span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 286.9pt; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Total</span></strong></p>
</td>
<td style="height: 15.75pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 55.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">18,871,000</ix:nonFraction></span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 55.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c145" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">100</ix:nonFraction>%</span></strong></p>
</td>
<td style="height: 15.75pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 55.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">7,199,000</ix:nonFraction></span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 55.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c146" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">100</ix:nonFraction>%</span></strong></p>
</td>
</tr>

</table></ix:nonNumeric></ix:continuation></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">NOTE 9: &#160;&#160;&#160;COMMITMENTS AND CONTINGENCIES</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric>  <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">OPERATING LEASES</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0in"><span style="FONT-SIZE:10pt">The Company leases its facilities. On May 31, 2022, the Company had approximately 22,000 square feet of floor space at its corporate headquarters at 17571 Von Karman Avenue in Irvine, California, which it has been leasing since 2009. The lease for its headquarters expired on August 31, 2016. &#160;The Company had an option to extend the term of its lease for two additional sixty-month periods. On November 30, 2015, the Company exercised its option to extend its lease for an additional sixty-month period and entered into the First Amendment to Lease wherein it extended its lease until <ix:nonNumeric contextRef="c147" format="ixt:date-monthname-day-year-en" name="us-gaap:LeaseExpirationDate1">August 31, 2021</ix:nonNumeric>. On April 9, 2021, the Company exercised its second option to extend its lease for an additional five years.&#160; When the Company extended its lease in April 2021, it was also granted an additional five-year lease extension option. The current rent is approximately $<ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" unitRef="usd">25,000</ix:nonFraction> per month and will increase on September 1, 2022, to $<ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="0" unitRef="usd">26,000</ix:nonFraction> per month.&#160; The security deposit is approximately $22,000.<span style="COLOR:black">&#160;</span> </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0in"><span style="FONT-SIZE:10pt">In November 2016, the Company&#8217;s Mexican subsidiary, Biomerica de Mexico, entered into a <ix:nonNumeric contextRef="c149" format="ixt-sec:duryear" name="bmra:LeaseExpirationPeriod">10</ix:nonNumeric>-year lease for approximately 8,100 square feet of manufacturing space. The Company has one 10-year option to renew at the end of the initial lease period. The current rent is approximately $<ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" unitRef="usd">3,400</ix:nonFraction> per month.&#160; Biomerica de Mexico also leases a smaller unit on a month-to-month basis for use in one manufacturing process. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">In addition, the Company leases a small office in Lindau, Germany on a month-to-month basis, as headquarters for BioEurope GmbH, its Germany subsidiary.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total gross rent expense in the United States for fiscal 2022 was approximately $<ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" unitRef="usd">310,000</ix:nonFraction>, and for fiscal 2021 was $<ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" unitRef="usd">295,000</ix:nonFraction>.&#160; Rent expense for the Mexico facility for fiscal 2022 and 2021 was approximately $<ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" unitRef="usd">42,000</ix:nonFraction> and $<ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" unitRef="usd">25,000</ix:nonFraction>, respectively. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.9pt 0in 0in"><span style="FONT-SIZE:10pt">For purposes of determining straight-line rent expense, the lease term is calculated from the date the Company first takes possession of the facility, including any periods of free rent and any renewal options periods that the Company is reasonably certain of exercising. The Company&#8217;s office and equipment leases generally have contractually specified minimum rent and annual rent increases are included in the measurement of the right-of-use asset and related lease liability.&#160; Additionally, under these lease arrangements, the Company may be required to pay directly, or reimburse the lessors, for some maintenance and operating costs. Such amounts are generally variable and therefore not included in the measurement of the right-of-use asset and related lease liability but are instead recognized as variable lease expense in the Consolidated Statements of Operations and Comprehensive Loss when they are incurred.&#160; </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 13.55pt 0in 0in">&#160;</p></ix:continuation>  <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">FS-18</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 13.55pt 0in 0in">&#160;</p> <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_8" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0in;"><span style="font-family: 'Times New Roman',serif;">Supplemental cash flow information related to leases for the year ended May 31, 2022: </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></ix:continuation>  <div style="text-align: left;"> <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_9" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" escape="true" name="bmra:ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock"><table cellpadding="0" cellspacing="0" style="WIDTH:550.1pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:467.1pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Operating cash flows from operating leases&#160;&#160;&#160;&#160;&#160;</span></p></td> <td style="HEIGHT:15pt; WIDTH:15.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:67.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd">338,206</ix:nonFraction></span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:467.1pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Right-of-use assets obtained in exchange for<br/>&#160;&#160;&#160; &#160;new operating lease liabilities</span></p></td> <td style="HEIGHT:0.2in; WIDTH:15.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:0.2in; WIDTH:67.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-30; FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">&#160;-</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:467.1pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Weighted average remaining lease term (in years)</span></p></td> <td style="HEIGHT:15pt; WIDTH:15.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:67.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><ix:nonNumeric contextRef="c3" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1"><span style="FONT-SIZE:10pt; COLOR:black">4.28</span></ix:nonNumeric></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:467.1pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Weighted average discount rate</span></p></td> <td style="HEIGHT:15pt; WIDTH:15.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:67.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">6.50</ix:nonFraction>%</span></p></td></tr></table></ix:nonNumeric></ix:continuation></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_10" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_9"><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">Future minimum lease payments under operating leases on May 31, 2022, are as follows:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></ix:continuation>  <div style="text-align: left;"> <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_11" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_10"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733">

<tr style="height: 15pt;">
<td style="height: 15pt; width: 462pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Less than 1 year</span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" unitRef="usd">351,000</ix:nonFraction></span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 462pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">1 to 2 years</span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" unitRef="usd">362,000</ix:nonFraction></span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 462pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">2 to 3 years</span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" unitRef="usd">373,000</ix:nonFraction></span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 462pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">3 to 4 years</span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" unitRef="usd">384,000</ix:nonFraction></span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 462pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">4 to 5 years</span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="0" unitRef="usd">104,000</ix:nonFraction></span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 462pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Total undiscounted lease payments</span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" unitRef="usd">1,574,000</ix:nonFraction></span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 462pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Less imputed interest</span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" unitRef="usd">194,000</ix:nonFraction></span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 462pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Total operating lease liabilities</span></p>
</td>
<td style="height: 15.75pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 66pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd">1,380,000</ix:nonFraction></span></strong></p>
</td>
</tr>

</table></ix:nonNumeric></ix:continuation></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_12" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_11"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">According to the terms of the lease in Irvine, the Company is also responsible for routine repairs of the building and for certain increases in property tax. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_13" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_12"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company also has various insignificant leases for office equipment.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_14" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_13"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">RETIREMENT SAVINGS PLAN</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_15" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_14"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Effective September 1, 1986, the Company established a 401(k) plan for the benefit of its employees. The plan permits eligible employees to contribute to the plan up to the maximum percentage of total annual compensation allowable under the limits of IRC Sections 415, 401(k) and 404. The Company, at the discretion of its Board of Directors, may make contributions to the plan in amounts determined by the Board each year. No contributions by the Company have been made since the plan's inception.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_16" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_15"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">LITIGATION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_17" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_16"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company is, from time to time, involved in legal proceedings, claims and litigation arising in the ordinary course of business. While the amounts claimed may be substantial, the ultimate liability cannot presently be determined because of considerable uncertainties that exist. Therefore, it is possible the outcome of such legal proceedings, claims and litigation could have a material effect on quarterly or annual operating results or cash flows when resolved in a future period. However, based on facts currently available, management believes such matters will not have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_18" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_17"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">There were no legal proceedings pending as of May 31, 2022.</span>&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_19" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_18"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">CONTRACTS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_20" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_19"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt">Contracts and Licensing Agreements</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_21" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_20"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company has one royalty agreement in which it has obtained rights to manufacture and market certain products for the life of the products. Royalty expense of approximately $<ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyExpense" scale="0" unitRef="usd">19,000</ix:nonFraction> and $<ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyExpense" scale="0" unitRef="usd">11,000</ix:nonFraction> is included in cost of sales for the agreement for each of the years ended May 31, 2022 and 2021, respectively. Sales of products manufactured under these agreements comprise approximately <ix:nonFraction contextRef="c154" decimals="3" format="ixt:num-dot-decimal" name="bmra:RoyaltyExpensePercentageOfSales" scale="-2" unitRef="pure">1.5</ix:nonFraction>% and <ix:nonFraction contextRef="c155" decimals="3" format="ixt:num-dot-decimal" name="bmra:RoyaltyExpensePercentageOfSales" scale="-2" unitRef="pure">1.5</ix:nonFraction>% of total sales for the years ended May 31, 2022 and 2021, respectively. The Company may license other products or technology in the future as it deems necessary for conducting business.&#160; The Company has other royalty agreements however they are not considered material.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">FS-19</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_22" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_21"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">On May 25, 2016, the Company entered into an Exclusive Marketing License Agreement (&#8220;Telcon Agreement&#8221;) with Celtis Pharm Co., Ltd., who subsequently changed their name to Telcon Pharmaceutical Co., LTD (&#8220;Telcon&#8221;), a medical company in South Korea. The Telcon Agreement grants to Telcon an exclusive license to market and sell Biomerica&#8217;s new InFoods&#174; IBS products (&#8220;IBS Products&#8221;) in South Korea. The term of the agreement is for a period of five years following Korean FDA clearance of the product and provides an additional two years for Telcon to attain such Korean FDA clearance. The sequential two-year and five-year terms do not begin until after Biomerica first receives final clearance for sale of the IBS Products in the United States from the FDA. Telcon, at its sole cost and expense, must use its commercially reasonable good faith efforts to obtain Korean FDA for the IBS Product to be sold in South Korea. The agreement may be cancelled if Biomerica has not obtained final USFDA clearance for sale of the IBS Products on or before December 31, 2019. The required FDA approval was not obtained by December 31, 2019, however, neither party has terminated the agreement. Once the IBS Product is cleared by the United States FDA, Biomerica is also obligated to maintain a full quality assurance system for the IBS Products following the harmonized standards according to Annex IV of Directive 98/79/EC.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_23" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_22"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">The terms of the Telcon Agreement provide up to $<ix:nonFraction contextRef="c156" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:AccruedFeesAndOtherRevenueReceivable" scale="6" unitRef="usd">1.25</ix:nonFraction> million in future exclusivity fees to be possibly paid to Biomerica based on certain milestones including Biomerica&#8217;s starting clinical trials in the United States, receipt of U.S. FDA clearance and Telcon&#8217;s first sales of IBS Products in Korea. If Biomerica commences FDA Trials and Telcon pays the initial $250,000 milestone-based exclusivity fees, and the Agreement is subsequently terminated by either party for lack of performance, then Biomerica shall issue to Telcon <ix:nonFraction contextRef="c157" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">83,333</ix:nonFraction> shares of Biomerica common stock in consideration for the $<ix:nonFraction contextRef="c157" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromFeesReceived" scale="0" unitRef="usd">250,000</ix:nonFraction> of paid exclusivity fee. No exclusivity fees have yet been paid.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_24" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_23"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">Additionally, the Telcon Agreement provides for&#160;a royalty of <ix:nonFraction contextRef="c157" decimals="2" format="ixt:num-dot-decimal" name="bmra:RoyaltyPercentage" scale="-2" unitRef="pure">15</ix:nonFraction>% paid to Biomerica on all sales in Korea of the IBS Product, and further sets the pricing of IBS Products sold to Telcon.&#160; In order to retain the exclusivity within South Korea, Telcon must meet certain annual minimum royalty payments to Biomerica following Telcon&#8217;s receipt of Korean FDA approval or clearance for the IBS Product to be sold in Korea, which in no case will be later than May 31, 2019.<b> </b>&#160;&#160;In September 2017, an agreement to extend this date was signed extending the date until April 30, 2020. &#160;During the quarter ended August 31, 2020, a second amendment was signed extending the required FDA approval date to December 31, 2021. The required FDA approval date hasn&#8217;t been delivered however, neither party has terminated the agreement.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_25" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_24"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">On April 1, 2020, the Company entered into two separate non-exclusive license agreements (the &#8220;Mount Sinai License Agreements&#8221;) with the Mount Sinai Icahn School of Medicine in New York (&#8220;Mount Sinai&#8221;) to license technology from Mount Sinai that the Company intends to use to scale up and manufacture a laboratory version serological test for SARS-CoV-2 coronavirus.&#160; The non-exclusive Mount Sinai License Agreements provide for royalty payments to Mount Sinai based on a percentage of gross sales of commercial products manufactured and sold by Biomerica that incorporate the Mount Sinai technology licensed under the Mount Sinai License Agreement. On June 20, 2020, the Company filed for Emergency Use Authorization (&#8220;EUA&#8221;) with the FDA for the sale of a product developed by the Company that is based on this technology. The FDA has still not approved the Company&#8217;s Emergency Use Authorization for this product to be sold. As such, no royalty fees have been paid yet on these agreements. The Company is selling a COVID-19 rapid test outside of the United States, which is unrelated to the EUA product discussed above. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_26" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_25"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">On May 7, 2020, the Company entered into an exclusive license agreement (the &#8220;UC License Agreement&#8221;) with The Regents of the University of California (&#8220;UC&#8221;) to license all patent rights pertaining to certain licensed technology from UC. This technology is being developed at UC-San Diego by one of the professors and his team utilizing CRISPR technology. This group is developing a viral detection test for SARS-CoV-2 coronavirus.&#160;If this technology development is successful, the Company will work with the UC to transfer the technology to Biomerica where the CRISPR based product will need to be further developed, validated, and cleared with regulatory agencies for commercial sale into the market.&#160; The exclusive UC License Agreement provides for an initial and annual license fee, and a royalty payment on all commercial revenues, to the UC Regents. The UC License Agreement also includes certain investment requirements and milestones the Company will need to meet for the launch of a commercial product based on the licensed technology. The Company paid an initial license fee of $<ix:nonFraction contextRef="c158" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd">5,000</ix:nonFraction> with the execution of the agreement. An additional $<ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd">5,000</ix:nonFraction> was paid in September 2020.&#160; No royalties have been paid yet on this agreement. A license maintenance fee of $<ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="bmra:LicenseMaintenanceFeePayable" scale="0" unitRef="usd">10,000</ix:nonFraction> is due annually. This is creditable against earned royalties due each year in the amount of five percent on net sales of licensed products.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_27" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_26"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0in 0in"><b><span style="FONT-SIZE:10pt">Clinical Trial Agreements</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0in 0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_28" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_27"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">In September 2017, the Company signed a Clinical Samples Agreement with the University of Southern California for the purpose of providing clinical samples for use by the Company in conducting future clinical trials for one of the products which the Company is developing.&#160; The initial budget was estimated to be approximately $<ix:nonFraction contextRef="c160" decimals="0" format="ixt:num-dot-decimal" name="bmra:ClinicalTrialAgreementMaximumBudgetedCosts" scale="0" unitRef="usd">82,000</ix:nonFraction>. The work started in October 2017 with charges for work performed being invoiced and paid monthly. This study ended in February 2020. Approximately $<ix:nonFraction contextRef="c161" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd">17,000</ix:nonFraction> in fees has been accrued for unbilled charges as of May 31, 2022.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_28"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">The Company entered into a Clinical Trial Agreement with a research institute for the purpose of conducting a clinical trial of the Biomerica InFoods&#174; product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be approximately $<ix:nonFraction contextRef="c162" decimals="0" format="ixt:num-dot-decimal" name="bmra:ClinicalTrialAgreementMaximumBudgetedCosts" scale="0" unitRef="usd">107,000</ix:nonFraction>. <span style="COLOR:black">This study ended in March 2022. Approximately $<ix:nonFraction contextRef="c162" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd">28,000</ix:nonFraction> in fees has been accrued for unbilled charges as of May 31, 2022.</span></span></p></ix:continuation> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">FS-20</span></p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0in 0in"><b><span style="FONT-SIZE:10pt; COLOR:black">NOTE 10:&#160;&#160;&#160; SUBSEQUENT EVENTS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></ix:nonNumeric>  <ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_2" id="_SubsequentEventsTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Subsequent to May 31, 2022, as of the filing of Form 10-K, the Company sold <ix:nonFraction contextRef="c163" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">523,977</ix:nonFraction> shares of its common stock under its Form S-3 &#8220;shelf&#8221; Registration statement. The average sale price was $<ix:nonFraction contextRef="c164" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares">3.46</ix:nonFraction> per share. Net proceeds to the Company were approximately $<ix:nonFraction contextRef="c163" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">1,765,000</ix:nonFraction>.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation id="_SubsequentEventsTextBlock-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">On July 14, 2022, the Company announced they had entered into a General Merchandise Supplier Agreement with Walmart, for the Company&#8217;s Aware<sup>&#174;</sup> Breast Self Exam product to be sold in Walmart&#8217;s retail system.</span></p></ix:continuation></div><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif"><span style="PAGE-BREAK-BEFORE:none; clear: both;"><br/></span></span> <div style="page:WordSection3"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt">FS-21</span></p></div>
<!-- EDGAR Validation Code: AA75B9F1 -->

</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c4" id="hidden-fact-0" name="us-gaap:ContractWithCustomerLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-2" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-3" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-4" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-5" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-6" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-7" name="us-gaap:InterestExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-8" name="us-gaap:SharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-9" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-10" name="us-gaap:SharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-11" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-12" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-13" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-14" name="bmra:WriteOffOfFixedAssetsCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-15" name="bmra:WriteOffOfFixedAssetsAccumulatedDepreciation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-16" name="bmra:WriteOffOfIntangibleAssetsCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-17" name="bmra:WriteOffOfIntangibleAssetsAccumulatedAmortization" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-18" name="us-gaap:FiniteLivedLicenseAgreementsGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-19" name="bmra:FiniteLivedLicenseAccumulatedAmortization" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-20" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-21" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-22" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-23" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-24" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-25" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-26" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-27" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-28" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-29" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-30" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0000073290</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="bmra-20220531.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources><xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-11-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bmra:A5PercentConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bmra:A5PercentConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmra:A5PercentConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmra:A5PercentConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmra:A5PercentConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmra:A5PercentConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:ATMAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:ATMAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:ATMAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:TwoDistributorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:TwoDistributorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:OneDistributorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:OneDistributorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:OneDistributorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:OneDistributorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:TwoDistributorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:DistributorsInAsiaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:OneVendorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:OneVendorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bmra:PurchasedTechnologyRightsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bmra:PolishDistributorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:PhysiciansOfficeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:PhysiciansOfficeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:ClinicalLabMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:ClinicalLabMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:OverthecounterMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:OverthecounterMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:ContractManufacturingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:ContractManufacturingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:TwoVendorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:OneVendorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmra:A2014PlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2014-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmra:A2014PlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2014-12-31</xbrli:startDate>
    <xbrli:endDate>2014-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmra:A2017PlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmra:A2017PlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-12-31</xbrli:startDate>
    <xbrli:endDate>2017-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmra:A2020PlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-11</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt+1Vq3zhhUlfDeP/RQUzUZihDO8dLtQrMZMNe4t6pAivP0axfdFZpsLdRcC6V+fMavTAOMD4FknVX18XpRs+KLunX2qipVKNpApCTOelknJAdDWusY2PGEvYpRrj0mxs78hkWjdoZPMe4E2T0OAgcNcAeqIj6oByjJGty9evb9RRfB+mY5eZhu8m1laqMYN65A=] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">bmra:ATMAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-22</xbrli:startDate>
    <xbrli:endDate>2021-01-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmra:A2020StockIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:StockPurchaseAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:PalmMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-02-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:StockPurchaseAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:PalmMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-24</xbrli:startDate>
    <xbrli:endDate>2020-02-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-02-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-24</xbrli:startDate>
    <xbrli:endDate>2020-03-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:PalmMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-24</xbrli:startDate>
    <xbrli:endDate>2020-03-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:PalmMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:PalmMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare082818Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare514870Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare082362Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare235818Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare082870Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare425446Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare120362Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare161818Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare082870Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:RangeOfExercisePrice082152Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:RangeOfExercisePrice082152Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:RangeOfExercisePrice225425Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:RangeOfExercisePrice225425Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:RangeOfExercisePrice434870Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:RangeOfExercisePrice434870Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bmra:CaliforniaStateIncomeTaxMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:AsiaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:AsiaMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:AsiaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:AsiaMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:EuropeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:EuropeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:EuropeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:EuropeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:NorthAmericaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:NorthAmericaMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:NorthAmericaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:NorthAmericaMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:SouthAmericaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:SouthAmericaMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:SouthAmericaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:SouthAmericaMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">us-gaap:MiddleEastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">us-gaap:MiddleEastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">us-gaap:MiddleEastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">us-gaap:MiddleEastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">bmra:FirstAmendmentToLeaseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">bmra:BuildingInIrvineCaliforniaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">bmra:FirstAmendmentToLeaseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">bmra:BuildingInIrvineCaliforniaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:PropertyAvailableForOperatingLeaseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-11-01</xbrli:startDate>
    <xbrli:endDate>2016-11-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:PropertyAvailableForOperatingLeaseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:PropertyAvailableForOperatingLeaseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:PropertyAvailableForOperatingLeaseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:PropertyAvailableForOperatingLeaseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:TelconAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:TelconAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:UCLicenseAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-07</xbrli:startDate>
    <xbrli:endDate>2020-05-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:UCLicenseAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-09-01</xbrli:startDate>
    <xbrli:endDate>2020-09-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:UniversityOFSouthernCaliforniaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:UniversityOFSouthernCaliforniaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:BiomericaInFoodsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>exhibit23_1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<head> </head> <body style=WORD-WRAP:break-word lang=EN-US> <div style=page:WordSection1> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0in'><b><font style="FONT-SIZE:10pt; COLOR:black">EXHIBIT 23.1</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0in'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0in' align=center><b><font style=FONT-SIZE:10pt>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in'><font style=FONT-SIZE:10pt>We consent to the incorporation by reference in the <font style="BACKGROUND:white; COLOR:black">Registration Statement on Form S-3 (No. 333-239980), as amended, and the Registration Statements on Form S-8 (Nos. 333-179443, 333-204410, 333-224836 and 333-256377) </font>of Biomerica, Inc<font style="BACKGROUND:white; COLOR:black">.</font> (the &#147;Company&#148;) of our report dated August 29, 2022, relating to our audit of the Company&#146;s consolidated financial statements as of May 31, 2022, and for the year then ended, included in the Company&#146;s Annual Report on Form 10-K for the year ended May 31, 2022.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0in' align=center><b></b>&nbsp;</p> <table width=620 style="WIDTH:465.1pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:14.5pt> <td width=107 nowrap style="HEIGHT:14.5pt; WIDTH:80pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=64 nowrap style="HEIGHT:14.5pt; WIDTH:48pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=161 nowrap style="HEIGHT:14.5pt; WIDTH:121pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0in'><i><font style="FONT-SIZE:10pt; COLOR:black">/s/ HASKELL &amp; WHITE LLP</font></i></p></td></tr> <tr style=HEIGHT:14.5pt> <td width=107 nowrap style="HEIGHT:14.5pt; WIDTH:80pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=64 nowrap style="HEIGHT:14.5pt; WIDTH:48pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=161 nowrap style="HEIGHT:14.5pt; WIDTH:121pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0in'><font style="FONT-SIZE:10pt; COLOR:black">HASKELL &amp; WHITE LLP </font></p></td></tr> <tr style=HEIGHT:14.5pt> <td width=107 nowrap style="HEIGHT:14.5pt; WIDTH:80pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=64 nowrap style="HEIGHT:14.5pt; WIDTH:48pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=161 nowrap style="HEIGHT:14.5pt; WIDTH:121pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:14.5pt> <td width=107 nowrap style="HEIGHT:14.5pt; WIDTH:80pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0in'><font style="FONT-SIZE:10pt; COLOR:black">Irvine, California</font></p></td> <td width=64 nowrap style="HEIGHT:14.5pt; WIDTH:48pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=161 nowrap style="HEIGHT:14.5pt; WIDTH:121pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:14.5pt> <td width=107 nowrap style="HEIGHT:14.5pt; WIDTH:80pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0in'><font style="FONT-SIZE:10pt; COLOR:black">August 29, 2022</font></p></td> <td width=64 nowrap style="HEIGHT:14.5pt; WIDTH:48pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=161 nowrap style="HEIGHT:14.5pt; WIDTH:121pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr></table> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0in'>&nbsp;</p></div></body>
<!-- EDGAR Validation Code: E3D9C711 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>exhibit23_2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<HTML>
<head><title>Exhibit 23.2</title> </head> <body style=WORD-WRAP:break-word lang=EN-US> <div style=page:WordSection1> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0in'><b><font style="FONT-SIZE:10pt; COLOR:black">EXHIBIT 23.2</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0in'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0in' align=center><b><font style="FONT-SIZE:10pt; COLOR:black">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0in'><font style="FONT-SIZE:10pt; COLOR:black">Biomerica, Inc. and Subsidiaries</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0in'><font style="FONT-SIZE:10pt; COLOR:black">Irvine, California</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in'><font style="FONT-SIZE:10pt; COLOR:black">We hereby consent to the incorporation by reference in, the previously filed Registration Statements on Form S-8 (Nos. 333-179443, &nbsp;333-204410, 333-224836 and 333-256377) and Form S-3 (No. 333-239980) of Biomerica, Inc. and Subsidiaries, of our report dated August 27, 2021, except for the effect of the restatement disclosed in Note 11 of the May 31, 2021 consolidated financial statements, as to which the date is October 14, 2021, relating to the consolidated financial statements as of May 31, 2021 and for the year ended May 31, 2021, which appears in this Form 10-K. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0in'><u><font style="FONT-SIZE:10pt; COLOR:black"></font></u>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0in'><u><font style="FONT-SIZE:10pt; COLOR:black">/s/ PKF San Diego, LLP</font></u></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0in'><font style="FONT-SIZE:10pt; COLOR:black">PKF San Diego, LLP</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0in'><font style="FONT-SIZE:10pt; COLOR:black">(formerly PKF, LLP)</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0in'><font style="FONT-SIZE:10pt; COLOR:black">San Diego, CA</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0in'><font style="FONT-SIZE:10pt; COLOR:black">August 29, 2022</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0in'>&nbsp;</p></div></body>
<!-- EDGAR Validation Code: 56A5703F -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exhibit31_1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<head> <title>Exhibit 31.1</title> </head> <body> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="left"><b>EXHIBIT 31.1</b></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center"><b>CERTIFICATION OF CHIEF EXECUTIVE OFFICER <br>PURSUANT TO</b></p><b> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center">18 U.S.C. SECTION 1350,</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center">AS ADOPTED PURSUANT TO</p> </b><p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center"><b>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="justify">&nbsp;</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="justify">I, Zackary S. Irani, certify that:</p> <p style="MARGIN:0px" align="justify"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="justify">1. I have reviewed this Annual Report on Form 10-K of Biomerica, Inc.;</p> <p style="MARGIN:0px" align="justify"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="justify">2.
 Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the period
covered by this report;</p> <p style="MARGIN:0px" align="justify"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="justify">3.
 Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material
respects, the financial condition, results of operations and cash flows
of the registrant as of, and for, the periods presented in this report;</p> <p style="MARGIN:0px" align="justify"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="justify">4.
 The registrant's other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:</p> <p style="MARGIN:0px" align="justify"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px; TEXT-INDENT:48px">a)
 designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our supervision,
 to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this
report is being prepared;</p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px; TEXT-INDENT:48px">b)
 designed such internal control over financial reporting, or caused such
 internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;</p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px; TEXT-INDENT:48px">c)
 evaluated the effectiveness of the registrant's disclosure controls and
 procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end
of the period covered by this report based on such evaluation; and</p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px; TEXT-INDENT:48px">d)
 disclosed in this report any change in the registrant's internal
control over financial reporting that occurred during the registrant's
most recent fiscal quarter (the registrant's fourth quarter in the case
of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant's internal control over
financial reporting; and</p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px">5.
 The registrant's other certifying officer and I have disclosed, based
on our most recent evaluation of our internal control over financial
reporting, to the registrant's auditors and the audit committee of the
registrant's board of directors (or other persons performing the
equivalent functions):</p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px; TEXT-INDENT:48px">a)
 all significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to
record, process, summarize and report financial information; and</p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px; TEXT-INDENT:48px">b)
 any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal
control over financial reporting.</p> <p style="MARGIN:0px">&nbsp;</p> <table style="WIDTH:210.75pt; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" width="281" cellspacing="0" cellpadding="0" bordercolor="transparent"> <tr style="HEIGHT:22pt"> <td style="HEIGHT:14.75pt; WIDTH:210.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0pt; PADDING-RIGHT:5.4pt" width="281" nowrap="nowrap"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;; COLOR:black"></font></p></td></tr> <tr style="HEIGHT:14.75pt"> <td style="BORDER-TOP:0px; HEIGHT:14.75pt; BORDER-RIGHT:0px; WIDTH:210.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0pt; BORDER-LEFT:0px; PADDING-RIGHT:5.4pt" width="281" nowrap="nowrap"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;; COLOR:black"><i>/s/ Zackary S. Irani</i></font></p></td></tr> <tr style="HEIGHT:14.75pt"> <td style="HEIGHT:14.75pt; WIDTH:210.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0pt; PADDING-RIGHT:5.4pt" width="281" nowrap="nowrap"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;; COLOR:black">Zackary S. Irani</font></p></td></tr> <tr style="HEIGHT:14.75pt"> <td style="HEIGHT:14.75pt; WIDTH:210.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0pt; PADDING-RIGHT:5.4pt" width="281" nowrap="nowrap"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;; COLOR:black">Chief Executive Officer</font></p></td></tr> <tr style="HEIGHT:14.75pt"> <td style="HEIGHT:14.75pt; WIDTH:210.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0pt; PADDING-RIGHT:5.4pt" width="281" nowrap="nowrap"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;; COLOR:black">Date: August 29, 2022</font></p></td></tr></table> <p style="MARGIN-BOTTOM:9px; MARGIN-TOP:0px">&nbsp;</p></body>
<!-- EDGAR Validation Code: 237E9F32 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exhibit31_2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<head> <title>Exhibit 31.2</title></head> <body> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="left"><font style="FONT-SIZE:9pt"><b>EXHIBIT 31.2</b></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center"><font style="FONT-SIZE:9pt"><b>CERTIFICATION OF CHIEF FINANCIAL OFFICER<br> PURSUANT TO</b></font></p><b> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center"><font style="FONT-SIZE:9pt">18 U.S.C. SECTION 1350,</font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center"><font style="FONT-SIZE:9pt">AS ADOPTED PURSUANT TO</font></p> </b><p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center"><b><font style="FONT-SIZE:9pt">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></b><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center">&nbsp;</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px"><font style="FONT-SIZE:9pt">I, Steve Sloan, certify that:</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px"><font style="FONT-SIZE:9pt">1. I have reviewed this Annual Report on Form 10-K of Biomerica, Inc.;</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">2.
 Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the period
covered by this report;</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">3.
 Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material
respects, the financial condition, results of operations and cash flows
of the registrant as of, and for, the periods presented in this report;</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">4.
 The registrant's other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)
 designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our supervision,
 to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this
report is being prepared;</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)
 designed such internal control over financial reporting, or caused such
 internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)
 evaluated the effectiveness of the registrant's disclosure controls and
 procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end
of the period covered by this report based on such evaluation; and</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)
 disclosed in this report any change in the registrant's internal
control over financial reporting that occurred during the registrant's
most recent fiscal quarter (the registrant's fourth quarter in the case
of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant's internal control over
financial reporting; and</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">5.
 The registrant's other certifying officer and I have disclosed, based
on our most recent evaluation of our internal control over financial
reporting, to the registrant's auditors and the audit committee of the
registrant's board of directors (or other persons performing the
equivalent functions):</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)
 all significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to
record, process, summarize and report financial information; and</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)
 any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal
control over financial reporting.</font></p> <p style="MARGIN:0px">&nbsp;</p> <table style="WIDTH:179pt; BORDER-COLLAPSE:collapse" width="239" cellspacing="0" cellpadding="0" bordercolor="transparent"><tr style="HEIGHT:15pt"> <td style="HEIGHT:22pt; WIDTH:179pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" width="239"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;"></font></font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;"><i>/s/ Steve Sloan</i></font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;">Steve Sloan</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;">Chief Financial Officer</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0pt; PADDING-RIGHT:0in"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;">Date: August 29, 2022</font></p></td></tr></table> <p style="MARGIN:0px"><br><br></p></body>
<!-- EDGAR Validation Code: 237E9F32 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>exhibit32_1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<head> <title>Exhibit 32.1</title></head> <body> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px">&nbsp;</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px"><b>EXHIBIT 32.1</b></p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center"><b>CERTIFICATION OF CHIEF EXECUTIVE OFFICER<br> PURSUANT TO</b></p><b> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center">18 U.S.C. SECTION 1350,</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center">AS ADOPTED PURSUANT TO</p> </b><p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center"><b>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify;MARGIN:0px">In
 connection with the Annual Report of Biomerica, Inc. (the "Company")
 on Form 10-K for the year ended May 31, 2022, as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I,
 Zackary Irani, Chief Executive Officer of the Company, certify, to the
best of my knowledge, pursuant to Exchange Act Rule 15d-14(b) and 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes
Oxley Act of 2002, as amended:</p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; MARGIN-BOTTOM:-2px; FONT-FAMILY:'Times New Roman'; WIDTH:48px; MARGIN-TOP:0px; FLOAT:left">i. &nbsp;&nbsp;</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px; TEXT-INDENT:-2px">The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934, and</p> <p style="CLEAR:left; MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; MARGIN-BOTTOM:-2px; FONT-FAMILY:'Times New Roman'; WIDTH:48px; MARGIN-TOP:0px; FLOAT:left">ii. &nbsp;</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px; TEXT-INDENT:-2px">The
 information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the
Company.</p> <p style="CLEAR:left; MARGIN:0px"><br></p> <p style="MARGIN:0px"><br></p> <p style="MARGIN:0px"><br></p> <table style="WIDTH:167pt; BORDER-COLLAPSE:collapse" width="223" cellspacing="0" cellpadding="0" bordercolor="transparent"><tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:167pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" width="223"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;">/s/ Zackary S. Irani</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;"><i>Zackary S. Irani</i></font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;">Chief Executive Officer</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;">Date: August 29, 2022</font></p></td></tr></table> <p style="MARGIN:0px"><br></p> <p style="MARGIN:0px"><br></p> <p style="MARGIN:0px"><br><br></p></body>
<!-- EDGAR Validation Code: 237E9F32 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>exhibit32_2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<head> <title>Exhibit 32.2</title></head> <body> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px">&nbsp;</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px"><b>EXHIBIT 32.2</b></p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center"><b>CERTIFICATION OF CHIEF FINANCIAL OFFICER<br> PURSUANT TO</b></p><b> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center">18 U.S.C. SECTION 1350</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center">AS ADOPTED PURSUANT TO</p> </b><p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center"><b>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify;MARGIN:0px">In
 connection with the Annual Report of Biomerica, Inc. (the "Company")
 on Form 10-K for the year ended May 31, 2022, as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I,
 Steve Sloan, Chief Financial Officer of the Company, certify, to the
best of my knowledge, pursuant to Exchange Act Rule 15d-14(b) and 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes
Oxley Act of 2002, as amended:</p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; MARGIN-BOTTOM:-2px; FONT-FAMILY:'Times New Roman'; WIDTH:48px; MARGIN-TOP:0px; FLOAT:left">i. &nbsp;&nbsp;</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px; TEXT-INDENT:-2px">The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934, and</p> <p style="CLEAR:left; MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; MARGIN-BOTTOM:-2px; FONT-FAMILY:'Times New Roman'; WIDTH:48px; MARGIN-TOP:0px; FLOAT:left">ii. &nbsp;</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px; TEXT-INDENT:-2px">The
 information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the
Company.</p> <p style="CLEAR:left; MARGIN:0px"><br></p> <p style="MARGIN:0px"><br></p>  <table style="WIDTH:179pt; BORDER-COLLAPSE:collapse" width="239" cellspacing="0" cellpadding="0" bordercolor="transparent"><tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:179pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" width="239" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;"><i>/s/ Steve Sloan</i></font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;">Steve Sloan</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;">Chief Financial Officer</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;">Date: August 29, 2022</font></p></td></tr></table><p style="MARGIN:0px"><br></p> <p style="MARGIN-BOTTOM:9px; MARGIN-TOP:0px"><br></p> <p style="MARGIN-BOTTOM:9px; MARGIN-TOP:0px"><br><br></p></body>
<!-- EDGAR Validation Code: 237E9F32 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>bmra-20220531.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Aug 29 19:33:49 UTC 2022 -->
<xs:schema xmlns:bmra="http://www.biomerica.com/20220531" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2022" targetNamespace="http://www.biomerica.com/20220531" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="bmra-20220531_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="bmra-20220531_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="bmra-20220531_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="bmra-20220531_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet" id="bmra_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals" id="bmra_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ConsolidatedIncomeStatement" id="bmra_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ConsolidatedIncomeStatementAlt0" id="bmra_r_ConsolidatedIncomeStatementAlt0">
        <link:definition>003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Alternate 0</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ShareholdersEquityType2or3" id="bmra_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS` EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ConsolidatedCashFlow" id="bmra_r_ConsolidatedCashFlow">
        <link:definition>005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ORGANIZATION" id="bmra_r_ORGANIZATION">
        <link:definition>006 - Disclosure - ORGANIZATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" id="bmra_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNET" id="bmra_r_PROPERTYANDEQUIPMENTNET">
        <link:definition>008 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/INTANGIBLEASSETSNET" id="bmra_r_INTANGIBLEASSETSNET">
        <link:definition>009 - Disclosure - INTANGIBLE ASSETS, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES" id="bmra_r_ACCOUNTSPAYABLEANDACCRUEDEXPENSES">
        <link:definition>010 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITY" id="bmra_r_SHAREHOLDERSEQUITY">
        <link:definition>011 - Disclosure - SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/INCOMETAXES" id="bmra_r_INCOMETAXES">
        <link:definition>012 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATION" id="bmra_r_GEOGRAPHICINFORMATION">
        <link:definition>013 - Disclosure - GEOGRAPHIC INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES" id="bmra_r_COMMITMENTSANDCONTINGENCIES">
        <link:definition>014 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SUBSEQUENTEVENTS" id="bmra_r_SUBSEQUENTEVENTS">
        <link:definition>015 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/AccountingPoliciesByPolicy" id="bmra_r_AccountingPoliciesByPolicy">
        <link:definition>016 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" id="bmra_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNETTables" id="bmra_r_PROPERTYANDEQUIPMENTNETTables">
        <link:definition>018 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/INTANGIBLEASSETSNETTables" id="bmra_r_INTANGIBLEASSETSNETTables">
        <link:definition>019 - Disclosure - INTANGIBLE ASSETS, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables" id="bmra_r_ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables">
        <link:definition>020 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables" id="bmra_r_SHAREHOLDERSEQUITYTables">
        <link:definition>021 - Disclosure - SHAREHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/INCOMETAXESTables" id="bmra_r_INCOMETAXESTables">
        <link:definition>022 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables" id="bmra_r_GEOGRAPHICINFORMATIONTables">
        <link:definition>023 - Disclosure - GEOGRAPHIC INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables" id="bmra_r_COMMITMENTSANDCONTINGENCIESTables">
        <link:definition>024 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" id="bmra_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
        <link:definition>025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/InventoriesTable" id="bmra_r_InventoriesTable">
        <link:definition>026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SharebasedcompensationassumptionsTable" id="bmra_r_SharebasedcompensationassumptionsTable">
        <link:definition>027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable" id="bmra_r_RevenuefromcontractswithcustomersTable">
        <link:definition>028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Revenue from contracts with customers</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/PropertyandequipmentnetTable" id="bmra_r_PropertyandequipmentnetTable">
        <link:definition>029 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details) - Property and equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/IntangibleassetsnetTable" id="bmra_r_IntangibleassetsnetTable">
        <link:definition>030 - Disclosure - INTANGIBLE ASSETS, NET (Details) - Intangible assets, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable" id="bmra_r_ExpectedamortizationofintangibleassetsTable">
        <link:definition>031 - Disclosure - INTANGIBLE ASSETS, NET (Details) - Expected amortization of intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails" id="bmra_r_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails">
        <link:definition>032 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable" id="bmra_r_AccountspayableandaccruedexpensebalancesTable">
        <link:definition>033 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Accounts payable and accrued expense balances</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS" id="bmra_r_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS">
        <link:definition>034 - Disclosure - SHAREHOLDERS' EQUITY (Details) - STOCK OPTION AND RESTRICTED STOCK PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY" id="bmra_r_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY">
        <link:definition>035 - Disclosure - SHAREHOLDERS' EQUITY (Details) - COMMON STOCK ACTIVITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY" id="bmra_r_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY">
        <link:definition>036 - Disclosure - SHAREHOLDERS' EQUITY (Details) - PREFERRED STOCK ACTIVITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ActivityastoaggregatestockoptionsoutstandingTable" id="bmra_r_ActivityastoaggregatestockoptionsoutstandingTable">
        <link:definition>037 - Disclosure - SHAREHOLDERS' EQUITY (Details) - Activity as to aggregate stock options outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt+1Vq3zhhUlfDeP/RQUzUZihDO8dLtQrMZMNe4t6pAivP0axfdFZpsLdRcC6V+fMavTAOMD4FknVX18XpRs+KLunX2qipVKNpApCTOelknJAdDWusY2PGEvYpRrj0mxs78hkWjdoZPMe4E2T0OAgcNcAeqIj6oByjLoUTr6WpLqW/alXnLVdBjquP1ZF6No898=] CSR-->
      <link:roleType roleURI="http://www.biomerica.com/role/NonvestedStockOptionsActivityTable" id="bmra_r_NonvestedStockOptionsActivityTable">
        <link:definition>038 - Disclosure - SHAREHOLDERS' EQUITY (Details) - Non-vested Stock Options Activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/StockOptionsSummaryTable" id="bmra_r_StockOptionsSummaryTable">
        <link:definition>039 - Disclosure - SHAREHOLDERS' EQUITY (Details) - Stock Options Summary</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/INCOMETAXESDetails" id="bmra_r_INCOMETAXESDetails">
        <link:definition>040 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/IncometaxexpenseTable" id="bmra_r_IncometaxexpenseTable">
        <link:definition>041 - Disclosure - INCOME TAXES (Details) - Income tax expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/IncomeTaxRateReconciliationTable" id="bmra_r_IncomeTaxRateReconciliationTable">
        <link:definition>042 - Disclosure - INCOME TAXES (Details) - Income Tax Rate Reconciliation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/DeferredTaxTable" id="bmra_r_DeferredTaxTable">
        <link:definition>043 - Disclosure - INCOME TAXES (Details) - Deferred Tax</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails" id="bmra_r_GEOGRAPHICINFORMATIONDetails">
        <link:definition>044 - Disclosure - GEOGRAPHIC INFORMATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable" id="bmra_r_GeographicinformationregardingnetsalesTable">
        <link:definition>045 - Disclosure - GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASES" id="bmra_r_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASES">
        <link:definition>046 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) - OPERATING LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS" id="bmra_r_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS">
        <link:definition>047 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) - CONTRACTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable" id="bmra_r_SupplementalcashflowinformationrelatedtoleasesTable">
        <link:definition>048 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) - Supplemental cash flow information related to leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/FutureminimumleasepaymentsunderoperatingleasesTable" id="bmra_r_FutureminimumleasepaymentsunderoperatingleasesTable">
        <link:definition>049 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) - Future minimum lease payments under operating leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SUBSEQUENTEVENTSDetails" id="bmra_r_SUBSEQUENTEVENTSDetails">
        <link:definition>050 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <xs:element name="InventoriesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_InventoriesAbstract"/>
  <xs:element name="ShareBasedCompensationAssumptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ShareBasedCompensationAssumptionsAbstract"/>
  <xs:element name="RevenueFromContractsWithCustomersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_RevenueFromContractsWithCustomersAbstract"/>
  <xs:element name="PropertyAndEquipmentNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_PropertyAndEquipmentNetAbstract"/>
  <xs:element name="IntangibleAssetsNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_IntangibleAssetsNetAbstract"/>
  <xs:element name="ExpectedAmortizationOfIntangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract"/>
  <xs:element name="AccountsPayableAndAccruedExpenseBalancesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_AccountsPayableAndAccruedExpenseBalancesAbstract"/>
  <xs:element name="ActivityAsToAggregateStockOptionsOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ActivityAsToAggregateStockOptionsOutstandingAbstract"/>
  <xs:element name="NonVestedStockOptionsActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_NonVestedStockOptionsActivityAbstract"/>
  <xs:element name="StockOptionsSummaryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_StockOptionsSummaryAbstract"/>
  <xs:element name="IncomeTaxExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_IncomeTaxExpenseAbstract"/>
  <xs:element name="IncomeTaxRateReconciliationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_IncomeTaxRateReconciliationAbstract"/>
  <xs:element name="DeferredTaxAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_DeferredTaxAbstract"/>
  <xs:element name="GeographicInformationDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_GeographicInformationDisclosureAbstract"/>
  <xs:element name="GeographicInformationRegardingNetSalesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_GeographicInformationRegardingNetSalesAbstract"/>
  <xs:element name="SupplementalCashFlowInformationRelatedToLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract"/>
  <xs:element name="FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract4"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract5"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract7"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract8"/>
  <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract9"/>
  <xs:element name="UnlabeledAbstract10" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract10"/>
  <xs:element name="SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract"/>
  <xs:element name="UnlabeledAbstract11" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract11"/>
  <xs:element name="UnlabeledAbstract12" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract12"/>
  <xs:element name="UnlabeledAbstract13" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract13"/>
  <xs:element name="UnlabeledAbstract14" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract14"/>
  <xs:element name="UnlabeledAbstract15" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract15"/>
  <xs:element name="UnlabeledAbstract16" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract16"/>
  <xs:element name="UnlabeledAbstract17" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract17"/>
  <xs:element name="UnlabeledAbstract18" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract18"/>
  <xs:element name="UnlabeledAbstract19" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract19"/>
  <xs:element name="UnlabeledAbstract20" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract20"/>
  <xs:element name="UnlabeledAbstract21" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract21"/>
  <xs:element name="UnlabeledAbstract22" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract22"/>
  <xs:element name="UnlabeledAbstract23" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract23"/>
  <xs:element name="UnlabeledAbstract24" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract24"/>
  <xs:element name="SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0"/>
  <xs:element name="UnlabeledAbstract25" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract25"/>
  <xs:element name="SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract1"/>
  <xs:element name="UnlabeledAbstract26" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract26"/>
  <xs:element name="UnlabeledAbstract27" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract27"/>
  <xs:element name="UnlabeledAbstract28" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract28"/>
  <xs:element name="UnlabeledAbstract29" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract29"/>
  <xs:element name="UnlabeledAbstract30" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract30"/>
  <xs:element name="UnlabeledAbstract31" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract31"/>
  <xs:element name="UnlabeledAbstract32" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract32"/>
  <xs:element name="UnlabeledAbstract33" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract33"/>
  <xs:element name="SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract2"/>
  <xs:element name="IncreaseReductionInIncomeTaxesResultingFromAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract"/>
  <xs:element name="DeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_DeferredTaxAssetsAbstract"/>
  <xs:element name="OperatingLeaseRightOfUseAssetAccumulatedAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization"/>
  <xs:element name="PreferredStockUndesignatedShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="bmra_PreferredStockUndesignatedShares"/>
  <xs:element name="IncreaseDecreaseInLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_IncreaseDecreaseInLeaseLiability"/>
  <xs:element name="IncreaseInRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_IncreaseInRightOfUseAsset"/>
  <xs:element name="IncreaseInLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_IncreaseInLeaseLiability"/>
  <xs:element name="WriteOffOfFixedAssetsCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_WriteOffOfFixedAssetsCost"/>
  <xs:element name="WriteOffOfFixedAssetsAccumulatedDepreciation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_WriteOffOfFixedAssetsAccumulatedDepreciation"/>
  <xs:element name="WriteOffOfIntangibleAssetsCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_WriteOffOfIntangibleAssetsCost"/>
  <xs:element name="WriteOffOfIntangibleAssetsAccumulatedAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization"/>
  <xs:element name="GeographicInformationDisclosureTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_GeographicInformationDisclosureTextBlock"/>
  <xs:element name="LiquidityPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_LiquidityPolicyTextBlock"/>
  <xs:element name="ConcentrationRiskGeographicPolicyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock"/>
  <xs:element name="PrepaidsPolicyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_PrepaidsPolicyPolicyTextBlock"/>
  <xs:element name="ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock"/>
  <xs:element name="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable"/>
  <xs:element name="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems"/>
  <xs:element name="Equipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_Equipment"/>
  <xs:element name="FurnitureFixturesAndLeaseholdImprovements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_FurnitureFixturesAndLeaseholdImprovements"/>
  <xs:element name="FiniteLivedLicenseAccumulatedAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_FiniteLivedLicenseAccumulatedAmortization"/>
  <xs:element name="FiniteLivedPatentsAccumulatedAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_FiniteLivedPatentsAccumulatedAmortization"/>
  <xs:element name="SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingTable"/>
  <xs:element name="SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems"/>
  <xs:element name="DefferedTaxAssetsStockOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_DefferedTaxAssetsStockOptions"/>
  <xs:element name="DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet"/>
  <xs:element name="DeferredTaxAssetsAccumulatedDepreciationAndAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization"/>
  <xs:element name="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable"/>
  <xs:element name="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems"/>
  <xs:element name="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable"/>
  <xs:element name="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems"/>
  <xs:element name="WorkingCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_WorkingCapital"/>
  <xs:element name="ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue"/>
  <xs:element name="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable"/>
  <xs:element name="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems"/>
  <xs:element name="SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSTable"/>
  <xs:element name="SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems"/>
  <xs:element name="SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable"/>
  <xs:element name="SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems"/>
  <xs:element name="SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYTable"/>
  <xs:element name="SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems"/>
  <xs:element name="INCOMETAXESDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_INCOMETAXESDetailsTable"/>
  <xs:element name="INCOMETAXESDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_INCOMETAXESDetailsLineItems"/>
  <xs:element name="PropertySubjectToOrAvailableForOperatingLease_Domain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain"/>
  <xs:element name="COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESTable"/>
  <xs:element name="COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems"/>
  <xs:element name="LeaseExpirationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_LeaseExpirationPeriod"/>
  <xs:element name="COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSTable"/>
  <xs:element name="COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems"/>
  <xs:element name="RoyaltyExpensePercentageOfSales" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_RoyaltyExpensePercentageOfSales"/>
  <xs:element name="RoyaltyPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_RoyaltyPercentage"/>
  <xs:element name="LicenseMaintenanceFeePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_LicenseMaintenanceFeePayable"/>
  <xs:element name="ClinicalTrialAgreementMaximumBudgetedCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_ClinicalTrialAgreementMaximumBudgetedCosts"/>
  <xs:element name="SUBSEQUENTEVENTSDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_SUBSEQUENTEVENTSDetailsTable"/>
  <xs:element name="SUBSEQUENTEVENTSDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SUBSEQUENTEVENTSDetailsLineItems"/>
  <xs:element name="A2014PlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_A2014PlanMember"/>
  <xs:element name="A2017PlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_A2017PlanMember"/>
  <xs:element name="A2020PlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_A2020PlanMember"/>
  <xs:element name="A2020StockIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_A2020StockIncentivePlanMember"/>
  <xs:element name="A5PercentConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_A5PercentConvertiblePreferredStockMember"/>
  <xs:element name="ATMAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ATMAgreementMember"/>
  <xs:element name="BiomericaInFoodsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_BiomericaInFoodsMember"/>
  <xs:element name="BuildingInIrvineCaliforniaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_BuildingInIrvineCaliforniaMember"/>
  <xs:element name="CaliforniaStateIncomeTaxMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_CaliforniaStateIncomeTaxMember"/>
  <xs:element name="ClinicalLabMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ClinicalLabMember"/>
  <xs:element name="ContractManufacturingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ContractManufacturingMember"/>
  <xs:element name="DistributorsInAsiaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_DistributorsInAsiaMember"/>
  <xs:element name="ExercisePriceRangePerShare082362Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ExercisePriceRangePerShare082362Member"/>
  <xs:element name="ExercisePriceRangePerShare082818Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ExercisePriceRangePerShare082818Member"/>
  <xs:element name="ExercisePriceRangePerShare082870Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ExercisePriceRangePerShare082870Member"/>
  <xs:element name="ExercisePriceRangePerShare120362Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ExercisePriceRangePerShare120362Member"/>
  <xs:element name="ExercisePriceRangePerShare161818Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ExercisePriceRangePerShare161818Member"/>
  <xs:element name="ExercisePriceRangePerShare235818Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ExercisePriceRangePerShare235818Member"/>
  <xs:element name="ExercisePriceRangePerShare425446Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ExercisePriceRangePerShare425446Member"/>
  <xs:element name="ExercisePriceRangePerShare514870Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ExercisePriceRangePerShare514870Member"/>
  <xs:element name="FirstAmendmentToLeaseMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_FirstAmendmentToLeaseMember"/>
  <xs:element name="OneDistributorMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_OneDistributorMember"/>
  <xs:element name="OneVendorMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_OneVendorMember"/>
  <xs:element name="OverthecounterMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_OverthecounterMember"/>
  <xs:element name="PalmMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_PalmMember"/>
  <xs:element name="PhysiciansOfficeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_PhysiciansOfficeMember"/>
  <xs:element name="PolishDistributorMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_PolishDistributorMember"/>
  <xs:element name="PurchasedTechnologyRightsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_PurchasedTechnologyRightsMember"/>
  <xs:element name="RangeOfExercisePrice082152Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_RangeOfExercisePrice082152Member"/>
  <xs:element name="RangeOfExercisePrice225425Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_RangeOfExercisePrice225425Member"/>
  <xs:element name="RangeOfExercisePrice434870Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_RangeOfExercisePrice434870Member"/>
  <xs:element name="StockPurchaseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_StockPurchaseAgreementMember"/>
  <xs:element name="TelconAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_TelconAgreementMember"/>
  <xs:element name="TwoDistributorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_TwoDistributorsMember"/>
  <xs:element name="TwoVendorMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_TwoVendorMember"/>
  <xs:element name="UCLicenseAgreementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UCLicenseAgreementsMember"/>
  <xs:element name="UniversityOFSouthernCaliforniaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UniversityOFSouthernCaliforniaMember"/>
  <xs:element name="CashPaidDuringThePeriodForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_CashPaidDuringThePeriodForAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>bmra-20220531_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Aug 29 19:33:49 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_ConsolidatedBalanceSheet" roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_ConsolidatedIncomeStatement" roleURI="http://www.biomerica.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_ConsolidatedCashFlow" roleURI="http://www.biomerica.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_InventoriesTable" roleURI="http://www.biomerica.com/role/InventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_PropertyandequipmentnetTable" roleURI="http://www.biomerica.com/role/PropertyandequipmentnetTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_IntangibleassetsnetTable" roleURI="http://www.biomerica.com/role/IntangibleassetsnetTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_ExpectedamortizationofintangibleassetsTable" roleURI="http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_AccountspayableandaccruedexpensebalancesTable" roleURI="http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_IncometaxexpenseTable" roleURI="http://www.biomerica.com/role/IncometaxexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_DeferredTaxTable" roleURI="http://www.biomerica.com/role/DeferredTaxTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_FutureminimumleasepaymentsunderoperatingleasesTable" roleURI="http://www.biomerica.com/role/FutureminimumleasepaymentsunderoperatingleasesTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Investments" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiability" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_StockOptionPlanExpense" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseDecreaseInLeaseLiability" xlink:href="bmra-20220531.xsd#bmra_IncreaseDecreaseInLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="bmra_IncreaseDecreaseInLeaseLiability" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt+1Vq3zhhUlfDeP/RQUzUZihDO8dLtQrMZMNe4t6pAivP0axfdFZpsLdRcC6V+fMavTAOMD4FknVX18XpRs+KLunX2qipVKNpApCTOelknJAdDWusY2PGEvYpRrj0mxs78hkWjdoZPMe4E2T0OAgcNcAeqIj6oByjJ0+v6BMru22bolDz9KQfnf] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="15" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/InventoriesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryValuationReserves" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/PropertyandequipmentnetTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:label="bmra_Equipment" xlink:href="bmra-20220531.xsd#bmra_Equipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="bmra_Equipment" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="bmra_FurnitureFixturesAndLeaseholdImprovements" xlink:href="bmra-20220531.xsd#bmra_FurnitureFixturesAndLeaseholdImprovements"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="bmra_FurnitureFixturesAndLeaseholdImprovements" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="3" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/IntangibleassetsnetTable">
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedLicenseAgreementsGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedLicenseAgreementsGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedPatentsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedPatentsGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedPatentsGross" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="bmra_FiniteLivedLicenseAccumulatedAmortization" xlink:href="bmra-20220531.xsd#bmra_FiniteLivedLicenseAccumulatedAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="bmra_FiniteLivedLicenseAccumulatedAmortization" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="bmra_FiniteLivedPatentsAccumulatedAmortization" xlink:href="bmra-20220531.xsd#bmra_FiniteLivedPatentsAccumulatedAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="bmra_FiniteLivedPatentsAccumulatedAmortization" order="4" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="6" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/IncometaxexpenseTable">
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/DeferredTaxTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInventory" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="bmra_DefferedTaxAssetsStockOptions" xlink:href="bmra-20220531.xsd#bmra_DefferedTaxAssetsStockOptions"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="bmra_DefferedTaxAssetsStockOptions" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" xlink:href="bmra-20220531.xsd#bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" xlink:href="bmra-20220531.xsd#bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/FutureminimumleasepaymentsunderoperatingleasesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>bmra-20220531_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Aug 29 19:33:49 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_ConsolidatedBalanceSheet" roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_ConsolidatedIncomeStatement" roleURI="http://www.biomerica.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_ShareholdersEquityType2or3" roleURI="http://www.biomerica.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_ConsolidatedCashFlow" roleURI="http://www.biomerica.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_ORGANIZATION" roleURI="http://www.biomerica.com/role/ORGANIZATION"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_PROPERTYANDEQUIPMENTNET" roleURI="http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNET"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_INTANGIBLEASSETSNET" roleURI="http://www.biomerica.com/role/INTANGIBLEASSETSNET"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_ACCOUNTSPAYABLEANDACCRUEDEXPENSES" roleURI="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_SHAREHOLDERSEQUITY" roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITY"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_INCOMETAXES" roleURI="http://www.biomerica.com/role/INCOMETAXES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_GEOGRAPHICINFORMATION" roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATION"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_COMMITMENTSANDCONTINGENCIES" roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_SUBSEQUENTEVENTS" roleURI="http://www.biomerica.com/role/SUBSEQUENTEVENTS"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_AccountingPoliciesByPolicy" roleURI="http://www.biomerica.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_PROPERTYANDEQUIPMENTNETTables" roleURI="http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNETTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_INTANGIBLEASSETSNETTables" roleURI="http://www.biomerica.com/role/INTANGIBLEASSETSNETTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables" roleURI="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_SHAREHOLDERSEQUITYTables" roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_INCOMETAXESTables" roleURI="http://www.biomerica.com/role/INCOMETAXESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_GEOGRAPHICINFORMATIONTables" roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_COMMITMENTSANDCONTINGENCIESTables" roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_InventoriesTable" roleURI="http://www.biomerica.com/role/InventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_SharebasedcompensationassumptionsTable" roleURI="http://www.biomerica.com/role/SharebasedcompensationassumptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_RevenuefromcontractswithcustomersTable" roleURI="http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_PropertyandequipmentnetTable" roleURI="http://www.biomerica.com/role/PropertyandequipmentnetTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_IntangibleassetsnetTable" roleURI="http://www.biomerica.com/role/IntangibleassetsnetTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_ExpectedamortizationofintangibleassetsTable" roleURI="http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_AccountspayableandaccruedexpensebalancesTable" roleURI="http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_ActivityastoaggregatestockoptionsoutstandingTable" roleURI="http://www.biomerica.com/role/ActivityastoaggregatestockoptionsoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_NonvestedStockOptionsActivityTable" roleURI="http://www.biomerica.com/role/NonvestedStockOptionsActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_StockOptionsSummaryTable" roleURI="http://www.biomerica.com/role/StockOptionsSummaryTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_IncometaxexpenseTable" roleURI="http://www.biomerica.com/role/IncometaxexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_IncomeTaxRateReconciliationTable" roleURI="http://www.biomerica.com/role/IncomeTaxRateReconciliationTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_DeferredTaxTable" roleURI="http://www.biomerica.com/role/DeferredTaxTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_GeographicinformationregardingnetsalesTable" roleURI="http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_SupplementalcashflowinformationrelatedtoleasesTable" roleURI="http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_FutureminimumleasepaymentsunderoperatingleasesTable" roleURI="http://www.biomerica.com/role/FutureminimumleasepaymentsunderoperatingleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails" roleURI="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS" roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY" roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY" roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_INCOMETAXESDetails" roleURI="http://www.biomerica.com/role/INCOMETAXESDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_GEOGRAPHICINFORMATIONDetails" roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASES" roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS" roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_SUBSEQUENTEVENTSDetails" roleURI="http://www.biomerica.com/role/SUBSEQUENTEVENTSDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#DocumentAndEntityInformation" roleURI="http://www.biomerica.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_A5PercentConvertiblePreferredStockMember" xlink:href="bmra-20220531.xsd#bmra_A5PercentConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="bmra_A5PercentConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Investments" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_A5PercentConvertiblePreferredStockMember" xlink:href="bmra-20220531.xsd#bmra_A5PercentConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="bmra_A5PercentConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="bmra-20220531.xsd#bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNoParValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockNoParValue" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_PreferredStockUndesignatedShares" xlink:href="bmra-20220531.xsd#bmra_PreferredStockUndesignatedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bmra_PreferredStockUndesignatedShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_GrossProfit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OperatingExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_A5PercentConvertiblePreferredStockMember" xlink:href="bmra-20220531.xsd#bmra_A5PercentConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="bmra_A5PercentConvertiblePreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_StockOptionPlanExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseDecreaseInLeaseLiability" xlink:href="bmra-20220531.xsd#bmra_IncreaseDecreaseInLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="bmra_IncreaseDecreaseInLeaseLiability" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_CashPaidDuringThePeriodForAbstract" xlink:href="bmra-20220531.xsd#bmra_CashPaidDuringThePeriodForAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="bmra_CashPaidDuringThePeriodForAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_CashPaidDuringThePeriodForAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseInRightOfUseAsset" xlink:href="bmra-20220531.xsd#bmra_IncreaseInRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="bmra_IncreaseInRightOfUseAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseInLeaseLiability" xlink:href="bmra-20220531.xsd#bmra_IncreaseInLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="bmra_IncreaseInLeaseLiability" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_WriteOffOfFixedAssetsCost" xlink:href="bmra-20220531.xsd#bmra_WriteOffOfFixedAssetsCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="bmra_WriteOffOfFixedAssetsCost" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_WriteOffOfFixedAssetsAccumulatedDepreciation" xlink:href="bmra-20220531.xsd#bmra_WriteOffOfFixedAssetsAccumulatedDepreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="bmra_WriteOffOfFixedAssetsAccumulatedDepreciation" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_WriteOffOfIntangibleAssetsCost" xlink:href="bmra-20220531.xsd#bmra_WriteOffOfIntangibleAssetsCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="bmra_WriteOffOfIntangibleAssetsCost" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization" xlink:href="bmra-20220531.xsd#bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ORGANIZATION">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNET">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INTANGIBLEASSETSNET">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SHAREHOLDERSEQUITY">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INCOMETAXES">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GEOGRAPHICINFORMATION">
    <loc xlink:type="locator" xlink:label="bmra_GeographicInformationDisclosureAbstract" xlink:href="bmra-20220531.xsd#bmra_GeographicInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="bmra_GeographicInformationDisclosureTextBlock" xlink:href="bmra-20220531.xsd#bmra_GeographicInformationDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_GeographicInformationDisclosureAbstract" xlink:to="bmra_GeographicInformationDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUBSEQUENTEVENTS">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_LiquidityPolicyTextBlock" xlink:href="bmra-20220531.xsd#bmra_LiquidityPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bmra_LiquidityPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock" xlink:href="bmra-20220531.xsd#bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_PrepaidsPolicyPolicyTextBlock" xlink:href="bmra-20220531.xsd#bmra_PrepaidsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bmra_PrepaidsPolicyPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="25" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNETTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INTANGIBLEASSETSNETTables">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INCOMETAXESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables">
    <loc xlink:type="locator" xlink:label="bmra_GeographicInformationDisclosureAbstract" xlink:href="bmra-20220531.xsd#bmra_GeographicInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_GeographicInformationDisclosureAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" xlink:href="bmra-20220531.xsd#bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/InventoriesTable">
    <loc xlink:type="locator" xlink:label="bmra_InventoriesAbstract" xlink:href="bmra-20220531.xsd#bmra_InventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_InventoriesAbstract" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_InventoriesAbstract" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_InventoriesAbstract" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_InventoriesAbstract" xlink:to="us-gaap_InventoryGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_InventoriesAbstract" xlink:to="us-gaap_InventoryValuationReserves" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_InventoriesAbstract" xlink:to="us-gaap_InventoryNet" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SharebasedcompensationassumptionsTable">
    <loc xlink:type="locator" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:href="bmra-20220531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" xlink:href="bmra-20220531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_PhysiciansOfficeMember" xlink:href="bmra-20220531.xsd#bmra_PhysiciansOfficeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="bmra_PhysiciansOfficeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ClinicalLabMember" xlink:href="bmra-20220531.xsd#bmra_ClinicalLabMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="bmra_ClinicalLabMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_OverthecounterMember" xlink:href="bmra-20220531.xsd#bmra_OverthecounterMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="bmra_OverthecounterMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ContractManufacturingMember" xlink:href="bmra-20220531.xsd#bmra_ContractManufacturingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="bmra_ContractManufacturingMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/PropertyandequipmentnetTable">
    <loc xlink:type="locator" xlink:label="bmra_PropertyAndEquipmentNetAbstract" xlink:href="bmra-20220531.xsd#bmra_PropertyAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="bmra_Equipment" xlink:href="bmra-20220531.xsd#bmra_Equipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_PropertyAndEquipmentNetAbstract" xlink:to="bmra_Equipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_FurnitureFixturesAndLeaseholdImprovements" xlink:href="bmra-20220531.xsd#bmra_FurnitureFixturesAndLeaseholdImprovements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_PropertyAndEquipmentNetAbstract" xlink:to="bmra_FurnitureFixturesAndLeaseholdImprovements" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_PropertyAndEquipmentNetAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_PropertyAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/IntangibleassetsnetTable">
    <loc xlink:type="locator" xlink:label="bmra_IntangibleAssetsNetAbstract" xlink:href="bmra-20220531.xsd#bmra_IntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedLicenseAgreementsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedLicenseAgreementsGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedPatentsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedPatentsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedPatentsGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_FiniteLivedLicenseAccumulatedAmortization" xlink:href="bmra-20220531.xsd#bmra_FiniteLivedLicenseAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IntangibleAssetsNetAbstract" xlink:to="bmra_FiniteLivedLicenseAccumulatedAmortization" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_FiniteLivedPatentsAccumulatedAmortization" xlink:href="bmra-20220531.xsd#bmra_FiniteLivedPatentsAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IntangibleAssetsNetAbstract" xlink:to="bmra_FiniteLivedPatentsAccumulatedAmortization" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IntangibleAssetsNetAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:href="bmra-20220531.xsd#bmra_ExpectedAmortizationOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable">
    <loc xlink:type="locator" xlink:label="bmra_AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:href="bmra-20220531.xsd#bmra_AccountsPayableAndAccruedExpenseBalancesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ActivityastoaggregatestockoptionsoutstandingTable">
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems" xlink:href="bmra-20220531.xsd#bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingTable" xlink:href="bmra-20220531.xsd#bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems" xlink:to="bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare082818Member" xlink:href="bmra-20220531.xsd#bmra_ExercisePriceRangePerShare082818Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_ExercisePriceRangePerShare082818Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare514870Member" xlink:href="bmra-20220531.xsd#bmra_ExercisePriceRangePerShare514870Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_ExercisePriceRangePerShare514870Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare082362Member" xlink:href="bmra-20220531.xsd#bmra_ExercisePriceRangePerShare082362Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_ExercisePriceRangePerShare082362Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare235818Member" xlink:href="bmra-20220531.xsd#bmra_ExercisePriceRangePerShare235818Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_ExercisePriceRangePerShare235818Member" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare082870Member" xlink:href="bmra-20220531.xsd#bmra_ExercisePriceRangePerShare082870Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_ExercisePriceRangePerShare082870Member" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare425446Member" xlink:href="bmra-20220531.xsd#bmra_ExercisePriceRangePerShare425446Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_ExercisePriceRangePerShare425446Member" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare120362Member" xlink:href="bmra-20220531.xsd#bmra_ExercisePriceRangePerShare120362Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_ExercisePriceRangePerShare120362Member" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare161818Member" xlink:href="bmra-20220531.xsd#bmra_ExercisePriceRangePerShare161818Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_ExercisePriceRangePerShare161818Member" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/NonvestedStockOptionsActivityTable">
    <loc xlink:type="locator" xlink:label="bmra_NonVestedStockOptionsActivityAbstract" xlink:href="bmra-20220531.xsd#bmra_NonVestedStockOptionsActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/StockOptionsSummaryTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_RangeOfExercisePrice082152Member" xlink:href="bmra-20220531.xsd#bmra_RangeOfExercisePrice082152Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_RangeOfExercisePrice082152Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_RangeOfExercisePrice225425Member" xlink:href="bmra-20220531.xsd#bmra_RangeOfExercisePrice225425Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_RangeOfExercisePrice225425Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_RangeOfExercisePrice434870Member" xlink:href="bmra-20220531.xsd#bmra_RangeOfExercisePrice434870Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_RangeOfExercisePrice434870Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/IncometaxexpenseTable">
    <loc xlink:type="locator" xlink:label="bmra_IncomeTaxExpenseAbstract" xlink:href="bmra-20220531.xsd#bmra_IncomeTaxExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncomeTaxExpenseAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncomeTaxExpenseAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" order="1" xbrldt:closed="true"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt+1Vq3zhhUlfDeP/RQUzUZihDO8dLtQrMZMNe4t6pAivP0axfdFZpsLdRcC6V+fMavTAOMD4FknVX18XpRs+KLunX2qipVKNpApCTOelknJAdDWusY2PGEvYpRrj0mxs78hkWjdoZPMe4E2T0OAgcNcAeqIj6oByjIRBP4fZSEe2m7Kx43RuoepACu8P/IfoyA=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncomeTaxExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/IncomeTaxRateReconciliationTable">
    <loc xlink:type="locator" xlink:label="bmra_IncomeTaxRateReconciliationAbstract" xlink:href="bmra-20220531.xsd#bmra_IncomeTaxRateReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:href="bmra-20220531.xsd#bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncomeTaxRateReconciliationAbstract" xlink:to="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/DeferredTaxTable">
    <loc xlink:type="locator" xlink:label="bmra_DeferredTaxAbstract" xlink:href="bmra-20220531.xsd#bmra_DeferredTaxAbstract"/>
    <loc xlink:type="locator" xlink:label="bmra_DeferredTaxAssetsAbstract" xlink:href="bmra-20220531.xsd#bmra_DeferredTaxAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAbstract" xlink:to="bmra_DeferredTaxAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsInventory" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_DefferedTaxAssetsStockOptions" xlink:href="bmra-20220531.xsd#bmra_DefferedTaxAssetsStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAbstract" xlink:to="bmra_DefferedTaxAssetsStockOptions" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" xlink:href="bmra-20220531.xsd#bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAbstract" xlink:to="bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" xlink:href="bmra-20220531.xsd#bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAbstract" xlink:to="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable">
    <loc xlink:type="locator" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:href="bmra-20220531.xsd#bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:href="bmra-20220531.xsd#bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:to="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueSegmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueSegmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeographicConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_GeographicConcentrationRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_AsiaMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_AsiaMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NorthAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NorthAmericaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_NorthAmericaMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SouthAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SouthAmericaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SouthAmericaMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MiddleEastMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MiddleEastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_MiddleEastMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:to="us-gaap_Revenues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable">
    <loc xlink:type="locator" xlink:label="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:href="bmra-20220531.xsd#bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/FutureminimumleasepaymentsunderoperatingleasesTable">
    <loc xlink:type="locator" xlink:label="bmra_FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:href="bmra-20220531.xsd#bmra_FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
    <loc xlink:type="locator" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:href="bmra-20220531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:href="bmra-20220531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="srt_RangeAxis" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_PolishDistributorMember" xlink:href="bmra-20220531.xsd#bmra_PolishDistributorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="bmra_PolishDistributorMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DistributionRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionRightsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DistributionRightsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_PurchasedTechnologyRightsMember" xlink:href="bmra-20220531.xsd#bmra_PurchasedTechnologyRightsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bmra_PurchasedTechnologyRightsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsPayableMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsProductLineMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsProductLineMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_CostOfGoodsProductLineMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_SupplierConcentrationRiskMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_MX" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MX"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_MX" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_TwoDistributorsMember" xlink:href="bmra-20220531.xsd#bmra_TwoDistributorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_TwoDistributorsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_OneDistributorMember" xlink:href="bmra-20220531.xsd#bmra_OneDistributorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_OneDistributorMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_OneVendorMember" xlink:href="bmra-20220531.xsd#bmra_OneVendorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_OneVendorMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ATMAgreementMember" xlink:href="bmra-20220531.xsd#bmra_ATMAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="bmra_ATMAgreementMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="bmra_OneDistributorMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_DistributorsInAsiaMember" xlink:href="bmra-20220531.xsd#bmra_DistributorsInAsiaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="bmra_DistributorsInAsiaMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_WorkingCapital" xlink:href="bmra-20220531.xsd#bmra_WorkingCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="bmra_WorkingCapital" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" xlink:href="bmra-20220531.xsd#bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_SharePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashUninsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_CashUninsuredAmount" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_Revenues" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_OtherReceivablesGrossCurrent" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_InventoryGross" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_InventoryValuationReserves" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_Investments" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AdvertisingExpense" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="33" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails">
    <loc xlink:type="locator" xlink:label="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems" xlink:href="bmra-20220531.xsd#bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:href="bmra-20220531.xsd#bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems" xlink:to="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsPayableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_TwoVendorMember" xlink:href="bmra-20220531.xsd#bmra_TwoVendorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_TwoVendorMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_OneVendorMember" xlink:href="bmra-20220531.xsd#bmra_OneVendorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_OneVendorMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS">
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" xlink:href="bmra-20220531.xsd#bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSTable" xlink:href="bmra-20220531.xsd#bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" xlink:to="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSTable" xlink:to="us-gaap_AwardTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSTable" xlink:to="us-gaap_PlanNameAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_A2014PlanMember" xlink:href="bmra-20220531.xsd#bmra_A2014PlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bmra_A2014PlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_A2017PlanMember" xlink:href="bmra-20220531.xsd#bmra_A2017PlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bmra_A2017PlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_A2020PlanMember" xlink:href="bmra-20220531.xsd#bmra_A2020PlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bmra_A2020PlanMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY">
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems" xlink:href="bmra-20220531.xsd#bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable" xlink:href="bmra-20220531.xsd#bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems" xlink:to="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable" xlink:to="srt_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable" xlink:to="us-gaap_TransactionTypeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable" xlink:to="us-gaap_PlanNameAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_A2020StockIncentivePlanMember" xlink:href="bmra-20220531.xsd#bmra_A2020StockIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bmra_A2020StockIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ATMAgreementMember" xlink:href="bmra-20220531.xsd#bmra_ATMAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="bmra_ATMAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY">
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems" xlink:href="bmra-20220531.xsd#bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYTable" xlink:href="bmra-20220531.xsd#bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems" xlink:to="bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_PalmMember" xlink:href="bmra-20220531.xsd#bmra_PalmMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_PalmMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_StockPurchaseAgreementMember" xlink:href="bmra-20220531.xsd#bmra_StockPurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="bmra_StockPurchaseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPayableAmountPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableAmountPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems" xlink:to="us-gaap_DividendsPayableAmountPerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INCOMETAXESDetails">
    <loc xlink:type="locator" xlink:label="bmra_INCOMETAXESDetailsLineItems" xlink:href="bmra-20220531.xsd#bmra_INCOMETAXESDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_INCOMETAXESDetailsTable" xlink:href="bmra-20220531.xsd#bmra_INCOMETAXESDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_INCOMETAXESDetailsLineItems" xlink:to="bmra_INCOMETAXESDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_INCOMETAXESDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_INCOMETAXESDetailsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_CaliforniaStateIncomeTaxMember" xlink:href="bmra-20220531.xsd#bmra_CaliforniaStateIncomeTaxMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="bmra_CaliforniaStateIncomeTaxMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_INCOMETAXESDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_INCOMETAXESDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_INCOMETAXESDetailsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_INCOMETAXESDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_INCOMETAXESDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails">
    <loc xlink:type="locator" xlink:label="bmra_GeographicInformationDisclosureAbstract" xlink:href="bmra-20220531.xsd#bmra_GeographicInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_GeographicInformationDisclosureAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASES">
    <loc xlink:type="locator" xlink:label="bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems" xlink:href="bmra-20220531.xsd#bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESTable" xlink:href="bmra-20220531.xsd#bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems" xlink:to="bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESTable" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain" xlink:href="bmra-20220531.xsd#bmra_PropertySubjectToOrAvailableForOperatingLease_Domain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain_0" xlink:href="bmra-20220531.xsd#bmra_PropertySubjectToOrAvailableForOperatingLease_Domain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESTable" xlink:to="srt_StatementGeographicalAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_BuildingInIrvineCaliforniaMember" xlink:href="bmra-20220531.xsd#bmra_BuildingInIrvineCaliforniaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain" xlink:to="bmra_BuildingInIrvineCaliforniaMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyAvailableForOperatingLeaseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyAvailableForOperatingLeaseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain" xlink:to="us-gaap_PropertyAvailableForOperatingLeaseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_MX" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MX"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_MX" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_FirstAmendmentToLeaseMember" xlink:href="bmra-20220531.xsd#bmra_FirstAmendmentToLeaseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="bmra_FirstAmendmentToLeaseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems" xlink:to="us-gaap_SecurityDeposit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_LeaseExpirationPeriod" xlink:href="bmra-20220531.xsd#bmra_LeaseExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems" xlink:to="bmra_LeaseExpirationPeriod" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS">
    <loc xlink:type="locator" xlink:label="bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems" xlink:href="bmra-20220531.xsd#bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSTable" xlink:href="bmra-20220531.xsd#bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems" xlink:to="bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RoyaltyAgreementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_TelconAgreementMember" xlink:href="bmra-20220531.xsd#bmra_TelconAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="bmra_TelconAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_UCLicenseAgreementsMember" xlink:href="bmra-20220531.xsd#bmra_UCLicenseAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="bmra_UCLicenseAgreementsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_UniversityOFSouthernCaliforniaMember" xlink:href="bmra-20220531.xsd#bmra_UniversityOFSouthernCaliforniaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="bmra_UniversityOFSouthernCaliforniaMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_BiomericaInFoodsMember" xlink:href="bmra-20220531.xsd#bmra_BiomericaInFoodsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="bmra_BiomericaInFoodsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems" xlink:to="us-gaap_RoyaltyExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_RoyaltyExpensePercentageOfSales" xlink:href="bmra-20220531.xsd#bmra_RoyaltyExpensePercentageOfSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems" xlink:to="bmra_RoyaltyExpensePercentageOfSales" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedFeesAndOtherRevenueReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedFeesAndOtherRevenueReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems" xlink:to="us-gaap_AccruedFeesAndOtherRevenueReceivable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromFeesReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems" xlink:to="us-gaap_ProceedsFromFeesReceived" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_RoyaltyPercentage" xlink:href="bmra-20220531.xsd#bmra_RoyaltyPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems" xlink:to="bmra_RoyaltyPercentage" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems" xlink:to="us-gaap_PaymentsForFees" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_LicenseMaintenanceFeePayable" xlink:href="bmra-20220531.xsd#bmra_LicenseMaintenanceFeePayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems" xlink:to="bmra_LicenseMaintenanceFeePayable" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ClinicalTrialAgreementMaximumBudgetedCosts" xlink:href="bmra-20220531.xsd#bmra_ClinicalTrialAgreementMaximumBudgetedCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems" xlink:to="bmra_ClinicalTrialAgreementMaximumBudgetedCosts" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUBSEQUENTEVENTSDetails">
    <loc xlink:type="locator" xlink:label="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:href="bmra-20220531.xsd#bmra_SUBSEQUENTEVENTSDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_SUBSEQUENTEVENTSDetailsTable" xlink:href="bmra-20220531.xsd#bmra_SUBSEQUENTEVENTSDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="bmra_SUBSEQUENTEVENTSDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_SharePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="35" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>bmra-20220531_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Aug 29 19:33:49 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, less allowance for doubtful accounts of $153,231 and $837,415 as of May 31, 2022 and 2021, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Allowance for doubtful accounts (in Dollars) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Net Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation and amortization of $1,305,360 and $1,972,357 as of May 31, 2022 and 2021, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Net property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation and amortization (in Dollars) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Less accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use assets, net of accumulated amortization of $724,802 and $469,077 as of May 31, 2022 and 2021, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <loc xlink:type="locator" xlink:label="bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="bmra-20220531.xsd#bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization, Right of Use Assets (in Dollars) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Investments_lbl" xml:lang="en-US">Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Investments" xlink:to="us-gaap_Investments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net of accumulated amortization of $18,994 and $126,769 as of May 31, 2022 and 2021, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0" xml:lang="en-US">Intangible asssets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization, Intangible Assets (in Dollars) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US">Advance from customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease liability, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liability, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Notes 6 and 9)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_lbl" xml:lang="en-US">Equity Interest Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, Series A 5% convertible, $0.08 par value, 571,429 shares authorized, none issued and outstanding as of May 31, 2022 and 2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred stock, undesignated, no par value, 4,428,571 shares authorized, none issued and outstanding as of May 31, 2022 and 2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par Value (in Dollars per share) (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNoParValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockNoParValue_lbl" xml:lang="en-US">Preferred Stock, No Par Value (in Dollars per share) (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNoParValue" xlink:to="us-gaap_PreferredStockNoParValue_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_PreferredStockUndesignatedShares" xlink:href="bmra-20220531.xsd#bmra_PreferredStockUndesignatedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_PreferredStockUndesignatedShares_lbl" xml:lang="en-US">Preferred Stock, undesignated shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PreferredStockUndesignatedShares" xlink:to="bmra_PreferredStockUndesignatedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.08 par value, 25,000,000 shares authorized, 12,867,924 and 12,307,157 issued and outstanding at May 31, 2022 and 2021, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock par value (in Dollars per share) (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in-capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Shareholders&apos; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Shareholders&apos; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Net sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Net Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl1" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xml:lang="en-US">Dividend and interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic net loss per common share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted net loss per common share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Foreign currency translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Balances (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Balances (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Options exercised, number of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Net proceeds from ATM</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Net proceeds from ATM (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Conversion of preferred to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Conversion of preferred to common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Converted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Compensation expense in connection with options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss on disposal of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provision for allowance on accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl0" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge_lbl" xml:lang="en-US">Inventory reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLIFOReservePeriodCharge" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionPlanExpense_lbl" xml:lang="en-US">Stock option expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseDecreaseInLeaseLiability" xlink:href="bmra-20220531.xsd#bmra_IncreaseDecreaseInLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_IncreaseDecreaseInLeaseLiability_lbl" xml:lang="en-US">Reduction in lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncreaseDecreaseInLeaseLiability" xlink:to="bmra_IncreaseDecreaseInLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Advance from customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Expenditure related to intangibles</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds from sale of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Costs from sale of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of exchange rate changes in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseInRightOfUseAsset" xlink:href="bmra-20220531.xsd#bmra_IncreaseInRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_IncreaseInRightOfUseAsset_lbl" xml:lang="en-US">Increase in right-of-use asset due to lease extension or establishment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncreaseInRightOfUseAsset" xlink:to="bmra_IncreaseInRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseInLeaseLiability" xlink:href="bmra-20220531.xsd#bmra_IncreaseInLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_IncreaseInLeaseLiability_lbl" xml:lang="en-US">Increase in lease liability due to lease extension or establishment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncreaseInLeaseLiability" xlink:to="bmra_IncreaseInLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_WriteOffOfFixedAssetsCost" xlink:href="bmra-20220531.xsd#bmra_WriteOffOfFixedAssetsCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_WriteOffOfFixedAssetsCost_lbl" xml:lang="en-US">Write off of fixed assets, cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_WriteOffOfFixedAssetsCost" xlink:to="bmra_WriteOffOfFixedAssetsCost_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_WriteOffOfFixedAssetsAccumulatedDepreciation" xlink:href="bmra-20220531.xsd#bmra_WriteOffOfFixedAssetsAccumulatedDepreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_WriteOffOfFixedAssetsAccumulatedDepreciation_lbl" xml:lang="en-US">Write off of fixed assets, accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_WriteOffOfFixedAssetsAccumulatedDepreciation" xlink:to="bmra_WriteOffOfFixedAssetsAccumulatedDepreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_WriteOffOfIntangibleAssetsCost" xlink:href="bmra-20220531.xsd#bmra_WriteOffOfIntangibleAssetsCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_WriteOffOfIntangibleAssetsCost_lbl" xml:lang="en-US">Write off of intangible assets, cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_WriteOffOfIntangibleAssetsCost" xlink:to="bmra_WriteOffOfIntangibleAssetsCost_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization" xlink:href="bmra-20220531.xsd#bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Write off of intangible assets, accumulated amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization" xlink:to="bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Work in progress</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished products</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryGross_lbl" xml:lang="en-US">Total Gross Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryGross_lbl0" xml:lang="en-US">Inventory, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US">Inventory Reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryValuationReserves_lbl0" xml:lang="en-US">Inventory Valuation Reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenue From Customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_Equipment" xlink:href="bmra-20220531.xsd#bmra_Equipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_Equipment_lbl" xml:lang="en-US">Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_Equipment" xlink:to="bmra_Equipment_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_FurnitureFixturesAndLeaseholdImprovements" xlink:href="bmra-20220531.xsd#bmra_FurnitureFixturesAndLeaseholdImprovements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_FurnitureFixturesAndLeaseholdImprovements_lbl" xml:lang="en-US">Furniture, fixtures and leasehold improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FurnitureFixturesAndLeaseholdImprovements" xlink:to="bmra_FurnitureFixturesAndLeaseholdImprovements_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedLicenseAgreementsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross_lbl" xml:lang="en-US">Licenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedLicenseAgreementsGross" xlink:to="us-gaap_FiniteLivedLicenseAgreementsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedPatentsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedPatentsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedPatentsGross_lbl" xml:lang="en-US">Patents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedPatentsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_FiniteLivedLicenseAccumulatedAmortization" xlink:href="bmra-20220531.xsd#bmra_FiniteLivedLicenseAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="bmra_FiniteLivedLicenseAccumulatedAmortization_lbl" xml:lang="en-US">Less accumulated amortization-licenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FiniteLivedLicenseAccumulatedAmortization" xlink:to="bmra_FiniteLivedLicenseAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_FiniteLivedPatentsAccumulatedAmortization" xlink:href="bmra-20220531.xsd#bmra_FiniteLivedPatentsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="bmra_FiniteLivedPatentsAccumulatedAmortization_lbl" xml:lang="en-US">Less accumulated amortization-patents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FiniteLivedPatentsAccumulatedAmortization" xlink:to="bmra_FiniteLivedPatentsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding, number of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Options outstanding, number of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options outstanding, weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Options outstanding, weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options granted, number of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Granted, number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options granted, weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options exercised, weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Options canceled or expired, number of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options canceled or expired, weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Non-vested shares, number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0" xml:lang="en-US">Non-vested shares, number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Non-vested shares, weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Non-vested shares, weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Granted, weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Vested, number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Vested, weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US">Forfeited, number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Forfeited, weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Range of Exercise Price, Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Range of Exercise Price, Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Options Outstanding, Number (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options Outstanding, Weighted Average Remaining Contractual Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Options Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Options Exercisable, Number (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Options Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">U.S. Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign Taxes Subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State and local</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">U.S. Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State and local</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Computed &quot;expected&quot; tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes, net of federal benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research and development tax credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Permanent tax differences and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xml:lang="en-US">Stock based compensation benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Foreign taxes of subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US">Accounts receivable, principally due to allowance for doubtful accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xml:lang="en-US">Inventory valuation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInventory" xlink:to="us-gaap_DeferredTaxAssetsInventory_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" xml:lang="en-US">Compensated absences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US">Tax credit carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xml:lang="en-US">Deferred rent expense/Capitalized leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_DefferedTaxAssetsStockOptions" xlink:href="bmra-20220531.xsd#bmra_DefferedTaxAssetsStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_DefferedTaxAssetsStockOptions_lbl" xml:lang="en-US">Stock Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DefferedTaxAssetsStockOptions" xlink:to="bmra_DefferedTaxAssetsStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" xlink:href="bmra-20220531.xsd#bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet_lbl" xml:lang="en-US">Losses of foreign subsidiaries &amp; Other, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" xlink:to="bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" xlink:href="bmra-20220531.xsd#bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US">Accumulated depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" xlink:to="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Net Sales Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl0" xml:lang="en-US">Concentration Risk, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Less than 1 year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">1 to 2 years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2 to 3 years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">3 to 4 years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">4 to 5 years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract" xlink:to="bmra_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract0" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract0" xlink:to="bmra_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract1" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract1" xlink:to="bmra_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract2" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract2" xlink:to="bmra_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract3" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract3" xlink:to="bmra_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract4" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract4" xlink:to="bmra_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract5" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract5" xlink:to="bmra_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Shareholders&apos; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract6" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract6" xlink:to="bmra_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract7" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract7" xlink:to="bmra_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract8" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract8" xlink:to="bmra_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders&apos; Equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract9" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract9_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract9" xlink:to="bmra_UnlabeledAbstract9_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract10" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract10"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract10_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract10" xlink:to="bmra_UnlabeledAbstract10_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract" xlink:href="bmra-20220531.xsd#bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract_lbl" xml:lang="en-US">See accompanying notes to consolidated financial statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract" xlink:to="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract11" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract11"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract11_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract11" xlink:to="bmra_UnlabeledAbstract11_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract12" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract12"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract12_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract12" xlink:to="bmra_UnlabeledAbstract12_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract13" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract13"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract13_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract13" xlink:to="bmra_UnlabeledAbstract13_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US">Other income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract14" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract14"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract14_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract14" xlink:to="bmra_UnlabeledAbstract14_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract15" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract15"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract15_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract15" xlink:to="bmra_UnlabeledAbstract15_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract16" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract16"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract16_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract16" xlink:to="bmra_UnlabeledAbstract16_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract17" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract17"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract17_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract17" xlink:to="bmra_UnlabeledAbstract17_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract18" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract18"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract18_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract18" xlink:to="bmra_UnlabeledAbstract18_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract19" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract19"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract19_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract19" xlink:to="bmra_UnlabeledAbstract19_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average number of common and common equivalent shares:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract20" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract20"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract20_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract20" xlink:to="bmra_UnlabeledAbstract20_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract21" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract21"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract21_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract21" xlink:to="bmra_UnlabeledAbstract21_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract22" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract22"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract22_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract22" xlink:to="bmra_UnlabeledAbstract22_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US">Other comprehensive loss, net of tax:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract23" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract23"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract23_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract23" xlink:to="bmra_UnlabeledAbstract23_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract24" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract24"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract24_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract24" xlink:to="bmra_UnlabeledAbstract24_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0" xlink:href="bmra-20220531.xsd#bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0_lbl" xml:lang="en-US">See accompanying notes to consolidated financial statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0" xlink:to="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract25" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract25"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract25_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract25" xlink:to="bmra_UnlabeledAbstract25_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract1" xlink:href="bmra-20220531.xsd#bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract1_lbl" xml:lang="en-US">See accompanying notes to consolidated financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract1" xlink:to="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract26" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract26"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract26_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract26" xlink:to="bmra_UnlabeledAbstract26_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract27" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract27"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract27_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract27" xlink:to="bmra_UnlabeledAbstract27_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract28" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract28"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract28_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract28" xlink:to="bmra_UnlabeledAbstract28_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract29" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract29"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract29_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract29" xlink:to="bmra_UnlabeledAbstract29_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract30" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract30"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract30_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract30" xlink:to="bmra_UnlabeledAbstract30_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract31" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract31"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract31_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract31" xlink:to="bmra_UnlabeledAbstract31_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Disclosure of Cash Flow Information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_CashPaidDuringThePeriodForAbstract" xlink:href="bmra-20220531.xsd#bmra_CashPaidDuringThePeriodForAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_CashPaidDuringThePeriodForAbstract_lbl" xml:lang="en-US">Cash paid during the year for:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_CashPaidDuringThePeriodForAbstract" xlink:to="bmra_CashPaidDuringThePeriodForAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract32" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract32"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract32_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract32" xlink:to="bmra_UnlabeledAbstract32_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Non-cash investing and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract33" xlink:href="bmra-20220531.xsd#bmra_UnlabeledAbstract33"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract33_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract33" xlink:to="bmra_UnlabeledAbstract33_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract2" xlink:href="bmra-20220531.xsd#bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract2_lbl" xml:lang="en-US">See accompanying notes to consolidated financial statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract2" xlink:to="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_A5PercentConvertiblePreferredStockMember" xlink:href="bmra-20220531.xsd#bmra_A5PercentConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_A5PercentConvertiblePreferredStockMember_lbl" xml:lang="en-US">5% Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A5PercentConvertiblePreferredStockMember" xlink:to="bmra_A5PercentConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Current:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Deferred:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:href="bmra-20220531.xsd#bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract_lbl" xml:lang="en-US">Increase (reduction) in income taxes resulting from:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_DeferredTaxAssetsAbstract" xlink:href="bmra-20220531.xsd#bmra_DeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DeferredTaxAssetsAbstract" xlink:to="bmra_DeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_GeographicInformationDisclosureTextBlock" xlink:href="bmra-20220531.xsd#bmra_GeographicInformationDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_GeographicInformationDisclosureTextBlock_lbl" xml:lang="en-US">Geographic Information Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GeographicInformationDisclosureTextBlock" xlink:to="bmra_GeographicInformationDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" xlink:href="bmra-20220531.xsd#bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock_lbl" xml:lang="en-US">Schedule Of Cash Flow Supplemental Disclosures Related To Lease [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" xlink:to="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_PhysiciansOfficeMember" xlink:href="bmra-20220531.xsd#bmra_PhysiciansOfficeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_PhysiciansOfficeMember_lbl" xml:lang="en-US">Physicians Office [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PhysiciansOfficeMember" xlink:to="bmra_PhysiciansOfficeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ClinicalLabMember" xlink:href="bmra-20220531.xsd#bmra_ClinicalLabMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ClinicalLabMember_lbl" xml:lang="en-US">Clinical Lab [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ClinicalLabMember" xlink:to="bmra_ClinicalLabMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_OverthecounterMember" xlink:href="bmra-20220531.xsd#bmra_OverthecounterMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_OverthecounterMember_lbl" xml:lang="en-US">Over-the-counter [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OverthecounterMember" xlink:to="bmra_OverthecounterMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ContractManufacturingMember" xlink:href="bmra-20220531.xsd#bmra_ContractManufacturingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ContractManufacturingMember_lbl" xml:lang="en-US">Contract Manufacturing [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ContractManufacturingMember" xlink:to="bmra_ContractManufacturingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare082818Member" xlink:href="bmra-20220531.xsd#bmra_ExercisePriceRangePerShare082818Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ExercisePriceRangePerShare082818Member_lbl" xml:lang="en-US">Exercise Price Range Per Share $0.82 - $8.18 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare082818Member" xlink:to="bmra_ExercisePriceRangePerShare082818Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare514870Member" xlink:href="bmra-20220531.xsd#bmra_ExercisePriceRangePerShare514870Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ExercisePriceRangePerShare514870Member_lbl" xml:lang="en-US">Exercise Price Range Per Share $5.14 - $8.70 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare514870Member" xlink:to="bmra_ExercisePriceRangePerShare514870Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare082362Member" xlink:href="bmra-20220531.xsd#bmra_ExercisePriceRangePerShare082362Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ExercisePriceRangePerShare082362Member_lbl" xml:lang="en-US">Exercise Price Range Per Share $0.82 - $3.62 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare082362Member" xlink:to="bmra_ExercisePriceRangePerShare082362Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare235818Member" xlink:href="bmra-20220531.xsd#bmra_ExercisePriceRangePerShare235818Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ExercisePriceRangePerShare235818Member_lbl" xml:lang="en-US">Exercise Price Range Per Share $2.35 - $8.18 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare235818Member" xlink:to="bmra_ExercisePriceRangePerShare235818Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare082870Member" xlink:href="bmra-20220531.xsd#bmra_ExercisePriceRangePerShare082870Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ExercisePriceRangePerShare082870Member_lbl" xml:lang="en-US">Exercise Price Range Per Share $0.82 - $8.70 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare082870Member" xlink:to="bmra_ExercisePriceRangePerShare082870Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare425446Member" xlink:href="bmra-20220531.xsd#bmra_ExercisePriceRangePerShare425446Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ExercisePriceRangePerShare425446Member_lbl" xml:lang="en-US">Exercise Price Range Per Share $4.25 - $4.46 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare425446Member" xlink:to="bmra_ExercisePriceRangePerShare425446Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare120362Member" xlink:href="bmra-20220531.xsd#bmra_ExercisePriceRangePerShare120362Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ExercisePriceRangePerShare120362Member_lbl" xml:lang="en-US">Exercise Price Range Per Share $1.20 - $3.62 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare120362Member" xlink:to="bmra_ExercisePriceRangePerShare120362Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare161818Member" xlink:href="bmra-20220531.xsd#bmra_ExercisePriceRangePerShare161818Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ExercisePriceRangePerShare161818Member_lbl" xml:lang="en-US">Exercise Price Range Per Share $1.61 - $8.18 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare161818Member" xlink:to="bmra_ExercisePriceRangePerShare161818Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_RangeOfExercisePrice082152Member" xlink:href="bmra-20220531.xsd#bmra_RangeOfExercisePrice082152Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_RangeOfExercisePrice082152Member_lbl" xml:lang="en-US">Range Of Exercise Price $0.82 - $1.52 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RangeOfExercisePrice082152Member" xlink:to="bmra_RangeOfExercisePrice082152Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_RangeOfExercisePrice225425Member" xlink:href="bmra-20220531.xsd#bmra_RangeOfExercisePrice225425Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_RangeOfExercisePrice225425Member_lbl" xml:lang="en-US">Range Of Exercise Price $2.25 - $4.25 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RangeOfExercisePrice225425Member" xlink:to="bmra_RangeOfExercisePrice225425Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_RangeOfExercisePrice434870Member" xlink:href="bmra-20220531.xsd#bmra_RangeOfExercisePrice434870Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_RangeOfExercisePrice434870Member_lbl" xml:lang="en-US">Range Of Exercise Price $4.34 - $8.70 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RangeOfExercisePrice434870Member" xlink:to="bmra_RangeOfExercisePrice434870Member_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_AsiaMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_AsiaMember_lbl" xml:lang="en-US">Asia [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AsiaMember" xlink:to="srt_AsiaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_EuropeMember_lbl" xml:lang="en-US">Europe [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_NorthAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NorthAmericaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_NorthAmericaMember_lbl" xml:lang="en-US">North America [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NorthAmericaMember" xlink:to="srt_NorthAmericaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SouthAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SouthAmericaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_SouthAmericaMember_lbl" xml:lang="en-US">South America [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SouthAmericaMember" xlink:to="srt_SouthAmericaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MiddleEastMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MiddleEastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MiddleEastMember_lbl" xml:lang="en-US">Middle East [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MiddleEastMember" xlink:to="us-gaap_MiddleEastMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueSegmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueSegmentMember_lbl" xml:lang="en-US">Revenue, Segment Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueSegmentMember" xlink:to="us-gaap_SalesRevenueSegmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeographicConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeographicConcentrationRiskMember_lbl" xml:lang="en-US">Geographic Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicConcentrationRiskMember" xlink:to="us-gaap_GeographicConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US">Accounting Standards Update [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransactionTypeAxis_lbl" xml:lang="en-US">Transaction Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US">Lease Contractual Term [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl" xml:lang="en-US">Property Subject to or Available for Operating Lease [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_WorkingCapital" xlink:href="bmra-20220531.xsd#bmra_WorkingCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_WorkingCapital_lbl" xml:lang="en-US">Working Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_WorkingCapital" xlink:to="bmra_WorkingCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" xlink:href="bmra-20220531.xsd#bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_lbl" xml:lang="en-US">Shelf Registration Statement, Maximum Authorized Common Stock Issuance, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" xlink:to="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashUninsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash, Uninsured Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesGrossCurrent_lbl" xml:lang="en-US">Other Receivables, Gross, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesGrossCurrent" xlink:to="us-gaap_OtherReceivablesGrossCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable_lbl" xml:lang="en-US">Threshold Period Past Due for Write-off of Trade Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" xlink:to="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Supplies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Asset Impairment Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US">Advertising Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt+1Vq3zhhUlfDeP/RQUzUZihDO8dLtQrMZMNe4t6pAivP0axfdFZpsLdRcC6V+fMavTAOMD4FknVX18XpRs+KLunX2qipVKNpApCTOelknJAdDWusY2PGEvYpRrj0mxs78hkWjdoZPMe4E2T0OAgcNcAeqIj6oByjK/v1vonkoZYfTfupCDTe9Sduk/PZPwyGg=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of Stock, Price Per Share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPayableAmountPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableAmountPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsPayableAmountPerShare_lbl" xml:lang="en-US">Dividends Payable, Amount Per Share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableAmountPerShare" xlink:to="us-gaap_DividendsPayableAmountPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Conversion of Stock, Shares Issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Lease Expiration Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating Lease, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_LeaseExpirationPeriod" xlink:href="bmra-20220531.xsd#bmra_LeaseExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_LeaseExpirationPeriod_lbl" xml:lang="en-US">Lease Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LeaseExpirationPeriod" xlink:to="bmra_LeaseExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_RoyaltyExpensePercentageOfSales" xlink:href="bmra-20220531.xsd#bmra_RoyaltyExpensePercentageOfSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_RoyaltyExpensePercentageOfSales_lbl" xml:lang="en-US">Royalty Expense Percentage Of Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RoyaltyExpensePercentageOfSales" xlink:to="bmra_RoyaltyExpensePercentageOfSales_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedFeesAndOtherRevenueReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedFeesAndOtherRevenueReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedFeesAndOtherRevenueReceivable_lbl" xml:lang="en-US">Accrued Fees and Other Revenue Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedFeesAndOtherRevenueReceivable" xlink:to="us-gaap_AccruedFeesAndOtherRevenueReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Other (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromFeesReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromFeesReceived_lbl" xml:lang="en-US">Proceeds from Fees Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromFeesReceived" xlink:to="us-gaap_ProceedsFromFeesReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_RoyaltyPercentage" xlink:href="bmra-20220531.xsd#bmra_RoyaltyPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_RoyaltyPercentage_lbl" xml:lang="en-US">Royalty Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RoyaltyPercentage" xlink:to="bmra_RoyaltyPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Payments for Other Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_LicenseMaintenanceFeePayable" xlink:href="bmra-20220531.xsd#bmra_LicenseMaintenanceFeePayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_LicenseMaintenanceFeePayable_lbl" xml:lang="en-US">License Maintenance Fee, Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LicenseMaintenanceFeePayable" xlink:to="bmra_LicenseMaintenanceFeePayable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ClinicalTrialAgreementMaximumBudgetedCosts" xlink:href="bmra-20220531.xsd#bmra_ClinicalTrialAgreementMaximumBudgetedCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ClinicalTrialAgreementMaximumBudgetedCosts_lbl" xml:lang="en-US">Clinical Trial Agreement Maximum Budgeted Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ClinicalTrialAgreementMaximumBudgetedCosts" xlink:to="bmra_ClinicalTrialAgreementMaximumBudgetedCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_LiquidityPolicyTextBlock" xlink:href="bmra-20220531.xsd#bmra_LiquidityPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_LiquidityPolicyTextBlock_lbl" xml:lang="en-US">Liquidity [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LiquidityPolicyTextBlock" xlink:to="bmra_LiquidityPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock" xlink:href="bmra-20220531.xsd#bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock_lbl" xml:lang="en-US">Concentration Risk Geographic Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock" xlink:to="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_PrepaidsPolicyPolicyTextBlock" xlink:href="bmra-20220531.xsd#bmra_PrepaidsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_PrepaidsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Prepaids Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PrepaidsPolicyPolicyTextBlock" xlink:to="bmra_PrepaidsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising Cost [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ATMAgreementMember" xlink:href="bmra-20220531.xsd#bmra_ATMAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ATMAgreementMember_lbl" xml:lang="en-US">ATM Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ATMAgreementMember" xlink:to="bmra_ATMAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_TwoDistributorsMember" xlink:href="bmra-20220531.xsd#bmra_TwoDistributorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_TwoDistributorsMember_lbl" xml:lang="en-US">Two Distributors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TwoDistributorsMember" xlink:to="bmra_TwoDistributorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_OneDistributorMember" xlink:href="bmra-20220531.xsd#bmra_OneDistributorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_OneDistributorMember_lbl" xml:lang="en-US">One Distributor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OneDistributorMember" xlink:to="bmra_OneDistributorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableMember_lbl" xml:lang="en-US">Accounts Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_DistributorsInAsiaMember" xlink:href="bmra-20220531.xsd#bmra_DistributorsInAsiaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_DistributorsInAsiaMember_lbl" xml:lang="en-US">Distributors in Asia [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DistributorsInAsiaMember" xlink:to="bmra_DistributorsInAsiaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsProductLineMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsProductLineMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsProductLineMember_lbl" xml:lang="en-US">Cost of Goods and Service, Product and Service Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsProductLineMember" xlink:to="us-gaap_CostOfGoodsProductLineMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US">Supplier Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_OneVendorMember" xlink:href="bmra-20220531.xsd#bmra_OneVendorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_OneVendorMember_lbl" xml:lang="en-US">One Vendor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OneVendorMember" xlink:to="bmra_OneVendorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_MX" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MX"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_MX_lbl" xml:lang="en-US">MEXICO</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_MX" xlink:to="country_MX_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DistributionRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionRightsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DistributionRightsMember_lbl" xml:lang="en-US">Distribution Rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DistributionRightsMember" xlink:to="us-gaap_DistributionRightsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_PurchasedTechnologyRightsMember" xlink:href="bmra-20220531.xsd#bmra_PurchasedTechnologyRightsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_PurchasedTechnologyRightsMember_lbl" xml:lang="en-US">Purchased Technology Rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PurchasedTechnologyRightsMember" xlink:to="bmra_PurchasedTechnologyRightsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_PolishDistributorMember" xlink:href="bmra-20220531.xsd#bmra_PolishDistributorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_PolishDistributorMember_lbl" xml:lang="en-US">Polish Distributor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PolishDistributorMember" xlink:to="bmra_PolishDistributorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_TwoVendorMember" xlink:href="bmra-20220531.xsd#bmra_TwoVendorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_TwoVendorMember_lbl" xml:lang="en-US">Two Vendor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TwoVendorMember" xlink:to="bmra_TwoVendorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_A2014PlanMember" xlink:href="bmra-20220531.xsd#bmra_A2014PlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_A2014PlanMember_lbl" xml:lang="en-US">2014 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A2014PlanMember" xlink:to="bmra_A2014PlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_A2017PlanMember" xlink:href="bmra-20220531.xsd#bmra_A2017PlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_A2017PlanMember_lbl" xml:lang="en-US">2017 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A2017PlanMember" xlink:to="bmra_A2017PlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_A2020PlanMember" xlink:href="bmra-20220531.xsd#bmra_A2020PlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_A2020PlanMember_lbl" xml:lang="en-US">2020 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A2020PlanMember" xlink:to="bmra_A2020PlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of Sales [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xml:lang="en-US">Selling and Marketing Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_A2020StockIncentivePlanMember" xlink:href="bmra-20220531.xsd#bmra_A2020StockIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_A2020StockIncentivePlanMember_lbl" xml:lang="en-US">2020 Stock Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A2020StockIncentivePlanMember" xlink:to="bmra_A2020StockIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_StockPurchaseAgreementMember" xlink:href="bmra-20220531.xsd#bmra_StockPurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_StockPurchaseAgreementMember_lbl" xml:lang="en-US">Stock Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_StockPurchaseAgreementMember" xlink:to="bmra_StockPurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_PalmMember" xlink:href="bmra-20220531.xsd#bmra_PalmMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_PalmMember_lbl" xml:lang="en-US">Palm [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PalmMember" xlink:to="bmra_PalmMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Authority [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_CaliforniaStateIncomeTaxMember" xlink:href="bmra-20220531.xsd#bmra_CaliforniaStateIncomeTaxMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_CaliforniaStateIncomeTaxMember_lbl" xml:lang="en-US">California State Income Tax [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_CaliforniaStateIncomeTaxMember" xlink:to="bmra_CaliforniaStateIncomeTaxMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US">Research Tax Credit Carryforward [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_FirstAmendmentToLeaseMember" xlink:href="bmra-20220531.xsd#bmra_FirstAmendmentToLeaseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_FirstAmendmentToLeaseMember_lbl" xml:lang="en-US">First Amendment To Lease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FirstAmendmentToLeaseMember" xlink:to="bmra_FirstAmendmentToLeaseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_BuildingInIrvineCaliforniaMember" xlink:href="bmra-20220531.xsd#bmra_BuildingInIrvineCaliforniaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_BuildingInIrvineCaliforniaMember_lbl" xml:lang="en-US">Building In Irvine California [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BuildingInIrvineCaliforniaMember" xlink:to="bmra_BuildingInIrvineCaliforniaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyAvailableForOperatingLeaseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyAvailableForOperatingLeaseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyAvailableForOperatingLeaseMember_lbl" xml:lang="en-US">Property Available for Operating Lease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyAvailableForOperatingLeaseMember" xlink:to="us-gaap_PropertyAvailableForOperatingLeaseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyAgreementsMember_lbl" xml:lang="en-US">Royalty Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyAgreementsMember" xlink:to="us-gaap_RoyaltyAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_TelconAgreementMember" xlink:href="bmra-20220531.xsd#bmra_TelconAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_TelconAgreementMember_lbl" xml:lang="en-US">Telcon Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TelconAgreementMember" xlink:to="bmra_TelconAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UCLicenseAgreementsMember" xlink:href="bmra-20220531.xsd#bmra_UCLicenseAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UCLicenseAgreementsMember_lbl" xml:lang="en-US">UC License Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UCLicenseAgreementsMember" xlink:to="bmra_UCLicenseAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UniversityOFSouthernCaliforniaMember" xlink:href="bmra-20220531.xsd#bmra_UniversityOFSouthernCaliforniaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UniversityOFSouthernCaliforniaMember_lbl" xml:lang="en-US">University OF Southern California [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UniversityOFSouthernCaliforniaMember" xlink:to="bmra_UniversityOFSouthernCaliforniaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_BiomericaInFoodsMember" xlink:href="bmra-20220531.xsd#bmra_BiomericaInFoodsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_BiomericaInFoodsMember_lbl" xml:lang="en-US">Biomerica InFoods [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BiomericaInFoodsMember" xlink:to="bmra_BiomericaInFoodsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_lbl" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" xlink:href="bmra-20220531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" xlink:to="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:href="bmra-20220531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US">Segments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US">Disaggregation of Revenue [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Exercise Price Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingTable" xlink:href="bmra-20220531.xsd#bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingTable_lbl" xml:lang="en-US">SHAREHOLDERS&apos; EQUITY (Details) - Activity as to aggregate stock options outstanding [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingTable" xlink:to="bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems" xlink:href="bmra-20220531.xsd#bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems_lbl" xml:lang="en-US">SHAREHOLDERS&apos; EQUITY (Details) - Activity as to aggregate stock options outstanding [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems" xlink:to="bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:href="bmra-20220531.xsd#bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable_lbl" xml:lang="en-US">GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:to="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:href="bmra-20220531.xsd#bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems_lbl" xml:lang="en-US">GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:to="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US">Investment, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US">Accounting Standards Update [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:href="bmra-20220531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:href="bmra-20220531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:href="bmra-20220531.xsd#bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable_lbl" xml:lang="en-US">ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:to="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems" xlink:href="bmra-20220531.xsd#bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems_lbl" xml:lang="en-US">ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems" xlink:to="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSTable" xlink:href="bmra-20220531.xsd#bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSTable_lbl" xml:lang="en-US">SHAREHOLDERS&apos; EQUITY (Details) - STOCK OPTION AND RESTRICTED STOCK PLANS [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSTable" xlink:to="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" xlink:href="bmra-20220531.xsd#bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems_lbl" xml:lang="en-US">SHAREHOLDERS&apos; EQUITY (Details) - STOCK OPTION AND RESTRICTED STOCK PLANS [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" xlink:to="bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransactionDomain_lbl" xml:lang="en-US">Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionDomain" xlink:to="us-gaap_TransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable" xlink:href="bmra-20220531.xsd#bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable_lbl" xml:lang="en-US">SHAREHOLDERS&apos; EQUITY (Details) - COMMON STOCK ACTIVITY [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable" xlink:to="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems" xlink:href="bmra-20220531.xsd#bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems_lbl" xml:lang="en-US">SHAREHOLDERS&apos; EQUITY (Details) - COMMON STOCK ACTIVITY [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems" xlink:to="bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYTable" xlink:href="bmra-20220531.xsd#bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYTable_lbl" xml:lang="en-US">SHAREHOLDERS&apos; EQUITY (Details) - PREFERRED STOCK ACTIVITY [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYTable" xlink:to="bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems" xlink:href="bmra-20220531.xsd#bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems_lbl" xml:lang="en-US">SHAREHOLDERS&apos; EQUITY (Details) - PREFERRED STOCK ACTIVITY [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems" xlink:to="bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_INCOMETAXESDetailsTable" xlink:href="bmra-20220531.xsd#bmra_INCOMETAXESDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_INCOMETAXESDetailsTable_lbl" xml:lang="en-US">INCOME TAXES (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_INCOMETAXESDetailsTable" xlink:to="bmra_INCOMETAXESDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_INCOMETAXESDetailsLineItems" xlink:href="bmra-20220531.xsd#bmra_INCOMETAXESDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_INCOMETAXESDetailsLineItems_lbl" xml:lang="en-US">INCOME TAXES (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_INCOMETAXESDetailsLineItems" xlink:to="bmra_INCOMETAXESDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain" xlink:href="bmra-20220531.xsd#bmra_PropertySubjectToOrAvailableForOperatingLease_Domain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain_lbl" xml:lang="en-US">PropertySubjectToOrAvailableForOperatingLease_ [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain" xlink:to="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xml:lang="en-US">Lease Contractual Term [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESTable" xlink:href="bmra-20220531.xsd#bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESTable_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES (Details) - OPERATING LEASES [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESTable" xlink:to="bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems" xlink:href="bmra-20220531.xsd#bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES (Details) - OPERATING LEASES [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems" xlink:to="bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSTable" xlink:href="bmra-20220531.xsd#bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSTable_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES (Details) - CONTRACTS [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSTable" xlink:to="bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems" xlink:href="bmra-20220531.xsd#bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES (Details) - CONTRACTS [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems" xlink:to="bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SUBSEQUENTEVENTSDetailsTable" xlink:href="bmra-20220531.xsd#bmra_SUBSEQUENTEVENTSDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SUBSEQUENTEVENTSDetailsTable_lbl" xml:lang="en-US">SUBSEQUENT EVENTS (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SUBSEQUENTEVENTSDetailsTable" xlink:to="bmra_SUBSEQUENTEVENTSDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:href="bmra-20220531.xsd#bmra_SUBSEQUENTEVENTSDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SUBSEQUENTEVENTSDetailsLineItems_lbl" xml:lang="en-US">SUBSEQUENT EVENTS (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="bmra_SUBSEQUENTEVENTSDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_ClinicalTrialAgreementMaximumBudgetedCosts_lbl0" xml:lang="en-US">The maximum budgeted costs related to clinical trial agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ClinicalTrialAgreementMaximumBudgetedCosts" xlink:to="bmra_ClinicalTrialAgreementMaximumBudgetedCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for the description of risks that arise due to concentrations of operating facilities, revenues, assets, customers, vendors or the like in a certain geographic area, either domestic or foreign. The description may address risks inherent in the geographic area, and, at a minimum, informs users of the general nature of the risk, but excludes &quot;Information about Geographic Areas&quot; that may be disclosed elsewhere.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock" xlink:to="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization_lbl0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accumulated depreciation and amortization.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" xlink:to="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet_lbl0" xml:lang="en-US">Amount of deferred tax assets related with foreign subsidiaries and other.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" xlink:to="bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_DefferedTaxAssetsStockOptions_lbl0" xml:lang="en-US">Amount of deferred tax assets related with stock options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DefferedTaxAssetsStockOptions" xlink:to="bmra_DefferedTaxAssetsStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_Equipment_lbl0" xml:lang="en-US">Amount before accumulated depletion of equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_Equipment" xlink:to="bmra_Equipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_FiniteLivedLicenseAccumulatedAmortization_lbl0" xml:lang="en-US">Accumulated amount of amortization of licenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FiniteLivedLicenseAccumulatedAmortization" xlink:to="bmra_FiniteLivedLicenseAccumulatedAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_FiniteLivedPatentsAccumulatedAmortization_lbl0" xml:lang="en-US">Accumulated amount of amortization of patents.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FiniteLivedPatentsAccumulatedAmortization" xlink:to="bmra_FiniteLivedPatentsAccumulatedAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_FurnitureFixturesAndLeaseholdImprovements_lbl0" xml:lang="en-US">Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities and additions or improvements to assets held under a lease arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FurnitureFixturesAndLeaseholdImprovements" xlink:to="bmra_FurnitureFixturesAndLeaseholdImprovements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_GeographicInformationDisclosureTextBlock_lbl0" xml:lang="en-US">The entire disclosure for reporting segments according to the geographic areas.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GeographicInformationDisclosureTextBlock" xlink:to="bmra_GeographicInformationDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_IncreaseDecreaseInLeaseLiability_lbl0" xml:lang="en-US">The increase (decrease) during the reporting period in LeaseLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncreaseDecreaseInLeaseLiability" xlink:to="bmra_IncreaseDecreaseInLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_IncreaseInLeaseLiability_lbl0" xml:lang="en-US">The increase (decrease) during the reporting period in lease liability due to lease extension or establishment in noncash investing or financing activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncreaseInLeaseLiability" xlink:to="bmra_IncreaseInLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_IncreaseInRightOfUseAsset_lbl0" xml:lang="en-US">The increase (decrease) during the reporting period in right of use asset due to lease extension or establishment in noncash investing or financing activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncreaseInRightOfUseAsset" xlink:to="bmra_IncreaseInRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_LeaseExpirationPeriod_lbl0" xml:lang="en-US">Represents the number of years in which the lease expires.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LeaseExpirationPeriod" xlink:to="bmra_LeaseExpirationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_LicenseMaintenanceFeePayable_lbl0" xml:lang="en-US">Amount of license maintenance fee payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LicenseMaintenanceFeePayable" xlink:to="bmra_LicenseMaintenanceFeePayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_LiquidityPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for liquidity position during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LiquidityPolicyTextBlock" xlink:to="bmra_LiquidityPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization_lbl0" xml:lang="en-US">Amount of accumulated amortization of right-of-use asset from operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_PreferredStockUndesignatedShares_lbl0" xml:lang="en-US">Number of preferred shares undesignated during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PreferredStockUndesignatedShares" xlink:to="bmra_PreferredStockUndesignatedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_PrepaidsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for prepaids.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PrepaidsPolicyPolicyTextBlock" xlink:to="bmra_PrepaidsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_RoyaltyExpensePercentageOfSales_lbl0" xml:lang="en-US">Royalty expenses expressed as a percentage of sales.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RoyaltyExpensePercentageOfSales" xlink:to="bmra_RoyaltyExpensePercentageOfSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_RoyaltyPercentage_lbl0" xml:lang="en-US">Percentage of royalty to be received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RoyaltyPercentage" xlink:to="bmra_RoyaltyPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of supplemental cash flow information related to lease for the periods.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" xlink:to="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_lbl0" xml:lang="en-US">Amount related with Maximum Authorized Common Stock Issuance of Shelf Registration Statement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" xlink:to="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_WorkingCapital_lbl0" xml:lang="en-US">Amount of working capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_WorkingCapital" xlink:to="bmra_WorkingCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_WriteOffOfFixedAssetsAccumulatedDepreciation_lbl0" xml:lang="en-US">Write off of fixed assets, accumulated depreciation in noncash investing or financing activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_WriteOffOfFixedAssetsAccumulatedDepreciation" xlink:to="bmra_WriteOffOfFixedAssetsAccumulatedDepreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_WriteOffOfFixedAssetsCost_lbl0" xml:lang="en-US">Write off of fixed assets, cost in noncash investing or financing activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_WriteOffOfFixedAssetsCost" xlink:to="bmra_WriteOffOfFixedAssetsCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization_lbl0" xml:lang="en-US">Write off of intangible assets, accumulated amortization in noncash investing or financing activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization" xlink:to="bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_WriteOffOfIntangibleAssetsCost_lbl0" xml:lang="en-US">Write off of intangible assets, cost in noncash investing or financing activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_WriteOffOfIntangibleAssetsCost" xlink:to="bmra_WriteOffOfIntangibleAssetsCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_CashPaidDuringThePeriodForAbstract_lbl0" xml:lang="en-US">No definition available</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_CashPaidDuringThePeriodForAbstract" xlink:to="bmra_CashPaidDuringThePeriodForAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock_lbl1" xml:lang="en-US">Concentration Risk Geographic Policy Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock" xlink:to="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl0" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_WorkingCapital_lbl1" xml:lang="en-US">Working Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_WorkingCapital" xlink:to="bmra_WorkingCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="bmra_ShareBasedCompensationAssumptionsAbstract" xlink:href="bmra-20220531.xsd#bmra_ShareBasedCompensationAssumptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ShareBasedCompensationAssumptionsAbstract_lbl" xml:lang="en-US">Share Based Compensation Assumptions Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ShareBasedCompensationAssumptionsAbstract" xlink:to="bmra_ShareBasedCompensationAssumptionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MiddleEastMember_lbl0" xml:lang="en-US">Middle East [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MiddleEastMember" xlink:to="us-gaap_MiddleEastMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl0" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ExercisePriceRangePerShare082870Member_lbl0" xml:lang="en-US">Exercise Price Range Per Share082870 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare082870Member" xlink:to="bmra_ExercisePriceRangePerShare082870Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_PurchasedTechnologyRightsMember_lbl0" xml:lang="en-US">Purchased Technology Rights Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PurchasedTechnologyRightsMember" xlink:to="bmra_PurchasedTechnologyRightsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_lbl1" xml:lang="en-US">Shelf Registration Statement Maximum Authorized Common Stock Issuance Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" xlink:to="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl0" xml:lang="en-US">Security Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_LiquidityPolicyTextBlock_lbl1" xml:lang="en-US">Liquidity Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LiquidityPolicyTextBlock" xlink:to="bmra_LiquidityPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl0" xml:lang="en-US">Supplier Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl0" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl1" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_PrepaidsPolicyPolicyTextBlock_lbl1" xml:lang="en-US">Prepaids Policy Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PrepaidsPolicyPolicyTextBlock" xlink:to="bmra_PrepaidsPolicyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_FirstAmendmentToLeaseMember_lbl0" xml:lang="en-US">First Amendment To Lease Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FirstAmendmentToLeaseMember" xlink:to="bmra_FirstAmendmentToLeaseMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:href="bmra-20220531.xsd#bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information Related To Leases Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract18_lbl0" xml:lang="en-US">Unlabeled Abstract18</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract18" xlink:to="bmra_UnlabeledAbstract18_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract19_lbl0" xml:lang="en-US">Unlabeled Abstract19</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract19" xlink:to="bmra_UnlabeledAbstract19_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract16_lbl0" xml:lang="en-US">Unlabeled Abstract16</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract16" xlink:to="bmra_UnlabeledAbstract16_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract17_lbl0" xml:lang="en-US">Unlabeled Abstract17</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract17" xlink:to="bmra_UnlabeledAbstract17_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl0" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="bmra_RevenueFromContractsWithCustomersAbstract" xlink:href="bmra-20220531.xsd#bmra_RevenueFromContractsWithCustomersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_RevenueFromContractsWithCustomersAbstract_lbl" xml:lang="en-US">Revenue From Contracts With Customers Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RevenueFromContractsWithCustomersAbstract" xlink:to="bmra_RevenueFromContractsWithCustomersAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_LeaseExpirationPeriod_lbl1" xml:lang="en-US">Lease Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LeaseExpirationPeriod" xlink:to="bmra_LeaseExpirationPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl0" xml:lang="en-US">Lease Expiration Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract_lbl0" xml:lang="en-US">Increase Reduction In Income Taxes Resulting From Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract21_lbl0" xml:lang="en-US">Unlabeled Abstract21</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract21" xlink:to="bmra_UnlabeledAbstract21_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract22_lbl0" xml:lang="en-US">Unlabeled Abstract22</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract22" xlink:to="bmra_UnlabeledAbstract22_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract20_lbl0" xml:lang="en-US">Unlabeled Abstract20</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract20" xlink:to="bmra_UnlabeledAbstract20_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract25_lbl0" xml:lang="en-US">Unlabeled Abstract25</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract25" xlink:to="bmra_UnlabeledAbstract25_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract26_lbl0" xml:lang="en-US">Unlabeled Abstract26</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract26" xlink:to="bmra_UnlabeledAbstract26_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract23_lbl0" xml:lang="en-US">Unlabeled Abstract23</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract23" xlink:to="bmra_UnlabeledAbstract23_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract24_lbl0" xml:lang="en-US">Unlabeled Abstract24</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract24" xlink:to="bmra_UnlabeledAbstract24_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract29_lbl0" xml:lang="en-US">Unlabeled Abstract29</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract29" xlink:to="bmra_UnlabeledAbstract29_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract27_lbl0" xml:lang="en-US">Unlabeled Abstract27</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract27" xlink:to="bmra_UnlabeledAbstract27_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract28_lbl0" xml:lang="en-US">Unlabeled Abstract28</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract28" xlink:to="bmra_UnlabeledAbstract28_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract32_lbl0" xml:lang="en-US">Unlabeled Abstract32</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract32" xlink:to="bmra_UnlabeledAbstract32_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_CaliforniaStateIncomeTaxMember_lbl0" xml:lang="en-US">California State Income Tax Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_CaliforniaStateIncomeTaxMember" xlink:to="bmra_CaliforniaStateIncomeTaxMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract33_lbl0" xml:lang="en-US">Unlabeled Abstract33</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract33" xlink:to="bmra_UnlabeledAbstract33_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract30_lbl0" xml:lang="en-US">Unlabeled Abstract30</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract30" xlink:to="bmra_UnlabeledAbstract30_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract31_lbl0" xml:lang="en-US">Unlabeled Abstract31</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract31" xlink:to="bmra_UnlabeledAbstract31_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ContractManufacturingMember_lbl0" xml:lang="en-US">Contract Manufacturing Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ContractManufacturingMember" xlink:to="bmra_ContractManufacturingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract2_lbl0" xml:lang="en-US">See Accompanying Notes To Consolidated Financial Statements Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract2" xlink:to="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract1_lbl0" xml:lang="en-US">See Accompanying Notes To Consolidated Financial Statements Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract1" xlink:to="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0_lbl0" xml:lang="en-US">See Accompanying Notes To Consolidated Financial Statements Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0" xlink:to="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0_lbl0"/>
    <loc xlink:type="locator" xlink:label="bmra_StockOptionsSummaryAbstract" xlink:href="bmra-20220531.xsd#bmra_StockOptionsSummaryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_StockOptionsSummaryAbstract_lbl" xml:lang="en-US">Stock Options Summary Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_StockOptionsSummaryAbstract" xlink:to="bmra_StockOptionsSummaryAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueSegmentMember_lbl0" xml:lang="en-US">Revenue, Segment Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueSegmentMember" xlink:to="us-gaap_SalesRevenueSegmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl0" xml:lang="en-US">Asset Impairment Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl1" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyAvailableForOperatingLeaseMember_lbl0" xml:lang="en-US">Property Available for Operating Lease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyAvailableForOperatingLeaseMember" xlink:to="us-gaap_PropertyAvailableForOperatingLeaseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract10_lbl0" xml:lang="en-US">Unlabeled Abstract10</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract10" xlink:to="bmra_UnlabeledAbstract10_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract11_lbl0" xml:lang="en-US">Unlabeled Abstract11</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract11" xlink:to="bmra_UnlabeledAbstract11_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract14_lbl0" xml:lang="en-US">Unlabeled Abstract14</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract14" xlink:to="bmra_UnlabeledAbstract14_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract15_lbl0" xml:lang="en-US">Unlabeled Abstract15</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract15" xlink:to="bmra_UnlabeledAbstract15_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract12_lbl0" xml:lang="en-US">Unlabeled Abstract12</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract12" xlink:to="bmra_UnlabeledAbstract12_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract13_lbl0" xml:lang="en-US">Unlabeled Abstract13</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract13" xlink:to="bmra_UnlabeledAbstract13_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_CashPaidDuringThePeriodForAbstract_lbl1" xml:lang="en-US">Cash Paid During The Period For Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_CashPaidDuringThePeriodForAbstract" xlink:to="bmra_CashPaidDuringThePeriodForAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_FiniteLivedLicenseAccumulatedAmortization_lbl1" xml:lang="en-US">Finite Lived License Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FiniteLivedLicenseAccumulatedAmortization" xlink:to="bmra_FiniteLivedLicenseAccumulatedAmortization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_A2020StockIncentivePlanMember_lbl0" xml:lang="en-US">A2020 Stock Incentive Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A2020StockIncentivePlanMember" xlink:to="bmra_A2020StockIncentivePlanMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl0" xml:lang="en-US">Patents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract2" xlink:to="bmra_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract1" xlink:to="bmra_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract4" xlink:to="bmra_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract3" xlink:to="bmra_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract0" xlink:to="bmra_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl0" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract9" xlink:to="bmra_UnlabeledAbstract9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract6" xlink:to="bmra_UnlabeledAbstract6_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract5" xlink:to="bmra_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract8" xlink:to="bmra_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract7" xlink:to="bmra_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_RoyaltyExpensePercentageOfSales_lbl1" xml:lang="en-US">Royalty Expense Percentage Of Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RoyaltyExpensePercentageOfSales" xlink:to="bmra_RoyaltyExpensePercentageOfSales_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_A2017PlanMember_lbl0" xml:lang="en-US">A2017 Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A2017PlanMember" xlink:to="bmra_A2017PlanMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="bmra_PropertyAndEquipmentNetAbstract" xlink:href="bmra-20220531.xsd#bmra_PropertyAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_PropertyAndEquipmentNetAbstract_lbl" xml:lang="en-US">Property And Equipment Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PropertyAndEquipmentNetAbstract" xlink:to="bmra_PropertyAndEquipmentNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_DeferredTaxAbstract" xlink:href="bmra-20220531.xsd#bmra_DeferredTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_DeferredTaxAbstract_lbl" xml:lang="en-US">Deferred Tax Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DeferredTaxAbstract" xlink:to="bmra_DeferredTaxAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_A5PercentConvertiblePreferredStockMember_lbl0" xml:lang="en-US">A5 Percent Convertible Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A5PercentConvertiblePreferredStockMember" xlink:to="bmra_A5PercentConvertiblePreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeographicConcentrationRiskMember_lbl0" xml:lang="en-US">Geographic Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicConcentrationRiskMember" xlink:to="us-gaap_GeographicConcentrationRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DistributionRightsMember_lbl0" xml:lang="en-US">Distribution Rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DistributionRightsMember" xlink:to="us-gaap_DistributionRightsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_IncomeTaxExpenseAbstract" xlink:href="bmra-20220531.xsd#bmra_IncomeTaxExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_IncomeTaxExpenseAbstract_lbl" xml:lang="en-US">Income Tax Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncomeTaxExpenseAbstract" xlink:to="bmra_IncomeTaxExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="bmra_GeographicInformationDisclosureAbstract" xlink:href="bmra-20220531.xsd#bmra_GeographicInformationDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_GeographicInformationDisclosureAbstract_lbl" xml:lang="en-US">Geographic Information Disclosure Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GeographicInformationDisclosureAbstract" xlink:to="bmra_GeographicInformationDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ATMAgreementMember_lbl0" xml:lang="en-US">ATMAgreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ATMAgreementMember" xlink:to="bmra_ATMAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract" xlink:to="bmra_UnlabeledAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="bmra_IncomeTaxRateReconciliationAbstract" xlink:href="bmra-20220531.xsd#bmra_IncomeTaxRateReconciliationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_IncomeTaxRateReconciliationAbstract_lbl" xml:lang="en-US">Income Tax Rate Reconciliation Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncomeTaxRateReconciliationAbstract" xlink:to="bmra_IncomeTaxRateReconciliationAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl0" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SouthAmericaMember_lbl0" xml:lang="en-US">South America [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SouthAmericaMember" xlink:to="srt_SouthAmericaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsProductLineMember_lbl0" xml:lang="en-US">Cost of Goods and Service, Product and Service Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsProductLineMember" xlink:to="us-gaap_CostOfGoodsProductLineMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl0" xml:lang="en-US">Royalty Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_GeographicInformationDisclosureTextBlock_lbl1" xml:lang="en-US">Geographic Information Disclosure Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GeographicInformationDisclosureTextBlock" xlink:to="bmra_GeographicInformationDisclosureTextBlock_lbl1"/>
    <loc xlink:type="locator" xlink:label="bmra_IntangibleAssetsNetAbstract" xlink:href="bmra-20220531.xsd#bmra_IntangibleAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_IntangibleAssetsNetAbstract_lbl" xml:lang="en-US">Intangible Assets Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IntangibleAssetsNetAbstract" xlink:to="bmra_IntangibleAssetsNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_StockPurchaseAgreementMember_lbl0" xml:lang="en-US">Stock Purchase Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_StockPurchaseAgreementMember" xlink:to="bmra_StockPurchaseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ExercisePriceRangePerShare235818Member_lbl0" xml:lang="en-US">Exercise Price Range Per Share235818 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare235818Member" xlink:to="bmra_ExercisePriceRangePerShare235818Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_RoyaltyPercentage_lbl1" xml:lang="en-US">Royalty Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RoyaltyPercentage" xlink:to="bmra_RoyaltyPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl0" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl0" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_DeferredTaxAssetsAbstract_lbl0" xml:lang="en-US">Deferred Tax Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DeferredTaxAssetsAbstract" xlink:to="bmra_DeferredTaxAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_DistributorsInAsiaMember_lbl0" xml:lang="en-US">Distributors In Asia Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DistributorsInAsiaMember" xlink:to="bmra_DistributorsInAsiaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_OneVendorMember_lbl0" xml:lang="en-US">One Vendor Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OneVendorMember" xlink:to="bmra_OneVendorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_A2020PlanMember_lbl0" xml:lang="en-US">A2020 Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A2020PlanMember" xlink:to="bmra_A2020PlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl0" xml:lang="en-US">Selling and Marketing Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_BuildingInIrvineCaliforniaMember_lbl0" xml:lang="en-US">Building In Irvine California Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BuildingInIrvineCaliforniaMember" xlink:to="bmra_BuildingInIrvineCaliforniaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EuropeMember_lbl0" xml:lang="en-US">Europe [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl0" xml:lang="en-US">Cash, Uninsured Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ExercisePriceRangePerShare082818Member_lbl0" xml:lang="en-US">Exercise Price Range Per Share082818 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare082818Member" xlink:to="bmra_ExercisePriceRangePerShare082818Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NorthAmericaMember_lbl0" xml:lang="en-US">North America [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NorthAmericaMember" xlink:to="srt_NorthAmericaMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="bmra_FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:href="bmra-20220531.xsd#bmra_FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract_lbl" xml:lang="en-US">Future Minimum Lease Payments Under Operating Leases Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="bmra_FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryGross_lbl1" xml:lang="en-US">Inventory, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyAgreementsMember_lbl0" xml:lang="en-US">Royalty Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyAgreementsMember" xlink:to="us-gaap_RoyaltyAgreementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_TwoDistributorsMember_lbl0" xml:lang="en-US">Two Distributors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TwoDistributorsMember" xlink:to="bmra_TwoDistributorsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_BiomericaInFoodsMember_lbl0" xml:lang="en-US">Biomerica In Foods Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BiomericaInFoodsMember" xlink:to="bmra_BiomericaInFoodsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl0" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedFeesAndOtherRevenueReceivable_lbl0" xml:lang="en-US">Accrued Fees and Other Revenue Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedFeesAndOtherRevenueReceivable" xlink:to="us-gaap_AccruedFeesAndOtherRevenueReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ExercisePriceRangePerShare161818Member_lbl0" xml:lang="en-US">Exercise Price Range Per Share161818 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare161818Member" xlink:to="bmra_ExercisePriceRangePerShare161818Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl0" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl0" xml:lang="en-US">Cost of Sales [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_PhysiciansOfficeMember_lbl0" xml:lang="en-US">Physicians Office Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PhysiciansOfficeMember" xlink:to="bmra_PhysiciansOfficeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_OverthecounterMember_lbl0" xml:lang="en-US">Overthecounter Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OverthecounterMember" xlink:to="bmra_OverthecounterMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl0" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl0" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl0" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl0" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl0" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_AsiaMember_lbl0" xml:lang="en-US">Asia [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AsiaMember" xlink:to="srt_AsiaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ExercisePriceRangePerShare425446Member_lbl0" xml:lang="en-US">Exercise Price Range Per Share425446 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare425446Member" xlink:to="bmra_ExercisePriceRangePerShare425446Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_TelconAgreementMember_lbl0" xml:lang="en-US">Telcon Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TelconAgreementMember" xlink:to="bmra_TelconAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl0" xml:lang="en-US">Research Tax Credit Carryforward [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ExercisePriceRangePerShare082362Member_lbl0" xml:lang="en-US">Exercise Price Range Per Share082362 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare082362Member" xlink:to="bmra_ExercisePriceRangePerShare082362Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_FiniteLivedPatentsAccumulatedAmortization_lbl1" xml:lang="en-US">Finite Lived Patents Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FiniteLivedPatentsAccumulatedAmortization" xlink:to="bmra_FiniteLivedPatentsAccumulatedAmortization_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_PolishDistributorMember_lbl0" xml:lang="en-US">Polish Distributor Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PolishDistributorMember" xlink:to="bmra_PolishDistributorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl0" xml:lang="en-US">Other Income and Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="bmra_NonVestedStockOptionsActivityAbstract" xlink:href="bmra-20220531.xsd#bmra_NonVestedStockOptionsActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_NonVestedStockOptionsActivityAbstract_lbl" xml:lang="en-US">Non Vested Stock Options Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_NonVestedStockOptionsActivityAbstract" xlink:to="bmra_NonVestedStockOptionsActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl0" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl0" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UCLicenseAgreementsMember_lbl0" xml:lang="en-US">UCLicense Agreements Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UCLicenseAgreementsMember" xlink:to="bmra_UCLicenseAgreementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl1" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="bmra_ActivityAsToAggregateStockOptionsOutstandingAbstract" xlink:href="bmra-20220531.xsd#bmra_ActivityAsToAggregateStockOptionsOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ActivityAsToAggregateStockOptionsOutstandingAbstract_lbl" xml:lang="en-US">Activity As To Aggregate Stock Options Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ActivityAsToAggregateStockOptionsOutstandingAbstract" xlink:to="bmra_ActivityAsToAggregateStockOptionsOutstandingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ClinicalTrialAgreementMaximumBudgetedCosts_lbl1" xml:lang="en-US">Clinical Trial Agreement Maximum Budgeted Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ClinicalTrialAgreementMaximumBudgetedCosts" xlink:to="bmra_ClinicalTrialAgreementMaximumBudgetedCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl0" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_RangeOfExercisePrice082152Member_lbl0" xml:lang="en-US">Range Of Exercise Price082152 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RangeOfExercisePrice082152Member" xlink:to="bmra_RangeOfExercisePrice082152Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl0" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_TwoVendorMember_lbl0" xml:lang="en-US">Two Vendor Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TwoVendorMember" xlink:to="bmra_TwoVendorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableMember_lbl0" xml:lang="en-US">Accounts Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesGrossCurrent_lbl0" xml:lang="en-US">Other Receivables, Gross, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesGrossCurrent" xlink:to="us-gaap_OtherReceivablesGrossCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl0" xml:lang="en-US">Domestic Tax Authority [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ExercisePriceRangePerShare120362Member_lbl0" xml:lang="en-US">Exercise Price Range Per Share120362 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare120362Member" xlink:to="bmra_ExercisePriceRangePerShare120362Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_lbl0" xml:lang="en-US">Advertising Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="bmra_AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:href="bmra-20220531.xsd#bmra_AccountsPayableAndAccruedExpenseBalancesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_AccountsPayableAndAccruedExpenseBalancesAbstract_lbl" xml:lang="en-US">Accounts Payable And Accrued Expense Balances Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:to="bmra_AccountsPayableAndAccruedExpenseBalancesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl0" xml:lang="en-US">Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl1" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Supplies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1"/>
    <loc xlink:type="locator" xlink:label="bmra_InventoriesAbstract" xlink:href="bmra-20220531.xsd#bmra_InventoriesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_InventoriesAbstract_lbl" xml:lang="en-US">Inventories Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_InventoriesAbstract" xlink:to="bmra_InventoriesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl0" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable_lbl0" xml:lang="en-US">Threshold Period Past Due for Write-off of Trade Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" xlink:to="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_RangeOfExercisePrice225425Member_lbl0" xml:lang="en-US">Range Of Exercise Price225425 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RangeOfExercisePrice225425Member" xlink:to="bmra_RangeOfExercisePrice225425Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Cash Flow Supplemental Disclosures Related To Lease Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" xlink:to="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl0" xml:lang="en-US">Advertising Cost [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromFeesReceived_lbl0" xml:lang="en-US">Proceeds from Fees Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromFeesReceived" xlink:to="us-gaap_ProceedsFromFeesReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_MX_lbl0" xml:lang="en-US">MEXICO</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_MX" xlink:to="country_MX_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableAmountPerShare_lbl0" xml:lang="en-US">Dividends Payable, Amount Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableAmountPerShare" xlink:to="us-gaap_DividendsPayableAmountPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl0" xml:lang="en-US">Payments for Other Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="bmra_GeographicInformationRegardingNetSalesAbstract" xlink:href="bmra-20220531.xsd#bmra_GeographicInformationRegardingNetSalesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_GeographicInformationRegardingNetSalesAbstract_lbl" xml:lang="en-US">Geographic Information Regarding Net Sales Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GeographicInformationRegardingNetSalesAbstract" xlink:to="bmra_GeographicInformationRegardingNetSalesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract_lbl0" xml:lang="en-US">See Accompanying Notes To Consolidated Financial Statements Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract" xlink:to="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_OneDistributorMember_lbl0" xml:lang="en-US">One Distributor Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OneDistributorMember" xlink:to="bmra_OneDistributorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_PalmMember_lbl0" xml:lang="en-US">Palm Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PalmMember" xlink:to="bmra_PalmMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl0" xml:lang="en-US">Cost of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl0" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_LicenseMaintenanceFeePayable_lbl1" xml:lang="en-US">License Maintenance Fee Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LicenseMaintenanceFeePayable" xlink:to="bmra_LicenseMaintenanceFeePayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_A2014PlanMember_lbl0" xml:lang="en-US">A2014 Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A2014PlanMember" xlink:to="bmra_A2014PlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryValuationReserves_lbl1" xml:lang="en-US">Inventory Valuation Reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_RangeOfExercisePrice434870Member_lbl0" xml:lang="en-US">Range Of Exercise Price434870 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RangeOfExercisePrice434870Member" xlink:to="bmra_RangeOfExercisePrice434870Member_lbl0"/>
    <loc xlink:type="locator" xlink:label="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:href="bmra-20220531.xsd#bmra_ExpectedAmortizationOfIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract_lbl" xml:lang="en-US">Expected Amortization Of Intangible Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ExercisePriceRangePerShare514870Member_lbl0" xml:lang="en-US">Exercise Price Range Per Share514870 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare514870Member" xlink:to="bmra_ExercisePriceRangePerShare514870Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl0" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl0" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl0" xml:lang="en-US">Payments to Acquire Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl0" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl0" xml:lang="en-US">Operating Lease, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ClinicalLabMember_lbl0" xml:lang="en-US">Clinical Lab Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ClinicalLabMember" xlink:to="bmra_ClinicalLabMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UniversityOFSouthernCaliforniaMember_lbl0" xml:lang="en-US">University OFSouthern California Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UniversityOFSouthernCaliforniaMember" xlink:to="bmra_UniversityOFSouthernCaliforniaMember_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>bmra-20220531_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Aug 29 19:33:49 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_ConsolidatedBalanceSheet" roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_ConsolidatedIncomeStatement" roleURI="http://www.biomerica.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_ShareholdersEquityType2or3" roleURI="http://www.biomerica.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_ConsolidatedCashFlow" roleURI="http://www.biomerica.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_ORGANIZATION" roleURI="http://www.biomerica.com/role/ORGANIZATION"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_PROPERTYANDEQUIPMENTNET" roleURI="http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNET"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_INTANGIBLEASSETSNET" roleURI="http://www.biomerica.com/role/INTANGIBLEASSETSNET"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_ACCOUNTSPAYABLEANDACCRUEDEXPENSES" roleURI="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_SHAREHOLDERSEQUITY" roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITY"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_INCOMETAXES" roleURI="http://www.biomerica.com/role/INCOMETAXES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_GEOGRAPHICINFORMATION" roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATION"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_COMMITMENTSANDCONTINGENCIES" roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_SUBSEQUENTEVENTS" roleURI="http://www.biomerica.com/role/SUBSEQUENTEVENTS"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_AccountingPoliciesByPolicy" roleURI="http://www.biomerica.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_PROPERTYANDEQUIPMENTNETTables" roleURI="http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNETTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_INTANGIBLEASSETSNETTables" roleURI="http://www.biomerica.com/role/INTANGIBLEASSETSNETTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables" roleURI="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_SHAREHOLDERSEQUITYTables" roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_INCOMETAXESTables" roleURI="http://www.biomerica.com/role/INCOMETAXESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_GEOGRAPHICINFORMATIONTables" roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_COMMITMENTSANDCONTINGENCIESTables" roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_InventoriesTable" roleURI="http://www.biomerica.com/role/InventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_SharebasedcompensationassumptionsTable" roleURI="http://www.biomerica.com/role/SharebasedcompensationassumptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_RevenuefromcontractswithcustomersTable" roleURI="http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_PropertyandequipmentnetTable" roleURI="http://www.biomerica.com/role/PropertyandequipmentnetTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_IntangibleassetsnetTable" roleURI="http://www.biomerica.com/role/IntangibleassetsnetTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_ExpectedamortizationofintangibleassetsTable" roleURI="http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_AccountspayableandaccruedexpensebalancesTable" roleURI="http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_ActivityastoaggregatestockoptionsoutstandingTable" roleURI="http://www.biomerica.com/role/ActivityastoaggregatestockoptionsoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_NonvestedStockOptionsActivityTable" roleURI="http://www.biomerica.com/role/NonvestedStockOptionsActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_StockOptionsSummaryTable" roleURI="http://www.biomerica.com/role/StockOptionsSummaryTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_IncometaxexpenseTable" roleURI="http://www.biomerica.com/role/IncometaxexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_IncomeTaxRateReconciliationTable" roleURI="http://www.biomerica.com/role/IncomeTaxRateReconciliationTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_DeferredTaxTable" roleURI="http://www.biomerica.com/role/DeferredTaxTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_GeographicinformationregardingnetsalesTable" roleURI="http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_SupplementalcashflowinformationrelatedtoleasesTable" roleURI="http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_FutureminimumleasepaymentsunderoperatingleasesTable" roleURI="http://www.biomerica.com/role/FutureminimumleasepaymentsunderoperatingleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails" roleURI="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS" roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY" roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY" roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_INCOMETAXESDetails" roleURI="http://www.biomerica.com/role/INCOMETAXESDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_GEOGRAPHICINFORMATIONDetails" roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASES" roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS" roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#bmra_r_SUBSEQUENTEVENTSDetails" roleURI="http://www.biomerica.com/role/SUBSEQUENTEVENTSDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220531.xsd#DocumentAndEntityInformation" roleURI="http://www.biomerica.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="A5PercentConvertiblePreferredStockMember" xlink:href="bmra-20220531.xsd#bmra_A5PercentConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="A5PercentConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Investments" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="A5PercentConvertiblePreferredStockMember" xlink:href="bmra-20220531.xsd#bmra_A5PercentConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="A5PercentConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="bmra-20220531.xsd#bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="OperatingLeaseRightOfUseAssetAccumulatedAmortization" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNoParValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockNoParValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PreferredStockUndesignatedShares" xlink:href="bmra-20220531.xsd#bmra_PreferredStockUndesignatedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="PreferredStockUndesignatedShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_GrossProfit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OperatingExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_0" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="A5PercentConvertiblePreferredStockMember" xlink:href="bmra-20220531.xsd#bmra_A5PercentConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="A5PercentConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="5.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued_0" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_StockOptionPlanExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInLeaseLiability" xlink:href="bmra-20220531.xsd#bmra_IncreaseDecreaseInLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="CashPaidDuringThePeriodForAbstract" xlink:href="bmra-20220531.xsd#bmra_CashPaidDuringThePeriodForAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="CashPaidDuringThePeriodForAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidDuringThePeriodForAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseInRightOfUseAsset" xlink:href="bmra-20220531.xsd#bmra_IncreaseInRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="IncreaseInRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="IncreaseInLeaseLiability" xlink:href="bmra-20220531.xsd#bmra_IncreaseInLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="IncreaseInLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="WriteOffOfFixedAssetsCost" xlink:href="bmra-20220531.xsd#bmra_WriteOffOfFixedAssetsCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="WriteOffOfFixedAssetsCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="WriteOffOfFixedAssetsAccumulatedDepreciation" xlink:href="bmra-20220531.xsd#bmra_WriteOffOfFixedAssetsAccumulatedDepreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="WriteOffOfFixedAssetsAccumulatedDepreciation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="WriteOffOfIntangibleAssetsCost" xlink:href="bmra-20220531.xsd#bmra_WriteOffOfIntangibleAssetsCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="WriteOffOfIntangibleAssetsCost" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="WriteOffOfIntangibleAssetsAccumulatedAmortization" xlink:href="bmra-20220531.xsd#bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="WriteOffOfIntangibleAssetsAccumulatedAmortization" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ORGANIZATION">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNET">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INTANGIBLEASSETSNET">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SHAREHOLDERSEQUITY">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INCOMETAXES">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GEOGRAPHICINFORMATION">
    <loc xlink:type="locator" xlink:label="GeographicInformationDisclosureAbstract" xlink:href="bmra-20220531.xsd#bmra_GeographicInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="GeographicInformationDisclosureTextBlock" xlink:href="bmra-20220531.xsd#bmra_GeographicInformationDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicInformationDisclosureAbstract" xlink:to="GeographicInformationDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUBSEQUENTEVENTS">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LiquidityPolicyTextBlock" xlink:href="bmra-20220531.xsd#bmra_LiquidityPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LiquidityPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConcentrationRiskGeographicPolicyPolicyTextBlock" xlink:href="bmra-20220531.xsd#bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ConcentrationRiskGeographicPolicyPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidsPolicyPolicyTextBlock" xlink:href="bmra-20220531.xsd#bmra_PrepaidsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PrepaidsPolicyPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNETTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INTANGIBLEASSETSNETTables">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INCOMETAXESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables">
    <loc xlink:type="locator" xlink:label="GeographicInformationDisclosureAbstract" xlink:href="bmra-20220531.xsd#bmra_GeographicInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicInformationDisclosureAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" xlink:href="bmra-20220531.xsd#bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/InventoriesTable">
    <loc xlink:type="locator" xlink:label="InventoriesAbstract" xlink:href="bmra-20220531.xsd#bmra_InventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesAbstract" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesAbstract" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesAbstract" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesAbstract" xlink:to="us-gaap_InventoryGross" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesAbstract" xlink:to="us-gaap_InventoryValuationReserves" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesAbstract" xlink:to="us-gaap_InventoryNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SharebasedcompensationassumptionsTable">
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationAssumptionsAbstract" xlink:href="bmra-20220531.xsd#bmra_ShareBasedCompensationAssumptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" xlink:href="bmra-20220531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable"/>
    <loc xlink:type="locator" xlink:label="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:href="bmra-20220531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAssumptionsAbstract" xlink:to="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" xlink:to="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable">
    <loc xlink:type="locator" xlink:label="RevenueFromContractsWithCustomersAbstract" xlink:href="bmra-20220531.xsd#bmra_RevenueFromContractsWithCustomersAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractsWithCustomersAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PhysiciansOfficeMember" xlink:href="bmra-20220531.xsd#bmra_PhysiciansOfficeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="PhysiciansOfficeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClinicalLabMember" xlink:href="bmra-20220531.xsd#bmra_ClinicalLabMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="ClinicalLabMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OverthecounterMember" xlink:href="bmra-20220531.xsd#bmra_OverthecounterMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="OverthecounterMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContractManufacturingMember" xlink:href="bmra-20220531.xsd#bmra_ContractManufacturingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="ContractManufacturingMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/PropertyandequipmentnetTable">
    <loc xlink:type="locator" xlink:label="PropertyAndEquipmentNetAbstract" xlink:href="bmra-20220531.xsd#bmra_PropertyAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="Equipment" xlink:href="bmra-20220531.xsd#bmra_Equipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyAndEquipmentNetAbstract" xlink:to="Equipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="FurnitureFixturesAndLeaseholdImprovements" xlink:href="bmra-20220531.xsd#bmra_FurnitureFixturesAndLeaseholdImprovements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyAndEquipmentNetAbstract" xlink:to="FurnitureFixturesAndLeaseholdImprovements" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyAndEquipmentNetAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/IntangibleassetsnetTable">
    <loc xlink:type="locator" xlink:label="IntangibleAssetsNetAbstract" xlink:href="bmra-20220531.xsd#bmra_IntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedLicenseAgreementsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedLicenseAgreementsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedPatentsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedPatentsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedPatentsGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="FiniteLivedLicenseAccumulatedAmortization" xlink:href="bmra-20220531.xsd#bmra_FiniteLivedLicenseAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetAbstract" xlink:to="FiniteLivedLicenseAccumulatedAmortization" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="FiniteLivedPatentsAccumulatedAmortization" xlink:href="bmra-20220531.xsd#bmra_FiniteLivedPatentsAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetAbstract" xlink:to="FiniteLivedPatentsAccumulatedAmortization" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:href="bmra-20220531.xsd#bmra_ExpectedAmortizationOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable">
    <loc xlink:type="locator" xlink:label="AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:href="bmra-20220531.xsd#bmra_AccountsPayableAndAccruedExpenseBalancesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ActivityastoaggregatestockoptionsoutstandingTable">
    <loc xlink:type="locator" xlink:label="ActivityAsToAggregateStockOptionsOutstandingAbstract" xlink:href="bmra-20220531.xsd#bmra_ActivityAsToAggregateStockOptionsOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingTable" xlink:href="bmra-20220531.xsd#bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingTable"/>
    <loc xlink:type="locator" xlink:label="SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems" xlink:href="bmra-20220531.xsd#bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ActivityAsToAggregateStockOptionsOutstandingAbstract" xlink:to="SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangePerShare082818Member" xlink:href="bmra-20220531.xsd#bmra_ExercisePriceRangePerShare082818Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangePerShare082818Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangePerShare514870Member" xlink:href="bmra-20220531.xsd#bmra_ExercisePriceRangePerShare514870Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangePerShare514870Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangePerShare082362Member" xlink:href="bmra-20220531.xsd#bmra_ExercisePriceRangePerShare082362Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangePerShare082362Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangePerShare235818Member" xlink:href="bmra-20220531.xsd#bmra_ExercisePriceRangePerShare235818Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangePerShare235818Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangePerShare082870Member" xlink:href="bmra-20220531.xsd#bmra_ExercisePriceRangePerShare082870Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangePerShare082870Member" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangePerShare425446Member" xlink:href="bmra-20220531.xsd#bmra_ExercisePriceRangePerShare425446Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangePerShare425446Member" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangePerShare120362Member" xlink:href="bmra-20220531.xsd#bmra_ExercisePriceRangePerShare120362Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangePerShare120362Member" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangePerShare161818Member" xlink:href="bmra-20220531.xsd#bmra_ExercisePriceRangePerShare161818Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangePerShare161818Member" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingTable" xlink:to="SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/NonvestedStockOptionsActivityTable">
    <loc xlink:type="locator" xlink:label="NonVestedStockOptionsActivityAbstract" xlink:href="bmra-20220531.xsd#bmra_NonVestedStockOptionsActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/StockOptionsSummaryTable">
    <loc xlink:type="locator" xlink:label="StockOptionsSummaryAbstract" xlink:href="bmra-20220531.xsd#bmra_StockOptionsSummaryAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsSummaryAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt+1Vq3zhhUlfDeP/RQUzUZihDO8dLtQrMZMNe4t6pAivP0axfdFZpsLdRcC6V+fMavTAOMD4FknVX18XpRs+KLunX2qipVKNpApCTOelknJAdDWusY2PGEvYpRrj0mxs78hkWjdoZPMe4E2T0OAgcNcAeqIj6oByjJ8+mz4y4M7pKUOz2fmXHViFHPyAid0zXI=] CSR-->
    <loc xlink:type="locator" xlink:label="RangeOfExercisePrice082152Member" xlink:href="bmra-20220531.xsd#bmra_RangeOfExercisePrice082152Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="RangeOfExercisePrice082152Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RangeOfExercisePrice225425Member" xlink:href="bmra-20220531.xsd#bmra_RangeOfExercisePrice225425Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="RangeOfExercisePrice225425Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RangeOfExercisePrice434870Member" xlink:href="bmra-20220531.xsd#bmra_RangeOfExercisePrice434870Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="RangeOfExercisePrice434870Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/IncometaxexpenseTable">
    <loc xlink:type="locator" xlink:label="IncomeTaxExpenseAbstract" xlink:href="bmra-20220531.xsd#bmra_IncomeTaxExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/IncomeTaxRateReconciliationTable">
    <loc xlink:type="locator" xlink:label="IncomeTaxRateReconciliationAbstract" xlink:href="bmra-20220531.xsd#bmra_IncomeTaxRateReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:href="bmra-20220531.xsd#bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxRateReconciliationAbstract" xlink:to="IncreaseReductionInIncomeTaxesResultingFromAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/DeferredTaxTable">
    <loc xlink:type="locator" xlink:label="DeferredTaxAbstract" xlink:href="bmra-20220531.xsd#bmra_DeferredTaxAbstract"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAbstract" xlink:href="bmra-20220531.xsd#bmra_DeferredTaxAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAbstract" xlink:to="DeferredTaxAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsInventory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DefferedTaxAssetsStockOptions" xlink:href="bmra-20220531.xsd#bmra_DefferedTaxAssetsStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAbstract" xlink:to="DefferedTaxAssetsStockOptions" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" xlink:href="bmra-20220531.xsd#bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAbstract" xlink:to="DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAccumulatedDepreciationAndAmortization" xlink:href="bmra-20220531.xsd#bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAbstract" xlink:to="DeferredTaxAssetsAccumulatedDepreciationAndAmortization" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable">
    <loc xlink:type="locator" xlink:label="GeographicInformationRegardingNetSalesAbstract" xlink:href="bmra-20220531.xsd#bmra_GeographicInformationRegardingNetSalesAbstract"/>
    <loc xlink:type="locator" xlink:label="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:href="bmra-20220531.xsd#bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable"/>
    <loc xlink:type="locator" xlink:label="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:href="bmra-20220531.xsd#bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicInformationRegardingNetSalesAbstract" xlink:to="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_AsiaMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_AsiaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_EuropeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_NorthAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NorthAmericaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_NorthAmericaMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_SouthAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SouthAmericaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SouthAmericaMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MiddleEastMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MiddleEastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="us-gaap_MiddleEastMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueSegmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueSegmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeographicConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_GeographicConcentrationRiskMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:to="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable">
    <loc xlink:type="locator" xlink:label="SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:href="bmra-20220531.xsd#bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/FutureminimumleasepaymentsunderoperatingleasesTable">
    <loc xlink:type="locator" xlink:label="FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:href="bmra-20220531.xsd#bmra_FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:href="bmra-20220531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:href="bmra-20220531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ATMAgreementMember" xlink:href="bmra-20220531.xsd#bmra_ATMAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ATMAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OneDistributorMember" xlink:href="bmra-20220531.xsd#bmra_OneDistributorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="OneDistributorMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DistributorsInAsiaMember" xlink:href="bmra-20220531.xsd#bmra_DistributorsInAsiaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="DistributorsInAsiaMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoDistributorsMember" xlink:href="bmra-20220531.xsd#bmra_TwoDistributorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="TwoDistributorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OneDistributorMember_0" xlink:href="bmra-20220531.xsd#bmra_OneDistributorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="OneDistributorMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OneVendorMember" xlink:href="bmra-20220531.xsd#bmra_OneVendorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="OneVendorMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PolishDistributorMember" xlink:href="bmra-20220531.xsd#bmra_PolishDistributorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="PolishDistributorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_MX" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MX"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_MX" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DistributionRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionRightsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_DistributionRightsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasedTechnologyRightsMember" xlink:href="bmra-20220531.xsd#bmra_PurchasedTechnologyRightsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="PurchasedTechnologyRightsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_PatentsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsPayableMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsProductLineMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsProductLineMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_CostOfGoodsProductLineMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_SupplierConcentrationRiskMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="srt_RangeAxis" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WorkingCapital" xlink:href="bmra-20220531.xsd#bmra_WorkingCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="WorkingCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" xlink:href="bmra-20220531.xsd#bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_SharePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashUninsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_CashUninsuredAmount" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_Revenues" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_OtherReceivablesGrossCurrent" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_InventoryGross" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_InventoryValuationReserves" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_Investments" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AdvertisingExpense" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:href="bmra-20220531.xsd#bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems" xlink:href="bmra-20220531.xsd#bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="TwoVendorMember" xlink:href="bmra-20220531.xsd#bmra_TwoVendorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="TwoVendorMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OneVendorMember" xlink:href="bmra-20220531.xsd#bmra_OneVendorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="OneVendorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsPayableMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:to="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSTable" xlink:href="bmra-20220531.xsd#bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSTable"/>
    <loc xlink:type="locator" xlink:label="SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" xlink:href="bmra-20220531.xsd#bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_CostOfSalesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_SellingAndMarketingExpenseMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSTable" xlink:to="us-gaap_AwardTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSTable" xlink:to="us-gaap_PlanNameAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="A2014PlanMember" xlink:href="bmra-20220531.xsd#bmra_A2014PlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="A2014PlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="A2017PlanMember" xlink:href="bmra-20220531.xsd#bmra_A2017PlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="A2017PlanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="A2020PlanMember" xlink:href="bmra-20220531.xsd#bmra_A2020PlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="A2020PlanMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSTable" xlink:to="SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable" xlink:href="bmra-20220531.xsd#bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable"/>
    <loc xlink:type="locator" xlink:label="SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems" xlink:href="bmra-20220531.xsd#bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable" xlink:to="us-gaap_TransactionTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ATMAgreementMember" xlink:href="bmra-20220531.xsd#bmra_ATMAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="ATMAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable" xlink:to="us-gaap_PlanNameAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="A2020StockIncentivePlanMember" xlink:href="bmra-20220531.xsd#bmra_A2020StockIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="A2020StockIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable" xlink:to="SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYTable" xlink:href="bmra-20220531.xsd#bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYTable"/>
    <loc xlink:type="locator" xlink:label="SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems" xlink:href="bmra-20220531.xsd#bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="StockPurchaseAgreementMember" xlink:href="bmra-20220531.xsd#bmra_StockPurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="StockPurchaseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PalmMember" xlink:href="bmra-20220531.xsd#bmra_PalmMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="PalmMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYTable" xlink:to="SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPayableAmountPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableAmountPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems" xlink:to="us-gaap_DividendsPayableAmountPerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INCOMETAXESDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="INCOMETAXESDetailsTable" xlink:href="bmra-20220531.xsd#bmra_INCOMETAXESDetailsTable"/>
    <loc xlink:type="locator" xlink:label="INCOMETAXESDetailsLineItems" xlink:href="bmra-20220531.xsd#bmra_INCOMETAXESDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="INCOMETAXESDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INCOMETAXESDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CaliforniaStateIncomeTaxMember" xlink:href="bmra-20220531.xsd#bmra_CaliforniaStateIncomeTaxMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="CaliforniaStateIncomeTaxMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INCOMETAXESDetailsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INCOMETAXESDetailsTable" xlink:to="INCOMETAXESDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INCOMETAXESDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INCOMETAXESDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INCOMETAXESDetailsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INCOMETAXESDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INCOMETAXESDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails">
    <loc xlink:type="locator" xlink:label="GeographicInformationDisclosureAbstract" xlink:href="bmra-20220531.xsd#bmra_GeographicInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicInformationDisclosureAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASES">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESTable" xlink:href="bmra-20220531.xsd#bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESTable"/>
    <loc xlink:type="locator" xlink:label="COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems" xlink:href="bmra-20220531.xsd#bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESTable" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BuildingInIrvineCaliforniaMember" xlink:href="bmra-20220531.xsd#bmra_BuildingInIrvineCaliforniaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="BuildingInIrvineCaliforniaMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyAvailableForOperatingLeaseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyAvailableForOperatingLeaseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertyAvailableForOperatingLeaseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FirstAmendmentToLeaseMember" xlink:href="bmra-20220531.xsd#bmra_FirstAmendmentToLeaseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="FirstAmendmentToLeaseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESTable" xlink:to="srt_StatementGeographicalAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_MX" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MX"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_MX" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESTable" xlink:to="COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems" xlink:to="us-gaap_SecurityDeposit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseExpirationPeriod" xlink:href="bmra-20220531.xsd#bmra_LeaseExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems" xlink:to="LeaseExpirationPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSTable" xlink:href="bmra-20220531.xsd#bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSTable"/>
    <loc xlink:type="locator" xlink:label="COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems" xlink:href="bmra-20220531.xsd#bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RoyaltyAgreementsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TelconAgreementMember" xlink:href="bmra-20220531.xsd#bmra_TelconAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="TelconAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UCLicenseAgreementsMember" xlink:href="bmra-20220531.xsd#bmra_UCLicenseAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="UCLicenseAgreementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UniversityOFSouthernCaliforniaMember" xlink:href="bmra-20220531.xsd#bmra_UniversityOFSouthernCaliforniaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="UniversityOFSouthernCaliforniaMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BiomericaInFoodsMember" xlink:href="bmra-20220531.xsd#bmra_BiomericaInFoodsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BiomericaInFoodsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSTable" xlink:to="COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems" xlink:to="us-gaap_RoyaltyExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyExpensePercentageOfSales" xlink:href="bmra-20220531.xsd#bmra_RoyaltyExpensePercentageOfSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems" xlink:to="RoyaltyExpensePercentageOfSales" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedFeesAndOtherRevenueReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedFeesAndOtherRevenueReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems" xlink:to="us-gaap_AccruedFeesAndOtherRevenueReceivable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromFeesReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems" xlink:to="us-gaap_ProceedsFromFeesReceived" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyPercentage" xlink:href="bmra-20220531.xsd#bmra_RoyaltyPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems" xlink:to="RoyaltyPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems" xlink:to="us-gaap_PaymentsForFees" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicenseMaintenanceFeePayable" xlink:href="bmra-20220531.xsd#bmra_LicenseMaintenanceFeePayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems" xlink:to="LicenseMaintenanceFeePayable" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClinicalTrialAgreementMaximumBudgetedCosts" xlink:href="bmra-20220531.xsd#bmra_ClinicalTrialAgreementMaximumBudgetedCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems" xlink:to="ClinicalTrialAgreementMaximumBudgetedCosts" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUBSEQUENTEVENTSDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SUBSEQUENTEVENTSDetailsTable" xlink:href="bmra-20220531.xsd#bmra_SUBSEQUENTEVENTSDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SUBSEQUENTEVENTSDetailsLineItems" xlink:href="bmra-20220531.xsd#bmra_SUBSEQUENTEVENTSDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SUBSEQUENTEVENTSDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsTable" xlink:to="SUBSEQUENTEVENTSDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_SharePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="bmra-20220531.xsd#bmra_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143086827984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Aug. 29, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOMERICA, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BMRA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--05-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,391,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,709,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000073290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-2645573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">17571 Von Karman Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Irvine<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">645-2111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">COMMON STOCK, PAR VALUE $0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">HASKELL & WHITE LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Irvine, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143084011408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,916,983<span></span>
</td>
<td class="nump">$ 4,199,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, less allowance for doubtful accounts of $153,231 and $837,415 as of May 31, 2022 and 2021, respectively</a></td>
<td class="nump">773,818<span></span>
</td>
<td class="nump">1,455,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">2,416,447<span></span>
</td>
<td class="nump">3,206,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">320,283<span></span>
</td>
<td class="nump">370,290<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">9,427,531<span></span>
</td>
<td class="nump">9,230,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation and amortization of $1,305,360 and $1,972,357 as of May 31, 2022 and 2021, respectively</a></td>
<td class="nump">214,487<span></span>
</td>
<td class="nump">310,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets, net of accumulated amortization of $724,802 and $469,077 as of May 31, 2022 and 2021, respectively</a></td>
<td class="nump">1,301,834<span></span>
</td>
<td class="nump">1,553,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="nump">165,324<span></span>
</td>
<td class="nump">165,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of accumulated amortization of $18,994 and $126,769 as of May 31, 2022 and 2021, respectively</a></td>
<td class="nump">169,516<span></span>
</td>
<td class="nump">294,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">95,588<span></span>
</td>
<td class="nump">264,151<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">11,374,280<span></span>
</td>
<td class="nump">11,818,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">972,372<span></span>
</td>
<td class="nump">583,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">646,944<span></span>
</td>
<td class="nump">388,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Advance from customers</a></td>
<td class="nump">50,670<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current portion</a></td>
<td class="nump">341,296<span></span>
</td>
<td class="nump">327,944<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,011,282<span></span>
</td>
<td class="nump">1,300,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, net of current portion</a></td>
<td class="nump">1,038,284<span></span>
</td>
<td class="nump">1,291,570<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">3,049,566<span></span>
</td>
<td class="nump">2,591,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Notes 6 and 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, Series A 5% convertible, $0.08 par value, 571,429 shares authorized, none issued and outstanding as of May 31, 2022 and 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, undesignated, no par value, 4,428,571 shares authorized, none issued and outstanding as of May 31, 2022 and 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.08 par value, 25,000,000 shares authorized, 12,867,924 and 12,307,157 issued and outstanding at May 31, 2022 and 2021, respectively</a></td>
<td class="nump">1,029,432<span></span>
</td>
<td class="nump">984,571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="nump">42,446,597<span></span>
</td>
<td class="nump">38,836,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(73,936)<span></span>
</td>
<td class="num">(47,956)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(35,077,379)<span></span>
</td>
<td class="num">(30,546,335)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Equity</a></td>
<td class="nump">8,324,714<span></span>
</td>
<td class="nump">9,227,023<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Shareholders' Equity</a></td>
<td class="nump">11,374,280<span></span>
</td>
<td class="nump">11,818,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5PercentConvertiblePreferredStockMember', window );">5% Convertible Preferred Stock [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, Series A 5% convertible, $0.08 par value, 571,429 shares authorized, none issued and outstanding as of May 31, 2022 and 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, undesignated, no par value, 4,428,571 shares authorized, none issued and outstanding as of May 31, 2022 and 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5PercentConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5PercentConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143086715424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts (in Dollars) (in Dollars)</a></td>
<td class="nump">$ 153,231<span></span>
</td>
<td class="nump">$ 837,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization (in Dollars) (in Dollars)</a></td>
<td class="nump">1,305,360<span></span>
</td>
<td class="nump">1,972,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization', window );">Accumulated amortization, Right of Use Assets (in Dollars) (in Dollars)</a></td>
<td class="nump">724,802<span></span>
</td>
<td class="nump">469,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization, Intangible Assets (in Dollars) (in Dollars)</a></td>
<td class="nump">$ 18,994<span></span>
</td>
<td class="nump">$ 126,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNoParValue', window );">Preferred Stock, No Par Value (in Dollars per share) (in Dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_PreferredStockUndesignatedShares', window );">Preferred Stock, undesignated shares</a></td>
<td class="nump">4,428,571<span></span>
</td>
<td class="nump">4,428,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in Dollars per share) (in Dollars per share)</a></td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">12,867,924<span></span>
</td>
<td class="nump">12,307,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">12,867,924<span></span>
</td>
<td class="nump">12,307,157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5PercentConvertiblePreferredStockMember', window );">5% Convertible Preferred Stock [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par Value (in Dollars per share) (in Dollars per share)</a></td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, shares authorized</a></td>
<td class="nump">571,429<span></span>
</td>
<td class="nump">571,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from operating lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_PreferredStockUndesignatedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of preferred shares undesignated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_PreferredStockUndesignatedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5PercentConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5PercentConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143086481920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">$ 18,871,409<span></span>
</td>
<td class="nump">$ 7,199,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="num">(15,893,991)<span></span>
</td>
<td class="num">(6,832,742)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">2,977,418<span></span>
</td>
<td class="nump">366,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">5,698,958<span></span>
</td>
<td class="nump">5,671,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,812,424<span></span>
</td>
<td class="nump">2,194,461<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expense</a></td>
<td class="nump">7,511,382<span></span>
</td>
<td class="nump">7,865,978<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(4,533,964)<span></span>
</td>
<td class="num">(7,499,693)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Dividend and interest income</a></td>
<td class="nump">26,639<span></span>
</td>
<td class="nump">66,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(367)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">26,639<span></span>
</td>
<td class="nump">66,496<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(4,507,325)<span></span>
</td>
<td class="num">(7,433,197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(23,719)<span></span>
</td>
<td class="num">(13,057)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,531,044)<span></span>
</td>
<td class="num">$ (7,446,254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (in Dollars per share)</a></td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (in Dollars per share)</a></td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of common and common equivalent shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in Shares)</a></td>
<td class="nump">12,673,245<span></span>
</td>
<td class="nump">11,928,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in Shares)</a></td>
<td class="nump">12,673,245<span></span>
</td>
<td class="nump">11,928,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,531,044)<span></span>
</td>
<td class="num">$ (7,446,254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss, net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">(25,980)<span></span>
</td>
<td class="num">(8,115)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (4,557,024)<span></span>
</td>
<td class="num">$ (7,454,369)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143086901184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF SHAREHOLDERS` EQUITY - USD ($)<br></strong></div></th>
<th class="th">
<div>Series A Preferred Stock [Member] </div>
<div>5% Convertible Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at May. 31, 2020</a></td>
<td class="nump">$ 25,714<span></span>
</td>
<td class="nump">$ 939,205<span></span>
</td>
<td class="nump">$ 36,388,056<span></span>
</td>
<td class="num">$ (39,841)<span></span>
</td>
<td class="num">$ (23,100,081)<span></span>
</td>
<td class="nump">$ 14,213,053<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balances (in Shares) at May. 31, 2020</a></td>
<td class="nump">321,429<span></span>
</td>
<td class="nump">11,740,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,940<span></span>
</td>
<td class="nump">95,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,712<span></span>
</td>
<td class="nump">998,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,011,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from ATM (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,115)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of preferred to common stock</a></td>
<td class="num">$ (25,714)<span></span>
</td>
<td class="nump">$ 25,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of preferred to common stock (in Shares)</a></td>
<td class="num">(321,429)<span></span>
</td>
<td class="nump">321,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Compensation expense in connection with options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,354,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,354,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,446,254)<span></span>
</td>
<td class="num">(7,446,254)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at May. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 984,571<span></span>
</td>
<td class="nump">38,836,743<span></span>
</td>
<td class="num">(47,956)<span></span>
</td>
<td class="num">(30,546,335)<span></span>
</td>
<td class="nump">9,227,023<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balances (in Shares) at May. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">12,307,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,160<span></span>
</td>
<td class="nump">74,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,701<span></span>
</td>
<td class="nump">2,275,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,317,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from ATM (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">521,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,980)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,980)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Compensation expense in connection with options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,260,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,260,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,531,044)<span></span>
</td>
<td class="num">(4,531,044)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at May. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,029,432<span></span>
</td>
<td class="nump">$ 42,446,597<span></span>
</td>
<td class="num">$ (73,936)<span></span>
</td>
<td class="num">$ (35,077,379)<span></span>
</td>
<td class="nump">$ 8,324,714<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balances (in Shares) at May. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">12,867,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143084205024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,531,044)<span></span>
</td>
<td class="num">$ (7,446,254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">339,096<span></span>
</td>
<td class="nump">138,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">52,587<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for allowance on accounts receivable</a></td>
<td class="num">(684,184)<span></span>
</td>
<td class="nump">766,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLIFOReservePeriodCharge', window );">Inventory reserve</a></td>
<td class="num">(771,736)<span></span>
</td>
<td class="nump">1,550,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option expense</a></td>
<td class="nump">1,260,195<span></span>
</td>
<td class="nump">1,354,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use asset</a></td>
<td class="nump">255,725<span></span>
</td>
<td class="nump">237,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">1,365,417<span></span>
</td>
<td class="num">(455,614)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">1,561,544<span></span>
</td>
<td class="num">(1,906,013)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other</a></td>
<td class="nump">50,007<span></span>
</td>
<td class="nump">1,138,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_IncreaseDecreaseInLeaseLiability', window );">Reduction in lease liability</a></td>
<td class="num">(244,412)<span></span>
</td>
<td class="num">(241,132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">168,563<span></span>
</td>
<td class="num">(95,958)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">388,992<span></span>
</td>
<td class="num">(403,331)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="nump">258,048<span></span>
</td>
<td class="nump">110,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Advance from customers</a></td>
<td class="nump">50,670<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(480,532)<span></span>
</td>
<td class="num">(5,251,748)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Expenditure related to intangibles</a></td>
<td class="num">(113,436)<span></span>
</td>
<td class="num">(159,727)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(56,900)<span></span>
</td>
<td class="num">(135,856)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(170,336)<span></span>
</td>
<td class="num">(295,583)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of common stock</a></td>
<td class="nump">2,401,734<span></span>
</td>
<td class="nump">1,177,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Costs from sale of common stock</a></td>
<td class="num">(84,574)<span></span>
</td>
<td class="num">(165,919)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">77,360<span></span>
</td>
<td class="nump">102,255<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,394,520<span></span>
</td>
<td class="nump">1,113,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes in cash</a></td>
<td class="num">(25,980)<span></span>
</td>
<td class="num">(8,115)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">1,717,672<span></span>
</td>
<td class="num">(4,441,716)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">4,199,311<span></span>
</td>
<td class="nump">8,641,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">5,916,983<span></span>
</td>
<td class="nump">4,199,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_CashPaidDuringThePeriodForAbstract', window );"><strong>Cash paid during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="nump">23,719<span></span>
</td>
<td class="nump">27,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_IncreaseInRightOfUseAsset', window );">Increase in right-of-use asset due to lease extension or establishment</a></td>
<td class="nump">4,478<span></span>
</td>
<td class="nump">79,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_IncreaseInLeaseLiability', window );">Increase in lease liability due to lease extension or establishment</a></td>
<td class="nump">4,478<span></span>
</td>
<td class="nump">79,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_WriteOffOfFixedAssetsCost', window );">Write off of fixed assets, cost</a></td>
<td class="nump">819,931<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_WriteOffOfFixedAssetsAccumulatedDepreciation', window );">Write off of fixed assets, accumulated depreciation</a></td>
<td class="nump">767,344<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_WriteOffOfIntangibleAssetsCost', window );">Write off of intangible assets, cost</a></td>
<td class="nump">246,756<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization', window );">Write off of intangible assets, accumulated amortization</a></td>
<td class="nump">$ 37,221<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_CashPaidDuringThePeriodForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>No definition available</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_CashPaidDuringThePeriodForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_IncreaseDecreaseInLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in LeaseLiability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_IncreaseDecreaseInLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_IncreaseInLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in lease liability due to lease extension or establishment in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_IncreaseInLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_IncreaseInRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in right of use asset due to lease extension or establishment in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_IncreaseInRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_WriteOffOfFixedAssetsAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write off of fixed assets, accumulated depreciation in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_WriteOffOfFixedAssetsAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_WriteOffOfFixedAssetsCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write off of fixed assets, cost in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_WriteOffOfFixedAssetsCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write off of intangible assets, accumulated amortization in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_WriteOffOfIntangibleAssetsCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write off of intangible assets, cost in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_WriteOffOfIntangibleAssetsCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReservePeriodCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e99989-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReservePeriodCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143092656160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">NOTE 1: &#160;&#160;&#160;ORGANIZATION </span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">Biomerica, Inc. and its subsidiaries (which includes wholly-owned subsidiaries, Biomerica de Mexico and BioEurope GmbH) is</span><span style="font-size: 10pt;"> a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care </span><span style="font-size: 10pt; color: black;">(physicians' offices and over-the-counter through drugstores and online) </span><span style="font-size: 10pt;">and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases</span><span style="font-size: 10pt; color: black;">. Our diagnostic test kits are used to analyze blood, urine, nasal or fecal material from patients in the diagnosis of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which may exist in the human body in extremely small concentrations. The</span><span style="font-size: 10pt;"> Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our primary focus is the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided therapy (&#8220;DGT&#8221;) products to treat gastrointestinal diseases, such as irritable bowel syndrome, and other inflammatory diseases. These products are directed at chronic inflammatory illnesses that are widespread and common, and as such address very large markets. Our InFoods&#174; IBS product uses a simple blood sample and is designed to identify patient-specific foods that, when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea and constipation. Instead of broad and difficult to manage dietary restrictions, the InFoods&#174; IBS product works by identifying a patient&#8217;s above normal immunoreactivity to specific foods.&#160; A food identified as positive and causing an abnormal immune response in the patient is simply removed from the diet to help alleviate IBS symptoms. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our existing medical diagnostic products are sold worldwide primarily in two markets: 1) clinical laboratories and 2) point-of-care (physicians' offices and over-the-counter drugstores like Walmart and Walgreens). The diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens, or other substances, which may exist in a patient&#8217;s body, stools, or blood, often in extremely small concentrations.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Due to the global 2019 SARS-CoV-2 novel coronavirus pandemic<span style="COLOR:black">, in March 2020 we</span> began developing COVID-19 products to indicate if a person has been infected by COVID-19 or is currently infected. While we offer a COVID-19 antibody diagnostic test to determine if a person has previously been infected by the COVID-19 virus, all of our COVID-19 revenues <span style="COLOR:black">in fiscal 2022</span> have come from international sales of our COVID-19 antigen tests that use a patient&#8217;s nasal fluid sample to detect if the patient is currently infected with the virus.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The other existing products that contributed to our 2022 revenues are primarily focused on gastrointestinal diseases, food intolerances, and certain esoteric tests. These diagnostic test products utilize immunoassay technology. Most of our products are CE marked and/or sold for diagnostic use where they are registered by each country&#8217;s regulatory agency. In addition, some products are cleared for sale in the United States by the FDA.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143086696736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">NOTE 2: &#160;&#160;&#160;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">PRINCIPLES OF CONSOLIDATION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">The consolidated financial statements for the years ended May 31, 2022 and 2021, include the accounts of Biomerica, Inc. ("Biomerica") as well as its wholly-owned German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ACCOUNTING ESTIMATES</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates, which are calculated based on historical data; inventory obsolescence, which is based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, the likelihood of lease extensions to occur, asset valuation, among other things; and other items that may be necessary to estimate using current, historical and judgment based information. Actual results could materially differ from those estimates. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">Due to the Coronavirus global pandemic, the Company&#8217;s operations have been negatively impacted. <span style="color: black;">The Company has faced disruptions in the following areas, (and may face further challenges): supply chain disruptions, loss of contracts and/or customers, closure of the Company&#8217;s manufacturing or distribution facilities or of the facilities of the Company&#8217;s suppliers, partners and customers, travel, shipping and logistical disruptions, government responses of all types, international business risks in countries where the Company makes and/or sells its products, loss of human capital or personnel at the Company, its partners and its customers, interruptions of production, customer credit risk, and general economic calamities. These ongoing pandemic related disruptions can materially negatively impact the Company&#8217;s operations and financial performance and may continue to have significant material negative impacts on the Company.&#160;&#160; </span></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">LIQUIDITY</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company has incurred net losses and negative cash flows from operations and has an accumulated deficit of approximately $35.3 million as of May 31, 2022.&#160; Management expects to continue to incur significant costs as it advances its trials and development activities. As of May 31, 2022, the Company had cash and cash equivalents of approximately $5,917,000 and working capital of approximately $7,416,000.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">On January 22, 2021, the Company filed a Prospectus Supplement for purposes of raising up to $15,000,000 to the base prospectus filed with the SEC on July 21, 2020, and was declared effective by the SEC on September 30, 2020, and an ATM &#8220;at the market offering&#8221; Agreement. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">The Company intends to use the net proceeds from such offering for general corporate purposes, including, without limitation, sales and marketing activities, clinical studies, and product development, making acquisitions of assets, businesses, companies or securities, capital expenditures, and for working capital needs.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Under an ATM Agreement, sales of the Placement Shares are deemed to be &#8220;at the market offering&#8221; as defined in Rule 415 promulgated under the Securities Act.&#160; The agent acts as sales agent under the ATM and uses commercially reasonable efforts to sell on the Company&#8217;s behalf all the Placement Shares requested to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the agent and the Company. The Company has no obligation to sell any of the Placement Shares under the ATM Agreement, and may at any time suspend offers under, or terminate the ATM Agreement.&#160; </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"><span style="FONT-SIZE:10pt">During the year ended May 31, 2022, the Company sold 521,267 shares of its common stock at prices ranging from $4.02 to $5.63 under its Form S-3 Registration Statement (</span><span style="FONT-SIZE:10pt; COLOR:black">File No. 333-239980) </span><span style="FONT-SIZE:10pt">and ATM Agreement which resulted in gross proceeds of approximately $2,402,000 and net proceeds to the Company of $2,317,000 after deducting commissions for each sale and legal, accounting, and other fees related to the filing of the Form S-3.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"><span style="FONT-SIZE:10pt">As a result of cash and cash equivalents on hand on May 31, 2022, and the ability to raise additional funds through the ATM noted above, management believes the Company has sufficient funds to operate through at least August 2023.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">FAIR VALUE OF FINANCIAL INSTRUMENTS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company has financial instruments whereby the fair market value of the financial instruments could be different than that recorded on a historical basis. The Company's financial instruments consist of its cash and cash equivalents, accounts receivable,&#160;and accounts payable. The carrying amounts of the Company's financial instruments approximate their fair values. The Company also maintains an investment in privately held company (see below). </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">CONCENTRATION OF CREDIT RISK</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies.&#160; As of May 31, 2022, the Company had approximately $5,702,000 of uninsured cash. The Company does not believe it is exposed to any significant credit risks.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company provides credit in the normal course of business to customers throughout the United States and in foreign markets.&#160; The Company performs ongoing credit evaluations of its customers and requires accelerated prepayment in some circumstances. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our net sales were approximately $18,871,000 for fiscal 2022 compared to $7,199,000 for fiscal 2021. For the fiscal years ended May 31, 2022 and 2021, the Company had two distributors, which accounted for a total of 65% and 60% of our net sales, respectively. Of this, for the fiscal years ended May 31, 2022 and 2021, the largest of the distributors mentioned above accounted for 55% and 33%, respectively, of net sales.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total gross receivables on May 31, 2022 and 2021 were approximately $927,000 and $2,292,000, respectively. On May 31, 2022 and 2021, the Company had one distributor and two distributors, respectively, which accounted for a total of 50% and 73%, respectively, of gross accounts receivable. Of the 50% as of May 31, 2022, 50% was owed by a distributor in Asia.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">For the fiscal years ended May 31, 2022 and 2021, the Company had one vendor, which accounted for 84% and 58%, respectively, of our purchases of raw materials.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">GEOGRAPHIC CONCENTRATION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">As of May 31, 2022 and 2021, a</span><span style="FONT-FAMILY:&quot;Times New Roman&quot;,serif">pproximately $621,000 <span style="COLOR:black">and $803,000, respectively</span> of Biomerica&#8217;s gross inventory was located in Mexicali, Mexico, respectively. <span style="COLOR:black">As of May 31, 2022 and 2021,</span> approximately $17,000 <span style="COLOR:black">and $25,000, respectively</span> of Biomerica&#8217;s property and equipment, net of accumulated depreciation and amortization, was located in Mexicali, Mexico, respectively.</span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">CASH AND</span></b><span style="FONT-SIZE:10pt"><b><span style="COLOR:black"> CASH EQUIVALENTS</span></b></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ACCOUNTS RECEIVABLE</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company extends unsecured credit to its customers on a regular basis. &#160;International accounts are usually required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. &#160;&#160;Initial credit levels for individual distributors are approved by designated officers and managers of the Company. All increases in credit limits are also approved by designated upper-level management. &#160;Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. &#160;Balances over ninety days old are usually reserved for unless collection is reasonably assured. &#160; </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables. &#160; Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">As of May 31, 2022 and 2021, the Company has established a reserve of approximately $153,000 and $837,000, respectively, for doubtful accounts. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">PREPAIDS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">The Company occasionally prepays for items such as inventory, insurance, and other items.&#160; These items are reported as prepaids, until either the inventory is physically received or the insurance and other items are utilized.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">As of May 31, 2022 and 2021, the prepaids were approximately $320,000 and $370,000, respectively, composed of prepayments to insurance and various other suppliers. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">INVENTORIES, NET</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black">The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The following is a summary of approximate net inventories:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733">

<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td colspan="5" style="border-top: 0px; height: 15pt; border-right: 0px; width: 29.82%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">May 31,</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">2022</span></p>
</td>
<td style="height: 15pt; width: 1.78%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">2021</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Raw materials</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 12.04%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">1,717,000 </span></p>
</td>
<td style="height: 15pt; width: 1.78%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;$ </span></p>
</td>
<td style="height: 15pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">1,812,000 </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Work in progress</span></p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 12.04%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">763,000 </span></p>
</td>
<td style="height: 15pt; width: 1.78%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">1,687,000 </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Finished products</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.04%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">782,000 </span></p>
</td>
<td style="height: 15pt; width: 1.78%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">1,324,000 </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Total gross inventory</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.04%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">3,262,000 </span></p>
</td>
<td style="height: 15pt; width: 1.78%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;$ </span></strong></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">4,823,000 </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Inventory reserve</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.04%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(846,000)</span></p>
</td>
<td style="height: 15pt; width: 1.78%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(1,617,000)</span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 70.18%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Net inventory </span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12.04%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">2,416,000 </span></strong></p>
</td>
<td style="height: 15.75pt; width: 1.78%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">3,206,000 </span></strong></p>
</td>
</tr>

</table><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically reserve for obsolete inventory. As of May 31, 2022 and 2021, inventory reserves were approximately $846,000 and $1,617,000, respectively. During the fiscal 2022 the Company disposed of COVID-19 antibody inventory that wasn&#8217;t sellable, this has been partially reserved for in fiscal 2021. The reduction in our inventory reserve relates to the COVID-19 antibody disposal. The Company continues to sell COVID-19 antigen tests. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">PROPERTY AND EQUIPMENT, NET</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment amounted to approximately $100,000 and $105,000 for the years ended May 31, 2022 and 2021, respectively. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">INTANGIBLE ASSETS, NET</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (&#8220;ASC&#8221;), ASC 350 Intangibles &#8211; Goodwill and Other (&#8220;ASC 350&#8221;). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Intangible assets are being amortized using the straight-line method over the useful life, not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, and 20 years for patents. Amortization amounted to approximately $239,000 and $34,000 for the years ended May 31, 2022 and 2021, respectively.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset's balance over its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine whether there was any impairment. As of May 31, 2022 and 2021, an impairment adjustment was made of $210,000 and $0, respectively.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">INVESTMENTS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">From time-to-time, the Company makes investments in privately held companies. Investments represent the Company&#8217;s investment in a Polish distributor, which is primarily engaged in distributing medical products and devices. The Company owns approximately 6% of the investee and, accordingly, applies the cost method holdings to account for the investment. The Company invested approximately $165,000 into the Polish distributor.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Equity holdings in nonmarketable unconsolidated entities in which the Company is not able to exercise significant influence ("Cost Method Holdings") are accounted for at the Company's initial cost, minus any impairment (if any), plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar holding or security of the same issuer. Dividends received are recorded as other income.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company assesses its equity holdings for impairment whenever events or changes in circumstances indicate that the carrying value of an equity holding may not be recoverable. Management reviewed the underlying net assets of the Company's equity method holding as of May 31, 2022 and determined that the Company's proportionate economic interest in the entity indicates that the equity holding was not impaired. There were no observable price changes in orderly transactions for identical or a similar holding or security of the Company&#8217;s Cost Method Holding during the year ended May 31, 2022.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">SHARE-BASED COMPENSATION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company follows the guidance of ASC 718, Share-based Compensation (&#8220;ASC 718&#8221;), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes options-pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the foreseeable future. Expected volatilities are based on weighted averages of the historical volatility of the Company&#8217;s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the &#8220;simplified method&#8221; which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited exercise activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. The grant date fair value of the award is recognized under the straight-line attribution method.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company expensed approximately $1,260,000 and $1,355,000 of stock-based compensation during the years ended May 31, 2022 and 2021, respectively.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">In applying the Black-Scholes options-pricing model, assumptions used were as follows: &#160;</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733">

<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td colspan="4" style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">For the year ended May 31,</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2022</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2021</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Dividend yield</span></p>
</td>
<td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">0%</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">0%</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Expected volatility</span></p>
</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">102.54 - 105.48% </span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">&#160;71.19 - 107.53% </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Risk free interest rate</span></p>
</td>
<td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">&#160;0.97-2.75% </span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">&#160;0.34-1.18% </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Expected term</span></p>
</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">&#160;5.50-6.25 Years </span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">&#160;5.50-6.25 Years </span></p>
</td>
</tr>

</table><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">REVENUE RECOGNITION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company has various contracts with customers.&#160; All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred, and at which point title passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company regularly evaluates the status of these contracts and does not believe that any additional discounts will be given through the end of the contract periods. </span><span style="FONT-SIZE:10pt">Services for contract work are invoiced and recognized for work that has been performed as the project progresses. <span style="COLOR:black">The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools, and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors. &#160;Physicians&#8217; office products are sold to physicians and distributors, all of whom are categorized below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international manufacturers. </span></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Disaggregation of revenue:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The following is an approximate breakdown of revenues according to primary markets to which the products are sold:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733">

<tr style="height: 15pt;">
<td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="5" style="border-top: 0px; height: 15pt; border-right: 0px; width: 165pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">For the year ended May 31,</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 77pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2022</span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 77pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2021</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 374pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Physician's office</span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">14,259,000 </span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">2,801,000 </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Clinical lab</span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">3,064,000 </span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">3,077,000 </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 374pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Over-the-counter</span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">1,089,000 </span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">766,000 </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Contract manufacturing</span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">459,000 </span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">555,000 </span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 374pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Total</span></strong></p>
</td>
<td style="height: 15.75pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 66pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">18,871,000 </span></strong></p>
</td>
<td style="height: 15.75pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 66pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">7,199,000 </span></strong></p>
</td>
</tr>

</table><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">See Note 8 for additional information regarding geographic revenue concentrations.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">SHIPPING AND HANDLING FEES </span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company includes shipping and handling fees billed to customers in net sales. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">RESEARCH AND DEVELOPMENT</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Research and development costs are expensed as incurred. The Company expensed approximately $1,812,000 and $2,194,000 of research and development costs during the years ended May 31, 2022 and 2021, respectively.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">INCOME TAXES</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company accounts for income taxes in accordance with ASC 740, Income Taxes (&#8220;ASC 740&#8221;). Deferred tax assets and liabilities arise from temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements that will result in taxable or deductible amounts in future years and the benefits of net operating loss and tax credit carryforwards. These temporary differences and the benefits of net operating loss and tax credit carryforwards are measured using enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets to the extent that management considers it is more likely than not that a deferred tax asset will not be realized. In determining the valuation allowance, the Company considers factors such as the reversal of deferred income tax assets, projected taxable income, and the character of income tax assets and tax planning strategies. A change to these factors could impact the estimated valuation allowance and income tax expense. On May 31, 2022 and 2021, in accordance with ASC 740, the Company has a valuation allowance for substantially all of its net deferred tax assets.&#160;&#160; During the fiscal year ended May 31, 2022, <span style="BACKGROUND:none">this valuation allowance was increased to $6,967,000, which fully covers the net tax asset of $6,967,000</span></span><span style="FONT-SIZE:9pt; BACKGROUND:none; COLOR:black">.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company accounts for its uncertain tax provisions by using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, based solely on the technical merits, that the position will be sustained in an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the appropriate amount of the benefit to recognize. The amount of benefit to recognize is measured as the maximum amount which is more likely than not to be realized. The tax position is derecognized when it is no longer more likely than not capable of being sustained. On subsequent recognition and measurement, the maximum amount which is more likely than not to be recognized at each reporting date will represent the Company&#8217;s best estimate, given the information available at the reporting date, although the outcome of the tax position is not absolute or final. The Company elected to follow an accounting policy to classify accrued interest related to liabilities for income taxes within the &#8220;Interest expense&#8221; line and penalties related to liabilities for income taxes within the &#8220;Other expense&#8221; line of the consolidated statements of operations and comprehensive loss. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ADVERTISING COSTS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company reports the cost of all advertising as expense in the period in which those costs are incurred. Advertising costs were approximately <span style="BACKGROUND:white">$76,000</span> and $<span style="BACKGROUND:white">10,000</span> for the years ended May 31, 2022 and 2021, respectively. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">FOREIGN CURRENCY TRANSLATION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the year, and revenues and costs are translated using average exchange rates for the year. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no foreign currency transactions that are included in the consolidated statements of operations for the years ended May 31, 2022 and 2021.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">RIGHT-OF-USE ASSETS AND LEASE LIABILITY</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued an accounting standard update which requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset.&#160; Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.&#160; Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term.&#160; Leases are classified as financing or operating which will drive the expense recognition pattern.&#160; The Company has elected to exclude short-term leases.&#160; The Company adopted this guidance as of June 1, 2019, the required effective date, &#160;which resulted in a right-of-use asset being recorded of approximately $1,943,000 and a lease liability being recorded of approximately $1,981,000. On April 9, 2021, the Company exercised its second option to extend its lease for an additional five years.&#160; As part of that lease extension agreement, the Company was granted an additional right to extend its lease for five years, up through August 2031. However, given the recent growth in the Company&#8217;s operations, and the expectation that operations will continue to grow in the near future, the Company believes that it will be necessary to relocate into larger facilities by the end of the current lease term. Therefore, the Company has elected to not include the additional five-year extension option, from August 2026 to August 2031, into its right-of-use asset or its lease liability accounts. For additional information, see Note 9-Commitments and Contingencies. The Company leases office space and copy machines, all of which are operating leases.&#160; Most leases include the option to renew and the exercise of the renewal options is at the Company&#8217;s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.&#160; The leases do not include the options to purchase the leased property.&#160; The depreciable life of assets and leasehold improvements are limited by the expected lease term.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">NET LOSS PER SHARE </span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amounts of anti-dilutive stock options not included in the loss per share calculation for the years ended May 31, 2022 and 2021 were 2,321,616 and 2,081,366, respectively. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">SEGMENT REPORTING</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">ASC 280, Segment Reporting (&#8220;ASC 280&#8221;), establishes standards for reporting, by public business enterprises, information about operating segments, products and services, geographic areas, and major customers. The Company&#8217;s operations are analyzed by management and its chief operating decision maker as being part of a single industry segment: the design, development, marketing, and sales of diagnostic kits.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">REPORTING COMPREHENSIVE LOSS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Comprehensive loss represents net loss and any revenues, expenses, gains and losses that, under GAAP, are excluded from net loss and recognized directly as a component of shareholders&#8217; equity. Items of other comprehensive loss consist solely of foreign currency translation adjustments for the years ended May 31, 2022 and 2021. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">RECENT ACCOUNTING PRONOUNCEMENTS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">Recent ASU's issued by the FASB and guidance issued by the SEC did not, or are not believed by management to, have a material effect on the Company&#8217;s present or future consolidated financial statements. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in">&#160;</p><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in 0.1in 0in 0in;"><span style="font-size: 10pt; color: black;">In June 2016, the FASB issued ASU 2016-13, "Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments." This ASU will require the measurement of all expected credit losses for financial assets, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The guidance was initially effective for the Company for annual reporting periods beginning after December 15, 2019, and interim periods within those fiscal years. In November 2019, the FASB issued ASU 201&#183;9- 10, "Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates," which, among other things, defers the effective date of ASU 2016-13 for public filers that are considered smaller reporting companies as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including interim periods within those years. Early adoption is permitted. The Company is currently reviewing the requirements of this ASU to determine its impact on the Company&#8217;s consolidated results of operations and financial position. </span></p><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in 0.1in 0in 0in;">&#160;</p><p style="margin: 0in; text-align: justify;"><span style="font-family: times new roman, times, serif; font-size: 10pt;"><strong><span style="color: black;">RECLASSIFICATIONS</span></strong></span></p><p style="margin: 0in; text-align: justify;"><span style="font-family: times new roman, times, serif; font-size: 10pt;"><strong><span style="color: black;">&#160;</span></strong></span></p><p style="margin: 0in; text-align: justify;"><span style="font-size: 10.0pt; color: black;"><span style="font-family: times new roman, times, serif;">Certain comparative figures in the 2021 Statement of Operations have been reclassified to conform to the current year&#8217;s presentation.</span> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143089388112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">NOTE 3: &#160;&#160;&#160;PROPERTY AND EQUIPMENT, NET</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The following is an approximate breakdown of property and equipment, net of accumulated depreciation:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; BACKGROUND:white; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:165pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">May 31,</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:77pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2022</span></p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:77pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2021</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Equipment</span></p></td> <td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:66pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,292,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:66pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,850,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Furniture, fixtures and leasehold improvements</span></p></td> <td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:66pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">227,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:66pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">433,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Less accumulated depreciation</span></p></td> <td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(1,305,000)</span></p></td> <td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(1,972,000)</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:374pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Net property and equipment</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">214,000</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">311,000</span></b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143092783552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets Disclosure [Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">NOTE 4: &#160;&#160;&#160;INTANGIBLE ASSETS, NET</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The following is an approximate breakdown of intangible assets, net of accumulated amortization:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; BACKGROUND:white; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:26%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 26%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black"> May 31,</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2022</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2021</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Licenses</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-18; FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-&#160;&#160; </span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">182,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Patents</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">189,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">240,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Less accumulated amortization-licenses</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-19; FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(107,000)</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Less accumulated amortization-patents</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(19,000)</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(20,000)</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Intangible asssets, net</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">170,000</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">295,000</span></b></p></td></tr></table><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Expected amortization of intangible assets for the years ending May 31:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">2023</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">13,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">2024</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">13,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">2025</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">13,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">2026</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">13,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">2027</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">13,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Thereafter</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">105,000</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Total</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">170,000</span></b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143086330960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">NOTE 5:&#160;&#160;&#160; ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The following is an approximate breakdown of accounts payable and accrued expenses balances:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p><table cellpadding="0" cellspacing="0" style="WIDTH:555.6pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="741"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:169pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">May 31,</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:78.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2022</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:78.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2021</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Accounts payable</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">736,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">431,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Accrued expenses</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">236,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">152,000</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Total</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">972,000</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">583,000</span></b></p></td></tr></table><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">As of May 31, 2022 and 2021 the Company had two vendors and one vendor, respectively, which accounted for 69% and 17%, respectively, of accounts payable.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143178391376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">NOTE 6: &#160;&#160;&#160;SHAREHOLDERS' EQUITY</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">STOCK OPTION AND RESTRICTED STOCK PLANS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">In December 2014, the Company adopted a stock option and restricted stock plan (the "2014 Plan") which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of 850,000 shares of the Company's unissued common stock may be granted to affiliates, employees, or consultants of the Company. This plan was approved by shareholders in December 2014. &#160;The 2014 Plan expires in December 2024. Options granted under the 2014 Plan will be granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">In December 2017, the Company adopted a stock option and restricted stock plan (the &#8220;2017 Plan&#8221;) which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of 900,000 shares of the Company&#8217;s unissued common stock may be granted to affiliates, employees, or consultants of the Company.&#160; This plan was approved by shareholders in December 2017.&#160; The 2017 Plan expires in December 2027.&#160; Options granted under the 2017 Plan will be granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">In February 2020, the Board approved the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;) and on December 11, 2020, the shareholders of the Company approved The Plan. The 2020 Plan authorizes the issuance of an aggregate number of common stock options and/or restricted common shares to be issued in an amount not to exceed 900,000. &#160;The 2020 Plan authorizes the issuance of common stock options and restricted common shares to employees, directors, and consultants of the Company. During fiscal 2020, certain common stock options were granted under this plan. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Stock option expense during fiscal 2022 was approximately $1,260,000. This included, by department, $954,000 for administrative, $159,000 for production, $80,000 for research and development and $67,000 for sales and marketing.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Stock option expense during fiscal 2021 was approximately $1,355,000. This included, by department, $957,000 for administrative, $205,000 for production, $125,000 for research and development and $68,000 for sales and marketing</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Activity as to aggregate stock options outstanding is as follows: </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </p><table cellpadding="0" cellspacing="0" style="width: 550.7pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="734">

<tr style="height: 15pt;">
<td style="height: 15pt; width: 300.25pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 67.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">NUMBER OF <br/>STOCK OPTIONS</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.6pt; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66.05pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">EXCERCISE <br/>PRICE RANGE <br/>PER SHARE</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.6pt; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 79.4pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">WEIGHTED <br/>AVERAGE <br/>EXERCISE PRICE</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 300.25pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Options outstanding at May 31, 2020</span></strong></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">1,789,251</span></strong></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 66.05pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$0.82-$8.18</span></strong></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$</span></strong></p>
</td>
<td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">2.75</span></strong></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 300.25pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Options granted</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 67.2pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">430,616</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 66.05pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">$5.14-$8.70</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12.2pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 67.2pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">6.73</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 300.25pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Options excercised</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(86,750)</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 66.05pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">$0.82-$3.62</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">1.20</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 300.25pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Options canceled or expired</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 67.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(51,751)</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66.05pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">$2.35-$8.18</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 67.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">4.77</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 300.25pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Options outstanding at May 31, 2021</span></strong></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-bottom: windowtext 1pt solid; height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">2,081,366</span></strong></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-bottom: windowtext 1pt solid; height: 15pt; width: 66.05pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$0.82-$8.70</span></strong></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$</span></strong></p>
</td>
<td style="border-bottom: windowtext 1pt solid; height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">3.59</span></strong></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 300.25pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Options granted</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 67.2pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">344,000</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 66.05pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">$4.25-$4.46</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12.2pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 67.2pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">4.43</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 300.25pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Options excercised</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(39,500)</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 66.05pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">$1.20-$3.62</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">1.99</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 300.25pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Options canceled or expired</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 67.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(64,250)</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66.05pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">$1.61-$8.18</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 67.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">4.41</span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 300.25pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Options outstanding at May 31, 2022</span></strong></p>
</td>
<td style="height: 15.75pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 67.2pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">2,321,616</span></strong></p>
</td>
<td style="height: 15.75pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 66.05pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$0.82-$8.70</span></strong></p>
</td>
<td style="height: 15.75pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12.2pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 67.2pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">3.72</span></strong></p>
</td>
</tr>

</table><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The weighted average fair value of options granted during 2022 and 2021 were $4.43 and $6.73, respectively. The aggregate intrinsic value of options exercised during 2022 and 2021 was approximately $90,000 and $501,000, respectively. The aggregate intrinsic value of options outstanding on May 31, 2022 and 2021 was approximately $1,838,000 and $2,132,000, respectively. The aggregate intrinsic value of options vested and exercisable on May 31, 2022 and 2021 was approximately $1,731,000 and $1,872,000, respectively.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt">The number of non-vested stock options included in the table above is as follows:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;&#160; </p><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:54.75pt"> <td style="HEIGHT:54.75pt; WIDTH:2.4in; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:54.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:54.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Number of<br/>&#160;shares</span></p></td> <td style="HEIGHT:54.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:54.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Stock options<br/>weighted<br/>average grant<br/>date fair value</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:2.4in; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Non-vested shares at May 31, 2021</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">793,241</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">5.54</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:2.4in; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Granted</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">344,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">4.43</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:2.4in; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Vested&#160;</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(347,279)</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">5.40</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:2.4in; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Forfeited</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(43,500)</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">5.22</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:2.4in; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Non-vested shares at May 31, 2022</span></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">746,462</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">5.11</span></b></p></td></tr></table><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">On May 31, 2022, total compensation cost related to non-vested stock option awards not yet recognized totaled approximately $1,982,000. The weighted-average period over which this amount is expected to be recognized is 2.32 years. The weighted average remaining contractual term of options that were exercisable on May 31, 2022, was 5.47 years.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The following summarizes information about all the Company's stock options outstanding on May 31, 2022. These options are comprised of those granted under the 2014, 2017 and 2020 plans.</span> </p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p><table cellpadding="0" cellspacing="0" style="WIDTH:550.1pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">RANGE OF<br/>EXERCISE PRICES</span></p></td> <td style="HEIGHT:15pt; WIDTH:1%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">NUMBER<br/>OUTSTANDING<br/>MAY 31, 2022</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">WEIGHTED<br/>AVERAGE<br/>REMAINING<br/>CONTRACTUAL<br/>LIFE IN YEARS</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">WEIGHTED<br/>&#160;AVERAGE<br/>EXERCISE PRICE</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">NUMBER<br/>EXCERCISABLE<br/>AT MAY 31, 2022</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">WEIGHTED<br/>AVERAGE<br/>EXERCISE PRICE</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$0.82-$1.52</span></p></td> <td style="HEIGHT:15pt; WIDTH:1%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">456,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">3.33</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$1.04</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">456,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$1.04</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$2.25-$4.25</span></p></td> <td style="HEIGHT:15pt; WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">1,015,750</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">6.14</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$2.90</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">852,500</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$2.88</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$4.34-$8.70</span></p></td> <td style="HEIGHT:15pt; WIDTH:1%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">849,866</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">8.75</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$6.13</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">266,654</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$7.06</span></p></td></tr></table><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">COMMON STOCK ACTIVITY</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">On January 22, 2021, the Company filed a Prospectus Supplement, for purposes of raising up to $15,000,000 to the base prospectus filed with the SEC on July 21, 2020, and declared effective by the SEC on September 30, and an ATM Agreement. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black">On May 21, 2021, in conjunction with the Company&#8217;s 2020 Stock Incentive Plan, that was approved by shareholders at the Company&#8217;s annual meeting in December 2020, the Company filed an S-8 Registration Statement to register up to 900,000 shares of the Company&#8217;s common stock that could be issued under this Plan.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Under ATM Agreements, sales of the Placement Shares are deemed to be &#8220;at the market offering&#8221; as defined in Rule 415 promulgated under the Securities Act.&#160; The agent acts as sales agent under the ATM and uses commercially reasonable efforts to sell on the Company&#8217;s behalf all of the Placement Shares requested to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the agent and the Company. The Company has no obligation to sell any of the Placement Shares under the ATM Agreement, and may at any time suspend offers under, or terminate the ATM Agreement.&#160; </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"><span style="FONT-SIZE:10pt">During the year ended May 31, 2022, the Company sold 521,267 shares of its common stock at prices ranging from $4.02 to $5.63 under its Form S-3 Registration Statement </span><span style="FONT-SIZE:10pt">(</span><span style="FONT-SIZE:10pt; COLOR:black">File No. 333-239980) </span><span style="FONT-SIZE:10pt">and ATM Agreement which resulted in gross proceeds of approximately $2,402,000 and net proceeds to the Company of $2,317,000 after deducting commissions for each sale and legal, accounting, and other fees related to the filing of the Form S-3.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"><span style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black">During the year ended May 31, 2021, the Company sold 158,889 shares of its common stock at prices ranging from $7.06 to $7.79 under its Form S-3 Registration Statement&#160;(File No. 333-239980)&#160;and ATM Agreement which resulted in gross proceeds of approximately $1,177,000 and net proceeds to the Company of $1,011,000 after deducting commissions for each sale and legal, accounting, and other fees related to the filing of the Form S-3.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">During the year ended May 31, 2022, options to purchase 39,500 shares of common stock were exercised at prices ranging from $1.20 to $3.62.&#160; Total net proceeds to the Company were approximately $77,000.</span></p><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">&#160;</span></p><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">During the year ended May 31, 2021, 321,429 shares of common stock were converted from Preferred Stock as described below in &#8220;Preferred Stock Activity&#8221;.</span></p><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">&#160;</span></p><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><strong><span style="font-size: 10pt;">PREFERRED STOCK ACTIVITY</span></strong></p><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">&#160;</span></p><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">On February 24, 2020, the Company entered into and closed on a Stock Purchase Agreement (the &#8220;Stock Purchase Agreement&#8221;) with Palm Global Small Cap Master Fund LP (&#8220;Palm&#8221;) pursuant to which the Company agreed to sell and issue to Palm, and Palm agreed to purchase from the Company, 571,429 shares of the Company&#8217;s Series A 5% Convertible Preferred Stock, $0.08 par value per share for a purchase price of approximately $2 million, or $3.50 per Series A Convertible Preferred Stock. Under the terms of the Stock Purchase Agreement, each share of issued Convertible Preferred Stock can be converted at any time by Palm into one share of the Company&#8217;s common stock, subject to certain adjustments.</span></p><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">&#160;</span></p><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">The Series A 5% Convertible Preferred Stock accrued annual preferred dividends at a rate of $0.175 per Series A 5% Convertible Preferred Share. However, accruing dividends were payable only when, as, and if declared by the Board and the Company had no obligation to pay such accruing dividends.</span></p><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">&#160;</span></p><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">On March 24, 2020, Palm converted 250,000 shares of Convertible Preferred Stock into 250,000 shares of unregistered common stock. On July 21, 2020, the Company filed with the SEC a registration statement on Form S-3, that among other things, registered 571,429 common shares issued, or to be issued, to Palm upon conversion of the Convertible Preferred Stock into common shares. On September 30, 2020, the Company received a Notice of Effectiveness from the Securities and Exchange Commission for registration of these shares. On January 21, 2021, Palm Converted their remaining 321,429 Convertible Preferred Shares into registered common shares. On May 30, 2021, the Company had no shares of Preferred Stock outstanding. Under the terms of the Preferred Stock Purchase Agreement, none of the cumulative Dividends were paid to Palm during the period they owned the Preferred Stock. Once converted to common shares, Palm lost all rights to receive any past cumulative dividends.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143091716336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; BACKGROUND:none; COLOR:black">NOTE 7: &#160;&#160;&#160;INCOME TAXES</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Provision for income taxes for the years ended May 31 consists of the following:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:169pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">&#160;For the year ended May 31,</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:78.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">2022</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:78.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">2021</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Current:</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">U.S. Federal</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-20; FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">&#160;-</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-21; FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">&#160;-</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Foreign Taxes Subsidiaries</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">(23,000)</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">(12,000)</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">State and local</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">(1,000)</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">(1,000)</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Total current</span></b></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">(24,000)</span></b></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">(13,000)</span></b></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Deferred:</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">U.S. Federal&#160;</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-22; FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">&#160;-</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-23; FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">&#160;-</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">State and local</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-24; FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">&#160;-</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-25; FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">&#160;-</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Total deferred</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-26; FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">&#160;-</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-27; FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">&#160;-</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Income tax expense</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">&#160;<span style="COLOR:black">$</span></span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">(24,000)</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">(13,000)</span></b></p></td></tr></table><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Provision for income taxes differs from the amounts computed by applying the U.S. Federal income tax rate applicable for each year (<span style="BACKGROUND:none">21%</span> for 2022 and 2021) to pretax income as a result of the following:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733">

<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td colspan="5" style="border-top: 0px; height: 15pt; border-right: 0px; width: 30%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">For the year ended May 31,</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 14%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">2022</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 14%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">2021</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Computed "expected" tax benefit</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">947,000</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">1,561,000</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Increase (reduction) in income taxes resulting from:</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Change in valuation allowance</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(1,022,000)</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(2,292,000)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">State income taxes, net of federal benefit</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">300,000</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="top">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">217,000</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Research and development tax credits</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">50,000</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="top">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">456,000</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Permanent tax differences and other</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">(217,000)</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">(88,000)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Stock based compensation&#160;benefit</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; text-align: right; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in; text-align: right;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">11,000</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; text-align: right; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="top">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">145,000</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Foreign taxes of subsidiaries</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">(113,000)</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(12,000)</span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Income tax expense</span></strong></p>
</td>
<td style="height: 15.75pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(24,000)</span></p>
</td>
<td style="height: 15.75pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(13,000)</span></p>
</td>
</tr>

</table><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The tax effect of significant temporary differences&#160;is presented below:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p><table cellpadding="0" cellspacing="0" style="WIDTH:550.1pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:30%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 30%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">May 31,</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">2022</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">2021</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Deferred tax assets:</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Accounts receivable, principally due to allowance for doubtful accounts</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">43,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">200,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Inventory valuation&#160;&#160;&#160;</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">237,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">387,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Compensated absences</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">120,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">85,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Net operating loss carryforwards&#160;&#160;&#160;</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">4,349,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">3,194,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Tax credit carryforwards</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">1,096,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">1,055,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Deferred rent expense/Capitalized leases</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">20,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">15,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Stock Options</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">1,035,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">613,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Losses of foreign subsidiaries &amp; Other, net</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">41,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">370,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Accumulated depreciation and amortization</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">26,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">(15,000)</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Total deferred tax assets&#160;&#160;&#160;</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">6,967,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">5,904,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Less valuation allowance</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">(6,967,000)</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">(5,904,000)</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Net deferred tax asset</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-28; FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">&#160;-</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-29; FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">&#160;-</span></b></p></td></tr></table><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">The Company has provided a valuation allowance of approximately <span style="background: none;">$6,967,000</span> and $5,904,000 as of May 31, 2022 and 2021, respectively. The net change in the valuation allowance for the years ended May 31, 2022 and 2021, was an increase of <span style="background: none;">$1,063,000</span> and $2,292,000, respectively.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">On May 31, 2022, the Company has Federal income tax net operating loss carryforwards of approximately <span style="BACKGROUND:none">$17,116,000</span>. &#160;On May 31, 2022, the Company has California state income tax net operating loss carryforwards of approximately <span style="BACKGROUND:none">$10,805,000</span>. For tax reporting purposes, operating loss carryforwards are available to offset future taxable income; such carryforwards expire in varying amounts beginning in <span style="BACKGROUND:none">2023 and 2037</span> for federal and state purposes, respectively.&#160; Federal net operating losses beginning in <span style="BACKGROUND:none">2018</span> have no expiration date. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">On May 31, 2022, the Company has Federal research and development tax credit carryforward of approximately <span style="BACKGROUND:none">$784,000</span>. &#160;The Federal credits begin to expire in <span style="BACKGROUND:none">2027</span>. &#160;The Company also had similar credit carryforwards for state purposes <span style="BACKGROUND:none">of $395,000</span> on May 31, 2022, which don&#8217;t expire.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Pursuant to Internal Revenue Code (&#8220;IRC&#8221;) Sections 382 and 383, annual use of the Company's net operating loss ("NOL") and credit carryforwards may be limited by statute because of a cumulative change in ownership of more than 50%. Pursuant to Sections 382 and 383 of the IRC, the annual use of the Company's NOLs and credit carryforwards would be limited if there is a cumulative change of ownership (as that term is defined in Section 382(g) of the IRC of greater than 50% in a three-year period. Management has not performed an analysis to determine if the Company has had a cumulative change in ownership of greater than 50%.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">For the year ended May 31, 2022, the Company did an analysis of its <span style="BACKGROUND:none">ASC 740 position and has not identified any uncertain tax positions as defined under ASC 740</span>. Should such position be identified in the future, and should the Company owe interest and penalties as a result of this, these would be recognized as interest expense and other expense, respectively, in the consolidated financial statements. The Company is no longer subject to any significant U.S. federal tax examinations by tax authorities for years before fiscal <span style="BACKGROUND:none">2018</span>.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143091716336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_GeographicInformationDisclosureAbstract', window );"><strong>Geographic Information Disclosure Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_GeographicInformationDisclosureTextBlock', window );">Geographic Information Disclosure [Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">NOTE 8: &#160;&#160;&#160;GEOGRAPHIC INFORMATION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company operates as one segment. Geographic information regarding net sales is approximately as follows: </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 557.3pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="743">

<tr style="height: 15pt;">
<td style="height: 15pt; width: 286.9pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="7" style="border-top: 0px; height: 15pt; border-right: 0px; width: 258.6pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">For the year ended May 31,</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 286.9pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="3" style="border-top: 0px; height: 15pt; border-right: 0px; width: 123.4pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2022</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="3" style="border-top: 0px; height: 15pt; border-right: 0px; width: 123.4pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2021</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 286.9pt; background: #b8cce4; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Asia</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">13,375,000</span></p>
</td>
<td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">71%</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">1,908,000</span></p>
</td>
<td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">26%</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 286.9pt; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Europe</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">4,339,000</span></p>
</td>
<td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">23%</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">4,301,000</span></p>
</td>
<td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">60%</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 286.9pt; background: #b8cce4; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">North America</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">997,000</span></p>
</td>
<td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">5%</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">548,000</span></p>
</td>
<td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">8%</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 286.9pt; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">South America</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">90,000</span></p>
</td>
<td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">1%</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">250,000</span></p>
</td>
<td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">3%</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 286.9pt; background: #b8cce4; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Middle East</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 55.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">70,000</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 55.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">0%</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 55.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">192,000</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 55.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">3%</span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 286.9pt; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Total</span></strong></p>
</td>
<td style="height: 15.75pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 55.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">18,871,000</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 55.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">100%</span></strong></p>
</td>
<td style="height: 15.75pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 55.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">7,199,000</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 55.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">100%</span></strong></p>
</td>
</tr>

</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_GeographicInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_GeographicInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_GeographicInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments according to the geographic areas.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_GeographicInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143091716336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">NOTE 9: &#160;&#160;&#160;COMMITMENTS AND CONTINGENCIES</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">OPERATING LEASES</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0in"><span style="FONT-SIZE:10pt">The Company leases its facilities. On May 31, 2022, the Company had approximately 22,000 square feet of floor space at its corporate headquarters at 17571 Von Karman Avenue in Irvine, California, which it has been leasing since 2009. The lease for its headquarters expired on August 31, 2016. &#160;The Company had an option to extend the term of its lease for two additional sixty-month periods. On November 30, 2015, the Company exercised its option to extend its lease for an additional sixty-month period and entered into the First Amendment to Lease wherein it extended its lease until August 31, 2021. On April 9, 2021, the Company exercised its second option to extend its lease for an additional five years.&#160; When the Company extended its lease in April 2021, it was also granted an additional five-year lease extension option. The current rent is approximately $25,000 per month and will increase on September 1, 2022, to $26,000 per month.&#160; The security deposit is approximately $22,000.<span style="COLOR:black">&#160;</span> </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0in"><span style="FONT-SIZE:10pt">In November 2016, the Company&#8217;s Mexican subsidiary, Biomerica de Mexico, entered into a 10-year lease for approximately 8,100 square feet of manufacturing space. The Company has one 10-year option to renew at the end of the initial lease period. The current rent is approximately $3,400 per month.&#160; Biomerica de Mexico also leases a smaller unit on a month-to-month basis for use in one manufacturing process. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">In addition, the Company leases a small office in Lindau, Germany on a month-to-month basis, as headquarters for BioEurope GmbH, its Germany subsidiary.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total gross rent expense in the United States for fiscal 2022 was approximately $310,000, and for fiscal 2021 was $295,000.&#160; Rent expense for the Mexico facility for fiscal 2022 and 2021 was approximately $42,000 and $25,000, respectively. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.9pt 0in 0in"><span style="FONT-SIZE:10pt">For purposes of determining straight-line rent expense, the lease term is calculated from the date the Company first takes possession of the facility, including any periods of free rent and any renewal options periods that the Company is reasonably certain of exercising. The Company&#8217;s office and equipment leases generally have contractually specified minimum rent and annual rent increases are included in the measurement of the right-of-use asset and related lease liability.&#160; Additionally, under these lease arrangements, the Company may be required to pay directly, or reimburse the lessors, for some maintenance and operating costs. Such amounts are generally variable and therefore not included in the measurement of the right-of-use asset and related lease liability but are instead recognized as variable lease expense in the Consolidated Statements of Operations and Comprehensive Loss when they are incurred.&#160; </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 13.55pt 0in 0in">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0in;"><span style="font-family: 'Times New Roman',serif;">Supplemental cash flow information related to leases for the year ended May 31, 2022: </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p><table cellpadding="0" cellspacing="0" style="WIDTH:550.1pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:467.1pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Operating cash flows from operating leases&#160;&#160;&#160;&#160;&#160;</span></p></td> <td style="HEIGHT:15pt; WIDTH:15.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:67.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">338,206</span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:467.1pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Right-of-use assets obtained in exchange for<br/>&#160;&#160;&#160; &#160;new operating lease liabilities</span></p></td> <td style="HEIGHT:0.2in; WIDTH:15.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:0.2in; WIDTH:67.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-30; FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">&#160;-</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:467.1pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Weighted average remaining lease term (in years)</span></p></td> <td style="HEIGHT:15pt; WIDTH:15.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:67.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">4.28</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:467.1pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Weighted average discount rate</span></p></td> <td style="HEIGHT:15pt; WIDTH:15.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:67.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">6.50%</span></p></td></tr></table><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">Future minimum lease payments under operating leases on May 31, 2022, are as follows:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733">

<tr style="height: 15pt;">
<td style="height: 15pt; width: 462pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Less than 1 year</span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">351,000</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 462pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">1 to 2 years</span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">362,000</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 462pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">2 to 3 years</span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">373,000</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 462pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">3 to 4 years</span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">384,000</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 462pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">4 to 5 years</span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">104,000</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 462pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Total undiscounted lease payments</span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">1,574,000</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 462pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Less imputed interest</span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">194,000</span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 462pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Total operating lease liabilities</span></p>
</td>
<td style="height: 15.75pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 66pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">1,380,000</span></strong></p>
</td>
</tr>

</table><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">According to the terms of the lease in Irvine, the Company is also responsible for routine repairs of the building and for certain increases in property tax. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company also has various insignificant leases for office equipment.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">RETIREMENT SAVINGS PLAN</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Effective September 1, 1986, the Company established a 401(k) plan for the benefit of its employees. The plan permits eligible employees to contribute to the plan up to the maximum percentage of total annual compensation allowable under the limits of IRC Sections 415, 401(k) and 404. The Company, at the discretion of its Board of Directors, may make contributions to the plan in amounts determined by the Board each year. No contributions by the Company have been made since the plan's inception.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">LITIGATION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company is, from time to time, involved in legal proceedings, claims and litigation arising in the ordinary course of business. While the amounts claimed may be substantial, the ultimate liability cannot presently be determined because of considerable uncertainties that exist. Therefore, it is possible the outcome of such legal proceedings, claims and litigation could have a material effect on quarterly or annual operating results or cash flows when resolved in a future period. However, based on facts currently available, management believes such matters will not have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">There were no legal proceedings pending as of May 31, 2022.</span>&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">CONTRACTS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt">Contracts and Licensing Agreements</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company has one royalty agreement in which it has obtained rights to manufacture and market certain products for the life of the products. Royalty expense of approximately $19,000 and $11,000 is included in cost of sales for the agreement for each of the years ended May 31, 2022 and 2021, respectively. Sales of products manufactured under these agreements comprise approximately 1.5% and 1.5% of total sales for the years ended May 31, 2022 and 2021, respectively. The Company may license other products or technology in the future as it deems necessary for conducting business.&#160; The Company has other royalty agreements however they are not considered material.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">On May 25, 2016, the Company entered into an Exclusive Marketing License Agreement (&#8220;Telcon Agreement&#8221;) with Celtis Pharm Co., Ltd., who subsequently changed their name to Telcon Pharmaceutical Co., LTD (&#8220;Telcon&#8221;), a medical company in South Korea. The Telcon Agreement grants to Telcon an exclusive license to market and sell Biomerica&#8217;s new InFoods&#174; IBS products (&#8220;IBS Products&#8221;) in South Korea. The term of the agreement is for a period of five years following Korean FDA clearance of the product and provides an additional two years for Telcon to attain such Korean FDA clearance. The sequential two-year and five-year terms do not begin until after Biomerica first receives final clearance for sale of the IBS Products in the United States from the FDA. Telcon, at its sole cost and expense, must use its commercially reasonable good faith efforts to obtain Korean FDA for the IBS Product to be sold in South Korea. The agreement may be cancelled if Biomerica has not obtained final USFDA clearance for sale of the IBS Products on or before December 31, 2019. The required FDA approval was not obtained by December 31, 2019, however, neither party has terminated the agreement. Once the IBS Product is cleared by the United States FDA, Biomerica is also obligated to maintain a full quality assurance system for the IBS Products following the harmonized standards according to Annex IV of Directive 98/79/EC.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">The terms of the Telcon Agreement provide up to $1.25 million in future exclusivity fees to be possibly paid to Biomerica based on certain milestones including Biomerica&#8217;s starting clinical trials in the United States, receipt of U.S. FDA clearance and Telcon&#8217;s first sales of IBS Products in Korea. If Biomerica commences FDA Trials and Telcon pays the initial $250,000 milestone-based exclusivity fees, and the Agreement is subsequently terminated by either party for lack of performance, then Biomerica shall issue to Telcon 83,333 shares of Biomerica common stock in consideration for the $250,000 of paid exclusivity fee. No exclusivity fees have yet been paid.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">Additionally, the Telcon Agreement provides for&#160;a royalty of 15% paid to Biomerica on all sales in Korea of the IBS Product, and further sets the pricing of IBS Products sold to Telcon.&#160; In order to retain the exclusivity within South Korea, Telcon must meet certain annual minimum royalty payments to Biomerica following Telcon&#8217;s receipt of Korean FDA approval or clearance for the IBS Product to be sold in Korea, which in no case will be later than May 31, 2019.<b> </b>&#160;&#160;In September 2017, an agreement to extend this date was signed extending the date until April 30, 2020. &#160;During the quarter ended August 31, 2020, a second amendment was signed extending the required FDA approval date to December 31, 2021. The required FDA approval date hasn&#8217;t been delivered however, neither party has terminated the agreement.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">On April 1, 2020, the Company entered into two separate non-exclusive license agreements (the &#8220;Mount Sinai License Agreements&#8221;) with the Mount Sinai Icahn School of Medicine in New York (&#8220;Mount Sinai&#8221;) to license technology from Mount Sinai that the Company intends to use to scale up and manufacture a laboratory version serological test for SARS-CoV-2 coronavirus.&#160; The non-exclusive Mount Sinai License Agreements provide for royalty payments to Mount Sinai based on a percentage of gross sales of commercial products manufactured and sold by Biomerica that incorporate the Mount Sinai technology licensed under the Mount Sinai License Agreement. On June 20, 2020, the Company filed for Emergency Use Authorization (&#8220;EUA&#8221;) with the FDA for the sale of a product developed by the Company that is based on this technology. The FDA has still not approved the Company&#8217;s Emergency Use Authorization for this product to be sold. As such, no royalty fees have been paid yet on these agreements. The Company is selling a COVID-19 rapid test outside of the United States, which is unrelated to the EUA product discussed above. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">On May 7, 2020, the Company entered into an exclusive license agreement (the &#8220;UC License Agreement&#8221;) with The Regents of the University of California (&#8220;UC&#8221;) to license all patent rights pertaining to certain licensed technology from UC. This technology is being developed at UC-San Diego by one of the professors and his team utilizing CRISPR technology. This group is developing a viral detection test for SARS-CoV-2 coronavirus.&#160;If this technology development is successful, the Company will work with the UC to transfer the technology to Biomerica where the CRISPR based product will need to be further developed, validated, and cleared with regulatory agencies for commercial sale into the market.&#160; The exclusive UC License Agreement provides for an initial and annual license fee, and a royalty payment on all commercial revenues, to the UC Regents. The UC License Agreement also includes certain investment requirements and milestones the Company will need to meet for the launch of a commercial product based on the licensed technology. The Company paid an initial license fee of $5,000 with the execution of the agreement. An additional $5,000 was paid in September 2020.&#160; No royalties have been paid yet on this agreement. A license maintenance fee of $10,000 is due annually. This is creditable against earned royalties due each year in the amount of five percent on net sales of licensed products.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0in 0in"><b><span style="FONT-SIZE:10pt">Clinical Trial Agreements</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">In September 2017, the Company signed a Clinical Samples Agreement with the University of Southern California for the purpose of providing clinical samples for use by the Company in conducting future clinical trials for one of the products which the Company is developing.&#160; The initial budget was estimated to be approximately $82,000. The work started in October 2017 with charges for work performed being invoiced and paid monthly. This study ended in February 2020. Approximately $17,000 in fees has been accrued for unbilled charges as of May 31, 2022.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">The Company entered into a Clinical Trial Agreement with a research institute for the purpose of conducting a clinical trial of the Biomerica InFoods&#174; product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be approximately $107,000. <span style="COLOR:black">This study ended in March 2022. Approximately $28,000 in fees has been accrued for unbilled charges as of May 31, 2022.</span></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143178391376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0in 0in"><b><span style="FONT-SIZE:10pt; COLOR:black">NOTE 10:&#160;&#160;&#160; SUBSEQUENT EVENTS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Subsequent to May 31, 2022, as of the filing of Form 10-K, the Company sold 523,977 shares of its common stock under its Form S-3 &#8220;shelf&#8221; Registration statement. The average sale price was $3.46 per share. Net proceeds to the Company were approximately $1,765,000.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">On July 14, 2022, the Company announced they had entered into a General Merchandise Supplier Agreement with Walmart, for the Company&#8217;s Aware<sup>&#174;</sup> Breast Self Exam product to be sold in Walmart&#8217;s retail system.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143083406880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">PRINCIPLES OF CONSOLIDATION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">The consolidated financial statements for the years ended May 31, 2022 and 2021, include the accounts of Biomerica, Inc. ("Biomerica") as well as its wholly-owned German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ACCOUNTING ESTIMATES</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates, which are calculated based on historical data; inventory obsolescence, which is based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, the likelihood of lease extensions to occur, asset valuation, among other things; and other items that may be necessary to estimate using current, historical and judgment based information. Actual results could materially differ from those estimates. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt;">Due to the Coronavirus global pandemic, the Company&#8217;s operations have been negatively impacted. <span style="color: black;">The Company has faced disruptions in the following areas, (and may face further challenges): supply chain disruptions, loss of contracts and/or customers, closure of the Company&#8217;s manufacturing or distribution facilities or of the facilities of the Company&#8217;s suppliers, partners and customers, travel, shipping and logistical disruptions, government responses of all types, international business risks in countries where the Company makes and/or sells its products, loss of human capital or personnel at the Company, its partners and its customers, interruptions of production, customer credit risk, and general economic calamities. These ongoing pandemic related disruptions can materially negatively impact the Company&#8217;s operations and financial performance and may continue to have significant material negative impacts on the Company.&#160;&#160; </span></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_LiquidityPolicyTextBlock', window );">Liquidity [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">LIQUIDITY</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company has incurred net losses and negative cash flows from operations and has an accumulated deficit of approximately $35.3 million as of May 31, 2022.&#160; Management expects to continue to incur significant costs as it advances its trials and development activities. As of May 31, 2022, the Company had cash and cash equivalents of approximately $5,917,000 and working capital of approximately $7,416,000.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">On January 22, 2021, the Company filed a Prospectus Supplement for purposes of raising up to $15,000,000 to the base prospectus filed with the SEC on July 21, 2020, and was declared effective by the SEC on September 30, 2020, and an ATM &#8220;at the market offering&#8221; Agreement. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">The Company intends to use the net proceeds from such offering for general corporate purposes, including, without limitation, sales and marketing activities, clinical studies, and product development, making acquisitions of assets, businesses, companies or securities, capital expenditures, and for working capital needs.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Under an ATM Agreement, sales of the Placement Shares are deemed to be &#8220;at the market offering&#8221; as defined in Rule 415 promulgated under the Securities Act.&#160; The agent acts as sales agent under the ATM and uses commercially reasonable efforts to sell on the Company&#8217;s behalf all the Placement Shares requested to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the agent and the Company. The Company has no obligation to sell any of the Placement Shares under the ATM Agreement, and may at any time suspend offers under, or terminate the ATM Agreement.&#160; </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"><span style="FONT-SIZE:10pt">During the year ended May 31, 2022, the Company sold 521,267 shares of its common stock at prices ranging from $4.02 to $5.63 under its Form S-3 Registration Statement (</span><span style="FONT-SIZE:10pt; COLOR:black">File No. 333-239980) </span><span style="FONT-SIZE:10pt">and ATM Agreement which resulted in gross proceeds of approximately $2,402,000 and net proceeds to the Company of $2,317,000 after deducting commissions for each sale and legal, accounting, and other fees related to the filing of the Form S-3.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"><span style="FONT-SIZE:10pt">As a result of cash and cash equivalents on hand on May 31, 2022, and the ability to raise additional funds through the ATM noted above, management believes the Company has sufficient funds to operate through at least August 2023.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement, Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">FAIR VALUE OF FINANCIAL INSTRUMENTS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company has financial instruments whereby the fair market value of the financial instruments could be different than that recorded on a historical basis. The Company's financial instruments consist of its cash and cash equivalents, accounts receivable,&#160;and accounts payable. The carrying amounts of the Company's financial instruments approximate their fair values. The Company also maintains an investment in privately held company (see below). </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk, Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">CONCENTRATION OF CREDIT RISK</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies.&#160; As of May 31, 2022, the Company had approximately $5,702,000 of uninsured cash. The Company does not believe it is exposed to any significant credit risks.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company provides credit in the normal course of business to customers throughout the United States and in foreign markets.&#160; The Company performs ongoing credit evaluations of its customers and requires accelerated prepayment in some circumstances. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our net sales were approximately $18,871,000 for fiscal 2022 compared to $7,199,000 for fiscal 2021. For the fiscal years ended May 31, 2022 and 2021, the Company had two distributors, which accounted for a total of 65% and 60% of our net sales, respectively. Of this, for the fiscal years ended May 31, 2022 and 2021, the largest of the distributors mentioned above accounted for 55% and 33%, respectively, of net sales.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total gross receivables on May 31, 2022 and 2021 were approximately $927,000 and $2,292,000, respectively. On May 31, 2022 and 2021, the Company had one distributor and two distributors, respectively, which accounted for a total of 50% and 73%, respectively, of gross accounts receivable. Of the 50% as of May 31, 2022, 50% was owed by a distributor in Asia.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">For the fiscal years ended May 31, 2022 and 2021, the Company had one vendor, which accounted for 84% and 58%, respectively, of our purchases of raw materials.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock', window );">Concentration Risk Geographic Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">GEOGRAPHIC CONCENTRATION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">As of May 31, 2022 and 2021, a</span><span style="FONT-FAMILY:&quot;Times New Roman&quot;,serif">pproximately $621,000 <span style="COLOR:black">and $803,000, respectively</span> of Biomerica&#8217;s gross inventory was located in Mexicali, Mexico, respectively. <span style="COLOR:black">As of May 31, 2022 and 2021,</span> approximately $17,000 <span style="COLOR:black">and $25,000, respectively</span> of Biomerica&#8217;s property and equipment, net of accumulated depreciation and amortization, was located in Mexicali, Mexico, respectively.</span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; MARGIN:0in 2.7pt 0in 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt">CASH AND</span></b><span style="FONT-SIZE:10pt"><b><span style="COLOR:black"> CASH EQUIVALENTS</span></b></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ACCOUNTS RECEIVABLE</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company extends unsecured credit to its customers on a regular basis. &#160;International accounts are usually required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. &#160;&#160;Initial credit levels for individual distributors are approved by designated officers and managers of the Company. All increases in credit limits are also approved by designated upper-level management. &#160;Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. &#160;Balances over ninety days old are usually reserved for unless collection is reasonably assured. &#160; </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables. &#160; Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">As of May 31, 2022 and 2021, the Company has established a reserve of approximately $153,000 and $837,000, respectively, for doubtful accounts. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_PrepaidsPolicyPolicyTextBlock', window );">Prepaids Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">PREPAIDS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">The Company occasionally prepays for items such as inventory, insurance, and other items.&#160; These items are reported as prepaids, until either the inventory is physically received or the insurance and other items are utilized.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">As of May 31, 2022 and 2021, the prepaids were approximately $320,000 and $370,000, respectively, composed of prepayments to insurance and various other suppliers. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">INVENTORIES, NET</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black">The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The following is a summary of approximate net inventories:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733">

<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td colspan="5" style="border-top: 0px; height: 15pt; border-right: 0px; width: 29.82%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">May 31,</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">2022</span></p>
</td>
<td style="height: 15pt; width: 1.78%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">2021</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Raw materials</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 12.04%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">1,717,000 </span></p>
</td>
<td style="height: 15pt; width: 1.78%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;$ </span></p>
</td>
<td style="height: 15pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">1,812,000 </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Work in progress</span></p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 12.04%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">763,000 </span></p>
</td>
<td style="height: 15pt; width: 1.78%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">1,687,000 </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Finished products</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.04%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">782,000 </span></p>
</td>
<td style="height: 15pt; width: 1.78%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">1,324,000 </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Total gross inventory</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.04%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">3,262,000 </span></p>
</td>
<td style="height: 15pt; width: 1.78%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;$ </span></strong></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">4,823,000 </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Inventory reserve</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.04%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(846,000)</span></p>
</td>
<td style="height: 15pt; width: 1.78%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(1,617,000)</span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 70.18%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Net inventory </span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12.04%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">2,416,000 </span></strong></p>
</td>
<td style="height: 15.75pt; width: 1.78%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">3,206,000 </span></strong></p>
</td>
</tr>

</table><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically reserve for obsolete inventory. As of May 31, 2022 and 2021, inventory reserves were approximately $846,000 and $1,617,000, respectively. During the fiscal 2022 the Company disposed of COVID-19 antibody inventory that wasn&#8217;t sellable, this has been partially reserved for in fiscal 2021. The reduction in our inventory reserve relates to the COVID-19 antibody disposal. The Company continues to sell COVID-19 antigen tests. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">PROPERTY AND EQUIPMENT, NET</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment amounted to approximately $100,000 and $105,000 for the years ended May 31, 2022 and 2021, respectively. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets, Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">INTANGIBLE ASSETS, NET</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (&#8220;ASC&#8221;), ASC 350 Intangibles &#8211; Goodwill and Other (&#8220;ASC 350&#8221;). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Intangible assets are being amortized using the straight-line method over the useful life, not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, and 20 years for patents. Amortization amounted to approximately $239,000 and $34,000 for the years ended May 31, 2022 and 2021, respectively.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset's balance over its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine whether there was any impairment. As of May 31, 2022 and 2021, an impairment adjustment was made of $210,000 and $0, respectively.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">INVESTMENTS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">From time-to-time, the Company makes investments in privately held companies. Investments represent the Company&#8217;s investment in a Polish distributor, which is primarily engaged in distributing medical products and devices. The Company owns approximately 6% of the investee and, accordingly, applies the cost method holdings to account for the investment. The Company invested approximately $165,000 into the Polish distributor.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Equity holdings in nonmarketable unconsolidated entities in which the Company is not able to exercise significant influence ("Cost Method Holdings") are accounted for at the Company's initial cost, minus any impairment (if any), plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar holding or security of the same issuer. Dividends received are recorded as other income.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company assesses its equity holdings for impairment whenever events or changes in circumstances indicate that the carrying value of an equity holding may not be recoverable. Management reviewed the underlying net assets of the Company's equity method holding as of May 31, 2022 and determined that the Company's proportionate economic interest in the entity indicates that the equity holding was not impaired. There were no observable price changes in orderly transactions for identical or a similar holding or security of the Company&#8217;s Cost Method Holding during the year ended May 31, 2022.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">SHARE-BASED COMPENSATION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company follows the guidance of ASC 718, Share-based Compensation (&#8220;ASC 718&#8221;), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes options-pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the foreseeable future. Expected volatilities are based on weighted averages of the historical volatility of the Company&#8217;s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the &#8220;simplified method&#8221; which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited exercise activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. The grant date fair value of the award is recognized under the straight-line attribution method.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company expensed approximately $1,260,000 and $1,355,000 of stock-based compensation during the years ended May 31, 2022 and 2021, respectively.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">In applying the Black-Scholes options-pricing model, assumptions used were as follows: &#160;</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733">

<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td colspan="4" style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">For the year ended May 31,</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2022</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2021</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Dividend yield</span></p>
</td>
<td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">0%</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">0%</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Expected volatility</span></p>
</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">102.54 - 105.48% </span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">&#160;71.19 - 107.53% </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Risk free interest rate</span></p>
</td>
<td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">&#160;0.97-2.75% </span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">&#160;0.34-1.18% </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Expected term</span></p>
</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">&#160;5.50-6.25 Years </span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">&#160;5.50-6.25 Years </span></p>
</td>
</tr>

</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">REVENUE RECOGNITION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company has various contracts with customers.&#160; All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred, and at which point title passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company regularly evaluates the status of these contracts and does not believe that any additional discounts will be given through the end of the contract periods. </span><span style="FONT-SIZE:10pt">Services for contract work are invoiced and recognized for work that has been performed as the project progresses. <span style="COLOR:black">The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools, and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors. &#160;Physicians&#8217; office products are sold to physicians and distributors, all of whom are categorized below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international manufacturers. </span></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Disaggregation of revenue:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The following is an approximate breakdown of revenues according to primary markets to which the products are sold:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733">

<tr style="height: 15pt;">
<td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="5" style="border-top: 0px; height: 15pt; border-right: 0px; width: 165pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">For the year ended May 31,</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 77pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2022</span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 77pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2021</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 374pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Physician's office</span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">14,259,000 </span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">2,801,000 </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Clinical lab</span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">3,064,000 </span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">3,077,000 </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 374pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Over-the-counter</span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">1,089,000 </span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">766,000 </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Contract manufacturing</span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">459,000 </span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">555,000 </span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 374pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Total</span></strong></p>
</td>
<td style="height: 15.75pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 66pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">18,871,000 </span></strong></p>
</td>
<td style="height: 15.75pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 66pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">7,199,000 </span></strong></p>
</td>
</tr>

</table><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">See Note 8 for additional information regarding geographic revenue concentrations.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Goods and Service [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">SHIPPING AND HANDLING FEES </span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company includes shipping and handling fees billed to customers in net sales. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">RESEARCH AND DEVELOPMENT</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Research and development costs are expensed as incurred. The Company expensed approximately $1,812,000 and $2,194,000 of research and development costs during the years ended May 31, 2022 and 2021, respectively.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">INCOME TAXES</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company accounts for income taxes in accordance with ASC 740, Income Taxes (&#8220;ASC 740&#8221;). Deferred tax assets and liabilities arise from temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements that will result in taxable or deductible amounts in future years and the benefits of net operating loss and tax credit carryforwards. These temporary differences and the benefits of net operating loss and tax credit carryforwards are measured using enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets to the extent that management considers it is more likely than not that a deferred tax asset will not be realized. In determining the valuation allowance, the Company considers factors such as the reversal of deferred income tax assets, projected taxable income, and the character of income tax assets and tax planning strategies. A change to these factors could impact the estimated valuation allowance and income tax expense. On May 31, 2022 and 2021, in accordance with ASC 740, the Company has a valuation allowance for substantially all of its net deferred tax assets.&#160;&#160; During the fiscal year ended May 31, 2022, <span style="BACKGROUND:none">this valuation allowance was increased to $6,967,000, which fully covers the net tax asset of $6,967,000</span></span><span style="FONT-SIZE:9pt; BACKGROUND:none; COLOR:black">.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company accounts for its uncertain tax provisions by using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, based solely on the technical merits, that the position will be sustained in an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the appropriate amount of the benefit to recognize. The amount of benefit to recognize is measured as the maximum amount which is more likely than not to be realized. The tax position is derecognized when it is no longer more likely than not capable of being sustained. On subsequent recognition and measurement, the maximum amount which is more likely than not to be recognized at each reporting date will represent the Company&#8217;s best estimate, given the information available at the reporting date, although the outcome of the tax position is not absolute or final. The Company elected to follow an accounting policy to classify accrued interest related to liabilities for income taxes within the &#8220;Interest expense&#8221; line and penalties related to liabilities for income taxes within the &#8220;Other expense&#8221; line of the consolidated statements of operations and comprehensive loss. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Cost [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ADVERTISING COSTS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company reports the cost of all advertising as expense in the period in which those costs are incurred. Advertising costs were approximately <span style="BACKGROUND:white">$76,000</span> and $<span style="BACKGROUND:white">10,000</span> for the years ended May 31, 2022 and 2021, respectively. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions and Translations Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">FOREIGN CURRENCY TRANSLATION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the year, and revenues and costs are translated using average exchange rates for the year. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no foreign currency transactions that are included in the consolidated statements of operations for the years ended May 31, 2022 and 2021.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lessee, Leases [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">RIGHT-OF-USE ASSETS AND LEASE LIABILITY</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued an accounting standard update which requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset.&#160; Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.&#160; Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term.&#160; Leases are classified as financing or operating which will drive the expense recognition pattern.&#160; The Company has elected to exclude short-term leases.&#160; The Company adopted this guidance as of June 1, 2019, the required effective date, &#160;which resulted in a right-of-use asset being recorded of approximately $1,943,000 and a lease liability being recorded of approximately $1,981,000. On April 9, 2021, the Company exercised its second option to extend its lease for an additional five years.&#160; As part of that lease extension agreement, the Company was granted an additional right to extend its lease for five years, up through August 2031. However, given the recent growth in the Company&#8217;s operations, and the expectation that operations will continue to grow in the near future, the Company believes that it will be necessary to relocate into larger facilities by the end of the current lease term. Therefore, the Company has elected to not include the additional five-year extension option, from August 2026 to August 2031, into its right-of-use asset or its lease liability accounts. For additional information, see Note 9-Commitments and Contingencies. The Company leases office space and copy machines, all of which are operating leases.&#160; Most leases include the option to renew and the exercise of the renewal options is at the Company&#8217;s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.&#160; The leases do not include the options to purchase the leased property.&#160; The depreciable life of assets and leasehold improvements are limited by the expected lease term.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">NET LOSS PER SHARE </span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amounts of anti-dilutive stock options not included in the loss per share calculation for the years ended May 31, 2022 and 2021 were 2,321,616 and 2,081,366, respectively. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting, Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">SEGMENT REPORTING</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">ASC 280, Segment Reporting (&#8220;ASC 280&#8221;), establishes standards for reporting, by public business enterprises, information about operating segments, products and services, geographic areas, and major customers. The Company&#8217;s operations are analyzed by management and its chief operating decision maker as being part of a single industry segment: the design, development, marketing, and sales of diagnostic kits.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income, Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">REPORTING COMPREHENSIVE LOSS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Comprehensive loss represents net loss and any revenues, expenses, gains and losses that, under GAAP, are excluded from net loss and recognized directly as a component of shareholders&#8217; equity. Items of other comprehensive loss consist solely of foreign currency translation adjustments for the years ended May 31, 2022 and 2021. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">RECENT ACCOUNTING PRONOUNCEMENTS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">Recent ASU's issued by the FASB and guidance issued by the SEC did not, or are not believed by management to, have a material effect on the Company&#8217;s present or future consolidated financial statements. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in">&#160;</p><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in 0.1in 0in 0in;"><span style="font-size: 10pt; color: black;">In June 2016, the FASB issued ASU 2016-13, "Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments." This ASU will require the measurement of all expected credit losses for financial assets, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The guidance was initially effective for the Company for annual reporting periods beginning after December 15, 2019, and interim periods within those fiscal years. In November 2019, the FASB issued ASU 201&#183;9- 10, "Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates," which, among other things, defers the effective date of ASU 2016-13 for public filers that are considered smaller reporting companies as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including interim periods within those years. Early adoption is permitted. The Company is currently reviewing the requirements of this ASU to determine its impact on the Company&#8217;s consolidated results of operations and financial position. </span></p><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in 0.1in 0in 0in;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification, Comparability Adjustment [Policy Text Block]</a></td>
<td class="text"><p style="margin: 0in; text-align: justify;"><span style="font-family: times new roman, times, serif; font-size: 10pt;"><strong><span style="color: black;">RECLASSIFICATIONS</span></strong></span></p><p style="margin: 0in; text-align: justify;"><span style="font-family: times new roman, times, serif; font-size: 10pt;"><strong><span style="color: black;">&#160;</span></strong></span></p><p style="margin: 0in; text-align: justify;"><span style="font-size: 10.0pt; color: black;"><span style="font-family: times new roman, times, serif;">Certain comparative figures in the 2021 Statement of Operations have been reclassified to conform to the current year&#8217;s presentation.</span> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the description of risks that arise due to concentrations of operating facilities, revenues, assets, customers, vendors or the like in a certain geographic area, either domestic or foreign. The description may address risks inherent in the geographic area, and, at a minimum, informs users of the general nature of the risk, but excludes "Information about Geographic Areas" that may be disclosed elsewhere.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for liquidity position during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_PrepaidsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for prepaids.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_PrepaidsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI https://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143088937952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733">

<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td colspan="5" style="border-top: 0px; height: 15pt; border-right: 0px; width: 29.82%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">May 31,</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">2022</span></p>
</td>
<td style="height: 15pt; width: 1.78%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">2021</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Raw materials</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 12.04%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">1,717,000 </span></p>
</td>
<td style="height: 15pt; width: 1.78%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;$ </span></p>
</td>
<td style="height: 15pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">1,812,000 </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Work in progress</span></p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 12.04%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">763,000 </span></p>
</td>
<td style="height: 15pt; width: 1.78%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">1,687,000 </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Finished products</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.04%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">782,000 </span></p>
</td>
<td style="height: 15pt; width: 1.78%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">1,324,000 </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Total gross inventory</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.04%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">3,262,000 </span></p>
</td>
<td style="height: 15pt; width: 1.78%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">&#160;$ </span></strong></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">4,823,000 </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 70.18%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Inventory reserve</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.04%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(846,000)</span></p>
</td>
<td style="height: 15pt; width: 1.78%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(1,617,000)</span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 70.18%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Net inventory </span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12.04%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">2,416,000 </span></strong></p>
</td>
<td style="height: 15.75pt; width: 1.78%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">3,206,000 </span></strong></p>
</td>
</tr>

</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733">

<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td colspan="4" style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">For the year ended May 31,</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2022</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2021</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Dividend yield</span></p>
</td>
<td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">0%</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">0%</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Expected volatility</span></p>
</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">102.54 - 105.48% </span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">&#160;71.19 - 107.53% </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Risk free interest rate</span></p>
</td>
<td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">&#160;0.97-2.75% </span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">&#160;0.34-1.18% </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Expected term</span></p>
</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">&#160;5.50-6.25 Years </span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">&#160;5.50-6.25 Years </span></p>
</td>
</tr>

</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733">

<tr style="height: 15pt;">
<td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="5" style="border-top: 0px; height: 15pt; border-right: 0px; width: 165pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">For the year ended May 31,</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 77pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2022</span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 77pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2021</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 374pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Physician's office</span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">14,259,000 </span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">2,801,000 </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Clinical lab</span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">3,064,000 </span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">3,077,000 </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 374pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Over-the-counter</span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">1,089,000 </span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">766,000 </span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Contract manufacturing</span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">459,000 </span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">555,000 </span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 374pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Total</span></strong></p>
</td>
<td style="height: 15.75pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 66pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">18,871,000 </span></strong></p>
</td>
<td style="height: 15.75pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 66pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">7,199,000 </span></strong></p>
</td>
</tr>

</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143092667680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; BACKGROUND:white; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:165pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">May 31,</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:77pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2022</span></p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:77pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2021</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Equipment</span></p></td> <td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:66pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,292,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:66pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,850,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Furniture, fixtures and leasehold improvements</span></p></td> <td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:66pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">227,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:66pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">433,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Less accumulated depreciation</span></p></td> <td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(1,305,000)</span></p></td> <td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(1,972,000)</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:374pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Net property and equipment</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">214,000</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">311,000</span></b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143092584544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; BACKGROUND:white; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:26%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 26%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black"> May 31,</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2022</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2021</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Licenses</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-18; FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-&#160;&#160; </span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">182,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Patents</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">189,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">240,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Less accumulated amortization-licenses</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-19; FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(107,000)</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Less accumulated amortization-patents</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(19,000)</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(20,000)</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Intangible asssets, net</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">170,000</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">295,000</span></b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">2023</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">13,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">2024</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">13,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">2025</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">13,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">2026</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">13,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">2027</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">13,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Thereafter</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">105,000</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Total</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">170,000</span></b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143092696416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="WIDTH:555.6pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="741"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:169pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">May 31,</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:78.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2022</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:78.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2021</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Accounts payable</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">736,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">431,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Accrued expenses</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">236,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">152,000</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Total</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">972,000</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">583,000</span></b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143089416016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 550.7pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="734">

<tr style="height: 15pt;">
<td style="height: 15pt; width: 300.25pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 67.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">NUMBER OF <br/>STOCK OPTIONS</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.6pt; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66.05pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">EXCERCISE <br/>PRICE RANGE <br/>PER SHARE</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.6pt; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 79.4pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">WEIGHTED <br/>AVERAGE <br/>EXERCISE PRICE</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 300.25pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Options outstanding at May 31, 2020</span></strong></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">1,789,251</span></strong></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 66.05pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$0.82-$8.18</span></strong></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$</span></strong></p>
</td>
<td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">2.75</span></strong></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 300.25pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Options granted</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 67.2pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">430,616</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 66.05pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">$5.14-$8.70</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12.2pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 67.2pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">6.73</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 300.25pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Options excercised</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(86,750)</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 66.05pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">$0.82-$3.62</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">1.20</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 300.25pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Options canceled or expired</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 67.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(51,751)</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66.05pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">$2.35-$8.18</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 67.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">4.77</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 300.25pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Options outstanding at May 31, 2021</span></strong></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-bottom: windowtext 1pt solid; height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">2,081,366</span></strong></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-bottom: windowtext 1pt solid; height: 15pt; width: 66.05pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$0.82-$8.70</span></strong></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$</span></strong></p>
</td>
<td style="border-bottom: windowtext 1pt solid; height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">3.59</span></strong></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 300.25pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Options granted</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 67.2pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">344,000</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 66.05pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">$4.25-$4.46</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12.2pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 67.2pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">4.43</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 300.25pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Options excercised</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(39,500)</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 66.05pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">$1.20-$3.62</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 12.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">1.99</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 300.25pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Options canceled or expired</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 67.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(64,250)</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66.05pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">$1.61-$8.18</span></p>
</td>
<td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 67.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">4.41</span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 300.25pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Options outstanding at May 31, 2022</span></strong></p>
</td>
<td style="height: 15.75pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 67.2pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">2,321,616</span></strong></p>
</td>
<td style="height: 15.75pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 66.05pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$0.82-$8.70</span></strong></p>
</td>
<td style="height: 15.75pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12.2pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 67.2pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">3.72</span></strong></p>
</td>
</tr>

</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of Nonvested Share Activity [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:54.75pt"> <td style="HEIGHT:54.75pt; WIDTH:2.4in; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:54.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:54.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Number of<br/>&#160;shares</span></p></td> <td style="HEIGHT:54.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:54.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Stock options<br/>weighted<br/>average grant<br/>date fair value</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:2.4in; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Non-vested shares at May 31, 2021</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">793,241</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">5.54</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:2.4in; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Granted</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">344,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">4.43</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:2.4in; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Vested&#160;</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(347,279)</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">5.40</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:2.4in; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Forfeited</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(43,500)</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">5.22</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:2.4in; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Non-vested shares at May 31, 2022</span></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">746,462</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">5.11</span></b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="WIDTH:550.1pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">RANGE OF<br/>EXERCISE PRICES</span></p></td> <td style="HEIGHT:15pt; WIDTH:1%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">NUMBER<br/>OUTSTANDING<br/>MAY 31, 2022</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">WEIGHTED<br/>AVERAGE<br/>REMAINING<br/>CONTRACTUAL<br/>LIFE IN YEARS</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">WEIGHTED<br/>&#160;AVERAGE<br/>EXERCISE PRICE</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">NUMBER<br/>EXCERCISABLE<br/>AT MAY 31, 2022</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">WEIGHTED<br/>AVERAGE<br/>EXERCISE PRICE</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$0.82-$1.52</span></p></td> <td style="HEIGHT:15pt; WIDTH:1%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">456,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">3.33</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$1.04</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">456,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$1.04</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$2.25-$4.25</span></p></td> <td style="HEIGHT:15pt; WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">1,015,750</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">6.14</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$2.90</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">852,500</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$2.88</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$4.34-$8.70</span></p></td> <td style="HEIGHT:15pt; WIDTH:1%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">849,866</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">8.75</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$6.13</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">266,654</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$7.06</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143089416272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:169pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">&#160;For the year ended May 31,</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:78.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">2022</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:78.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">2021</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Current:</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">U.S. Federal</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-20; FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">&#160;-</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-21; FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">&#160;-</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Foreign Taxes Subsidiaries</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">(23,000)</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">(12,000)</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">State and local</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">(1,000)</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">(1,000)</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Total current</span></b></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">(24,000)</span></b></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">(13,000)</span></b></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Deferred:</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">U.S. Federal&#160;</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-22; FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">&#160;-</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-23; FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">&#160;-</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">State and local</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-24; FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">&#160;-</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-25; FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">&#160;-</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Total deferred</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-26; FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">&#160;-</span></p></td> <td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-27; FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">&#160;-</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Income tax expense</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">&#160;<span style="COLOR:black">$</span></span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">(24,000)</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">(13,000)</span></b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733">

<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td colspan="5" style="border-top: 0px; height: 15pt; border-right: 0px; width: 30%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">For the year ended May 31,</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 14%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">2022</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 14%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">2021</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Computed "expected" tax benefit</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">947,000</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">1,561,000</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Increase (reduction) in income taxes resulting from:</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Change in valuation allowance</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(1,022,000)</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(2,292,000)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">State income taxes, net of federal benefit</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">300,000</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="top">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">217,000</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Research and development tax credits</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">50,000</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="top">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">456,000</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Permanent tax differences and other</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">(217,000)</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">(88,000)</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Stock based compensation&#160;benefit</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; text-align: right; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in; text-align: right;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">11,000</span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; text-align: right; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="top">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">145,000</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Foreign taxes of subsidiaries</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">(113,000)</span></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(12,000)</span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Income tax expense</span></strong></p>
</td>
<td style="height: 15.75pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(24,000)</span></p>
</td>
<td style="height: 15.75pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><strong><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(13,000)</span></p>
</td>
</tr>

</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="WIDTH:550.1pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:30%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 30%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">May 31,</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">2022</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">2021</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Deferred tax assets:</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Accounts receivable, principally due to allowance for doubtful accounts</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">43,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">200,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Inventory valuation&#160;&#160;&#160;</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">237,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">387,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Compensated absences</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">120,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">85,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Net operating loss carryforwards&#160;&#160;&#160;</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">4,349,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">3,194,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Tax credit carryforwards</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">1,096,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">1,055,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Deferred rent expense/Capitalized leases</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">20,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">15,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Stock Options</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">1,035,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">613,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Losses of foreign subsidiaries &amp; Other, net</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">41,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">370,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Accumulated depreciation and amortization</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">26,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">(15,000)</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Total deferred tax assets&#160;&#160;&#160;</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">6,967,000</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">5,904,000</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Less valuation allowance</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">(6,967,000)</span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif">(5,904,000)</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">Net deferred tax asset</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-28; FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">&#160;-</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-29; FONT-SIZE:11pt; FONT-FAMILY:&quot;Calibri&quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">&#160;-</span></b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143092717024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_GeographicInformationDisclosureAbstract', window );"><strong>Geographic Information Disclosure Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue from External Customers by Geographic Areas [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 557.3pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="743">

<tr style="height: 15pt;">
<td style="height: 15pt; width: 286.9pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="7" style="border-top: 0px; height: 15pt; border-right: 0px; width: 258.6pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">For the year ended May 31,</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 286.9pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="3" style="border-top: 0px; height: 15pt; border-right: 0px; width: 123.4pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2022</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="3" style="border-top: 0px; height: 15pt; border-right: 0px; width: 123.4pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2021</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 286.9pt; background: #b8cce4; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Asia</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">13,375,000</span></p>
</td>
<td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">71%</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">1,908,000</span></p>
</td>
<td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">26%</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 286.9pt; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Europe</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">4,339,000</span></p>
</td>
<td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">23%</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">4,301,000</span></p>
</td>
<td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">60%</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 286.9pt; background: #b8cce4; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">North America</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">997,000</span></p>
</td>
<td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">5%</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">548,000</span></p>
</td>
<td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">8%</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 286.9pt; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">South America</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">90,000</span></p>
</td>
<td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">1%</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">250,000</span></p>
</td>
<td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">3%</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 286.9pt; background: #b8cce4; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Middle East</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 55.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">70,000</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 55.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">0%</span></p>
</td>
<td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 55.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">192,000</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 55.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">3%</span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 286.9pt; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Total</span></strong></p>
</td>
<td style="height: 15.75pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 55.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">18,871,000</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 55.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">100%</span></strong></p>
</td>
<td style="height: 15.75pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">$</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 55.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">7,199,000</span></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 55.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">100%</span></strong></p>
</td>
</tr>

</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_GeographicInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_GeographicInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143092589008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock', window );">Schedule Of Cash Flow Supplemental Disclosures Related To Lease [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="WIDTH:550.1pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:467.1pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Operating cash flows from operating leases&#160;&#160;&#160;&#160;&#160;</span></p></td> <td style="HEIGHT:15pt; WIDTH:15.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15pt; WIDTH:67.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">338,206</span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:467.1pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Right-of-use assets obtained in exchange for<br/>&#160;&#160;&#160; &#160;new operating lease liabilities</span></p></td> <td style="HEIGHT:0.2in; WIDTH:15.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:0.2in; WIDTH:67.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-30; FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">&#160;-</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:467.1pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Weighted average remaining lease term (in years)</span></p></td> <td style="HEIGHT:15pt; WIDTH:15.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:67.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">4.28</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:467.1pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Weighted average discount rate</span></p></td> <td style="HEIGHT:15pt; WIDTH:15.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/> <td style="HEIGHT:15pt; WIDTH:67.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">6.50%</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733">

<tr style="height: 15pt;">
<td style="height: 15pt; width: 462pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Less than 1 year</span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">351,000</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 462pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">1 to 2 years</span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">362,000</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 462pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">2 to 3 years</span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">373,000</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 462pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">3 to 4 years</span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">384,000</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 462pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">4 to 5 years</span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">104,000</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 462pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Total undiscounted lease payments</span></p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">1,574,000</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 462pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Less imputed interest</span></p>
</td>
<td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">194,000</span></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 462pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Total operating lease liabilities</span></p>
</td>
<td style="height: 15.75pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 66pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">1,380,000</span></strong></p>
</td>
</tr>

</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information related to lease for the periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143081211152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Jan. 22, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="num">$ (35,077,379)<span></span>
</td>
<td class="num">$ (30,546,335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="nump">5,916,983<span></span>
</td>
<td class="nump">4,199,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_WorkingCapital', window );">Working Capital</a></td>
<td class="nump">7,416,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue', window );">Shelf Registration Statement, Maximum Authorized Common Stock Issuance, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">2,401,734<span></span>
</td>
<td class="nump">1,177,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="nump">77,360<span></span>
</td>
<td class="nump">102,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash, Uninsured Amount</a></td>
<td class="nump">5,702,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">18,871,409<span></span>
</td>
<td class="nump">7,199,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesGrossCurrent', window );">Other Receivables, Gross, Current</a></td>
<td class="nump">927,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, Gross</a></td>
<td class="nump">3,262,000<span></span>
</td>
<td class="nump">4,823,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">$ 214,487<span></span>
</td>
<td class="nump">310,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable', window );">Threshold Period Past Due for Write-off of Trade Accounts Receivable</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Accounts Receivable, Credit Loss Expense (Reversal)</a></td>
<td class="num">$ (684,184)<span></span>
</td>
<td class="nump">766,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidSupplies', window );">Increase (Decrease) in Prepaid Supplies</a></td>
<td class="nump">320,000<span></span>
</td>
<td class="nump">370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory Valuation Reserves</a></td>
<td class="nump">846,000<span></span>
</td>
<td class="nump">1,617,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, Depletion and Amortization</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="nump">239,000<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="nump">210,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="nump">165,324<span></span>
</td>
<td class="nump">165,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="nump">1,260,000<span></span>
</td>
<td class="nump">1,355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="nump">1,812,424<span></span>
</td>
<td class="nump">2,194,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
<td class="nump">6,967,000<span></span>
</td>
<td class="nump">5,904,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred Tax Assets, Gross</a></td>
<td class="nump">6,967,000<span></span>
</td>
<td class="nump">5,904,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising Expense</a></td>
<td class="nump">76,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">1,301,834<span></span>
</td>
<td class="nump">$ 1,553,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">$ 1,380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)</a></td>
<td class="nump">2,321,616<span></span>
</td>
<td class="nump">2,081,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="nump">$ 35,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">$ 1,943,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">1,981,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Accounts Receivable, Credit Loss Expense (Reversal)</a></td>
<td class="nump">$ 153,000<span></span>
</td>
<td class="nump">$ 837,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember', window );">Distribution Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bmra_PurchasedTechnologyRightsMember', window );">Purchased Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MX', window );">MEXICO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, Gross</a></td>
<td class="nump">$ 621,000<span></span>
</td>
<td class="nump">803,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bmra_PolishDistributorMember', window );">Polish Distributor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_TwoDistributorsMember', window );">Two Distributors [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_TwoDistributorsMember', window );">Two Distributors [Member] | Accounts Payable [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_OneDistributorMember', window );">One Distributor [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">55.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_OneDistributorMember', window );">One Distributor [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesGrossCurrent', window );">Other Receivables, Gross, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,292,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_OneVendorMember', window );">One Vendor [Member] | Accounts Payable [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_OneVendorMember', window );">One Vendor [Member] | Cost of Goods and Service, Product and Service Benchmark [Member] | Supplier Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">84.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bmra_ATMAgreementMember', window );">ATM Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in Shares)</a></td>
<td class="nump">521,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 2,402,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="nump">$ 2,317,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bmra_ATMAgreementMember', window );">ATM Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in Dollars per share)</a></td>
<td class="nump">$ 4.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bmra_ATMAgreementMember', window );">ATM Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in Dollars per share)</a></td>
<td class="nump">$ 5.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bmra_OneDistributorMember', window );">One Distributor [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bmra_DistributorsInAsiaMember', window );">Distributors in Asia [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount related with Maximum Authorized Common Stock Issuance of Shelf Registration Statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for supplies that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period past due for trade accounts receivable to write off as uncollectible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bmra_PurchasedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bmra_PurchasedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bmra_PolishDistributorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bmra_PolishDistributorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_TwoDistributorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_TwoDistributorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_OneDistributorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_OneDistributorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_OneVendorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_OneVendorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bmra_ATMAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bmra_ATMAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bmra_OneDistributorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bmra_OneDistributorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bmra_DistributorsInAsiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bmra_DistributorsInAsiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143082101744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Inventories - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_InventoriesAbstract', window );"><strong>Inventories Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 1,717,000<span></span>
</td>
<td class="nump">$ 1,812,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">763,000<span></span>
</td>
<td class="nump">1,687,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished products</a></td>
<td class="nump">782,000<span></span>
</td>
<td class="nump">1,324,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total Gross Inventory</a></td>
<td class="nump">3,262,000<span></span>
</td>
<td class="nump">4,823,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory Reserve</a></td>
<td class="num">(846,000)<span></span>
</td>
<td class="num">(1,617,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Net Inventory</a></td>
<td class="nump">$ 2,416,447<span></span>
</td>
<td class="nump">$ 3,206,255<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_InventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_InventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143088882272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">102.54%<span></span>
</td>
<td class="nump">71.19%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.97%<span></span>
</td>
<td class="nump">0.34%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">105.48%<span></span>
</td>
<td class="nump">107.53%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="nump">1.18%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143081941568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Revenue from contracts with customers - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue From Customers</a></td>
<td class="nump">$ 18,871,000<span></span>
</td>
<td class="nump">$ 7,199,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bmra_PhysiciansOfficeMember', window );">Physicians Office [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue From Customers</a></td>
<td class="nump">14,259,000<span></span>
</td>
<td class="nump">2,801,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bmra_ClinicalLabMember', window );">Clinical Lab [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue From Customers</a></td>
<td class="nump">3,064,000<span></span>
</td>
<td class="nump">3,077,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bmra_OverthecounterMember', window );">Over-the-counter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue From Customers</a></td>
<td class="nump">1,089,000<span></span>
</td>
<td class="nump">766,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bmra_ContractManufacturingMember', window );">Contract Manufacturing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue From Customers</a></td>
<td class="nump">$ 459,000<span></span>
</td>
<td class="nump">$ 555,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bmra_PhysiciansOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bmra_PhysiciansOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bmra_ClinicalLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bmra_ClinicalLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bmra_OverthecounterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bmra_OverthecounterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bmra_ContractManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bmra_ContractManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143087649408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Details) - Property and equipment, net - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_PropertyAndEquipmentNetAbstract', window );"><strong>Property And Equipment Net Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_Equipment', window );">Equipment</a></td>
<td class="nump">$ 1,292,000<span></span>
</td>
<td class="nump">$ 1,850,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_FurnitureFixturesAndLeaseholdImprovements', window );">Furniture, fixtures and leasehold improvements</a></td>
<td class="nump">227,000<span></span>
</td>
<td class="nump">433,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(1,305,360)<span></span>
</td>
<td class="num">(1,972,357)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net property and equipment</a></td>
<td class="nump">$ 214,487<span></span>
</td>
<td class="nump">$ 310,520<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_Equipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_Equipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_FurnitureFixturesAndLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities and additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_FurnitureFixturesAndLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_PropertyAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_PropertyAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143088878608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET (Details) - Intangible assets, net - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_IntangibleAssetsNetAbstract', window );"><strong>Intangible Assets Net Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedLicenseAgreementsGross', window );">Licenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 182,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedPatentsGross', window );">Patents</a></td>
<td class="nump">189,000<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_FiniteLivedLicenseAccumulatedAmortization', window );">Less accumulated amortization-licenses</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(107,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_FiniteLivedPatentsAccumulatedAmortization', window );">Less accumulated amortization-patents</a></td>
<td class="num">(19,000)<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible asssets, net</a></td>
<td class="nump">$ 169,516<span></span>
</td>
<td class="nump">$ 294,830<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_FiniteLivedLicenseAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of licenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_FiniteLivedLicenseAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_FiniteLivedPatentsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of patents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_FiniteLivedPatentsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_IntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_IntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedLicenseAgreementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount as of the balance sheet date of certain rights acquired to exercise a certain privilege or pursue a particular business or occupation and which is deemed to have a finite economic life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedLicenseAgreementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedPatentsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedPatentsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143089289504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET (Details) - Expected amortization of intangible assets<br></strong></div></th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_ExpectedAmortizationOfIntangibleAssetsAbstract', window );"><strong>Expected Amortization Of Intangible Assets Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 13,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">105,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 170,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_ExpectedAmortizationOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_ExpectedAmortizationOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143089444656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Accounts Payable [Member] - Customer Concentration Risk [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_TwoVendorMember', window );">Two Vendor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems', window );"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">69.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_OneVendorMember', window );">One Vendor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems', window );"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_TwoVendorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_TwoVendorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_OneVendorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_OneVendorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143089328784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Accounts payable and accrued expense balances - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_AccountsPayableAndAccruedExpenseBalancesAbstract', window );"><strong>Accounts Payable And Accrued Expense Balances Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 736,000<span></span>
</td>
<td class="nump">$ 431,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">236,000<span></span>
</td>
<td class="nump">152,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 972,372<span></span>
</td>
<td class="nump">$ 583,380<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_AccountsPayableAndAccruedExpenseBalancesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_AccountsPayableAndAccruedExpenseBalancesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143087611120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Details) - STOCK OPTION AND RESTRICTED STOCK PLANS - Share-Based Payment Arrangement, Option [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Dec. 11, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - STOCK OPTION AND RESTRICTED STOCK PLANS [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,260,000<span></span>
</td>
<td class="nump">$ 1,355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.43<span></span>
</td>
<td class="nump">$ 6.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="nump">$ 501,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,838,000<span></span>
</td>
<td class="nump">2,132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,731,000<span></span>
</td>
<td class="nump">1,872,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,982,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 5 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">2014 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - STOCK OPTION AND RESTRICTED STOCK PLANS [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">2017 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - STOCK OPTION AND RESTRICTED STOCK PLANS [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in Shares)</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">2020 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - STOCK OPTION AND RESTRICTED STOCK PLANS [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - STOCK OPTION AND RESTRICTED STOCK PLANS [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 954,000<span></span>
</td>
<td class="nump">957,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - STOCK OPTION AND RESTRICTED STOCK PLANS [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,000<span></span>
</td>
<td class="nump">205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - STOCK OPTION AND RESTRICTED STOCK PLANS [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Selling and Marketing Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - STOCK OPTION AND RESTRICTED STOCK PLANS [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,000<span></span>
</td>
<td class="nump">$ 68,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bmra_A2014PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bmra_A2014PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bmra_A2017PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bmra_A2017PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bmra_A2020PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bmra_A2020PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143084018400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Details) - COMMON STOCK ACTIVITY - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 22, 2021</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>May 21, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - COMMON STOCK ACTIVITY [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,401,734<span></span>
</td>
<td class="nump">$ 1,177,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,360<span></span>
</td>
<td class="nump">$ 102,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - COMMON STOCK ACTIVITY [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,500<span></span>
</td>
<td class="nump">86,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bmra_A2020StockIncentivePlanMember', window );">2020 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - COMMON STOCK ACTIVITY [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - COMMON STOCK ACTIVITY [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,402,000<span></span>
</td>
<td class="nump">$ 1,177,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">521,267<span></span>
</td>
<td class="nump">158,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,317,000<span></span>
</td>
<td class="nump">$ 1,011,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - COMMON STOCK ACTIVITY [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.63<span></span>
</td>
<td class="nump">$ 7.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Maximum [Member] | ATM Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - COMMON STOCK ACTIVITY [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - COMMON STOCK ACTIVITY [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.02<span></span>
</td>
<td class="nump">$ 7.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - COMMON STOCK ACTIVITY [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - COMMON STOCK ACTIVITY [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Common Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - COMMON STOCK ACTIVITY [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Common Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - COMMON STOCK ACTIVITY [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bmra_A2020StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bmra_A2020StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=bmra_ATMAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=bmra_ATMAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143081983984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Details) - PREFERRED STOCK ACTIVITY - Convertible Preferred Stock [Member] - Series A Preferred Stock [Member] - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Mar. 24, 2020</div></th>
<th class="th"><div>Feb. 24, 2020</div></th>
<th class="th"><div>Jan. 21, 2021</div></th>
<th class="th"><div>Jul. 21, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - PREFERRED STOCK ACTIVITY [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Dividends Payable, Amount Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted (in Shares)</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_PalmMember', window );">Palm [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - PREFERRED STOCK ACTIVITY [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued (in Shares)</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible Preferred Stock, Shares Issued upon Conversion (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,429<span></span>
</td>
<td class="nump">571,429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bmra_StockPurchaseAgreementMember', window );">Stock Purchase Agreement [Member] | Palm [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - PREFERRED STOCK ACTIVITY [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableAmountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share amount of a dividend declared, but not paid, as of the financial reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableAmountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_PalmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_PalmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bmra_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bmra_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143082364640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Details) - Activity as to aggregate stock options outstanding - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082818Member', window );">Exercise Price Range Per Share $0.82 - $8.18 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - Activity as to aggregate stock options outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, number of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,789,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare514870Member', window );">Exercise Price Range Per Share $5.14 - $8.70 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - Activity as to aggregate stock options outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted, number of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082362Member', window );">Exercise Price Range Per Share $0.82 - $3.62 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - Activity as to aggregate stock options outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, number of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86,750)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised, weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare235818Member', window );">Exercise Price Range Per Share $2.35 - $8.18 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - Activity as to aggregate stock options outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options canceled or expired, number of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,751)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options canceled or expired, weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082870Member', window );">Exercise Price Range Per Share $0.82 - $8.70 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - Activity as to aggregate stock options outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, number of stock options</a></td>
<td class="nump">2,081,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price</a></td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, number of stock options</a></td>
<td class="nump">2,321,616<span></span>
</td>
<td class="nump">2,081,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price</a></td>
<td class="nump">$ 3.72<span></span>
</td>
<td class="nump">$ 3.59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare425446Member', window );">Exercise Price Range Per Share $4.25 - $4.46 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - Activity as to aggregate stock options outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted, number of stock options</a></td>
<td class="nump">344,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, weighted average exercise price</a></td>
<td class="nump">$ 4.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare120362Member', window );">Exercise Price Range Per Share $1.20 - $3.62 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - Activity as to aggregate stock options outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, number of stock options</a></td>
<td class="num">(39,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised, weighted average exercise price</a></td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare161818Member', window );">Exercise Price Range Per Share $1.61 - $8.18 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - Activity as to aggregate stock options outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options canceled or expired, number of stock options</a></td>
<td class="num">(64,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options canceled or expired, weighted average exercise price</a></td>
<td class="nump">$ 4.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082818Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082818Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare514870Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare514870Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082362Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082362Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare235818Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare235818Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082870Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082870Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare425446Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare425446Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare120362Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare120362Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare161818Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare161818Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143082284720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Details) - Non-vested Stock Options Activity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>May 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_NonVestedStockOptionsActivityAbstract', window );"><strong>Non Vested Stock Options Activity Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested shares, number of shares | shares</a></td>
<td class="nump">793,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested shares, weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 5.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, number of shares | shares</a></td>
<td class="nump">344,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 4.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested, number of shares | shares</a></td>
<td class="num">(347,279)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested, weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 5.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited, number of shares | shares</a></td>
<td class="num">(43,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Forfeited, weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 5.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested shares, number of shares | shares</a></td>
<td class="nump">746,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested shares, weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 5.11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_NonVestedStockOptionsActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_NonVestedStockOptionsActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143081998992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Details) - Stock Options Summary<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>May 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_RangeOfExercisePrice082152Member', window );">Range Of Exercise Price $0.82 - $1.52 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Price, Minimum</a></td>
<td class="nump">$ 0.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Price, Maximum</a></td>
<td class="nump">$ 1.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number (in Shares) | shares</a></td>
<td class="nump">456,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">3 years 3 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number (in Shares) | shares</a></td>
<td class="nump">456,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.04<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_RangeOfExercisePrice225425Member', window );">Range Of Exercise Price $2.25 - $4.25 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Price, Minimum</a></td>
<td class="nump">2.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Price, Maximum</a></td>
<td class="nump">$ 4.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number (in Shares) | shares</a></td>
<td class="nump">1,015,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">6 years 1 month 20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 2.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number (in Shares) | shares</a></td>
<td class="nump">852,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 2.88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_RangeOfExercisePrice434870Member', window );">Range Of Exercise Price $4.34 - $8.70 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Price, Minimum</a></td>
<td class="nump">4.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Price, Maximum</a></td>
<td class="nump">$ 8.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number (in Shares) | shares</a></td>
<td class="nump">849,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">8 years 9 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 6.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number (in Shares) | shares</a></td>
<td class="nump">266,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 7.06<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_RangeOfExercisePrice082152Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_RangeOfExercisePrice082152Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_RangeOfExercisePrice225425Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_RangeOfExercisePrice225425Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_RangeOfExercisePrice434870Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_RangeOfExercisePrice434870Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143082372864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_INCOMETAXESDetailsLineItems', window );"><strong>INCOME TAXES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
<td class="nump">$ 6,967,000<span></span>
</td>
<td class="nump">$ 5,904,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</a></td>
<td class="nump">1,063,000<span></span>
</td>
<td class="nump">$ 2,292,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_INCOMETAXESDetailsLineItems', window );"><strong>INCOME TAXES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">17,116,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_INCOMETAXESDetailsLineItems', window );"><strong>INCOME TAXES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">784,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=bmra_CaliforniaStateIncomeTaxMember', window );">California State Income Tax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_INCOMETAXESDetailsLineItems', window );"><strong>INCOME TAXES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">10,805,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_INCOMETAXESDetailsLineItems', window );"><strong>INCOME TAXES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">$ 395,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_INCOMETAXESDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_INCOMETAXESDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=bmra_CaliforniaStateIncomeTaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=bmra_CaliforniaStateIncomeTaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143082286384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - Income tax expense - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">U.S. Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign Taxes Subsidiaries</a></td>
<td class="num">(23,000)<span></span>
</td>
<td class="num">(12,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and local</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="num">(24,000)<span></span>
</td>
<td class="num">(13,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">U.S. Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State and local</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">$ (23,719)<span></span>
</td>
<td class="num">$ (13,057)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143087562880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - Income Tax Rate Reconciliation - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_IncomeTaxRateReconciliationAbstract', window );"><strong>Income Tax Rate Reconciliation Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Computed "expected" tax benefit</a></td>
<td class="nump">$ 947<span></span>
</td>
<td class="nump">$ 1,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract', window );"><strong>Increase (reduction) in income taxes resulting from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(1,022)<span></span>
</td>
<td class="num">(2,292)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Permanent tax differences and other</a></td>
<td class="num">(217)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Stock based compensation benefit</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign taxes of subsidiaries</a></td>
<td class="num">(113)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">$ (24)<span></span>
</td>
<td class="num">$ (13)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_IncomeTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_IncomeTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143082001712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details) - Deferred Tax - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_DeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Accounts receivable, principally due to allowance for doubtful accounts</a></td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory valuation</a></td>
<td class="nump">237,000<span></span>
</td>
<td class="nump">387,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences', window );">Compensated absences</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">4,349,000<span></span>
</td>
<td class="nump">3,194,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">1,096,000<span></span>
</td>
<td class="nump">1,055,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Deferred rent expense/Capitalized leases</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_DefferedTaxAssetsStockOptions', window );">Stock Options</a></td>
<td class="nump">1,035,000<span></span>
</td>
<td class="nump">613,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet', window );">Losses of foreign subsidiaries &amp; Other, net</a></td>
<td class="nump">41,000<span></span>
</td>
<td class="nump">370,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization', window );">Accumulated depreciation and amortization</a></td>
<td class="nump">26,000<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">6,967,000<span></span>
</td>
<td class="nump">5,904,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(6,967,000)<span></span>
</td>
<td class="num">(5,904,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_DeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_DeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accumulated depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets related with foreign subsidiaries and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_DefferedTaxAssetsStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets related with stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_DefferedTaxAssetsStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143086989856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_GeographicInformationDisclosureAbstract', window );"><strong>Geographic Information Disclosure Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_GeographicInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_GeographicInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143086887232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems', window );"><strong>GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="nump">$ 18,871,409<span></span>
</td>
<td class="nump">$ 7,199,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueSegmentMember', window );">Revenue, Segment Benchmark [Member] | Geographic Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems', window );"><strong>GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net Sales Percent</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaMember', window );">Asia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems', window );"><strong>GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="nump">$ 13,375,000<span></span>
</td>
<td class="nump">$ 1,908,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaMember', window );">Asia [Member] | Revenue, Segment Benchmark [Member] | Geographic Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems', window );"><strong>GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net Sales Percent</a></td>
<td class="nump">71.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems', window );"><strong>GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="nump">$ 4,339,000<span></span>
</td>
<td class="nump">$ 4,301,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member] | Revenue, Segment Benchmark [Member] | Geographic Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems', window );"><strong>GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net Sales Percent</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems', window );"><strong>GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="nump">$ 997,000<span></span>
</td>
<td class="nump">$ 548,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America [Member] | Revenue, Segment Benchmark [Member] | Geographic Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems', window );"><strong>GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net Sales Percent</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_SouthAmericaMember', window );">South America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems', window );"><strong>GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_SouthAmericaMember', window );">South America [Member] | Revenue, Segment Benchmark [Member] | Geographic Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems', window );"><strong>GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net Sales Percent</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_MiddleEastMember', window );">Middle East [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems', window );"><strong>GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="nump">$ 192,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_MiddleEastMember', window );">Middle East [Member] | Revenue, Segment Benchmark [Member] | Geographic Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems', window );"><strong>GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net Sales Percent</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_SouthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_SouthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_MiddleEastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_MiddleEastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143088890896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - OPERATING LEASES - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2016</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=bmra_BuildingInIrvineCaliforniaMember', window );">Building In Irvine California [Member] | First Amendment To Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) - OPERATING LEASES [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=us-gaap_PropertyAvailableForOperatingLeaseMember', window );">Property Available for Operating Lease [Member] | MEXICO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) - OPERATING LEASES [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_LeaseExpirationPeriod', window );">Lease Expiration Period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=us-gaap_PropertyAvailableForOperatingLeaseMember', window );">Property Available for Operating Lease [Member] | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) - OPERATING LEASES [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310,000<span></span>
</td>
<td class="nump">$ 295,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_LeaseExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of years in which the lease expires.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_LeaseExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=bmra_BuildingInIrvineCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=bmra_BuildingInIrvineCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=bmra_FirstAmendmentToLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=bmra_FirstAmendmentToLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=us-gaap_PropertyAvailableForOperatingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=us-gaap_PropertyAvailableForOperatingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143081145264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - CONTRACTS - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 01, 2020</div></th>
<th class="th"><div>May 07, 2020</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RoyaltyAgreementsMember', window );">Royalty Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) - CONTRACTS [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_RoyaltyExpensePercentageOfSales', window );">Royalty Expense Percentage Of Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bmra_TelconAgreementMember', window );">Telcon Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) - CONTRACTS [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedFeesAndOtherRevenueReceivable', window );">Accrued Fees and Other Revenue Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock Issued During Period, Shares, Other (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromFeesReceived', window );">Proceeds from Fees Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_RoyaltyPercentage', window );">Royalty Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bmra_UCLicenseAgreementsMember', window );">UC License Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) - CONTRACTS [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for Other Fees</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_LicenseMaintenanceFeePayable', window );">License Maintenance Fee, Payable</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bmra_UniversityOFSouthernCaliforniaMember', window );">University OF Southern California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) - CONTRACTS [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts', window );">Clinical Trial Agreement Maximum Budgeted Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Liabilities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bmra_BiomericaInFoodsMember', window );">Biomerica InFoods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) - CONTRACTS [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts', window );">Clinical Trial Agreement Maximum Budgeted Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Liabilities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum budgeted costs related to clinical trial agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_ClinicalTrialAgreementMaximumBudgetedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_LicenseMaintenanceFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of license maintenance fee payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_LicenseMaintenanceFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_RoyaltyExpensePercentageOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty expenses expressed as a percentage of sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_RoyaltyExpensePercentageOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_RoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty to be received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_RoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedFeesAndOtherRevenueReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, the amount of fees and other revenue, excluding investment income receivable, earned but not yet received, which were recognized in conformity with revenue recognition criteria based on estimates or specific contractual terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedFeesAndOtherRevenueReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for fees during the current period. This element excludes cash proceeds from license fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RoyaltyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_RoyaltyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bmra_TelconAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bmra_TelconAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bmra_UCLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bmra_UCLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bmra_UniversityOFSouthernCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bmra_UniversityOFSouthernCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bmra_BiomericaInFoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bmra_BiomericaInFoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143089439360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - Supplemental cash flow information related to leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract', window );"><strong>Supplemental Cash Flow Information Related To Leases Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 338,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">4 years 3 months 10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">6.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143089285088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - Future minimum lease payments under operating leases<br></strong></div></th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract', window );"><strong>Future Minimum Lease Payments Under Operating Leases Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Less than 1 year</a></td>
<td class="nump">$ 351,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">1 to 2 years</a></td>
<td class="nump">362,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2 to 3 years</a></td>
<td class="nump">373,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">3 to 4 years</a></td>
<td class="nump">384,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">4 to 5 years</a></td>
<td class="nump">104,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">1,574,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="nump">194,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 1,380,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140143086277440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - Subsequent Event [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SUBSEQUENTEVENTSDetailsLineItems', window );"><strong>SUBSEQUENT EVENTS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="nump">523,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="nump">$ 3.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock | $</a></td>
<td class="nump">$ 1,765,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_SUBSEQUENTEVENTSDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_SUBSEQUENTEVENTSDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>bmra-20220531_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bmra="http://www.biomerica.com/20220531"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pf0="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bmra-20220531.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <instant>2022-08-29</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bmra:A5PercentConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bmra:A5PercentConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmra:A5PercentConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmra:A5PercentConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmra:A5PercentConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmra:A5PercentConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <instant>2021-01-22</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:TwoDistributorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:TwoDistributorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:OneDistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:OneDistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:OneDistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:OneDistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:TwoDistributorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:DistributorsInAsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:OneVendorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:OneVendorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bmra:PurchasedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bmra:PolishDistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:PhysiciansOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:PhysiciansOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:ClinicalLabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:ClinicalLabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:OverthecounterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:OverthecounterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:TwoVendorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:OneVendorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmra:A2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmra:A2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-12-31</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmra:A2017PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmra:A2017PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-31</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmra:A2020PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-11</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">bmra:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-22</startDate>
            <endDate>2021-01-22</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmra:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-21</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:StockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:PalmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-24</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:StockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:PalmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-24</startDate>
            <endDate>2020-02-24</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-24</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-24</startDate>
            <endDate>2020-03-24</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:PalmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-24</startDate>
            <endDate>2020-03-24</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:PalmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-21</instant>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:PalmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-21</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare082818Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare514870Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare082362Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare235818Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare082870Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare425446Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare120362Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare161818Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare082870Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:RangeOfExercisePrice082152Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:RangeOfExercisePrice082152Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:RangeOfExercisePrice225425Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:RangeOfExercisePrice225425Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:RangeOfExercisePrice434870Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:RangeOfExercisePrice434870Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bmra:CaliforniaStateIncomeTaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:AsiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:AsiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:NorthAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:NorthAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:SouthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:SouthAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:SouthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">pf0:SouthAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">us-gaap:MiddleEastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">us-gaap:MiddleEastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">us-gaap:MiddleEastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">us-gaap:MiddleEastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">bmra:FirstAmendmentToLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">bmra:BuildingInIrvineCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">bmra:FirstAmendmentToLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">bmra:BuildingInIrvineCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:PropertyAvailableForOperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-01</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:PropertyAvailableForOperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:PropertyAvailableForOperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:PropertyAvailableForOperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:PropertyAvailableForOperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:TelconAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:TelconAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:UCLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-07</startDate>
            <endDate>2020-05-07</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:UCLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-01</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:UniversityOFSouthernCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:UniversityOFSouthernCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:BiomericaInFoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <dei:DocumentType contextRef="c0">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0">2022-05-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0">--05-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0">001-37863</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0">BIOMERICA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0">95-2645573</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0">17571 Von Karman Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0">Irvine</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0">92614</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0">949</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0">645-2111</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0">COMMON STOCK, PAR VALUE $0.08</dei:Security12bTitle>
    <dei:SecurityExchangeName contextRef="c0">NASDAQ</dei:SecurityExchangeName>
    <dei:TradingSymbol contextRef="c0">BMRA</dei:TradingSymbol>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c0">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c1" decimals="0" unitRef="usd">55709903</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c2" decimals="INF" unitRef="shares">13391901</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName contextRef="c0">HASKELL &amp; WHITE LLP</dei:AuditorName>
    <dei:AuditorFirmId contextRef="c0">200</dei:AuditorFirmId>
    <dei:AuditorLocation contextRef="c0">Irvine, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="INF" unitRef="usd">5916983</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="INF" unitRef="usd">4199311</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c3" decimals="INF" unitRef="usd">153231</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c4" decimals="INF" unitRef="usd">837415</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="INF" unitRef="usd">773818</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c4" decimals="INF" unitRef="usd">1455051</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c3" decimals="INF" unitRef="usd">2416447</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c4" decimals="INF" unitRef="usd">3206255</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="INF" unitRef="usd">320283</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c4" decimals="INF" unitRef="usd">370290</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="INF" unitRef="usd">9427531</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c4" decimals="INF" unitRef="usd">9230907</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="INF" unitRef="usd">1305360</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c4" decimals="INF" unitRef="usd">1972357</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="INF" unitRef="usd">214487</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="INF" unitRef="usd">310520</us-gaap:PropertyPlantAndEquipmentNet>
    <bmra:OperatingLeaseRightOfUseAssetAccumulatedAmortization contextRef="c3" decimals="INF" unitRef="usd">724802</bmra:OperatingLeaseRightOfUseAssetAccumulatedAmortization>
    <bmra:OperatingLeaseRightOfUseAssetAccumulatedAmortization contextRef="c4" decimals="INF" unitRef="usd">469077</bmra:OperatingLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="INF" unitRef="usd">1301834</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c4" decimals="INF" unitRef="usd">1553081</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Investments contextRef="c3" decimals="INF" unitRef="usd">165324</us-gaap:Investments>
    <us-gaap:Investments contextRef="c4" decimals="INF" unitRef="usd">165324</us-gaap:Investments>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c3" decimals="INF" unitRef="usd">18994</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c4" decimals="INF" unitRef="usd">126769</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c3" decimals="INF" unitRef="usd">169516</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c4" decimals="INF" unitRef="usd">294830</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="c3" decimals="INF" unitRef="usd">95588</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c4" decimals="INF" unitRef="usd">264151</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c3" decimals="INF" unitRef="usd">11374280</us-gaap:Assets>
    <us-gaap:Assets contextRef="c4" decimals="INF" unitRef="usd">11818813</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c3" decimals="INF" unitRef="usd">972372</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c4" decimals="INF" unitRef="usd">583380</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c3" decimals="INF" unitRef="usd">646944</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c4" decimals="INF" unitRef="usd">388896</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiability contextRef="c3" decimals="INF" unitRef="usd">50670</us-gaap:ContractWithCustomerLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="INF" unitRef="usd">341296</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c4" decimals="INF" unitRef="usd">327944</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="INF" unitRef="usd">2011282</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c4" decimals="INF" unitRef="usd">1300220</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="INF" unitRef="usd">1038284</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c4" decimals="INF" unitRef="usd">1291570</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c3" decimals="INF" unitRef="usd">3049566</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c4" decimals="INF" unitRef="usd">2591790</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c5" decimals="INF" unitRef="usdPershares">0.08</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c6" decimals="INF" unitRef="usdPershares">0.08</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c5" decimals="INF" unitRef="shares">571429</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c6" decimals="INF" unitRef="shares">571429</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c5" decimals="INF" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c6" decimals="INF" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c5" decimals="INF" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c6" decimals="INF" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockNoParValue contextRef="c3" decimals="INF" unitRef="usdPershares">0</us-gaap:PreferredStockNoParValue>
    <us-gaap:PreferredStockNoParValue contextRef="c4" decimals="INF" unitRef="usdPershares">0</us-gaap:PreferredStockNoParValue>
    <bmra:PreferredStockUndesignatedShares contextRef="c3" decimals="INF" unitRef="shares">4428571</bmra:PreferredStockUndesignatedShares>
    <bmra:PreferredStockUndesignatedShares contextRef="c4" decimals="INF" unitRef="shares">4428571</bmra:PreferredStockUndesignatedShares>
    <us-gaap:PreferredStockSharesIssued contextRef="c3" decimals="INF" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c4" decimals="INF" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c3" decimals="INF" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c4" decimals="INF" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c3" decimals="INF" unitRef="usdPershares">0.08</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c4" decimals="INF" unitRef="usdPershares">0.08</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="INF" unitRef="shares">25000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c4" decimals="INF" unitRef="shares">25000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="INF" unitRef="shares">12867924</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="INF" unitRef="shares">12867924</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c4" decimals="INF" unitRef="shares">12307157</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c4" decimals="INF" unitRef="shares">12307157</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c3" decimals="INF" unitRef="usd">1029432</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c4" decimals="INF" unitRef="usd">984571</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="INF" unitRef="usd">42446597</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c4" decimals="INF" unitRef="usd">38836743</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c3" decimals="INF" unitRef="usd">-73936</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c4" decimals="INF" unitRef="usd">-47956</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="INF" unitRef="usd">-35077379</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c4" decimals="INF" unitRef="usd">-30546335</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="INF" unitRef="usd">8324714</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="INF" unitRef="usd">9227023</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="INF" unitRef="usd">11374280</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c4" decimals="INF" unitRef="usd">11818813</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c0" decimals="INF" unitRef="usd">18871409</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c7" decimals="INF" unitRef="usd">7199027</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c0" decimals="INF" unitRef="usd">15893991</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c7" decimals="INF" unitRef="usd">6832742</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c0" decimals="INF" unitRef="usd">2977418</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c7" decimals="INF" unitRef="usd">366285</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c0" decimals="INF" unitRef="usd">5698958</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c7" decimals="INF" unitRef="usd">5671517</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="INF" unitRef="usd">1812424</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c7" decimals="INF" unitRef="usd">2194461</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="INF" unitRef="usd">7511382</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c7" decimals="INF" unitRef="usd">7865978</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="INF" unitRef="usd">-4533964</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c7" decimals="INF" unitRef="usd">-7499693</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c0" decimals="INF" unitRef="usd">26639</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c7" decimals="INF" unitRef="usd">66863</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InterestExpense contextRef="c7" decimals="INF" unitRef="usd">367</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="INF" unitRef="usd">26639</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c7" decimals="INF" unitRef="usd">66496</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="INF" unitRef="usd">-4507325</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c7" decimals="INF" unitRef="usd">-7433197</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="INF" unitRef="usd">23719</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c7" decimals="INF" unitRef="usd">13057</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="INF" unitRef="usd">-4531044</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="INF" unitRef="usd">-7446254</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic contextRef="c0" decimals="INF" unitRef="usdPershares">-0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c7" decimals="INF" unitRef="usdPershares">-0.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted contextRef="c0" decimals="INF" unitRef="usdPershares">-0.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="c7" decimals="INF" unitRef="usdPershares">-0.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c0" decimals="INF" unitRef="shares">12673245</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c7" decimals="INF" unitRef="shares">11928941</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c0" decimals="INF" unitRef="shares">12673245</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c7" decimals="INF" unitRef="shares">11928941</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="INF" unitRef="usd">-4531044</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="INF" unitRef="usd">-7446254</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c0" decimals="INF" unitRef="usd">-25980</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c7" decimals="INF" unitRef="usd">-8115</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c0" decimals="INF" unitRef="usd">-4557024</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c7" decimals="INF" unitRef="usd">-7454369</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued contextRef="c8" decimals="INF" unitRef="shares">11740089</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c8" decimals="INF" unitRef="usd">939205</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued contextRef="c9" decimals="INF" unitRef="shares">321429</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="INF" unitRef="usd">25714</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="INF" unitRef="usd">36388056</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c11" decimals="INF" unitRef="usd">-39841</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c12" decimals="INF" unitRef="usd">-23100081</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c13" decimals="INF" unitRef="usd">14213053</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c14" decimals="INF" unitRef="shares">86750</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c14" decimals="INF" unitRef="usd">6940</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c15" decimals="INF" unitRef="usd">95315</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c7" decimals="INF" unitRef="usd">102255</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c14" decimals="INF" unitRef="shares">158889</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c14" decimals="INF" unitRef="usd">12712</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c15" decimals="INF" unitRef="usd">998763</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c7" decimals="INF" unitRef="usd">1011475</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c16" decimals="INF" unitRef="usd">-8115</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c7" decimals="INF" unitRef="usd">-8115</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="c14" decimals="INF" unitRef="shares">321429</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="c14" decimals="INF" unitRef="usd">25714</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="c17" decimals="INF" unitRef="shares">-321429</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="c17" decimals="INF" unitRef="usd">-25714</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c15" decimals="INF" unitRef="usd">1354609</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c7" decimals="INF" unitRef="usd">1354609</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c18" decimals="INF" unitRef="usd">-7446254</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="INF" unitRef="usd">-7446254</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued contextRef="c19" decimals="INF" unitRef="shares">12307157</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="INF" unitRef="usd">984571</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="INF" unitRef="usd">38836743</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="INF" unitRef="usd">-47956</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c23" decimals="INF" unitRef="usd">-30546335</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="INF" unitRef="usd">9227023</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c24" decimals="INF" unitRef="shares">39500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c24" decimals="INF" unitRef="usd">3160</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c25" decimals="INF" unitRef="usd">74200</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c0" decimals="INF" unitRef="usd">77360</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c24" decimals="INF" unitRef="shares">521267</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c24" decimals="INF" unitRef="usd">41701</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c25" decimals="INF" unitRef="usd">2275459</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c0" decimals="INF" unitRef="usd">2317160</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c26" decimals="INF" unitRef="usd">-25980</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c0" decimals="INF" unitRef="usd">-25980</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c25" decimals="INF" unitRef="usd">1260195</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c0" decimals="INF" unitRef="usd">1260195</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c27" decimals="INF" unitRef="usd">-4531044</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="INF" unitRef="usd">-4531044</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued contextRef="c28" decimals="INF" unitRef="shares">12867924</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c28" decimals="INF" unitRef="usd">1029432</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c30" decimals="INF" unitRef="usd">42446597</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c31" decimals="INF" unitRef="usd">-73936</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c32" decimals="INF" unitRef="usd">-35077379</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="INF" unitRef="usd">8324714</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="INF" unitRef="usd">-4531044</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="INF" unitRef="usd">-7446254</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c0" decimals="INF" unitRef="usd">339096</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c7" decimals="INF" unitRef="usd">138267</us-gaap:DepreciationAndAmortization>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c0" decimals="INF" unitRef="usd">-52587</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c0" decimals="INF" unitRef="usd">-684184</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c7" decimals="INF" unitRef="usd">766434</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:InventoryLIFOReservePeriodCharge contextRef="c0" decimals="INF" unitRef="usd">-771736</us-gaap:InventoryLIFOReservePeriodCharge>
    <us-gaap:InventoryLIFOReservePeriodCharge contextRef="c7" decimals="INF" unitRef="usd">1550594</us-gaap:InventoryLIFOReservePeriodCharge>
    <us-gaap:StockOptionPlanExpense contextRef="c0" decimals="INF" unitRef="usd">1260195</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="c7" decimals="INF" unitRef="usd">1354609</us-gaap:StockOptionPlanExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c0" decimals="INF" unitRef="usd">255725</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c7" decimals="INF" unitRef="usd">237588</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c0" decimals="INF" unitRef="usd">-1365417</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c7" decimals="INF" unitRef="usd">455614</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c0" decimals="INF" unitRef="usd">-1561544</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c7" decimals="INF" unitRef="usd">1906013</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="INF" unitRef="usd">-50007</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c7" decimals="INF" unitRef="usd">-1138793</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <bmra:IncreaseDecreaseInLeaseLiability contextRef="c0" decimals="INF" unitRef="usd">-244412</bmra:IncreaseDecreaseInLeaseLiability>
    <bmra:IncreaseDecreaseInLeaseLiability contextRef="c7" decimals="INF" unitRef="usd">-241132</bmra:IncreaseDecreaseInLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c0" decimals="INF" unitRef="usd">-168563</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c7" decimals="INF" unitRef="usd">95958</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="INF" unitRef="usd">388992</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c7" decimals="INF" unitRef="usd">-403331</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c0" decimals="INF" unitRef="usd">258048</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c7" decimals="INF" unitRef="usd">110269</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c0" decimals="INF" unitRef="usd">50670</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="INF" unitRef="usd">-480532</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c7" decimals="INF" unitRef="usd">-5251748</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c0" decimals="INF" unitRef="usd">113436</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c7" decimals="INF" unitRef="usd">159727</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="INF" unitRef="usd">56900</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c7" decimals="INF" unitRef="usd">135856</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="INF" unitRef="usd">-170336</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c7" decimals="INF" unitRef="usd">-295583</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c0" decimals="INF" unitRef="usd">2401734</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c7" decimals="INF" unitRef="usd">1177394</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c0" decimals="INF" unitRef="usd">84574</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c7" decimals="INF" unitRef="usd">165919</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c0" decimals="INF" unitRef="usd">77360</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c7" decimals="INF" unitRef="usd">102255</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="INF" unitRef="usd">2394520</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c7" decimals="INF" unitRef="usd">1113730</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c0" decimals="INF" unitRef="usd">-25980</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c7" decimals="INF" unitRef="usd">-8115</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="INF" unitRef="usd">1717672</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c7" decimals="INF" unitRef="usd">-4441716</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="INF" unitRef="usd">4199311</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c13" decimals="INF" unitRef="usd">8641027</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="INF" unitRef="usd">5916983</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="INF" unitRef="usd">4199311</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid contextRef="c0" decimals="INF" unitRef="usd">23719</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c7" decimals="INF" unitRef="usd">27171</us-gaap:IncomeTaxesPaid>
    <bmra:IncreaseInRightOfUseAsset contextRef="c0" decimals="INF" unitRef="usd">4478</bmra:IncreaseInRightOfUseAsset>
    <bmra:IncreaseInRightOfUseAsset contextRef="c7" decimals="INF" unitRef="usd">79159</bmra:IncreaseInRightOfUseAsset>
    <bmra:IncreaseInLeaseLiability contextRef="c0" decimals="INF" unitRef="usd">4478</bmra:IncreaseInLeaseLiability>
    <bmra:IncreaseInLeaseLiability contextRef="c7" decimals="INF" unitRef="usd">79159</bmra:IncreaseInLeaseLiability>
    <bmra:WriteOffOfFixedAssetsCost contextRef="c0" decimals="INF" unitRef="usd">819931</bmra:WriteOffOfFixedAssetsCost>
    <bmra:WriteOffOfFixedAssetsAccumulatedDepreciation contextRef="c0" decimals="INF" unitRef="usd">767344</bmra:WriteOffOfFixedAssetsAccumulatedDepreciation>
    <bmra:WriteOffOfIntangibleAssetsCost contextRef="c0" decimals="INF" unitRef="usd">246756</bmra:WriteOffOfIntangibleAssetsCost>
    <bmra:WriteOffOfIntangibleAssetsAccumulatedAmortization contextRef="c0" decimals="INF" unitRef="usd">37221</bmra:WriteOffOfIntangibleAssetsAccumulatedAmortization>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;NOTE 1: &#160;&#160;&#160;ORGANIZATION &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Biomerica, Inc. and its subsidiaries (which includes wholly-owned subsidiaries, Biomerica de Mexico and BioEurope GmbH) is&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt; a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care &lt;/span&gt;&lt;span style="font-size: 10pt; color: black;"&gt;(physicians' offices and over-the-counter through drugstores and online) &lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases&lt;/span&gt;&lt;span style="font-size: 10pt; color: black;"&gt;. Our diagnostic test kits are used to analyze blood, urine, nasal or fecal material from patients in the diagnosis of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which may exist in the human body in extremely small concentrations. The&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt; Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Our primary focus is the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided therapy (&#x201c;DGT&#x201d;) products to treat gastrointestinal diseases, such as irritable bowel syndrome, and other inflammatory diseases. These products are directed at chronic inflammatory illnesses that are widespread and common, and as such address very large markets. Our InFoods&#xae; IBS product uses a simple blood sample and is designed to identify patient-specific foods that, when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea and constipation. Instead of broad and difficult to manage dietary restrictions, the InFoods&#xae; IBS product works by identifying a patient&#x2019;s above normal immunoreactivity to specific foods.&#160; A food identified as positive and causing an abnormal immune response in the patient is simply removed from the diet to help alleviate IBS symptoms. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Our existing medical diagnostic products are sold worldwide primarily in two markets: 1) clinical laboratories and 2) point-of-care (physicians' offices and over-the-counter drugstores like Walmart and Walgreens). The diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens, or other substances, which may exist in a patient&#x2019;s body, stools, or blood, often in extremely small concentrations.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;Due to the global 2019 SARS-CoV-2 novel coronavirus pandemic&lt;span style="COLOR:black"&gt;, in March 2020 we&lt;/span&gt; began developing COVID-19 products to indicate if a person has been infected by COVID-19 or is currently infected. While we offer a COVID-19 antibody diagnostic test to determine if a person has previously been infected by the COVID-19 virus, all of our COVID-19 revenues &lt;span style="COLOR:black"&gt;in fiscal 2022&lt;/span&gt; have come from international sales of our COVID-19 antigen tests that use a patient&#x2019;s nasal fluid sample to detect if the patient is currently infected with the virus.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The other existing products that contributed to our 2022 revenues are primarily focused on gastrointestinal diseases, food intolerances, and certain esoteric tests. These diagnostic test products utilize immunoassay technology. Most of our products are CE marked and/or sold for diagnostic use where they are registered by each country&#x2019;s regulatory agency. In addition, some products are cleared for sale in the United States by the FDA.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;NOTE 2: &#160;&#160;&#160;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;PRINCIPLES OF CONSOLIDATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;The consolidated financial statements for the years ended May 31, 2022 and 2021, include the accounts of Biomerica, Inc. ("Biomerica") as well as its wholly-owned German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;ACCOUNTING ESTIMATES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates, which are calculated based on historical data; inventory obsolescence, which is based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, the likelihood of lease extensions to occur, asset valuation, among other things; and other items that may be necessary to estimate using current, historical and judgment based information. Actual results could materially differ from those estimates. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"&gt;&lt;span style="font-size: 10pt;"&gt;Due to the Coronavirus global pandemic, the Company&#x2019;s operations have been negatively impacted. &lt;span style="color: black;"&gt;The Company has faced disruptions in the following areas, (and may face further challenges): supply chain disruptions, loss of contracts and/or customers, closure of the Company&#x2019;s manufacturing or distribution facilities or of the facilities of the Company&#x2019;s suppliers, partners and customers, travel, shipping and logistical disruptions, government responses of all types, international business risks in countries where the Company makes and/or sells its products, loss of human capital or personnel at the Company, its partners and its customers, interruptions of production, customer credit risk, and general economic calamities. These ongoing pandemic related disruptions can materially negatively impact the Company&#x2019;s operations and financial performance and may continue to have significant material negative impacts on the Company.&#160;&#160; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;LIQUIDITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company has incurred net losses and negative cash flows from operations and has an accumulated deficit of approximately $35.3 million as of May 31, 2022.&#160; Management expects to continue to incur significant costs as it advances its trials and development activities. As of May 31, 2022, the Company had cash and cash equivalents of approximately $5,917,000 and working capital of approximately $7,416,000.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;On January 22, 2021, the Company filed a Prospectus Supplement for purposes of raising up to $15,000,000 to the base prospectus filed with the SEC on July 21, 2020, and was declared effective by the SEC on September 30, 2020, and an ATM &#x201c;at the market offering&#x201d; Agreement. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;The Company intends to use the net proceeds from such offering for general corporate purposes, including, without limitation, sales and marketing activities, clinical studies, and product development, making acquisitions of assets, businesses, companies or securities, capital expenditures, and for working capital needs.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Under an ATM Agreement, sales of the Placement Shares are deemed to be &#x201c;at the market offering&#x201d; as defined in Rule 415 promulgated under the Securities Act.&#160; The agent acts as sales agent under the ATM and uses commercially reasonable efforts to sell on the Company&#x2019;s behalf all the Placement Shares requested to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the agent and the Company. The Company has no obligation to sell any of the Placement Shares under the ATM Agreement, and may at any time suspend offers under, or terminate the ATM Agreement.&#160; &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;During the year ended May 31, 2022, the Company sold 521,267 shares of its common stock at prices ranging from $4.02 to $5.63 under its Form S-3 Registration Statement (&lt;/span&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;File No. 333-239980) &lt;/span&gt;&lt;span style="FONT-SIZE:10pt"&gt;and ATM Agreement which resulted in gross proceeds of approximately $2,402,000 and net proceeds to the Company of $2,317,000 after deducting commissions for each sale and legal, accounting, and other fees related to the filing of the Form S-3.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;As a result of cash and cash equivalents on hand on May 31, 2022, and the ability to raise additional funds through the ATM noted above, management believes the Company has sufficient funds to operate through at least August 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;FAIR VALUE OF FINANCIAL INSTRUMENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company has financial instruments whereby the fair market value of the financial instruments could be different than that recorded on a historical basis. The Company's financial instruments consist of its cash and cash equivalents, accounts receivable,&#160;and accounts payable. The carrying amounts of the Company's financial instruments approximate their fair values. The Company also maintains an investment in privately held company (see below). &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;CONCENTRATION OF CREDIT RISK&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies.&#160; As of May 31, 2022, the Company had approximately $5,702,000 of uninsured cash. The Company does not believe it is exposed to any significant credit risks.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company provides credit in the normal course of business to customers throughout the United States and in foreign markets.&#160; The Company performs ongoing credit evaluations of its customers and requires accelerated prepayment in some circumstances. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"/&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Our net sales were approximately $18,871,000 for fiscal 2022 compared to $7,199,000 for fiscal 2021. For the fiscal years ended May 31, 2022 and 2021, the Company had two distributors, which accounted for a total of 65% and 60% of our net sales, respectively. Of this, for the fiscal years ended May 31, 2022 and 2021, the largest of the distributors mentioned above accounted for 55% and 33%, respectively, of net sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"/&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Total gross receivables on May 31, 2022 and 2021 were approximately $927,000 and $2,292,000, respectively. On May 31, 2022 and 2021, the Company had one distributor and two distributors, respectively, which accounted for a total of 50% and 73%, respectively, of gross accounts receivable. Of the 50% as of May 31, 2022, 50% was owed by a distributor in Asia.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;For the fiscal years ended May 31, 2022 and 2021, the Company had one vendor, which accounted for 84% and 58%, respectively, of our purchases of raw materials.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;GEOGRAPHIC CONCENTRATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;As of May 31, 2022 and 2021, a&lt;/span&gt;&lt;span style="FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;pproximately $621,000 &lt;span style="COLOR:black"&gt;and $803,000, respectively&lt;/span&gt; of Biomerica&#x2019;s gross inventory was located in Mexicali, Mexico, respectively. &lt;span style="COLOR:black"&gt;As of May 31, 2022 and 2021,&lt;/span&gt; approximately $17,000 &lt;span style="COLOR:black"&gt;and $25,000, respectively&lt;/span&gt; of Biomerica&#x2019;s property and equipment, net of accumulated depreciation and amortization, was located in Mexicali, Mexico, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;CASH AND&lt;/span&gt;&lt;/b&gt;&lt;span style="FONT-SIZE:10pt"&gt;&lt;b&gt;&lt;span style="COLOR:black"&gt; CASH EQUIVALENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;ACCOUNTS RECEIVABLE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company extends unsecured credit to its customers on a regular basis. &#160;International accounts are usually required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. &#160;&#160;Initial credit levels for individual distributors are approved by designated officers and managers of the Company. All increases in credit limits are also approved by designated upper-level management. &#160;Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. &#160;Balances over ninety days old are usually reserved for unless collection is reasonably assured. &#160; &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables. &#160; Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;As of May 31, 2022 and 2021, the Company has established a reserve of approximately $153,000 and $837,000, respectively, for doubtful accounts. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;PREPAIDS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;The Company occasionally prepays for items such as inventory, insurance, and other items.&#160; These items are reported as prepaids, until either the inventory is physically received or the insurance and other items are utilized.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;As of May 31, 2022 and 2021, the prepaids were approximately $320,000 and $370,000, respectively, composed of prepayments to insurance and various other suppliers. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;INVENTORIES, NET&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black"&gt;The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The following is a summary of approximate net inventories:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733"&gt;

&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 70.18%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="5" style="border-top: 0px; height: 15pt; border-right: 0px; width: 29.82%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;May 31,&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 70.18%; background: white; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif;"&gt;2022&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.78%; background: white; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif;"&gt;2021&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 70.18%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.04%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;1,717,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.78%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;&#160;$ &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;1,812,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 70.18%; background: white; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Work in progress&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.04%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;763,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.78%; background: white; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;1,687,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 70.18%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Finished products&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.04%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;782,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.78%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;1,324,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 70.18%; background: white; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Total gross inventory&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.04%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;3,262,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.78%; background: white; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;&#160;$ &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;4,823,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 70.18%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Inventory reserve&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.04%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;(846,000)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.78%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;(1,617,000)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15.75pt;"&gt;
&lt;td style="height: 15.75pt; width: 70.18%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Net inventory &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;$&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12.04%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;2,416,000 &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15.75pt; width: 1.78%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;$&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;3,206,000 &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically reserve for obsolete inventory. As of May 31, 2022 and 2021, inventory reserves were approximately $846,000 and $1,617,000, respectively. During the fiscal 2022 the Company disposed of COVID-19 antibody inventory that wasn&#x2019;t sellable, this has been partially reserved for in fiscal 2021. The reduction in our inventory reserve relates to the COVID-19 antibody disposal. The Company continues to sell COVID-19 antigen tests. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment amounted to approximately $100,000 and $105,000 for the years ended May 31, 2022 and 2021, respectively. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;INTANGIBLE ASSETS, NET&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (&#x201c;ASC&#x201d;), ASC 350 Intangibles &#x2013; Goodwill and Other (&#x201c;ASC 350&#x201d;). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Intangible assets are being amortized using the straight-line method over the useful life, not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, and 20 years for patents. Amortization amounted to approximately $239,000 and $34,000 for the years ended May 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset's balance over its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine whether there was any impairment. As of May 31, 2022 and 2021, an impairment adjustment was made of $210,000 and $0, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;INVESTMENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;From time-to-time, the Company makes investments in privately held companies. Investments represent the Company&#x2019;s investment in a Polish distributor, which is primarily engaged in distributing medical products and devices. The Company owns approximately 6% of the investee and, accordingly, applies the cost method holdings to account for the investment. The Company invested approximately $165,000 into the Polish distributor.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Equity holdings in nonmarketable unconsolidated entities in which the Company is not able to exercise significant influence ("Cost Method Holdings") are accounted for at the Company's initial cost, minus any impairment (if any), plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar holding or security of the same issuer. Dividends received are recorded as other income.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company assesses its equity holdings for impairment whenever events or changes in circumstances indicate that the carrying value of an equity holding may not be recoverable. Management reviewed the underlying net assets of the Company's equity method holding as of May 31, 2022 and determined that the Company's proportionate economic interest in the entity indicates that the equity holding was not impaired. There were no observable price changes in orderly transactions for identical or a similar holding or security of the Company&#x2019;s Cost Method Holding during the year ended May 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;SHARE-BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company follows the guidance of ASC 718, Share-based Compensation (&#x201c;ASC 718&#x201d;), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes options-pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the foreseeable future. Expected volatilities are based on weighted averages of the historical volatility of the Company&#x2019;s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the &#x201c;simplified method&#x201d; which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited exercise activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. The grant date fair value of the award is recognized under the straight-line attribution method.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company expensed approximately $1,260,000 and $1,355,000 of stock-based compensation during the years ended May 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;In applying the Black-Scholes options-pricing model, assumptions used were as follows: &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733"&gt;

&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="4" style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;For the year ended May 31,&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;2022&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;2021&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;0%&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;0%&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;102.54 - 105.48% &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;&#160;71.19 - 107.53% &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;&#160;0.97-2.75% &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;&#160;0.34-1.18% &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;&#160;5.50-6.25 Years &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;&#160;5.50-6.25 Years &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;REVENUE RECOGNITION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company has various contracts with customers.&#160; All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred, and at which point title passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company regularly evaluates the status of these contracts and does not believe that any additional discounts will be given through the end of the contract periods. &lt;/span&gt;&lt;span style="FONT-SIZE:10pt"&gt;Services for contract work are invoiced and recognized for work that has been performed as the project progresses. &lt;span style="COLOR:black"&gt;The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools, and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors. &#160;Physicians&#x2019; office products are sold to physicians and distributors, all of whom are categorized below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international manufacturers. &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Disaggregation of revenue:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The following is an approximate breakdown of revenues according to primary markets to which the products are sold:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733"&gt;

&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="5" style="border-top: 0px; height: 15pt; border-right: 0px; width: 165pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;For the year ended May 31,&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 77pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;2022&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 77pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;2021&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 374pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Physician's office&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;14,259,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;2,801,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Clinical lab&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;3,064,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;3,077,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 374pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Over-the-counter&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;1,089,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;766,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Contract manufacturing&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;459,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;555,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15.75pt;"&gt;
&lt;td style="height: 15.75pt; width: 374pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Total&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15.75pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 66pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;18,871,000 &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15.75pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 66pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;7,199,000 &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;See Note 8 for additional information regarding geographic revenue concentrations.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;SHIPPING AND HANDLING FEES &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company includes shipping and handling fees billed to customers in net sales. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;RESEARCH AND DEVELOPMENT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Research and development costs are expensed as incurred. The Company expensed approximately $1,812,000 and $2,194,000 of research and development costs during the years ended May 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company accounts for income taxes in accordance with ASC 740, Income Taxes (&#x201c;ASC 740&#x201d;). Deferred tax assets and liabilities arise from temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements that will result in taxable or deductible amounts in future years and the benefits of net operating loss and tax credit carryforwards. These temporary differences and the benefits of net operating loss and tax credit carryforwards are measured using enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets to the extent that management considers it is more likely than not that a deferred tax asset will not be realized. In determining the valuation allowance, the Company considers factors such as the reversal of deferred income tax assets, projected taxable income, and the character of income tax assets and tax planning strategies. A change to these factors could impact the estimated valuation allowance and income tax expense. On May 31, 2022 and 2021, in accordance with ASC 740, the Company has a valuation allowance for substantially all of its net deferred tax assets.&#160;&#160; During the fiscal year ended May 31, 2022, &lt;span style="BACKGROUND:none"&gt;this valuation allowance was increased to $6,967,000, which fully covers the net tax asset of $6,967,000&lt;/span&gt;&lt;/span&gt;&lt;span style="FONT-SIZE:9pt; BACKGROUND:none; COLOR:black"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company accounts for its uncertain tax provisions by using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, based solely on the technical merits, that the position will be sustained in an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the appropriate amount of the benefit to recognize. The amount of benefit to recognize is measured as the maximum amount which is more likely than not to be realized. The tax position is derecognized when it is no longer more likely than not capable of being sustained. On subsequent recognition and measurement, the maximum amount which is more likely than not to be recognized at each reporting date will represent the Company&#x2019;s best estimate, given the information available at the reporting date, although the outcome of the tax position is not absolute or final. The Company elected to follow an accounting policy to classify accrued interest related to liabilities for income taxes within the &#x201c;Interest expense&#x201d; line and penalties related to liabilities for income taxes within the &#x201c;Other expense&#x201d; line of the consolidated statements of operations and comprehensive loss. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;ADVERTISING COSTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company reports the cost of all advertising as expense in the period in which those costs are incurred. Advertising costs were approximately &lt;span style="BACKGROUND:white"&gt;$76,000&lt;/span&gt; and $&lt;span style="BACKGROUND:white"&gt;10,000&lt;/span&gt; for the years ended May 31, 2022 and 2021, respectively. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;FOREIGN CURRENCY TRANSLATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the year, and revenues and costs are translated using average exchange rates for the year. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no foreign currency transactions that are included in the consolidated statements of operations for the years ended May 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;RIGHT-OF-USE ASSETS AND LEASE LIABILITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;In February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued an accounting standard update which requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset.&#160; Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.&#160; Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term.&#160; Leases are classified as financing or operating which will drive the expense recognition pattern.&#160; The Company has elected to exclude short-term leases.&#160; The Company adopted this guidance as of June 1, 2019, the required effective date, &#160;which resulted in a right-of-use asset being recorded of approximately $1,943,000 and a lease liability being recorded of approximately $1,981,000. On April 9, 2021, the Company exercised its second option to extend its lease for an additional five years.&#160; As part of that lease extension agreement, the Company was granted an additional right to extend its lease for five years, up through August 2031. However, given the recent growth in the Company&#x2019;s operations, and the expectation that operations will continue to grow in the near future, the Company believes that it will be necessary to relocate into larger facilities by the end of the current lease term. Therefore, the Company has elected to not include the additional five-year extension option, from August 2026 to August 2031, into its right-of-use asset or its lease liability accounts. For additional information, see Note 9-Commitments and Contingencies. The Company leases office space and copy machines, all of which are operating leases.&#160; Most leases include the option to renew and the exercise of the renewal options is at the Company&#x2019;s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.&#160; The leases do not include the options to purchase the leased property.&#160; The depreciable life of assets and leasehold improvements are limited by the expected lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;NET LOSS PER SHARE &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amounts of anti-dilutive stock options not included in the loss per share calculation for the years ended May 31, 2022 and 2021 were 2,321,616 and 2,081,366, respectively. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;SEGMENT REPORTING&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;ASC 280, Segment Reporting (&#x201c;ASC 280&#x201d;), establishes standards for reporting, by public business enterprises, information about operating segments, products and services, geographic areas, and major customers. The Company&#x2019;s operations are analyzed by management and its chief operating decision maker as being part of a single industry segment: the design, development, marketing, and sales of diagnostic kits.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;REPORTING COMPREHENSIVE LOSS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Comprehensive loss represents net loss and any revenues, expenses, gains and losses that, under GAAP, are excluded from net loss and recognized directly as a component of shareholders&#x2019; equity. Items of other comprehensive loss consist solely of foreign currency translation adjustments for the years ended May 31, 2022 and 2021. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;RECENT ACCOUNTING PRONOUNCEMENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Recent ASU's issued by the FASB and guidance issued by the SEC did not, or are not believed by management to, have a material effect on the Company&#x2019;s present or future consolidated financial statements. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in 0.1in 0in 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;In June 2016, the FASB issued ASU 2016-13, "Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments." This ASU will require the measurement of all expected credit losses for financial assets, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The guidance was initially effective for the Company for annual reporting periods beginning after December 15, 2019, and interim periods within those fiscal years. In November 2019, the FASB issued ASU 201&#xb7;9- 10, "Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates," which, among other things, defers the effective date of ASU 2016-13 for public filers that are considered smaller reporting companies as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including interim periods within those years. Early adoption is permitted. The Company is currently reviewing the requirements of this ASU to determine its impact on the Company&#x2019;s consolidated results of operations and financial position. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in 0.1in 0in 0in;"&gt;&#160;&lt;/p&gt;&lt;p style="margin: 0in; text-align: justify;"&gt;&lt;span style="font-family: times new roman, times, serif; font-size: 10pt;"&gt;&lt;strong&gt;&lt;span style="color: black;"&gt;RECLASSIFICATIONS&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin: 0in; text-align: justify;"&gt;&lt;span style="font-family: times new roman, times, serif; font-size: 10pt;"&gt;&lt;strong&gt;&lt;span style="color: black;"&gt;&#160;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin: 0in; text-align: justify;"&gt;&lt;span style="font-size: 10.0pt; color: black;"&gt;&lt;span style="font-family: times new roman, times, serif;"&gt;Certain comparative figures in the 2021 Statement of Operations have been reclassified to conform to the current year&#x2019;s presentation.&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;PRINCIPLES OF CONSOLIDATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;The consolidated financial statements for the years ended May 31, 2022 and 2021, include the accounts of Biomerica, Inc. ("Biomerica") as well as its wholly-owned German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;ACCOUNTING ESTIMATES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates, which are calculated based on historical data; inventory obsolescence, which is based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, the likelihood of lease extensions to occur, asset valuation, among other things; and other items that may be necessary to estimate using current, historical and judgment based information. Actual results could materially differ from those estimates. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"&gt;&lt;span style="font-size: 10pt;"&gt;Due to the Coronavirus global pandemic, the Company&#x2019;s operations have been negatively impacted. &lt;span style="color: black;"&gt;The Company has faced disruptions in the following areas, (and may face further challenges): supply chain disruptions, loss of contracts and/or customers, closure of the Company&#x2019;s manufacturing or distribution facilities or of the facilities of the Company&#x2019;s suppliers, partners and customers, travel, shipping and logistical disruptions, government responses of all types, international business risks in countries where the Company makes and/or sells its products, loss of human capital or personnel at the Company, its partners and its customers, interruptions of production, customer credit risk, and general economic calamities. These ongoing pandemic related disruptions can materially negatively impact the Company&#x2019;s operations and financial performance and may continue to have significant material negative impacts on the Company.&#160;&#160; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <bmra:LiquidityPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;LIQUIDITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company has incurred net losses and negative cash flows from operations and has an accumulated deficit of approximately $35.3 million as of May 31, 2022.&#160; Management expects to continue to incur significant costs as it advances its trials and development activities. As of May 31, 2022, the Company had cash and cash equivalents of approximately $5,917,000 and working capital of approximately $7,416,000.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;On January 22, 2021, the Company filed a Prospectus Supplement for purposes of raising up to $15,000,000 to the base prospectus filed with the SEC on July 21, 2020, and was declared effective by the SEC on September 30, 2020, and an ATM &#x201c;at the market offering&#x201d; Agreement. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;The Company intends to use the net proceeds from such offering for general corporate purposes, including, without limitation, sales and marketing activities, clinical studies, and product development, making acquisitions of assets, businesses, companies or securities, capital expenditures, and for working capital needs.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Under an ATM Agreement, sales of the Placement Shares are deemed to be &#x201c;at the market offering&#x201d; as defined in Rule 415 promulgated under the Securities Act.&#160; The agent acts as sales agent under the ATM and uses commercially reasonable efforts to sell on the Company&#x2019;s behalf all the Placement Shares requested to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the agent and the Company. The Company has no obligation to sell any of the Placement Shares under the ATM Agreement, and may at any time suspend offers under, or terminate the ATM Agreement.&#160; &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;During the year ended May 31, 2022, the Company sold 521,267 shares of its common stock at prices ranging from $4.02 to $5.63 under its Form S-3 Registration Statement (&lt;/span&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;File No. 333-239980) &lt;/span&gt;&lt;span style="FONT-SIZE:10pt"&gt;and ATM Agreement which resulted in gross proceeds of approximately $2,402,000 and net proceeds to the Company of $2,317,000 after deducting commissions for each sale and legal, accounting, and other fees related to the filing of the Form S-3.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;As a result of cash and cash equivalents on hand on May 31, 2022, and the ability to raise additional funds through the ATM noted above, management believes the Company has sufficient funds to operate through at least August 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;</bmra:LiquidityPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c32" decimals="-5" unitRef="usd">35300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" unitRef="usd">5917000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <bmra:WorkingCapital contextRef="c0" decimals="0" unitRef="usd">7416000</bmra:WorkingCapital>
    <bmra:ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue contextRef="c33" decimals="0" unitRef="usd">15000000</bmra:ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c34" decimals="0" unitRef="shares">521267</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice contextRef="c35" decimals="2" unitRef="usdPershares">4.02</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="c36" decimals="2" unitRef="usdPershares">5.63</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c34" decimals="0" unitRef="usd">2402000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c34" decimals="0" unitRef="usd">2317000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;FAIR VALUE OF FINANCIAL INSTRUMENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company has financial instruments whereby the fair market value of the financial instruments could be different than that recorded on a historical basis. The Company's financial instruments consist of its cash and cash equivalents, accounts receivable,&#160;and accounts payable. The carrying amounts of the Company's financial instruments approximate their fair values. The Company also maintains an investment in privately held company (see below). &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;CONCENTRATION OF CREDIT RISK&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies.&#160; As of May 31, 2022, the Company had approximately $5,702,000 of uninsured cash. The Company does not believe it is exposed to any significant credit risks.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company provides credit in the normal course of business to customers throughout the United States and in foreign markets.&#160; The Company performs ongoing credit evaluations of its customers and requires accelerated prepayment in some circumstances. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"/&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Our net sales were approximately $18,871,000 for fiscal 2022 compared to $7,199,000 for fiscal 2021. For the fiscal years ended May 31, 2022 and 2021, the Company had two distributors, which accounted for a total of 65% and 60% of our net sales, respectively. Of this, for the fiscal years ended May 31, 2022 and 2021, the largest of the distributors mentioned above accounted for 55% and 33%, respectively, of net sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"/&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Total gross receivables on May 31, 2022 and 2021 were approximately $927,000 and $2,292,000, respectively. On May 31, 2022 and 2021, the Company had one distributor and two distributors, respectively, which accounted for a total of 50% and 73%, respectively, of gross accounts receivable. Of the 50% as of May 31, 2022, 50% was owed by a distributor in Asia.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;For the fiscal years ended May 31, 2022 and 2021, the Company had one vendor, which accounted for 84% and 58%, respectively, of our purchases of raw materials.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashUninsuredAmount contextRef="c3" decimals="0" unitRef="usd">5702000</us-gaap:CashUninsuredAmount>
    <us-gaap:Revenues contextRef="c0" decimals="-3" unitRef="usd">18871000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c7" decimals="-3" unitRef="usd">7199000</us-gaap:Revenues>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c37" decimals="2" unitRef="pure">0.65</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c38" decimals="2" unitRef="pure">0.60</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c39" decimals="2" unitRef="pure">0.55</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c40" decimals="2" unitRef="pure">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:OtherReceivablesGrossCurrent contextRef="c3" decimals="0" unitRef="usd">927000</us-gaap:OtherReceivablesGrossCurrent>
    <us-gaap:OtherReceivablesGrossCurrent contextRef="c41" decimals="0" unitRef="usd">2292000</us-gaap:OtherReceivablesGrossCurrent>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c42" decimals="2" unitRef="pure">0.50</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c43" decimals="2" unitRef="pure">0.73</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c44" decimals="2" unitRef="pure">0.50</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c45" decimals="2" unitRef="pure">0.84</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c46" decimals="2" unitRef="pure">0.58</us-gaap:ConcentrationRiskPercentage1>
    <bmra:ConcentrationRiskGeographicPolicyPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;GEOGRAPHIC CONCENTRATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;As of May 31, 2022 and 2021, a&lt;/span&gt;&lt;span style="FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;pproximately $621,000 &lt;span style="COLOR:black"&gt;and $803,000, respectively&lt;/span&gt; of Biomerica&#x2019;s gross inventory was located in Mexicali, Mexico, respectively. &lt;span style="COLOR:black"&gt;As of May 31, 2022 and 2021,&lt;/span&gt; approximately $17,000 &lt;span style="COLOR:black"&gt;and $25,000, respectively&lt;/span&gt; of Biomerica&#x2019;s property and equipment, net of accumulated depreciation and amortization, was located in Mexicali, Mexico, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;</bmra:ConcentrationRiskGeographicPolicyPolicyTextBlock>
    <us-gaap:InventoryGross contextRef="c47" decimals="0" unitRef="usd">621000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross contextRef="c48" decimals="0" unitRef="usd">803000</us-gaap:InventoryGross>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c47" decimals="0" unitRef="usd">17000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c48" decimals="0" unitRef="usd">25000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;CASH AND&lt;/span&gt;&lt;/b&gt;&lt;span style="FONT-SIZE:10pt"&gt;&lt;b&gt;&lt;span style="COLOR:black"&gt; CASH EQUIVALENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;ACCOUNTS RECEIVABLE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company extends unsecured credit to its customers on a regular basis. &#160;International accounts are usually required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. &#160;&#160;Initial credit levels for individual distributors are approved by designated officers and managers of the Company. All increases in credit limits are also approved by designated upper-level management. &#160;Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. &#160;Balances over ninety days old are usually reserved for unless collection is reasonably assured. &#160; &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables. &#160; Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;As of May 31, 2022 and 2021, the Company has established a reserve of approximately $153,000 and $837,000, respectively, for doubtful accounts. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable contextRef="c0">P90D</us-gaap:ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c49" decimals="0" unitRef="usd">153000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c50" decimals="0" unitRef="usd">837000</us-gaap:ProvisionForDoubtfulAccounts>
    <bmra:PrepaidsPolicyPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;PREPAIDS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;The Company occasionally prepays for items such as inventory, insurance, and other items.&#160; These items are reported as prepaids, until either the inventory is physically received or the insurance and other items are utilized.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;As of May 31, 2022 and 2021, the prepaids were approximately $320,000 and $370,000, respectively, composed of prepayments to insurance and various other suppliers. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;</bmra:PrepaidsPolicyPolicyTextBlock>
    <us-gaap:IncreaseDecreaseInPrepaidSupplies contextRef="c0" decimals="0" unitRef="usd">320000</us-gaap:IncreaseDecreaseInPrepaidSupplies>
    <us-gaap:IncreaseDecreaseInPrepaidSupplies contextRef="c7" decimals="0" unitRef="usd">370000</us-gaap:IncreaseDecreaseInPrepaidSupplies>
    <us-gaap:InventoryPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;INVENTORIES, NET&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black"&gt;The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The following is a summary of approximate net inventories:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733"&gt;

&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 70.18%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="5" style="border-top: 0px; height: 15pt; border-right: 0px; width: 29.82%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;May 31,&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 70.18%; background: white; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif;"&gt;2022&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.78%; background: white; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif;"&gt;2021&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 70.18%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.04%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;1,717,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.78%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;&#160;$ &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;1,812,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 70.18%; background: white; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Work in progress&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.04%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;763,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.78%; background: white; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;1,687,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 70.18%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Finished products&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.04%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;782,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.78%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;1,324,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 70.18%; background: white; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Total gross inventory&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.04%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;3,262,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.78%; background: white; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;&#160;$ &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;4,823,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 70.18%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Inventory reserve&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.04%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;(846,000)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.78%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;(1,617,000)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15.75pt;"&gt;
&lt;td style="height: 15.75pt; width: 70.18%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Net inventory &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;$&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12.04%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;2,416,000 &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15.75pt; width: 1.78%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;$&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;3,206,000 &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically reserve for obsolete inventory. As of May 31, 2022 and 2021, inventory reserves were approximately $846,000 and $1,617,000, respectively. During the fiscal 2022 the Company disposed of COVID-19 antibody inventory that wasn&#x2019;t sellable, this has been partially reserved for in fiscal 2021. The reduction in our inventory reserve relates to the COVID-19 antibody disposal. The Company continues to sell COVID-19 antigen tests. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733"&gt;

&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 70.18%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="5" style="border-top: 0px; height: 15pt; border-right: 0px; width: 29.82%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;May 31,&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 70.18%; background: white; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif;"&gt;2022&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.78%; background: white; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif;"&gt;2021&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 70.18%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.04%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;1,717,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.78%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;&#160;$ &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;1,812,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 70.18%; background: white; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Work in progress&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.04%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;763,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.78%; background: white; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;1,687,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 70.18%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Finished products&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.04%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;782,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.78%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;1,324,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 70.18%; background: white; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Total gross inventory&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.04%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;3,262,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.78%; background: white; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;&#160;$ &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 0pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;4,823,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 70.18%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Inventory reserve&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.04%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;(846,000)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.78%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;(1,617,000)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15.75pt;"&gt;
&lt;td style="height: 15.75pt; width: 70.18%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Net inventory &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;$&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12.04%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;2,416,000 &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15.75pt; width: 1.78%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;$&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;3,206,000 &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c3" decimals="-3" unitRef="usd">1717000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c4" decimals="-3" unitRef="usd">1812000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c3" decimals="-3" unitRef="usd">763000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c4" decimals="-3" unitRef="usd">1687000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c3" decimals="-3" unitRef="usd">782000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c4" decimals="-3" unitRef="usd">1324000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryGross contextRef="c3" decimals="-3" unitRef="usd">3262000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross contextRef="c4" decimals="-3" unitRef="usd">4823000</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves contextRef="c3" decimals="-3" unitRef="usd">846000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="c4" decimals="-3" unitRef="usd">1617000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet contextRef="c3" decimals="-3" unitRef="usd">2416000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c4" decimals="-3" unitRef="usd">3206000</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves contextRef="c3" decimals="0" unitRef="usd">846000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="c4" decimals="0" unitRef="usd">1617000</us-gaap:InventoryValuationReserves>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment amounted to approximately $100,000 and $105,000 for the years ended May 31, 2022 and 2021, respectively. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c51">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c52">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c0" decimals="0" unitRef="usd">100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c7" decimals="0" unitRef="usd">105000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;INTANGIBLE ASSETS, NET&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (&#x201c;ASC&#x201d;), ASC 350 Intangibles &#x2013; Goodwill and Other (&#x201c;ASC 350&#x201d;). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Intangible assets are being amortized using the straight-line method over the useful life, not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, and 20 years for patents. Amortization amounted to approximately $239,000 and $34,000 for the years ended May 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset's balance over its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine whether there was any impairment. As of May 31, 2022 and 2021, an impairment adjustment was made of $210,000 and $0, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c53">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c54">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c55">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c0" decimals="0" unitRef="usd">239000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c7" decimals="0" unitRef="usd">34000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AssetImpairmentCharges contextRef="c0" decimals="0" unitRef="usd">210000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c7" decimals="0" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;INVESTMENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;From time-to-time, the Company makes investments in privately held companies. Investments represent the Company&#x2019;s investment in a Polish distributor, which is primarily engaged in distributing medical products and devices. The Company owns approximately 6% of the investee and, accordingly, applies the cost method holdings to account for the investment. The Company invested approximately $165,000 into the Polish distributor.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Equity holdings in nonmarketable unconsolidated entities in which the Company is not able to exercise significant influence ("Cost Method Holdings") are accounted for at the Company's initial cost, minus any impairment (if any), plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar holding or security of the same issuer. Dividends received are recorded as other income.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company assesses its equity holdings for impairment whenever events or changes in circumstances indicate that the carrying value of an equity holding may not be recoverable. Management reviewed the underlying net assets of the Company's equity method holding as of May 31, 2022 and determined that the Company's proportionate economic interest in the entity indicates that the equity holding was not impaired. There were no observable price changes in orderly transactions for identical or a similar holding or security of the Company&#x2019;s Cost Method Holding during the year ended May 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c56" decimals="2" unitRef="pure">0.06</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:Investments contextRef="c56" decimals="0" unitRef="usd">165000</us-gaap:Investments>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;SHARE-BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company follows the guidance of ASC 718, Share-based Compensation (&#x201c;ASC 718&#x201d;), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes options-pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the foreseeable future. Expected volatilities are based on weighted averages of the historical volatility of the Company&#x2019;s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the &#x201c;simplified method&#x201d; which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited exercise activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. The grant date fair value of the award is recognized under the straight-line attribution method.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company expensed approximately $1,260,000 and $1,355,000 of stock-based compensation during the years ended May 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;In applying the Black-Scholes options-pricing model, assumptions used were as follows: &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733"&gt;

&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="4" style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;For the year ended May 31,&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;2022&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;2021&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;0%&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;0%&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;102.54 - 105.48% &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;&#160;71.19 - 107.53% &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;&#160;0.97-2.75% &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;&#160;0.34-1.18% &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;&#160;5.50-6.25 Years &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;&#160;5.50-6.25 Years &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="0" unitRef="usd">1260000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c7" decimals="0" unitRef="usd">1355000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733"&gt;

&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="4" style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;For the year ended May 31,&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;2022&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;2021&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;0%&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;0%&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;102.54 - 105.48% &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;&#160;71.19 - 107.53% &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;&#160;0.97-2.75% &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;&#160;0.34-1.18% &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;&#160;5.50-6.25 Years &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 1.98%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;&#160;5.50-6.25 Years &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c0" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c7" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c51" decimals="4" unitRef="pure">1.0254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c52" decimals="4" unitRef="pure">1.0548</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c58" decimals="4" unitRef="pure">0.7119</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c59" decimals="4" unitRef="pure">1.0753</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c51" decimals="4" unitRef="pure">0.0097</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c52" decimals="4" unitRef="pure">0.0275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c58" decimals="4" unitRef="pure">0.0034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c59" decimals="4" unitRef="pure">0.0118</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c51">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c52">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c58">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c59">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;REVENUE RECOGNITION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company has various contracts with customers.&#160; All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred, and at which point title passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company regularly evaluates the status of these contracts and does not believe that any additional discounts will be given through the end of the contract periods. &lt;/span&gt;&lt;span style="FONT-SIZE:10pt"&gt;Services for contract work are invoiced and recognized for work that has been performed as the project progresses. &lt;span style="COLOR:black"&gt;The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools, and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors. &#160;Physicians&#x2019; office products are sold to physicians and distributors, all of whom are categorized below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international manufacturers. &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Disaggregation of revenue:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The following is an approximate breakdown of revenues according to primary markets to which the products are sold:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733"&gt;

&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="5" style="border-top: 0px; height: 15pt; border-right: 0px; width: 165pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;For the year ended May 31,&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 77pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;2022&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 77pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;2021&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 374pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Physician's office&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;14,259,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;2,801,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Clinical lab&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;3,064,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;3,077,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 374pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Over-the-counter&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;1,089,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;766,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Contract manufacturing&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;459,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;555,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15.75pt;"&gt;
&lt;td style="height: 15.75pt; width: 374pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Total&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15.75pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 66pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;18,871,000 &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15.75pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 66pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;7,199,000 &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;See Note 8 for additional information regarding geographic revenue concentrations.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733"&gt;

&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="5" style="border-top: 0px; height: 15pt; border-right: 0px; width: 165pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;For the year ended May 31,&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 77pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;2022&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 77pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;2021&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 374pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Physician's office&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;14,259,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;2,801,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Clinical lab&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;3,064,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;3,077,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 374pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Over-the-counter&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;1,089,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;766,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 374pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Contract manufacturing&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;459,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;555,000 &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15.75pt;"&gt;
&lt;td style="height: 15.75pt; width: 374pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Total&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15.75pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 66pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;18,871,000 &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15.75pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 66pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;7,199,000 &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c60" decimals="INF" unitRef="usd">14259000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c61" decimals="INF" unitRef="usd">2801000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c62" decimals="INF" unitRef="usd">3064000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c63" decimals="INF" unitRef="usd">3077000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c64" decimals="INF" unitRef="usd">1089000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c65" decimals="INF" unitRef="usd">766000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c66" decimals="INF" unitRef="usd">459000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c67" decimals="INF" unitRef="usd">555000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c0" decimals="INF" unitRef="usd">18871000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c7" decimals="INF" unitRef="usd">7199000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;SHIPPING AND HANDLING FEES &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company includes shipping and handling fees billed to customers in net sales. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;RESEARCH AND DEVELOPMENT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Research and development costs are expensed as incurred. The Company expensed approximately $1,812,000 and $2,194,000 of research and development costs during the years ended May 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" unitRef="usd">1812000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c7" decimals="-3" unitRef="usd">2194000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company accounts for income taxes in accordance with ASC 740, Income Taxes (&#x201c;ASC 740&#x201d;). Deferred tax assets and liabilities arise from temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements that will result in taxable or deductible amounts in future years and the benefits of net operating loss and tax credit carryforwards. These temporary differences and the benefits of net operating loss and tax credit carryforwards are measured using enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets to the extent that management considers it is more likely than not that a deferred tax asset will not be realized. In determining the valuation allowance, the Company considers factors such as the reversal of deferred income tax assets, projected taxable income, and the character of income tax assets and tax planning strategies. A change to these factors could impact the estimated valuation allowance and income tax expense. On May 31, 2022 and 2021, in accordance with ASC 740, the Company has a valuation allowance for substantially all of its net deferred tax assets.&#160;&#160; During the fiscal year ended May 31, 2022, &lt;span style="BACKGROUND:none"&gt;this valuation allowance was increased to $6,967,000, which fully covers the net tax asset of $6,967,000&lt;/span&gt;&lt;/span&gt;&lt;span style="FONT-SIZE:9pt; BACKGROUND:none; COLOR:black"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company accounts for its uncertain tax provisions by using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, based solely on the technical merits, that the position will be sustained in an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the appropriate amount of the benefit to recognize. The amount of benefit to recognize is measured as the maximum amount which is more likely than not to be realized. The tax position is derecognized when it is no longer more likely than not capable of being sustained. On subsequent recognition and measurement, the maximum amount which is more likely than not to be recognized at each reporting date will represent the Company&#x2019;s best estimate, given the information available at the reporting date, although the outcome of the tax position is not absolute or final. The Company elected to follow an accounting policy to classify accrued interest related to liabilities for income taxes within the &#x201c;Interest expense&#x201d; line and penalties related to liabilities for income taxes within the &#x201c;Other expense&#x201d; line of the consolidated statements of operations and comprehensive loss. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="0" unitRef="usd">6967000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsGross contextRef="c3" decimals="0" unitRef="usd">6967000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;ADVERTISING COSTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company reports the cost of all advertising as expense in the period in which those costs are incurred. Advertising costs were approximately &lt;span style="BACKGROUND:white"&gt;$76,000&lt;/span&gt; and $&lt;span style="BACKGROUND:white"&gt;10,000&lt;/span&gt; for the years ended May 31, 2022 and 2021, respectively. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense contextRef="c0" decimals="0" unitRef="usd">76000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c7" decimals="0" unitRef="usd">10000</us-gaap:AdvertisingExpense>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;FOREIGN CURRENCY TRANSLATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the year, and revenues and costs are translated using average exchange rates for the year. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no foreign currency transactions that are included in the consolidated statements of operations for the years ended May 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;RIGHT-OF-USE ASSETS AND LEASE LIABILITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;In February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued an accounting standard update which requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset.&#160; Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.&#160; Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term.&#160; Leases are classified as financing or operating which will drive the expense recognition pattern.&#160; The Company has elected to exclude short-term leases.&#160; The Company adopted this guidance as of June 1, 2019, the required effective date, &#160;which resulted in a right-of-use asset being recorded of approximately $1,943,000 and a lease liability being recorded of approximately $1,981,000. On April 9, 2021, the Company exercised its second option to extend its lease for an additional five years.&#160; As part of that lease extension agreement, the Company was granted an additional right to extend its lease for five years, up through August 2031. However, given the recent growth in the Company&#x2019;s operations, and the expectation that operations will continue to grow in the near future, the Company believes that it will be necessary to relocate into larger facilities by the end of the current lease term. Therefore, the Company has elected to not include the additional five-year extension option, from August 2026 to August 2031, into its right-of-use asset or its lease liability accounts. For additional information, see Note 9-Commitments and Contingencies. The Company leases office space and copy machines, all of which are operating leases.&#160; Most leases include the option to renew and the exercise of the renewal options is at the Company&#x2019;s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.&#160; The leases do not include the options to purchase the leased property.&#160; The depreciable life of assets and leasehold improvements are limited by the expected lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c57" decimals="0" unitRef="usd">1943000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="c57" decimals="0" unitRef="usd">1981000</us-gaap:OperatingLeaseLiability>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;NET LOSS PER SHARE &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amounts of anti-dilutive stock options not included in the loss per share calculation for the years ended May 31, 2022 and 2021 were 2,321,616 and 2,081,366, respectively. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c0" decimals="0" unitRef="shares">2321616</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c7" decimals="0" unitRef="shares">2081366</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;SEGMENT REPORTING&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;ASC 280, Segment Reporting (&#x201c;ASC 280&#x201d;), establishes standards for reporting, by public business enterprises, information about operating segments, products and services, geographic areas, and major customers. The Company&#x2019;s operations are analyzed by management and its chief operating decision maker as being part of a single industry segment: the design, development, marketing, and sales of diagnostic kits.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;REPORTING COMPREHENSIVE LOSS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Comprehensive loss represents net loss and any revenues, expenses, gains and losses that, under GAAP, are excluded from net loss and recognized directly as a component of shareholders&#x2019; equity. Items of other comprehensive loss consist solely of foreign currency translation adjustments for the years ended May 31, 2022 and 2021. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;RECENT ACCOUNTING PRONOUNCEMENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Recent ASU's issued by the FASB and guidance issued by the SEC did not, or are not believed by management to, have a material effect on the Company&#x2019;s present or future consolidated financial statements. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in 0.1in 0in 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;In June 2016, the FASB issued ASU 2016-13, "Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments." This ASU will require the measurement of all expected credit losses for financial assets, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The guidance was initially effective for the Company for annual reporting periods beginning after December 15, 2019, and interim periods within those fiscal years. In November 2019, the FASB issued ASU 201&#xb7;9- 10, "Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates," which, among other things, defers the effective date of ASU 2016-13 for public filers that are considered smaller reporting companies as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including interim periods within those years. Early adoption is permitted. The Company is currently reviewing the requirements of this ASU to determine its impact on the Company&#x2019;s consolidated results of operations and financial position. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in 0.1in 0in 0in;"&gt;&#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="c0">&lt;p style="margin: 0in; text-align: justify;"&gt;&lt;span style="font-family: times new roman, times, serif; font-size: 10pt;"&gt;&lt;strong&gt;&lt;span style="color: black;"&gt;RECLASSIFICATIONS&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin: 0in; text-align: justify;"&gt;&lt;span style="font-family: times new roman, times, serif; font-size: 10pt;"&gt;&lt;strong&gt;&lt;span style="color: black;"&gt;&#160;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin: 0in; text-align: justify;"&gt;&lt;span style="font-size: 10.0pt; color: black;"&gt;&lt;span style="font-family: times new roman, times, serif;"&gt;Certain comparative figures in the 2021 Statement of Operations have been reclassified to conform to the current year&#x2019;s presentation.&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;NOTE 3: &#160;&#160;&#160;PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The following is an approximate breakdown of property and equipment, net of accumulated depreciation:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; BACKGROUND:white; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:165pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;May 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:77pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:77pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:66pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,292,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:66pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,850,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Furniture, fixtures and leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:66pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;227,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:66pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;433,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;(1,305,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;(1,972,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15.75pt"&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:374pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Net property and equipment&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;214,000&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;311,000&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; BACKGROUND:white; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:165pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;May 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:77pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:77pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:66pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,292,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:66pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,850,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Furniture, fixtures and leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:66pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;227,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:66pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;433,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;(1,305,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;(1,972,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15.75pt"&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:374pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Net property and equipment&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;214,000&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;311,000&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <bmra:Equipment contextRef="c3" decimals="-3" unitRef="usd">1292000</bmra:Equipment>
    <bmra:Equipment contextRef="c4" decimals="-4" unitRef="usd">1850000</bmra:Equipment>
    <bmra:FurnitureFixturesAndLeaseholdImprovements contextRef="c3" decimals="-3" unitRef="usd">227000</bmra:FurnitureFixturesAndLeaseholdImprovements>
    <bmra:FurnitureFixturesAndLeaseholdImprovements contextRef="c4" decimals="-3" unitRef="usd">433000</bmra:FurnitureFixturesAndLeaseholdImprovements>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="-3" unitRef="usd">1305000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c4" decimals="-3" unitRef="usd">1972000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" unitRef="usd">214000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="-3" unitRef="usd">311000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;NOTE 4: &#160;&#160;&#160;INTANGIBLE ASSETS, NET&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The following is an approximate breakdown of intangible assets, net of accumulated amortization:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; BACKGROUND:white; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:26%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 26%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt; May 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Licenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-18; FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;-&#160;&#160; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;182,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Patents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;189,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;240,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Less accumulated amortization-licenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-19; FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;(107,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Less accumulated amortization-patents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;(19,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;(20,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15.75pt"&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Intangible asssets, net&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;170,000&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;295,000&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Expected amortization of intangible assets for the years ending May 31:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;13,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;13,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;13,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;13,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;13,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;105,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15.75pt"&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Total&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;170,000&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; BACKGROUND:white; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:26%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 26%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt; May 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Licenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-18; FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;-&#160;&#160; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;182,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Patents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;189,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;240,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Less accumulated amortization-licenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-19; FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;(107,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Less accumulated amortization-patents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;(19,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;(20,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15.75pt"&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Intangible asssets, net&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;170,000&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;295,000&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedLicenseAgreementsGross contextRef="c4" decimals="-3" unitRef="usd">182000</us-gaap:FiniteLivedLicenseAgreementsGross>
    <us-gaap:FiniteLivedPatentsGross contextRef="c3" decimals="-3" unitRef="usd">189000</us-gaap:FiniteLivedPatentsGross>
    <us-gaap:FiniteLivedPatentsGross contextRef="c4" decimals="-4" unitRef="usd">240000</us-gaap:FiniteLivedPatentsGross>
    <bmra:FiniteLivedLicenseAccumulatedAmortization contextRef="c4" decimals="-3" unitRef="usd">107000</bmra:FiniteLivedLicenseAccumulatedAmortization>
    <bmra:FiniteLivedPatentsAccumulatedAmortization contextRef="c3" decimals="-3" unitRef="usd">19000</bmra:FiniteLivedPatentsAccumulatedAmortization>
    <bmra:FiniteLivedPatentsAccumulatedAmortization contextRef="c4" decimals="-4" unitRef="usd">20000</bmra:FiniteLivedPatentsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c3" decimals="-4" unitRef="usd">170000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c4" decimals="-3" unitRef="usd">295000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;13,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;13,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;13,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;13,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;13,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;105,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15.75pt"&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Total&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;170,000&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c3" decimals="INF" unitRef="usd">13000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c3" decimals="INF" unitRef="usd">13000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c3" decimals="INF" unitRef="usd">13000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c3" decimals="INF" unitRef="usd">13000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c3" decimals="INF" unitRef="usd">13000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c3" decimals="INF" unitRef="usd">105000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c3" decimals="INF" unitRef="usd">170000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;NOTE 5:&#160;&#160;&#160; ACCOUNTS PAYABLE AND ACCRUED EXPENSES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The following is an approximate breakdown of accounts payable and accrued expenses balances:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="WIDTH:555.6pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="741"&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:169pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;May 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:78.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:78.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;736,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;431,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;236,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;152,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15.75pt"&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Total&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;972,000&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;583,000&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"&gt;&lt;span style="font-size: 10pt;"&gt;As of May 31, 2022 and 2021 the Company had two vendors and one vendor, respectively, which accounted for 69% and 17%, respectively, of accounts payable.&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="WIDTH:555.6pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="741"&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:169pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;May 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:78.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:78.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;736,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;431,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;236,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;152,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15.75pt"&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Total&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;972,000&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;583,000&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent contextRef="c3" decimals="-3" unitRef="usd">736000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c4" decimals="-3" unitRef="usd">431000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">236000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c4" decimals="-3" unitRef="usd">152000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">972000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c4" decimals="-3" unitRef="usd">583000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c68" decimals="2" unitRef="pure">0.69</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c69" decimals="2" unitRef="pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;NOTE 6: &#160;&#160;&#160;SHAREHOLDERS' EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;STOCK OPTION AND RESTRICTED STOCK PLANS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;In December 2014, the Company adopted a stock option and restricted stock plan (the "2014 Plan") which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of 850,000 shares of the Company's unissued common stock may be granted to affiliates, employees, or consultants of the Company. This plan was approved by shareholders in December 2014. &#160;The 2014 Plan expires in December 2024. Options granted under the 2014 Plan will be granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;In December 2017, the Company adopted a stock option and restricted stock plan (the &#x201c;2017 Plan&#x201d;) which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of 900,000 shares of the Company&#x2019;s unissued common stock may be granted to affiliates, employees, or consultants of the Company.&#160; This plan was approved by shareholders in December 2017.&#160; The 2017 Plan expires in December 2027.&#160; Options granted under the 2017 Plan will be granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;In February 2020, the Board approved the 2020 Stock Incentive Plan (the &#x201c;2020 Plan&#x201d;) and on December 11, 2020, the shareholders of the Company approved The Plan. The 2020 Plan authorizes the issuance of an aggregate number of common stock options and/or restricted common shares to be issued in an amount not to exceed 900,000. &#160;The 2020 Plan authorizes the issuance of common stock options and restricted common shares to employees, directors, and consultants of the Company. During fiscal 2020, certain common stock options were granted under this plan. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;Stock option expense during fiscal 2022 was approximately $1,260,000. This included, by department, $954,000 for administrative, $159,000 for production, $80,000 for research and development and $67,000 for sales and marketing.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;Stock option expense during fiscal 2021 was approximately $1,355,000. This included, by department, $957,000 for administrative, $205,000 for production, $125,000 for research and development and $68,000 for sales and marketing&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Activity as to aggregate stock options outstanding is as follows: &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 550.7pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="734"&gt;

&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 300.25pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 67.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;NUMBER OF &lt;br/&gt;STOCK OPTIONS&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.6pt; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66.05pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;EXCERCISE &lt;br/&gt;PRICE RANGE &lt;br/&gt;PER SHARE&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.6pt; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 79.4pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;WEIGHTED &lt;br/&gt;AVERAGE &lt;br/&gt;EXERCISE PRICE&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 300.25pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Options outstanding at May 31, 2020&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;1,789,251&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 66.05pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$0.82-$8.18&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;2.75&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 300.25pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 67.2pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;430,616&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 66.05pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$5.14-$8.70&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.2pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 67.2pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;6.73&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 300.25pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Options excercised&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;(86,750)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 66.05pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$0.82-$3.62&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;1.20&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 300.25pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Options canceled or expired&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 67.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;(51,751)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66.05pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$2.35-$8.18&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 67.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;4.77&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 300.25pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Options outstanding at May 31, 2021&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: windowtext 1pt solid; height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;2,081,366&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: windowtext 1pt solid; height: 15pt; width: 66.05pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$0.82-$8.70&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: windowtext 1pt solid; height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;3.59&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 300.25pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 67.2pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;344,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 66.05pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$4.25-$4.46&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.2pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 67.2pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;4.43&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 300.25pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Options excercised&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;(39,500)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 66.05pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$1.20-$3.62&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;1.99&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 300.25pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Options canceled or expired&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 67.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;(64,250)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66.05pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$1.61-$8.18&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 67.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;4.41&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15.75pt;"&gt;
&lt;td style="height: 15.75pt; width: 300.25pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Options outstanding at May 31, 2022&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15.75pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 67.2pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;2,321,616&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15.75pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 66.05pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$0.82-$8.70&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15.75pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12.2pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 67.2pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;3.72&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The weighted average fair value of options granted during 2022 and 2021 were $4.43 and $6.73, respectively. The aggregate intrinsic value of options exercised during 2022 and 2021 was approximately $90,000 and $501,000, respectively. The aggregate intrinsic value of options outstanding on May 31, 2022 and 2021 was approximately $1,838,000 and $2,132,000, respectively. The aggregate intrinsic value of options vested and exercisable on May 31, 2022 and 2021 was approximately $1,731,000 and $1,872,000, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;The number of non-vested stock options included in the table above is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&#160; &lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:54.75pt"&gt; &lt;td style="HEIGHT:54.75pt; WIDTH:2.4in; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:54.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:54.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Number of&lt;br/&gt;&#160;shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:54.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:54.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Stock options&lt;br/&gt;weighted&lt;br/&gt;average grant&lt;br/&gt;date fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:2.4in; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Non-vested shares at May 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;793,241&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;5.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:2.4in; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;344,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;4.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:2.4in; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Vested&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;(347,279)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;5.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:2.4in; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;(43,500)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;5.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15.75pt"&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:2.4in; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Non-vested shares at May 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;746,462&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;5.11&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;On May 31, 2022, total compensation cost related to non-vested stock option awards not yet recognized totaled approximately $1,982,000. The weighted-average period over which this amount is expected to be recognized is 2.32 years. The weighted average remaining contractual term of options that were exercisable on May 31, 2022, was 5.47 years.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The following summarizes information about all the Company's stock options outstanding on May 31, 2022. These options are comprised of those granted under the 2014, 2017 and 2020 plans.&lt;/span&gt; &lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550.1pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;RANGE OF&lt;br/&gt;EXERCISE PRICES&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:1%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;NUMBER&lt;br/&gt;OUTSTANDING&lt;br/&gt;MAY 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;WEIGHTED&lt;br/&gt;AVERAGE&lt;br/&gt;REMAINING&lt;br/&gt;CONTRACTUAL&lt;br/&gt;LIFE IN YEARS&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;WEIGHTED&lt;br/&gt;&#160;AVERAGE&lt;br/&gt;EXERCISE PRICE&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;NUMBER&lt;br/&gt;EXCERCISABLE&lt;br/&gt;AT MAY 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;WEIGHTED&lt;br/&gt;AVERAGE&lt;br/&gt;EXERCISE PRICE&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$0.82-$1.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:1%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;456,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;3.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$1.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;456,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$1.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$2.25-$4.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,015,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;6.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$2.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;852,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$2.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$4.34-$8.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:1%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;849,866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;8.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$6.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;266,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$7.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;COMMON STOCK ACTIVITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;On January 22, 2021, the Company filed a Prospectus Supplement, for purposes of raising up to $15,000,000 to the base prospectus filed with the SEC on July 21, 2020, and declared effective by the SEC on September 30, and an ATM Agreement. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black"&gt;On May 21, 2021, in conjunction with the Company&#x2019;s 2020 Stock Incentive Plan, that was approved by shareholders at the Company&#x2019;s annual meeting in December 2020, the Company filed an S-8 Registration Statement to register up to 900,000 shares of the Company&#x2019;s common stock that could be issued under this Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Under ATM Agreements, sales of the Placement Shares are deemed to be &#x201c;at the market offering&#x201d; as defined in Rule 415 promulgated under the Securities Act.&#160; The agent acts as sales agent under the ATM and uses commercially reasonable efforts to sell on the Company&#x2019;s behalf all of the Placement Shares requested to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the agent and the Company. The Company has no obligation to sell any of the Placement Shares under the ATM Agreement, and may at any time suspend offers under, or terminate the ATM Agreement.&#160; &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;During the year ended May 31, 2022, the Company sold 521,267 shares of its common stock at prices ranging from $4.02 to $5.63 under its Form S-3 Registration Statement &lt;/span&gt;&lt;span style="FONT-SIZE:10pt"&gt;(&lt;/span&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;File No. 333-239980) &lt;/span&gt;&lt;span style="FONT-SIZE:10pt"&gt;and ATM Agreement which resulted in gross proceeds of approximately $2,402,000 and net proceeds to the Company of $2,317,000 after deducting commissions for each sale and legal, accounting, and other fees related to the filing of the Form S-3.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"/&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black"&gt;During the year ended May 31, 2021, the Company sold 158,889 shares of its common stock at prices ranging from $7.06 to $7.79 under its Form S-3 Registration Statement&#160;(File No. 333-239980)&#160;and ATM Agreement which resulted in gross proceeds of approximately $1,177,000 and net proceeds to the Company of $1,011,000 after deducting commissions for each sale and legal, accounting, and other fees related to the filing of the Form S-3.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"&gt;&lt;span style="font-size: 10pt;"&gt;During the year ended May 31, 2022, options to purchase 39,500 shares of common stock were exercised at prices ranging from $1.20 to $3.62.&#160; Total net proceeds to the Company were approximately $77,000.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"&gt;&lt;span style="font-size: 10pt;"&gt;During the year ended May 31, 2021, 321,429 shares of common stock were converted from Preferred Stock as described below in &#x201c;Preferred Stock Activity&#x201d;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt;"&gt;PREFERRED STOCK ACTIVITY&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"&gt;&lt;span style="font-size: 10pt;"&gt;On February 24, 2020, the Company entered into and closed on a Stock Purchase Agreement (the &#x201c;Stock Purchase Agreement&#x201d;) with Palm Global Small Cap Master Fund LP (&#x201c;Palm&#x201d;) pursuant to which the Company agreed to sell and issue to Palm, and Palm agreed to purchase from the Company, 571,429 shares of the Company&#x2019;s Series A 5% Convertible Preferred Stock, $0.08 par value per share for a purchase price of approximately $2 million, or $3.50 per Series A Convertible Preferred Stock. Under the terms of the Stock Purchase Agreement, each share of issued Convertible Preferred Stock can be converted at any time by Palm into one share of the Company&#x2019;s common stock, subject to certain adjustments.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"&gt;&lt;span style="font-size: 10pt;"&gt;The Series A 5% Convertible Preferred Stock accrued annual preferred dividends at a rate of $0.175 per Series A 5% Convertible Preferred Share. However, accruing dividends were payable only when, as, and if declared by the Board and the Company had no obligation to pay such accruing dividends.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"&gt;&lt;span style="font-size: 10pt;"&gt;On March 24, 2020, Palm converted 250,000 shares of Convertible Preferred Stock into 250,000 shares of unregistered common stock. On July 21, 2020, the Company filed with the SEC a registration statement on Form S-3, that among other things, registered 571,429 common shares issued, or to be issued, to Palm upon conversion of the Convertible Preferred Stock into common shares. On September 30, 2020, the Company received a Notice of Effectiveness from the Securities and Exchange Commission for registration of these shares. On January 21, 2021, Palm Converted their remaining 321,429 Convertible Preferred Shares into registered common shares. On May 30, 2021, the Company had no shares of Preferred Stock outstanding. Under the terms of the Preferred Stock Purchase Agreement, none of the cumulative Dividends were paid to Palm during the period they owned the Preferred Stock. Once converted to common shares, Palm lost all rights to receive any past cumulative dividends.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="c70" decimals="0" unitRef="shares">850000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="c71" decimals="2" unitRef="pure">0.80</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c71">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="c72" decimals="0" unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="c73" decimals="2" unitRef="pure">0.80</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c73">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="c74" decimals="0" unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c75" decimals="0" unitRef="usd">1260000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c76" decimals="0" unitRef="usd">954000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c77" decimals="0" unitRef="usd">159000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c78" decimals="0" unitRef="usd">80000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c79" decimals="0" unitRef="usd">67000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c80" decimals="0" unitRef="usd">1355000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c81" decimals="0" unitRef="usd">957000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c82" decimals="0" unitRef="usd">205000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c83" decimals="0" unitRef="usd">125000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c84" decimals="0" unitRef="usd">68000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="width: 550.7pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="734"&gt;

&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 300.25pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 67.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;NUMBER OF &lt;br/&gt;STOCK OPTIONS&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.6pt; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66.05pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;EXCERCISE &lt;br/&gt;PRICE RANGE &lt;br/&gt;PER SHARE&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.6pt; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 79.4pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;WEIGHTED &lt;br/&gt;AVERAGE &lt;br/&gt;EXERCISE PRICE&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 300.25pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Options outstanding at May 31, 2020&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;1,789,251&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 66.05pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$0.82-$8.18&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;2.75&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 300.25pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 67.2pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;430,616&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 66.05pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$5.14-$8.70&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.2pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 67.2pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;6.73&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 300.25pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Options excercised&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;(86,750)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 66.05pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$0.82-$3.62&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;1.20&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 300.25pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Options canceled or expired&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 67.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;(51,751)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66.05pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$2.35-$8.18&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 67.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;4.77&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 300.25pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Options outstanding at May 31, 2021&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: windowtext 1pt solid; height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;2,081,366&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: windowtext 1pt solid; height: 15pt; width: 66.05pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$0.82-$8.70&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: windowtext 1pt solid; height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;3.59&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 300.25pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 67.2pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;344,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 66.05pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$4.25-$4.46&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.2pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 67.2pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;4.43&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 300.25pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Options excercised&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;(39,500)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 66.05pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$1.20-$3.62&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 67.2pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;1.99&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 300.25pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Options canceled or expired&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 67.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;(64,250)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66.05pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$1.61-$8.18&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12.6pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 67.2pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;4.41&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15.75pt;"&gt;
&lt;td style="height: 15.75pt; width: 300.25pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Options outstanding at May 31, 2022&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15.75pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 67.2pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;2,321,616&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15.75pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 66.05pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$0.82-$8.70&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15.75pt; width: 12.6pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12.2pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 67.2pt; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;3.72&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c106" decimals="INF" unitRef="shares">1789251</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c106" decimals="INF" unitRef="usdPershares">2.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c107" decimals="INF" unitRef="shares">430616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c107" decimals="INF" unitRef="usdPershares">6.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c108" decimals="INF" unitRef="shares">86750</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c108" decimals="INF" unitRef="usdPershares">1.2</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c109" decimals="INF" unitRef="shares">51751</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="c109" decimals="INF" unitRef="usdPershares">4.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c110" decimals="INF" unitRef="shares">2081366</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c110" decimals="INF" unitRef="usdPershares">3.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c111" decimals="INF" unitRef="shares">344000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c111" decimals="INF" unitRef="usdPershares">4.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c112" decimals="INF" unitRef="shares">39500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c112" decimals="INF" unitRef="usdPershares">1.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c113" decimals="INF" unitRef="shares">64250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="c113" decimals="INF" unitRef="usdPershares">4.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c114" decimals="INF" unitRef="shares">2321616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c114" decimals="INF" unitRef="usdPershares">3.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="c75" decimals="2" unitRef="usdPershares">4.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="c80" decimals="2" unitRef="usdPershares">6.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c75" decimals="0" unitRef="usd">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c80" decimals="0" unitRef="usd">501000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c85" decimals="0" unitRef="usd">1838000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c86" decimals="0" unitRef="usd">2132000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c85" decimals="0" unitRef="usd">1731000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c86" decimals="0" unitRef="usd">1872000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:54.75pt"&gt; &lt;td style="HEIGHT:54.75pt; WIDTH:2.4in; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:54.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:54.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Number of&lt;br/&gt;&#160;shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:54.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:54.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Stock options&lt;br/&gt;weighted&lt;br/&gt;average grant&lt;br/&gt;date fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:2.4in; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Non-vested shares at May 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;793,241&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;5.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:2.4in; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;344,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;4.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:2.4in; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Vested&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;(347,279)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;5.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:2.4in; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;(43,500)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;5.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15.75pt"&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:2.4in; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Non-vested shares at May 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;746,462&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;5.11&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="c4" decimals="INF" unitRef="shares">793241</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c4" decimals="INF" unitRef="usdPershares">5.54</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c0" decimals="INF" unitRef="shares">344000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="c0" decimals="INF" unitRef="usdPershares">4.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="c0" decimals="INF" unitRef="shares">347279</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="c0" decimals="INF" unitRef="usdPershares">5.4</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares contextRef="c0" decimals="INF" unitRef="shares">43500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="c0" decimals="INF" unitRef="usdPershares">5.22</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="c3" decimals="INF" unitRef="shares">746462</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c3" decimals="INF" unitRef="usdPershares">5.11</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c85" decimals="0" unitRef="usd">1982000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c75">P2Y3M25D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c75">P5Y5M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550.1pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;RANGE OF&lt;br/&gt;EXERCISE PRICES&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:1%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;NUMBER&lt;br/&gt;OUTSTANDING&lt;br/&gt;MAY 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;WEIGHTED&lt;br/&gt;AVERAGE&lt;br/&gt;REMAINING&lt;br/&gt;CONTRACTUAL&lt;br/&gt;LIFE IN YEARS&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;WEIGHTED&lt;br/&gt;&#160;AVERAGE&lt;br/&gt;EXERCISE PRICE&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;NUMBER&lt;br/&gt;EXCERCISABLE&lt;br/&gt;AT MAY 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid;PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;WEIGHTED&lt;br/&gt;AVERAGE&lt;br/&gt;EXERCISE PRICE&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$0.82-$1.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:1%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;456,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;3.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$1.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;456,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$1.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$2.25-$4.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,015,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;6.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$2.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;852,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$2.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$4.34-$8.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:1%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;849,866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;8.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$6.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;266,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$7.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="c115" decimals="INF" unitRef="usdPershares">0.82</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="c115" decimals="INF" unitRef="usdPershares">1.52</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c116" decimals="INF" unitRef="shares">456000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c115">P3Y3M29D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c116" decimals="INF" unitRef="usdPershares">1.04</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c116" decimals="INF" unitRef="shares">456000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="c116" decimals="INF" unitRef="usdPershares">1.04</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="c117" decimals="INF" unitRef="usdPershares">2.25</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="c117" decimals="INF" unitRef="usdPershares">4.25</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c118" decimals="INF" unitRef="shares">1015750</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c117">P6Y1M20D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c118" decimals="INF" unitRef="usdPershares">2.9</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c118" decimals="INF" unitRef="shares">852500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="c118" decimals="INF" unitRef="usdPershares">2.88</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="c119" decimals="INF" unitRef="usdPershares">4.34</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="c119" decimals="INF" unitRef="usdPershares">8.7</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c120" decimals="INF" unitRef="shares">849866</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c119">P8Y9M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c120" decimals="INF" unitRef="usdPershares">6.13</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c120" decimals="INF" unitRef="shares">266654</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="c120" decimals="INF" unitRef="usdPershares">7.06</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c87" decimals="0" unitRef="usd">15000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="c88" decimals="0" unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c89" decimals="0" unitRef="shares">521267</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare contextRef="c90" decimals="2" unitRef="usdPershares">4.02</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare contextRef="c91" decimals="2" unitRef="usdPershares">5.63</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c89" decimals="0" unitRef="usd">2402000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c89" decimals="0" unitRef="usd">2317000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c92" decimals="0" unitRef="shares">158889</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare contextRef="c93" decimals="2" unitRef="usdPershares">7.06</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare contextRef="c94" decimals="2" unitRef="usdPershares">7.79</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c92" decimals="0" unitRef="usd">1177000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c92" decimals="0" unitRef="usd">1011000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c95" decimals="0" unitRef="shares">39500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c96" decimals="2" unitRef="usdPershares">1.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c97" decimals="2" unitRef="usdPershares">3.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c95" decimals="0" unitRef="usd">77000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="c98" decimals="0" unitRef="shares">321429</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:PreferredStockSharesIssued contextRef="c99" decimals="0" unitRef="shares">571429</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c99" decimals="2" unitRef="usdPershares">0.08</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c100" decimals="-6" unitRef="usd">2000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare contextRef="c99" decimals="2" unitRef="usdPershares">3.5</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:DividendsPayableAmountPerShare contextRef="c101" decimals="3" unitRef="usdPershares">0.175</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="c102" decimals="0" unitRef="shares">250000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1 contextRef="c103" decimals="0" unitRef="shares">250000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="c104" decimals="0" unitRef="shares">571429</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="c105" decimals="0" unitRef="shares">321429</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; BACKGROUND:none; COLOR:black"&gt;NOTE 7: &#160;&#160;&#160;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Provision for income taxes for the years ended May 31 consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:169pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;&#160;For the year ended May 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:78.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:78.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;U.S. Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-20; FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;&#160;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-21; FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;&#160;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Foreign Taxes Subsidiaries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;(23,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;(12,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;State and local&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;(1,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;(1,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Total current&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;(24,000)&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;(13,000)&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;U.S. Federal&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-22; FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;&#160;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-23; FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;&#160;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;State and local&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-24; FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;&#160;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-25; FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;&#160;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Total deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-26; FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;&#160;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-27; FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;&#160;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15.75pt"&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Income tax expense&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;&#160;&lt;span style="COLOR:black"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;(24,000)&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;(13,000)&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Provision for income taxes differs from the amounts computed by applying the U.S. Federal income tax rate applicable for each year (&lt;span style="BACKGROUND:none"&gt;21%&lt;/span&gt; for 2022 and 2021) to pretax income as a result of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733"&gt;

&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="5" style="border-top: 0px; height: 15pt; border-right: 0px; width: 30%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;For the year ended May 31,&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 14%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;2022&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 14%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;2021&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Computed "expected" tax benefit&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;947,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;1,561,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Increase (reduction) in income taxes resulting from:&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;(1,022,000)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="top"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;(2,292,000)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif;"&gt;300,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="top"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif;"&gt;217,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;50,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="top"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;456,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Permanent tax differences and other&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif;"&gt;(217,000)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="top"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif;"&gt;(88,000)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Stock based compensation&#160;benefit&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; text-align: right; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in; text-align: right;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;11,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; text-align: right; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="top"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;145,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Foreign taxes of subsidiaries&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif;"&gt;(113,000)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="top"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;(12,000)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15.75pt;"&gt;
&lt;td style="height: 15.75pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Income tax expense&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15.75pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;(24,000)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15.75pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;$&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="top"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;(13,000)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The tax effect of significant temporary differences&#160;is presented below:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550.1pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:30%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 30%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;May 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Accounts receivable, principally due to allowance for doubtful accounts&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;43,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;200,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Inventory valuation&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;237,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;387,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Compensated absences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;120,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;85,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Net operating loss carryforwards&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;4,349,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;3,194,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;1,096,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;1,055,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Deferred rent expense/Capitalized leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;20,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;15,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;1,035,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;613,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Losses of foreign subsidiaries &amp;amp; Other, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;41,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;370,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;26,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;(15,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Total deferred tax assets&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;6,967,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;5,904,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Less valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;(6,967,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;(5,904,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15.75pt"&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Net deferred tax asset&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-28; FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;&#160;-&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-29; FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;&#160;-&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;The Company has provided a valuation allowance of approximately &lt;span style="background: none;"&gt;$6,967,000&lt;/span&gt; and $5,904,000 as of May 31, 2022 and 2021, respectively. The net change in the valuation allowance for the years ended May 31, 2022 and 2021, was an increase of &lt;span style="background: none;"&gt;$1,063,000&lt;/span&gt; and $2,292,000, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;On May 31, 2022, the Company has Federal income tax net operating loss carryforwards of approximately &lt;span style="BACKGROUND:none"&gt;$17,116,000&lt;/span&gt;. &#160;On May 31, 2022, the Company has California state income tax net operating loss carryforwards of approximately &lt;span style="BACKGROUND:none"&gt;$10,805,000&lt;/span&gt;. For tax reporting purposes, operating loss carryforwards are available to offset future taxable income; such carryforwards expire in varying amounts beginning in &lt;span style="BACKGROUND:none"&gt;2023 and 2037&lt;/span&gt; for federal and state purposes, respectively.&#160; Federal net operating losses beginning in &lt;span style="BACKGROUND:none"&gt;2018&lt;/span&gt; have no expiration date. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;On May 31, 2022, the Company has Federal research and development tax credit carryforward of approximately &lt;span style="BACKGROUND:none"&gt;$784,000&lt;/span&gt;. &#160;The Federal credits begin to expire in &lt;span style="BACKGROUND:none"&gt;2027&lt;/span&gt;. &#160;The Company also had similar credit carryforwards for state purposes &lt;span style="BACKGROUND:none"&gt;of $395,000&lt;/span&gt; on May 31, 2022, which don&#x2019;t expire.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Pursuant to Internal Revenue Code (&#x201c;IRC&#x201d;) Sections 382 and 383, annual use of the Company's net operating loss ("NOL") and credit carryforwards may be limited by statute because of a cumulative change in ownership of more than 50%. Pursuant to Sections 382 and 383 of the IRC, the annual use of the Company's NOLs and credit carryforwards would be limited if there is a cumulative change of ownership (as that term is defined in Section 382(g) of the IRC of greater than 50% in a three-year period. Management has not performed an analysis to determine if the Company has had a cumulative change in ownership of greater than 50%.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;For the year ended May 31, 2022, the Company did an analysis of its &lt;span style="BACKGROUND:none"&gt;ASC 740 position and has not identified any uncertain tax positions as defined under ASC 740&lt;/span&gt;. Should such position be identified in the future, and should the Company owe interest and penalties as a result of this, these would be recognized as interest expense and other expense, respectively, in the consolidated financial statements. The Company is no longer subject to any significant U.S. federal tax examinations by tax authorities for years before fiscal &lt;span style="BACKGROUND:none"&gt;2018&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:169pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;&#160;For the year ended May 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:78.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:78.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;U.S. Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-20; FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;&#160;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-21; FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;&#160;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Foreign Taxes Subsidiaries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;(23,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;(12,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;State and local&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;(1,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;(1,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Total current&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;(24,000)&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;(13,000)&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;U.S. Federal&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-22; FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;&#160;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-23; FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;&#160;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;State and local&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-24; FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;&#160;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:66.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-25; FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;&#160;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:374.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Total deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-26; FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;&#160;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:11.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-27; FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;&#160;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15.75pt"&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:374.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Income tax expense&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;&#160;&lt;span style="COLOR:black"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;(24,000)&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:11.8pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.8pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66.8pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;(13,000)&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c0" decimals="-3" unitRef="usd">-23000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c7" decimals="-3" unitRef="usd">-12000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c0" decimals="-3" unitRef="usd">-1000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c7" decimals="-3" unitRef="usd">-1000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c0" decimals="-3" unitRef="usd">-24000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c7" decimals="-3" unitRef="usd">-13000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="-3" unitRef="usd">24000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c7" decimals="-3" unitRef="usd">13000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="2" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c7" decimals="2" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733"&gt;

&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="5" style="border-top: 0px; height: 15pt; border-right: 0px; width: 30%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;For the year ended May 31,&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 14%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;2022&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-top: 0px; height: 15pt; border-right: 0px; width: 14%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;2021&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Computed "expected" tax benefit&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;947,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;1,561,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Increase (reduction) in income taxes resulting from:&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;(1,022,000)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="top"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;(2,292,000)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif;"&gt;300,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="top"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif;"&gt;217,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;50,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="top"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;456,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Permanent tax differences and other&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif;"&gt;(217,000)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="top"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif;"&gt;(88,000)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Stock based compensation&#160;benefit&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; text-align: right; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0in 2.9pt 0in 0in; text-align: right;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;11,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; text-align: right; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="top"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;145,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Foreign taxes of subsidiaries&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif;"&gt;(113,000)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="top"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;(12,000)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15.75pt;"&gt;
&lt;td style="height: 15.75pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;Income tax expense&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15.75pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;(24,000)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15.75pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;$&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="top"&gt;
&lt;p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"&gt;(13,000)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="-3" unitRef="usd">947000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c7" decimals="-3" unitRef="usd">1561000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="-3" unitRef="usd">-1022000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c7" decimals="-3" unitRef="usd">-2292000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c0" decimals="-5" unitRef="usd">300000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c7" decimals="-3" unitRef="usd">217000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c0" decimals="-4" unitRef="usd">50000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c7" decimals="-3" unitRef="usd">456000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c0" decimals="-3" unitRef="usd">-217000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c7" decimals="-3" unitRef="usd">-88000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount contextRef="c0" decimals="-3" unitRef="usd">11000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount contextRef="c7" decimals="-3" unitRef="usd">145000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c0" decimals="-3" unitRef="usd">-113000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c7" decimals="-3" unitRef="usd">-12000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c0" decimals="-3" unitRef="usd">-24000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c7" decimals="-3" unitRef="usd">-13000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550.1pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:30%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 30%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;May 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; LINE-HEIGHT:normal; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Accounts receivable, principally due to allowance for doubtful accounts&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;43,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;200,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Inventory valuation&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;237,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;387,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Compensated absences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;120,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;85,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Net operating loss carryforwards&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;4,349,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;3,194,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;1,096,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;1,055,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Deferred rent expense/Capitalized leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;20,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;15,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;1,035,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;613,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Losses of foreign subsidiaries &amp;amp; Other, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;41,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;370,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;26,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;(15,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Total deferred tax assets&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;6,967,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;5,904,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Less valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;(6,967,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;(5,904,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15.75pt"&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;Net deferred tax asset&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-28; FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;&#160;-&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; MARGIN:0in; LINE-HEIGHT:normal"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-29; FONT-SIZE:11pt; FONT-FAMILY:&amp;quot;Calibri&amp;quot;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; LINE-HEIGHT:normal; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;&#160;-&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="c3" decimals="-3" unitRef="usd">43000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="c4" decimals="-5" unitRef="usd">200000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c3" decimals="-3" unitRef="usd">237000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c4" decimals="-3" unitRef="usd">387000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences contextRef="c3" decimals="-4" unitRef="usd">120000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences contextRef="c4" decimals="-3" unitRef="usd">85000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c3" decimals="-3" unitRef="usd">4349000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c4" decimals="-3" unitRef="usd">3194000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c3" decimals="-3" unitRef="usd">1096000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c4" decimals="-3" unitRef="usd">1055000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent contextRef="c3" decimals="-4" unitRef="usd">20000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent contextRef="c4" decimals="-3" unitRef="usd">15000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <bmra:DefferedTaxAssetsStockOptions contextRef="c3" decimals="-3" unitRef="usd">1035000</bmra:DefferedTaxAssetsStockOptions>
    <bmra:DefferedTaxAssetsStockOptions contextRef="c4" decimals="-3" unitRef="usd">613000</bmra:DefferedTaxAssetsStockOptions>
    <bmra:DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet contextRef="c3" decimals="-3" unitRef="usd">41000</bmra:DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet>
    <bmra:DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet contextRef="c4" decimals="-4" unitRef="usd">370000</bmra:DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet>
    <bmra:DeferredTaxAssetsAccumulatedDepreciationAndAmortization contextRef="c3" decimals="-3" unitRef="usd">26000</bmra:DeferredTaxAssetsAccumulatedDepreciationAndAmortization>
    <bmra:DeferredTaxAssetsAccumulatedDepreciationAndAmortization contextRef="c4" decimals="-3" unitRef="usd">-15000</bmra:DeferredTaxAssetsAccumulatedDepreciationAndAmortization>
    <us-gaap:DeferredTaxAssetsGross contextRef="c3" decimals="-3" unitRef="usd">6967000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c4" decimals="-3" unitRef="usd">5904000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="-3" unitRef="usd">6967000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c4" decimals="-3" unitRef="usd">5904000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="0" unitRef="usd">6967000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c4" decimals="0" unitRef="usd">5904000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c0" decimals="0" unitRef="usd">1063000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c7" decimals="0" unitRef="usd">2292000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="c121" decimals="0" unitRef="usd">17116000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c122" decimals="0" unitRef="usd">10805000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c123" decimals="0" unitRef="usd">784000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c124" decimals="0" unitRef="usd">395000</us-gaap:TaxCreditCarryforwardAmount>
    <bmra:GeographicInformationDisclosureTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;NOTE 8: &#160;&#160;&#160;GEOGRAPHIC INFORMATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company operates as one segment. Geographic information regarding net sales is approximately as follows: &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 557.3pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="743"&gt;

&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 286.9pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-top: 0px; height: 15pt; border-right: 0px; width: 258.6pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;For the year ended May 31,&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 286.9pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-top: 0px; height: 15pt; border-right: 0px; width: 123.4pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;2022&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-top: 0px; height: 15pt; border-right: 0px; width: 123.4pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;2021&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 286.9pt; background: #b8cce4; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Asia&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;13,375,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;71%&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;1,908,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;26%&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 286.9pt; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Europe&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;4,339,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;23%&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;4,301,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;60%&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 286.9pt; background: #b8cce4; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;North America&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;997,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;5%&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;548,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;8%&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 286.9pt; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;South America&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;90,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;1%&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;250,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;3%&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 286.9pt; background: #b8cce4; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Middle East&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 55.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;70,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 55.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;0%&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 55.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;192,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 55.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;3%&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15.75pt;"&gt;
&lt;td style="height: 15.75pt; width: 286.9pt; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Total&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15.75pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 55.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;18,871,000&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 55.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;100%&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15.75pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 55.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;7,199,000&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 55.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;100%&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;</bmra:GeographicInformationDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments contextRef="c0" decimals="0" unitRef="pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="width: 557.3pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="743"&gt;

&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 286.9pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-top: 0px; height: 15pt; border-right: 0px; width: 258.6pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;For the year ended May 31,&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 286.9pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-top: 0px; height: 15pt; border-right: 0px; width: 123.4pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;2022&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-top: 0px; height: 15pt; border-right: 0px; width: 123.4pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;2021&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 286.9pt; background: #b8cce4; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Asia&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;13,375,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;71%&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;1,908,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;26%&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 286.9pt; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Europe&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;4,339,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;23%&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;4,301,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;60%&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 286.9pt; background: #b8cce4; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;North America&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;997,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;5%&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;548,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;8%&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 286.9pt; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;South America&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;90,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;1%&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;250,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 55.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;3%&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 286.9pt; background: #b8cce4; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Middle East&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 55.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;70,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 55.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;0%&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11.8pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 55.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;192,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 55.8pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;3%&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15.75pt;"&gt;
&lt;td style="height: 15.75pt; width: 286.9pt; white-space: nowrap; padding: 0in 0in 0in 0.15in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Total&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15.75pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 55.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;18,871,000&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 55.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;100%&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15.75pt; width: 11.8pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 55.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;7,199,000&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 55.8pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;100%&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues contextRef="c125" decimals="-3" unitRef="usd">13375000</us-gaap:Revenues>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c126" decimals="2" unitRef="pure">0.71</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:Revenues contextRef="c127" decimals="-3" unitRef="usd">1908000</us-gaap:Revenues>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c128" decimals="2" unitRef="pure">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:Revenues contextRef="c129" decimals="-3" unitRef="usd">4339000</us-gaap:Revenues>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c130" decimals="2" unitRef="pure">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:Revenues contextRef="c131" decimals="-3" unitRef="usd">4301000</us-gaap:Revenues>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c132" decimals="2" unitRef="pure">0.60</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:Revenues contextRef="c133" decimals="-3" unitRef="usd">997000</us-gaap:Revenues>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c134" decimals="2" unitRef="pure">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:Revenues contextRef="c135" decimals="-3" unitRef="usd">548000</us-gaap:Revenues>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c136" decimals="2" unitRef="pure">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:Revenues contextRef="c137" decimals="-4" unitRef="usd">90000</us-gaap:Revenues>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c138" decimals="2" unitRef="pure">0.01</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:Revenues contextRef="c139" decimals="-4" unitRef="usd">250000</us-gaap:Revenues>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c140" decimals="2" unitRef="pure">0.03</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:Revenues contextRef="c141" decimals="-4" unitRef="usd">70000</us-gaap:Revenues>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c142" decimals="2" unitRef="pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:Revenues contextRef="c143" decimals="-3" unitRef="usd">192000</us-gaap:Revenues>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c144" decimals="2" unitRef="pure">0.03</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:Revenues contextRef="c0" decimals="-3" unitRef="usd">18871000</us-gaap:Revenues>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c145" decimals="2" unitRef="pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:Revenues contextRef="c7" decimals="-3" unitRef="usd">7199000</us-gaap:Revenues>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c146" decimals="2" unitRef="pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;NOTE 9: &#160;&#160;&#160;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;OPERATING LEASES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;The Company leases its facilities. On May 31, 2022, the Company had approximately 22,000 square feet of floor space at its corporate headquarters at 17571 Von Karman Avenue in Irvine, California, which it has been leasing since 2009. The lease for its headquarters expired on August 31, 2016. &#160;The Company had an option to extend the term of its lease for two additional sixty-month periods. On November 30, 2015, the Company exercised its option to extend its lease for an additional sixty-month period and entered into the First Amendment to Lease wherein it extended its lease until August 31, 2021. On April 9, 2021, the Company exercised its second option to extend its lease for an additional five years.&#160; When the Company extended its lease in April 2021, it was also granted an additional five-year lease extension option. The current rent is approximately $25,000 per month and will increase on September 1, 2022, to $26,000 per month.&#160; The security deposit is approximately $22,000.&lt;span style="COLOR:black"&gt;&#160;&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;In November 2016, the Company&#x2019;s Mexican subsidiary, Biomerica de Mexico, entered into a 10-year lease for approximately 8,100 square feet of manufacturing space. The Company has one 10-year option to renew at the end of the initial lease period. The current rent is approximately $3,400 per month.&#160; Biomerica de Mexico also leases a smaller unit on a month-to-month basis for use in one manufacturing process. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;In addition, the Company leases a small office in Lindau, Germany on a month-to-month basis, as headquarters for BioEurope GmbH, its Germany subsidiary.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Total gross rent expense in the United States for fiscal 2022 was approximately $310,000, and for fiscal 2021 was $295,000.&#160; Rent expense for the Mexico facility for fiscal 2022 and 2021 was approximately $42,000 and $25,000, respectively. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.9pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;For purposes of determining straight-line rent expense, the lease term is calculated from the date the Company first takes possession of the facility, including any periods of free rent and any renewal options periods that the Company is reasonably certain of exercising. The Company&#x2019;s office and equipment leases generally have contractually specified minimum rent and annual rent increases are included in the measurement of the right-of-use asset and related lease liability.&#160; Additionally, under these lease arrangements, the Company may be required to pay directly, or reimburse the lessors, for some maintenance and operating costs. Such amounts are generally variable and therefore not included in the measurement of the right-of-use asset and related lease liability but are instead recognized as variable lease expense in the Consolidated Statements of Operations and Comprehensive Loss when they are incurred.&#160; &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 13.55pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0in;"&gt;&lt;span style="font-family: 'Times New Roman',serif;"&gt;Supplemental cash flow information related to leases for the year ended May 31, 2022: &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550.1pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:467.1pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Operating cash flows from operating leases&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:67.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;338,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:467.1pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Right-of-use assets obtained in exchange for&lt;br/&gt;&#160;&#160;&#160; &#160;new operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:15.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:67.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-30; FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;&#160;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:467.1pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Weighted average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:67.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;4.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:467.1pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Weighted average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:67.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;6.50%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Future minimum lease payments under operating leases on May 31, 2022, are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733"&gt;

&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 462pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Less than 1 year&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;351,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 462pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;1 to 2 years&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;362,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 462pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;2 to 3 years&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;373,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 462pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;3 to 4 years&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;384,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 462pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;4 to 5 years&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;104,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 462pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;1,574,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 462pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Less imputed interest&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;194,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15.75pt;"&gt;
&lt;td style="height: 15.75pt; width: 462pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15.75pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 66pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;1,380,000&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;According to the terms of the lease in Irvine, the Company is also responsible for routine repairs of the building and for certain increases in property tax. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company also has various insignificant leases for office equipment.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;RETIREMENT SAVINGS PLAN&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Effective September 1, 1986, the Company established a 401(k) plan for the benefit of its employees. The plan permits eligible employees to contribute to the plan up to the maximum percentage of total annual compensation allowable under the limits of IRC Sections 415, 401(k) and 404. The Company, at the discretion of its Board of Directors, may make contributions to the plan in amounts determined by the Board each year. No contributions by the Company have been made since the plan's inception.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;LITIGATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company is, from time to time, involved in legal proceedings, claims and litigation arising in the ordinary course of business. While the amounts claimed may be substantial, the ultimate liability cannot presently be determined because of considerable uncertainties that exist. Therefore, it is possible the outcome of such legal proceedings, claims and litigation could have a material effect on quarterly or annual operating results or cash flows when resolved in a future period. However, based on facts currently available, management believes such matters will not have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;There were no legal proceedings pending as of May 31, 2022.&lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;CONTRACTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;Contracts and Licensing Agreements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company has one royalty agreement in which it has obtained rights to manufacture and market certain products for the life of the products. Royalty expense of approximately $19,000 and $11,000 is included in cost of sales for the agreement for each of the years ended May 31, 2022 and 2021, respectively. Sales of products manufactured under these agreements comprise approximately 1.5% and 1.5% of total sales for the years ended May 31, 2022 and 2021, respectively. The Company may license other products or technology in the future as it deems necessary for conducting business.&#160; The Company has other royalty agreements however they are not considered material.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;On May 25, 2016, the Company entered into an Exclusive Marketing License Agreement (&#x201c;Telcon Agreement&#x201d;) with Celtis Pharm Co., Ltd., who subsequently changed their name to Telcon Pharmaceutical Co., LTD (&#x201c;Telcon&#x201d;), a medical company in South Korea. The Telcon Agreement grants to Telcon an exclusive license to market and sell Biomerica&#x2019;s new InFoods&#xae; IBS products (&#x201c;IBS Products&#x201d;) in South Korea. The term of the agreement is for a period of five years following Korean FDA clearance of the product and provides an additional two years for Telcon to attain such Korean FDA clearance. The sequential two-year and five-year terms do not begin until after Biomerica first receives final clearance for sale of the IBS Products in the United States from the FDA. Telcon, at its sole cost and expense, must use its commercially reasonable good faith efforts to obtain Korean FDA for the IBS Product to be sold in South Korea. The agreement may be cancelled if Biomerica has not obtained final USFDA clearance for sale of the IBS Products on or before December 31, 2019. The required FDA approval was not obtained by December 31, 2019, however, neither party has terminated the agreement. Once the IBS Product is cleared by the United States FDA, Biomerica is also obligated to maintain a full quality assurance system for the IBS Products following the harmonized standards according to Annex IV of Directive 98/79/EC.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;The terms of the Telcon Agreement provide up to $1.25 million in future exclusivity fees to be possibly paid to Biomerica based on certain milestones including Biomerica&#x2019;s starting clinical trials in the United States, receipt of U.S. FDA clearance and Telcon&#x2019;s first sales of IBS Products in Korea. If Biomerica commences FDA Trials and Telcon pays the initial $250,000 milestone-based exclusivity fees, and the Agreement is subsequently terminated by either party for lack of performance, then Biomerica shall issue to Telcon 83,333 shares of Biomerica common stock in consideration for the $250,000 of paid exclusivity fee. No exclusivity fees have yet been paid.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;Additionally, the Telcon Agreement provides for&#160;a royalty of 15% paid to Biomerica on all sales in Korea of the IBS Product, and further sets the pricing of IBS Products sold to Telcon.&#160; In order to retain the exclusivity within South Korea, Telcon must meet certain annual minimum royalty payments to Biomerica following Telcon&#x2019;s receipt of Korean FDA approval or clearance for the IBS Product to be sold in Korea, which in no case will be later than May 31, 2019.&lt;b&gt; &lt;/b&gt;&#160;&#160;In September 2017, an agreement to extend this date was signed extending the date until April 30, 2020. &#160;During the quarter ended August 31, 2020, a second amendment was signed extending the required FDA approval date to December 31, 2021. The required FDA approval date hasn&#x2019;t been delivered however, neither party has terminated the agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;On April 1, 2020, the Company entered into two separate non-exclusive license agreements (the &#x201c;Mount Sinai License Agreements&#x201d;) with the Mount Sinai Icahn School of Medicine in New York (&#x201c;Mount Sinai&#x201d;) to license technology from Mount Sinai that the Company intends to use to scale up and manufacture a laboratory version serological test for SARS-CoV-2 coronavirus.&#160; The non-exclusive Mount Sinai License Agreements provide for royalty payments to Mount Sinai based on a percentage of gross sales of commercial products manufactured and sold by Biomerica that incorporate the Mount Sinai technology licensed under the Mount Sinai License Agreement. On June 20, 2020, the Company filed for Emergency Use Authorization (&#x201c;EUA&#x201d;) with the FDA for the sale of a product developed by the Company that is based on this technology. The FDA has still not approved the Company&#x2019;s Emergency Use Authorization for this product to be sold. As such, no royalty fees have been paid yet on these agreements. The Company is selling a COVID-19 rapid test outside of the United States, which is unrelated to the EUA product discussed above. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;On May 7, 2020, the Company entered into an exclusive license agreement (the &#x201c;UC License Agreement&#x201d;) with The Regents of the University of California (&#x201c;UC&#x201d;) to license all patent rights pertaining to certain licensed technology from UC. This technology is being developed at UC-San Diego by one of the professors and his team utilizing CRISPR technology. This group is developing a viral detection test for SARS-CoV-2 coronavirus.&#160;If this technology development is successful, the Company will work with the UC to transfer the technology to Biomerica where the CRISPR based product will need to be further developed, validated, and cleared with regulatory agencies for commercial sale into the market.&#160; The exclusive UC License Agreement provides for an initial and annual license fee, and a royalty payment on all commercial revenues, to the UC Regents. The UC License Agreement also includes certain investment requirements and milestones the Company will need to meet for the launch of a commercial product based on the licensed technology. The Company paid an initial license fee of $5,000 with the execution of the agreement. An additional $5,000 was paid in September 2020.&#160; No royalties have been paid yet on this agreement. A license maintenance fee of $10,000 is due annually. This is creditable against earned royalties due each year in the amount of five percent on net sales of licensed products.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;Clinical Trial Agreements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;In September 2017, the Company signed a Clinical Samples Agreement with the University of Southern California for the purpose of providing clinical samples for use by the Company in conducting future clinical trials for one of the products which the Company is developing.&#160; The initial budget was estimated to be approximately $82,000. The work started in October 2017 with charges for work performed being invoiced and paid monthly. This study ended in February 2020. Approximately $17,000 in fees has been accrued for unbilled charges as of May 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;The Company entered into a Clinical Trial Agreement with a research institute for the purpose of conducting a clinical trial of the Biomerica InFoods&#xae; product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be approximately $107,000. &lt;span style="COLOR:black"&gt;This study ended in March 2022. Approximately $28,000 in fees has been accrued for unbilled charges as of May 31, 2022.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LeaseExpirationDate1 contextRef="c147">2021-08-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:OperatingLeaseExpense contextRef="c147" decimals="0" unitRef="usd">25000</us-gaap:OperatingLeaseExpense>
    <us-gaap:SecurityDeposit contextRef="c148" decimals="0" unitRef="usd">26000</us-gaap:SecurityDeposit>
    <bmra:LeaseExpirationPeriod contextRef="c149">P10Y</bmra:LeaseExpirationPeriod>
    <us-gaap:OperatingLeaseExpense contextRef="c149" decimals="0" unitRef="usd">3400</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c150" decimals="0" unitRef="usd">310000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c151" decimals="0" unitRef="usd">295000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c152" decimals="0" unitRef="usd">42000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c153" decimals="0" unitRef="usd">25000</us-gaap:OperatingLeaseExpense>
    <bmra:ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550.1pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:467.1pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Operating cash flows from operating leases&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:67.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;338,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:467.1pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Right-of-use assets obtained in exchange for&lt;br/&gt;&#160;&#160;&#160; &#160;new operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:15.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:67.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-30; FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;&#160;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:467.1pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Weighted average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:67.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;4.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:467.1pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Weighted average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:15.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"/&gt; &lt;td style="HEIGHT:15pt; WIDTH:67.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;6.50%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bmra:ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="INF" unitRef="usd">338206</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c3">P4Y3M10D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c3" decimals="4" unitRef="pure">0.065</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733"&gt;

&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 462pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Less than 1 year&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;351,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 462pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;1 to 2 years&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;362,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 462pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;2 to 3 years&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;373,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 462pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;3 to 4 years&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;384,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 462pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;4 to 5 years&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;104,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 462pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 66pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;1,574,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15pt;"&gt;
&lt;td style="height: 15pt; width: 462pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Less imputed interest&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15pt; width: 11pt; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 11pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15pt; border-right: 0px; width: 66pt; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;194,000&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height: 15.75pt;"&gt;
&lt;td style="height: 15.75pt; width: 462pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="height: 15.75pt; width: 11pt; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 11pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 66pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"&gt;
&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"&gt;&lt;strong&gt;&lt;span style="font-size: 10pt; color: black;"&gt;1,380,000&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c3" decimals="INF" unitRef="usd">351000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c3" decimals="INF" unitRef="usd">362000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c3" decimals="INF" unitRef="usd">373000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c3" decimals="INF" unitRef="usd">384000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c3" decimals="INF" unitRef="usd">104000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c3" decimals="INF" unitRef="usd">1574000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c3" decimals="INF" unitRef="usd">194000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c3" decimals="INF" unitRef="usd">1380000</us-gaap:OperatingLeaseLiability>
    <us-gaap:RoyaltyExpense contextRef="c154" decimals="0" unitRef="usd">19000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense contextRef="c155" decimals="0" unitRef="usd">11000</us-gaap:RoyaltyExpense>
    <bmra:RoyaltyExpensePercentageOfSales contextRef="c154" decimals="3" unitRef="pure">0.015</bmra:RoyaltyExpensePercentageOfSales>
    <bmra:RoyaltyExpensePercentageOfSales contextRef="c155" decimals="3" unitRef="pure">0.015</bmra:RoyaltyExpensePercentageOfSales>
    <us-gaap:AccruedFeesAndOtherRevenueReceivable contextRef="c156" decimals="-4" unitRef="usd">1250000</us-gaap:AccruedFeesAndOtherRevenueReceivable>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c157" decimals="0" unitRef="shares">83333</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ProceedsFromFeesReceived contextRef="c157" decimals="0" unitRef="usd">250000</us-gaap:ProceedsFromFeesReceived>
    <bmra:RoyaltyPercentage contextRef="c157" decimals="2" unitRef="pure">0.15</bmra:RoyaltyPercentage>
    <us-gaap:PaymentsForFees contextRef="c158" decimals="0" unitRef="usd">5000</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees contextRef="c159" decimals="0" unitRef="usd">5000</us-gaap:PaymentsForFees>
    <bmra:LicenseMaintenanceFeePayable contextRef="c159" decimals="0" unitRef="usd">10000</bmra:LicenseMaintenanceFeePayable>
    <bmra:ClinicalTrialAgreementMaximumBudgetedCosts contextRef="c160" decimals="0" unitRef="usd">82000</bmra:ClinicalTrialAgreementMaximumBudgetedCosts>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c161" decimals="0" unitRef="usd">17000</us-gaap:AccruedLiabilitiesCurrent>
    <bmra:ClinicalTrialAgreementMaximumBudgetedCosts contextRef="c162" decimals="0" unitRef="usd">107000</bmra:ClinicalTrialAgreementMaximumBudgetedCosts>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c162" decimals="0" unitRef="usd">28000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;NOTE 10:&#160;&#160;&#160; SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;Subsequent to May 31, 2022, as of the filing of Form 10-K, the Company sold 523,977 shares of its common stock under its Form S-3 &#x201c;shelf&#x201d; Registration statement. The average sale price was $3.46 per share. Net proceeds to the Company were approximately $1,765,000.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;On July 14, 2022, the Company announced they had entered into a General Merchandise Supplier Agreement with Walmart, for the Company&#x2019;s Aware&lt;sup&gt;&#xae;&lt;/sup&gt; Breast Self Exam product to be sold in Walmart&#x2019;s retail system.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c163" decimals="0" unitRef="shares">523977</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice contextRef="c164" decimals="2" unitRef="usdPershares">3.46</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c163" decimals="0" unitRef="usd">1765000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="c4"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c4"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c5"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c6"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c3"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c4"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="c0"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesIssued
      contextRef="c20"
      id="hidden-fact-8"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c20"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesIssued
      contextRef="c29"
      id="hidden-fact-10"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c29"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="c7"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="c7"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <bmra:WriteOffOfFixedAssetsCost
      contextRef="c7"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <bmra:WriteOffOfFixedAssetsAccumulatedDepreciation
      contextRef="c7"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <bmra:WriteOffOfIntangibleAssetsCost
      contextRef="c7"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <bmra:WriteOffOfIntangibleAssetsAccumulatedAmortization
      contextRef="c7"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedLicenseAgreementsGross
      contextRef="c3"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <bmra:FiniteLivedLicenseAccumulatedAmortization
      contextRef="c3"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c7"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="c7"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="c7"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c7"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c3"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c4"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c0"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="c0">2022</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey contextRef="c0">0000073290</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>65
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M"?8(DP>([Y>4\MV./$&^YG[T/U!+ P04    " #6AAU5)]D[^%8'   ^(0
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M@/OK'%:3[8G^A+[_DXG9WU!+ P04    " #6AAU5]IW&@2($  "4$   &
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M-\UV!"U#-R3/;57@(<PU'!-:):RFQ"B5&-U*?#^)DA )',C%*S>R3U"^/>(
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MWE[-V[-%']]"X\E9PG,3R]*5%JZZO>S'. P#[#G1:+@_9- U#' 4.22H[8[
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M<L/9DDMM .]70JB7&SU ?4 ]_A]02P,$%     @ UH8=5:L] !'+!@  A"X
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MY8*3F9C=7,P ':O%?/E?C<G</,0:"'897L(^F,Q!<T'@C6VDJK]B!$^J+]R
M)VI$32 6:QT3'$$S'OTP%CV"FY=B0^#-.C/#(ZU-IL6Y1E=@50:Q,J:/OB(
M(MTG,^NC:A<SM38 *'A,8G2Z_(C$Y.+80"J*DN3;1H^(X$W(9M0/(=9QEI$B
M/,H[:2!%-*8]/4=)I8W0A QM<RW.-]A9*3MD4I28Z4S)&,2<73T8V2GA:14E
M!<0R944[#;@<P@VTSNREGS#J;>W"\"JXNAS2-J !7B<EJB,EN$GZ"N8P@/WA
M]77'8\,^VEFQ!_3A#R3,VY)1/>4NZ9 7+O'%>JH9'(9 B$0B%^<_T7 7@Y_P
MU]Q?9D ) @;V*8"*.]3B!#Y>_RDZ(538:#8WE'_UR%3(>M@S8]];])X+D>/Q
M3TV: AS,T@L20LMBI^M,5=GV0I:PSHV\'KG8#3SNZ)ITZX@9SPQYO">P+'^Q
M[ &/]JFYK._LVOF &7+9R1!>?X?-EBW4_'Z'H<'/,;#+G]@\A0W"034F91+^
M;\@I\N01WLB+[K5>G?$"SZ^Z%HA2"F%;!&[7A+E/+C/<5^]G=^\7D_L/\VG+
MQA\;5X_&4#7EX&(T=')P-1@?2\%WQB/Y.>]X;3I9?E"3VW?\P^R_/\\!:Q"H
MF#X+J#QG'>L=9S/ ;"=2X #TJP\&7-BMIW@#@ & 8-@G6)B)L2AK798&4 "
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M4CDMPZNP]X%"X+G)<JHH?TDJJ@::7<..V,7LP^QV.?]]QAH^/0K,'/;V-)H
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MT8]XO8HN\ 'X?IT#[)9?< +[E^M^^_]02P,$%     @ UH8=57-W,E?, @
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M7S8#T&7#+ =6%;Y)396EEN?-!?UC4#L'6I\I9;<#%V#WU^K^!5!+ P04
M" #6AAU5DY3 W.@"  !I!@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6R-56MOVC 4_2M7V>-3U83P:,< *5"F35H[5.@>FO;!)!=BU;$SVS3P[W?M
M!,8JBO8EL9U[SCTGL4\&E=*/)D>TL"V$-,,@M[;LAZ%)<RR8N50E2GJR4KI@
MEJ9Z'9I2(\L\J!!A'$6]L&!<!J.!7YOIT4!MK. 29QK,IBB8WHU1J&H8M(+]
MPCU?Y]8MA*-!R=8X1_M0SC3-P@-+Q@N4ABL)&E?#(&GUQQU7[PN^<JS,T1B<
MDZ52CV[R*1L&D1.$ E/K&!C=GG""0C@BDO&[X0P.+1WP>+QG_^"]DY<E,SA1
MXAO/;#X,K@/(<,4VPMZKZB,V?KJ.+U7"^"M4=6VO&T"Z,585#9@4%%S6=[9M
MWL,1X#IZ 1 W@-CKKAMYE3?,LM% JPJTJR8V-_!6/9K$<>D^RMQJ>LH)9T?)
M9/+EX6XQAUGR(QE_GD)R=P.T>/\PO8'I]]GT;CZ=#T)+K1P@3!O:<4T;OT#;
MBN%629L;F,H,LW\)0M)X$!KOA8[CLXRW; ?MU@7$41R?H6L??+<]7?L%NAG;
ML:5  TQFD*2IWC!AX&>R-%;33OEURG+-V#G-Z$Y/WY0LQ6% Q\.@?L)@]/95
MJQ>]/Z.W<]#;.<<^(HEJ(ZV!1OA?W9C!9\Z67'#+R<\--ZE09J,1?BYP:V$L
M5/IXTL_YCG=?%E/H]N&_=@@L<H25$G3&N5P#=^\56%EJM>5T=!"6E!B/F:HD
MJ!4=Q<9,>62&-69P2X%CR,F2"293-'TX_O;NTH+D.<-KN&KW+J(HHE&':MTH
M><X8-R6M;NSO"V69(,"[J[B!=J_;-=0XG?_T=1I];TM6)ZHHF=Q!SC*PE8(G
ME)G2]6Y2$IOY!<66*=$'C]A=0)7S--^[)V&4J=![]\:C6E=OGI>?>%.7I[92
M>'3\"]1K'W(&/+).@L/J(4>3.C[^EM<A?,OTFDL# E<$C2ZO*+9T'6SUQ*K2
MA\E268HF/\SI7X#:%=#SE5)V/W$-#G^7T1]02P,$%     @ UH8=570A8%IT
M#0  OR<  !D   !X;"]W;W)K<VAE971S+W-H965T,3(N>&ULU5KI<]O&%?^N
MOV*'41)G!H9P$J0/S<@292N))564DW8Z_; $EB1B $OC$*7^]7WO[>+B925M
MI^D'6P1W]]W'[RWX9BWSS\52B)(]IDE6O!TLRW+UZN2D")<BY84I5R*#E;G,
M4U["8[XX*5:YX!$=2I,3Q[*&)RF/L\'I&_KN-C]](ZLRB3-QF[.B2E.>/[T3
MB5R_'=B#^HN[>+$L\8N3TS<KOA!347Y:W>;P=-)0B>)49$4L,Y:+^=O!F?WJ
MG8?[:<,OL5@7G<\,-9E)^1D?KJ*W PL%$HD(2Z3 X<^#.!=)@H1 C"^:YJ!A
MB0>[GVOJEZ0[Z#+CA3B7R:]Q5"[?#D8#%HDYKY+R3JX_"*V/C_1"F13T/UNK
MO;XU8&%5E#+5AT&"-,[47_ZH[= Y,-IWP-$''));,2(I+WC)3]_D<LURW W4
M\ .I2J=!N#A#ITS+'%9C.%>>3C^<W4T^W/Q\,;F;?L\F?_ET=?^W-R<E4,;U
MDU!3>:>H.'NHV [[*+-R6;!)%HFH3^ $1&KD<FJYWCD'*7[D3\RU#>98CG.
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MZOFA[[Z6/7H#:=9^T2P8K\JES.-_4D@+AI'$032DTXO&K"+.\'7/=)VX/H%
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M <:A N(JPB.@#FR>RP0&HN+5T?6GC^\F=^SF\FCRU_/)W?G5='+TZ^3J_0?
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MFCKS@QKD/M$7/>O"$*,0JN8"&T,EUU276TC "/?6-4G/G-H\>E26X%YL]WH
MQ782B7F<J7YS5T&!\6P?0RBMD@7OI^Y4A( 5RABX 3*NNRR!Z;"DUJ1!-'W7
MGD-%,&(J#&,T!U8SJ#U/8%!>R(SJ&@2>S$O"V86 NB2SG=:<B25/YE2Y]EDB
M%U\JU224(0H(%#8'C5@9IX)2!?_J^-8,#)H/T;M B (U+K&C0,&$&IES!?M
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MN '6YU*6]0,R:'ZS=_HO4$L#!!0    ( -:&'54(=;G_H@8  /$/   9
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MC\H&T/U62G,R;('VTS'[ 5!+ P04    " #6AAU5-QV@Y?@2  !",P  &0
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MHYE<73XA IA<?^;((^VN@]5UO*M?J+T;#]_<F32AP6?\@B^/WOR*O"]7ZL(
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M1EQ0W91+")B)(Z>* '>(HHKV_6!*3#L)1E8C^A3 7S&3LK=ZJ<;9$N >B;R
M(*[F9#5"QE:Z*V\NL68,._N$G;4P_VXSSO\.$>I9@68V#J0*C4F$S6LJ7<US
M'?+=;N]&D_M_4!H!,PAW6-YB,ZR)8^BPIHJ.!*&/*<Y$7=GV1@Z"@A-]4HK4
M4=X_<2?7%*I)L8?@KH2L8-]J@IZ3B0H)FT+.CBCC3(EN#6T-DL>WT*NV]_>5
M(I5TD&X(N5#8"PJR\9RA^_2(Q5-'H'T!1G,]ETR+5+L<:!;P<!Z)9L_0SH#T
M_EO<"5(::PI+!:VJ'&PTX?NH% ,O"E*,L38Z8XWD"9L81$X9&EXN,H)"85Z
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M(OU+D6[H"^QG:0&N-?V(%R2J#!^ OR]2B#3E%YP 6R:(O(__!U!+ P04
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MQ'M1WT/<(9>D$T61QQ>]R..[2@EF*H4=6+&M ]KKY6BK*)<\ U:42KZ@8]%
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M:J"K^5LMK"K\S)LI2Q/4FTNZLE [!WH_5\IN%BY!?0D._@!02P,$%     @
MUH8=5;U1,45Z @  :@4  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
M?53O;]HP$/U73MXT;5+5) 9*UT&D0)DVJ>U0H?NA:1],<A"K3IS93J'__6PG
MI$RB?(G/]KWG]^S<C;92/>H<T<"N$*4>D]R8ZBH(=)ICP?2YK+"T.VNI"F;L
M5&T"72EDF0<5(J!A>!$4C)<D'OFUN8I'LC:"ESA7H.NB8.IY@D)NQR0B^X5[
MOLF-6PCB4<4VN$#S4,V5G04=2\8++#67)2A<CTD274WZ+M\G?.>XU0<Q."<K
M*1_=Y&LV)J$3A )3XQB8'9YPBD(X(BOC;\M)NB,=\##>LW_VWJV7%=,XE>('
MSTP^)I<$,ERS6IA[N?V"K9^!XTNET/X+VR9W2 FDM3:R:,%60<'+9F2[]AX.
M )?A*P#: JC7W1SD55XSP^*1DEM0+MNRN<!;]6@KCI?N419&V5UN<29.IM-O
M#W?+!<R37\GD9@;)W378Q?N'V37,?LYG=XO9 MXOV4J@_C *C#W3(8.TY9\T
M_/05_HC"K2Q-KF%69IC]3Q!8L9UBNE<\H2<9;]DS]*(SH"&E)^AZW07T/%WO
M%;HY>_;>@)49)&FJ:B8T_$Y6VBC[R_PY9KEA[!]G=&5TI2N6XIC8.M&HGI#$
M[]Y$%^&G$WK[G=[^*?9X8<LRJP6"7#NYLBZ-AM;$BP?,X(:S%1?<<.OMMW\_
M6.+.P$3(]/&HK9,''[<%AZ_A/M&+J*H5]1:&O8NS, QMU+>Y+MJ+Q)WM+MHJ
MI&U*-*!^7$K#A 5\'-(6.KCLN>C8%08'_W^!:N.K7(/7T91"M]HUDJ2IGY?T
MI@O=,K7AI0:!:PL-SX<# JJI[&9B9.6K:26-K4T?YK89HG()=G\MI=E/W %=
M>XW_ 5!+ P04    " #6AAU5C"78DAH$  #I"0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6RM5FUSHS80_NY?L4,];3)#, @A<.IXQDZX)#.7E]K)
M73LW_8!!MID#Y!-RG/S[K@ 3-W7<=*9?;"3M/OL\VEU)@XV0W\LEYPJ>\ZPH
MSXRE4JO37J^,ESR/2DNL>($K<R'S2.%0+GKE2O(HJ9SRK$=LF_7R*"V,X:":
MNY?#@5BK+"WXO81RG>>1?!GS3&S.#,?83DS2Q5+IB=YPL(H6?,K5X^I>XJC7
MHB1ISHLR%05(/C\S1L[IF&G[RN!+RC?ESC=H)3,AONO!=7)FV)H0SWBL-$*$
M?T_\G&>9!D(:/QI,HPVI'7>_M^B?*NVH91:5_%QD7]-$+<^,P("$SZ-UIB9B
M<\4;/9[&BT565K^P:6QM ^)UJ43>.".#/"WJ_^BYV8>/.)#&@52\ZT 5RXM(
M1<.!%!N0VAK1]$<EM?)&<FFADS)5$E=3]%/#Z=5H$E[=?;X()]-?(/SM\?KA
M#SAZB&89+X\'/84AM&$O;N#&-1QY!\XA<",*M2PA+!*>_!V@A]Q:@F1+<$P.
M(MY$+^ Z)A";D -P;JO7K>#<]_0J$7]?BBSALD2]/]:I>H%;H3A\&\U*);%*
M_MPGNT:E^U%UYYR6JRCF9P:V1LGE$S>&/__D,/O7 YQIRYD>0A].EY'D)V.L
MO03NHQ=L"04C*:-BP?6W"7<K7>$FC'2):T'?J@3" W]6,,Y0\5Y-AZ/>/MZ,
MPPG<?>J$OY^'D_/K:=CY&EY?7CV$%YTZ8@G8YJ6*BB0M%A IV$F6W7%,/^B;
MQ',Z7=L*R$DWL)R@T^T0R_=:@ 7*4#SI4-<VF<,Z7<]RJ#;U;31EEN^VIOPY
MYC).<1<Z1P$S?<\^WB*[%B-H[E@8=FL>1T6,S9^ D.BZ2J7V\Y"4YZ ?L5RO
M940MW_^ )*=#3#MP3)>Q5TD53]?R^O^0Y%)JVC8N4XM@+&I15L6B^R6Y?=.S
MM22M8D=2OW]8$J.XQ[4?<W8D4><#D@A*<HE3;_T;2?ZA?O/:VO4.UR[>(LD:
M:U',L<V*)U[BUD!5T?^U7 \&VM^"<+O.9USJX%7C@VAV!*F<-%Q*S:5\FVKP
M^ZY)J -=\"R/PF6=5&B2"CJ-\*5&.'*I;Q*_?XRFU :\+>8\K1:H6^44YPGY
MUY@$?,I,RD@5TW$.[#YK=Y_]/R='^%S7(=S+-.8PT18?3,M!!N^D93*ZO0SQ
M:('FD-F>*Z\?;Q>:XG0LCP#U6)4#UW)=P"F;ME/U"+N[[CCB@6/:CJ</"V!X
MLNBEO@V!1W1B]"@(  W=YLR!@/;-@#' @0==='&!,&8R+(&N;]EL7U)Z.]=O
MSN6B>F1@MXIUH>J;N)UMWS&C^OI^-:\?03>17*18GQF?HZN-) R0]<.B'BBQ
MJB[SF5#X-*@^E_@6XU(;X/I<X%W6#'2 ]G4W_ M02P,$%     @ UH8=53!@
MF2[Z!   \PL  !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&ULC5;;;MLX
M$'WW5PRT06$#;BS)E\1I;,!Q4FR!I GB='>!8A]H:603D40M2=EQOWZ'I*1X
M<_$&32W>YO#,S!F2YULA']4:4<-3EN9JXJVU+LYZ/16M,6/J6!28TTPB9,8T
M=>6JIPJ)++9&6=H+?7_4RQC/O>FY';N3TW-1ZI3G>"=!E5G&Y.X"4[&=>(%7
M#]SSU5J;@=[TO& K7*#^4=Q)ZO4:E)AGF"LN<I"83+Q9<'8Q,NOM@C\X;M5>
M&XPG2R$>3>=;//%\0PA3C+1!8/39X!S3U  1C7\J3*_9TACNMVOTK]9W\F7)
M%,Y%^B>/]7KBG7H08\+*5-^+[>]8^3,T>)%(E?V%K5M[,O @*I46665,##*>
MNR][JN*P9W#JOV,05@:AY>TVLBPOF6;3<RFV(,UJ0C,-ZZJU)G(\-TE9:$FS
MG.ST]-OW^>W-%3S,_KI:0/N!+5-4G?.>)FBSH!=5,!<.)GP')@CA1N1ZK> J
MCS'^+T"/.#7$PIK817@0\8;MH!]T(?3#\ !<O_&S;^'Z[_F91R)#>&!/<,E5
ME I52H2?LZ72DI3Q]ULN.\3!VXBF6LY4P2*<>%0."N4&O>FGWX*1_^4 WT'#
M=W (?;J@ZHO+%$$D,!=9(7+,M3*]/4^NGJ@V%4+[ G-,N.[ 3YM!>, G#1>I
MB![?=.S@UF\[!E0#H-<(.V02T"09]E-D?@*8EU(2SS/X<;PXAJ\8HV0I',%G
M^Y\@J$AR0QT5+,JEXC%GDE.G'?:[ON]WH!V$KK'03".P/ 9R@T#:0;W ?1^$
MIM'(;4CV@WJZ KK$!&DN?L'E,_U["6W&'%Q<&=FA*M": HU5H(^>-SIJMCJ0
M[6&3[>&'LWV5)&B/JOU,WQO&]QB)/.(I9_9 ^UBN#V_\?E9;)JOF)V@9_96:
MICP3AXA:GHW*TJFN==0:#TY,**@5=(<CFZ$6L:=;PJB3 EK:,[@#/*>_.JR4
M=](7'9\\7T$B17;6FJ]9OD*S;,/2TOG)4KHY6!YAR^0^=/IHM<-N.*[:+J'[
MP%W(Z4*C:"95WFNN?=^W[,+ ,;XG@3,9K:T<8MS0+55D1E'&07(@YEJUALYF
M,!S9[QW2=9#7BV)."2,11N2. 1$43TGTW 9$]/2T9DDYLE=(#,34*,HY6',+
M7.""P=!^ZW)QD2)?U%[%4"PJ^;7JDFF]%BPEI!:L:?Z_8$>-8$<?%FQ=:5:H
M,Z50NT!<<[8DL6I3WQ_3ZL$]WSF77A]"#1\3"&;YG,$LBD1I3E")$?*-8=.%
M0I)F>$$"VT%<4N3$L]B 'CP0BW*IDS*EQT-E?@0#&T1JA$Y*5*8;TH*0NSW-
MAGV;?>B?NN^\SC?18DOEU!*$#N#4YAN^&\46I%9;#W1#*8B8E#LBLF4R5C#H
M]@=C!]L-QC:M-N9.IB\6DY;&5JZF-70[-)&Q9V:ED=Z<%9P./_Z+)E)3L0HJ
M8H$S<\*]+8QG%KCOQD=.3W!-5)U"DTJR^TJ%3RPKOL"M*0M7EH/ .7'B=J'4
ME%F9VMC$2*F-J@/.B(AE0FK^JXJJ<ZCM>'5>'MK/^891=SQRD1]VQ[X+U352
M1-\X5J#=K*;[HUG?L0EY#5Y?9V]546_O(9:A7-GG)J71:,>]R9K1YD4[<P^Y
MY^7N.7S#Y(I3N%-,R-0_/J&#7+HGINMH4=AGW5)H>B3:YII>Y2C- II/A-!U
MQVS0O/.G_P)02P,$%     @ UH8=50FB]]#1 @  VP4  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL?51-C]HP$+WG5UAIJ5H);;Z P!8BA2V[RX%=
MQ-+V4/5@DH%8Z\34=A;X]_4'I%1BN1#/>.;->XQGACO&7T4!(-&^I)48N864
MVUO/$UD!)18W; N5NEDS7F*I3+[QQ)8#SDU22;W0]WM>B4GE)D/CF_-DR&I)
M205SCD1=EI@?QD#9;N0&[LFQ()M":H>7#+=X R\@OV_G7%E>@Y*3$BI!6(4X
MK$=N&MR..SK>!/P@L!-G9Z25K!A[U<8T'[F^)@04,JD1L/J\P1U0JH$4C3]'
M3+<IJ1//SR?T>Z-=:5EA 7>,_B2Y+$9NWT4YK'%-Y8+M'N&HIZOQ,D:%^44[
M&QNKBEDM)"N/R<HN266_>'_\'\X2^OX[">$Q(32\;2'#\AN6.!ERMD-<1RLT
M?3!23;8B1RK=E!?)U2U1>3)YF#P_+-+YX_0.39_NGQ>S=#E]?D*?EWA%07P9
M>E(5T:%>=@0<6\#P'< @1#-6R4*@295#_C^ I]@U%,,3Q7%X%7&&#R@*VBCT
MP_ *7-0HC@Q<])YB8!N.MP7)T+2RKUH_CV]$9)2)F@-*5T)R]5PNB;?8G<O8
M>H)NQ19G,'+5B C@;^ FGSX$/?_K%>:=AGGG&GJR@#>H:D!KSDHTV4O@%:;H
MSCP2X *M#NA,7*IF5*!?II%H"7N)QI1EK[\OJ;I>5SU_) M !\ <@>XJ.O;$
MT3W1/X&3"H*=CTX0M:.XV_9]WXF#EG:T!W[?V&&OY4QJKO:)TVE'T< ZHY:V
M_,!8/;_E/#$N"Y0J123#SF 0FYMNR^EV+$Z_Y;RH]7(6XQN_*A=V[5&!SDB>
M*^$3+*036Z\"#P;A*6#))*::8+_=CVWYP/<UY;@=# :-XU+CO+.!4R0V9JT(
ME+&ZDG;V&F^SN5([L/_"[=J;8;XAE4 4UBK5OXF[+N)VE5A#LJT9WQ63JL_F
M6*CM"UP'J/LU8_)DZ +-/D_^ E!+ P04    " #6AAU5(Q2)&54#  !I!P
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MU?JZZ6Q;AJBHE8Z!Y=RQ844K%J(>+"R;R^6\:F!2'GSC8I04;8FP)"'J=L'
M\=L=L)O*EAK!:X=>L(P[,F!;2G]96X/O,;F30U"Q$++O#&;Y(BN-PLKJQMG
MHMW  U^Q;Q? 0M/Y6=.G]I9Q^I%G"UX8&;&[=S@, ]NUV@.Q(64@QQZ+!JW&
M )=FU]I255L*UO:RG'(A0^V(RS'X/N5R"/XD\D+^&"Z$X!L:!NU4+J*!H5V
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M4P7R^8Y2\=I1YT?]=R'\!U!+ P04    " #6AAU5"<:$77X#  "^#@  &0
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M-A>ZP 1A#/3W&>?JJ6,FJ$K6^ =02P,$%     @ UH8=57X_,G*H P  B1
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M>BK6M[#QXQN^2"2J_))U%=O!X*A06J0;,"I(>5;]V>LF#SL USL H!L _2S
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MJ4J^:6[4HPQ<!ZCY%6/RM:/K?OG,1[\!4$L#!!0    ( -:&'56GHF=W=0(
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ME*A3G @F5U/I)_P@#*]OKVXF* I^!OW+(0JN!D@:Q[?# 1K^B(97D^$$?1B
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MPPW^(4#H GR^XEP=)KH)-?^<Z"]02P,$%     @ UH8=55*9LD#L!P  L4@
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M7*AI2]$$J7&+(X\% OW&PBU';U0(2<*0B11MN)H%90=K&B-.C"?3M2@@8:2
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M%*U'HDB@*Y8GV,P?.=P5T9]![?="V>^PFMVB*P(Z)H&BJ1I+]\32NR>0N?<
MWU@_F]IZ@9HKH#0"15-UE>:*=11SQ0(U5T!I-BB-0-%4_:2Y8NG-E?]#[@6U
M;C):?*N_O*;7+.5>T+L]H&BIQJV=+Z)[C*^27P (T3S8^E'Z?>[\:/XK Z/D
MN_6%XV/SU$Y_*T!BTI\NF%"^<D1!XK*E0!K-GM@@\/37 -(G4;!)ONY^&T11
MX"4/UXPN&(\;B->701 ]/8D'R'^38?@O4$L#!!0    ( -:&'55?$+E^= 0
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M43*A++M!?/Z<)'Q]DG50[GD;_0=02P,$%     @ UH8=54PX-WX? P  ?PH
M !D   !X;"]W;W)K<VAE971S+W-H965T,SDN>&ULM99=;YLP%(;_BL6F?4AM
M $-"TB5(R9JME=:U2]9.NW3@D* "9K:3M-)^_&Q,2+(2U$CM#6#C\Y['+]@^
M_35E]WP!(-!#FF1\8"R$R,],DP<+2 EOT1PR^2:B+"5"-MG<Y#D#$A9!:6)B
MR^J8*8DSP^\7?3?,[].E2.(,;ACBRS0E['$$"5T/#-O8=$SB^4*H#M/OYV0.
M4Q"W^0V3+;-2">,4,A[3##&(!L;0/AO9C@HH1MS%L.8[STA-94;IO6I<A@/#
M4D200""4!)&W%7R&)%%*DN-/*6I4.57@[O-&_4LQ>3F9&>'PF2:_XE L!D;7
M0"%$9)F("5U?0#FAMM(+:,*+*UKKL9[,&"RYH&D9+-MIG.D[>2B-V EP#@7@
M,@ 7W#I107E.!/'[C*X14Z.EFGHHIEI$2[@X4U]E*IA\&\LXX4\OAI/QQ?6W
M\_%D^AZ-?]Q>_OR-/IR#(''"/Z)3])UFIRO@ D(T%32X1]>YLI.CH?(S%H]]
M4T@.I68&9<Z1SHD/Y+0QNJ*96' TSD((]P5,.8%J%G@SBQ%N5+PBC\BQ3Q"V
M,$9OD8GX@C#@Y:TA@5/9Y!0)G ,)I OHKLD%-)QQP>0_5F>'UG;KM=6Z.^,Y
M"6!@R(7%@:W \-^]L3O6IP9RMR)WF]3]G>^GW3A!V3*= 4,TVMCTM]8HS:[5
MVX6Z6N(KW^LYV+7[YJJ&JEU1M8^E6A<+2':0%3"Y(: Y(YE (1& (A(SM"+)
M$B3K]OO6\>J\W@YON]5VZVD[%6VGD?:K(H'P2.<Z3YQS7->RK'H6KV+QGL?R
M0GYY3_QR6ZY3S]BM&+N-C'JE'&E7]XE=IX[K8:]7S]*K6'K/8GDANW0RV]K[
MOP[\7K:UW82M1DAYP$00'^]9*;MGFNNT#_UC]LZI8#\7Z(6,*Q/N+TR,#X#B
M+2A^U>VME-_;W]R.VSD$MCTP[,9=_15WN#+QOI/V_QNRN5,3I,#F1>7#44"7
MF=#E0=5;55=#75-LA^O2[(JP>2S/N@0B&6JU/.D6T]6.;@B:%Q7&C I9KQ2/
M"UDA E,#Y/N(4K%IJ 15S>G_ U!+ P04    " #6AAU5.R\M-XL$  !Y%0
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M+5G+6-969A-!E[HSFU(A^SP]7,A6')@*D,]GE(K=1&U0-/?!/U!+ P04
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M95FZ=@K7G*Z>!GZW&_@M+^RY3\T,=@T#/PP]&-1V2G#M.KBV,;@)?L+9&G\
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M$*^ _8/^0U\)XP(-Y3(,Y9] 2XH>0"Z"HD^-*_>-8ZLP<\=3O(:^)>,(!W8
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M;KES[+BC=\(<5(H -:PAS$DES(E5F'L6AV:M6^4_:_JSHKK* 0G#D+  $D:
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M?@_NO(_"U7LJ7/]_;_0;4$L#!!0    ( -:&'567BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ UH8=5;UR6I0K!
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M96QS+W=O<FMB;V]K+GAM;"YR96QSS=FY;L) %(7A5T%^ (:[F"R"5&G21KR
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MLBH4616*K$,468?_*>N[,:N__CG:W--*%_4QG[5_H*>?4$L! A0#%     @
MUH8=50=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " #6AAU5-U$C/^\    K @  $0
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M965T-"YX;6Q02P$"% ,4    " #6AAU5JST $<L&  "$+@  &
M    @(%-(0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @
MUH8=5?J.6# >"   9B0  !@              ("!3B@  'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;%!+ 0(4 Q0    ( -:&'57@K@8S1P<  -40   8
M          " @:(P  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M    " #6AAU5@9/=']LF  #%;@  &               @($?.   >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ UH8=57-W,E?, @  )P8
M !@              ("!,%\  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+
M 0(4 Q0    ( -:&'57!XF#5_ (  ,$&   9              " @3)B  !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ UH8=59.4P-SH
M @  :08  !D              ("!964  'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"% ,4    " #6AAU5="%@6G0-  "_)P  &0
M@(&$:   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( -:&
M'54(=;G_H@8  /$/   9              " @2]V  !X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L! A0#%     @ UH8=56IJ"[;V @  1@8  !D
M         ("!"'T  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M    " #6AAU5-QV@Y?@2  !",P  &0              @($U@   >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( -:&'54_7 ZW"P,  &(&
M   9              " @623  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L! A0#%     @ UH8=5?]H]M)I*0  WH   !D              ("!II8
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " #6AAU596\"
MS@8$   D"0  &0              @(%&P   >&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+ 0(4 Q0    ( -:&'54O>' !F@(  +<%   9
M  " @8/$  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @
MUH8=5=L P_CK @  $ <  !D              ("!5,<  'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"% ,4    " #6AAU5O5$Q17H"  !J!0  &0
M            @(%VR@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4
M Q0    ( -:&'56,)=B2&@0  .D)   9              " @2?-  !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ UH8=53!@F2[Z!
M\PL  !D              ("!>-$  'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6Q02P$"% ,4    " #6AAU5":+WT-$"  #;!0  &0              @(&I
MU@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( -:&'54C
M%(D950,  &D'   9              " @;'9  !X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L! A0#%     @ UH8=5==6XH=R#@  W'L  !D
M     ("!/=T  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M" #6AAU58]@RMM8"   Z"   &0              @('FZP  >&PO=V]R:W-H
M965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( -:&'54)QH1=?@,  +X.   9
M              " @?/N  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L!
M A0#%     @ UH8=57X_,G*H P  B1   !D              ("!J/(  'AL
M+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #6AAU530!N.[L"
M   P!P  &0              @(&']@  >&PO=V]R:W-H965T<R]S:&5E=#,P
M+GAM;%!+ 0(4 Q0    ( -:&'55+ ].SIP(  /('   9              "
M@7GY  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ UH8=
M5:>B9W=U @  V 8  !D              ("!5_P  'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"% ,4    " #6AAU5PN/= ,X"   ("@  &0
M        @($#_P  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0
M   ( -:&'54UGLT*A (  '\&   9              " @0@" 0!X;"]W;W)K
M<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ UH8=55*9LD#L!P  L4@
M !D              ("!PP0! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q0
M2P$"% ,4    " #6AAU5&8)M#WP'  "?00  &0              @('F# $
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( -:&'55?$+E^
M= 0  &@9   9              " @9D4 0!X;"]W;W)K<VAE971S+W-H965T
M,S<N>&UL4$L! A0#%     @ UH8=59N]O_-Y!0  _R8  !D
M ("!1!D! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " #6
MAAU53#@W?A\#  !_"@  &0              @('T'@$ >&PO=V]R:W-H965T
M<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( -:&'54[+RTWBP0  'D5   9
M          " @4HB 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#
M%     @ UH8=5?-&55X8!   -!,  !D              ("!#"<! 'AL+W=O
M<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " #6AAU5>]:(WQ@#  #H
M"P  &0              @(%;*P$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM
M;%!+ 0(4 Q0    ( -:&'56!Z1:$LP,  )L+   9              " @:HN
M 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ UH8=51OW
M]ZW5 P  [0P  !D              ("!E#(! 'AL+W=O<FMS:&5E=',O<VAE
M970T-"YX;6Q02P$"% ,4    " #6AAU5]_@42R\"  "D!   &0
M    @(&@-@$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (
M -:&'54AW/5B,P4  (8F   9              " @08Y 0!X;"]W;W)K<VAE
M971S+W-H965T-#8N>&UL4$L! A0#%     @ UH8=51;,#NCS P  @!,  !D
M             ("!<#X! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"
M% ,4    " #6AAU5&%O*[]H%  "V+0  &0              @(&:0@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( -:&'57#?3TC[ (
M "L'   9              " @:M( 0!X;"]W;W)K<VAE971S+W-H965T-#DN
M>&UL4$L! A0#%     @ UH8=5;Y'-L34 @  W <  !D              ("!
MSDL! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " #6AAU5
M\L$#"I\"   (!@  &0              @('93@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4Q+GAM;%!+ 0(4 Q0    ( -:&'56"_-V_.0,  .P3   -
M      "  :]1 0!X;"]S='EL97,N>&UL4$L! A0#%     @ UH8=59>*NQS
M    $P(   L              ( !$U4! %]R96QS+RYR96QS4$L! A0#%
M  @ UH8=5;UR6I0K!   5B(   \              ( !_%4! 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( -:&'56AE^J4R0$  * >   :
M  "  51: 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M -:&'54HM&@3PP$  (D>   3              "  55< 0!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     [ #L %!   $E> 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>165</ContextCount>
  <ElementCount>321</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>78</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS` EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF SHAREHOLDERS` EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ConsolidatedCashFlow</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - ORGANIZATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ORGANIZATION</Role>
      <ShortName>ORGANIZATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNET</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - INTANGIBLE ASSETS, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/INTANGIBLEASSETSNET</Role>
      <ShortName>INTANGIBLE ASSETS, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SHAREHOLDERSEQUITY</Role>
      <ShortName>SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - GEOGRAPHIC INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/GEOGRAPHICINFORMATION</Role>
      <ShortName>GEOGRAPHIC INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNETTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNET</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - INTANGIBLE ASSETS, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/INTANGIBLEASSETSNETTables</Role>
      <ShortName>INTANGIBLE ASSETS, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/INTANGIBLEASSETSNET</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - SHAREHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SHAREHOLDERSEQUITY</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/INCOMETAXES</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - GEOGRAPHIC INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables</Role>
      <ShortName>GEOGRAPHIC INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/GEOGRAPHICINFORMATION</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/InventoriesTable</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Inventories</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SharebasedcompensationassumptionsTable</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Revenue from contracts with customers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Revenue from contracts with customers</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details) - Property and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/PropertyandequipmentnetTable</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Details) - Property and equipment, net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNETTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - INTANGIBLE ASSETS, NET (Details) - Intangible assets, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/IntangibleassetsnetTable</Role>
      <ShortName>INTANGIBLE ASSETS, NET (Details) - Intangible assets, net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/INTANGIBLEASSETSNETTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - INTANGIBLE ASSETS, NET (Details) - Expected amortization of intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable</Role>
      <ShortName>INTANGIBLE ASSETS, NET (Details) - Expected amortization of intangible assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/INTANGIBLEASSETSNETTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Accounts payable and accrued expense balances</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Accounts payable and accrued expense balances</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - SHAREHOLDERS' EQUITY (Details) - STOCK OPTION AND RESTRICTED STOCK PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Details) - STOCK OPTION AND RESTRICTED STOCK PLANS</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - SHAREHOLDERS' EQUITY (Details) - COMMON STOCK ACTIVITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Details) - COMMON STOCK ACTIVITY</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - SHAREHOLDERS' EQUITY (Details) - PREFERRED STOCK ACTIVITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Details) - PREFERRED STOCK ACTIVITY</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - SHAREHOLDERS' EQUITY (Details) - Activity as to aggregate stock options outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ActivityastoaggregatestockoptionsoutstandingTable</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Details) - Activity as to aggregate stock options outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - SHAREHOLDERS' EQUITY (Details) - Non-vested Stock Options Activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/NonvestedStockOptionsActivityTable</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Details) - Non-vested Stock Options Activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - SHAREHOLDERS' EQUITY (Details) - Stock Options Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/StockOptionsSummaryTable</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Details) - Stock Options Summary</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/INCOMETAXESDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/INCOMETAXESTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - INCOME TAXES (Details) - Income tax expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/IncometaxexpenseTable</Role>
      <ShortName>INCOME TAXES (Details) - Income tax expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/INCOMETAXESTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - INCOME TAXES (Details) - Income Tax Rate Reconciliation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/IncomeTaxRateReconciliationTable</Role>
      <ShortName>INCOME TAXES (Details) - Income Tax Rate Reconciliation</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/INCOMETAXESTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - INCOME TAXES (Details) - Deferred Tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/DeferredTaxTable</Role>
      <ShortName>INCOME TAXES (Details) - Deferred Tax</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/INCOMETAXESTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - GEOGRAPHIC INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails</Role>
      <ShortName>GEOGRAPHIC INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable</Role>
      <ShortName>GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) - OPERATING LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details) - OPERATING LEASES</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) - CONTRACTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details) - CONTRACTS</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) - Supplemental cash flow information related to leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details) - Supplemental cash flow information related to leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) - Future minimum lease payments under operating leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/FutureminimumleasepaymentsunderoperatingleasesTable</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details) - Future minimum lease payments under operating leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="bmra-20220531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="bmra-20220531.htm">bmra-20220531.htm</File>
    <File>bmra-20220531.xsd</File>
    <File>bmra-20220531_cal.xml</File>
    <File>bmra-20220531_def.xml</File>
    <File>bmra-20220531_lab.xml</File>
    <File>bmra-20220531_pre.xml</File>
    <File>exhibit23_1.htm</File>
    <File>exhibit23_2.htm</File>
    <File>exhibit31_1.htm</File>
    <File>exhibit31_2.htm</File>
    <File>exhibit32_1.htm</File>
    <File>exhibit32_2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="617">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="35">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>70
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bmra-20220531.htm": {
   "axisCustom": 0,
   "axisStandard": 23,
   "contextCount": 165,
   "dts": {
    "calculationLink": {
     "local": [
      "bmra-20220531_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bmra-20220531_def.xml"
     ]
    },
    "inline": {
     "local": [
      "bmra-20220531.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bmra-20220531_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bmra-20220531_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bmra-20220531.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd"
     ]
    }
   },
   "elementCount": 518,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 26,
    "http://www.biomerica.com/20220531": 5,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 35
   },
   "keyCustom": 28,
   "keyStandard": 293,
   "memberCustom": 37,
   "memberStandard": 37,
   "nsprefix": "bmra",
   "nsuri": "http://www.biomerica.com/20220531",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.biomerica.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - INTANGIBLE ASSETS, NET",
     "role": "http://www.biomerica.com/role/INTANGIBLEASSETSNET",
     "shortName": "INTANGIBLE ASSETS, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES",
     "role": "http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - SHAREHOLDERS' EQUITY",
     "role": "http://www.biomerica.com/role/SHAREHOLDERSEQUITY",
     "shortName": "SHAREHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - INCOME TAXES",
     "role": "http://www.biomerica.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bmra:GeographicInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - GEOGRAPHIC INFORMATION",
     "role": "http://www.biomerica.com/role/GEOGRAPHICINFORMATION",
     "shortName": "GEOGRAPHIC INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bmra:GeographicInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://www.biomerica.com/role/SUBSEQUENTEVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Accounting Policies, by Policy (Policies)",
     "role": "http://www.biomerica.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)",
     "role": "http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNETTables",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.biomerica.com/role/ConsolidatedBalanceSheet",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - INTANGIBLE ASSETS, NET (Tables)",
     "role": "http://www.biomerica.com/role/INTANGIBLEASSETSNETTables",
     "shortName": "INTANGIBLE ASSETS, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)",
     "role": "http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - SHAREHOLDERS' EQUITY (Tables)",
     "role": "http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables",
     "shortName": "SHAREHOLDERS' EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://www.biomerica.com/role/INCOMETAXESTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - GEOGRAPHIC INFORMATION (Tables)",
     "role": "http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables",
     "shortName": "GEOGRAPHIC INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bmra:ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "role": "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bmra:ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "role": "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "bmra:WorkingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Inventories",
     "role": "http://www.biomerica.com/role/InventoriesTable",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Inventories",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions",
     "role": "http://www.biomerica.com/role/SharebasedcompensationassumptionsTable",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Revenue from contracts with customers",
     "role": "http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Revenue from contracts with customers",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)",
     "role": "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "bmra:Equipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details) - Property and equipment, net",
     "role": "http://www.biomerica.com/role/PropertyandequipmentnetTable",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Details) - Property and equipment, net",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "bmra:Equipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedLicenseAgreementsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - INTANGIBLE ASSETS, NET (Details) - Intangible assets, net",
     "role": "http://www.biomerica.com/role/IntangibleassetsnetTable",
     "shortName": "INTANGIBLE ASSETS, NET (Details) - Intangible assets, net",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedLicenseAgreementsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - INTANGIBLE ASSETS, NET (Details) - Expected amortization of intangible assets",
     "role": "http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable",
     "shortName": "INTANGIBLE ASSETS, NET (Details) - Expected amortization of intangible assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c68",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)",
     "role": "http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c68",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Accounts payable and accrued expense balances",
     "role": "http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Accounts payable and accrued expense balances",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c75",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - SHAREHOLDERS' EQUITY (Details) - STOCK OPTION AND RESTRICTED STOCK PLANS",
     "role": "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS",
     "shortName": "SHAREHOLDERS' EQUITY (Details) - STOCK OPTION AND RESTRICTED STOCK PLANS",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c75",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - SHAREHOLDERS' EQUITY (Details) - COMMON STOCK ACTIVITY",
     "role": "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY",
     "shortName": "SHAREHOLDERS' EQUITY (Details) - COMMON STOCK ACTIVITY",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c88",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c101",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DividendsPayableAmountPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - SHAREHOLDERS' EQUITY (Details) - PREFERRED STOCK ACTIVITY",
     "role": "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY",
     "shortName": "SHAREHOLDERS' EQUITY (Details) - PREFERRED STOCK ACTIVITY",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c101",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DividendsPayableAmountPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c106",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - SHAREHOLDERS' EQUITY (Details) - Activity as to aggregate stock options outstanding",
     "role": "http://www.biomerica.com/role/ActivityastoaggregatestockoptionsoutstandingTable",
     "shortName": "SHAREHOLDERS' EQUITY (Details) - Activity as to aggregate stock options outstanding",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c106",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - SHAREHOLDERS' EQUITY (Details) - Non-vested Stock Options Activity",
     "role": "http://www.biomerica.com/role/NonvestedStockOptionsActivityTable",
     "shortName": "SHAREHOLDERS' EQUITY (Details) - Non-vested Stock Options Activity",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://www.biomerica.com/role/ConsolidatedIncomeStatement",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c115",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - SHAREHOLDERS' EQUITY (Details) - Stock Options Summary",
     "role": "http://www.biomerica.com/role/StockOptionsSummaryTable",
     "shortName": "SHAREHOLDERS' EQUITY (Details) - Stock Options Summary",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c115",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - INCOME TAXES (Details)",
     "role": "http://www.biomerica.com/role/INCOMETAXESDetails",
     "shortName": "INCOME TAXES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - INCOME TAXES (Details) - Income tax expense",
     "role": "http://www.biomerica.com/role/IncometaxexpenseTable",
     "shortName": "INCOME TAXES (Details) - Income tax expense",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - INCOME TAXES (Details) - Income Tax Rate Reconciliation",
     "role": "http://www.biomerica.com/role/IncomeTaxRateReconciliationTable",
     "shortName": "INCOME TAXES (Details) - Income Tax Rate Reconciliation",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - INCOME TAXES (Details) - Deferred Tax",
     "role": "http://www.biomerica.com/role/DeferredTaxTable",
     "shortName": "INCOME TAXES (Details) - Deferred Tax",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - GEOGRAPHIC INFORMATION (Details)",
     "role": "http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails",
     "shortName": "GEOGRAPHIC INFORMATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales",
     "role": "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable",
     "shortName": "GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c145",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c147",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseExpirationDate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) - OPERATING LEASES",
     "role": "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASES",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details) - OPERATING LEASES",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c147",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseExpirationDate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c154",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) - CONTRACTS",
     "role": "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details) - CONTRACTS",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c154",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "bmra:ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) - Supplemental cash flow information related to leases",
     "role": "http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details) - Supplemental cash flow information related to leases",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "bmra:ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c9",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS` EQUITY",
     "role": "http://www.biomerica.com/role/ShareholdersEquityType2or3",
     "shortName": "CONSOLIDATED STATEMENTS OF SHAREHOLDERS` EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c9",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) - Future minimum lease payments under operating leases",
     "role": "http://www.biomerica.com/role/FutureminimumleasepaymentsunderoperatingleasesTable",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details) - Future minimum lease payments under operating leases",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c163",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "050 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "role": "http://www.biomerica.com/role/SUBSEQUENTEVENTSDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c163",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.biomerica.com/role/ConsolidatedCashFlow",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "006 - Disclosure - ORGANIZATION",
     "role": "http://www.biomerica.com/role/ORGANIZATION",
     "shortName": "ORGANIZATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - PROPERTY AND EQUIPMENT, NET",
     "role": "http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNET",
     "shortName": "PROPERTY AND EQUIPMENT, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220531.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 78,
   "tag": {
    "bmra_A2014PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A2014 Plan Member",
        "terseLabel": "2014 Plan [Member]"
       }
      }
     },
     "localname": "A2014PlanMember",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_A2017PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A2017 Plan Member",
        "terseLabel": "2017 Plan [Member]"
       }
      }
     },
     "localname": "A2017PlanMember",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_A2020PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A2020 Plan Member",
        "terseLabel": "2020 Plan [Member]"
       }
      }
     },
     "localname": "A2020PlanMember",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_A2020StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A2020 Stock Incentive Plan Member",
        "terseLabel": "2020 Stock Incentive Plan [Member]"
       }
      }
     },
     "localname": "A2020StockIncentivePlanMember",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_A5PercentConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A5 Percent Convertible Preferred Stock Member",
        "terseLabel": "5% Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "A5PercentConvertiblePreferredStockMember",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet",
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) [Line Items]"
       }
      }
     },
     "localname": "ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) [Table]"
       }
      }
     },
     "localname": "ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_ATMAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ATMAgreement Member",
        "terseLabel": "ATM Agreement [Member]"
       }
      }
     },
     "localname": "ATMAgreementMember",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_AccountsPayableAndAccruedExpenseBalancesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable And Accrued Expense Balances Abstract"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedExpenseBalancesAbstract",
     "nsuri": "http://www.biomerica.com/20220531",
     "xbrltype": "stringItemType"
    },
    "bmra_ActivityAsToAggregateStockOptionsOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Activity As To Aggregate Stock Options Outstanding Abstract"
       }
      }
     },
     "localname": "ActivityAsToAggregateStockOptionsOutstandingAbstract",
     "nsuri": "http://www.biomerica.com/20220531",
     "xbrltype": "stringItemType"
    },
    "bmra_BiomericaInFoodsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Biomerica In Foods Member",
        "terseLabel": "Biomerica InFoods [Member]"
       }
      }
     },
     "localname": "BiomericaInFoodsMember",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_BuildingInIrvineCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Building In Irvine California Member",
        "terseLabel": "Building In Irvine California [Member]"
       }
      }
     },
     "localname": "BuildingInIrvineCaliforniaMember",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASES"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES (Details) - CONTRACTS [Line Items]"
       }
      }
     },
     "localname": "COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSLineItems",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES (Details) - CONTRACTS [Table]"
       }
      }
     },
     "localname": "COMMITMENTSANDCONTINGENCIESDetailsCONTRACTSTable",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES (Details) - OPERATING LEASES [Line Items]"
       }
      }
     },
     "localname": "COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESLineItems",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASES"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES (Details) - OPERATING LEASES [Table]"
       }
      }
     },
     "localname": "COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASESTable",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASES"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_CaliforniaStateIncomeTaxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "California State Income Tax Member",
        "terseLabel": "California State Income Tax [Member]"
       }
      }
     },
     "localname": "CaliforniaStateIncomeTaxMember",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_CashPaidDuringThePeriodForAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available",
        "label": "Cash Paid During The Period For Abstract",
        "terseLabel": "Cash paid during the year for:"
       }
      }
     },
     "localname": "CashPaidDuringThePeriodForAbstract",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_ClinicalLabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Lab Member",
        "terseLabel": "Clinical Lab [Member]"
       }
      }
     },
     "localname": "ClinicalLabMember",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_ClinicalTrialAgreementMaximumBudgetedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum budgeted costs related to clinical trial agreement.",
        "label": "Clinical Trial Agreement Maximum Budgeted Costs",
        "terseLabel": "Clinical Trial Agreement Maximum Budgeted Costs"
       }
      }
     },
     "localname": "ClinicalTrialAgreementMaximumBudgetedCosts",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the description of risks that arise due to concentrations of operating facilities, revenues, assets, customers, vendors or the like in a certain geographic area, either domestic or foreign. The description may address risks inherent in the geographic area, and, at a minimum, informs users of the general nature of the risk, but excludes \"Information about Geographic Areas\" that may be disclosed elsewhere.",
        "label": "Concentration Risk Geographic Policy Policy Text Block",
        "terseLabel": "Concentration Risk Geographic Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ConcentrationRiskGeographicPolicyPolicyTextBlock",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bmra_ContractManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Manufacturing Member",
        "terseLabel": "Contract Manufacturing [Member]"
       }
      }
     },
     "localname": "ContractManufacturingMember",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_DeferredTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Abstract"
       }
      }
     },
     "localname": "DeferredTaxAbstract",
     "nsuri": "http://www.biomerica.com/20220531",
     "xbrltype": "stringItemType"
    },
    "bmra_DeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Abstract",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsAbstract",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/DeferredTaxTable"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.biomerica.com/role/DeferredTaxTable": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accumulated depreciation and amortization.",
        "label": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxAssetsAccumulatedDepreciationAndAmortization",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/DeferredTaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.biomerica.com/role/DeferredTaxTable": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets related with foreign subsidiaries and other.",
        "label": "Losses of foreign subsidiaries &amp; Other, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/DeferredTaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmra_DefferedTaxAssetsStockOptions": {
     "auth_ref": [],
     "calculation": {
      "http://www.biomerica.com/role/DeferredTaxTable": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets related with stock options.",
        "label": "Stock Options"
       }
      }
     },
     "localname": "DefferedTaxAssetsStockOptions",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/DeferredTaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmra_DistributorsInAsiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distributors In Asia Member",
        "terseLabel": "Distributors in Asia [Member]"
       }
      }
     },
     "localname": "DistributorsInAsiaMember",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.biomerica.com/20220531",
     "xbrltype": "stringItemType"
    },
    "bmra_Equipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.biomerica.com/role/PropertyandequipmentnetTable": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depletion of equipment",
        "label": "Equipment"
       }
      }
     },
     "localname": "Equipment",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/PropertyandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmra_ExercisePriceRangePerShare082362Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range Per Share082362 Member",
        "terseLabel": "Exercise Price Range Per Share $0.82 - $3.62 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangePerShare082362Member",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/ActivityastoaggregatestockoptionsoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_ExercisePriceRangePerShare082818Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range Per Share082818 Member",
        "terseLabel": "Exercise Price Range Per Share $0.82 - $8.18 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangePerShare082818Member",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/ActivityastoaggregatestockoptionsoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_ExercisePriceRangePerShare082870Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range Per Share082870 Member",
        "terseLabel": "Exercise Price Range Per Share $0.82 - $8.70 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangePerShare082870Member",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/ActivityastoaggregatestockoptionsoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_ExercisePriceRangePerShare120362Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range Per Share120362 Member",
        "terseLabel": "Exercise Price Range Per Share $1.20 - $3.62 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangePerShare120362Member",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/ActivityastoaggregatestockoptionsoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_ExercisePriceRangePerShare161818Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range Per Share161818 Member",
        "terseLabel": "Exercise Price Range Per Share $1.61 - $8.18 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangePerShare161818Member",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/ActivityastoaggregatestockoptionsoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_ExercisePriceRangePerShare235818Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range Per Share235818 Member",
        "terseLabel": "Exercise Price Range Per Share $2.35 - $8.18 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangePerShare235818Member",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/ActivityastoaggregatestockoptionsoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_ExercisePriceRangePerShare425446Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range Per Share425446 Member",
        "terseLabel": "Exercise Price Range Per Share $4.25 - $4.46 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangePerShare425446Member",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/ActivityastoaggregatestockoptionsoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_ExercisePriceRangePerShare514870Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range Per Share514870 Member",
        "terseLabel": "Exercise Price Range Per Share $5.14 - $8.70 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangePerShare514870Member",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/ActivityastoaggregatestockoptionsoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_ExpectedAmortizationOfIntangibleAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected Amortization Of Intangible Assets Abstract"
       }
      }
     },
     "localname": "ExpectedAmortizationOfIntangibleAssetsAbstract",
     "nsuri": "http://www.biomerica.com/20220531",
     "xbrltype": "stringItemType"
    },
    "bmra_FiniteLivedLicenseAccumulatedAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.biomerica.com/role/IntangibleassetsnetTable": {
       "order": 3.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of licenses.",
        "label": "Finite Lived License Accumulated Amortization",
        "negatedLabel": "Less accumulated amortization-licenses"
       }
      }
     },
     "localname": "FiniteLivedLicenseAccumulatedAmortization",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/IntangibleassetsnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmra_FiniteLivedPatentsAccumulatedAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.biomerica.com/role/IntangibleassetsnetTable": {
       "order": 4.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of patents.",
        "label": "Finite Lived Patents Accumulated Amortization",
        "negatedLabel": "Less accumulated amortization-patents"
       }
      }
     },
     "localname": "FiniteLivedPatentsAccumulatedAmortization",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/IntangibleassetsnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmra_FirstAmendmentToLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Amendment To Lease Member",
        "terseLabel": "First Amendment To Lease [Member]"
       }
      }
     },
     "localname": "FirstAmendmentToLeaseMember",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASES"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_FurnitureFixturesAndLeaseholdImprovements": {
     "auth_ref": [],
     "calculation": {
      "http://www.biomerica.com/role/PropertyandequipmentnetTable": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities and additions or improvements to assets held under a lease arrangement.",
        "label": "Furniture, fixtures and leasehold improvements"
       }
      }
     },
     "localname": "FurnitureFixturesAndLeaseholdImprovements",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/PropertyandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmra_FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Future Minimum Lease Payments Under Operating Leases Abstract"
       }
      }
     },
     "localname": "FutureMinimumLeasePaymentsUnderOperatingLeasesAbstract",
     "nsuri": "http://www.biomerica.com/20220531",
     "xbrltype": "stringItemType"
    },
    "bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]"
       }
      }
     },
     "localname": "GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Table]"
       }
      }
     },
     "localname": "GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_GeographicInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Information Disclosure Abstract"
       }
      }
     },
     "localname": "GeographicInformationDisclosureAbstract",
     "nsuri": "http://www.biomerica.com/20220531",
     "xbrltype": "stringItemType"
    },
    "bmra_GeographicInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments according to the geographic areas.",
        "label": "Geographic Information Disclosure Text Block",
        "terseLabel": "Geographic Information Disclosure [Text Block]"
       }
      }
     },
     "localname": "GeographicInformationDisclosureTextBlock",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/GEOGRAPHICINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bmra_GeographicInformationRegardingNetSalesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Information Regarding Net Sales Abstract"
       }
      }
     },
     "localname": "GeographicInformationRegardingNetSalesAbstract",
     "nsuri": "http://www.biomerica.com/20220531",
     "xbrltype": "stringItemType"
    },
    "bmra_INCOMETAXESDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES (Details) [Line Items]"
       }
      }
     },
     "localname": "INCOMETAXESDetailsLineItems",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_INCOMETAXESDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES (Details) [Table]"
       }
      }
     },
     "localname": "INCOMETAXESDetailsTable",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_IncomeTaxExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense Abstract"
       }
      }
     },
     "localname": "IncomeTaxExpenseAbstract",
     "nsuri": "http://www.biomerica.com/20220531",
     "xbrltype": "stringItemType"
    },
    "bmra_IncomeTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Rate Reconciliation Abstract"
       }
      }
     },
     "localname": "IncomeTaxRateReconciliationAbstract",
     "nsuri": "http://www.biomerica.com/20220531",
     "xbrltype": "stringItemType"
    },
    "bmra_IncreaseDecreaseInLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in LeaseLiability",
        "label": "Reduction in lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiability",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmra_IncreaseInLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in lease liability due to lease extension or establishment in noncash investing or financing activities.",
        "label": "Increase in lease liability due to lease extension or establishment"
       }
      }
     },
     "localname": "IncreaseInLeaseLiability",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmra_IncreaseInRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in right of use asset due to lease extension or establishment in noncash investing or financing activities.",
        "label": "Increase in right-of-use asset due to lease extension or establishment"
       }
      }
     },
     "localname": "IncreaseInRightOfUseAsset",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Reduction In Income Taxes Resulting From Abstract",
        "terseLabel": "Increase (reduction) in income taxes resulting from:"
       }
      }
     },
     "localname": "IncreaseReductionInIncomeTaxesResultingFromAbstract",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/IncomeTaxRateReconciliationTable"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_IntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets Net Abstract"
       }
      }
     },
     "localname": "IntangibleAssetsNetAbstract",
     "nsuri": "http://www.biomerica.com/20220531",
     "xbrltype": "stringItemType"
    },
    "bmra_InventoriesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories Abstract"
       }
      }
     },
     "localname": "InventoriesAbstract",
     "nsuri": "http://www.biomerica.com/20220531",
     "xbrltype": "stringItemType"
    },
    "bmra_LeaseExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of years in which the lease expires.",
        "label": "Lease Expiration Period",
        "terseLabel": "Lease Expiration Period"
       }
      }
     },
     "localname": "LeaseExpirationPeriod",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASES"
     ],
     "xbrltype": "durationItemType"
    },
    "bmra_LicenseMaintenanceFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of license maintenance fee payable.",
        "label": "License Maintenance Fee Payable",
        "terseLabel": "License Maintenance Fee, Payable"
       }
      }
     },
     "localname": "LicenseMaintenanceFeePayable",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmra_LiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for liquidity position during the period.",
        "label": "Liquidity Policy Text Block",
        "terseLabel": "Liquidity [Policy Text Block]"
       }
      }
     },
     "localname": "LiquidityPolicyTextBlock",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bmra_NonVestedStockOptionsActivityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Vested Stock Options Activity Abstract"
       }
      }
     },
     "localname": "NonVestedStockOptionsActivityAbstract",
     "nsuri": "http://www.biomerica.com/20220531",
     "xbrltype": "stringItemType"
    },
    "bmra_OneDistributorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "One Distributor Member",
        "terseLabel": "One Distributor [Member]"
       }
      }
     },
     "localname": "OneDistributorMember",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_OneVendorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "One Vendor Member",
        "terseLabel": "One Vendor [Member]"
       }
      }
     },
     "localname": "OneVendorMember",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of right-of-use asset from operating lease",
        "label": "Accumulated amortization, Right of Use Assets (in Dollars) (in Dollars)"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAccumulatedAmortization",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmra_OverthecounterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Overthecounter Member",
        "terseLabel": "Over-the-counter [Member]"
       }
      }
     },
     "localname": "OverthecounterMember",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_PalmMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Palm Member",
        "terseLabel": "Palm [Member]"
       }
      }
     },
     "localname": "PalmMember",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_PhysiciansOfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Physicians Office Member",
        "terseLabel": "Physicians Office [Member]"
       }
      }
     },
     "localname": "PhysiciansOfficeMember",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_PolishDistributorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Polish Distributor Member",
        "terseLabel": "Polish Distributor [Member]"
       }
      }
     },
     "localname": "PolishDistributorMember",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_PreferredStockUndesignatedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of preferred shares undesignated during the period.",
        "label": "Preferred Stock, undesignated shares"
       }
      }
     },
     "localname": "PreferredStockUndesignatedShares",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "bmra_PrepaidsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for prepaids.",
        "label": "Prepaids Policy Policy Text Block",
        "terseLabel": "Prepaids Policy [Policy Text Block]"
       }
      }
     },
     "localname": "PrepaidsPolicyPolicyTextBlock",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bmra_PropertyAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property And Equipment Net Abstract"
       }
      }
     },
     "localname": "PropertyAndEquipmentNetAbstract",
     "nsuri": "http://www.biomerica.com/20220531",
     "xbrltype": "stringItemType"
    },
    "bmra_PurchasedTechnologyRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchased Technology Rights Member",
        "terseLabel": "Purchased Technology Rights [Member]"
       }
      }
     },
     "localname": "PurchasedTechnologyRightsMember",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_RangeOfExercisePrice082152Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Of Exercise Price082152 Member",
        "terseLabel": "Range Of Exercise Price $0.82 - $1.52 [Member]"
       }
      }
     },
     "localname": "RangeOfExercisePrice082152Member",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/StockOptionsSummaryTable"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_RangeOfExercisePrice225425Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Of Exercise Price225425 Member",
        "terseLabel": "Range Of Exercise Price $2.25 - $4.25 [Member]"
       }
      }
     },
     "localname": "RangeOfExercisePrice225425Member",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/StockOptionsSummaryTable"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_RangeOfExercisePrice434870Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Of Exercise Price434870 Member",
        "terseLabel": "Range Of Exercise Price $4.34 - $8.70 [Member]"
       }
      }
     },
     "localname": "RangeOfExercisePrice434870Member",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/StockOptionsSummaryTable"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_RevenueFromContractsWithCustomersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From Contracts With Customers Abstract"
       }
      }
     },
     "localname": "RevenueFromContractsWithCustomersAbstract",
     "nsuri": "http://www.biomerica.com/20220531",
     "xbrltype": "stringItemType"
    },
    "bmra_RoyaltyExpensePercentageOfSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty expenses expressed as a percentage of sales.",
        "label": "Royalty Expense Percentage Of Sales",
        "terseLabel": "Royalty Expense Percentage Of Sales"
       }
      }
     },
     "localname": "RoyaltyExpensePercentageOfSales",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS"
     ],
     "xbrltype": "percentItemType"
    },
    "bmra_RoyaltyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty to be received.",
        "label": "Royalty Percentage",
        "terseLabel": "Royalty Percentage"
       }
      }
     },
     "localname": "RoyaltyPercentage",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS"
     ],
     "xbrltype": "percentItemType"
    },
    "bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY (Details) - Activity as to aggregate stock options outstanding [Line Items]"
       }
      }
     },
     "localname": "SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingLineItems",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/ActivityastoaggregatestockoptionsoutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY (Details) - Activity as to aggregate stock options outstanding [Table]"
       }
      }
     },
     "localname": "SHAREHOLDERSEQUITYDetailsActivityastoaggregatestockoptionsoutstandingTable",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/ActivityastoaggregatestockoptionsoutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY (Details) - COMMON STOCK ACTIVITY [Line Items]"
       }
      }
     },
     "localname": "SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYLineItems",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY (Details) - COMMON STOCK ACTIVITY [Table]"
       }
      }
     },
     "localname": "SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITYTable",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY (Details) - PREFERRED STOCK ACTIVITY [Line Items]"
       }
      }
     },
     "localname": "SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYLineItems",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY (Details) - PREFERRED STOCK ACTIVITY [Table]"
       }
      }
     },
     "localname": "SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITYTable",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY (Details) - STOCK OPTION AND RESTRICTED STOCK PLANS [Line Items]"
       }
      }
     },
     "localname": "SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSLineItems",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY (Details) - STOCK OPTION AND RESTRICTED STOCK PLANS [Table]"
       }
      }
     },
     "localname": "SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANSTable",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_SUBSEQUENTEVENTSDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS (Details) [Line Items]"
       }
      }
     },
     "localname": "SUBSEQUENTEVENTSDetailsLineItems",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_SUBSEQUENTEVENTSDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS (Details) [Table]"
       }
      }
     },
     "localname": "SUBSEQUENTEVENTSDetailsTable",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]"
       }
      }
     },
     "localname": "SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions [Line Items]"
       }
      }
     },
     "localname": "SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/SharebasedcompensationassumptionsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions [Table]"
       }
      }
     },
     "localname": "SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/SharebasedcompensationassumptionsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Table]"
       }
      }
     },
     "localname": "SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information related to lease for the periods.",
        "label": "Schedule Of Cash Flow Supplemental Disclosures Related To Lease Table Text Block",
        "terseLabel": "Schedule Of Cash Flow Supplemental Disclosures Related To Lease [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bmra_ShareBasedCompensationAssumptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Assumptions Abstract"
       }
      }
     },
     "localname": "ShareBasedCompensationAssumptionsAbstract",
     "nsuri": "http://www.biomerica.com/20220531",
     "xbrltype": "stringItemType"
    },
    "bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount related with Maximum Authorized Common Stock Issuance of Shelf Registration Statement.",
        "label": "Shelf Registration Statement Maximum Authorized Common Stock Issuance Value",
        "terseLabel": "Shelf Registration Statement, Maximum Authorized Common Stock Issuance, Value"
       }
      }
     },
     "localname": "ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmra_StockOptionsSummaryAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Summary Abstract"
       }
      }
     },
     "localname": "StockOptionsSummaryAbstract",
     "nsuri": "http://www.biomerica.com/20220531",
     "xbrltype": "stringItemType"
    },
    "bmra_StockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Purchase Agreement Member",
        "terseLabel": "Stock Purchase Agreement [Member]"
       }
      }
     },
     "localname": "StockPurchaseAgreementMember",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information Related To Leases Abstract"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationRelatedToLeasesAbstract",
     "nsuri": "http://www.biomerica.com/20220531",
     "xbrltype": "stringItemType"
    },
    "bmra_TelconAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Telcon Agreement Member",
        "terseLabel": "Telcon Agreement [Member]"
       }
      }
     },
     "localname": "TelconAgreementMember",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_TwoDistributorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Distributors Member",
        "terseLabel": "Two Distributors [Member]"
       }
      }
     },
     "localname": "TwoDistributorsMember",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_TwoVendorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Vendor Member",
        "terseLabel": "Two Vendor [Member]"
       }
      }
     },
     "localname": "TwoVendorMember",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_UCLicenseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UCLicense Agreements Member",
        "terseLabel": "UC License Agreements [Member]"
       }
      }
     },
     "localname": "UCLicenseAgreementsMember",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_UniversityOFSouthernCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "University OFSouthern California Member",
        "terseLabel": "University OF Southern California [Member]"
       }
      }
     },
     "localname": "UniversityOFSouthernCaliforniaMember",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_WorkingCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of working capital.",
        "label": "Working Capital",
        "terseLabel": "Working Capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmra_WriteOffOfFixedAssetsAccumulatedDepreciation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write off of fixed assets, accumulated depreciation in noncash investing or financing activities.",
        "label": "Write off of fixed assets, accumulated depreciation"
       }
      }
     },
     "localname": "WriteOffOfFixedAssetsAccumulatedDepreciation",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmra_WriteOffOfFixedAssetsCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write off of fixed assets, cost in noncash investing or financing activities.",
        "label": "Write off of fixed assets, cost"
       }
      }
     },
     "localname": "WriteOffOfFixedAssetsCost",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write off of intangible assets, accumulated amortization in noncash investing or financing activities.",
        "label": "Write off of intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "WriteOffOfIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmra_WriteOffOfIntangibleAssetsCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write off of intangible assets, cost in noncash investing or financing activities.",
        "label": "Write off of intangible assets, cost"
       }
      }
     },
     "localname": "WriteOffOfIntangibleAssetsCost",
     "nsuri": "http://www.biomerica.com/20220531",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "country_MX": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MEXICO",
        "terseLabel": "MEXICO"
       }
      }
     },
     "localname": "MX",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASES",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASES"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r569",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r569",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r569",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r569",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AsiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asia [Member]",
        "terseLabel": "Asia [Member]"
       }
      }
     },
     "localname": "AsiaMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe [Member]"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r256",
      "r269",
      "r272",
      "r305",
      "r306",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r532",
      "r534",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.biomerica.com/role/SharebasedcompensationassumptionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r256",
      "r269",
      "r272",
      "r305",
      "r306",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r532",
      "r534",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.biomerica.com/role/SharebasedcompensationassumptionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NorthAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "North America [Member]",
        "terseLabel": "North America [Member]"
       }
      }
     },
     "localname": "NorthAmericaMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r246",
      "r253",
      "r254",
      "r255",
      "r256",
      "r269",
      "r272",
      "r303",
      "r305",
      "r306",
      "r339",
      "r340",
      "r341",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r532",
      "r534",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.biomerica.com/role/SharebasedcompensationassumptionsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r246",
      "r253",
      "r254",
      "r255",
      "r256",
      "r269",
      "r272",
      "r303",
      "r305",
      "r306",
      "r339",
      "r340",
      "r341",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r532",
      "r534",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.biomerica.com/role/SharebasedcompensationassumptionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r184",
      "r185",
      "r293",
      "r296",
      "r533",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASES",
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SouthAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "South America [Member]",
        "terseLabel": "South America [Member]"
       }
      }
     },
     "localname": "SouthAmericaMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r184",
      "r185",
      "r293",
      "r296",
      "r533",
      "r548",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASES",
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts payable and accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable",
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r40",
      "r474"
     ],
     "calculation": {
      "http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableMember": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations incurred and payable to vendors for goods and services received.",
        "label": "Accounts Payable [Member]",
        "terseLabel": "Accounts Payable [Member]"
       }
      }
     },
     "localname": "AccountsPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r188",
      "r189"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable, less allowance for doubtful accounts of $153,231 and $837,415 as of May 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedFeesAndOtherRevenueReceivable": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, the amount of fees and other revenue, excluding investment income receivable, earned but not yet received, which were recognized in conformity with revenue recognition criteria based on estimates or specific contractual terms.",
        "label": "Accrued Fees and Other Revenue Receivable",
        "terseLabel": "Accrued Fees and Other Revenue Receivable"
       }
      }
     },
     "localname": "AccruedFeesAndOtherRevenueReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses",
        "terseLabel": "Accrued Liabilities, Current"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable",
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r16",
      "r241"
     ],
     "calculation": {
      "http://www.biomerica.com/role/PropertyandequipmentnetTable": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated depreciation and amortization (in Dollars) (in Dollars)",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.biomerica.com/role/PropertyandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r27",
      "r51",
      "r52",
      "r53",
      "r519",
      "r542",
      "r546"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r50",
      "r53",
      "r60",
      "r61",
      "r62",
      "r107",
      "r108",
      "r109",
      "r401",
      "r468",
      "r537",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r25",
      "r474"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r348",
      "r349",
      "r350",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r110",
      "r111",
      "r112",
      "r113",
      "r122",
      "r198",
      "r199",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r348",
      "r349",
      "r350",
      "r377",
      "r378",
      "r379",
      "r380",
      "r394",
      "r395",
      "r396",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r441",
      "r442",
      "r447",
      "r448",
      "r449",
      "r450",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r490",
      "r491",
      "r492",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "Compensation expense in connection with options granted"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Cost [Policy Text Block]"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising Expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-Based Payment Arrangement, Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r31",
      "r194",
      "r209"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Allowance for doubtful accounts (in Dollars) (in Dollars)"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r86",
      "r228",
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of Intangible Assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r86",
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset Impairment Charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r19",
      "r102",
      "r164",
      "r175",
      "r181",
      "r202",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r398",
      "r402",
      "r420",
      "r472",
      "r474",
      "r507",
      "r518"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r11",
      "r39",
      "r102",
      "r202",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r398",
      "r402",
      "r420",
      "r472",
      "r474"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r330",
      "r331",
      "r333",
      "r334",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r9",
      "r15",
      "r88"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "terseLabel": "Cash and Cash Equivalents, at Carrying Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r80",
      "r88",
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r80",
      "r431"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashUninsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, Uninsured Amount",
        "terseLabel": "Cash, Uninsured Amount"
       }
      }
     },
     "localname": "CashUninsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r20",
      "r22",
      "r23",
      "r100",
      "r102",
      "r125",
      "r126",
      "r127",
      "r129",
      "r131",
      "r138",
      "r139",
      "r140",
      "r202",
      "r258",
      "r262",
      "r263",
      "r264",
      "r267",
      "r268",
      "r270",
      "r271",
      "r274",
      "r278",
      "r285",
      "r420",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet",
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r46",
      "r509",
      "r523"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and contingencies (Notes 6 and 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r257",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies Disclosure [Text Block]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r107",
      "r108",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY",
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock par value (in Dollars per share) (in Dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r23",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r23",
      "r474"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.08 par value, 25,000,000 shares authorized, 12,867,924 and 12,307,157 issued and outstanding at May 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r55",
      "r57",
      "r58",
      "r67",
      "r512",
      "r526"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r148",
      "r149",
      "r187",
      "r418",
      "r419",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r148",
      "r149",
      "r187",
      "r418",
      "r419",
      "r547",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails",
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r148",
      "r149",
      "r187",
      "r418",
      "r419",
      "r547",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails",
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r143",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration Risk, Credit Risk, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r148",
      "r149",
      "r187",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Net Sales Percent",
        "terseLabel": "Concentration Risk, Percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails",
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r148",
      "r149",
      "r187",
      "r418",
      "r419",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r96",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r290",
      "r291",
      "r294"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Advance from customers"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r91",
      "r92",
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of preferred to common stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r91",
      "r92",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Conversion of preferred to common stock (in Shares)",
        "verboseLabel": "Conversion of Stock, Shares Converted (in Shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY",
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r91",
      "r92",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Conversion of Stock, Shares Issued (in Shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r270",
      "r271",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r21",
      "r22",
      "r281",
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Convertible Preferred Stock, Shares Issued upon Conversion (in Shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CostOfGoodsProductLineMember": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sold and service rendered from specified product or service, when it serves as benchmark in concentration of risk calculation.",
        "label": "Cost of Goods and Service, Product and Service Benchmark [Member]",
        "terseLabel": "Cost of Goods and Service, Product and Service Benchmark [Member]"
       }
      }
     },
     "localname": "CostOfGoodsProductLineMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r72",
      "r102",
      "r202",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r420"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "negatedLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of Sales [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Goods and Service [Policy Text Block]"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/IncometaxexpenseTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r103",
      "r374",
      "r383"
     ],
     "calculation": {
      "http://www.biomerica.com/role/IncometaxexpenseTable": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "U.S. Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/IncometaxexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r103",
      "r374"
     ],
     "calculation": {
      "http://www.biomerica.com/role/IncometaxexpenseTable": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Foreign Taxes Subsidiaries"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/IncometaxexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r103",
      "r374",
      "r383",
      "r385"
     ],
     "calculation": {
      "http://www.biomerica.com/role/IncometaxexpenseTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Income tax expense",
        "totalLabel": "Total current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/IncomeTaxRateReconciliationTable",
      "http://www.biomerica.com/role/IncometaxexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r103",
      "r374",
      "r383"
     ],
     "calculation": {
      "http://www.biomerica.com/role/IncometaxexpenseTable": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "State and local"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/IncometaxexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r146",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r103",
      "r375",
      "r383"
     ],
     "calculation": {
      "http://www.biomerica.com/role/IncometaxexpenseTable": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "U.S. Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/IncometaxexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/IncometaxexpenseTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r86",
      "r103",
      "r375",
      "r383",
      "r384",
      "r385"
     ],
     "calculation": {
      "http://www.biomerica.com/role/IncometaxexpenseTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/IncometaxexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r103",
      "r375",
      "r383"
     ],
     "calculation": {
      "http://www.biomerica.com/role/IncometaxexpenseTable": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State and local"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/IncometaxexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.biomerica.com/role/DeferredTaxTable": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/DeferredTaxTable",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "calculation": {
      "http://www.biomerica.com/role/DeferredTaxTable": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Inventory valuation"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/DeferredTaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://www.biomerica.com/role/DeferredTaxTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/DeferredTaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "calculation": {
      "http://www.biomerica.com/role/DeferredTaxTable": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/DeferredTaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r370",
      "r372",
      "r373"
     ],
     "calculation": {
      "http://www.biomerica.com/role/DeferredTaxTable": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/DeferredTaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "calculation": {
      "http://www.biomerica.com/role/DeferredTaxTable": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days).",
        "label": "Compensated absences"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/DeferredTaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "calculation": {
      "http://www.biomerica.com/role/DeferredTaxTable": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.",
        "label": "Accounts receivable, principally due to allowance for doubtful accounts"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/DeferredTaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "calculation": {
      "http://www.biomerica.com/role/DeferredTaxTable": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.",
        "label": "Deferred rent expense/Capitalized leases"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/DeferredTaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.biomerica.com/role/DeferredTaxTable": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance",
        "terseLabel": "Deferred Tax Assets, Valuation Allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/DeferredTaxTable",
      "http://www.biomerica.com/role/INCOMETAXESDetails",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r86",
      "r240"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r86",
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation, Depletion and Amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue [Table Text Block]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DistributionRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal rights, generally of a limited duration, to distribute a product or products, often within specific geographic areas or supply channels.",
        "label": "Distribution Rights [Member]",
        "terseLabel": "Distribution Rights [Member]"
       }
      }
     },
     "localname": "DistributionRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsPayableAmountPerShare": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date.",
        "label": "Dividends Payable, Amount Per Share",
        "terseLabel": "Dividends Payable, Amount Per Share (in Dollars per share)"
       }
      }
     },
     "localname": "DividendsPayableAmountPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r68",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r123",
      "r125",
      "r129",
      "r130",
      "r131",
      "r134",
      "r135",
      "r415",
      "r416",
      "r513",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic net loss per common share (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r68",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r125",
      "r129",
      "r130",
      "r131",
      "r134",
      "r135",
      "r415",
      "r416",
      "r513",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Diluted net loss per common share (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings Per Share, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r431"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of exchange rate changes in cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r104",
      "r360",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r352",
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Stock based compensation benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/IncomeTaxRateReconciliationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r60",
      "r61",
      "r62",
      "r107",
      "r108",
      "r109",
      "r111",
      "r119",
      "r121",
      "r137",
      "r206",
      "r285",
      "r288",
      "r348",
      "r349",
      "r350",
      "r379",
      "r380",
      "r414",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r468",
      "r537",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of equity interests that are issued or issuable in a business combination.",
        "label": "Equity Interest Type [Axis]"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet",
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination.",
        "label": "Equity Interest Issued or Issuable, Type [Domain]"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet",
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity Method Investment, Ownership Percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite-Lived Intangible Asset, Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r17",
      "r234"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Accumulated amortization, Intangible Assets (in Dollars) (in Dollars)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r236"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r236"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r236"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r236"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r236"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r229",
      "r230",
      "r234",
      "r237",
      "r489",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r229",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r234",
      "r489"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedLicenseAgreementsGross": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://www.biomerica.com/role/IntangibleassetsnetTable": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross carrying amount as of the balance sheet date of certain rights acquired to exercise a certain privilege or pursue a particular business or occupation and which is deemed to have a finite economic life.",
        "label": "Licenses"
       }
      }
     },
     "localname": "FiniteLivedLicenseAgreementsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/IntangibleassetsnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedPatentsGross": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://www.biomerica.com/role/IntangibleassetsnetTable": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.",
        "label": "Patents"
       }
      }
     },
     "localname": "FiniteLivedPatentsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/IntangibleassetsnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Transactions and Translations Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "auth_ref": [
      "r147",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic Concentration Risk [Member]"
       }
      }
     },
     "localname": "GeographicConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r225",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r71",
      "r102",
      "r164",
      "r174",
      "r177",
      "r180",
      "r182",
      "r202",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r420"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r65",
      "r164",
      "r174",
      "r177",
      "r180",
      "r182",
      "r506",
      "r510",
      "r515",
      "r529"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r243",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r104",
      "r361",
      "r363",
      "r369",
      "r381",
      "r387",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Tax Disclosure [Text Block]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r105",
      "r120",
      "r121",
      "r162",
      "r359",
      "r382",
      "r388",
      "r530"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Provision for income taxes",
        "negatedTerseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement",
      "http://www.biomerica.com/role/IncometaxexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r357",
      "r358",
      "r363",
      "r364",
      "r368",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Tax, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/IncomeTaxRateReconciliationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Foreign taxes of subsidiaries"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/IncomeTaxRateReconciliationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Computed \"expected\" tax benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/IncomeTaxRateReconciliationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Permanent tax differences and other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/IncomeTaxRateReconciliationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/IncomeTaxRateReconciliationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Research and development tax credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/IncomeTaxRateReconciliationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r82",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r85",
      "r485"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Advance from customers"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidSupplies": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for supplies that provide economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Supplies",
        "terseLabel": "Increase (Decrease) in Prepaid Supplies"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidSupplies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets Disclosure [Text Block]"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/INTANGIBLEASSETSNET"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r227",
      "r232"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.biomerica.com/role/IntangibleassetsnetTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible assets, net of accumulated amortization of $18,994 and $126,769 as of May 31, 2022 and 2021, respectively",
        "totalLabel": "Intangible asssets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet",
      "http://www.biomerica.com/role/IntangibleassetsnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r63",
      "r158",
      "r443",
      "r444",
      "r514"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r32",
      "r215"
     ],
     "calculation": {
      "http://www.biomerica.com/role/InventoriesTable": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Finished products"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/InventoriesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.biomerica.com/role/InventoriesTable": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "terseLabel": "Inventory, Gross",
        "totalLabel": "Total Gross Inventory"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/InventoriesTable",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLIFOReservePeriodCharge": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.",
        "label": "Inventory reserve"
       }
      }
     },
     "localname": "InventoryLIFOReservePeriodCharge",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r10",
      "r38",
      "r474"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.biomerica.com/role/InventoriesTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventories, net",
        "totalLabel": "Net Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet",
      "http://www.biomerica.com/role/InventoriesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r13",
      "r36",
      "r97",
      "r136",
      "r211",
      "r212",
      "r216",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r34",
      "r215"
     ],
     "calculation": {
      "http://www.biomerica.com/role/InventoriesTable": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/InventoriesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r38",
      "r214"
     ],
     "calculation": {
      "http://www.biomerica.com/role/InventoriesTable": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "negatedLabel": "Inventory Reserve",
        "terseLabel": "Inventory Valuation Reserves"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/InventoriesTable",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r33",
      "r215"
     ],
     "calculation": {
      "http://www.biomerica.com/role/InventoriesTable": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/InventoriesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.",
        "label": "Dividend and interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterestAndDividend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r201",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investment, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r524"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASES"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASES"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date",
        "terseLabel": "Lease Expiration Date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASES"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Lessee, Leases [Policy Text Block]"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://www.biomerica.com/role/FutureminimumleasepaymentsunderoperatingleasesTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/FutureminimumleasepaymentsunderoperatingleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://www.biomerica.com/role/FutureminimumleasepaymentsunderoperatingleasesTable": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Less than 1 year"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/FutureminimumleasepaymentsunderoperatingleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://www.biomerica.com/role/FutureminimumleasepaymentsunderoperatingleasesTable": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "4 to 5 years"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/FutureminimumleasepaymentsunderoperatingleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://www.biomerica.com/role/FutureminimumleasepaymentsunderoperatingleasesTable": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "3 to 4 years"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/FutureminimumleasepaymentsunderoperatingleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://www.biomerica.com/role/FutureminimumleasepaymentsunderoperatingleasesTable": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2 to 3 years"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/FutureminimumleasepaymentsunderoperatingleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://www.biomerica.com/role/FutureminimumleasepaymentsunderoperatingleasesTable": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "1 to 2 years"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/FutureminimumleasepaymentsunderoperatingleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r461"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/FutureminimumleasepaymentsunderoperatingleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r43",
      "r102",
      "r176",
      "r202",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r399",
      "r402",
      "r403",
      "r420",
      "r472",
      "r473"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r30",
      "r102",
      "r202",
      "r420",
      "r474",
      "r508",
      "r521"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Shareholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r45",
      "r102",
      "r202",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r399",
      "r402",
      "r403",
      "r420",
      "r472",
      "r473",
      "r474"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MiddleEastMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region of Middle East.",
        "label": "Middle East [Member]",
        "terseLabel": "Middle East [Member]"
       }
      }
     },
     "localname": "MiddleEastMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r80",
      "r84",
      "r87"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r7",
      "r54",
      "r56",
      "r62",
      "r66",
      "r87",
      "r102",
      "r110",
      "r114",
      "r115",
      "r116",
      "r117",
      "r120",
      "r121",
      "r128",
      "r164",
      "r174",
      "r177",
      "r180",
      "r182",
      "r202",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r416",
      "r420",
      "r511",
      "r525"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow",
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement",
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of Operating Segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expense"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r164",
      "r174",
      "r177",
      "r180",
      "r182"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r453"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating Lease, Expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASES"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r452"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Total operating lease liabilities",
        "terseLabel": "Operating Lease, Liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/FutureminimumleasepaymentsunderoperatingleasesTable",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r452"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Lease liability, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r452"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r454",
      "r457"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right of use assets, net of accumulated amortization of $724,802 and $469,077 as of May 31, 2022 and 2021, respectively",
        "terseLabel": "Operating Lease, Right-of-Use Asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Amortization of right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r460",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r459",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating Loss Carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r8",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ORGANIZATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r49",
      "r51",
      "r429",
      "r430",
      "r432"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement",
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss, net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other income:"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherReceivablesGrossCurrent": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Gross, Current",
        "terseLabel": "Other Receivables, Gross, Current"
       }
      }
     },
     "localname": "OtherReceivablesGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents [Member]"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForFees": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for fees classified as other.",
        "label": "Payments for Other Fees",
        "terseLabel": "Payments for Other Fees"
       }
      }
     },
     "localname": "PaymentsForFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Costs from sale of common stock"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Expenditure related to intangibles"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r330",
      "r331",
      "r333",
      "r334",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r330",
      "r331",
      "r333",
      "r334",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNoParValue": {
     "auth_ref": [
      "r22",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, No Par Value (in Dollars per share) (in Dollars per share)"
       }
      }
     },
     "localname": "PreferredStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par Value (in Dollars per share) (in Dollars per share)",
        "terseLabel": "Preferred Stock, Par or Stated Value Per Share (in Dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r22",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, shares issued",
        "terseLabel": "Preferred Stock, Shares Issued (in Shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r22",
      "r474"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock, undesignated, no par value, 4,428,571 shares authorized, none issued and outstanding as of May 31, 2022 and 2021",
        "terseLabel": "Preferred stock, Series A 5% convertible, $0.08 par value, 571,429 shares authorized, none issued and outstanding as of May 31, 2022 and 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassification, Comparability Adjustment [Policy Text Block]"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromFeesReceived": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received for fees during the current period. This element excludes cash proceeds from license fees.",
        "label": "Proceeds from Fees Received",
        "terseLabel": "Proceeds from Fees Received"
       }
      }
     },
     "localname": "ProceedsFromFeesReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Gross proceeds from sale of common stock",
        "terseLabel": "Proceeds from Issuance of Common Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY",
      "http://www.biomerica.com/role/SUBSEQUENTEVENTSDetails",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r78",
      "r347"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of stock options",
        "terseLabel": "Proceeds from Stock Options Exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyAvailableForOperatingLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property available for operating lease.",
        "label": "Property Available for Operating Lease [Member]",
        "terseLabel": "Property Available for Operating Lease [Member]"
       }
      }
     },
     "localname": "PropertyAvailableForOperatingLeaseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASES"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r245",
      "r551",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment Disclosure [Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNET"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r242",
      "r474",
      "r516",
      "r522"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.biomerica.com/role/PropertyandequipmentnetTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net of accumulated depreciation and amortization of $1,305,360 and $1,972,357 as of May 31, 2022 and 2021, respectively",
        "terseLabel": "Property, Plant and Equipment, Net",
        "totalLabel": "Net property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet",
      "http://www.biomerica.com/role/PropertyandequipmentnetTable",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r242",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment [Table Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNETTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, Plant and Equipment, Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by property that could be leased or is available for lease.",
        "label": "Property Subject to or Available for Operating Lease [Axis]"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASES"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r70",
      "r210"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Provision for allowance on accounts receivable",
        "terseLabel": "Accounts Receivable, Credit Loss Expense (Reversal)"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r304",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r304",
      "r469",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r304",
      "r469",
      "r471",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r356",
      "r487",
      "r565"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward [Member]"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r26",
      "r288",
      "r474",
      "r520",
      "r541",
      "r546"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit",
        "terseLabel": "Retained Earnings (Accumulated Deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r107",
      "r108",
      "r109",
      "r111",
      "r119",
      "r121",
      "r206",
      "r348",
      "r349",
      "r350",
      "r379",
      "r380",
      "r414",
      "r537",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r155",
      "r156",
      "r173",
      "r178",
      "r179",
      "r183",
      "r184",
      "r187",
      "r292",
      "r293",
      "r488"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Revenue from External Customers by Geographic Areas [Table Text Block]"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r98",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue [Policy Text Block]"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r64",
      "r102",
      "r155",
      "r156",
      "r173",
      "r178",
      "r179",
      "r183",
      "r184",
      "r187",
      "r202",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r420",
      "r515"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Net sales",
        "terseLabel": "Net Sales",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement",
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r458",
      "r462"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyAgreementsMember": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement, generally for a defined period of time, entitling the entity to use the rights and property of another party. Examples include, but not limited to, licensing the use of copyrighted materials and leasing the extraction of natural resources.",
        "label": "Royalty Agreements [Member]",
        "terseLabel": "Royalty Agreements [Member]"
       }
      }
     },
     "localname": "RoyaltyAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty Expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Sale of Stock, Consideration Received on Transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of Stock, Number of Shares Issued in Transaction (in Shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of Stock, Price Per Share (in Dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r148",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueSegmentMember": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from specified business segment, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources.",
        "label": "Revenue, Segment Benchmark [Member]",
        "terseLabel": "Revenue, Segment Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r229",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/INTANGIBLEASSETSNETTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r13",
      "r35",
      "r36",
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory, Current [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.",
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "terseLabel": "Schedule of Nonvested Share Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/StockOptionsSummaryTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "terseLabel": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r311",
      "r329",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/INTANGIBLEASSETSNETTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r18"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security Deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsOPERATINGLEASES"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r153",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r187",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r248",
      "r249",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling and marketing expense.",
        "label": "Selling and Marketing Expense [Member]",
        "terseLabel": "Selling and Marketing Expense [Member]"
       }
      }
     },
     "localname": "SellingAndMarketingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r20",
      "r22",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet",
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY",
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SharebasedcompensationassumptionsTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SharebasedcompensationassumptionsTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SharebasedcompensationassumptionsTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Options canceled or expired, number of stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ActivityastoaggregatestockoptionsoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Options canceled or expired, weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ActivityastoaggregatestockoptionsoutstandingTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Options granted, number of stock options",
        "terseLabel": "Granted, number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ActivityastoaggregatestockoptionsoutstandingTable",
      "http://www.biomerica.com/role/NonvestedStockOptionsActivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Granted, weighted average grant date fair value",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/NonvestedStockOptionsActivityTable",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r312",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding, number of stock options",
        "periodStartLabel": "Options outstanding, number of stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ActivityastoaggregatestockoptionsoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r312",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding, weighted average exercise price",
        "periodStartLabel": "Options outstanding, weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ActivityastoaggregatestockoptionsoutstandingTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r330",
      "r331",
      "r333",
      "r334",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Options exercised, weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ActivityastoaggregatestockoptionsoutstandingTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Options granted, weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ActivityastoaggregatestockoptionsoutstandingTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r310",
      "r336",
      "r337",
      "r338",
      "r339",
      "r342",
      "r351",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Payment Arrangement [Policy Text Block]"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ActivityastoaggregatestockoptionsoutstandingTable",
      "http://www.biomerica.com/role/StockOptionsSummaryTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/StockOptionsSummaryTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Range of Exercise Price, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/StockOptionsSummaryTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Options Exercisable, Number (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/StockOptionsSummaryTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Options Outstanding, Number (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/StockOptionsSummaryTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Range of Exercise Price, Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/StockOptionsSummaryTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share Price (in Dollars per share)",
        "verboseLabel": "Share Price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUBSEQUENTEVENTSDetails",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SharebasedcompensationassumptionsTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Non-vested shares, number of shares",
        "periodStartLabel": "Non-vested shares, number of shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/NonvestedStockOptionsActivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options forfeited.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "negatedLabel": "Forfeited, number of shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/NonvestedStockOptionsActivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Forfeited, weighted average grant date fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/NonvestedStockOptionsActivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Non-vested shares, weighted average grant date fair value",
        "periodStartLabel": "Non-vested shares, weighted average grant date fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/NonvestedStockOptionsActivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "negatedLabel": "Vested, number of shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/NonvestedStockOptionsActivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Vested, weighted average grant date fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/NonvestedStockOptionsActivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsSTOCKOPTIONANDRESTRICTEDSTOCKPLANS"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Options Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/StockOptionsSummaryTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Options Outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/StockOptionsSummaryTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Options Outstanding, Weighted Average Remaining Contractual Life"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/StockOptionsSummaryTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balances (in Shares)",
        "periodStartLabel": "Balances (in Shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r95",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies [Text Block]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r6",
      "r153",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r187",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r244",
      "r248",
      "r249",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r20",
      "r22",
      "r23",
      "r100",
      "r102",
      "r125",
      "r126",
      "r127",
      "r129",
      "r131",
      "r138",
      "r139",
      "r140",
      "r202",
      "r258",
      "r262",
      "r263",
      "r264",
      "r267",
      "r268",
      "r270",
      "r271",
      "r274",
      "r278",
      "r285",
      "r420",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet",
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY",
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r47",
      "r60",
      "r61",
      "r62",
      "r107",
      "r108",
      "r109",
      "r111",
      "r119",
      "r121",
      "r137",
      "r206",
      "r285",
      "r288",
      "r348",
      "r349",
      "r350",
      "r379",
      "r380",
      "r414",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r468",
      "r537",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsPREFERREDSTOCKACTIVITY",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet",
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r137",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet",
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r285",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "netLabel": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Net proceeds from ATM (in Shares)",
        "verboseLabel": "Stock Issued During Period, Shares, New Issues (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUBSEQUENTEVENTSDetails",
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Stock Issued During Period, Shares, Other (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetailsCONTRACTS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r22",
      "r23",
      "r285",
      "r288",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised, number of stock options",
        "terseLabel": "Exercise of stock options (in Shares)",
        "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ActivityastoaggregatestockoptionsoutstandingTable",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY",
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r285",
      "r288"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Net proceeds from ATM"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r47",
      "r285",
      "r288"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionPlanExpense": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for option under share-based payment arrangement.",
        "label": "Stock option expense"
       }
      }
     },
     "localname": "StockOptionPlanExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r23",
      "r28",
      "r29",
      "r102",
      "r196",
      "r202",
      "r420",
      "r474"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balances",
        "periodStartLabel": "Balances",
        "totalLabel": "Total Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet",
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r101",
      "r271",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r288",
      "r289",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity Note Disclosure [Text Block]"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r439",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r439",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r475",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events [Text Block]"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.",
        "label": "Supplier Concentration Risk [Member]",
        "terseLabel": "Supplier Concentration Risk [Member]"
       }
      }
     },
     "localname": "SupplierConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax Credit Carryforward, Amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period past due for trade accounts receivable to write off as uncollectible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Threshold Period Past Due for Write-off of Trade Accounts Receivable",
        "terseLabel": "Threshold Period Past Due for Write-off of Trade Accounts Receivable"
       }
      }
     },
     "localname": "ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r193",
      "r195",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable [Policy Text Block]"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransactionDomain": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction [Domain]"
       }
      }
     },
     "localname": "TransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransactionTypeAxis": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction Type [Axis]"
       }
      }
     },
     "localname": "TransactionTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetailsCOMMONSTOCKACTIVITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r110",
      "r111",
      "r112",
      "r113",
      "r122",
      "r198",
      "r199",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r348",
      "r349",
      "r350",
      "r377",
      "r378",
      "r379",
      "r380",
      "r394",
      "r395",
      "r396",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r441",
      "r442",
      "r447",
      "r448",
      "r449",
      "r450",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r490",
      "r491",
      "r492",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r141",
      "r142",
      "r144",
      "r145",
      "r150",
      "r151",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r124",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Diluted (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average number of common and common equivalent shares:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r123",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Basic (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.L)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e99989-122729"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "https://asc.fasb.org/topic&trid=2122478"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28129-110885"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123405975&loc=d3e41551-112718"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r566": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r567": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r568": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r569": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r570": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r571": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r572": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r573": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r574": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r575": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>71
<FILENAME>0001513162-22-000114-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001513162-22-000114-xbrl.zip
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M-[)_]O[]V:EW>75V]*OOG7<OO-^Z[S[TO)\VVYO[*QSW_6Y)4\>GB3*59@K
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MJ(/%E105()%ZBLLLBN-&VLLX+<%PK'W+;YS7OZ8U&C2^GL9!TO@25)<(L5;
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MVY7"9P%?F[%]:C5V5)Y;Y12FC,%@[4QBOP 9#^)]0FZ,+DM)=U8( &P\>]8
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MUEH"AJN3 'P^;A^W;?4$N0G0EL&S_M3EVI6%HWQ+'8@GMSCR7%IKIRS//IJ
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M\["E5;*D;^DT?^[9B$(MQB#G_PU@.K[W*V(EVB@@M2*"DQ+ ?@!'=L)&4UF
MJ2D 11Z+43C1K>L8*C?*==9:Y 3>>+'[RI7D;WI7[LVQM()^4;&#6Q;DJC&8
M1X'C\I!ZBY ;5QF8 $N(%-5<C(6]KDC[['5P<RET69-&LF;9=RA:T>LR"65K
MCN=PI*8Y[NI1EHX3A_AI=K[WP8)W'#%XAZ^!@3"Q*Q@I"I<-X_*31?[0.$&]
M"Z,$ J$(X ?B"PZ"<(P,^EA1#$[+A#.PN5/@LV,TRR3I8QAE>:%IB#-JB%=H
M9&[]U&>"\BK+2WF(2  (S:9O@$TEXL4_=!-2$(<"12C/H-Z,#+5;VMY2U</D
MYJVDE:0@ <%E)0(3NC5H#_&9@7E?0TW8LTD?!&HUR1Z3(Z,D6N"@8X4]=%.G
M0K-:@>FF8 ;>N:GH[ K0+_YACJ#>I//W%N<-UE/*0;4JL9R'K.6?F&:<@GAK
M92XR#=JXHA _/&839@)N:XT<73VC-Q5W(EQ #+)1;K7NU7B!<8+W5\L)""FQ
M@D!:-, [+T%7!5I*W!B#%59']E0'DH0!R^2,P,A^G.'&YY&J(.,T;.2@&)9#
M+U[3"C2"F*2IF33-' T<@>FE9XEB@)_QA>%EIW8Y-9-FMP_Y"@6[W&"E?W?D
M_&5"NL_7(=UO;-__NG,.;ORU=W5)OKGWO:NW9\>7WMEK[_CD\NKBY-6'%8GU
MVO+W_<W.9F=_YZ!>_?Y(Z81N B%EK55LZZW=3>/ZURE\S*,CBU:+SI<^XH>#
MJN [S0$K(^UO2O%9IF"NM0K>#O\X@.%I-/=74]G1#V)N85BI<#+WZ-X33H9J
M#>?&-V$;8VB[P*'VYYSPI]&W,@ZR21!2KPP7(0M--<S*L\@W/G5M49C[F-&-
M#>P<-CFP"(,<"<JNYW?'S#^KL%XRO@/IC\#=9Q95TR/U2?HD&7$H^KVND#"B
M>D:5Y%?6H]\H;(!I #DOL3XA$,3NK4UQ05$%OG%!ZA3,6BU_M9D*:!N*L\I#
M-_T]S%)0[2<:2=LM=:KX#:6Y20A7X?%IT\2P_HG[/[#%7 W^ZI/F3-77)1@.
MVHF7?P0+([?O[GN]9(1I%;YWB52,?[S&G$-V-V%G>S Q5*YT0;U)#J<#:%R[
ME,>&P$0#44H6%!8V*H+XQ4QJ+-X -U,]*1Z]<305'P&ZT=@=/8+;*756LDAT
M\FPOP%H_^_D=AC#U_F.221((&/UB2WEFL!3)R,W'@K?BUN=2_9*3TCL8:-!%
MRY:0#)M%FA2*D\OE2P+QX.NE%:49!_>I/P>[[4>)NMT'(E&7*@1#S#4-"BD!
M*1/GBQH0Q. :86H)*]$I-&0S%XL+_P#+(B'_N?HTCOJZ!*V0G_-Q.LM]84"8
M;,XIKASCM3%W9DI4T\%%;NS+K642&<K_W4!T,AJ;;9MUZ#T);L)D>]*O@[)I
M\^!^X&R"X/*TW2AG6+V-7]9:<37_?8QC>P=XC[O$*<57:U$^! Y$@WWX;HX(
M'A/KB]3-L!$( C0B MVXP:^I4QR& 7<CR[-R:NHS=(&##A:;XL@@(T>XK@_%
MFS%WFYV<8_1Q)R.-\$S1L+E6RNP#?##A&=I?Q[!RG;-HM"\L:TTI,<:V97>S
MA[(JNW;2AUA%H5D[7_(@$I\C75"P7%DQM8^%^5QCU ZEGW',<B6J+JZS[S'"
M@YU0,$@WY*%G84(^-;[PEZD)W"":4GJT?YS+?G3FOBZVQZB?FYIF%V]<PIIX
M8<#Z-?J)3;6=>&-TQT6NZ'%?&+]P7IHF:?8?&WF9J*Y3)!1BW_:"ILX4P,C>
ML:=@'U,@3IA,#)81U]IQ[2$H%"EW_6#Z-6@5+L%A(J+3 +Q!R'6:)S<,%4%%
M'-6N-%)'NJRH#4CE;J*I?I1M'\^/H7A]J1LTU5G)5^8H7J?3WIL6:"QZ*Z\7
MH(L]0=0_DL'D&JQ'@_?]_;T.AG]9Y;*.3;;?I$[GISV_<W"PX+(.-AS)ZIDK
MM\2GW;C7&-$29VE--]%M-EDNZV  =QV$8_!\]^\TW//-OVL68EZS'L8^XP)W
M6S=VOWE2!-JFYU24V@GW!D%5BWJ-5>>[*Y/<WOY[=4X^-UZ7^5:4V34)-Y Q
M:,]'9"&"HJFB:TSUS:6U5G/7%E+YP=8>T:XD/&P=;"U)>,#.5G>C603$=YN_
MDMK<H./JMM]"U;N;3#!["PF&ET!N=M="2%SQ_8UW\.E[#)11E*P_KW6M17,P
M1_#3'\.FNE<'[N[1K^_.WJR 0W353N59LNR<N/Y1S!?IP_6@IB%5EN2ZP#02
MJBAFC:QZ4/=V=^Q!W=]==$IKC_8Y'4(7$ P<9R<5C]*#, 5E(=&O:;Z1O=O]
M'6Z^ZEV<=-]=KBE_(>88D%B"C;CJF>62V5E+W!/2=-'5PS'JW)R:J+)R0I("
MH;;$)V8+;73F(DBGF-*$';3$6EI[I228#3T)TDJ"KJ\]>MS3#8$(,$L6K:1R
M*D7:Z V*=?H[^9396"1)A4GPQE33\"/\[UL0+M<(\3.PB)D:/B<IJ6F0'BR2
MHT\H8DZ2)IURMC0**L;0>'DN\KMI(\/!0,[M(@0LSL)U4TM58MPZNO/L7.<$
MB6^1T:-PH=&56EU0';>I6KC2 (\-6O:)E@0VKV_#)_?1:RJ]J@@U/"^0=?UU
M31FU#BZ&6*Q-[.^P"K&[7U,A3"655%QP!S_W?7\07G@OVRE*8+$%QX,.<:5'
M K?0=#.-G0Z7B]L5]-.B(!NEGW["_S08 NV>X06&H0C5.N6D>D.=>E.;B^SV
MD-&/R(M@I,2[HUO1K?>\N>?$^K2#B;5L"=U4V<.-#CZ7#8JGT *7BLNEC35S
M\X8+S,7DUZ/U*>L/RQK&9=$:I#-*@RTD:=5XL298&48)2%@90:%38B[N76ZC
M;4G5IHH&ZE::)E7W'8)1)*I"UZC"(< $9EH 94>9_B"!@S+\2! VP01C5CI=
M#R,#VO5DW]3D6YK@G*1<15PY5G-^FIVI\BUQ")U0?E&94#H5KOT,F3.52Q25
M.[249(&A^ZZ:M=8" F, 2@FL&)XX%I_C5!>"X8V.'\PIN*"(8,.V_RX.V)?)
M/-I;9QY]8_O^UPV+D]/7[[HKDE_TZ')G$;(\93?H_)SE,1H=MT1#($J&G!.
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M/QE&*#(BVQ$J2JZ9SV$3 -@B4CN#4:8<$4B/MVVIW%<@A95;V"72W!#7LCX
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MJH0V9\6^76PO1[E+9LW7.7EU:08R;\%1?O%)\ALH.W^\I^U]X)?2>7RP/_
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MX+,?4;<,KNI/CC0#&H-304<B,3XVVOT1><DHW*"3KN$Q8((+%;[PMI$0_F\
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M&/M!^/-?"Y!3^@?77F!5 YT\*T@I2B $B\S;QJB%2"O8-<+AZ$I3&"*6Z8(
M!:64".>SX?G&<WS[$$(YH'%-,,.&;.GH(J.^^\T8?%%9R*?VFC22M=M)JYZP
M'RF6G2]Q[SC(U"X\7I-P3%2']Q<_-K>X&A[70$BR7\S#*O*SCB%%"%LP*R=:
M;S9>^_27NL[0?Z1GWGA6/7@OC)L)26!>:7SRA#GL:\D#;*D4:4,:HLLW&$(W
M"0;?Q2CG=4(G-[FG"N*H;>_4.6.YAD$9P:$7.^Z.Q\YS,T^:ITVPEAH'KLH5
M;CAH),XEJRQ(<HX[PGR<?3>W:UR5^$?AZ;?XW9B9$O$!1ZT!H^MR)GN<JK#
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M6;U5#=)4V>P=84,HD@#\&F^\C!GSOKO_Q\>3XV]'!V]!G.2J8MCH/2DWY$G
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MG,%MO,XV0I.WMWFTMW13_9IY%1A$3#Z *!2XW*,@"X-_>_N"Y_N%Q&G+JQ"
M.7D:HHR8YS@<F2!8C2/NM'"A7FSOO,N\$E2['1,09$PQ>,? W%,#1;KYVI<
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M%[FHB0+R3'%_WZWL%90,;SB.8H)\S;%#'0<;G".LM-O(3@U34O^+1;H>-C+
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MTC6*1^-@,N&EZEN0_,I412(1) 8KXB$H1E!BY5]'XS&"4BC'!7&&A.,C&1[
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M5N!\.@=?:)BP.W\9J.G\$F,E1LQJFQBN!K$<Q I\'K3.0<K@7I4%C1B%)L9
MHHM'5!%OU#%WC#2MJ==KR->0+YT6;9Z&F:6$ D[C10&&-@Y")I]'T]_&T1#G
M[&$V88KN%\[_XGP)!41G-$!(B;&V3/0+S&-.^:'+QFZ5I'' TE'&IJ(Y/!AQ
M*;)2=%6121> KA^7I"V*N$NLSAB5PE.EP>MY=?BXR>\A.:^,F%N1]#,K/O2:
MX?"U*>QD!4MAX"R!\Z*![!C<%;\,UDO;?IGHX"T\ZHU7G^K$H^B\J21RET_*
M.LE84FU_!>,)5F7@Q? W.,5 QN(AWTUJDP(!(-JRA\IM#F:2V)1)Y9(8%L%'
M1T6*0-+$\XG/03"D;*Q_9RG0^:@NID)](+$$'#RZC^QA,LHY;G!-CG15F'!%
MA/6"""H%,(!UPY**E=C<IY;W=881SCE")]DJNATQ@D?V #VJ=ANQ-VP< 'LK
M33LMYS.^7HQB>ZYN/@<>@=E'G$Y+82F@!#1*QE2"E["UDVDO#0>XS9!V)@$0
MVA#)#L?*'CCHT/ ?6)I,7RL[^[PS-+P(P_>()SIO03BV>'XN3L56>_WU=TRF
MJ8D,L"@&DXCJ[,CXH?%I PE[X<L5L69*NU/X+)!2E^QF6#,,+:*U8@I+QHR<
M]O79O2.+T,ZXI8A2D%%%K<+!&R;PXLQ_NPPX_'*5=813?^%#^AIWO.RJ\$M6
M[26M'C%XQ5=HA['AR 51!P>J? T\.B:_.$X*JF B7M-:B =CGQ4QP=%K:NY>
MPOG,N[[O4W(1^FH\\GH_@LF<'\PN6A)SI)R&"= ]I^,@1]1O7S^W!=1:CMXA
M3>J\L-22"A'KI3H^H<,L3!Z11#>YAI0?[+'6?7[1J3NJ'=EJ:D>>V,'?:MP$
MS]@,,5*&'K("RRV9*0+BYVD(P;A4ZTA5YQCHX4H^O"JEN4B)G47.OP'9;LQP
M8W,OK@N8BZ1WT.@EP:$]8?;QU0AD!2:$<'F]_\\[('.2O(#8>/CG6)>0#=%Z
M)HVA9.X*_F;Q&FXJV&1A :>7)'6OMR&L1%-9[*#9H&,F(KJPXB'C  =5=E/N
MPRP=GG66!A,^$+)MR75 W^.Y2:Z;$_!!84)"9^-D0(33WO/ZW1-,W_VYUO'B
M!+V)89*"J7(1I066F\2AFD3#Q61 V8\OE,@ .EP'_:@ID*>)B>V*I[-__.?A
MP1H\TBUITI:J&*IPY$"9K$K)&!-K%?PB\W/L#'#GY>J+]/#B2R7:+;"_$1=H
M-F\NN^G&ZAJF,JEL/)M?#N46].UIMWS*_"+7F,]-F'CQ!I*V-GRL-X]$#<TW
M)GX@[C"!%",S2L\2SXY>2T(L.&]YWGUC'W<T+B)3-26[@$; J%HS,[_1UB*F
M]V[\N4KPC:B0#\F-O25#V$JM*^:8P5\JLH:;/@G^!9Y9;NHT=+TB%W@YOJ)(
M?[(,J<*1FX+<2W1M7KFP$6X<@^E):^3),BJT7*M%<MD/-<DAK3JNJ.-I"&9N
M8!JKJWDC0*>?):@?ZOD^CLRP4H9S?#HLYQSY%26C<T$JJ:\3[U9E.-%0I*4I
M#ZU*4=NOD4<8LY!:OR#+@IG3--+ROL@DOH2*;YW@XGZ/C:90A[8HVDB]$?99
M*,],:F1&OW/F?0UPTAH&%4CGVXRO6Y$+ G(XHQ2<=LI]>-*D4O J7C4]'OFX
M/K L2@"\],>5@*O8\K5,URHA:*YD(^F1 @O6&//[0K/TR<OI\+MJMQR( T)Q
MJ!%HMO$VPAS\ .S\[V%R&4M!DPBL(0X E9(!W2 &?W(8VHE=V0S$VT=6'O<P
MCVQKZV[GD>UL;-3/(UL&G&>S F$AYWN'L!^XR+<>/6>U0'K,A+:M5Q:TN?.3
MXP_JM_.QIR'P&70>_@SN%ZWJ]%*-P7'Z O;2>>;U<+;DDQN-(*6,-P20[CP,
MUW:>!,'<$+>GV;K;;EU[_6YQ]WFGZ*YW!V;5N8\U+G^:SV2)JW'4/X4[^()-
MFT;ZW5KZN59A8PD^%4OP4"?87A\H_NLV4T%?I"RY8[/A=LRRRKSR(D^$-/6J
M'LD-S(BG(;Z<7&"CR%> ^AMYM&HGTLBC!Y9'<QCPC3RZ(\?B)T/,[5463NVG
M<3XWF,W1L,%#LD$]W39\L7)\\?=[=:__SV!SN*UVGH>#?;LJH:^Z3>[73-KD
M?DX2W=^6/CQIWVY';RK*JR;G_>W@X]J/5%2P6#CPUS<:(K3I=[;V_/7U]9O.
MQ7TA-/M3(?OGNBDW8.2;DE7#R;?D9!H&UC!RP\@O@I$[K3U\U/-DY7;;W]S:
M;7BYX>7[X65W"M)*<?4S5L^;ZWOWZX<_HS3W[:AZWP&V:2*!/RLT%R1Q&C:_
MF@@W_/7MS3O0W T)-EO2<.4=<N7.3L.5#5<V7+E"7/FZO8$\.5?]V1!@PY,-
M3SX.3ZXWR>)[=E./*]BI383O[IF]B4HM&VGVUW>;[&\3:&YX<_5X<V=[N^',
MAC.?*F<^ZPSM1F>CX<V&-Y\J;SYCK;G9:=*L]YMF1<3#8)CCC.)B!'\0XO%5
M@K!IZWLH0=*TZZVZ=+J36NL7%]]M),A*[W0C01Y.@FQM;342I)$@SVRG&PGR
M@&GWO>TF[=Y(D&>VTXT$>3@)LM;>N4&0I;6S.,Y"WS7% HM1DY,\&-\JMB([
MNZ1@,EN]D%\ZK0[<T N38C"^O=Q_,N+ICEK5;WL\"\._JW,^3T.FW60R1GO7
MW]VIM- .KK&/2@*LR60TXNC1Q=&5D8%&'CTA>;3CM_?V&G'4B*.5V_)&'-4>
MT%,L>;F1@=3VMW<ZC41J)-+*;?G=@Q\\,]GTO$VE]K93]C.H1*7@/SCY[??'
M&Y(>>%'XSU?_^VG\?7-OL]W>:V_CT)3@P>9#+M^<4J1>K'(9D7N)\SR#Z31-
M?D23(%?CF?>+XR3C#$YWV.DPF4QI.&>>>+]8X[5\6=MWIXOCR,%?K%KQ<8(T
MGF6+=^_T/,KLM5$,/XT+,V8YRIR1JD'.<UAIQA\LP$QB-N-\94QJ,^%V[L2'
M,D;SBE/?\G?W-J\_]6U_=V-CN5,'XMANVT/?V/@[CK!US_LRR+PPC2Y4K >Z
MZH7J";%P<W.\M'B:@HMSPA$F-3BC)Y7?KCS4FYZQN_EWW[M0:59DWM[6W\N7
MM&DD;>E-+G&V+4['Q)&X-(X9_EFD*4W4C&&Y/- 6AVSBV%X?ENZ\%H]@+B\*
MM@X>+$3O_:5 %\0R)#?WU(\ICO^&:_BI\,P,)&4TBH8!S@&??R*]09$7<(XS
M%:3/A>CGLSMW.EKV&,@FH!'//=CQ.+NWB;(W?X^5V,OEDQ;S,V:S8@)RFN>B
MFVU6LLWW,3?V<<7O2YI*N['1VMJ][]J E7+E#"SZWMT-H]W<::W7[^)C9["?
M$1#Z,YI!>]/ZO_76-N:\'YHEEVIU:6WLKNC2=EI[J[MK=SR9],Y6MMMJ/]JF
M_52KS\O39"LG+\0#:L1&(S8:L?&DK+ K#>7-GYS/N]%:S4+:E3^5FXVUO*51
M^;()_T9Y"J/?%F1/K^:8GYBXU;#02DYB;#CHGE5'>[>UW<155G>B>V>;DM^U
M1I9\U]A9=S>NU&SI0G[9:.TV_'+/_#*7::J:!8N51X4G&OUQJ_G5U[+![J)]
M?50N6*UM7Y[>NY@"_#LF_ZB?R3M1%RHNG/QJ0^^-"FA40*,"&A70J("&WA]?
M!>RU-C97C_:?PL'<[8CK"NFW%\3P7CKE_[2D;Z^@I'\*A[$\M=\M*&=-*.@^
M>HF>0#=+7XW'8$7ZWD<5@T4Y]H(X]+KA)(JC+$<+\T*9<M;E3<P2[D]KXP':
MMI[ 5O/V+2.V2PGW=FOK 7!-5KV99WE\.W^[VO1\VU3*D]_GVY?OS#LO3WXS
M[A7.?7[L44-M-T!P;U1$*;U_==-[HR3N0DE4^] ;MFV4Q#W/XYD?X-Y0VPTF
M6G"][G/=C!O[$3<575)4_)SV[SZYM7.K><]S$;8GO\<_HQZJ8;$GOQE/:'+J
M\ZMVNIVT/%&9"M+A.06V#M2%&B?3B8KSGXYBO<C=O+,8UA/?O?N=J;K;OB/G
MY(GO\EVZ)D]\*^Z5X.X@>O7$M_<N8U?/:"L>)7+UQ/?O7IT2ORTH2@W#-JKA
MB20VGOCVWF7$ZAEMQ2/$JY[X[MWK3*:-W<YMAC(]MXJPNXQ6/?&M>)0!/H\/
ME;J2Q6Q@N6V7D*(<4+<'7Z?WC_/TM_(:OG8_]M;>G_2Z?ZR][WTX/NF]]8+Q
M93#+EH:",R?^? [^YQ$A;U)<=T]8D2NX@\OWN!2IE^DM/'.V,"AOH<:!K$6>
MM?5@5P+/VHJ :X%G.3-$J+/K%FA857!G"T(1AM\ZZRG?9Q-N@@^,8OC%F<I\
M[Y<-^]$PB;-B3!T^(X5?XHO_TK$7!),DS:/_!(ACV_+^.H^&Y_1D"VF<C$:9
MRA'[-O!"Y3QYU]YE$(3PW2#7F^BE:@PKI4T)O&RJAH@3ZPWA)).)2KWA.3 _
M <0BGFX)YO998,3>*?]?FWMH>-WE]=3=KM!NU]4,;L/E5S*X#9W,,WB9.\24
M9ECIG;_[+D@X=B'!,H$Q\5+]LXP9-LLSEWV00?0K^:7WP?=#LR\DYG5!QGWO
M\'V?OO_4\K[.QDD:M;R^4AZB.7?6WRVB*/JZ_8[>+?! ,J!4S&'34#Z&*ANF
MT50_RUV7-U H84#8A,40UMUP<1TZ!=A-*N-C.X@NHE#!'X<QD)=: 4ZVLP':
MZ^L;ZSL[NWO5X0"C),[7LN@_X';P8NB#43 !FG[K_5I9R:]Z%:[U:);!QM];
M#^W+"H.[CZ%M'"9 P&\]VL=WSD9J7:/Y)ZRBJB/# @,"NY5X>&-[IP9<W3F=
M4)].1*=#[)"?)_"H+)@(F+GS5-1Q96$B51^C-)EXOVR+HH?;(X(ZL-)XQ@#Q
MH+OI.B,W')4_3D!*V95,@QGQ/-T2D=L1;SW+\;/6R^"UF^!;?3[\[V^'!X>G
M_^-UCPZ\_>[7P]/N9^^DUS_^=K+?ZU=PKY[QIEVU8_,QBBO@TX%Y2.*#$HN'
MT12'7P 5#GFVQ3CZ=Q&%43Y[2 AUQ^^<@MW[]J\D#?O(7TG<?O7[0L!SZ[_>
M$/-<AM8(Z/D YRZD:QKK_*WW<ZCG?_N;4Y]SKO@ZBBO!=T[$J?25GJ.SL]YJ
M8Y_L ,[M+$V*.'SKR8G6Q8H\>5D1OG.1H[_52_SVO,3?AU\.T@@D?1!G:W)>
MKF0'RHC5FEYTG*238%QJGOP;Q7S^5NH;WC);+IN<)U.X'78GEE]?OI9=I0OT
M$*B]UNYV_8[(C_AEX=/:;DJYB(^0;_SP&UE#M<ML[M6Z=#F57=&X O;M,+<^
M-PS6-:1;T_)^:])M;[;6%^Q(0[HW)UVT VOHUI*E>U#U.[KTR;5VESHW^LU3
M/J;;\,!/;BTP1:=ABCMDBO:-A#G/&EPDSV42X14BW51LSXV>65$Q?P^;OA]D
M'&\9XA\*+&9X+2"#;&GQ5-$CLNU76$&+3F$QSU1F0*X$WSS.<?UR;\?2[LQK
M^"=Z-//IWT<ZK2U_KSW7:3-_;(MDUKSJ-@>RF@1?JX(;D?'((N-JXOM9F?%,
MSF9E9,:F&0U[$UMHNW6%*<1?+N'<OF [Z*\D_4[)HF :(01?% _'1<B?W*V%
M)*>QO+2[UJ5817YZ6N;1M6=29QT]R7-9&3FWXV^VMV]@&Y6%V,*HQFJ2^NT,
MHT92K*!5M)2H>!8'LT*B8F^C?:5)]+=[+\V]!03G2J13JSC#R<C30U*I& $-
M&RX4PCSJ/A8DQ#/O/ @7VSTT8[Y:AZ@=72KD,S9LM;R -^=&R[BL&&;S#[>:
MA!YNJ*7Z\+^4-U#C2%U@SCC(Z4G!V5FJSK!Z$8=O%ZFG?D19?J79AS.[LV(T
MBH81EC[DB3=1*J<?V^G=]*,4?Y6J"?T*;T5%G>HL&GK)X%^\L(S*.$!.7.;G
M7."4@^D=9+R\&&4#%G:TO-/$R^#>V6A&C]+;X3[#=ZS6)#Y+J+R2)]W+RI(8
M+KI4P,<S+U/J.ZX^#:(,-@(D"7X/MQQ%<1!CGAF6 /+K[)QK*/$%\&'YS%Z1
MO9 JCYM45%GP^BZ>,.SJ2M0_ERJI=C=W=G<W5[22ZJ!(B7)MR93/_%1(,95E
ML\#L<&WUY.;N-@N":JW5EM_9JBV(Y@HHKHD$.H?[)VG&XF((RTZC06$*($$.
M7%+-Y#C)ZH3BIK^E!9%3A!G%5"05PXUG5*F87G"YRB\[.U*:257@I5^0J,*B
M%V [8.887GP(E@659 X52":L&,%[;.]2&2B]!E9NX:; :^<1_'I!S72T^&YM
M?V-[ZZHWB&3I;7]KVRS>%H*[MYX&,[HOO=QPF!:PC:;TE2M3]^SKQTF\QH+7
MN62^-G:+5O="A-#2$FB.@6K4:@"Z)5]$N:!1-[>O/LX*I6QNU5\_3RA[Z]L.
ME9>OGJ9J&D05NFC[[8V].:)V2'ENA41;R.]P$U.$7"6>]KHF;$-K69X,OX-T
MH9_H,D[A Z8T*=Z&=0XCOC.]A=.LP-=O[+X@NKQ9N3'6AZZ<<GQR*C R^WB-
M"FSOK->KP,[>=KT"K'NV*SVF13H\IPKCJA/ '@ P 'P,*CJ?&9O1=@:@[ 'F
MV] M.L1F8'J"D5KJ+YC"'R!G:I;37G(Y[8WM)=;S"Q#!TFMY;OQ\1]V?.TWW
MYQ,[^)\7Y!^,D[A2@MQZ.3M[VSM;FWOK52=G16PTJKL!N82-%"&:,=;K=B1Z
MM>FK3L)W_(T],4XJ(AXLIW9M5YCT=7J'Y<:4Q4$8>.!0J3#C1@_\5OU0Z3!B
M^\BUFVK-22<TU%[OU,5FYI7.@M6PW3DO[6$7W @4^%WMFB 01DC(\)U_H2Q@
M4Q9V<)+$_$[L#;J?8.E>2(^(LJRH]O:T]:([Y!G*)44<JI2>T5_;T+UNV;D:
MCW1CVXDZDX9?>$X_AU<B_31 DQ962NLO8*W1&&YW&>7G?+?>/KJ"_[> ]^]P
M(&W=>XW?R#/H@SX^:,$3Y/EOQ*P=CHETU&C$^X5DZ3RHKZ;PLP&\R\8Z/XV-
M>/M^SEJS8CH=\VLL6'80%^ACHWE!6_?:KKKM?;5WZIL[F>6^QJ;!_CFL]AR.
M0Z49?M/>>>?U.#Z%J^H7@PQ4/2Z@=\%Q._:CXR0'SI(61FQ$3JA7$98H+(A=
M)'J'A 6+%"Y.88OR(!J#RS](BIQ>)'7V-7NS,@;_BIBQR#W7$J'L(9RBX30\
M68FZ8*1RH#0K"4%J88#N'EP!4J"8.*%<\,? 1T5F+J8D"/?8!D:73"3?\3P!
M4F"4:37G=2\@0VF\LR)#GM+>TD\AH<@O(6'ED@S!9</_Y6MPDS78WN\8/@:F
M(Q%HN>G:G?/Q[I?4&__+GK^]ON?O;6[!=DZ"".1P< &T2@XZKI?66KKW@K>S
M5NY5)ZUS"=WB#.C$Z^SYCJ<04CP]EJ51H*P;PV;C8,,IN,KXW8<DG<"MUOXP
MNREB%*/='ICA< QNAL#'L/N\)/%I=VFG%E(7;T=64,A=,[[9[W$TB8#-,9@
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MT,;K=<X[H3(4^-^S5#$YE99U!3MBSC6S2;AQ,-"\0>&)$%8,_#_D\D0TH>-
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M3(Y@'?'4*U1Q6"1# 1,<V2/S;'@23,6EM>NX>JK6"Q(=S$3MLN[@_[&<\P!
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MV.8$(=28DW8J".@T>>A78!_;L, ^0<>"\Q+]D@W7ZI52#?Z["!L^)7O=U9P
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MQ2R6*S-.VFYJ-C-2;B]AI:00^[A!PA5ROG]ND,05/HUJL=2(K)0&(>'_8]E
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MN"IK-+D8*>R4?F3OKZZN-L0&+ZWFB4UG%-"9!T:^V 65T/NY!9/*LEB79%Y
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M!W32K/?'Q*B L]D<L%G,()V8NDHLN_/77',6^])$2W)3K)3EZ(QVNRJ4Z^X
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M0KQRN2F6FIOM&N*A,S<A\[A73KHA2/<H^S 6Z4KEABC7]K6?XB9B]$-&"UV
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M+ 'IWIH"2]I8 VB%;\AGX"$;RT$X^K>GT!)1[B.#,('3^Q_!+0@@L2WLAB%
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M'F6+U:RA92[M%<:T8N;]28<3_\)0;#D"=:<Q?R2(>=A8%3N,>@CE9O:[X18
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M!1(;)]IKR-#=ZIW%LA&67]]BJ*P+,/[0IFR& !LUR#:Q7#LMHP3%-C 301%
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M,(^V%I9'&Q<8JQL#8Q8#3UQVY_("B -<QF,SE"4[,V#L= :8-G.9VQ(6;N3
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MO"YUG"5GP/$C'/<:T%M8SF#SP0_NM E?@6_.!M>[R%/0O!7E#%/@\.\1OM+
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M3M=1#Y$@)(>F@R62^*!)B,%:0&JG<7CM"%CS"(:82\]ASJ(GEIY*;0]'T_.
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M6_$_IJ8Q)WLRF]ZE):<TMVAXBJ Y3S,NN*Z--)OR:8IWSFV5-7P7> VM6?#
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M4PY,YPY,M3T#4[6U&3 ==Q+1,1NX7E$*IDK*P*:\X3P(<H AYL&#@T<KXY6
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M#_:Z@]:0F(":(%$6UA#\#SP011*OX:%?(, 0 >U'J5_RO&.D,/NI@,0JG,@
MH)1Q-'/&IJ71E-%&X3'B <,:A3 6- 4V]X,#\KLL3CO>#-KY5M-\PVLIQAVT
M%[XP\\E2IF#]W!K<*(/Y1X+%A<2 U%,8O&/-6. H^*8/2PUN M"R9JLQF,[6
M>^Q*K4MI^4SREV[ORT/G_NOME71[!][S]\[C;>]N<9MQEPNXN&.YUN:+O885
M8?XE6/R=K-S&R^;'%FZ5<?A+NJ^#V^?H?[R88/0P8]'U@!48,*LW\@*=??9$
M*!?J>("WA,Z0P9;WRFS^NY(TIS@@JD=RP-HG,+O0PD1[TX9'VV1H!=Q>!6$/
MMV7LRQT$ZV)8&KY8DS\FA5$EBDB%6B()F/33&B0+PR%WZ80K<&.9D^Y/[AY<
M@4$"QI!E?WZ=#Z:#FX<45/*C$Z4.2$.FZU-%Q76AE<;/F)OA?A8T$ D<]7JS
M5$6R#X"9F%4<PEHI4YM=2NY?&\??>$[(/R^:M>K%IS=O?,G08\;OHX1\N.;+
MC@E<\I*'6@V191*262*)R8F]_*4\$Y<-''7]BV2YU$KK/4 OY&Z8OT=C05/'
MG,)#,)4F. AQ61"1;G )4&^5&KY;^#LOI? #"N(FOC[\,0GF\R;5Q LW%+Q%
MWL5J6]J'(V_$ F#RS/FR7'5[EI,KU5+MW%D.?;00YLJ7]*B75-XE7O@3=KP4
MS;64F__'2Y3N@I!;$*UC:TIR.4A&DCW08&XAGLJ,8JWJV_A+6J]O0P")DH5=
M7M\Y6HB,WRTHM&8_J+[%241AVD<EF50+U>;:5C][6;CC7ZJ&?ZDJL5;JRC10
M[_ TDP?-_NN>6?B%\L1D;_6*E24?NBDOK=LO.8@>P8QR$-VG9#9W"Z*%=KF5
M8V@J*]7:/X96&AMAZ/Z\_8P;ZMV994[985W6++S'%=6S0]/V3M&T5JA6VRFC
MZ>D#9[5\ ."LIFE\YK!PY!PH[QH6RFN[E.6PL+@HE?W#0F-YB79J3YUD-/3.
MM)RQU*'MW#PL>I(SREUT/U!M4PMRO?9HM]<6,,\=](W6J;9_A5+/8YSG,:,<
M$?V2MMN=GWHM#UFFLTX'V/9IY1'+. O8-V=I&--YA.+();69H'UQ#!MS;5/B
M/#RQN"('V.Y)=<<\AX0C9\#V3B&A4L\Q(>Z2U ZPD['91D8>L8Q:U>^:JNI,
MZBJVDP'O? 7X)<]KCAK@4>4Z;^ZC)R96I$>X*V*=F&:JR3O53,T$BNFX^.'X
M.>  >W>;;=WE8)X5?LS!_#A$>;>[6_**^K$YFF>(!0ZP<;:M6\.[!:SR;$0O
M@:,(%CN6:3S%+,%N.HKND<M]PAHM&*3)-M&;C.@&,:$-=.E*P5]H$9$5X4^!
M1=YNQA[;D-<#VQV2-QO*-@']-R]FDK[*;15:S37YB$?-%*?"!G*M?H ]AA"V
M^"77);DNR77)48+(;L\/-@MR>\V)EZ/FB5/A KEV@%2?V*J$W+DWAVKJE:0R
M?]**C%?F9*(Y5&:N8ZA7=.V)&4.-V0GJ,LX7*LY3]U</-G;1QG98T<:KWO?O
MMX_?NW>/?:ES=PT_NWN\O?O2O;NZ[?9W4[LQ9K7>./4<$W* 6]4Q,0-E<M%[
M]]V'#BZF]*W;Z6=D->/59$^X(-7MUK.RI_7D5A&WCM:T3O&7[]2Q:9M-99I'
MRE#3J:YO25K31D)=J(E9H1"Q9/]WAKU_1HQ1!>21;F(/ ]3=DN+0.X:F-36Q
M7BB8$8J*MP-*VWA5;M:;LO0[K-J_%-![AM3A1>1A5K?6LV:P@J]?D]LH0.-U
MQP>,&303+-T)_\#[*N5RFQ=!IAE2I6(<0."UO+> BFT(.K,GH*F8L-P(:]M
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M?:8EF]]4"-9]Z+W9@=^0V[&PFA$:J=2EQ^]2-,8FR]08DAN+8VST0RUE@DY
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M7@-BUR:91WT[N!>C8X'1E/@F*SJ0;SYNUT.SEL!?S-PF582#1 \4>J]QZ_O
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M2'O9E$390:)Z?F]4R+7R1D5YHR)ZH^*%]K%Q?V40I*>=SW#Y&5>%7^XX^^P
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M)'2NQ6:JEX5!6.[P6M&UGME5)OI4,1804!3J246G7AC?HFJN^)S-1CC:C''
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M'Q_TO?YT JNV7%ME#O]SQ!2-(@+P*"SF@___]Y8VAW]&T['QX?\!4$L#!!0
M   ( -:&'56.;KPME10  *3M   1    8FUR82TR,#(R,#4S,2YX<V3M76EW
MHSC:_=Z_0F^^3,_I3MG&V4^EYA O*4][:]M)+7/FU$M ME6%P84@%=>O'TF
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MBJL+K+B]!AH)Y-H3OW ]E4._BX^@X>D41<=:K_B!> 2Q9])OYW1)L#P^W%U
M\SRWT;5 DBUXY4,3++B*+W<8H=G<'4SOL+\ZEM0A;^&Q=2'15;1QJ@O;@J[F
MK-+(3C43I[+U=_.XX:O@<-_K(R*4@=S=RV G.OSJ/G2",F6K#^GZ$(QF%DV
M+?3'6Z*S9[N5P^X+U#,09K?E)O3_=BQ6:%VD/2 3N:L#R+RIU%LZ&_!A'YDS
MH6>S[EA;M>,5T$UB%K3L3:27DW7?YLO%S-?S@T/2&$RG@VD;/9&&S7J^AHV?
M5<]]>?)!BSX&I\:*=&I-N'2@C@[51[\L>QZ//,IO;^IX/?*G(L]7!Q([69YM
ML/X+RJ'X4)VQG'D"G]P;DPR187D8KG/EA@]W+(YG6GJ]P<JS0KOHNX=(T:^&
MQ)[75U*1XV(3C%5D9J)#NH.0K41&^-NFA/Q4).19&#-WMDELN*6&#"PM53%
M@:YC?4[F7"9IX^&*\^@J]$V-Q_'5Y^P,%:E*X#!$1"55Y-K2O-<NOO",U'"O
MYB2FHWL/L+-5?L] 3S1,'C:_+K(8H>WYWE_AV7DF8H)]O^&^YV><]N\Y/]I
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M[V.HGM,5W<8H+5[[!FA==.==QU!.MOQ\_-+B_SEDYUS$$ 3*;UI<ZI@US&?
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M^PDFR\L)LU8S-GSJ&)"M3\RDRC_]V2&QP%RKEVLO4IE&AO<&THRM\W<-PB$
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M%BZI9@N8C3?U/59AP[K:W0>LLN>^SDV/6E:/2==RG(DI,' >;@<.YD=[0EK
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M0*C0[J]>=N ^BA+:4ZHE\=$J4.DD1D4YX;@\2I;$X23+GUAB5I[P:-IR@(3
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MIT80#B)R[?F_^G9(O.5RLESXAD5. Y>! 6[ R(N OPD0V>* +A!(E^2CS=)
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MJ3D;G@S?0O*X%L=&M#WUZ<0C\2%='\I3.WJ^S_KOQ.D[5[O#WTR-'?LL9NW
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M":A3PRE--*MX",W]N=84D6H7Y_X9,S\SI-JZER0K-5>*2I(5?#\,XMLDZ+4
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MJ&O/9\!";XBCT<_Y*5-P)QS+J[9$N<(;9G*_O:,3"HG+BEE04FGS K&G3-X
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M1ZM!,S8;I(U:6?6>&< J/O$@VIB1U5SAQ09@:%*HXZ$S(-TF49@X/L\D:C-
MLWS0GT#Y73F?+V VU>V4FPCN',\]?][!((;(*%HD&QC-XQ@F\3@*7Z9'LVI>
M@B/&&LQ; I@UC8F9$>+6-M'30Z9U4,E.@[))/"*H:/ QJU]DX++$1, J^P99
MJ;B%7;4M! 5=_(JJ)MS!*-G?H#E)$+SPT6NW163U;]S<K@P?B7B\,-5*UH2H
M$UA\3W9Y?+!!MF.Z37WBD';A#IV;/.* )9\[VS!*O-^R7Y 3TL')T9N#D[='
MV1GI^.##N]G!R9MW"J<D*[I,#)JF$A/,MG8S3J@91"RQ+)$=%04U?6%%8^@6
MR-$(F[W0/R9BZIBS* \ :46D<EZMS6O;%KANP1PW!=/7^U5HJ+.:@D(_^Q#_
M@+J;U_04DQ7]GC(];!D]"^KBFNU_D]Q-)%P5MAQI6M'6<KKIFWQ=9U[:5=[X
MV*'M4U?$3\M T/_ 0G)>54]4BQT.2_""AROHQ/#6>]@DB_47=';#1KMFW<GO
MZ_N_F-.'7$X82HY\A<W=-(;YP8MJ3G>LYW>SUP?OCS++^'>OWWXX.'JG8CE;
M60!2\*BC6CRS8YRL1<::D"N:8BH; =+J )!VA^'Z$+4$I*EM2UJ_>(YJ.XR4
M(KG?1@Z?;$W1U15:4[E@,D1C'+W)(G;^CSIA(Z:5,GL2-E1=A>2PP]JBA)W4
ME8]91 Z& 4;IL#EM*I;>%T!Q@G?3>(3[GX*RYOL*T>5/WBWG[B?_PNHU(67J
MV]<4]8&H'R@O@P2-W[OW,R3%Z(QZ_KSR4QRR^2D,W2?/][4+7Z)+HZ@0\\.$
M2]&TE^US_/[@PX?7N=MP]O;@W=L/+R2TH@]<FH"5G.,1?%;B"TPYWFC64!,
M)0)L6T!CB^EHR+9RX05> J\0F-UV?U)&T6 %I," V7O3_@SV-I]JP.UC/%G
MLCI<ZLA6G%)E!T)UPWN-ACC*U2R]#X,;)Y4!!A+)MY.XF>6*IG$J9 YO@/^>
MD!OECMYXX$_6+?=&?CX!>3>GO'L%/U2B>>S=C;/'@7?8/[E:12ETKSSGWO.]
MQ(-CA6;TZ-E2M+($:Z+@Y5U&(KLTR8B444&VS2P%V=/BCF5GR?P->T\.:18R
M403V+RP,RNEH@#8YW^[\< _A+23VR.@Z1-R?8<TA9(BM+XAJP ]$D6YH7Y-9
M )VT*.M0DQN^<J38:1@DD;-*?O22S6D:)^$61D4?>\W0XO=E\EZ+RPD+3^YC
M]K8 R12L\D:QS8 M*=DU'F,)ASW@$-_T1Y=DQ]%2@L[,'L[YS##@1+X%?O'Q
M01FKNL,'SKJJLGY?QI(E^\*,.@>J)^?1MSPS>YS0M)+>V9JQS7[5S.[V)K>?
MZ=[ &, ;S\<B[,^P?21D2%8!Y?<4+T /";PT4A.B#+@:@,?30\9=-[6^N5KG
M:H+:1J!F!KIS3L/MULMN5O%#=F1"(6C!8*5?_KR>S":>8#/"2C=1M<BR3M3;
M@&^OPP3]YRWYTP>[SVTEQ-DTF?E3T3,*J#S5_9HBE709)!#)+KF,8W12743X
MO]B?\'&_1#3FSYYNA$EW:]: EF6+ ;ZL.2C: _PY^ DW^*=5J/45<N/8WV=*
M5"WKN\1)(,;VJ>_$\6)]EX2KKR/ CMV/69PQ^6!I-?P9MHG(AVU(64"44&!U
M"/%'.^ 5\QHB,\HEY,;(Q$3K0;=S2.+94H<)]L/D[$L0XT\/P!W$B0+ '+SY
MOW@??(3(CB:95GYW].KH/=@Y$7C$] [ FW?'!Z]G'T"\<2+\HCE--F'D_09=
M9(R' 00>6?;92^<TP>G@<-@%+S#(]OT'!QVM]\_4V37^7I3*!NW2HB/E-'!A
M[#T$V"F+Q567ZVLDU?<'2+HC2?;%";9WM#2=WHT3+2*BUEQ"^@9&=WB"1U5
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M5\, 1HZ/4_>Y6R_PX@0G#7F$>4U6W>=WN4X-6R!R7#&@DS<^  ]9\RP?9X.
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MTX&F2-X2X.3.B^JE*./!YD48(2:"K%+8:K^,G"!V5MC7,@]<\B^?>%X^.5Z
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MS\J)-V"-3HLQP.*KQ_HT[YWM;'I\\=7QPQF_(G1N<2[9Q?I+#,E1:7&?.%Z
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MWT;.SU\"\B_HTN6.OR'"/'IS<DP$RFAE3N/3&6!(U-)FSY]:+$K.* 8D6<Z
MD5\#C[J2VWV8\N!RN1!DTLG:_,%FNCJN@+I+G#:^_M8?'6M':BO]R*A[EL&#
MQ&JWO]R/Q.O]2,F72J=UK";/42I-]90GZQ'QM.1Y+);GL49YSM3D.9N /&<O
M0IXSL3QG&N5YHB;/DPG(\^1%R/-$+,\3C?)\K2;/UQ.0Y^L7(<_78GF^UBC/
M-VKR?#,!>;YY$?)\(Y;GFV&)Z*N4U// )9?7F]!WT5R>_YKBU[?C'(BDNS7H
M >O+&^OE;=4<.(&;Q3;D!'[O[,+XCR"C8[4>4D^Q-S+-]YD?/7KFK9J>>3L!
M/?/V1>B9MV(]\U:7GAG7U<+IR+2_A<V*P.E2:VC5\R(6&D,OC.F#>:>F"]Y-
M0!>\>Q&ZX)U8%[S3J-O?J\GS_03D^?Y%R/.]6)[O!^EV8U8CWTXTJMM[FX5,
M,_ /5N*GY&575_$2QIX.E?!!325\F(!*^/ B5,('L4KXH-/-KGAO<GQD[M*;
MQ8%(GM9E>2QQ9W)\-&1]WD$X7ZVR%S%>\' =)C!>AJ=A$(>^YSH)="^\P E6
MGN.35'VD0EZON_%A/9C2_<-996;R@<"I$04!IHI+?JYJ=,&Z( SBDK*5S4,?
M*DK(#I_6W@]W&$M%]4[08')A%@?3UU4R]X&JN8([%=/.GW<PB.%8X5GL?BPX
M+9G,,#!1U<:#>8,_6(K[D18;M2H>=;B:K!;%V^3CF75-(+Q,MJ\))&Z2CV=:
M3Q7'BK?)QR?6Y2F\3+8O3XF;Y..3H9H]V< (E[#8PGG@CJW>^9W9T/%<CEB*
M'C<"'FGU!SL/>OJ)KZ'FQ2/6I.L5(Q..7UO7#<+ !/NZ02(JX?BU7EVO&)EP
M_,:Z/(6!"?;E*1&5</Q&KSP5;X"/WUJ7I_ "V+X\)6Y_C]_JE:?B+=[Q.^OR
M%%[BV9>GQ W>\3N]\E2\Q3M^;UV>PDL\^_*4N,$[?J]7GHI7,,<?K,M3> -C
M7YX2UR_''P:>E7Z$WL,F000?8>0\Y'45%NM.9IJ13D^]NS=Y=:?*) -9!1G@
M9'1 0 CAF@RK+,T1C@/,?X2_IMZCX^,PGYCT8S7"1Q4E]4.:TBQJ\M;/%&\6
M9]9O%F?3OUF<2=PLS@;=+';)*=Z^S*S?OLRF?_LRD[A]F:G>OC#(J;[(LNY#
MGTW?ASZ3>8VEZD-ON.!P.LP(;F 0>X\P\\==A7%\#9/%>ND\9\E6T.\CZ,3P
M#&;_'=,O.XPAT\%BPUGF.G=7=<K #W$9OP FV/Y(G.<I.'VUX*?C&!X^H]K4
MG.+5TLSZU=)L^E=+,XFKI9GJU1*#G.)UP,SZ=<!L^M<!,XGK@-F@ZX!!P41R
M)XJ!71A._3*,VS&CUEY6V%KW0*1A9K6E(9HI7GK-K%]ZS:9_Z363N/2:#;KT
M&@0EN7/SP"Y>DM9B'<<':*U7-C-CZ4&''KUUK*JW"O,=F>BG3KPA%=U=Z'[<
M?XDALM3+J+XY+L^4O3 >YQ"IP("%@)_^7+(>EB(J8.V'3S' D )A&?WIE"3L
MOD-21T3]6*@X8:H/W^;N+VF<D*6Q#&\A'J;G0\1$=1A%:\HJT$=AT7PFRA%&
MP<IG676%-X6HZ(QX5+!O!?\6_[S":RI%O0 O$"TH.SDQ1T1G(^W>6,(9L,&T
MO3ZUSDZ=G9<X_DCKK4?'YJRI_LRQ]A%2M#O&B'=(LD5RL^E/)%U!?Z'78=QS
M<GHF#&8<&!3#VF;6P]IFTP]KFTF$M<U4P]H$%L=E\ ACFY8LCX'I6+(<+B4M
M6:^@,'5+5@(1$I:L:,(TI=%4C,Z<68_.G$T_.G,F$9TY4XW.%, G/]/;4TL\
M!J:CECA<2JJE=4%AZFI) A$2:DDT89K4DF*0\<QZD/%L^D'&,XD@XYG>(..9
M8I#QS'J0\6SZ0<8SB2#CF6J0,9W<B6(PYHGU8,R3Z0=CGD@$8Y[H#<8\40S&
M/+$>C'DR_6#,$XE@S).AJ3#NTMW.)W<WCH_W[0MDH5P&ZS#:DI*((]E^LKT:
M=R-+,L:Z.:RU!F=>O/+#.(T@#K,CYA^F!FKD+ ?>]91](\U;CWE2C5X@9J3C
MN6=IA.S&Y086%?LB.BH9RD>"C%E=)&:(=X38H9; )4U!LH%@CPOMH8FWXE?M
M*:=2CTE.@;9M2C'&_,1ZC/G)]&/,3R1BS$^&QIA?(ZX09BKG5N"6)\K+!&Y'
M<U)(]VLZ8ER:,P: 4/M#<D%9\X\&KL@M86>CZBW]AD.BUT1I4SFJA6FLQWN?
M3#_>^T2F*,V@>.]!P4]RN\W +EY2I!UK$_LWC _N;I8:9E;5PIZ_07;7"M%#
MO3W"*/'N?7B#, NC"&9E.SY#_%17"L_2Q QZ\7LQQ@#IF_\+:@U!V1*0IN"G
MK/$_K6G'OD(L@==K7A2K']\ANQ[&<S&HAKL4.#V9CZ/A<,/4A;@%F(L!9LD(
MDQ!EPT,@F %%0)V2' GCP:A+WSQX.CRP_ %9O@@F3"R A"F>.C3HXU.MK^ZZ
M'G8Y.3YV*%P&>236*.#@]V4AYI7##C-XM6@#<*-#+P!Y,ZJBL1*4*B'09G2I
M:!J&U/Y>K=)MZF,SC/6B>!RH2?=KO$:X+&<L!"Y.+\$\22+O/DT<;%(A>__&
M(66MNA"T <"^(F^ L=?LJ#O$;F'B> %TSYTH0*>&>!00,CHQOR/2&6$ K/@8
M%%]/9&_DBZP.(LYP%7?)1?3@!-YOY'*F.EKBFYK 129:C"]R\#\7:\IAL[K)
M6L+GY"/JZ:MFH&EGST;N9<UC8"7TJ'5S !H=$0=NO2M\\5AV!JK>ZG>3/^$.
M >G1KMH="Z*-I"!CR$BY*)KW$'AK;^4$"78 I0'V3M\@EE;HX#362I/LU$:N
M/3G66,?GJC&H6H.B^71@WD_JC1.U_/STSIU7]K':0#?UX6*-[TL"].$^K]2Y
MQ*;::*B4[=:"7I?EC07,O#G6Q24!I+CS0JX_$2* BDX[^.R)@ 9"^TR5LMHL
M.R'Y(S\Z,71OG#U6T?,G)\H<38L=5N/Q#XZ?9OH]CM-M]CM#0-;"G!4UK'4(
M$JN"='-(^@%Y1X#T=)"[MO+.#D#9':CUQUU"5A>03GS2EYDV"2EO&,@H<AX>
M(OB0VTVW$"W\%(ZZR.3Z-']*E>*+L2":;?&RR%OSX&T!W;WD70>M_.0H'G%O
M(OS$/MG?^-A "EQ<?7:'U\3XQ]=>71MW$_?ACH'.@L0!($3(0;,D,\G3I H:
MZG#M/6D#?,S,OHSC=8HH'8;-B1D'\J*6 J,V"%X&"9I3' $P)UD;QM>9,CU:
M..U)L,7 8=429$V%>M%* @QI.3<S7\C-RO SW847> F\\A[QH]%FIX8.;O(<
MF+YY4^!1XOB5T3HDQ$ 7Q!-3H .00C]"]9O* 0^M\AY#7H\7:8+6U'P;1DGN
MI<XK&AK!OA;6;"T*'<P/7BT'(.L)U+L">5\3.\F- 4C:$M,F&/6UE[O+XQMG
MC\DB"PK])DJA>U7EI1K?XE'EPH(5I,@J*^(CIP9R<L1$SPF"&D7Q0=)6/,@0
M]+2B0Y3G=;AM)=.[(2-+@16K5S_]^9782Z37Q30WCB& HMMBBK.LO#*PGWP3
M^B[" 3Y2)WO\^&+\C4"^7^/&E"QG+'37VO_>V87Q'T%&!F Z,OK="J#[XJ"!
MWEY3-OS\4+_TP<&%R%@B=E/]TB?/L;0W?M79DR%[!VA5EEFXIUUA1A%.A8I_
M/LBO, ] 077*]_Y#\26ZJE28<1W+YCHD+X"A2S@QO$2D.K>W'&38DS!H2C+9
MG;X4VJU"O0\FZ+"6GKD1-3\IHSI/DTT8>;]!]TN ]J+:PL*W!O''_?DSC%9>
M#&\B;P5OL6JRMC,,9W@J@3%ZAS5T=RE( T(;$.+\G6:*&XTV./?:B/0(3SF.
M)GL:LG2>3=R\<;JRL;!X##$OVW 3@-I,,OI 1IJMS/+\&= 0T(O1'@8XD!V'
M9^;]Y=[6CS" :\]4C&]_3LSG@5-G5L).JFAF4<$EEHN;@F]SRM]-]_I-&4YT
MK:PVS0,B'O+ Y N(]'S^RF,>N%>HC=_I>:3D4DHL6'B.KL FZ\5Z1LIZ0JDA
MPF^\9%>=&L48Q[,\F8)-U*KQ8,.N4.*4%9^;T[*;HGV0_!O1N,I3H\$2.5^O
M(3XHPU+1WZ+NB[I0'K''#9DB"JQ8O8?JSZ^$.5(2K9LBF"YH$IZL&T<=4'1C
M1'&6E6H8%$6E;E'?*TP8EW#)>X7Q+8Q3'[_SNT!#[Y7V5H6N*0>D*H/LPR"A
M!+Z-"EK?X0)D7H;F!-,#44&0E-^P9H$,E7F9O4MU^C3H[V+S0#UE43QXYS >
M0M"/"ZM:NQ>K$@J[H$<4];PJL_<28@:4P$-7T_VG54E#=[OIHX?9K4WG061R
M(C!YL0+-BSG:L7[EI%!J1OXX5:HR?H+A0^3L-MZJEN->Z*AE $*:F&E\R#+&
M@$O5O%[B0"+FPS22^DJS!%:O"5(\X>?/(O&V??Z,Y!4X_FD:)VA?C^*/^XJ#
M.=[\1]UIAW!BW%\[@%EF%JGL^2TIUE;0!"51<+\'-<03NM,+ZM" IF9>JF&S
M/,1=&VZW7E9"&NWRIR%)?@*#E9'([9Z=FX[CZ,<>)YEH3H38D@TR$XW,5@-%
M.Q5ISZE3S2A?777D]7+J-72JSM#1C60/7(97^'C'4_&LQ/):>C);A4 +SZ*3
MTZ)>AHE1JRD&>0]@&0+2QV0"*/3#J,I!KVWZU<.<KB RUF%949UT4)SF]I^=
M)(W&#M=3X<"TKE?@D;$L,DHX>"BGE<']H/0B[ ] 07!ZELT M-3UO^IT#BFX
M=Q_#7U.TL,YQBJSQ$OTQ^['A"F,QPRRD5WP/L@;3>B\@$F&S4AYOZ'T=4G&4
M_/S9"[QMNI7/^(L:U1"#_E6AI4O/(#HZG3/0D']CO1("<_*QO.F#43CQ$$+.
MLUX1-^B9%G&]<Y:(LV^F(6+:Y)<B[@Q&M?C.S68?>RO/">+%>NVMJ&GD&18^
MHZGADE!T+EA9>LJ/0?:U=5%+"*&TCSE#5:YNBG[CK1P?36\/R7=;&19ZAP&6
M.R'_#J /IR%JYH1754FI8U,5\ +75-I \J(51CUD3&UH^C* Q@0K(SGZ]!!]
M>YA_;+>*@W#N2W$SAZAR181=1_B.Z;,3I&OT7U+8ML_"YK0WO<39K#!]AUD+
MT&@RD64O%DRE  0C5U4%W5<C-S B+TZ.WL_>'[_O@1-)4B;#+7OPQ< /]=T2
M:I\_(_S=T:OW,W (?O?^U?%[R\4\%.19PJO''"D%*K#IOSE^_?[=D1:8-4A-
M"&9UOA1A]N;5\>L,9N^.I@TSFCPE8-:9(\TP0S ^>3O3I<TJ4A."69VO@=KL
MY-7;V;1A1I.GG#9KSI%FF,U.WNC:-!ND)@2S.E^*,)N].GGS,C9-FCPE8-:9
M(_W:3->FV2 U(9C5^1ILFTU]TZ3)4](V&W/3?#U[\_KU6RTP:Y":$,SJ?"G"
M[/6K&=%FKU^]?CMMF-'D*0&SSAQIAMGQ[$B7;=8@-2&8U?E2A-GQJ]G1R[#-
M:/*4@%EGCG3#[.VQ+MNL06I*,*OQI0RSM\<OPS:CR5,&9NTY4H(9(;E8-[I!
MV_'QFSYZ3$C$L'M5Q \K'IE@:+%N)_DI#;#C5V^H*LL\FF3%5N)(:DI4G:\T
MXC.TV<[># 11@\@$0%3GIR^(9J5YA?X[61#1Q,8%46=*=(+H]4E/IZJ0R 1
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ML4S;LDHUPF#6M,P'E+4^R!$YF?R9TO)NV,1R$S0@ O4F"E<0NC'.>XOQ7KP
MT(P^9C?&,<?BA%TCC7R>95(FZJYH8?,\)1);JQ :>\0#K2Y620V^G=4LB&$(
M '0&!-:4Y=H6_*EN6TO4*A5J6B$+:HTOP@@C1K<R:%&W432QR0)K\>=?D6?:
MV7Z"O[;KJV?(IK'B*:-3<Z5X*VQ_?W:\(($!OMA&]/*04CF/"H^ R:@'(3<L
M'TO6!-3:8 P<%!'$]M2"C&PJIXMHY$KP.$6_\5:.OXP\QY\_1)!$QW]VGKUM
MNOV8N@\PP3'T<?L:D &6'N0,;QORG+$B*W,"@%  )0F0TP %$9(QPDH!+T6)
MEA#K.4<#=B?\9#7T/3?S'Z*?5OLE?$X^HE9?-6]5W*YL1&WQ&&)']59-D.(B
MC<!/^7]Q:T":_].RUU!&K*T@7?Y4*#N(OL1PL3Z/$V_K)-JMGQ9QXP>@9O\,
MS*"/2*F8XC-)V%A #5U6=9Q0!JQZZKGR?DT]UT.F-D_K,&TA1F-C$."RP32
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MV($II#E"'29 3+.2A)Q-9B=NI1<.6G$L\A.F>ESX%(;ND^?[B/YED* )QSE
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M0/RCA%S*W4DT<-7(^8^IY[M>\' 97$:/7@"K7; '0(1$#*-$Q \#*D4S9,>
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M^W'_)8;N95!>8,Y+NTMH'< DVWD*6N!^#[[]D@4]?P=*BJ B2=^3+"R&_K-
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M76A 5JU!U1P4[>D1\7;,1JEQ4LW%'C-D,%"M<_2<,?>3[KEZ=CRA<_7LN*.
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MJ*]8BAAD+EFD5OE,"^-1!FY.B[E,XB0<]M'"^:2115RR&WQ>-OFZHWAZ:]Y
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M"W-1U5N:MVSG;(#$JZLPVEQJ-5W?FF9 FX1@3.NG 2#T447<GY#IQZMEXW4
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MLKA?!337>4L_L7-C,RZI(:+@JUU5M_D_N14OKR6!I17E,R15.'O*K_PQ9%*
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MNLX?79;3N/-"P,MK$0P&&C8UF#/&FB0#($X#IG?C,"TBNZ+[Z")_]U2F4V
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M(%L3WIRP]HFK/HUF;[[?&T7$?*'904#S^U+<C-;/&B(>/C_^SX*?):')KG)
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MJA?T.BK52]S$G^=!W;3\'L;E-/RE6W)]D#XG1!:U6L1D14AGG=LY^C,DQBA
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MXT;)J::8AD[7BDFCL](K@4D^7C1'<>GZH>'12N1JTD=*B.@]47++H PJ^)<
MG3$NHK5_4LAT%#W)"[%GFN$VC)[:#= *FQBZ2!0#P?;O*K?53:3J(=7=7LKP
M-SW'HO^AJWUOV-%"#_J&YQT(SY\-&[QL)1O-#D1+*X7/B*R6D,XOKO<'8:%O
M['!@V$R)JV=?Z>C*/)\XE/O.519N@^S5'*UI;G.$VG&_3<X6O3#8N![^"UED
MZ]W2W[OF'V/?#PW'1 4+LJQ&' "=KBY"$(P!\U_%#G<)2V2W"#UZ'8<\[%J+
M#<'-GZ#'Z%?PISPFHIUPRBK-,RNZXBDE>^0]N #)7A%+,P^;T/MP9N NY(-4
MBS,#DD0):)CW!IYK(F3Y(S+'U*1,5QD[ RS'>GK=7ZX,F(HGL$.$XK(,1@Q-
MH_P5?_B$/!/[IVK "H1>3.]Y";T$4_'D+@BA4^?^GASM_)!055+*O8A"1WWO
M2M#$4TA ?*WGVB4;,I9QUA!;X'84RB-ZZ3VQ =<B4_MK7<&I:;!!WNGUA7_C
MN;[?#SV*"["<*TEU7\[52$H$G4'D3,L,.>37AX@M8,F>#=[QS?,<JE1T^AY7
M1YU*@\/,-IR@YU@TUKFC@98)@EZCE:2ZOT:KD4P%K2L:1;OS^1O7MN(XR<SP
M@T%(NWG_XN$ N:O5=+7T# M=/IH#U@()1KJO(S)22#5(U^LHHM][[!.T";L#
M-WP(5J&=\@EO*<I)=5\+JI%,Y0P1_Q+;S4V/]F,:H/B_8V?FH9V!K20/%GZ#
MKZ/7?8DS8)J*'2#^)>?$T=N3^#Q!@/;V"N1=2JCUF<=LOET!@JETY0-=H$[>
MO8^([;G%*^A=GH5BYR\MF&!-)2\=&A,J7H8(11-'L)*?;13AZ]"PG1?@OZ+/
M@27/1++;"YT-U53P H$VI?4IE:UY)I+=ECP;JFE6BGS<3>BA=$8+IZOS.F+
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MN2DY%IX-KC?%JD!!B\0!<-+K77WX^ T=CR,-X_P[FNU0&5H74]-SOJ)L?"^
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M'J:$AKU$WK;%W@?S#)Z9SFM1 L@6LRUYL]B?WMU-)Q'HO?YR_)G\YO618@U
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M9'!A;L99C;_=_5H!L(_,K];N_GWRQS'&R3].$&>&TK+=,\.9G;,60Y4R<+\
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M286/#JN JJI236VW6]7[,J 4$#<+<<C;-,R=_CU0>H+4$DCI 4IIMNMUM7R
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MU9AW>MX?LU^Y_2Z2QO>!BF!(^^!G[_W909O5:B39</^V_Q]02P,$%     @
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M?*08<3;#4R(1Q0GW,90P-4-M214S\W8F1,(76O-D6:U@SHQ_%MA9L+51C;$
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M?U-;?[B#8-0^>:=#R^&!=ZTGQ*%CSPG:,9LKH\=K4&RU/W3#+;7M3@9D$N2
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MK-ZDVP%=5Y&MZM>./P%02P$"% ,4    " #6AAU5R0-&GI'= 0#$I14 $0
M            @ $     8FUR82TR,#(R,#4S,2YH=&U02P$"% ,4    " #6
MAAU5CFZ\+944  "D[0  $0              @ ' W0$ 8FUR82TR,#(R,#4S
M,2YX<V102P$"% ,4    " #6AAU5](\!],X/  "#RP  %0
M@ &$\@$ 8FUR82TR,#(R,#4S,5]C86PN>&UL4$L! A0#%     @ UH8=56DH
MF"7H2P  YMT$ !4              ( !A0(" &)M<F$M,C R,C U,S%?9&5F
M+GAM;%!+ 0(4 Q0    ( -:&'55 %?E^Y9X  .@/"  5              "
M :!. @!B;7)A+3(P,C(P-3,Q7VQA8BYX;6Q02P$"% ,4    " #6AAU5\4A/
MGFA+  ")\@0 %0              @ &X[0( 8FUR82TR,#(R,#4S,5]P<F4N
M>&UL4$L! A0#%     @ UH8=55>:$A^L P  QA,   \              ( !
M4SD# &5X:&EB:70R,U\Q+FAT;5!+ 0(4 Q0    ( -:&'56@Q(<3$P,   \,
M   /              "  2P] P!E>&AI8FET,C-?,BYH=&U02P$"% ,4
M" #6AAU5@X?2Q_,'  "_'P  #P              @ %L0 , 97AH:6)I=#,Q
M7S$N:'1M4$L! A0#%     @ UH8=5<T2@\C;!P  ZB(   \
M ( !C$@# &5X:&EB:70S,5\R+FAT;5!+ 0(4 Q0    ( -:&'569F'WMB@0
M *00   /              "  910 P!E>&AI8FET,S)?,2YH=&U02P$"% ,4
M    " #6AAU5>SN=+),$  #V$   #P              @ %+50, 97AH:6)I
?=#,R7S(N:'1M4$L%!@     ,  P ^ (   M: P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
